<SEC-DOCUMENT>0001737287-22-000083.txt : 20221102
<SEC-HEADER>0001737287-22-000083.hdr.sgml : 20221102
<ACCEPTANCE-DATETIME>20221102162210
ACCESSION NUMBER:		0001737287-22-000083
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221102
DATE AS OF CHANGE:		20221102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		221354447

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>allo-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:3bc7a964-10eb-47e7-910c-f5ea785aeb6d,g:304a2d5e-50f8-4210-a420-41588b836a7a,d:ad69808f292f43f6bbc63337efb1d90e--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:allo="http://allogene.com/20220930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl8yLTEtMS0xLTM4MzQz_f8de3c3a-05ea-4f4d-ba67-7801c75b24ee">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl8zLTEtMS0xLTM4MzQz_b6467e34-9d64-4d1e-b954-4a9a906496e8">false</ix:nonNumeric><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl80LTEtMS0xLTM4MzQz_ab029bca-7167-427f-88ae-bb9a09c2c900">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl81LTEtMS0xLTM4MzQz_ff1220d3-fa56-4566-a698-dd170424ec18">2022</ix:nonNumeric><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl82LTEtMS0xLTM4MzQz_39b583d2-01ca-4d82-8afd-628002b0488f">Q3</ix:nonNumeric><ix:nonNumeric contextRef="iecc019de3c544aa08930db1891672917_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_090f2506-4094-4262-920e-2e1663730d2d">http://allogene.com/20220930#AccruedAndOtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_c2737ca9-b04a-4d28-a3da-5b7ccec47c9f">http://allogene.com/20220930#AccruedAndOtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="allo-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0782ce963cba40ac97e2f2e475fbde26_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i851ceebb52594744ab16edeb67e8db95_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iecc019de3c544aa08930db1891672917_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia16e1786ad8b4304b2dea68bd40ec715_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2768721624b646e4b4102030fc534111_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62204640c1dd4c7e84683bae3464411b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90fc78fa954a4298bce5f60606ef9a4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idab67126ce664974bc2dd9963d5c3ba0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660319721ce344d8a0b9154850955702_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i568599dba7e143dfae2ed582eab3cff3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c2e5335e0bc41c785958fd6330aacc7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i328d6792e081436fa76276a9678f424c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0adaff1a464431da2afd3e58a0fc274_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic900f2b82bd74b6ab94b987c5117fc3a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8c5743ca8a348359d46ddb287076e9d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67020356c6204f40b4841f871a50d053_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ea312ec5214b9caacbbb7ac02ee5ff_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b1e6139112545ef9da1ebd8710ab2f1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e087f2a6e34ff89eb1651f147dcc07_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53bc2cfd3e704820a725a843f0e2fdf8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i666c9e4e34704eb890ea456c2f944a0d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25f5c9a7d2bc4d3ca5014da4f40097b1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e354ae71e34ceea20c3c9ba63e8763_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45581b958f3f4670b5c86820707bb668_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if440df8de9ff4378a42f14411ea24199_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice884c5236d74ae4aed903a5266a526b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ed3bf5b05643c09d7e7b6060b8df59_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d45c7d7a79444cbab51b762db8a92a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e40da32cd9649fda45dd94c8886a401_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52a77f5cfce4da693d48878535ff579_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e4663ddd5e4d3fb00c03d8227b3e83_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc217acd2be43718fb7e4ed4c014def_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3533121d864f4c0583c7555923834700_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8448819002f446acb79abaf404098bfb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4c0e6ec7e054c1da14d802766b50abf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibefeee67a5174cca8fc8c95afe569cb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27bc23f568da4811a9958f2effaa11a7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52c6c38d96b3496c83a3c3f4292c5f08_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60949035a3624cc68a5f08899693ed89_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3285731b68de4e41ad0c1865ada7997c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36b261d41d814a7cb5646538703fecb1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i656fbffbeb434eb49eeae23b018e4fe7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a49ed55a0642638b964d93a55082ef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027d2deea89848eba3b25676ffe40a68_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c3681993a340ce9e153807ca820af8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a08f54165449009616a55b4debdf18_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1192f2bcfd174e4e87c6a48a6b229311_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b441d0ab9104d6f906ea50fc1740b98_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ced53064cd42a28878d18228552b20_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9545d58a43c140a2a6a71474a6ee1920_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia77b5caccc864c93a8578007ada8f202_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i470e7ef6e8484f10a411d5c0a26a3342_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i970726c2db304fcbb4d9a0c045073a76_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66f164bd81e042c9bdbbf51049d8b187_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2793cc8b4294f6aa53a79a343ce1cd5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie199bf4d5f3d4388984d9af23f496b4a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e8df77f75814bb3bd276293c61def27_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ff97a82a1149f0a766b4dd2aeb2039_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44eb82ada8fc4b7aac17b9def190f34b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c9685093544f8e9743c24c6b40e4fc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96730d707ea04cf892c0873970a6389c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie730bc1281e742289f7b14d42eff7b48_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59dec0676034b50b7ad0a219c00b9ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16d0ead330c24d62aeb2da5efcc4a64a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e54a3337efd4d039762b588776fa199_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b727b1deb0471d88a053257c9a4611_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e1772a9a774e75a2d532c1fa03dfd9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4d50cd1236423f81f303edc85b5416_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcdb27b9bd024ba9aa1c201ba5aa6171_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c83b117241041978e86a79078e74505_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c093d5bad964a0cb856275d022daf5c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9e4e9b1f287486c97e5fdc273885d36_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e850a333e249b0925d51da049c0000_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia80be28ab7b844ffac2c1c656f493915_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b938fa488644558a07b02468cca245_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d843d66f73450085167330c08fa8f4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7957a6a04a864f12ad0b9fd205fb2027_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a8d37d4b41e43ae8b50608fce513cf9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a332d398be94f8283d48f49a486acd4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided01fd1fae3479a887f1df9839cb3c9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae16a63b5e8d410aaea9422f95a58df3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6229e7a19925408a883eeb53268596c3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb1e9f69fd5145b2a82d1c99cf574c36_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7be2e87e35f4e328aca6856dd8c331c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb03622518f4a8aa208f441ff5ed3e5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9664a6d74d14cd2b0e6999a7746fbb3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b39ce52bb534d8ab364d55d7a5a4845_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b26963b040c464ab654260f9b024c8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9196dc684bfe4858b5edf3e1ffd737c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08414a6efbee44f99241e34feca223cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib21f092a53bd4a75b19b5ea1f96f0dca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac26891f51c43f698aa0fcfa42259de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5742857dc7946a285456adb1db7f9b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e46bf35fc4476db2f52c28e5fdfe66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f1616b693e482bbe1bc2c39cb50669_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cc072cc86b04dd09d83c1d2c3602144_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d45516c51f84306a30498bb283d1dae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22fda346a3b44f58bf392876c6af2d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie368da95aed94f39a8028a7fe3264ca2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7b7966b0834b118a6dddf7f31e7efc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceda1e0793a444bfbea8f6f96fc85ca1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d0b55b1ab65461dbc838d478634fbc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a6f4571309a4989846c43edc13b9607_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba287fafeb24922afb0bd5704ca7f09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43eb4f2c71bd40acade960ac4537414f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274296360e7f471b817e447bda912e0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eadb3f0fcf547ddab8ff0ef26f06f52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a34f9b02232491b96689d6036cda254_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8c3e4c35b6d4a5fa0398b1187be86ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67454b2a010e4042ac9e965a1600e8a8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f21a84a447d4ac69ec3d11a73e75977_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id75fdfd77e0748c8bb330bc88f7cea38_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i495066fc809c46088689104229f96bd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc8586da0577480cb7a0240005555a9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bbc0838fe244d26ba01e286b31789de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb2b5f01151e42a08a9681956bf850f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d24e7b9e4e46139098c072d28e3b8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db76501bbc74787965531c11d212d58_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b3bb83a6f447df99a6eb708011d28b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09d16f1562c4ea7a6206e6000a0d8c9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f488c95563e4fc0abd6053e7cdbcef3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26accf762170429ebb2cfab586faf0e3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86caf7b4d7f94d6a815a266b3f51ee53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icda10573477f47fda5d385ccafcf2a6b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6c9232fcc104c6894737b6331f6e04d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1f3fff4077416faac3922039ac158c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d4d159174f4bfea30e39a7ea47463f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba32805724354181ae04c6b3cacb4be2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dddb67349574083921a243e6e892161_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aade5c20f2244a3ade2b713c171949b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief48337bd67341b9bb41f73b0b3c18f3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb2b0edcdf44e7894b474bef1a2f72c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9534ed89959b476bb3c61a21f111f0ac_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ccb9c3e12e4bfbbafab7c1c5ed2261_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida71502c322b490db719e60631ed9186_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12d3205699d44a1595452c484f84725b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:DevelopmentAndSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd514b962e246c6931c985ac1c2ec04_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1dcad80d4e4790ae883499a22385cc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5454ce81effa43ec82d692544d01340c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82036ec2aaa24cc88e17cb24559ae7cd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc896b3a0a744c0b48d522995094a4c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i72513027aa40456ea894b7c240d9529e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eeda0f2399347eba9a1d3c03cd7ed64_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d882b41ba7546aaa56039ced1a10287_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dbfd0aa1f5c4f6d8ac7bf09374fbbcb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="id7323529b23b45e7b1f3558682b81cd8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic72e6bbd73b24d50b42d5a271012c22c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664e2401aa7b4ff9b1bca0d363df47d4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e4f3d045a2243009dac024b2e80a3ca_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic983cd690af84de59565ffe50d5f5432_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58179b3cdca14b9aa3417426bdb601bb_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66aa59ed9c4048298f0a3a33feba7cc5_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3871a5c9adb14fedb9c83c1425f51c54_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8a195a8a56445a3999166ac9339894c_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44b0b5f2e18c49b2991662b317cd0227_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="allo:EquityInvestmentBasisAxis">allo:VotingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36321bc5549f4fdf84b022c72c2623e0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25e249ab3ca0464995456f2a93a352ff_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b6f12ac8d143eda9f281cbcc802324_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ClinicalRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb1c70c0e2a408eba7c119e0cecf3a3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i190dbd12ad724f999de964f8944f43f9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aa0b52e31cb47caa5b6de4a921c9b55_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb0223ba204941ab82cb484b7e33f56a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9bf9785d75b4721b9ff6232ef70d39b_D20201006-20201006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-06</xbrli:startDate><xbrli:endDate>2020-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee875a3ae84d46ed987a1b307db20e6e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3240a374c5ab440e8b5e1aabbdba7c25_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff52c9c9567540af853d7d4e7492d0ca_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f6257251904aeda6581f6bfc8b2065_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f8ae51b31a40de91e52c6738e4e6d5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9fc1bf30b194863ae80b306bfcfbb2f_I20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2742005271e46328201e1c4c09f2efc_I20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">allo:OverlandPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae425c05634344d4904101d51eef4cc6_D20201214-20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:OverlandPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717e3fb1a0d945d5851037cc406f873a_D20201214-20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d1cf8a7bcb44874baee49aa53e9d5ce_I20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8499187e402947009dcd0f43cd08b023_I20220105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00af316994b480e903873475c1e0166_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b7af3feeda4ecd91976cd1a7640903_I20220105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMilestoneAchievementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bbcb65830e9469e8584561b4ed503d6_I20220105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMilestoneAchievementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab46440194c44e0abc3230ea0acaa11_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0599d7f096e54faa830326a4b07be324_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12798b13b2e34a1f8b05f08a0a198299_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:CurrentAccruedAndOtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1861d08a2de4faebc1dfeee012e2263_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:CurrentAccruedAndOtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db19e8474cf4b47a8a2c996ea80614d_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i6c0fcddb98e0438fbee11a2250f1b7bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">allo:LeaseOneAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ee1a949aa34bb7bc017891ce79e050_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1bb308e19ad469187b256dd69806dce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">allo:LeaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e8ea8f25c7b4bfb9cf53b843eb1b98b_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica7aec93cbca455f9d73fe168f4f412b_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewal"><xbrli:measure>allo:renewal</xbrli:measure></xbrli:unit><xbrli:context id="id1877d8c1c9d40b58cdc5a256ab21b2b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i285646cc47ee4e0781be1e398f978e9a_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i936368d1ad874c5791721226f6432723_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i186cd8de8d9844958fcbdfb4ccfb61ed_D20191101-20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b45cc2e745b42e9b32d37a59ae969d4_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="allo:EquityInvestmentBasisAxis">allo:VotingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1492a2fea02e4f998d775344e68d1e5f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b00d6b5fecd421bb33ba50571717267_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed593580aad4f18a35e79239d80c7d7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da13d9ff1754a2f85537e5c6a6528e9_I20220621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>allo:employee</xbrli:measure></xbrli:unit><xbrli:context id="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-19</xbrli:startDate><xbrli:endDate>2022-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ab7bde48b24a23bcc9d3eec9a88153_I20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2930cb3944834b138006d0840c8071b9_D20220719-20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-19</xbrli:startDate><xbrli:endDate>2022-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i335a2face5cf44a58769ff4969fb2cc1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87b1b7f6f25749da9e0c6010a3a596c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80967c9edd9c4b2c9d93991aba2977e3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ac5f114f4b4675aa3371c31e9a9f93_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9b3aebda244d37a641882195bc9a25_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91b0bb6bd0945bbac49f373c6dce054_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11560b36616e4aaeba3be6911de62405_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11744c3dcc0478fbe1ac19d5b674e5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f197f101d1c490f9238233b8c06f878_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf5a81c459045259eb6e048191ed8b9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6627a5e0bcb745a7bcf2b1a0bcfb8913_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b8c2dddec8a42c2a41bd9069f28fb76_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3949326941ae44ad8b85a5116571b2d9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb04d23e1b334eea8232a278c94030b1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f95a2fe74e8495c8a44a351002ab5f1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i692e53151ed54db2bcad88681554f8e5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i657be91ad1cf4834ae3e495d97c6b831_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b0292c40a9540d5afb21ac604de6b00_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3d377e6ef446be87bcdb339dfc0b9b_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55782e475b6a49e68f013ee57e855017_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10cdf1fbcbd24042b88e39c59ceb0185_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6835c65c40e448ee9cdf956aa442f14c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f07bcc60d124644b17029e7a86498b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244e669df12d499393987c604e57d35f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70d6feb00c574d04aecd098830cbbe99_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i311fa2e0db8b4c88adb07d7473de0631_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f691c5f7eea4a9b9059a123b37ca9aa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ffebc0cc88b45c683f02d07c9da34b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48fcbfbc97c948488803f2fa246b65ec_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83ba27cde25d42a1bcb8d43b98591e86_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71270f28c9f44b26884a7a3c29b0a8c6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad6cc93503974700a19e1ba725f39da7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b84fdd9ca2b4e34a5b489c6cfd75f6b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3537c96671a47618355dfe9daa3ab84_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c288bc903b4445db1aca2a0589bff15_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2735eb3759f4c978a3d46ef79aa58c4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09654a2f64fc4baea96c1b7e18d63c05_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia29bfb086dc54826adc5a81036ef756f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168b193cba9e427089753a5b30b8c90f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774d91333c954992bc09c9a46d392ded_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a0727775830468a9e27ab2c44c1b6ff_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3e864f70414a80bc0964777b022263_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf062f962ee04c1fad713216e1f06041_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6de817bdd944afad54fb6f862dd4cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c392be59f54e6f9714301ddcb1bc63_I20221006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-06</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iad69808f292f43f6bbc63337efb1d90e_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzIw_c44218f9-29db-471d-95d1-fd85bbb016c0">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YTY0YWQ3OTI0MThkNDVhYWJlNzMyMWE5MmU3MTBjYTMvdGFibGVyYW5nZTphNjRhZDc5MjQxOGQ0NWFhYmU3MzIxYTkyZTcxMGNhM18wLTAtMS0xLTM4MzQz_4aad8fb9-5128-4869-bbbc-589f81b6c31a">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yNDU_e95ffc29-bd16-4ce5-9d1c-6c2522d3137a">September&#160;30, 2022</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6NzM3NzkwZmQ4Y2U2NDEzYzhiN2IwNzMwNzEyZDAwZTcvdGFibGVyYW5nZTo3Mzc3OTBmZDhjZTY0MTNjOGI3YjA3MzA3MTJkMDBlN18wLTAtMS0xLTM4MzQz_17e9bb21-b27c-441a-9e67-a4a4f114cf42">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzEx_fea6aeb3-ae9e-4dd5-b526-c1993a6b8b1c">001-38693</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV80MjE_74764728-7de0-4b94-844b-c566af9b221b">Allogene Therapeutics, Inc.</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YTFiODIwZmU3MmFhNDA1YmFlYjMyMTRlMDg1OTdlNzYvdGFibGVyYW5nZTphMWI4MjBmZTcyYWE0MDViYWViMzIxNGUwODU5N2U3Nl8wLTAtMS0xLTM4MzQz_16f09e21-6b35-49eb-b411-7a78d93e5da6">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YTFiODIwZmU3MmFhNDA1YmFlYjMyMTRlMDg1OTdlNzYvdGFibGVyYW5nZTphMWI4MjBmZTcyYWE0MDViYWViMzIxNGUwODU5N2U3Nl8wLTItMS0xLTM4MzQz_e4dca1a3-9e67-44bc-bf6f-51b40570cc55">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzEy_1615e505-66d2-4dbf-b921-05d19adde96e">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE1_e3f48eef-545d-408c-894a-35205344db7b">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzEz_66f6f547-c157-4a6f-96ce-ca929c810d28">California</ix:nonNumeric> <ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE2_8e2adc5d-dfa8-48dd-8c2b-7faf5a6fbf0c">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV83MTI_172bab56-ee7b-4138-9110-d42daeb29ea5">650</ix:nonNumeric>) <ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE0_f266a9a8-4204-4dd2-82c2-54cd81a8b784">457-2700</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Former name, former address and former fiscal year, if changed since last report)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YzhmZjNhOTU3YjM0NDhiY2FkMTc0YjdjYThjNDY4M2MvdGFibGVyYW5nZTpjOGZmM2E5NTdiMzQ0OGJjYWQxNzRiN2NhOGM0NjgzY18xLTAtMS0xLTM4MzQz_2dc2c1f5-c63f-465b-ac51-a518da7b6046">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YzhmZjNhOTU3YjM0NDhiY2FkMTc0YjdjYThjNDY4M2MvdGFibGVyYW5nZTpjOGZmM2E5NTdiMzQ0OGJjYWQxNzRiN2NhOGM0NjgzY18xLTItMS0xLTM4MzQz_dcf4d226-6abd-46d2-9bc4-66a7ba00de6a">ALLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YzhmZjNhOTU3YjM0NDhiY2FkMTc0YjdjYThjNDY4M2MvdGFibGVyYW5nZTpjOGZmM2E5NTdiMzQ0OGJjYWQxNzRiN2NhOGM0NjgzY18xLTQtMS0xLTM4MzQz_9f5db61c-7dbd-453b-9b02-414d7384dffc">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzI1_df043de1-229f-4b47-b6de-3f54a976b21b">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE3_9022b18d-e775-4a77-a1fd-2dd70158bca3">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6MmI4ZGI2OTNiOWZiNDQ1MzgyZmM4MjJjNzEyNzZmMTcvdGFibGVyYW5nZToyYjhkYjY5M2I5ZmI0NDUzODJmYzgyMmM3MTI3NmYxN18wLTAtMS0xLTM4MzQz_5cec9b27-0929-4354-bb85-b2311d4d577c">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6MmI4ZGI2OTNiOWZiNDQ1MzgyZmM4MjJjNzEyNzZmMTcvdGFibGVyYW5nZToyYjhkYjY5M2I5ZmI0NDUzODJmYzgyMmM3MTI3NmYxN18xLTQtMS0xLTM4MzQz_ed251bbb-fe9d-4adb-9530-4e2ed7d706e6">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6MmI4ZGI2OTNiOWZiNDQ1MzgyZmM4MjJjNzEyNzZmMTcvdGFibGVyYW5nZToyYjhkYjY5M2I5ZmI0NDUzODJmYzgyMmM3MTI3NmYxN18yLTEtMS0xLTM4MzQz_7d9bb09f-8d2e-4f3c-8286-29dc80235771">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#9744;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE5_33dd9c14-1c73-4f42-8af3-ce1e386bdf60">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span><br/></span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of October&#160;31, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i0782ce963cba40ac97e2f2e475fbde26_I20221031" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMjQz_d6f10165-fb95-48f5-9ac6-4e440ce9c813">144,210,154</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page no.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_10">PART I:</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_19">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_22">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_70">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_70">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_97">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_97">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_97">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_100">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_100">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_100">32</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_103">PART II:</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_103">OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_106">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_106">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_106">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_109">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_109">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_109">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_112">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_112">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_112">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_115">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_115">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_115">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_118">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_118">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_118">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_121">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_121">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_121">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_124">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_124">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_124">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_127">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iad69808f292f43f6bbc63337efb1d90e_127">74</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I: FINANCIAL INFORMATION</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMy0xLTEtMS0zODM0Mw_801a670a-c699-409d-958a-f5530cf2bcb0">74,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMy0zLTEtMS0zODM0Mw_70c41522-cc1a-4b9b-993c-8c5196417aa1">173,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNC0xLTEtMS0zODM0Mw_588ac64c-73d3-4ddf-9e6f-53ce2d1eb4fe">477,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNC0zLTEtMS0zODM0Mw_0be2bb55-3755-409c-913b-476cff29cd17">283,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNS0xLTEtMS0zODM0Mw_2d7a46a5-3220-446c-af6e-df2a985dc8e4">16,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNS0zLTEtMS0zODM0Mw_55e9e4cb-53ed-4048-97c6-89e0e59863b2">14,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNi0xLTEtMS0zODM0Mw_e32cc850-2675-4028-ab25-0e4d2aede48f">569,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNi0zLTEtMS0zODM0Mw_636e2eba-fdd7-4fc2-a6e5-35a52a5225b3">471,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNy0xLTEtMS0zODM0Mw_3147246b-c08e-4e75-93d5-401280face62">85,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNy0zLTEtMS0zODM0Mw_71241424-43ab-4d92-a6ce-77a180408b03">352,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfOC0xLTEtMS0zODM0Mw_63b64c55-803a-470a-9149-ffe4def53fe2">85,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfOC0zLTEtMS0zODM0Mw_a55b49d4-a577-411e-8303-85ebb730236f">58,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfOS0xLTEtMS0zODM0Mw_e1e2ebe2-213d-4beb-a413-d2ca37de51d4">114,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfOS0zLTEtMS0zODM0Mw_f2c201a8-cea5-4a64-8b1e-a0246d1c80cc">122,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTAtMS0xLTEtMzgzNDM_004bcc86-7913-493c-bee9-0a01bb3b966e">10,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTAtMy0xLTEtMzgzNDM_b945f89b-cac0-4b4e-95e3-399d961752ad">10,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTEtMS0xLTEtMzgzNDM_aa652073-fea7-4d91-baf7-6ed1c4ab3d95">9,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTEtMy0xLTEtMzgzNDM_67a50cb3-f3ab-4825-9714-de3b1debbb50">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTItMS0xLTEtMzgzNDM_2afefa32-38dd-41a2-88d8-9d9ce4f6a293">14,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTItMy0xLTEtMzgzNDM_b6707882-fcf6-4066-9668-76500ee691df">18,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTMtMS0xLTEtMzgzNDM_313af2ad-6319-4841-81c9-0e6c088d0971">887,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTMtMy0xLTEtMzgzNDM_889efd0d-2847-42f1-8e0d-7c6b9d5d2c76">1,038,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTYtMS0xLTEtMzgzNDM_eecdf4f3-cd65-4441-839f-7b120306d8ff">11,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTYtMy0xLTEtMzgzNDM_45e06c86-8131-4ee3-ae41-917673482e46">10,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="allo:AccruedAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTctMS0xLTEtMzgzNDM_48388e6f-e0cf-4ad4-86f6-b44bd9824c13">36,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="allo:AccruedAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTctMy0xLTEtMzgzNDM_49bf68aa-ad6f-4fc3-800a-0c474af30eaa">37,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTgtMS0xLTEtMzgzNDM_c7fec969-34e4-40ff-aba2-cb7d80002639">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTgtMy0xLTEtMzgzNDM_001249ce-b25a-4ec7-9ff0-e171a23b3fc3">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTktMS0xLTEtMzgzNDM_95837fe6-b207-4e57-9dae-0fb80a66daeb">48,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTktMy0xLTEtMzgzNDM_093174a5-33b0-4ea1-8cfb-4adf843b5624">48,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjAtMS0xLTEtMzgzNDM_27d84ebd-9ffc-4910-8db6-68aebb32e270">96,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjAtMy0xLTEtMzgzNDM_6d2e6dc8-5f1c-4329-90a8-d9c7c0338f04">69,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjEtMS0xLTEtMzgzNDM_af381973-55b1-4a27-a26d-d6ff93b75a73">2,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjEtMy0xLTEtMzgzNDM_0f99c5b2-2e1a-4d9e-ae8b-00c3b3abe1f2">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjItMS0xLTEtMzgzNDM_68187c54-252e-4d0d-87f2-00d0deef4c06">147,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjItMy0xLTEtMzgzNDM_1e841012-1224-4a6e-8ec6-6600e9a6818e">122,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Notes 6 and 7)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjMtMS0xLTEtMzgzNDM_becf93cb-5a65-4f91-a115-7ae5b936a561"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjMtMy0xLTEtMzgzNDM_0c977842-8945-4a11-b309-438463fe2026"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml8yMQ_c0d5ed3c-e6bc-49d8-86fa-cae5dbf2a483"><ix:nonFraction unitRef="usdPerShare" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml8yMQ_c33e9cc0-8e82-4fe2-9e31-9c25c27545ef">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml8zNQ_0cc1e859-6333-4401-9a1d-153dd9fbf1fb"><ix:nonFraction unitRef="shares" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml8zNQ_731caa5f-b755-484e-8644-bf704bdec1d4">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September 30, 2022 and December 31, 2021; <ix:nonFraction unitRef="shares" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml85OQ_456c9786-b7d4-44e5-b804-d16efadf91bf"><ix:nonFraction unitRef="shares" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml85OQ_b205d5cf-9626-47bc-b313-dbfa6ae17aa5"><ix:nonFraction unitRef="shares" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml85OQ_b91398ab-a5eb-4413-a51c-b57dd4661bfd"><ix:nonFraction unitRef="shares" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml85OQ_f4734302-5542-4ec6-9738-31411683201d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of September 30, 2022 and December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMS0xLTEtMzgzNDM_75fef5bb-20f7-42b0-9cb0-34c9548e93ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMy0xLTEtMzgzNDM_fb9063d0-50f2-4d6a-bfff-729420fdcc34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xOA_6eac5942-623b-4185-bcb1-7423e7f87338"><ix:nonFraction unitRef="usdPerShare" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xOA_e2541893-9b82-4d9a-99b7-6f8f8886bdcc">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8zMg_e8434ae2-f299-42d9-bc12-ebd7883dba90">400,000,000</ix:nonFraction> shares authorized as of September 30, 2022 and <ix:nonFraction unitRef="shares" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl83Nw_30bb18d6-9cc0-4463-a3a8-b1c26c48589b">200,000,000</ix:nonFraction> shares authorized as of December 31, 2021; <ix:nonFraction unitRef="shares" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xMjM_aca6960a-0208-42ff-8bcc-665a4ff7935d"><ix:nonFraction unitRef="shares" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xMjM_fda5f1e0-545d-4e25-a106-182add89ca42">144,031,588</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xMzA_c24ca4b7-f700-4b52-b190-4fee2552898b"><ix:nonFraction unitRef="shares" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xMzA_c88814ee-0eaa-4de3-89e0-8499a011c231">142,623,065</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMS0xLTEtMzgzNDM_4b117b5c-1198-48fe-8133-b1ce169a8a23">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMy0xLTEtMzgzNDM_f9db70e3-00e2-4b4e-8ab6-774ac959ec04">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjctMS0xLTEtMzgzNDM_641758eb-e3bb-4810-81c1-90220c9988ff">1,893,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjctMy0xLTEtMzgzNDM_795838e1-cb51-4ccf-ab5d-cb7b17c48b30">1,822,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjgtMS0xLTEtMzgzNDM_ddb96c39-036a-4e4c-9349-7bdfa3b06a57">1,141,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjgtMy0xLTEtMzgzNDM_cd31e605-0bbf-438f-af94-c3d6b47b50ed">903,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjktMS0xLTEtMzgzNDM_6f9b42f2-5032-4b7a-9d05-3e1b95cf7a8c">12,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjktMy0xLTEtMzgzNDM_c87e16c4-0f87-480d-9ef4-49e61eab0b0a">2,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMzAtMS0xLTEtMzgzNDM_59aecf22-862d-48f7-942c-612bea8501f8">739,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMzAtMy0xLTEtMzgzNDM_5c033c2a-2b65-4997-8356-95793006a522">916,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMzEtMS0xLTEtMzgzNDM_ee031887-1730-4fa2-894b-b330518ce755">887,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMzEtMy0xLTEtMzgzNDM_c33e2645-8fb0-4ba6-9cfb-3329a8dcdfdc">1,038,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMi0xLTEtMS0zODM0Mw_7c3f28fc-442b-46fe-a969-41de9745ae42">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMi0zLTEtMS0zODM0Mw_e2d80ecb-cfbd-49a1-abd9-ced135bf4da3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMi01LTEtMS0zODM0Mw_ae5b05bc-d0c2-447f-9774-47328286305e">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMi03LTEtMS0zODM0Mw_ed4b9c49-39fd-4067-ae11-832a94ae7352">38,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNC0xLTEtMS0zODM0Mw_d26149e0-03c5-4e88-9ddc-f07f84ef0f8b">63,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNC0zLTEtMS0zODM0Mw_865eb2a8-a053-4ecd-a6ac-8843c9a0cf4d">58,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNC01LTEtMS0zODM0Mw_11a9fddd-ce90-4a32-a610-62460fc0bfec">180,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNC03LTEtMS0zODM0Mw_ad974330-c7c8-4334-b413-c2b48335dec6">166,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNS0xLTEtMS0zODM0Mw_528a6580-46a9-4d03-9a8a-f3e5455a12b1">18,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNS0zLTEtMS0zODM0Mw_58caea82-efe8-4205-b865-8d095afd68b1">18,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNS01LTEtMS0zODM0Mw_676f3a87-7feb-47d3-82f9-d252f1c7fbee">58,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNS03LTEtMS0zODM0Mw_d281ea3c-f8cb-4136-8534-058606f31abc">54,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNi0xLTEtMS0zODM0Mw_4defc37a-34ee-45d5-a539-d6f905ef3f34">82,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNi0zLTEtMS0zODM0Mw_2294dfe1-3be3-4d18-b7cb-510e4d84d8c7">77,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNi01LTEtMS0zODM0Mw_9dc5ee44-d621-4059-83a9-befc3366fcbd">239,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNi03LTEtMS0zODM0Mw_52ea863d-f63f-4656-9030-8ec8f7a89a20">220,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNy0xLTEtMS0zODM0Mw_c6f7f332-77bc-4b40-8c2a-f4864e67528a">82,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNy0zLTEtMS0zODM0Mw_676159d4-a361-49d6-948d-a122804daa1a">77,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNy01LTEtMS0zODM0Mw_8ef7065f-ff4f-451e-a1ff-6dfd5deaa6ca">239,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNy03LTEtMS0zODM0Mw_00aacdd3-01d6-4d15-942e-f7231664a9d4">181,899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfOS0xLTEtMS0zODM0Mw_48a53041-caa5-4f25-bc58-006a403a7bfd">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfOS0zLTEtMS0zODM0Mw_0485b00f-58ba-4f2e-96af-083e50553217">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfOS01LTEtMS0zODM0Mw_3d18867d-9be8-478f-af59-7b86e2453b14">1,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfOS03LTEtMS0zODM0Mw_9c6e2abe-a13c-4a85-b228-0326773d225d">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTAtMS0xLTEtMzgzNDM_21dca4e4-2c22-453b-aa6a-8fb5f62d2b24">1,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTAtMy0xLTEtMzgzNDM_0ea2692a-a71d-4ae6-8b21-c59b02288b70">909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTAtNS0xLTEtMzgzNDM_8e21bb2e-89bb-48ea-8681-ce4da42aa32b">519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTAtNy0xLTEtMzgzNDM_cc64e808-0838-4cad-9a02-e92286fd38f8">1,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTEtMS0xLTEtMzgzNDM_4ae8f7f4-32d6-4f8c-ad07-c055ec79bdd1">659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTEtMy0xLTEtMzgzNDM_375e5e7a-ee65-4bd1-9902-056680d5eb8a">516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTEtNS0xLTEtMzgzNDM_2bddd2a0-7159-47d6-bedb-0959e58911ea">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTEtNy0xLTEtMzgzNDM_2687f901-3057-4e10-a6a1-3f9df8db8137">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTItMS0xLTEtMzgzNDM_bf287306-f171-49e2-a1c3-cadee2aca150">83,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTItMy0xLTEtMzgzNDM_82130f46-a9a8-4e4a-9faf-3925e6d6c3e3">78,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTItNS0xLTEtMzgzNDM_61fff86e-2abc-4d51-8a17-bd302c3bbe4b">237,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTItNy0xLTEtMzgzNDM_9e935801-2083-4968-8b80-3329973e7cd6">182,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTQtMS0xLTEtMzgzNDM_df3b76b8-7f27-43ad-8727-852bb3a115cc">1,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTQtMy0xLTEtMzgzNDM_d43238aa-5bf8-4aec-807b-6f83d2c72b1c">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTQtNS0xLTEtMzgzNDM_0c29a7d7-c65b-4927-a8cb-ca6732423d9b">10,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTQtNy0xLTEtMzgzNDM_05c38180-7e51-4097-898f-e1232cfb17af">666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTUtMS0xLTEtMzgzNDM_ba0b95ab-857d-41d7-9501-d7de713e75b1">84,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTUtMy0xLTEtMzgzNDM_5174755d-3dbc-4efe-af53-d8d67aa40b51">78,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTUtNS0xLTEtMzgzNDM_ff757873-f6aa-49f1-9b0f-0bdc1b728696">248,176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTUtNy0xLTEtMzgzNDM_79a0c2e5-29c6-4fce-9417-662bebe3b50c">182,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtMS0xLTEtMzgzNDM_cf2788e1-c4ee-48fb-bfd8-01bdb4f651f5"><ix:nonFraction unitRef="usdPerShare" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtMS0xLTEtMzgzNDM_e3198f39-847e-4db6-80b6-c218e6b195ce">0.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtMy0xLTEtMzgzNDM_79658dbb-f35b-489d-b692-25785d4aa9f6"><ix:nonFraction unitRef="usdPerShare" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtMy0xLTEtMzgzNDM_b4c9fb0b-10bd-4764-acb0-55052b09f980">0.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtNS0xLTEtMzgzNDM_958916e7-7234-4dba-8851-59d823328030"><ix:nonFraction unitRef="usdPerShare" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtNS0xLTEtMzgzNDM_d2d472ed-0132-48b4-9396-6932f664c5a0">1.67</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtNy0xLTEtMzgzNDM_baf9c3ad-d448-49c1-b7a3-f166af4c3784"><ix:nonFraction unitRef="usdPerShare" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtNy0xLTEtMzgzNDM_cd220fd0-729a-447b-bf33-434e2beda2b3">1.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in computing net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctMS0xLTEtMzgzNDM_8c326c88-5699-4f9c-8e12-90610a5e310b"><ix:nonFraction unitRef="shares" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctMS0xLTEtMzgzNDM_97cc9aae-7b95-44e7-b55d-04f4d6abcd27">143,661,721</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctMy0xLTEtMzgzNDM_6ccdee17-94a0-4eb2-8e51-38c168ecff13"><ix:nonFraction unitRef="shares" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctMy0xLTEtMzgzNDM_e01b3850-6be4-4965-a7fe-8647dfb8d72f">137,025,698</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctNS0xLTEtMzgzNDM_99c4b472-2be1-437d-93cc-b07d285e6a23"><ix:nonFraction unitRef="shares" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctNS0xLTEtMzgzNDM_d5a84cab-adba-4cb2-be94-89bf67dc5f64">142,809,469</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctNy0xLTEtMzgzNDM_2fe66ecc-64d4-4356-bd8a-fb5115a2e335"><ix:nonFraction unitRef="shares" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctNy0xLTEtMzgzNDM_3701c443-7d19-4f97-8aa2-6d84050d5b1b">134,690,310</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.890%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia16e1786ad8b4304b2dea68bd40ec715_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi0xLTEtMS0zODc2Ng_63cfb356-77af-4b5a-b905-2db7028a22e1">142,623,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia16e1786ad8b4304b2dea68bd40ec715_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi0zLTEtMS0zODc2Ng_81a9e926-62f1-4ac3-83b8-a40ae3b9e454">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2768721624b646e4b4102030fc534111_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi01LTEtMS0zODc2Ng_7f6b648c-2232-477c-90a7-a60754536183">1,822,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62204640c1dd4c7e84683bae3464411b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi03LTEtMS0zODc2Ng_b46cdf0a-860c-4145-99b7-d8528fd80bce">903,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90fc78fa954a4298bce5f60606ef9a4e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi05LTEtMS0zODc2Ng_ddcf9411-e5d5-4c1d-be06-a22c7b786b61">2,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi0xMS0xLTEtMzg3NjY_170eead4-3e14-4ec3-a27b-3bf0dec9fb3b">916,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idab67126ce664974bc2dd9963d5c3ba0_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMy0xLTEtMS0zODc2Ng_9384444b-a4a6-46d0-ab85-94cc5d859903">715,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab67126ce664974bc2dd9963d5c3ba0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMy0zLTEtMS0zODc2Ng_fc29fba1-7d43-4c62-9e4c-1cfedbecb529">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMy01LTEtMS0zODc2Ng_a4ae9fcb-558b-4329-b42c-ec9a28f2d5c7">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMy0xMS0xLTEtMzg3NjY_e00702df-3512-4fda-bb09-c42474718b83">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNC01LTEtMS0zODc2Ng_022de0f7-5d9c-41bb-96b0-5458e7b99b0e">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNC0xMS0xLTEtMzg3NjY_3b3eeeb8-a447-4f3a-a4d0-5602ae067c44">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNS01LTEtMS0zODc2Ng_4df1d782-ad47-4fd6-8f97-8270e83e8c6e">22,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNS0xMS0xLTEtMzg3NjY_bf967e9d-fbf8-44e9-89cb-ed664f6ce33b">22,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idab67126ce664974bc2dd9963d5c3ba0_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNi0xLTEtMS0zODc2Ng_432f174e-a1dc-47fa-8d76-7905118825d8">230,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNi01LTEtMS0zODc2Ng_ac7e1670-3a2f-4cef-88f2-f38d48ed9b8a">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNi0xMS0xLTEtMzg3NjY_c9ffe7c1-593f-4199-a80e-22be09e1f3ed">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i660319721ce344d8a0b9154850955702_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNy03LTEtMS0zODc2Ng_6a3ba58c-c0b3-4341-ab93-74162f678af3">79,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNy0xMS0xLTEtMzg3NjY_27853ef2-464a-4694-bbbd-060309a01ead">79,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i568599dba7e143dfae2ed582eab3cff3_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOC05LTEtMS0zODc2Ng_a536bad7-7433-486e-aae2-3b9b9e5397b9">6,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOC0xMS0xLTEtMzg3NjY_be3536c4-4055-4e9d-b906-75a834ee9c64">6,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c2e5335e0bc41c785958fd6330aacc7_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS0xLTEtMS0zODc2Ng_d770bd41-9868-4e40-9ee5-0ec3fd7b8282">143,569,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2e5335e0bc41c785958fd6330aacc7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS0zLTEtMS0zODc2Ng_d9aeb180-6757-4925-8e4a-a7ad89e483e6">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328d6792e081436fa76276a9678f424c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS01LTEtMS0zODc2Ng_445bca50-33e5-4e81-9511-a9dd14ce6e7a">1,847,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0adaff1a464431da2afd3e58a0fc274_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS03LTEtMS0zODc2Ng_78cc6048-1f49-4acb-a99f-eb40b381c2ed">983,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic900f2b82bd74b6ab94b987c5117fc3a_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS05LTEtMS0zODc2Ng_0eab4895-fb72-48c4-ab50-1e52f05c4196">9,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c5743ca8a348359d46ddb287076e9d_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS0xMS0xLTEtMzg3NjY_dfc10d45-6a6b-446c-b813-c38ba055c8b6">855,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of RSUs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67020356c6204f40b4841f871a50d053_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTAtMS0xLTEtMzg3NjY_ec6d69e9-8621-424b-8422-5d63e3306430">153,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67020356c6204f40b4841f871a50d053_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTAtMy0xLTEtMzg3NjY_2d53ca3b-4d6d-4fd1-b645-995e04d8f93d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ea312ec5214b9caacbbb7ac02ee5ff_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTAtNS0xLTEtMzg3NjY_9c33bc7b-0bf0-4255-8aef-882707076825">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTAtMTEtMS0xLTM4NzY2_c07f5c65-298e-4393-80e2-ff3101253997">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ea312ec5214b9caacbbb7ac02ee5ff_D20220401-20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTEtNS0xLTEtMzg3NjY_5645f377-dda6-4f7e-b9aa-1b6f9e9b2900">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTEtMTEtMS0xLTM4NzY2_341639a2-1c58-42cf-a1ae-f64592c6ed92">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ea312ec5214b9caacbbb7ac02ee5ff_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTItNS0xLTEtMzg3NjY_dffac374-4a4c-4c2d-93ec-d801603b02ee">22,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTItMTEtMS0xLTM4NzY2_aec5c181-e7cb-4700-bd32-2f89214b6c2a">22,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTMtMTEtMS0xLTM4NzY2_083ebb50-4cfd-426f-a306-86b45329b799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b1e6139112545ef9da1ebd8710ab2f1_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTQtNy0xLTEtMzg3NjY_a77e1ea8-5c46-4a6c-ba4a-4271f5950c30">74,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTQtMTEtMS0xLTM4NzY2_559b876b-1ec9-4fe4-98bd-a4bb552f1ad4">74,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1e087f2a6e34ff89eb1651f147dcc07_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTUtOS0xLTEtMzg3NjY_a43c8797-93f1-4243-b76d-b1088a15ac8b">2,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTUtMTEtMS0xLTM4NzY2_6c3a554e-6ecf-4325-a4fb-f56c9061a9e8">2,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53bc2cfd3e704820a725a843f0e2fdf8_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtMS0xLTEtMzg3NjY_f9549b6a-affa-4833-b495-917407ff8604">143,723,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53bc2cfd3e704820a725a843f0e2fdf8_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtMy0xLTEtMzg3NjY_ac7374ff-9a2b-451b-a498-c07ad75229d6">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666c9e4e34704eb890ea456c2f944a0d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtNS0xLTEtMzg3NjY_1a1b3c60-4061-4f4a-8e3e-ad86bb4f94db">1,871,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25f5c9a7d2bc4d3ca5014da4f40097b1_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtNy0xLTEtMzg3NjY_5f4fd556-327a-44e6-b2db-a2a2b1cfe592">1,057,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00e354ae71e34ceea20c3c9ba63e8763_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtOS0xLTEtMzg3NjY_7ad63d10-2e4e-4e85-9ff5-fd262ebee8e2">11,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45581b958f3f4670b5c86820707bb668_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtMTEtMS0xLTM4NzY2_105fa0ba-3551-41ec-ad2b-0c0af33e6ecc">801,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if440df8de9ff4378a42f14411ea24199_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTctMS0xLTEtMzg3NjY_d36e2120-5690-4a14-bac4-2fab951ccb65">177,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTctNS0xLTEtMzg3NjY_38fbef60-edf5-4d1c-a90a-60c53ad25e03">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTctMTEtMS0xLTM4NzY2_e31c76cd-878d-4cff-b965-3c080b59f10d">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTgtNS0xLTEtMzg3NjY_52e1dad7-3fdc-489e-a34d-7ecdbd7726e5">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTgtMTEtMS0xLTM4NzY2_af9e5a27-bb70-40e9-927d-379d837ec046">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTktNS0xLTEtMzg3NjY_a31d6639-07d4-41f3-b76f-ee13f9610b07">21,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTktMTEtMS0xLTM4NzY2_593567ef-d77f-499a-97aa-5a92791deeee">21,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if440df8de9ff4378a42f14411ea24199_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjAtMS0xLTEtMzg3NjY_3400a7cc-34c0-477c-a9ea-542ffd189f10">130,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjAtNS0xLTEtMzg3NjY_b87c4915-85f5-4c1d-9be5-abc2d8da0b5a">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjAtMTEtMS0xLTM4NzY2_05946377-3e0a-4696-96c7-03bb6f08d439">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice884c5236d74ae4aed903a5266a526b_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjEtNy0xLTEtMzg3NjY_4d225eac-5526-40a1-86d3-62fd7bce8bff">83,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjEtMTEtMS0xLTM4NzY2_e901d96c-3821-4b62-8627-066ce1bca989">83,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ed3bf5b05643c09d7e7b6060b8df59_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjItOS0xLTEtMzg3NjY_965ee2bd-32b6-49a2-a91a-e523f5c83e38">1,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjItMTEtMS0xLTM4NzY2_f5a1eeb5-acf6-44b9-9eab-384cf5f9d9a6">1,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29d45c7d7a79444cbab51b762db8a92a_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtMS0xLTEtMzg3NjY_5d782182-39a2-40f9-b893-5104454251fc">144,031,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d45c7d7a79444cbab51b762db8a92a_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtMy0xLTEtMzg3NjY_21c8d871-7e07-4bdc-8cb5-3d13da1b2515">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e40da32cd9649fda45dd94c8886a401_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtNS0xLTEtMzg3NjY_c21b5bda-b1c2-491b-927c-f636bf568ad2">1,893,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52a77f5cfce4da693d48878535ff579_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtNy0xLTEtMzg3NjY_239c4dd1-cd4d-4cf3-8da9-90740b871afc">1,141,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7e4663ddd5e4d3fb00c03d8227b3e83_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtOS0xLTEtMzg3NjY_e1c1cce6-0b39-409e-92d5-91ef3d87721a">12,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtMTEtMS0xLTM4NzY2_9d4edd1a-24d3-4796-9bf5-794854c2d0b0">739,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.890%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fc217acd2be43718fb7e4ed4c014def_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi0xLTEtMS0zODc4Mg_4d8972cd-27ef-4e9d-90cd-dd235bee52ae">140,474,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc217acd2be43718fb7e4ed4c014def_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi0zLTEtMS0zODc4Mg_b16d5c39-fd6b-4bc9-a690-4bc8b2533653">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3533121d864f4c0583c7555923834700_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi01LTEtMS0zODc4Mg_20cb49b6-e364-4eef-8f38-de9598e0fd8d">1,725,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8448819002f446acb79abaf404098bfb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi03LTEtMS0zODc4Mg_3a85a4be-d43f-44e5-9e98-71968bac8f00">646,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0e6ec7e054c1da14d802766b50abf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi05LTEtMS0zODc4Mg_904ecfa3-59bb-47f5-8137-37024a23fbf9">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibefeee67a5174cca8fc8c95afe569cb8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi0xMS0xLTEtMzg3ODI_730a2245-0c24-4ae1-a4ba-14d8940a3827">1,079,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27bc23f568da4811a9958f2effaa11a7_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMy0xLTEtMS0zODc4Mg_f3adc966-3804-4ec3-9c88-052c68e84054">897,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27bc23f568da4811a9958f2effaa11a7_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMy0zLTEtMS0zODc4Mg_687a0bcd-8662-4944-b6f3-f2e81fec849d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMy01LTEtMS0zODc4Mg_df995052-7dca-4d34-9909-140b7fe54b92">4,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMy0xMS0xLTEtMzg3ODI_c2e08ac3-3c91-4cef-bd59-2b3f4702cc53">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNC01LTEtMS0zODc4Mg_e9abd7d3-63a9-4faf-949f-a6cd871e8fc2">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNC0xMS0xLTEtMzg3ODI_3dc38bd8-b22d-4420-8e40-a619252255a4">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNS01LTEtMS0zODc4Mg_90932875-e608-4c29-97d0-7f490e82c754">16,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNS0xMS0xLTEtMzg3ODI_56681308-d2ed-45b8-b86c-d4e101d78132">16,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27bc23f568da4811a9958f2effaa11a7_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNi0xLTEtMS0zODc4Mg_3e1c83cf-b7f4-4bcb-a995-7e386e344c6c">98,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNi01LTEtMS0zODc4Mg_7abd7f3d-dad5-46be-8b3c-3289cd3ad350">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNi0xMS0xLTEtMzg3ODI_3ca10999-69a7-458d-b790-5c61eeddad03">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52c6c38d96b3496c83a3c3f4292c5f08_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNy03LTEtMS0zODc4Mg_5f09d0eb-f39d-43e6-93fe-61587abdb30a">33,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNy0xMS0xLTEtMzg3ODI_8313ba3a-4306-4655-91ed-206ac76dba1b">33,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60949035a3624cc68a5f08899693ed89_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOC05LTEtMS0zODc4Mg_d6fc7055-91a7-4aa1-9829-3171004b5816">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOC0xMS0xLTEtMzg3ODI_781b329a-c52a-4975-801a-03c2f553c57a">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3285731b68de4e41ad0c1865ada7997c_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS0xLTEtMS0zODc4Mg_14a74129-3b14-4fdb-8e37-3f421f6b3d66">141,470,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3285731b68de4e41ad0c1865ada7997c_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS0zLTEtMS0zODc4Mg_57cd33f0-6d8b-458b-8156-05717e824304">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36b261d41d814a7cb5646538703fecb1_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS01LTEtMS0zODc4Mg_34ed6594-cfad-45e0-b9af-d049ca646956">1,749,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i656fbffbeb434eb49eeae23b018e4fe7_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS03LTEtMS0zODc4Mg_a66395da-c3ac-4258-a372-c531bb5b12ff">679,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93a49ed55a0642638b964d93a55082ef_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS05LTEtMS0zODc4Mg_f65f87c8-0bdf-4f6a-85a9-80cd03277b2b">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027d2deea89848eba3b25676ffe40a68_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS0xMS0xLTEtMzg3ODI_42b7cd2a-38b3-4900-a087-c9b66af93d00">1,069,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of RSUs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3c3681993a340ce9e153807ca820af8_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTAtMS0xLTEtMzg3ODI_4c4c6e7c-e4cf-4ba0-9d52-245f0854b566">650,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3c3681993a340ce9e153807ca820af8_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTAtMy0xLTEtMzg3ODI_c3cdd465-7b2b-4f6b-9615-b9d8c74c6407">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a08f54165449009616a55b4debdf18_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTAtNS0xLTEtMzg3ODI_af5305ab-2b0e-4c62-8d68-12ca656db7c7">3,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTAtMTEtMS0xLTM4Nzgy_aaf61626-b244-486c-8843-13b0273e8c43">3,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a08f54165449009616a55b4debdf18_D20210401-20210630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTEtNS0xLTEtMzg3ODI_96ef8838-03a0-4430-988f-5879f476b8dd">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTEtMTEtMS0xLTM4Nzgy_38a9302b-5d68-4a99-9976-e7c48e7a6166">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a08f54165449009616a55b4debdf18_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTItNS0xLTEtMzg3ODI_de7a1f9e-02ed-4326-a4d7-7bf4369394eb">21,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTItMTEtMS0xLTM4Nzgy_48cc2767-e8e9-4281-a27e-94f473bf0bd0">21,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTMtMTEtMS0xLTM4Nzgy_ac71aa4d-50ce-4eee-a220-5a2ae0bd20ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1192f2bcfd174e4e87c6a48a6b229311_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTQtNy0xLTEtMzg3ODI_997a750a-eaf0-4bed-a3c2-b086ebe2f9d8">70,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTQtMTEtMS0xLTM4Nzgy_f87d3a30-5f53-4b43-a3c1-b1a5440040f3">70,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b441d0ab9104d6f906ea50fc1740b98_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTUtOS0xLTEtMzg3ODI_64e94043-e2b0-42db-ac1e-8630a0e930cc">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTUtMTEtMS0xLTM4Nzgy_8bf8f975-6ef8-4bb0-8d3b-0debe83cab0b">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1ced53064cd42a28878d18228552b20_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtMS0xLTEtMzg3ODI_e171da23-7f9b-4217-afe8-4a26c6d26305">142,120,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ced53064cd42a28878d18228552b20_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtMy0xLTEtMzg3ODI_628c3414-5d51-4e83-8b83-b5506f972121">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9545d58a43c140a2a6a71474a6ee1920_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtNS0xLTEtMzg3ODI_4c25de49-8076-499f-819e-9930b1dbeb39">1,774,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia77b5caccc864c93a8578007ada8f202_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtNy0xLTEtMzg3ODI_53f71ed2-0f7e-4235-a8c2-d9546dc9dfee">750,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i470e7ef6e8484f10a411d5c0a26a3342_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtOS0xLTEtMzg3ODI_715437f4-d072-48a1-8149-77395d1fc9dc">334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970726c2db304fcbb4d9a0c045073a76_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtMTEtMS0xLTM4Nzgy_c99c1bb7-2df4-45de-bc0a-aa5f8735f9f3">1,023,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66f164bd81e042c9bdbbf51049d8b187_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTctMS0xLTEtMzg3ODI_a751fc46-c3b1-4600-8211-bc0ab5e35f54">229,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTctNS0xLTEtMzg3ODI_19b8dcde-952f-4544-9128-db09c302a27b">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTctMTEtMS0xLTM4Nzgy_8aaeb8fb-7bdb-4107-b515-5bdd511cb8c5">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTgtNS0xLTEtMzg3ODI_a468d556-4ff1-40c4-aad5-fdd9359e8e38">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTgtMTEtMS0xLTM4Nzgy_501212f7-aaa5-46b4-b62b-5a62ae4d2bfe">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTktNS0xLTEtMzg3ODI_2dce8238-797d-4707-ac6d-10eb90a7be7c">20,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTktMTEtMS0xLTM4Nzgy_2b82cd82-770f-41d4-ab81-91a0d6a66b26">20,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66f164bd81e042c9bdbbf51049d8b187_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjAtMS0xLTEtMzg3ODI_ed7e6a1b-ee46-4783-b254-4298aac27ec2">89,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjAtNS0xLTEtMzg3ODI_06f5e595-c018-4d24-9786-94171cca5f12">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjAtMTEtMS0xLTM4Nzgy_b3dc893a-3f87-415b-83e7-83fbd4b8f4b5">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2793cc8b4294f6aa53a79a343ce1cd5_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjEtNy0xLTEtMzg3ODI_be506cb9-6757-49c2-bbf1-2f88b5276b84">78,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjEtMTEtMS0xLTM4Nzgy_feef81a5-b240-4a81-9310-b828186d43ff">78,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie199bf4d5f3d4388984d9af23f496b4a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjItOS0xLTEtMzg3ODI_69ea448a-2425-4a43-9850-72abc67f6947">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjItMTEtMS0xLTM4Nzgy_d34e38ec-6b0f-429b-9848-de22588b7cb8">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e8df77f75814bb3bd276293c61def27_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtMS0xLTEtMzg3ODI_f0b3636b-45ca-42f3-bd64-42afdb61fdbe">142,439,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8df77f75814bb3bd276293c61def27_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtMy0xLTEtMzg3ODI_7b472dd1-cc89-4ae1-9f19-87a539df9453">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ff97a82a1149f0a766b4dd2aeb2039_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtNS0xLTEtMzg3ODI_c59460ab-6d28-411c-b23d-ca2d28a625d6">1,798,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44eb82ada8fc4b7aac17b9def190f34b_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtNy0xLTEtMzg3ODI_af9faf6b-7cb8-4adf-94fe-68c4f32d700f">828,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66c9685093544f8e9743c24c6b40e4fc_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtOS0xLTEtMzg3ODI_76e7d0f7-bc70-439f-be76-2d32762150a2">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96730d707ea04cf892c0873970a6389c_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtMTEtMS0xLTM4Nzgy_115b2605-865c-41b8-9c2a-5a14a5c338a3">969,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMy0xLTEtMS0zODM0Mw_28c7e70b-7679-47d0-bbad-bb500d8be9a4">237,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMy0zLTEtMS0zODM0Mw_9f46dcc5-a28e-433e-9d8a-db4b4d42c0f7">182,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNS0xLTEtMS0zODM0Mw_0656494c-ae38-489f-bd0c-daf3ad1fdfd3">66,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNS0zLTEtMS0zODM0Mw_328d7caf-aa86-4130-b8dc-34d91475ac53">58,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNi0xLTEtMS0zODM0Mw_77bf2c3f-5714-4102-9a24-d706eb788974">11,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNi0zLTEtMS0zODM0Mw_342edce3-f185-4957-863a-6e73ad740c61">6,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization/accretion on investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNy0xLTEtMS0zODM0Mw_8a632ee5-267e-481b-a3a8-70c9b6ee8b44">2,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNy0zLTEtMS0zODM0Mw_cef7afe4-53b1-4721-bfab-fe5b937bb4c1">5,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfOC0xLTEtMS0zODM0Mw_bf2fc6e1-7f8e-4612-b286-194e8b121d67">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfOC0zLTEtMS0zODM0Mw_8d4419a8-04ec-407b-a049-b086a1b98d39">2,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share of loss from equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="allo:IncomeLossFromCostMethodInvestment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfOS0xLTEtMS0zODM0Mw_a0344c03-3468-426f-894c-0388ba8dd106">3,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="allo:IncomeLossFromCostMethodInvestment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfOS0zLTEtMS0zODM0Mw_b5ce206f-8896-4cf0-b73c-80ecc8c912ad">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTEtMS0xLTEtMzgzNDM_97710cee-8685-4867-b0a3-6b6eec9fc2fc">2,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTEtMy0xLTEtMzgzNDM_176e4597-f51b-499f-8ca2-0413baa97dcd">2,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTItMS0xLTEtMzgzNDM_6f05a0ba-1dfe-453c-9900-a287d04afbce">3,211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTItMy0xLTEtMzgzNDM_35411dd0-3ad4-4a97-84b7-4350f23b0e24">991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTMtMS0xLTEtMzgzNDM_6a2dc69c-db28-4230-91fb-ef546863fa66">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTMtMy0xLTEtMzgzNDM_9fbcc9c7-3a60-4100-a192-0bb17d075cba">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTQtMS0xLTEtMzgzNDM_4b39b6c0-4bbf-49b5-8145-7896a0b84fa7">1,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTQtMy0xLTEtMzgzNDM_10f61a6a-9cb8-4563-9853-a31a7ed6e74f">6,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTUtMS0xLTEtMzgzNDM_a14b369e-9501-4d6e-8bff-8a6f91e466b7">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTUtMy0xLTEtMzgzNDM_bd6f7792-1558-476c-8316-7b1513d570ec">38,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTYtMS0xLTEtMzgzNDM_8c13543e-7370-4b94-9bd6-ace07ab20f60">2,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTYtMy0xLTEtMzgzNDM_ca12d2b3-dc62-4484-a402-1aa54a36bc76">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTctMS0xLTEtMzgzNDM_614612f2-3813-42bb-bd74-79f2656588c1">158,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTctMy0xLTEtMzgzNDM_57d71e17-7107-4fb5-bc08-f015d85b23d7">139,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTktMS0xLTEtMzgzNDM_34bfb1b5-4b2b-4f82-a6ad-26afb61518dd">3,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTktMy0xLTEtMzgzNDM_5b2a0d54-c58c-4e8b-ae76-673b4771b741">20,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of stock in equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjAtMS0xLTEtMzgzNDM_1e950e39-805e-43b5-8b1f-9266a8431894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjAtMy0xLTEtMzgzNDM_52171e7f-f301-401c-b1f4-ebe3783ff833">15,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjEtMS0xLTEtMzgzNDM_f601f681-788f-4259-b39b-caec6acf3280">260,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjEtMy0xLTEtMzgzNDM_63a313ce-e441-49ef-85a4-d774203eee28">645,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjItMS0xLTEtMzgzNDM_769970e7-754c-4a0d-aedb-d8caf846e976">200,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjItMy0xLTEtMzgzNDM_5e96f7d6-5376-4392-a9b5-8f4bef23f5e5">474,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjMtMS0xLTEtMzgzNDM_572dbfff-c13a-4cb4-bacd-0ceeb16cfe01">56,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjMtMy0xLTEtMzgzNDM_c2cc0b87-2269-4896-b43b-d82b7880851d">134,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjUtMS0xLTEtMzgzNDM_c686a5e8-4f8e-4940-8b96-f0f6b7f3bf84">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjUtMy0xLTEtMzgzNDM_a656ed77-17fe-4ce9-99ec-3965475b3024">8,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjYtMS0xLTEtMzgzNDM_7d4e743f-3ddc-4a25-8c2d-0eb2643cd732">2,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjYtMy0xLTEtMzgzNDM_2430274a-e86d-4201-bee9-d33edf08a109">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjctMS0xLTEtMzgzNDM_b7056c8c-e8b8-4fc3-b9d5-afc6ef6c594a">2,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjctMy0xLTEtMzgzNDM_6eb5acfa-7f19-47c3-90dd-900e23522b5a">11,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjgtMS0xLTEtMzgzNDM_d88f7e5e-01ee-49d8-8161-12168e6ae5ca">98,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjgtMy0xLTEtMzgzNDM_fdada77e-75c7-4661-a934-b9a6cce87a24">6,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash &#8212; beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjktMS0xLTEtMzgzNDM_130e89fe-e599-430d-9624-57df910b9ed4">183,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibefeee67a5174cca8fc8c95afe569cb8_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjktMy0xLTEtMzgzNDM_4dd84f02-6cf8-4207-8184-c2150a12b327">192,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash &#8212; end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzAtMS0xLTEtMzgzNDM_013e6a44-6bfd-4b94-9d41-b6e402ba8805">84,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96730d707ea04cf892c0873970a6389c_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzAtMy0xLTEtMzgzNDM_ab061cf3-0adf-4021-b35b-7d845d51b06d">199,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzItMS0xLTEtMzgzNDM_c941c333-408d-46f6-b691-77379589ef35">31,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzItMy0xLTEtMzgzNDM_8b8e27af-66a2-4fb6-b3d1-f23068794794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzYtMS0xLTEtMzgzNDM_dce8d531-d210-47db-9184-751799a40bc6">6,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzYtMy0xLTEtMzgzNDM_eafca573-76b8-42a4-b029-360e4234daa0">4,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for amounts related to tenant improvement allowances</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzctMS0xLTEtMzgzNDM_3103417f-0622-4f8c-8152-936e41e5928b">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsForProceedsFromTenantAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzctMy0xLTEtMzgzNDM_70ab137a-9aaf-4706-8f93-0f077e776223">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_31"></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zMS9mcmFnOjFiZjJhZGViZTczZjRlYTFhMGFmZjM5NGQ1YmI1Y2YwL3RleHRyZWdpb246MWJmMmFkZWJlNzNmNGVhMWEwYWZmMzk0ZDViYjVjZjBfMjU1OA_df1f4d11-64b1-47c2-bc01-35edaf8d97fc" continuedAt="ib5dc27d566cf4472927e93e65e1097d7" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="ib5dc27d566cf4472927e93e65e1097d7" continuedAt="icceba089acb84d839f6b6ef1e5d66c8c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is an immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company had cash and cash equivalents and investments of $<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zMS9mcmFnOjFiZjJhZGViZTczZjRlYTFhMGFmZjM5NGQ1YmI1Y2YwL3RleHRyZWdpb246MWJmMmFkZWJlNzNmNGVhMWEwYWZmMzk0ZDViYjVjZjBfODky_a185f8f9-9dcb-43be-ba32-00393a15fe51">637.3</ix:nonFraction> million as of September&#160;30, 2022. Since inception through September&#160;30, 2022, the Company has incurred cumulative net losses of $<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zMS9mcmFnOjFiZjJhZGViZTczZjRlYTFhMGFmZjM5NGQ1YmI1Y2YwL3RleHRyZWdpb246MWJmMmFkZWJlNzNmNGVhMWEwYWZmMzk0ZDViYjVjZjBfOTgz_3c90995c-b47b-4d75-b494-4fb847821e4f">1.1</ix:nonFraction> billion. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). </span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icceba089acb84d839f6b6ef1e5d66c8c">The Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition and operations. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If business conditions, financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div id="iad69808f292f43f6bbc63337efb1d90e_34"></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzU5OA_1ab7e878-752f-4247-bc88-663982176484" continuedAt="ib76443b65709463781e8f88c5475b867" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ib76443b65709463781e8f88c5475b867" continuedAt="ibee72c21ed374f6f8d51b9a06120f4dc"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzU5MQ_9434650c-16b2-4dcf-9fd0-4606437db053" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of stockholders&#8217; equity as of September&#160;30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended December&#160;31, 2021, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 23, 2022.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzU5NQ_cf295076-ccc8-455f-a82b-d34c109a4a7d" continuedAt="ifd522cc8abc249b1916defb9252d2524" escape="true">Use of Estimates</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="ibee72c21ed374f6f8d51b9a06120f4dc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifd522cc8abc249b1916defb9252d2524">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</ix:continuation></span></div><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="allo:ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzYwMQ_980c2a06-7203-482a-93dd-3f257aa1effa" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the accounting policies during the three and nine months ended September&#160;30, 2022, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzYwMg_6b1bae21-eb3e-46a5-aabe-6ad76546b23a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued or effective that are expected to have a material impact on the Company's condensed financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="iad69808f292f43f6bbc63337efb1d90e_37"></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfODg3_f5a38763-7987-493b-a728-f22d0ac0cbd0" continuedAt="i384e873fc9624befa8020c787a9e4d1d" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i384e873fc9624befa8020c787a9e4d1d" continuedAt="ia92d756bcec54894aa9583340dd01026"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs including quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ie730bc1281e742289f7b14d42eff7b48_I20220930" decimals="INF" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfNTE4_1af78d78-56a9-41cb-964e-aa8a879b578d"><ix:nonFraction unitRef="usd" contextRef="ic59dec0676034b50b7ad0a219c00b9ba_I20211231" decimals="INF" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfNTE4_4d138bcf-1f8e-42d9-b64f-465382638db3"><ix:nonFraction unitRef="usd" contextRef="ic59dec0676034b50b7ad0a219c00b9ba_I20211231" decimals="INF" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfNTE4_df1ab980-ce90-46dd-a578-7ed6f388b1c6"><ix:nonFraction unitRef="usd" contextRef="ie730bc1281e742289f7b14d42eff7b48_I20220930" decimals="INF" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfNTE4_f2dc2491-bddb-4cbb-a9ce-e11c090a221d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> Level 3 assets or liabilities as of September&#160;30, 2022 and as of December&#160;31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="ia92d756bcec54894aa9583340dd01026"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfODg4_7a4a6e0c-b133-478b-9fe0-a33250f07eb9" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:&#160;</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d0ead330c24d62aeb2da5efcc4a64a_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNC0xLTEtMS0zODM0Mw_8a68b493-a92a-4e69-9e37-4bafd069ae12">19,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e54a3337efd4d039762b588776fa199_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNC0zLTEtMS0zODM0Mw_f0ed939a-e2a3-43cc-80ed-9f438a83b6ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0b727b1deb0471d88a053257c9a4611_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNC01LTEtMS0zODM0Mw_523074ee-1a04-4aef-b0e4-e58f5f52ef19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e1772a9a774e75a2d532c1fa03dfd9_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNC03LTEtMS0zODM0Mw_91ff7a48-8550-4a47-b1d9-55934760cef4">19,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd4d50cd1236423f81f303edc85b5416_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNS0xLTEtMS0zODM0Mw_c211334e-754a-439d-9ea9-2e5c4b1d48ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcdb27b9bd024ba9aa1c201ba5aa6171_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNS0zLTEtMS0zODM0Mw_d5f48a4c-b0dc-4fa8-a583-b16328547a4c">17,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c83b117241041978e86a79078e74505_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNS01LTEtMS0zODM0Mw_fb2addd4-f6f6-4bd6-8d12-8c1020274146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c093d5bad964a0cb856275d022daf5c_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNS03LTEtMS0zODM0Mw_a97f58a7-a2d8-4a01-8733-8e5a42ec354e">17,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e4e9b1f287486c97e5fdc273885d36_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNi0xLTEtMS0zODM0Mw_a12f61ab-d8ae-4a55-a4c1-fb0d3f3e8a07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e850a333e249b0925d51da049c0000_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNi0zLTEtMS0zODM0Mw_bf3be695-e2b8-4813-b07d-fc13751effe0">168,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80be28ab7b844ffac2c1c656f493915_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNi01LTEtMS0zODM0Mw_6ab9946d-1dc3-4111-87dd-8a23dcaaa458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b938fa488644558a07b02468cca245_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNi03LTEtMS0zODM0Mw_ddb87d09-5333-4a2d-829c-cabcc28d5909">168,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d843d66f73450085167330c08fa8f4_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNy0xLTEtMS0zODM0Mw_2d134654-ea07-4642-a5b8-cf5ecce40cb7">332,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7957a6a04a864f12ad0b9fd205fb2027_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNy0zLTEtMS0zODM0Mw_6912594e-d3e8-4eaa-89b1-9d92ac5b0fb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8d37d4b41e43ae8b50608fce513cf9_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNy01LTEtMS0zODM0Mw_0bdc19a1-a41b-499b-9027-691b0cca385b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a332d398be94f8283d48f49a486acd4_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNy03LTEtMS0zODM0Mw_0e96148f-df4b-4dbf-a9c9-8f5191907af7">332,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided01fd1fae3479a887f1df9839cb3c9_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOC0xLTEtMS0zODM0Mw_94b85661-14ee-455a-bfb3-c947d65a3dff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae16a63b5e8d410aaea9422f95a58df3_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOC0zLTEtMS0zODM0Mw_7a4492e8-0d04-4739-85df-5135505675f3">44,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6229e7a19925408a883eeb53268596c3_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOC01LTEtMS0zODM0Mw_80f69e96-bc82-4069-bff0-8b6e2fe0d303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1e9f69fd5145b2a82d1c99cf574c36_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOC03LTEtMS0zODM0Mw_671039bb-1cd0-4128-87b6-a9861c4ad46e">44,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7be2e87e35f4e328aca6856dd8c331c_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOS0xLTEtMS0zODM0Mw_1778e48c-5749-4cf5-8939-ae6cfe3b0ccc">351,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb03622518f4a8aa208f441ff5ed3e5_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOS0zLTEtMS0zODM0Mw_665b0f4e-e999-4aea-9ce0-a6f5a3701fe8">230,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie730bc1281e742289f7b14d42eff7b48_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOS01LTEtMS0zODM0Mw_5b978b47-4f75-4446-9ef3-659aaa61c796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9664a6d74d14cd2b0e6999a7746fbb3_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOS03LTEtMS0zODM0Mw_02ad9d08-3529-45a4-9b65-58a42a452b66">582,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:49.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b39ce52bb534d8ab364d55d7a5a4845_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNC0xLTEtMS0zODM0Mw_56ad2f68-72ac-4b89-8c3f-1bd32eae6f9f">115,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b26963b040c464ab654260f9b024c8b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNC0zLTEtMS0zODM0Mw_552fe46d-93b4-4dbb-97be-c0e266b8acd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9196dc684bfe4858b5edf3e1ffd737c1_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNC01LTEtMS0zODM0Mw_c8c27b22-4028-4280-a4d1-a1108ef244e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08414a6efbee44f99241e34feca223cc_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNC03LTEtMS0zODM0Mw_c0ee4776-5f6a-4771-8fc1-160afa371079">115,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21f092a53bd4a75b19b5ea1f96f0dca_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNS0xLTEtMS0zODM0Mw_e92a8f91-4498-4486-a361-2bd74c88457c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac26891f51c43f698aa0fcfa42259de_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNS0zLTEtMS0zODM0Mw_a15fd14e-e54a-4c67-9f98-76398327f417">58,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5742857dc7946a285456adb1db7f9b4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNS01LTEtMS0zODM0Mw_a8a03cc8-5d61-42ed-a6bd-eb1401e8571a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e46bf35fc4476db2f52c28e5fdfe66_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNS03LTEtMS0zODM0Mw_10343387-ae7d-452b-9aa9-ae9c21c430fe">58,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f1616b693e482bbe1bc2c39cb50669_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNi0xLTEtMS0zODM0Mw_2a5d7a02-0cad-4228-bd55-7cd163330342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc072cc86b04dd09d83c1d2c3602144_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNi0zLTEtMS0zODM0Mw_d37a00b8-2592-4028-b272-3c6d7ffc7cda">223,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d45516c51f84306a30498bb283d1dae_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNi01LTEtMS0zODM0Mw_20c0d7a1-937f-4e8f-9241-873ad5f974dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22fda346a3b44f58bf392876c6af2d7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNi03LTEtMS0zODM0Mw_7b7f3549-dc2c-4e24-97aa-306f072279a3">223,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie368da95aed94f39a8028a7fe3264ca2_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNy0xLTEtMS0zODM0Mw_d5c986ba-c811-4002-af64-6508be3a4b3d">303,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7b7966b0834b118a6dddf7f31e7efc_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNy0zLTEtMS0zODM0Mw_27f64fed-59f3-4d64-9416-577be7286c87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceda1e0793a444bfbea8f6f96fc85ca1_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNy01LTEtMS0zODM0Mw_36f6c2cb-326c-4097-8b98-67ce650bb05d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0b55b1ab65461dbc838d478634fbc7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNy03LTEtMS0zODM0Mw_97c8eb86-25a9-4932-89a3-12d3eb0acc68">303,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6f4571309a4989846c43edc13b9607_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOC0xLTEtMS0zODM0Mw_2589974f-d833-4e08-a1a1-005667cec027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba287fafeb24922afb0bd5704ca7f09_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOC0zLTEtMS0zODM0Mw_e8b64642-6de2-4c20-9594-57b26ae5e49b">50,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43eb4f2c71bd40acade960ac4537414f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOC01LTEtMS0zODM0Mw_169303dc-2671-441d-bae6-46d8cf729587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274296360e7f471b817e447bda912e0c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOC03LTEtMS0zODM0Mw_90aa988a-a1e6-46d9-a2d6-ce9a46568bcd">50,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eadb3f0fcf547ddab8ff0ef26f06f52_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOS0xLTEtMS0zODM0Mw_c592071d-5632-4ad9-a5dd-2edaf3267322">418,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a34f9b02232491b96689d6036cda254_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOS0zLTEtMS0zODM0Mw_7a8b6951-98b5-4aea-8352-ffb4822cac2b">333,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic59dec0676034b50b7ad0a219c00b9ba_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOS01LTEtMS0zODM0Mw_7e2b6718-e813-4f8c-b90b-aaa250cf48fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c3e4c35b6d4a5fa0398b1187be86ac_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOS03LTEtMS0zODM0Mw_3f4f5a82-1c0c-4100-91a7-25ffdf425704">752,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Included within cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div id="iad69808f292f43f6bbc63337efb1d90e_40"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMTMxOA_55fb60a7-46f5-43b3-89ac-35d497b0a48e" continuedAt="ibc39382d129747039c6d2587ce69f653" escape="true">Financial Instruments</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibc39382d129747039c6d2587ce69f653" continuedAt="i24fad78d3af24293a9f50d6bbf7ed396"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMTMxOQ_dea5ecaa-253b-4249-8f7d-a3a6e1c9edcb" continuedAt="i1ce7d127451145db89fe63cfe37cee47" escape="true">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:</ix:nonNumeric></ix:continuation></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="i24fad78d3af24293a9f50d6bbf7ed396"><ix:continuation id="i1ce7d127451145db89fe63cfe37cee47"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67454b2a010e4042ac9e965a1600e8a8_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMy0xLTEtMS0zODM0Mw_8119b529-7ff9-42d7-a070-fb595a8733e0">19,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67454b2a010e4042ac9e965a1600e8a8_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMy0zLTEtMS0zODM0Mw_d07fd6e3-e1ef-4352-acb5-6ebaad22b4a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67454b2a010e4042ac9e965a1600e8a8_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMy01LTEtMS0zODM0Mw_e11a4cea-d866-4c9b-9289-16a4f9437809">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67454b2a010e4042ac9e965a1600e8a8_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMy03LTEtMS0zODM0Mw_a1e313bd-2a69-46cd-bb13-f6340ee2b7cc">19,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f21a84a447d4ac69ec3d11a73e75977_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNC0xLTEtMS0zODM0Mw_c9ed3365-ee9c-4e59-81e1-5d170e708f3f">17,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f21a84a447d4ac69ec3d11a73e75977_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNC0zLTEtMS0zODM0Mw_3c0e85a3-e452-4ed6-89e6-3b10e850cdca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f21a84a447d4ac69ec3d11a73e75977_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNC01LTEtMS0zODM0Mw_8e9f408c-64ed-4614-843f-8e526bd1eb1e">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f21a84a447d4ac69ec3d11a73e75977_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNC03LTEtMS0zODM0Mw_d9cf1da9-6fa6-4ad1-9312-3337ff18d384">17,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNS0xLTEtMS0zODM0Mw_e7dc47f7-eb75-43fc-9174-76bb6790739f">172,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNS0zLTEtMS0zODM0Mw_136198c4-dee4-46fe-9747-c6a525399350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNS01LTEtMS0zODM0Mw_0882fe56-916c-4c48-a7f2-4e882a5ddb0c">3,761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNS03LTEtMS0zODM0Mw_2f4aebe1-09a1-494e-a077-04a7f13304eb">168,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNi0xLTEtMS0zODM0Mw_6ac1f5f9-525a-4e14-b18b-e380c124d7f5">339,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNi0zLTEtMS0zODM0Mw_eb496ca4-a665-4102-8b7e-75ef7781f374">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNi01LTEtMS0zODM0Mw_de072650-0c04-4be4-81f6-c0bde699500e">6,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNi03LTEtMS0zODM0Mw_371a3f2a-5895-4116-8294-293444888f9f">332,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75fdfd77e0748c8bb330bc88f7cea38_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNy0xLTEtMS0zODM0Mw_0ed438b2-5ee8-43dd-b0f4-80ac1e709386">46,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75fdfd77e0748c8bb330bc88f7cea38_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNy0zLTEtMS0zODM0Mw_4cfe6240-633a-4804-a1a6-7d9cb4a90448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id75fdfd77e0748c8bb330bc88f7cea38_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNy01LTEtMS0zODM0Mw_532d5e87-2912-4b14-8895-ad9ba6c3da6d">1,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75fdfd77e0748c8bb330bc88f7cea38_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNy03LTEtMS0zODM0Mw_3ff2faf8-5129-4297-b83f-4c43c18d1890">44,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfOC0xLTEtMS0zODM0Mw_9e82ccb9-0bbc-49c3-bc30-6d079a556c7e">594,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfOC0zLTEtMS0zODM0Mw_303b8a5f-df83-40d5-8d92-f0eb56043cee">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfOC01LTEtMS0zODM0Mw_62b7dbf9-3a38-4c31-acf3-2cd71e545d0a">12,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfOC03LTEtMS0zODM0Mw_755faf1f-736d-4b1c-ab40-53d9cad7a13f">582,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMTEtNy0xLTEtMzgzNDM_7c2c2735-e0a9-4189-a6af-a0dd4c27f9b8">19,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMTItNy0xLTEtMzgzNDM_2cc853f5-6b94-4784-9b29-6bec8bec05b2">477,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMTMtNy0xLTEtMzgzNDM_46ae0b87-4cbd-4255-afe2-361e5d0db8c0">85,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="allo:CashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMTQtNy0xLTEtMzgzNDM_6469591d-5b80-4318-b6b4-afd01632a5a4">582,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495066fc809c46088689104229f96bd4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMy0xLTEtMS0zODM0Mw_b59efb7f-13ec-47f0-a977-38535adeb8ac">115,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495066fc809c46088689104229f96bd4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMy0zLTEtMS0zODM0Mw_5833c2b8-6817-4ad0-bc32-4e0d9bbcea3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495066fc809c46088689104229f96bd4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMy01LTEtMS0zODM0Mw_210788bb-a97b-4603-8fe5-043e59035ab3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495066fc809c46088689104229f96bd4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMy03LTEtMS0zODM0Mw_f8cd23ce-a8bd-44a3-986c-331c2a35de3b">115,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc8586da0577480cb7a0240005555a9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNC0xLTEtMS0zODM0Mw_119be231-5fea-4f13-871e-31aae17664a1">58,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc8586da0577480cb7a0240005555a9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNC0zLTEtMS0zODM0Mw_80cc290c-1c6d-41e5-9db6-bf0cd8a6ee1e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc8586da0577480cb7a0240005555a9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNC01LTEtMS0zODM0Mw_92523ef2-2c85-4cc6-9d74-b4da28cafba5">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc8586da0577480cb7a0240005555a9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNC03LTEtMS0zODM0Mw_d0501603-dfdb-4272-9355-02c3029fc499">58,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bbc0838fe244d26ba01e286b31789de_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNS0xLTEtMS0zODM0Mw_ad7e7fb4-4752-42a5-b50a-888c1814b702">224,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bbc0838fe244d26ba01e286b31789de_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNS0zLTEtMS0zODM0Mw_0f0f43c8-4541-419a-87dd-105011ac9ff8">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bbc0838fe244d26ba01e286b31789de_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNS01LTEtMS0zODM0Mw_b1418c78-ab74-4bad-8016-b9e9de1c63de">647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bbc0838fe244d26ba01e286b31789de_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNS03LTEtMS0zODM0Mw_04f1d7d6-d7a0-479f-b3d3-c191940799aa">223,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2b5f01151e42a08a9681956bf850f6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNi0xLTEtMS0zODM0Mw_0e56991c-6f52-46ea-9610-b36c73e79f01">304,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2b5f01151e42a08a9681956bf850f6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNi0zLTEtMS0zODM0Mw_4c17ceec-4ce8-40b1-9c12-cf053a0647a3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2b5f01151e42a08a9681956bf850f6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNi01LTEtMS0zODM0Mw_96c7db82-e073-4e4a-9aa0-af72b40acec5">1,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2b5f01151e42a08a9681956bf850f6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNi03LTEtMS0zODM0Mw_5776c58f-c89f-4d92-be09-65e2e21a1c8b">303,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d24e7b9e4e46139098c072d28e3b8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNy0xLTEtMS0zODM0Mw_62a66028-1894-48a0-af0b-0da3d7403263">51,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d24e7b9e4e46139098c072d28e3b8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNy0zLTEtMS0zODM0Mw_8edc6bc4-68a1-4da9-a54b-6694fc2d25a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32d24e7b9e4e46139098c072d28e3b8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNy01LTEtMS0zODM0Mw_825a5423-88ab-41c2-835c-92312719dd6c">374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d24e7b9e4e46139098c072d28e3b8c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNy03LTEtMS0zODM0Mw_6431ce3e-578e-4443-ab7d-355d6a64d2f8">50,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfOC0xLTEtMS0zODM0Mw_1e5bc7b1-c7eb-486b-82aa-a26604016e32">754,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfOC0zLTEtMS0zODM0Mw_fbfcb829-ab14-4598-8761-f8ef671047af">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfOC01LTEtMS0zODM0Mw_93981a90-ad21-45fe-bbec-8c0e0e60496a">2,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfOC03LTEtMS0zODM0Mw_4d22b42e-b36a-4730-9532-7b8d19d280d1">752,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMTEtNy0xLTEtMzgzNDM_3ae5ab2d-dd4e-4d98-ad17-e8ec65d24f1a">115,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMTItNy0xLTEtMzgzNDM_d5ad9e89-5633-42d9-9c48-a73abec1885d">283,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMTMtNy0xLTEtMzgzNDM_bd34b449-915a-40f3-974c-adcbefaccb61">352,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="allo:CashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMTQtNy0xLTEtMzgzNDM_ab9bdccb-86b1-48d0-95a0-6137ac57062c">752,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022,&#160;the remaining contractual maturities of available-for-sale securities were less than <ix:nonNumeric contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMzEw_70a93e3e-c21e-49f5-a513-b2e05fed3a7b">2</ix:nonNumeric> years. There have been no significant realized losses on available-for-sale securities for the periods presented. As of September&#160;30, 2022, unrealized losses on available-for-sale securities are not attributed to credit risk. The Company believes that it is more likely than not that investments in an unrealized loss position will be held until maturity and all interest and principal will be received. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company&#8217;s available-for-sale securities are due to market factors. As of September&#160;30, 2022 and December&#160;31, 2021, securities with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfOTMx_5d2227ff-eecd-4251-a9c6-53f9dc61991a">153.7</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfOTM4_6751046e-e524-45cf-8884-57e678af8245">zero</ix:nonFraction>, respectively, were in a continuous net unrealized loss position for more than 12 months. To date, the Company has not recorded any impairment charges on available-for-sale securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMTE2Ng_38585da8-e298-4fb9-a100-80283b6f0a51">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMzI5ODUzNDg4NDY2NA_9dc45d2f-7568-4e4e-b9a9-b20b9b442b44">1.9</ix:nonFraction> million, respectively, of accrued interest receivable from available-for-sale securities within prepaid expenses and other current assets on the consolidated balance sheets.</span></div></ix:continuation><div id="iad69808f292f43f6bbc63337efb1d90e_43"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RleHRyZWdpb246OTdkM2NhOWFiZjI3NGZkOWJlYmQ5N2I5NTg3NmMyYWZfMTIw_062d5c4d-53e4-44e5-8d06-a2fc7bd79e36" continuedAt="id01a5f42a7634176846a35b0e422c8e8" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="id01a5f42a7634176846a35b0e422c8e8" continuedAt="ib168469ebfd9495997981a0f17f534c4">Property and Equipment, Net</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><ix:continuation id="ib168469ebfd9495997981a0f17f534c4"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RleHRyZWdpb246OTdkM2NhOWFiZjI3NGZkOWJlYmQ5N2I5NTg3NmMyYWZfMTIx_81da32de-4b4e-4796-9bd7-2fc0fd207b43" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db76501bbc74787965531c11d212d58_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfMi0xLTEtMS0zODM0Mw_c1135cbd-67f4-474f-9fbb-b78ec48d7105">108,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b3bb83a6f447df99a6eb708011d28b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfMi0zLTEtMS0zODM0Mw_e059214e-9b1b-406f-b6d9-5033fbd0fab3">108,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09d16f1562c4ea7a6206e6000a0d8c9_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfMy0xLTEtMS0zODM0Mw_65e83944-75b0-44da-8111-1c05a7deacdd">31,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f488c95563e4fc0abd6053e7cdbcef3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfMy0zLTEtMS0zODM0Mw_e36fc403-0b3d-4dbb-8642-0c4fbf0e361e">29,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and purchased software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26accf762170429ebb2cfab586faf0e3_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNC0xLTEtMS0zODM0Mw_6f870673-8e56-4ee4-819a-9582182903ff">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86caf7b4d7f94d6a815a266b3f51ee53_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNC0zLTEtMS0zODM0Mw_7652e680-6b00-40e0-b6f2-437ef6bb89e9">4,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda10573477f47fda5d385ccafcf2a6b_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNS0xLTEtMS0zODM0Mw_14067bb4-7470-42a4-84c3-9e603e030340">3,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6c9232fcc104c6894737b6331f6e04d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNS0zLTEtMS0zODM0Mw_dffead09-d01e-46a0-a6ef-761d94cef228">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1f3fff4077416faac3922039ac158c_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNi0xLTEtMS0zODM0Mw_4885d4d7-12e2-4076-b88a-d73e9c567640">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d4d159174f4bfea30e39a7ea47463f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNi0zLTEtMS0zODM0Mw_b398b895-dd22-40e6-b1dc-f55c26af4305">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNy0xLTEtMS0zODM0Mw_6fe69f10-9b0b-4c98-a9f2-05c748432144">149,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNy0zLTEtMS0zODM0Mw_ec7d354c-624e-4273-b723-f90658f94fc3">146,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfOC0xLTEtMS0zODM0Mw_7a3b4320-3395-4e27-8476-5cc8c095e43b">34,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfOC0zLTEtMS0zODM0Mw_56417fea-11e3-4f34-b22d-a90c2ac1dcb2">23,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfOS0xLTEtMS0zODM0Mw_1d1cd343-9c40-4b6e-9d59-5e80315f84da">114,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfOS0zLTEtMS0zODM0Mw_2916a23e-ebe0-4b9c-ada2-2d7f7cbf975e">122,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:6pt"><span><br/></span></div><div id="iad69808f292f43f6bbc63337efb1d90e_46"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="allo:LicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjg1OTU_de499512-8eb1-40e4-8d7c-59dbb5bfd2f2" continuedAt="id667a060f5ea46259a2baf03b99b5f19" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="id667a060f5ea46259a2baf03b99b5f19" continuedAt="i21ae497f4d274a5aaa648128fd55a142"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Contribution Agreement with Pfizer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets, including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $<ix:nonFraction unitRef="usd" contextRef="iba32805724354181ae04c6b3cacb4be2_D20220101-20220930" decimals="-5" name="allo:AggregatePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfODE2_1ce516fc-5f8d-4c2d-bca0-ba9cde10da35">30.0</ix:nonFraction> million or $<ix:nonFraction unitRef="usd" contextRef="i7dddb67349574083921a243e6e892161_D20220101-20220930" decimals="-5" name="allo:AggregatePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfODIy_27b1de97-438d-44ed-8925-8f798643c735">60.0</ix:nonFraction> million, depending on the target, with aggregate potential regulatory and development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i7dddb67349574083921a243e6e892161_D20220101-20220930" decimals="-5" name="allo:AggregatePotentialRegulatoryAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfOTIz_ca732ee9-acae-49e0-87d6-07fabe84d1c3">840.0</ix:nonFraction> million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $<ix:nonFraction unitRef="usd" contextRef="i6aade5c20f2244a3ade2b713c171949b_D20220101-20220930" decimals="-5" name="allo:AggregatePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM3Nw_5504a56c-924c-46ba-b741-1ec16608f49c">325.0</ix:nonFraction> million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. <ix:nonFraction unitRef="usd" contextRef="ief48337bd67341b9bb41f73b0b3c18f3_D20210701-20210930" decimals="INF" name="allo:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OQ_4a8c8003-acdb-40a8-a3d2-f357d737823b"><ix:nonFraction unitRef="usd" contextRef="i7eb2b0edcdf44e7894b474bef1a2f72c_D20210101-20210930" decimals="INF" name="allo:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OQ_529931ef-b245-4939-8b07-10826e9437a5"><ix:nonFraction unitRef="usd" contextRef="i6aade5c20f2244a3ade2b713c171949b_D20220101-20220930" decimals="INF" name="allo:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OQ_b2cfbe39-8bef-43fa-b8ec-03c3ddfc8f96"><ix:nonFraction unitRef="usd" contextRef="i9534ed89959b476bb3c61a21f111f0ac_D20220701-20220930" decimals="INF" name="allo:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OQ_c6921256-134f-4a75-8a9f-30523e683cff">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> milestone or royalty payments were made in the three and nine months ended September&#160;30, 2022 or 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) <ix:nonNumeric contextRef="ic8ccb9c3e12e4bfbbafab7c1c5ed2261_D20220101-20220930" name="allo:RoyaltyObligationPeriodFromDateOfFirstSale" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjMzNA_90541c57-be94-4119-a530-cbf7e3162479">12</ix:nonNumeric> years from the first sale of such product in such country.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Cellectis</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="i21ae497f4d274a5aaa648128fd55a142" continuedAt="iebc46ede86c74cb9992df3f69eb78fd1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $<ix:nonFraction unitRef="usd" contextRef="ida71502c322b490db719e60631ed9186_D20220101-20220930" decimals="-5" name="allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfNDYxMg_5a33e303-4009-4586-b946-46563eb829e6">185.0</ix:nonFraction> million per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i12d3205699d44a1595452c484f84725b_D20220101-20220930" decimals="-8" name="allo:AggregatePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfNDc1Mw_d46ea29a-d5cc-46d4-899c-14e8862c1a8b">2.8</ix:nonFraction> billion. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalties are payable, on a licensed-product-by-licensed-product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs the Company incurred in connection with this agreement were recognized as research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, <ix:nonFraction unitRef="usd" contextRef="i5cd514b962e246c6931c985ac1c2ec04_D20220101-20220930" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfODM0Mw_665c2643-8766-464a-b729-8abba1ebf7fd"><ix:nonFraction unitRef="usd" contextRef="ibd1dcad80d4e4790ae883499a22385cc_D20220701-20220930" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfODM0Mw_ca9f3608-967c-4ef1-8664-58522dd04c13">zero</ix:nonFraction></ix:nonFraction> costs were incurred related to the achievement of a clinical development milestone under this agreement. For the three and nine months ended September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i5454ce81effa43ec82d692544d01340c_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMTkyOQ_551f3a56-2c84-46f2-9081-5b2c581a749e">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82036ec2aaa24cc88e17cb24559ae7cd_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMTkzMw_4b1de15e-e6a2-49c2-bb16-b18dca16913b">10.0</ix:nonFraction> million, respectively, in costs were incurred related to the achievement of a clinical development milestone under this agreement. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreement with Servier</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="iebc46ede86c74cb9992df3f69eb78fd1" continuedAt="i3e89b63c49a54710b43bb49ffffad95a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19, ALLO-501 and ALLO-501A in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for <ix:nonFraction unitRef="number" contextRef="i8cc896b3a0a744c0b48d522995094a4c_D20220101-20220930" decimals="2" name="allo:PercentageOfDevelopmentCostPayableByTheCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTA5Mjg_fa1a73f0-de73-4582-93e7-287fa1613e49">60</ix:nonFraction>% of the specified development costs and Servier is responsible for the remaining <ix:nonFraction unitRef="number" contextRef="i8cc896b3a0a744c0b48d522995094a4c_D20220101-20220930" decimals="2" name="allo:PercentageOfDevelopmentCostPayableByCollaborationPartner" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTEwMTE_9256614c-a9d0-4c50-bdee-061dc578e749">40</ix:nonFraction>% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $<ix:nonFraction unitRef="usd" contextRef="i72513027aa40456ea894b7c240d9529e_D20220101-20220930" decimals="-5" name="allo:AggregatePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTE2NTI_77b232e6-c694-4dcb-a23e-3f96866b328d">137.5</ix:nonFraction> million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $<ix:nonFraction unitRef="usd" contextRef="i4eeda0f2399347eba9a1d3c03cd7ed64_D20220101-20220930" decimals="-5" name="allo:AggregatePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTE3ODQ_3b636ac4-eda9-460f-b65f-57841ce62ae2">78.0</ix:nonFraction> million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $<ix:nonFraction unitRef="usd" contextRef="i3d882b41ba7546aaa56039ced1a10287_I20220930" decimals="-5" name="allo:AggregatePotentialMilestoneReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTIyNDQ_5cea55d5-b4e5-4ee4-af38-be73cf907764">42.0</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="i6dbfd0aa1f5c4f6d8ac7bf09374fbbcb_I20220930" decimals="-5" name="allo:AggregatePotentialMilestoneReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTIyNTE_05bd45b0-9b83-4e6a-8f49-a4d8e2ce1b87">70.5</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i6dbfd0aa1f5c4f6d8ac7bf09374fbbcb_I20220930" decimals="-5" name="allo:AggregatePotentialMilestoneReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTIyNTU_163e576d-f3cb-402e-ab2e-03c4031c22a1">69.1</ix:nonFraction> million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="id7323529b23b45e7b1f3558682b81cd8_D20220701-20220930" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM1ODg_5abc8c25-c96f-435b-afde-d8c9eff7e531">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8cc896b3a0a744c0b48d522995094a4c_D20220101-20220930" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM1OTU_40efdada-e10b-433f-8c3b-f0e0a85bfd4a">20.4</ix:nonFraction> million, respectively, of net cost recoveries under the cost-sharing terms of the Servier Agreement as a reduction to research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ic72e6bbd73b24d50b42d5a271012c22c_D20210701-20210930" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM3OTI_988f6e27-cca4-41d3-a377-cc5ceae7cc4f">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i664e2401aa7b4ff9b1bca0d363df47d4_D20210101-20210930" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM3OTk_6c1f4f72-880d-43a3-ac75-cd6a123cebab">13.2</ix:nonFraction> million, respectively, of net cost recoveries. As of September&#160;30, 2022 and December&#160;31, 2021, amounts due from Servier of $<ix:nonFraction unitRef="usd" contextRef="i8e4f3d045a2243009dac024b2e80a3ca_I20220930" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM4ODY_65f96134-09b0-4f33-b0d0-1304cf9dfe78">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic983cd690af84de59565ffe50d5f5432_I20211231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM4OTM_0f8bd1df-3bf6-4b78-8c37-a6a355fa4999">4.1</ix:nonFraction> million, respectively, were recorded in other current assets in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, Servier sent a notice of discontinuation (Discontinuation) of its involvement in the development of all licensed products directed against CD19, including UCART19, ALLO-501 and ALLO-501A (collectively, CD19 Products), pursuant to the Servier Agreement. Servier&#8217;s Discontinuation provides the Company with the right to elect a license to the CD19 Products outside of the United States (Ex-US Option) and does not otherwise affect the Company's current exclusive license for the development and commercialization of CD19 Products in the United States. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Notch</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="i3e89b63c49a54710b43bb49ffffad95a" continuedAt="i7a404d5464684ed68e93a0ddb1250b9e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $<ix:nonFraction unitRef="usd" contextRef="i58179b3cdca14b9aa3417426bdb601bb_I20191101" decimals="-5" name="allo:CollaborationAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTU4MjA_d3efe371-2df4-487a-80d3-38681e4a1b7f">10.0</ix:nonFraction>&#160;million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. In addition, Allogene made a $<ix:nonFraction unitRef="usd" contextRef="i66aa59ed9c4048298f0a3a33feba7cc5_I20191101" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTU5Njc_c7275cb8-a235-442f-aa84-de4d035bff19">5.0</ix:nonFraction>&#160;million investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a <ix:nonFraction unitRef="number" contextRef="i66aa59ed9c4048298f0a3a33feba7cc5_I20191101" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTYwNjQ_fba75af2-dd51-4a65-b91a-d71985e00be6">25</ix:nonFraction>% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, an Allogene representative serves on the Notch Board of Directors. In February 2021, the Company made an additional $<ix:nonFraction unitRef="usd" contextRef="i3871a5c9adb14fedb9c83c1425f51c54_D20210201-20210228" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTYzMzg_0b50eb7b-6015-4dde-bcc1-d20e6b37aa01">15.9</ix:nonFraction> million investment in Notch's Series A preferred stock. In October 2021, the Company made an additional $<ix:nonFraction unitRef="usd" contextRef="ie8a195a8a56445a3999166ac9339894c_D20211001-20211031" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY0Mzc_d1c2fe8f-59f4-4f5b-998b-b31982e25ae7">1.8</ix:nonFraction>&#160;million investment in Notch's common stock. Immediately following this transaction, the Company's share in Notch was <ix:nonFraction unitRef="number" contextRef="i44b0b5f2e18c49b2991662b317cd0227_I20211031" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY1NDk_ba6689e7-8ef8-4ec8-b9de-b4dfd79c226b">23.0</ix:nonFraction>% on a voting interest basis. The Company did not have a controlling interest in Notch as of September&#160;30, 2022, and continued to account for its investment in Notch as an equity method investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Notch Agreement, Notch will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i36321bc5549f4fdf84b022c72c2623e0_I20220930" decimals="-4" name="allo:AggregatePotentialMilestonePayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OTk_8916d27a-b094-426e-bf1c-4baae65a5d77">7.25</ix:nonFraction>&#160;million upon achieving certain agreed research milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i25e249ab3ca0464995456f2a93a352ff_D20220101-20220930" decimals="-5" name="allo:AggregatePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY4NTk_84a38748-7659-4e6f-a8a4-0f49d19a154c">4.0</ix:nonFraction>&#160;million per exclusive target upon achieving certain pre-clinical development milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="ib6b6f12ac8d143eda9f281cbcc802324_D20220101-20220930" decimals="-5" name="allo:AggregatePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY5NTM_73f4a9cc-031b-45a9-8997-87bc475dcfb6">283.0</ix:nonFraction>&#160;million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three and nine months ended September&#160;30, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i7bb1c70c0e2a408eba7c119e0cecf3a3_D20220701-20220930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTg1MTk_bb62045b-8725-423c-97f0-990ddd161ef6">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i190dbd12ad724f999de964f8944f43f9_D20220101-20220930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTg1MjY_67d92a62-1c73-4388-9707-f2eb8aabbf63">2.8</ix:nonFraction> million, respectively, in collaboration costs as research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i7aa0b52e31cb47caa5b6de4a921c9b55_D20210701-20210930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTg2NTQ_8ec9060b-4126-4b7c-95a0-b4654be5b441">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibb0223ba204941ab82cb484b7e33f56a_D20210101-20210930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTg2NjE_99d6d665-8fcd-4f9d-b2e5-c719a4cbe73b">3.9</ix:nonFraction> million, respectively, in collaboration costs as research and development expenses.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Strategic Alliance with The University of Texas MD Anderson Cancer Center</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2020, the Company entered into a strategic <ix:nonNumeric contextRef="ia9bf9785d75b4721b9ff6232ef70d39b_D20201006-20201006" name="allo:CollaborationAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjg1OTE_338e6a90-18a5-4da7-8015-a11d996e889d">five-year</ix:nonNumeric> collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The Company and MD Anderson are collaborating on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company has committed up to $<ix:nonFraction unitRef="usd" contextRef="ia9bf9785d75b4721b9ff6232ef70d39b_D20201006-20201006" decimals="-5" name="allo:CollaborationAgreementCommittedFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTkyODk_fa04c7e8-5ffe-4a1b-856f-c8afd4c1dd7b">15.0</ix:nonFraction>&#160;million of funding for the duration of the agreement. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iee875a3ae84d46ed987a1b307db20e6e_I20201231" decimals="-5" name="allo:CollaborationAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTk1MDk_5c54ddfb-4b53-45cb-b72d-adaf6a38047d">3.0</ix:nonFraction>&#160;million to MD Anderson in the year ended December 31, 2020. The Company is obligated to make further payments to MD Anderson each year upon the anniversary of the agreement </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="i7a404d5464684ed68e93a0ddb1250b9e" continuedAt="ia8d6bfa3a6a24ccc98614940e06aeb46"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective date through the duration of the agreement term. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, among other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i3240a374c5ab440e8b5e1aabbdba7c25_D20220701-20220930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjAzODU_6b203226-568a-49af-8059-386e14d37727">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff52c9c9567540af853d7d4e7492d0ca_D20220101-20220930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjAzOTI_241b3f4d-575e-4654-9031-3ae98bbc64f4">1.1</ix:nonFraction> million in collaboration costs as research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="if7f6257251904aeda6581f6bfc8b2065_D20210701-20210930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMTk0NA_0f8461f5-6e37-4c28-b7c4-0222123a1b89">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i93f8ae51b31a40de91e52c6738e4e6d5_D20210101-20210930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjA1MDU_5ed97c6d-3002-4248-856d-5969919f6b47">0.8</ix:nonFraction> million, respectively, in collaboration costs as research and development expenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture and License Agreement with Allogene Overland Biopharm (CY) Limited </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, the Company entered into a License Agreement with Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by the Company and Overland Pharmaceuticals (CY) Inc. (Overland), pursuant to a Share Purchase Agreement, dated December 14, 2020, for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore (the JV Territory). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Share Purchase Agreement, the Company acquired Seed Preferred Shares in Allogene Overland representing <ix:nonFraction unitRef="number" contextRef="ib9fc1bf30b194863ae80b306bfcfbb2f_I20201214" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjEyNTQ_3daad150-ebbb-435c-9014-81fcb4a70b4a">49</ix:nonFraction>% of Allogene Overland's outstanding stock as partial consideration for the License Agreement, and Overland acquired Seed Preferred Shares representing <ix:nonFraction unitRef="number" contextRef="if2742005271e46328201e1c4c09f2efc_I20201214" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjE0MDc_174661ba-8a0a-4483-9f57-9ab9a59e8730">51</ix:nonFraction>% of Allogene Overland's outstanding stock for $<ix:nonFraction unitRef="usd" contextRef="iae425c05634344d4904101d51eef4cc6_D20201214-20201214" decimals="-5" name="allo:UpfrontAndQuarterlyCashPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjE0NTU_63924da3-d005-4af2-89ba-810f37aec128">117.0</ix:nonFraction>&#160;million in upfront and certain quarterly cash payments, to support operations of Allogene Overland. As of September&#160;30, 2022, the Company and Overland are the sole equity holders in Allogene Overland. The Company received $<ix:nonFraction unitRef="usd" contextRef="iae425c05634344d4904101d51eef4cc6_D20201214-20201214" decimals="-6" name="allo:JointVentureCapitalSupportPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjE2NzE_04c29abe-028c-4a22-98ae-e4d76ec89054">40</ix:nonFraction>&#160;million from Allogene Overland as partial consideration for the License Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the License Agreement, the Company granted Allogene Overland an exclusive license to develop, manufacture and commercialize certain allogeneic CAR T cell candidates directed at four targets, BCMA, CD70, FLT3, and DLL3, in the JV Territory. As consideration, the Company would also be entitled to additional regulatory milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i717e3fb1a0d945d5851037cc406f873a_D20201214-20201214" decimals="-5" name="allo:AggregatePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjIxMDk_77a2828c-16cb-4809-808e-1d4b1e8c4f96">40.0</ix:nonFraction>&#160;million and, subject to certain conditions, tiered low-to-mid single-digit sales royalties. Subsequent to entering into the License Agreement, Allogene Overland assigned the License Agreement to a wholly-owned subsidiary, Allogene Overland BioPharm (HK) Limited. On April 1, 2022, Allogene Overland HK assigned the License Agreement to Allogene Overland Biopharm (PRC) Co., Limited.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promises that the Company concluded were distinct performance obligations in the License Agreement included: (1) the license of intellectual property and delivery of know-how, (2) the manufacturing license, related know-how and support, (3) if and when available know-how developed in future periods, and (4) participation in the joint steering committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Fixed consideration exists in the form of the upfront payment. Regulatory milestones and royalties were considered variable consideration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. Milestone fees were constrained and not included in the transaction price due to the uncertainties of research and development. The Company re-evaluates the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The shares of Series Seed Preferred Stock were accounted for as part of the Company&#8217;s joint venture and equity method accounting upon formation of the joint venture, and as such, were excluded from the transaction price. The Company determined that the initial transaction price consists of the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i5d1cf8a7bcb44874baee49aa53e9d5ce_I20201214" decimals="-5" name="allo:CollaborationAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjQwMTg_3721af02-96e3-4e9d-b16a-17f067446830">40.0</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price allocated to the license of intellectual property and delivery of know-how will be recognized upon grant of license and delivery of know-how. The transaction price allocated to (i) the manufacturing license, related know-how and support services, (ii) if and when available know-how developed in future periods, and (iii) participation in the joint steering committee, will be recognized over time as the services are delivered. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received in advance are recorded as deferred revenue and will be recognized as the performance obligations are satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that Allogene Overland is a variable interest entity as of September&#160;30, 2022 and December 31, 2021. The Company does not have the power to independently direct the activities which most significantly affect Allogene Overland's economic performance. Accordingly, the Company did not consolidate Allogene Overland because the Company determined that it was not the primary beneficiary.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="ia8d6bfa3a6a24ccc98614940e06aeb46"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recognized less than $<ix:nonFraction unitRef="usd" contextRef="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMTk5OQ_5ca8f499-5558-4c4b-80bf-0698b3b0ea0c">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjUyODk_c501bd90-a6c5-466b-8ac4-b31ac0810044">0.2</ix:nonFraction> million of collaboration revenue, respectively. For the three and nine months ended September&#160;30, 2021, the Company recognized less than $<ix:nonFraction unitRef="usd" contextRef="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjUzOTM_325ea679-ebad-4b93-a5a1-7d9bf327a330">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjU0MDA_4c2ca9ad-b2e3-42e3-b5a8-4e70af542233">38.4</ix:nonFraction> million, respectively, of collaboration revenue, primarily related to the license of intellectual property and delivery of the know-how performance obligation which was delivered in the first quarter of 2021. For the three and nine months ended September&#160;30, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMjA0MA_7da459d2-8cd1-403d-8811-063d64c0f6e9">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjU2NjA_52b0e83a-13e0-4a42-a6ef-db290d969310">0.6</ix:nonFraction> million, respectively, of net cost recoveries under the terms of the license agreement as a reduction to research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded <ix:nonFraction unitRef="usd" contextRef="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930" decimals="INF" name="allo:ReductionToResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjU4NDQ_52657244-4853-405e-82b4-3c7abe4de04b"><ix:nonFraction unitRef="usd" contextRef="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930" decimals="INF" name="allo:ReductionToResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjU4NDQ_c30bfd29-878d-470e-9b57-c1b4637e4a3b">zero</ix:nonFraction></ix:nonFraction> net cost recoveries. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and License Agreement with Antion </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2022, the Company entered into an exclusive collaboration and global license agreement (Antion Collaboration and License Agreement) with Antion Biosciences SA (Antion) for Antion&#8217;s miRNA technology (miCAR), to advance multiplex gene silencing as an additional tool to develop next generation allogeneic CAR T products. Pursuant to the agreement, Antion will exclusively collaborate with the Company on oncology products for a defined period. The Company will also have exclusive worldwide rights to commercialize products incorporating Antion technology developed during the collaboration. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Antion Collaboration and License Agreement includes an exclusive research collaboration to conduct research and development of the use of Antion&#8217;s proprietary technologies to produce certain products for a defined period, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint steering committee. The Company will reimburse Antion's costs incurred in accordance with such plan and budget. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Antion Collaboration and License Agreement, the Company made an upfront payment to Antion of $<ix:nonFraction unitRef="usd" contextRef="i8499187e402947009dcd0f43cd08b023_I20220105" decimals="-5" name="allo:CollaborationAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjcxMDQ_083add54-482e-433a-964e-02687c8601b3">3.5</ix:nonFraction> million in return for a license to access Antion's technology in order to conduct research pursuant to the agreement. The upfront payment was fully recognized as research and development expense as the license had no foreseeable alternative future use. In addition, the Company made a $<ix:nonFraction unitRef="usd" contextRef="ib00af316994b480e903873475c1e0166_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjczODQ_c0aa879b-3470-4472-b7b5-f2530c77650c">3.0</ix:nonFraction> million investment in Antion's preferred stock and is expected to make an additional $<ix:nonFraction unitRef="usd" contextRef="ib00af316994b480e903873475c1e0166_D20220101-20220930" decimals="-5" name="allo:PaymentsToAcquireInvestmentsUponMilestoneAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjc0NjQ_5145b74f-dd1c-412f-af06-470c92124815">3.0</ix:nonFraction>&#160;million investment in Antion's preferred stock upon achievement of an agreed milestone. The Company accounts for its investment in Antion's preferred stock as an equity investment measured at cost less any impairment. In connection with this investment, a Company representative was appointed to Antion&#8217;s Board of Directors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Antion Collaboration and License Agreement, Antion will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ia7b7af3feeda4ecd91976cd1a7640903_I20220105" decimals="-5" name="allo:AggregatePotentialMilestonePayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjc4ODE_fedd4053-3167-48cc-886d-93180b09b1b9">35.3</ix:nonFraction> million for four products upon achievement of certain development and regulatory milestones. For each additional product, Antion will be eligible to receive $<ix:nonFraction unitRef="usd" contextRef="i7bbcb65830e9469e8584561b4ed503d6_I20220105" decimals="-5" name="allo:AggregatePotentialMilestonePayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgwMzM_8f7be2ee-a8f9-42c7-965c-a27d16063fa1">2.0</ix:nonFraction> million upon achievement of a regulatory milestone. Antion is also entitled to receive a low single-digit royalty on the Company&#8217;s sales of licensed products, subject to certain reductions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i7ab46440194c44e0abc3230ea0acaa11_D20220701-20220930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgyNjc_e32488e5-4c96-48b3-ad39-bc4311cba7cd">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0599d7f096e54faa830326a4b07be324_D20220101-20220930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgyNzQ_298faa38-058d-4f8a-a37a-245ab88bf122">4.5</ix:nonFraction> million in research and development expenses related to the upfront payment and collaboration costs, of which $<ix:nonFraction unitRef="usd" contextRef="i12798b13b2e34a1f8b05f08a0a198299_D20220701-20220930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgzNzk_52f26ba4-9435-4114-9cf2-d6f97552210d"><ix:nonFraction unitRef="usd" contextRef="ia1861d08a2de4faebc1dfeee012e2263_D20220101-20220930" decimals="-5" name="allo:CollaborationArrangementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgzNzk_9a66aa7e-835c-4f6c-b422-59c5f7bc8ccf">0.5</ix:nonFraction></ix:nonFraction> million is recorded in accrued and other liabilities as of September&#160;30, 2022. The Company's total equity investment in Antion was $<ix:nonFraction unitRef="usd" contextRef="ib00af316994b480e903873475c1e0166_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjg0ODk_c0aa879b-3470-4472-b7b5-f2530c77650c">3.0</ix:nonFraction> million as of September&#160;30, 2022 and is recognized in other long-term assets in the condensed consolidated balance sheets.</span></div></ix:continuation><div id="iad69808f292f43f6bbc63337efb1d90e_49"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM4MQ_190f87e0-68a1-4464-b74f-df6bb873dc8c" continuedAt="i0e4e10b973004398bf0b01cf73547dd2" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i0e4e10b973004398bf0b01cf73547dd2" continuedAt="ifb9971b8f03b48c8bafc52183f49c83b"><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into an operating lease agreement (HQ Lease) for office and laboratory space which consists of approximately <ix:nonFraction unitRef="sqft" contextRef="i0db19e8474cf4b47a8a2c996ea80614d_I20180831" decimals="-3" name="allo:AreaOfNewOfficeBuilding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTk4_9bfd60f6-e7a5-4f06-b896-f242449e9a40">68,000</ix:nonFraction> square feet located in South San Francisco, California. The lease term was <ix:nonNumeric contextRef="i0db19e8474cf4b47a8a2c996ea80614d_I20180831" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjc2_e12e555b-1def-435b-a76c-a68c18507796">127</ix:nonNumeric> months beginning August 2018 through February 2029 with an option to extend the term for <ix:nonNumeric contextRef="i0db19e8474cf4b47a8a2c996ea80614d_I20180831" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzQx_b3365129-44ca-4adb-9874-c3e02fcf0dd7">seven years</ix:nonNumeric> which was not reasonably assured of exercise. The Company has made certain tenant improvements, including the addition of laboratory space, and has received $<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTAx_718cf183-5136-477f-bcc9-8bec7c8ff4fb">5.0</ix:nonFraction> million of tenant improvement allowances. The rent payments began on March 1, 2019 after an abatement period. In December 2021, the Company amended its lease agreement to lease an additional <ix:nonFraction unitRef="sqft" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="0" name="allo:AdditionalAreaOfNewOfficeBuilding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNjc2_9ae59f0b-09d1-44f1-9aa4-091f54ed8374">47,566</ix:nonFraction> square feet of office and laboratory space in South San Francisco, California, as part of the same building as the Company&#8217;s current headquarters. The lease term commenced in April 2022 and is for a period of <ix:nonNumeric contextRef="i6c0fcddb98e0438fbee11a2250f1b7bd_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfODg4_7e1ac45d-2a97-43b3-a5e0-1e682663479e">120</ix:nonNumeric> months. The rent payments for the expansion premises began in August 2022 after an abatement period. The lease term for the existing premises was also extended and the lease for both the existing and expansion premises will expire on March 31, 2032 with an option to extend the term for <ix:nonNumeric contextRef="i6c0fcddb98e0438fbee11a2250f1b7bd_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTE2Ng_091b3dbf-f406-4c7d-a590-8f71085ad72e">eight years</ix:nonNumeric> which is not reasonably assured of exercise. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an operating lease agreement for office and laboratory space which consists of <ix:nonFraction unitRef="sqft" contextRef="i87ee1a949aa34bb7bc017891ce79e050_I20181031" decimals="0" name="allo:AreaOfNewOfficeBuilding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTMzNg_6786abf8-44cf-450b-9e21-3418f027e1f7">14,943</ix:nonFraction> square feet located in South San Francisco, California. The lease term was <ix:nonNumeric contextRef="i87ee1a949aa34bb7bc017891ce79e050_I20181031" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTQxNA_7f878595-3262-44f7-82f2-e87e1a331f58">124</ix:nonNumeric> months beginning November 2018 through February 2029, with an option to extend the term for another <ix:nonNumeric contextRef="i87ee1a949aa34bb7bc017891ce79e050_I20181031" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTQ4OA_88a2867c-4894-4e0d-ab18-6a462f6cef15">seven years</ix:nonNumeric> which was not reasonably assured of exercise. The Company has made certain tenant improvements, including the upgrading of current office and laboratory space with a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="ifb9971b8f03b48c8bafc52183f49c83b" continuedAt="i04f2d46921d2460eb6f6f86fdcfae3ef"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease incentive allowance of $<ix:nonFraction unitRef="usd" contextRef="i87ee1a949aa34bb7bc017891ce79e050_I20181031" decimals="-5" name="allo:TenantImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTY4Ng_e36a6738-171c-4164-8c73-0c612d08cfc5">0.8</ix:nonFraction> million. Rent payments began in November 2018. In December 2021, the Company amended its lease agreement to extend the term of the lease to be co-terminus with the HQ Lease. The lease term will expire March 31, 2032 with an option to extend the term for <ix:nonNumeric contextRef="ic1bb308e19ad469187b256dd69806dce_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTkxMg_4c90edb1-945d-444c-8548-115e27c71af0">eight years</ix:nonNumeric> which is not reasonably assured of exercise. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company entered into a lease agreement for approximately <ix:nonFraction unitRef="sqft" contextRef="i0e8ea8f25c7b4bfb9cf53b843eb1b98b_D20190201-20190228" decimals="-3" name="allo:AreaOfOperatingLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjA0MA_55a15781-4e54-4e8f-8649-4e3977b2bdea">118,000</ix:nonFraction> square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease term is <ix:nonNumeric contextRef="ica7aec93cbca455f9d73fe168f4f412b_I20190228" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjE1NA_d7cb74b5-9528-48d1-acc0-ab98146f6864">188</ix:nonNumeric> months beginning November 2020 through July 2036. Upon certain conditions, the Company has <ix:nonFraction unitRef="renewal" contextRef="i0e8ea8f25c7b4bfb9cf53b843eb1b98b_D20190201-20190228" decimals="INF" name="allo:NumberOfOptionsToExtendLease" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjIyMw_561223b2-8a02-42c4-b744-9b2bf38642ef">two</ix:nonFraction> <ix:nonNumeric contextRef="ica7aec93cbca455f9d73fe168f4f412b_I20190228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM3NQ_2d3045e4-c1a7-4d5a-97c2-a9df379610c9">ten-year</ix:nonNumeric> options to extend the lease, both of which are not reasonably assured of exercise. The Company has received $<ix:nonFraction unitRef="usd" contextRef="id1877d8c1c9d40b58cdc5a256ab21b2b_I20220930" decimals="-5" name="allo:TenantImprovementAllowanceUtilizedToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjM0Mg_2b7243fc-92f3-4bfa-b022-1bd4b4132a17">3.0</ix:nonFraction> million of tenant improvement allowances for costs related to the design and construction of certain Company improvements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains letters of credit for the benefit of landlords which is disclosed as restricted cash in the condensed consolidated balance sheets. Restricted cash related to letters of credit due to landlords was $<ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjY3OQ_ba40c7a5-e2b3-4221-b39d-1e7f914891d5"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjY3OQ_d49df4d7-6460-4d8d-837c-b9fd38262958">6.0</ix:nonFraction></ix:nonFraction> million as of September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="allo:LiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM3Nw_589e2150-0e0d-4290-b53e-58a941948b6c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_090f2506-4094-4262-920e-2e1663730d2d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_c2737ca9-b04a-4d28-a3da-5b7ccec47c9f">Current portion included in accrued and other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0yLTEtMS0zODM0Mw_0656954e-07df-4e73-8df5-a0f50cecfc19">5,831</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi00LTEtMS0zODM0Mw_48ebcfa3-df0f-4c1c-bce5-f661f35ab0de">3,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMy0yLTEtMS0zODM0Mw_ee872195-3691-4ccd-bf1b-c6acbb6da049">96,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMy00LTEtMS0zODM0Mw_f46daf91-a236-49b2-b69e-bded397359a0">69,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfNC0yLTEtMS0zODM0Mw_14f6a0e9-71ca-4ae8-a193-d60fbaac41ad">102,537</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfNC00LTEtMS0zODM0Mw_6769cb80-e53b-46ed-a06e-4220c502b00f">73,129</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM4MA_72a9b440-30e9-46bb-9df9-355263139341" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMi0yLTEtMS0zODM0Mw_0d4535b5-8a40-4cda-9fe3-84d61162e5a8">3,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMi00LTEtMS0zODM0Mw_d6233f70-38fb-4ba3-883e-e5c1d4141bf5">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMi02LTEtMS0zODM0Mw_e3798551-b401-4854-8836-78759b8e0e65">8,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMi04LTEtMS0zODM0Mw_258871d1-de6b-4aa2-b75e-511df5798243">5,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMy0yLTEtMS0zODM0Mw_dfe7979c-d2b5-4763-af67-b9ab74e9330f">616</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMy00LTEtMS0zODM0Mw_c08c09bf-bd92-46aa-8e0e-5b231617a5d0">448</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMy02LTEtMS0zODM0Mw_cbeab18b-ec2b-4049-9e51-f40998095f92">1,468</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMy04LTEtMS0zODM0Mw_073708e0-78a9-4a45-9384-07c98e7ac012">979</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfNC0yLTEtMS0zODM0Mw_b88721f6-b8c9-4d78-88a9-7b4d978ea21e">3,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfNC00LTEtMS0zODM0Mw_1d86c074-66a1-4619-b18d-5396761a6d3c">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfNC02LTEtMS0zODM0Mw_d1d2da8f-dccf-42bc-a2d7-3f97e4215e2a">9,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfNC04LTEtMS0zODM0Mw_69c86198-8372-4ba0-bd5e-64a020981388">6,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzAyMg_e99167dc-f363-428b-b190-dfc4a674a339">2.6</ix:nonFraction> million and was included in net cash used in operating activities in our condensed consolidated statements of cash flows. </span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM3OA_c7e02eed-3f00-4865-beb6-7de2fa962867" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undiscounted future lease payments under the lease agreements as of September&#160;30, 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2022 (remaining 6 months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfMS0yLTEtMS0zODM0Mw_f859d183-9164-435a-ab8f-6351409dd5ca">2,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfMi0yLTEtMS0zODM0Mw_1dc32f49-826b-4ac4-aefa-d6f0b8facaa0">12,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfMy0yLTEtMS0zODM0Mw_d6d4f2d5-4a32-434d-a173-547de204aebb">12,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfNC0yLTEtMS0zODM0Mw_d14e09b4-0fc9-463f-a103-0502f28600d0">12,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfNS0yLTEtMS0zODM0Mw_601d2dd7-3602-40a1-af90-f1fa27bec105">12,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="allo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfNi0yLTEtMS0zODM0Mw_52fcaa79-ccdb-4343-ba2a-257170a8b3ad">90,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfNy0yLTEtMS0zODM0Mw_b0cd8426-34bb-49ac-8c4f-d9536d287e12">143,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfOC0yLTEtMS0zODM0Mw_8db7da96-5137-4be7-a243-c8aacd3b2d2c">40,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfOS0yLTEtMS0zODM0Mw_95033e32-7f0c-4535-bd45-c70f43ee00ef">102,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our estimated incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was&#160;<ix:nonFraction unitRef="number" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzU0Nw_830ae212-c293-435b-ba8f-40c90fd93ac9">6.19</ix:nonFraction>%. As of&#160;September&#160;30, 2022, the weighted average remaining lease term for our operating leases is&#160;<ix:nonNumeric contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzYzMQ_b1d43b1d-f9c5-4247-8e62-5b12423a3aa2">10.21</ix:nonNumeric> years.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="i04f2d46921d2460eb6f6f86fdcfae3ef"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, the Company entered into a Solar Power Purchase and Energy Services Agreement for the installation and operation of a solar photovoltaic generating system and battery energy storage system at the Company's cell therapy manufacturing facility in Newark, California. The agreement has a term of <ix:nonNumeric contextRef="i285646cc47ee4e0781be1e398f978e9a_I20200731" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzk2MA_bf15d468-9147-45bf-8909-8eedf10e0ed1">20</ix:nonNumeric> years and commenced in September 2022. The Company is obligated to pay for electricity generated from the system at an agreed rate for the duration of the agreement term. Termination of the agreement by the Company will result in a termination payment due of approximately $<ix:nonFraction unitRef="usd" contextRef="i285646cc47ee4e0781be1e398f978e9a_I20200731" decimals="-5" name="allo:LesseeFinanceLeasePaymentUponContractTermination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNDI1Mw_a3913d31-3413-4fc4-b493-f25c82a7f918">4.3</ix:nonFraction> million. In connection with the agreement, the Company maintains a letter of credit for the benefit of the service provider in the amount of $<ix:nonFraction unitRef="usd" contextRef="i936368d1ad874c5791721226f6432723_I20220930" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNDM4OQ_14309dcf-bfd7-4338-b20a-7fb7453d9ed4">4.3</ix:nonFraction> million which is disclosed as restricted cash in the condensed consolidated balance sheets as of September&#160;30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into certain license agreements for intellectual property which is used as part of our development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of September&#160;30, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into contracts in the normal course of business that includes arrangements with clinical research organizations, vendors for preclinical research and vendors for manufacturing. These agreements generally allow for cancellation with notice. As of September&#160;30, 2022, the Company had non-cancellable purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-5" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM3Mg_d59d4f01-f5f6-4e88-943a-7a9e40292c5e">0.4</ix:nonFraction> million.</span></div></ix:continuation><div id="iad69808f292f43f6bbc63337efb1d90e_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTk2NQ_9099e2f3-8f4b-49c9-a3b8-7311ef699306" continuedAt="ifceaf84f865841c3835e0a32b4eeec50" escape="true">Equity Method Investments</ix:nonNumeric></span></div><ix:continuation id="ifceaf84f865841c3835e0a32b4eeec50"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notch Therapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the execution of the Notch Agreement (see Note 6), the Company also entered into a Share Purchase Agreement with the Company acquiring shares of Notch&#8217;s Series Seed convertible preferred stock for a total investment cost of $<ix:nonFraction unitRef="usd" contextRef="i186cd8de8d9844958fcbdfb4ccfb61ed_D20191101-20191101" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMzA1_0e6c10d3-02cc-4404-9e3d-94c95e8470c2">5.1</ix:nonFraction>&#160;million which includes transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i186cd8de8d9844958fcbdfb4ccfb61ed_D20191101-20191101" decimals="-5" name="allo:CostMethodInvestmentTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMzQ0_2ca59cd5-92ee-4ed6-8d1f-093857f27359">0.1</ix:nonFraction>&#160;million, resulting in a <ix:nonFraction unitRef="number" contextRef="i66aa59ed9c4048298f0a3a33feba7cc5_I20191101" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMzYz_a8f88573-53c8-4b12-80e6-20bb2c71cd98">25</ix:nonFraction>% ownership interest in Notch. In February 2021, the Company made a $<ix:nonFraction unitRef="usd" contextRef="i3871a5c9adb14fedb9c83c1425f51c54_D20210201-20210228" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfNDMy_1cab1103-de1f-4271-b9da-175157dfc14b">15.9</ix:nonFraction> million investment in Notch's Series A preferred stock. Immediately following this transaction, the Company's share in Notch was <ix:nonFraction unitRef="number" contextRef="i1b45cc2e745b42e9b32d37a59ae969d4_I20210228" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfNTU2_0e429964-e1f9-4752-8370-51ab837352eb">20.7</ix:nonFraction>% on a voting interest basis. In October 2021, the Company made an additional $<ix:nonFraction unitRef="usd" contextRef="ie8a195a8a56445a3999166ac9339894c_D20211001-20211031" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfNjM1_d1c2fe8f-59f4-4f5b-998b-b31982e25ae7">1.8</ix:nonFraction>&#160;million investment in Notch's common stock. Immediately following this transaction, the Company's share in Notch was <ix:nonFraction unitRef="number" contextRef="i44b0b5f2e18c49b2991662b317cd0227_I20211031" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfNzQ3_ba6689e7-8ef8-4ec8-b9de-b4dfd79c226b">23.0</ix:nonFraction>% on a voting interest basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s total equity investment in Notch as of September&#160;30, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfODQ1_7edc75e4-8151-4c1f-a353-e8244a14b9cf">14.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfODUy_20022319-2957-499a-ac72-5235a4fb0373">18.0</ix:nonFraction> million, respectively, and the Company accounted for the investment using the equity method of accounting. During the three and nine months ended September&#160;30, 2022 and 2021, the Company recognized its share of Notch's net loss under the other expenses caption within the condensed consolidated statement of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allogene Overland </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the execution of the License Agreement with Allogene Overland (see Note 6), the Company also entered into a Share Purchase Agreement and Shareholders' Agreement with the joint venture company acquiring shares of Allogene Overland&#8217;s Seed Preferred Shares representing a <ix:nonFraction unitRef="number" contextRef="ib9fc1bf30b194863ae80b306bfcfbb2f_I20201214" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTQ0NQ_8f860595-0178-4025-a377-bb7e4cee67b5">49</ix:nonFraction>% ownership interest in exchange for entering into a License Agreement which had a carrying value of <ix:nonFraction unitRef="usd" contextRef="ib9fc1bf30b194863ae80b306bfcfbb2f_I20201214" decimals="INF" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTU0Nw_7f3bd603-6af7-4a35-93e1-d7fda0244154">zero</ix:nonFraction>. The Company accounts for its investment in Allogene Overland as an equity method investment at carrying value. The Company's total equity investment in Allogene Overland was <ix:nonFraction unitRef="usd" contextRef="i1492a2fea02e4f998d775344e68d1e5f_I20220930" decimals="INF" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTcyNQ_a62ad43a-ec11-4e53-87f9-35083d22e668"><ix:nonFraction unitRef="usd" contextRef="i7b00d6b5fecd421bb33ba50571717267_I20211231" decimals="INF" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTcyNQ_dd0818d5-c4e6-4a00-b2f1-79dd63ebb677">zero</ix:nonFraction></ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s equity investment in Allogene Overland as of September&#160;30, 2022 and December&#160;31, 2021 had a <ix:nonFraction unitRef="usd" contextRef="i1492a2fea02e4f998d775344e68d1e5f_I20220930" decimals="INF" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTgyMA_0e31affc-2cc1-442b-bc36-0f876c09938d"><ix:nonFraction unitRef="usd" contextRef="i7b00d6b5fecd421bb33ba50571717267_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTgyMA_ed20d06d-c5f5-4511-9b50-2470440fb2a3">zero</ix:nonFraction></ix:nonFraction> carryover basis. Therefore, the Company did not account for its share of losses incurred by Allogene Overland. See Note 6 for further details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ3MA_61de9ef5-f9cd-4a54-8646-53fe5a972f81" continuedAt="i49898a800d3d4064b4cf65c304847496" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i49898a800d3d4064b4cf65c304847496" continuedAt="i620043736ebd47e082dfca5ac0ed2acc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company adopted its 2018 Equity Incentive Plan (Prior 2018 Plan). The Prior 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s Board of Directors and consultants of the Company under terms and provisions established by the Company&#8217;s Board of Directors. In September 2018, the Board of Directors adopted a new amended and restated 2018 Equity Incentive Plan as a successor to and continuation of the Prior 2018 Plan, which became effective in October 2018 (the 2018 Plan), which authorized additional shares for issuance and provided for an automatic annual increase to the number of shares issuable under the 2018 Plan by an amount equal to <ix:nonFraction unitRef="number" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="INF" name="allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfODgx_7446c473-bf2c-43e7-b96a-27d9de8a2aa8">5</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed <ix:nonNumeric contextRef="i2ed593580aad4f18a35e79239d80c7d7_D20220101-20220930" name="allo:StockOptionGrantedPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA2Mg_9c1d40ef-e5f6-482e-81b6-6c1ce372fae0">10</ix:nonNumeric> years. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than <ix:nonFraction unitRef="number" contextRef="i2ed593580aad4f18a35e79239d80c7d7_D20220101-20220930" decimals="INF" name="allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTE5NQ_615e697a-49f6-4291-a08b-6da8133baaac">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the grant date. Options granted typically vest over a <ix:nonNumeric contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ2Mw_a19e1a81-077c-4d12-8afd-ae4d12c2b013">four-year</ix:nonNumeric> period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a <ix:nonNumeric contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ2NA_c1d0408e-25b5-4132-a1f5-2a171c9b6862">four-year</ix:nonNumeric> period but may be granted with different vesting terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTUyMQ_d97677e4-832a-473f-8149-d3b573fbe508">12,035,820</ix:nonFraction> shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Exchange program</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, the Company commenced an offer to exchange certain eligible options held by eligible employees of the Company for new options (the Exchange Offer). The Exchange Offer expired on July 19, 2022. Pursuant to the Exchange Offer, <ix:nonFraction unitRef="employee" contextRef="i8da13d9ff1754a2f85537e5c6a6528e9_I20220621" decimals="INF" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDcyMQ_7cf1228b-486d-4296-ab4c-28f8ad47a832">199</ix:nonFraction> eligible holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8da13d9ff1754a2f85537e5c6a6528e9_I20220621" decimals="0" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDY4MA_e01f15fb-6c02-41b9-b69d-a76d516eac2c">3,666,600</ix:nonFraction> shares of the Company&#8217;s common stock, representing approximately <ix:nonFraction unitRef="number" contextRef="i8da13d9ff1754a2f85537e5c6a6528e9_I20220621" decimals="3" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDcwMQ_fcef03f8-8c57-4e14-b5f4-9278de41e0b6">93.5</ix:nonFraction>% of the total shares of common stock underlying the eligible options. On July 19, 2022, immediately following the expiration of the Exchange Offer, the Company granted new options to purchase <ix:nonFraction unitRef="shares" contextRef="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDY2OA_fefc5b7a-4b8f-49d7-a88e-e3e5c917e3dc">3,666,600</ix:nonFraction> shares of common stock, pursuant to the terms of the Exchange Offer and the 2018 Plan. The exercise price of the new options granted pursuant to the Exchange Offer was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib2ab7bde48b24a23bcc9d3eec9a88153_I20220719" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDY5Mg_ee46b2ea-0f78-4d29-bc83-4d1079ff0e65">13.31</ix:nonFraction> per share, which was the closing price of the common stock on the Nasdaq Global Select Market on the grant date of the new options. The new options are subject to a new <ix:nonNumeric contextRef="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDc0OQ_6392a3dc-eeb9-493a-b0a5-60c020f0b3b5">three-year</ix:nonNumeric> vesting schedule, vesting in equal annual installments over the vesting term. Each new option has a maximum term of <ix:nonNumeric contextRef="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMjE5OTAyMzI3NDcwOA_c32c9417-9c3f-4863-9cd6-49d464225926">seven years</ix:nonNumeric>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange of stock options was treated as a modification for accounting purposes. The incremental expense of $<ix:nonFraction unitRef="usd" contextRef="i2930cb3944834b138006d0840c8071b9_D20220719-20220719" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDcwOA_7cbadd4f-06ca-491a-8d2a-164cfe482001">5.2</ix:nonFraction>&#160;million for the new options was calculated using a lattice option pricing model. The incremental expense and the unamortized expense remaining on the exchanged options as of the modification date will be recognized over the new <ix:nonNumeric contextRef="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDc1MA_c9c1fc86-0568-4ba7-b4c9-2d35e6c2ba7b">three-year</ix:nonNumeric> service period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ2NQ_0f0e86d0-902c-4616-b53e-f543b136156f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes option activity under the 2018 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:42.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contract<br/>Term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i335a2face5cf44a58769ff4969fb2cc1_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfMy0xLTEtMS0zODM0Mw_9e05601b-ec6a-471c-aec0-b05f49adebdf">10,239,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i335a2face5cf44a58769ff4969fb2cc1_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfMy0zLTEtMS0zODM0Mw_ce4ab3d4-b894-4351-bbe5-cfc51d80a0e2">21.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87b1b7f6f25749da9e0c6010a3a596c8_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfMy01LTEtMS0zODM0Mw_64ebb216-64d5-437c-98e4-14f0fb47c3ec">7.68</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335a2face5cf44a58769ff4969fb2cc1_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfMy03LTEtMS0zODM0Mw_e0a22089-1567-4e68-9a51-10143eeb5c7b">26,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNC0xLTEtMS0zODM0Mw_f3d18bc1-7f25-4479-bf71-461440e937a8">8,627,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNC0zLTEtMS0zODM0Mw_0316cf08-c245-457f-a9a0-600dc0754d0a">9.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNS0xLTEtMS00MDExNA_7f8a9b62-c164-4eb7-84d8-61d72e9a57a3">174,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNS0zLTEtMS00MDEzMw_a5388822-379c-49b2-98d5-153f3e845c48">2.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNS0xLTEtMS0zODM0Mw_60bc21d8-efd9-4f48-b537-264d2d497116">569,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNS0zLTEtMS0zODM0Mw_7e1e06d3-b0fb-487a-9042-5c8fd3056a31">24.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled under the Option Exchange</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="INF" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNi0xLTEtMS0zODM0Mw_d65233ca-29e6-4d9a-bfae-7be856bb746b">3,666,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="2" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNi0zLTEtMS0zODM0Mw_22d17b83-672c-4973-93a2-c11cf3f2161e">26.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted under the Option Exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="INF" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC0xLTEtMS00MDEyMg_40014646-25f1-4c65-88e1-e070c98492ed">3,666,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="2" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC0zLTEtMS00MDE0MQ_39206546-0d05-41ac-9ffa-e8806983dfd5">13.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNy0xLTEtMS0zODM0Mw_264b9b00-047a-4626-815b-55fec3f5bd82">18,122,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNy0zLTEtMS0zODM0Mw_8ff15cc4-0f98-4e53-bdb5-d873a0e654e5">12.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNy01LTEtMS0zODM0Mw_c2abf7fa-45c7-4d1d-976a-4b86713da34d">8.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNy03LTEtMS0zODM0Mw_d4ace53c-bf26-4f57-afb4-3a139d4a48d2">25,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC0xLTEtMS0zODM0Mw_6e607e30-4497-4b31-99e4-06de83c0019e">13,657,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC0zLTEtMS0zODM0Mw_fce1a325-53d4-4feb-b64c-c33e236ae191">13.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC01LTEtMS0zODM0Mw_727c76aa-7de6-40e3-8e90-1dd43a795c99">8.29</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC03LTEtMS0zODM0Mw_2acc81e8-2f0f-4756-895b-feb86d8b9287">24,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOS0xLTEtMS0zODM0Mw_0390bed6-4318-4973-a205-2790890de87c">18,122,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOS0zLTEtMS0zODM0Mw_c50a8852-e190-425b-ba08-e51ecd582543">12.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOS01LTEtMS0zODM0Mw_989927f7-696b-4034-b985-92ad406d7fb3">8.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOS03LTEtMS0zODM0Mw_d0542444-6df8-495f-947a-5df6f0cb21fd">25,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="i620043736ebd47e082dfca5ac0ed2acc" continuedAt="i45d6eb8a3c7c48dc8b0aa607a4cf7027"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on September&#160;30, 2022. For the nine months ended September&#160;30, 2022, the estimated weighted-average grant-date fair value of employee options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMjA4MQ_751ab59d-79e2-4878-a302-2d0514164c8a">9.99</ix:nonFraction> per share. As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i80967c9edd9c4b2c9d93991aba2977e3_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMjExNQ_a26aabce-32ab-4633-8065-5b703cdcb25a">96.7</ix:nonFraction>&#160;million of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMjI2Mw_4967237b-0d5e-4479-a321-e482921a94b1">2 years, 324 days</ix:nonNumeric>.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ2Nw_c1550b35-d1b5-4947-bc5a-4680b493da86" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:67.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0ac5f114f4b4675aa3371c31e9a9f93_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMi0xLTEtMS0zODM0My90ZXh0cmVnaW9uOjY1ZWRkMjcxYmU1MjQ2ZjRhN2RlYzY5NGI0ZGM5ZDU0XzQ_2f4a7f5c-ec78-467e-a3d0-2b5650af6610">5.25</ix:nonNumeric> - <ix:nonNumeric contextRef="ibf9b3aebda244d37a641882195bc9a25_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMi0xLTEtMS0zODM0My90ZXh0cmVnaW9uOjY1ZWRkMjcxYmU1MjQ2ZjRhN2RlYzY5NGI0ZGM5ZDU0Xzk_506c0257-c3cc-4110-b378-307c765009f5">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic91b0bb6bd0945bbac49f373c6dce054_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMi0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjIyOTNkNzQxNTQyMzRlYWFiOGJiNmI4YjZkNTUwYmJiXzQ_c9626c87-2793-456e-8735-39535676f5dd">5.27</ix:nonNumeric> - <ix:nonNumeric contextRef="i11560b36616e4aaeba3be6911de62405_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMi0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjIyOTNkNzQxNTQyMzRlYWFiOGJiNmI4YjZkNTUwYmJiXzk_caf241d4-ba22-4b6e-8415-2c4c3cfd4df0">6.08</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMy0xLTEtMS0zODM0My90ZXh0cmVnaW9uOmQ4ZjVjOGJiYzAzNjQ3ZTA4NjU0MGIyNTM5MTI5OTU1XzQ_22371e3c-2e1f-4a0e-baad-e6067f5e69ef">70.82</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMy0xLTEtMS0zODM0My90ZXh0cmVnaW9uOmQ4ZjVjOGJiYzAzNjQ3ZTA4NjU0MGIyNTM5MTI5OTU1Xzk_e25c1465-ad02-4654-b933-82dbff0c5970">73.39</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMy0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjU1MmMxMjFlYjcxODRhN2FiNWY1Nzk4YjcwZmY4OGU3XzQ_4f9d9fe3-2b8e-44b9-99e0-2a937be700e5">69.73</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMy0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjU1MmMxMjFlYjcxODRhN2FiNWY1Nzk4YjcwZmY4OGU3Xzk_758ff83d-d5b4-4299-bcb1-e0eeaa6c0644">70.80</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNC0xLTEtMS0zODM0My90ZXh0cmVnaW9uOjg2ZWYzNzMwZTAxMzRmMDE4ZWFkY2VjYzY3OTdkOWZlXzQ_5e3dfd33-4e66-4a95-a964-c5e50017920c">1.61</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNC0xLTEtMS0zODM0My90ZXh0cmVnaW9uOjg2ZWYzNzMwZTAxMzRmMDE4ZWFkY2VjYzY3OTdkOWZlXzk_35130cc6-29c5-4ac9-a349-a1244ee9be41">3.49</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNC0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjc5NzVmOWRhMTc1MTRkZjg5ZmMyNjRkZmVhZDA2MTk5XzQ_31047be7-1afc-4f28-a57b-bd668edb033b">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNC0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjc5NzVmOWRhMTc1MTRkZjg5ZmMyNjRkZmVhZDA2MTk5Xzk_c40e445a-239f-45ff-ab7e-24ed1872fedd">1.16</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNS0xLTEtMS0zODM0Mw_c181017a-f4b0-48fc-a816-59d6e0d4746e">0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNS0zLTEtMS0zODM0Mw_bbbe9dfb-48d8-46b8-9704-0e5a668910c6">0</ix:nonFraction>%</span></div></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the new options granted under the Option Exchange program was estimated at the date of grant using a lattice option pricing model with the following assumptions: expected volatility of <ix:nonFraction unitRef="number" contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY1Mw_7282c949-d55f-419e-959b-96a389fdad4a">73.74</ix:nonFraction>%, expected risk-free rate of <ix:nonFraction unitRef="number" contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY3NA_43f51916-1554-4b20-9eb9-09081d85109a">3.06</ix:nonFraction>%, expected dividends of <ix:nonFraction unitRef="number" contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY2OQ_937ad984-17f8-4b3b-804f-73e2a8dbcd79">0</ix:nonFraction>% and expected exercise barrier of <ix:nonFraction unitRef="usdPerShare" contextRef="i80967c9edd9c4b2c9d93991aba2977e3_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY2MQ_e4b8c9de-f963-4824-9083-f2f6bdef97c1">2.57</ix:nonFraction>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMzYzMA_31d2fa78-1196-4137-8534-32a7766e79f3">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected exercise barrier - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The modified options are assumed to be exercised upon vesting and when the ratio of stock market price to exercise price reaches <ix:nonFraction unitRef="usdPerShare" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY0Nw_8af81088-71ef-44bb-92a6-f0d72cca23d7">2.57</ix:nonFraction>, or expiration, whichever is earlier.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Activity</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ3Mg_fa2643f2-a0af-48ba-9776-3695906b7197" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes restricted stock unit activity under the 2018 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant Date Fair<br/>Value per<br/>Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id11744c3dcc0478fbe1ac19d5b674e5c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfMy0xLTEtMS0zODM0Mw_8d9807e8-35b4-425d-a0fb-b66f3abdd19e">4,261,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id11744c3dcc0478fbe1ac19d5b674e5c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfMy0zLTEtMS0zODM0Mw_0e034100-9d17-4ba3-96d8-e71fcf7f90f9">26.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f197f101d1c490f9238233b8c06f878_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfMy01LTEtMS0zODM0Mw_d36a359c-9b0d-4c2a-aa7b-a75ebd8e3f54">1.72</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11744c3dcc0478fbe1ac19d5b674e5c_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfMy03LTEtMS0zODM0Mw_8a42ac3b-43cd-4cd9-b1a1-b8867d598d5f">63,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNC0xLTEtMS0zODM0Mw_660e4dc6-eaa6-406f-a433-9686b5c0d57d">3,316,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNC0zLTEtMS0zODM0Mw_511679c2-54a4-4510-abe5-c5c4db93c8c8">9.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNC01LTEtMS0zODM0Mw_692e41d3-d2a5-48c1-8a12-aed87c65a7f6">1.89</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNS0xLTEtMS0zODM0Mw_78938a94-dd83-4809-86b3-14dc78cb8b41">991,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNS0zLTEtMS0zODM0Mw_d26ebcea-c0b8-4a2b-9e10-05f635ac05a1">27.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNi0xLTEtMS0zODM0Mw_b0066b28-b258-4029-9031-003829531c32">476,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNi0zLTEtMS0zODM0Mw_0e0fb1e7-87af-45dc-86c2-af45d82ec38e">22.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNy0xLTEtMS0zODM0Mw_a86133cd-1f87-46e5-8480-be35837d3863">6,108,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNy0zLTEtMS0zODM0Mw_f8f2c9fd-1f63-4b96-8e03-381fff5aeec4">17.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNy01LTEtMS0zODM0Mw_471f826e-edac-449e-ade7-1bf4118b8fff">1.70</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNy03LTEtMS0zODM0Mw_d8a0b853-1f28-4e40-b150-189f9864bad7">65,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930" decimals="INF" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfOC0xLTEtMS0zODM0Mw_eccbde8c-bc7a-4284-9d2c-4598e69cae61">6,108,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930" decimals="2" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfOC0zLTEtMS0zODM0Mw_dd06b095-2240-4435-9177-3f3d64c6d572">17.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfOC01LTEtMS0zODM0Mw_01feeb33-b8c2-4a11-9d70-69a3c4656cc2">1.70</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930" decimals="-3" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfOC03LTEtMS0zODM0Mw_263c4e1f-48e9-4a3a-a4c7-fa659ecf4266">65,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><ix:continuation id="i45d6eb8a3c7c48dc8b0aa607a4cf7027"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMzc2Mw_8451fe74-d866-4fb4-9643-dad87e994987">85.0</ix:nonFraction>&#160;million of unrecognized stock-based compensation related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMzkyMA_ab5a7bbf-4fa0-4bf3-9d88-23db14445637">2 years, 240 days</ix:nonNumeric>.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ3MQ_e2a2c51b-bdeb-4d84-9f5f-d999da20cb44" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6627a5e0bcb745a7bcf2b1a0bcfb8913_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMi0xLTEtMS0zODM0Mw_2154825e-d706-4621-843b-0c2371536437">11,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b8c2dddec8a42c2a41bd9069f28fb76_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMi0zLTEtMS0zODM0Mw_ee273737-e5ec-4192-88e5-8e4e717309e0">10,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3949326941ae44ad8b85a5116571b2d9_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMi01LTEtMS0zODM0Mw_30bf4ce6-e889-4476-b318-6310cad7f310">35,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb04d23e1b334eea8232a278c94030b1_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMi03LTEtMS0zODM0Mw_9a9ad789-b9ac-4163-9a78-7aa7e0c82b3c">28,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f95a2fe74e8495c8a44a351002ab5f1_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMy0xLTEtMS0zODM0Mw_49d9ba35-43d4-4755-b223-2182b505f577">10,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i692e53151ed54db2bcad88681554f8e5_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMy0zLTEtMS0zODM0Mw_d6e85cc9-701e-4400-b3b3-8611adffdeb6">10,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657be91ad1cf4834ae3e495d97c6b831_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMy01LTEtMS0zODM0Mw_6111ffad-0a15-46ac-80a0-4c22848686a1">31,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0292c40a9540d5afb21ac604de6b00_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMy03LTEtMS0zODM0Mw_731e1cd5-c34e-4a8d-b391-ec774f5b949c">30,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfNC0xLTEtMS0zODM0Mw_e9b912f7-4835-4b5d-8a7f-ef0f7a49e7fc">21,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfNC0zLTEtMS0zODM0Mw_b3222a3a-875d-4813-ac88-b87fd187ffbe">20,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfNC01LTEtMS0zODM0Mw_56278697-c423-4b38-9971-42e38634d530">66,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfNC03LTEtMS0zODM0Mw_3649baf6-d4b6-4bc1-9a42-84d85bed6c7b">58,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercised Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows certain of its employees and its directors to exercise options granted under the Prior 2018 Plan and the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the non-current portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. During the nine months ended September 30, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNDkzNw_869282b9-1ef1-4e59-a858-ba7b3e5ab32a">zero</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNDk0NA_797a82a6-d9f9-4a3a-a6f9-4d73ec2f6f34">293,594</ix:nonFraction> options were early exercised. As of September&#160;30, 2022 and December&#160;31, 2021 there was $<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-5" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTAwMw_dd38eef2-aa60-48ed-825b-32a34302f9dd">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-5" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTAxMA_34b72b29-7c5c-413b-85c4-8d9d0ffe9b0b">2.9</ix:nonFraction> million, respectively, recorded in accrued and other liabilities and $<ix:nonFraction unitRef="usd" contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930" decimals="-5" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTA3NA_c6e7f384-df8e-4c4a-8425-779295bc5951">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iecc019de3c544aa08930db1891672917_I20211231" decimals="-5" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTA4MQ_b86d618d-57ca-4ce3-9ea6-96a47bd9e9c7">2.5</ix:nonFraction> million, respectively, recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed consolidated financial statements since the exercise date but the shares which are subject to future vesting conditions are not included in the calculation of earnings per share.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTY0OTI2NzQ0NTkxMg_4f64c0ff-bfc1-45ea-b9ac-1b82039ae256" continuedAt="i3228d13f14584687a161b5b0769362f7" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i3228d13f14584687a161b5b0769362f7" continuedAt="i4738b091239140b29c4c1e40045511a5"><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a license agreement with Allogene Overland, a corporate joint venture entity and related party (see Note 6). The license agreement was subsequently assigned to a wholly-owned subsidiary of Allogene Overland, Allogene Overland BioPharm (HK) Limited. On April 1, 2022, Allogene Overland HK assigned the License Agreement to Allogene Overland Biopharm (PRC) Co., Limited. During the three and nine months ended September&#160;30, 2022, the Company recognized less than $<ix:nonFraction unitRef="usd" contextRef="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzQyMQ_7a99ce65-e25c-4831-a792-6db5e2fcecac">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzQzMg_486aca37-4706-4758-92dd-3ef8c9b907f1">0.2</ix:nonFraction> million of collaboration revenue under this arrangement, respectively. During the three and nine months ended September&#160;30, 2021, the Company recognized less than $<ix:nonFraction unitRef="usd" contextRef="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfNjY2_939f0e9a-766d-47a0-9c39-41535958f2f2">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfNjcz_4c2ca9ad-b2e3-42e3-b5a8-4e70af542233">38.4</ix:nonFraction> million, respectively, of collaboration revenue under this arrangement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzQxMg_df9d1e84-a3aa-469b-9282-9223785f5398">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfNzk2_52b0e83a-13e0-4a42-a6ef-db290d969310">0.6</ix:nonFraction> million, respectively, of net cost recoveries under the terms of the license agreement as a reduction to research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded <ix:nonFraction unitRef="usd" contextRef="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930" decimals="INF" name="us-gaap:RecoveryOfDirectCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfOTgw_413ea916-22ea-4798-b7c6-51fade0ceb7d"><ix:nonFraction unitRef="usd" contextRef="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930" decimals="INF" name="us-gaap:RecoveryOfDirectCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfOTgw_457d4764-8a82-45a0-bae2-a309a9303f87">zero</ix:nonFraction></ix:nonFraction> net cost recoveries under the terms of the license agreement. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for <ix:nonFraction unitRef="sqft" contextRef="ide3d377e6ef446be87bcdb339dfc0b9b_D20181201-20181231" decimals="0" name="allo:AreaOfOffice" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTE1Ng_92308ae3-0750-40df-bf1f-12a8c4a5e4f4">1,293</ix:nonFraction> square feet of office space in Los Angeles, California for a <ix:nonNumeric contextRef="i55782e475b6a49e68f013ee57e855017_I20181231" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzU5Mw_84a50560-ca37-4692-9893-f37d0c37322b">three year</ix:nonNumeric> term. On April 1, 2020, Bellco Capital Advisors Inc. assumed all rights, title, interests and obligations under the sublease from Bellco Capital LLC. In November 2021, the sublease was extended to June 30, 2025. The sublease was amended, effective in July 2022, to move to a nearby location, with office space of <ix:nonFraction unitRef="sqft" contextRef="i10cdf1fbcbd24042b88e39c59ceb0185_D20220701-20220731" decimals="0" name="allo:AreaOfOffice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzM4Mg_c75606ce-6e69-43bc-851e-49413b5b88d3">737</ix:nonFraction> square feet. The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is a trustee of the Belldegrun Family Trust, which controls Bellco Capital Advisors Inc. The total right of use asset and associated liability recorded related to this related party lease was $<ix:nonFraction unitRef="usd" contextRef="i6835c65c40e448ee9cdf956aa442f14c_I20220930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTY5NQ_418582ec-1498-4d46-a0a0-d51122cdea6d"><ix:nonFraction unitRef="usd" contextRef="i6835c65c40e448ee9cdf956aa442f14c_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTY5NQ_d0cca3bb-1c74-43fe-9183-83b28a85d3ac">0.2</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2f07bcc60d124644b17029e7a86498b5_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTcwMg_6349bb82-8eef-460d-a10e-559f00985239"><ix:nonFraction unitRef="usd" contextRef="i2f07bcc60d124644b17029e7a86498b5_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTcwMg_f39da07c-dd46-4f60-ae92-0f7e6c7e04f1">0.3</ix:nonFraction></ix:nonFraction>&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a services agreement with Two River, LLC (Two River), a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chair of the board of directors, and a director of the Company to provide various managerial, clinical development, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $<ix:nonFraction unitRef="usd" contextRef="i244e669df12d499393987c604e57d35f_D20220701-20220930" decimals="-5" name="us-gaap:RelatedPartyCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjE5Nw_0abf1efb-3a20-45e5-81a5-3e8b670071dc">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70d6feb00c574d04aecd098830cbbe99_D20220101-20220930" decimals="-5" name="us-gaap:RelatedPartyCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjIwNA_5677b936-c8dd-4f27-a345-9e08f7973b9b">0.6</ix:nonFraction> million for the three and nine months ended September&#160;30, 2022, respectively. The costs incurred for services provided under this agreement were $<ix:nonFraction unitRef="usd" contextRef="i311fa2e0db8b4c88adb07d7473de0631_D20210701-20210930" decimals="-5" name="us-gaap:RelatedPartyCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjMxNg_8e67978a-f581-4e1a-a1f6-3b3b62637213">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3f691c5f7eea4a9b9059a123b37ca9aa_D20210101-20210930" decimals="-5" name="us-gaap:RelatedPartyCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzM5MA_ac42250c-8b7e-4ee3-8e45-e7a45bcbf968">0.4</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021, respectively.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4738b091239140b29c4c1e40045511a5">In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $<ix:nonFraction unitRef="usd" contextRef="i5ffebc0cc88b45c683f02d07c9da34b6_D20210101-20211231" decimals="INF" name="allo:RelatedPartyTransactionMonthlyPaymentsInArrears" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjg4Nw_69e7de88-ca77-42e7-beec-79f1ccc48435">38,583</ix:nonFraction> per month in arrears commencing January 2021 and $<ix:nonFraction unitRef="usd" contextRef="i48fcbfbc97c948488803f2fa246b65ec_D20220101-20220930" decimals="INF" name="allo:RelatedPartyTransactionMonthlyPaymentsInArrears" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjkzOQ_c5050c5e-5353-44dd-93be-8f5fafe71ccf">40,217</ix:nonFraction> per month in arrears commencing January 2022. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to <ix:nonFraction unitRef="number" contextRef="i83ba27cde25d42a1bcb8d43b98591e86_D20180801-20180831" decimals="2" name="allo:RelatedPartyTransactionCompensationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzA4Nw_b83ede72-a2c6-46ab-b335-b84387c9f7a1">60</ix:nonFraction>% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The costs incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $<ix:nonFraction unitRef="usd" contextRef="i71270f28c9f44b26884a7a3c29b0a8c6_D20220701-20220930" decimals="-5" name="us-gaap:RelatedPartyCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzM3MQ_91e42e41-2e1e-45c7-9020-9c5c38819eff">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iad6cc93503974700a19e1ba725f39da7_D20220101-20220930" decimals="-5" name="us-gaap:RelatedPartyCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzM3OA_b5c2d1aa-4bd9-4dda-b863-e04a450ff7ed">0.6</ix:nonFraction> million for the three and nine months ended September&#160;30, 2022, respectively. The costs incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $<ix:nonFraction unitRef="usd" contextRef="i9b84fdd9ca2b4e34a5b489c6cfd75f6b_D20210701-20210930" decimals="-5" name="us-gaap:RelatedPartyCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzUzNw_31cfe62c-8cd3-4404-ba4e-9a4ef333f76a">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib3537c96671a47618355dfe9daa3ab84_D20210101-20210930" decimals="-5" name="us-gaap:RelatedPartyCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzU0NA_5f3c8059-c19c-45f7-80f5-a6cce3dfd7b8">0.6</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021, respectively.</ix:continuation>  </span></div><div id="iad69808f292f43f6bbc63337efb1d90e_61"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82MS9mcmFnOjA3YWNkNWYxNzdjODRkYWE5OWVkNDQ5NDQ4N2IwNDg5L3RleHRyZWdpb246MDdhY2Q1ZjE3N2M4NGRhYTk5ZWQ0NDk0NDg3YjA0ODlfMTk5_33a33ba7-f8bb-4889-b0d8-9f86134000bc" continuedAt="i0d72a53b22b74f289b6e643989810d42" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0d72a53b22b74f289b6e643989810d42">The Company has a history of losses and expects to record a loss in 2022. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RleHRyZWdpb246ZTRiY2Y2YjdiODc5NGQ4YzlmMWY2YTViY2VhYzYwNzlfMjIw_4f9e082a-567d-436d-a487-ad98b2367d75" continuedAt="i2ea144beca0b419fbdc885608bbf3c84" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i2ea144beca0b419fbdc885608bbf3c84"><ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RleHRyZWdpb246ZTRiY2Y2YjdiODc5NGQ4YzlmMWY2YTViY2VhYzYwNzlfMjIx_23e7c00a-9077-4436-8745-fd769a1dfa60" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c288bc903b4445db1aca2a0589bff15_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfMi0xLTEtMS0zODM0Mw_d2f1ec89-890d-452b-8722-a588b3fd7ddd">18,122,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2735eb3759f4c978a3d46ef79aa58c4_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfMi0zLTEtMS0zODM0Mw_04d77178-93f7-451a-b399-359d952f3130">10,109,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units subject to vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09654a2f64fc4baea96c1b7e18d63c05_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfMy0xLTEtMS0zODM0Mw_179194de-3a82-45ff-918a-d3348db2e987">6,108,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia29bfb086dc54826adc5a81036ef756f_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfMy0zLTEtMS0zODM0Mw_6b94b365-d205-4b2d-b3ec-93da5fb5a079">3,393,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected shares to be purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i168b193cba9e427089753a5b30b8c90f_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNC0xLTEtMS0zODM0Mw_f6aac80e-9475-4341-8c44-c7e93315da1f">750,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i774d91333c954992bc09c9a46d392ded_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNC0zLTEtMS0zODM0Mw_fa89e086-1fd7-4429-b518-fef0e9a4e53d">276,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Founders' shares of common stock subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a0727775830468a9e27ab2c44c1b6ff_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNS0xLTEtMS0zODM0Mw_8e2e59e9-a432-49ee-a8c7-8be37a302e35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d3e864f70414a80bc0964777b022263_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNS0zLTEtMS0zODM0Mw_74e77177-fd15-4941-848f-f48a2ef88092">3,028,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf062f962ee04c1fad713216e1f06041_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNi0xLTEtMS0zODM0Mw_ba74e022-2ae2-45b7-ba06-ba160fd603f5">162,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b6de817bdd944afad54fb6f862dd4cc_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNi0zLTEtMS0zODM0Mw_d9213852-b68e-401a-a192-e32de542da92">1,057,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNy0xLTEtMS0zODM0Mw_414a54af-9678-4699-bcfe-ba3313b81fb2">25,143,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNy0zLTEtMS0zODM0Mw_f87abf66-38d0-46bc-9f2f-aff1a6756093">17,865,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div id="iad69808f292f43f6bbc63337efb1d90e_67"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82Ny9mcmFnOjQwYmE2NGFiZTUyMDRhYTk4MmJlNzc4YWQ3MmQ5MGNkL3RleHRyZWdpb246NDBiYTY0YWJlNTIwNGFhOTgyYmU3NzhhZDcyZDkwY2RfMTExMg_ddde992e-987a-4483-9e60-16f971f30caa" continuedAt="i1c5fc7504c1d4ae9a7972d251d899274" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1c5fc7504c1d4ae9a7972d251d899274">On October 6, 2022, the Company announced the initiation of the Phase 2 clinical trial of ALLO-501A (the ALPHA2 trial) in patients with relapsed/refractory large B-cell lymphoma. The Company is also in the process of initiating the EXPAND trial, which is intended to demonstrate the contribution of ALLO-647 to the lymphodepletion regimen. In accordance with the Servier Agreement, the Company is required to make a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i34c392be59f54e6f9714301ddcb1bc63_I20221006" decimals="-5" name="allo:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82Ny9mcmFnOjQwYmE2NGFiZTUyMDRhYTk4MmJlNzc4YWQ3MmQ5MGNkL3RleHRyZWdpb246NDBiYTY0YWJlNTIwNGFhOTgyYmU3NzhhZDcyZDkwY2RfMTA5OTUxMTYzMzM4OA_1b772efd-475b-44e2-b2b4-bb6f7f0d6d29">8.0</ix:nonFraction>&#160;million upon first dosing of the first patient in a Phase 2 clinical trial. The milestone payment is expected to be recognized in the fourth quarter.</ix:continuation>  </span></div><div id="iad69808f292f43f6bbc63337efb1d90e_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December&#160;31, 2021 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2021 (Annual Report), which was filed with the Securities and Exchange Commission (SEC) on February 23, 2022. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;Allogene,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Allogene Therapeutics, Inc., and references to &#8220;Servier&#8221; collectively refer to Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part II, Item 1A below. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements</span><span style="color:#32406b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient&#8217;s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a deep pipeline of allogeneic chimeric antigen receptor (CAR) T cell product candidates targeting multiple promising antigens in a host of hematological malignancies and solid tumors. Pursuant to our Exclusive Collaboration and License Agreement with Servier (Servier Agreement), we have exclusive rights to ALLO-501 and ALLO-501A, CAR T cell product candidates targeting CD19, in the United States. ALLO-501 and ALLO-501A use Cellectis S.A. (Cellectis) technologies under which Servier holds an exclusive worldwide license from Cellectis. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, Servier sent a notice of discontinuation (Discontinuation) of its involvement in the development of all licensed products directed against CD19, including UCART19, ALLO-501 and ALLO-501A (collectively, CD19 Products), pursuant to the Servier Agreement. Servier&#8217;s Discontinuation provides us with the right to elect a license to the CD19 Products outside of the United States (Ex-US Option) and does not otherwise affect our current exclusive license for the development and commercialization of CD19 Products in the United States. Upon any exercise of the Ex-US Option by us, our potential milestone payments with respect to ALLO-501A would increase for any first dosing in Phase 2, first dosing in Phase 3 and regulatory approval by &#8364;46 million in the aggregate. In addition, upon any such exercise of the Ex-US Option, Servier's obligation to reimburse us for 40% of the development costs for CD19 Products would cease. See &#8220;Risk Factors&#8212;Servier&#8217;s Discontinuation of its involvement in the development of CD19 Products may have adverse consequences.*&#8221;</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are conducting long-term follow-up in our Phase 1 clinical trial (the ALPHA trial) of ALLO-501 in patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). We are also progressing the development of the second-generation version of ALLO-501, known as ALLO-501A. We have removed rituximab recognition domains in ALLO-501A, which we believe will potentially facilitate treatment of more patients, as rituximab is a typical part of a treatment regimen for a patient with NHL. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recently initiated a Phase 2 clinical trial for ALLO-501A (the ALPHA2 trial) in R/R large B cell lymphoma (LBCL). We conducted an extensive Phase 1 program designed to evaluate and optimize all aspects of our therapy, including multiple doses and schedules of ALLO-501A and one of our lymphodepletion agents, ALLO-647. In addition, we conducted a review of the Phase 1 program, which determined a manufacturing process associated with robust clinical performance. Our selected manufacturing process, named Alloy, will be deployed in the ALPHA2 trial and the EXPAND trial discussed below. The Phase 2 trial will begin with previously manufactured material from our prior contract manufacturing organization and we may transition to product from our manufacturing facility during the course of the ALPHA2 and EXPAND trials.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The single-arm ALPHA2 trial will utilize a single dose of ALLO-501A at 120 million CAR+ cells with a lymphodepletion regimen comprised of fludarabine (30 mg/m2/day x 3 days) and cyclophosphamide (300 mg/m2/day x 3 days) plus ALLO-647 (90 mg). We plan to enroll approximately 100 patients who have received at least two prior lines of therapy and have not received any prior anti-CD19 therapy, including CAR T therapy. The primary endpoint is objective response rate (ORR) and the key secondary endpoint is duration of response (DoR). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are also in the process of initiating the EXPAND trial, which is expected to enroll approximately 70 patients with R/R LBCL and is intended to demonstrate the contribution of ALLO-647 to the overall benefit of the lymphodepletion regimen. Patients will be randomized to receive the same single 120 million CAR+ cell dose of ALLO-501A as in the ALPHA2 trial and either lymphodepletion with fludarabine and cyclophosphamide (control arm) or the lymphodepletion regimen of the ALPHA2 trial (active arm). The primary endpoint of this trial is progression free survival, and the key secondary endpoints are ORR, DoR, and the safety of ALLO-647.  Assuming favorable outcomes and subject to FDA discussions, we plan to seek FDA approval of ALLO-501A and ALLO-647 on the basis of the ALPHA2 trial and the EXPAND companion trial.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are sponsoring two clinical trials in adult patients with R/R multiple myeloma, a Phase 1 clinical trial (the UNIVERSAL trial) of ALLO-715 and a Phase 1 clinical trial (the IGNITE trial) of ALLO-605, our first product candidate to incorporate our TurboCAR technology. TurboCAR technology allows cytokine signaling to be engineered selectively into CAR T cells and has shown the ability to improve the potency and persistence of the cells and to delay exhaustion of the cells in preclinical models. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also continue to advance the Phase 1 clinical trial (the TRAVERSE trial) of ALLO-316, an allogeneic CAR T cell product candidate targeting CD70, in adult patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC). Subject to results from the TRAVERSE trial, we may investigate the use of ALLO-316 for other solid tumor and hematologic indications.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are planning an Allogene R&amp;D Showcase on November 29, 2022 to provide an update on certain of our research and development programs, including additional data from the ALPHA, ALPHA2 and UNIVERSAL trials.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment of patients and the ability to conduct patient follow-up has been adversely impacted by the COVID-19 pandemic. The exact timing of delays and overall impact of the COVID-19 pandemic to our business, preclinical studies and clinical trials is currently unknown, and we are monitoring the pandemic as it continues to evolve.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have had significant operating losses. Our net losses were $83.1 million and $237.8 million for the three and nine months ended September&#160;30, 2022, respectively. As of September&#160;30, 2022, we had an accumulated deficit of $1.1 billion.&#160;As of September&#160;30, 2022, we had $637.3 million in cash and cash equivalents and investments.&#160;We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses and general and administrative expenses will continue to increase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Research and Development and License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Contribution Agreement with Pfizer</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, we entered into an Asset Contribution Agreement (Pfizer Agreement) with Pfizer pursuant to which we acquired certain assets and assumed certain liabilities from Pfizer, including agreements with Cellectis and Servier as described below, and other intellectual property for the development and administration of CAR T cells for the treatment of cancer. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further description of the Pfizer Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Cellectis</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, Pfizer entered into a Research Collaboration and License Agreement with Cellectis. In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement. In March 2019, we terminated the agreement with Cellectis and entered into a new license agreement with Cellectis. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further descriptions of the prior agreement with Cellectis and the new license agreement with Cellectis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement with Servier</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, Pfizer entered into the Servier Agreement to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR products in the United States with the option to obtain the rights over certain additional allogeneic anti-CD19 CAR product candidates and for allogeneic CAR T cell product candidates directed against one additional target. In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement. In October 2019, we agreed to waive our rights to the one additional target. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further description of the Servier Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and License Agreement with Notch</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2019, we entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted us an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in NHL, ALL and multiple myeloma. In addition, Notch has granted us an option to add certain specified targets to our exclusive license in exchange for an agreed upon per-target option fee.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to our exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. In connection with the execution of the Notch Agreement, we made an upfront payment to Notch of $10.0 million. In addition, we made a $5.0 million investment in Notch&#8217;s series seed convertible preferred stock, resulting in us having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In February 2021, we made an additional $15.9 million investment in Notch's Series A preferred stock. In October 2021, we made an additional $1.8&#160;million investment in Notch's common stock. Immediately following this transaction, our share in Notch was 23.0% on a voting interest basis. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further description of the Notch Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Alliance with The University of Texas MD Anderson Cancer Center</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2020, we entered into a strategic five-year collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. See Note 6 to our consolidated financial statements included elsewhere in this report for further description of the agreement with MD Anderson.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Allogene Overland </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 14, 2020, we entered into a License Agreement with Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by us and Overland Pharmaceuticals (CY) Inc. (Overland), pursuant to a Share Purchase Agreement, dated December 14, 2020, for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore (the JV Territory). Allogene </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Overland subsequently assigned the Licensed Agreement to a wholly-owned subsidiary, Allogene Overland BioPharm (HK) Limited (Allogene Overland HK). On April 1, 2022, Allogene Overland HK assigned the License Agreement to Allogene Overland Biopharm (PRC) Co., Limited. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further description of the License Agreement and Share Purchase Agreement with Allogene Overland.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and License Agreement with Antion</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2022, we entered into an exclusive collaboration and global license agreement (Antion Agreement) with Antion Biosciences SA (Antion) for Antion&#8217;s miRNA technology (miCAR), to advance multiplex gene silencing as an additional tool to develop next generation allogeneic CAR T products. Pursuant to the agreement, Antion will exclusively collaborate with us on oncology products for a defined period. We will also have exclusive worldwide rights to commercialize products incorporating Antion technology developed during the collaboration. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further description of the Antion Agreement.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, our revenue has been exclusively generated from our collaboration and license agreement with Allogene Overland Biopharm (PRC) Co., Limited. See Note 6 to our financial statements appearing elsewhere in this Quarterly Report for more information related to our recognition of revenue and the Allogene Overland Biopharm (PRC) Co., Limited agreement.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from a combination of product sales, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestones and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval of them, our ability to generate future revenue, and our results of operations and financial position, will be materially adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our research and development expenses have related primarily to discovery efforts, preclinical and clinical development, and manufacturing of our product candidates. Research and development expenses for the three and nine months ended September&#160;30, 2022 included costs associated with our clinical and preclinical stage pipeline candidates and research into newer technologies. The most significant research and development expenses for the year to date relate to costs incurred for the development of our most advanced product candidates and include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expenses incurred under agreements with our collaboration partners and third-party contract organizations, investigative clinical trial sites that conduct research and development activities on our behalf, and consultants;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costs related to production of clinical materials, including fees paid for raw materials and to contract manufacturers;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">laboratory and vendor expenses related to the execution of preclinical and clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">employee-related expenses, which include salaries, benefits and stock-based compensation; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and amortization expense and supplies; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">other significant research and development costs including overhead costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense all research and development costs in the periods in which they are incurred. We accrue for costs incurred as the services are being provided by monitoring the status of&#160;the project and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to reimburse Servier for 60% of the costs associated with the prior development of UCART19, including for the long-term follow-up of patients in the CALM and PALL clinical trials of UCART19. We accrue for costs </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred by monitoring the status of clinical trials and the invoices received from Servier. We adjust our accrual as actual costs become known. Pending any exercise by us of the Ex-US Option, Servier is required to reimburse us for 40% of the costs associated with the development of ALLO-501 and ALLO-501A.&#160;Collaboration expenses and cost reimbursement are recorded on a net basis as a research and development expense in our condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase in the future as&#160;our clinical programs progress and as we seek to initiate clinical trials of additional product candidates. The cost of advancing our manufacturing process as well as the cost of manufacturing product candidates for clinical trials are included in our research and development expense. We also expect to incur increased research and development expenses as we selectively identify and develop additional product candidates. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">biomarker analysis costs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost and timing of manufacturing for the trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of patients that participate in the trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of sites included in the trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the countries in which the trials are conducted;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the total number of cells that patients receive;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential additional safety monitoring or other studies requested by regulatory agencies, including to resolve any future clinical hold;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the duration of patient follow-up; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the efficacy and safety profile of the product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the probability of success for each product candidate will depend on numerous factors, including safety, efficacy, competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our product candidates are still in clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other staff-related costs, including stock-based compensation for options and restricted stock units granted. Other significant costs include costs relating to facilities and overhead costs, legal fees relating to corporate and patent matters, insurance, investor relations costs, fees for accounting and consulting services, information technology, costs and support for our board of directors and board committees, and other general and administrative costs. General and administrative costs are expensed as incurred, and we accrue for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from our service providers, and adjusting our accruals as actual costs become known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, potential commercialization of our product candidates and the increased costs of operating as a public company, including additional compliance-related expenses as a result of no longer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being an emerging growth company. These increases are anticipated to include increased costs related to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, complying with and advancing environmental, social and governance matters, and insurance and investor relations costs.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net consists of interest earned on our cash and cash equivalents and investments, as well as investment gains and losses recognized during the period.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense consists of non-operating expenses, including our share of equity investments' net losses for the period.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September&#160;30, 2022 and 2021</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth our results of operations for the three months ended September&#160;30, 2022 and 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:51.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,489)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,670)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,819)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,148)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,186)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,962)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue - related party</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was less than $0.1 million for the three months ended September&#160;30, 2022 and 2021. Revenue recognized in the three months ended September 30, 2022 and 2021 was due to the delivery of the know-how performance obligations related to the License Agreement entered into with Allogene Overland on December 14, 2020.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $63.6&#160;million and $58.7 million for the three months ended September&#160;30, 2022 and 2021, respectively. The increase of $4.9 million was driven primarily by an increase in personnel related costs of $5.9 million, of which $0.9 million was stock-based compensation expense, and an increase in facilities costs and depreciation expense of $4.3 million, offset by a $5.9 million decrease in external costs relating to the advancement of our product candidates primarily due to the timing of development activities and manufacturing runs. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $18.9&#160;million and $19.0 million for the three months ended September&#160;30, 2022 and 2021, respectively. The decrease of $0.1 million was primarily due to a decrease in business and consulting fees of $1.4 million, offset by a $0.9 million increase in personnel related costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net was $1.0 million and $0.4&#160;million for the three months ended September&#160;30, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September&#160;30, 2022 and 2021</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth our results of operations for the nine months ended September&#160;30, 2022 and 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:51.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239,075)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,899)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,176)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,785)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,137)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,648)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* - Percentage is not meaningful</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue - related party</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $0.2 million and $38.4 million for the nine months ended September&#160;30, 2022 and 2021, respectively. The decrease of $38.2 million was due to the revenue recognized related to the license of intellectual property and delivery of the know-how performance obligation, which was delivered in the first quarter of 2021, under the License Agreement entered into with Allogene Overland in December 2020.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $181.0 million and $166.2 million for the nine months ended September&#160;30, 2022 and 2021, respectively. The increase of $14.8 million was driven primarily by an increase in personnel related costs of $18.5 million, of which $6.6 million was stock-based compensation expense, and an increase in facilities costs and depreciation expense of $14.0 million, offset by a $20.3 million decrease in external costs relating to the advancement of our product candidates due to the timing of development activities and manufacturing runs. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $58.3 million and $54.1 million for the nine months ended September&#160;30, 2022 and 2021, respectively. The increase of $4.2 million was primarily due to an increase in personnel related costs of $5.0 million, of which $1.0 million was stock-based compensation expense, and an increase in expenses related to corporate communications of $1.2 million, offset by a $2.0 million decrease in business and consulting fees.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net was $1.8&#160;million and $1.5&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have incurred significant net losses and negative cash flows from operations. As of September&#160;30, 2022, we had $637.3 million&#160;in cash and cash equivalents and investments. We anticipate that the aggregate of our current cash and cash equivalents and investments available for operations will enable us to maintain our operations for a period of at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have been financed primarily by net proceeds from the sale and issuance of our convertible preferred stock, the issuance of convertible promissory notes, net proceeds from our IPO, our at-the-market (ATM) offerings, our June 2020 underwritten public offering, and upfront cash payment of $40.0 million received in December 2020 pursuant to our License Agreement with Allogene Overland. In connection with our IPO in 2018, we sold an aggregate of 20,700,000 shares of our common stock (inclusive of 2,700,000 shares of common stock pursuant to the over-allotment option granted to the underwriters) at a price of $18.00 per share and received approximately $343.3 million in net proceeds. In November 2019, we entered into a sales agreement with Cowen and Company, LLC (Cowen) under which we may from time to time issue and sell shares of our common stock through Cowen in ATM offerings for an aggregate offering price of up to $250.0 million. As of September&#160;30, 2022, $167.3 million remains available for sale under the sales agreement with Cowen.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we sold 13,457,447 shares of our common stock, which included 1,755,319 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, in an underwritten public offering at a price of $47.00 per share, which resulted in net proceeds of approximately $595.7 million after deducting the underwriting discounts and commissions and other expenses.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:72.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,423)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,376)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,562&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,405&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,641&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,957)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,670&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, cash used in operating activities of $158.4 million was attributable to a net loss of $237.8 million, partially offset by non-cash charges of $86.5 million and an increase of $7.1 million in our net operating assets and liabilities. The non-cash charges consisted primarily of stock-based compensation expense of $66.4 million, depreciation of $11.2 million, our share of equity investments' net losses for the period of $4.0 million, net amortization and accretion on investment securities of $2.7 million, and non-cash rent expense of $2.2 million. The change in operating assets and liabilities was primarily due to a $3.2&#160;million increase in other long-term assets, a $2.8&#160;million increase in prepaid expenses and other current assets, a $1.4&#160;million decrease in accrued and other current liabilities, and a $2.1&#160;million decrease in other long-term liabilities, offset by a $1.9&#160;million increase in accounts payable and a $0.5&#160;million increase in deferred revenue. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, net cash provided by investing activities of $56.6 million was related to cash provided by investment maturities of $260.4 million, offset by cash used in purchases of investments of $200.3 million and cash used in the purchase of property and equipment of $3.5 million.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, cash provided by financing activities of $2.9 million was related to $2.5 million of cash provided by the sale of common stock through our employee stock purchase plan and $0.4 million of cash provided by the issuance of common stock upon exercise of stock options.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Cash Commitments and Requirements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our primary use of cash is for operating expenses, which consist primarily of clinical manufacturing and research and development expenditures related to our lead product candidates, other research efforts, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses and other current liabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are still in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain. Accordingly, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration and license arrangements. If, and when, we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise capital when needed, we will need to delay, reduce or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments primarily consist of obligations under our agreements with Pfizer, Cellectis, Servier and Notch. Under these agreements we are required to make milestone payments upon successful completion of certain regulatory and sales milestones on a target-by-target and country-by-country basis. The payment obligations under the license agreements are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under these agreements. As of September&#160;30, 2022, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. For additional information regarding our agreements, see Note 6 to our condensed consolidated financial statements included elsewhere in this report. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have entered into agreements with third-party contract manufacturers for the manufacture and processing of certain of our product candidates for clinical testing purposes, and we have entered and will enter into other contracts in the normal course of business with contract research organizations for clinical trials and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred. As of September&#160;30, 2022, the Company had non-cancellable purchase commitments of $0.4&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2020, we announced we entered into a strategic five-year collaboration agreement with MD Anderson for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. We and MD Anderson are collaborating on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. Under the terms of the agreement, we have committed up to $15.0 million of funding for the duration of the agreement. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance. We made an upfront payment of $3.0 million to MD Anderson in the year ended December 31, 2020. We are obligated to make further payments to MD Anderson each year upon the anniversary of the agreement effective date through the duration of the agreement term. The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, among other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into a Solar Power Purchase and Energy Services Agreement for the installation and operation of a solar photovoltaic generating system and battery energy storage system at our manufacturing facility in Newark, California. The agreement has a term of 20 years and commenced in September 2022. We are obligated to pay for electricity generated from the system at an agreed rate for the duration of the agreement term. Termination of the agreement by us will result in a termination payment due of approximately $4.3 million. In connection with the agreement, we maintain a letter of credit for the benefit of the service provider in the amount of $4.3 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a Change in Control and Severance Plan that require the funding of specific payments, if certain events occur, such as a change of control and the termination of employment without cause.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting principles. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the assumptions and estimates associated with accrued research and development expenditures and stock-based compensation have the most significant impact on our condensed consolidated financial statements. Therefore, we consider these to be our critical accounting policies and estimates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Operations&#8221; included in our Annual Report.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued or effective that are expected to have a material impact on our unaudited condensed financial statements.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate fluctuations.</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents and investments of $637.3 million as of September&#160;30, 2022 consist of bank deposits, money market funds and available-for-sale securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. A 10% change in the interest rates in effect on September&#160;30, 2022 would not have had a material effect on the fair market value of our cash equivalents and available-for-sale securities.</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Rate Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration agreement with Servier requires collaboration payments for shared clinical development costs to be paid in Euros, and thus we face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. An adverse movement in foreign exchange rates could have an effect on payments due and made to our collaboration partner as well as other foreign suppliers and for license agreements. A 10% change in the applicable foreign exchange rates during the periods presented would not have had a material effect on our condensed consolidated financial statements. As of September&#160;30, 2022, we had $4.3 million of other receivables denominated in foreign currency.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div id="iad69808f292f43f6bbc63337efb1d90e_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of implementing new enterprise resource planning software, SAP, as part of a plan to integrate and upgrade our systems and processes. The implementation of this software is scheduled to continue in phases over a number of years. During the first quarter of 2021, we migrated certain areas of our business to SAP, including financial reporting, asset management, procurement, clinical inventory and warehouse management. As the phased implementation of future modules occurs, we expect to experience certain changes to our processes and procedures which, in turn, result in changes to our internal control over financial reporting. While we expect SAP to strengthen our internal financial controls by automating certain manual processes and standardizing business processes and reporting, management will continue to evaluate and monitor our internal controls as processes and procedures in each of the affected areas evolve.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as discussed above, no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended September&#160;30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II-OTHER INFORMATION</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">RISK FACTOR SUMMARY</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission (SEC) before making investment decisions regarding our common stock. </span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future. </span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us. </span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Gene-editing is a relatively new technology, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">The COVID-19 global pandemic is adversely impacting our business, including our preclinical studies and clinical trials.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We are heavily reliant on our partners for access to TALEN gene editing technology for the manufacturing and development of our product candidates.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Servier's Discontinuation may have adverse consequences.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our business is highly dependent on the success of our lead product candidates. If we are unable to advance clinical development, obtain approval of and successfully commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our product candidates may cause undesirable side effects or have other properties that have halted and could in the future halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We may fail to successfully manufacture our product candidates, operate our own manufacturing facility, or obtain regulatory approval to utilize or commercialize from our manufacturing facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We rely and will continue to rely on third parties to conduct our clinical trials and manufacture our product candidates and critical raw materials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We rely on T cells from healthy donors and other specialty raw materials to manufacture our product candidates, and if we do not obtain an adequate supply of T cells from qualified donors or other raw materials, development of those product candidates would be adversely impacted. </span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-align:center;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:95%">RISK FACTORS</span></div><div style="text-align:center;text-indent:24.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described below when evaluating our business. The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in, or did not appear as separate risk factors in, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021 (Annual Report), which was filed with the SEC on February 23, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company and investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We are advancing an allogeneic CAR T platform of primarily early-stage product candidates and have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. For the year ended December 31, 2021, we reported a net loss of $257.0 million. For the nine months ended September&#160;30, 2022, we reported a net loss of $237.8 million. As of September&#160;30, 2022, we had an accumulated deficit of $1.1 billion. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seek regulatory approvals for, product candidates based on our engineered allogeneic T cell platform. Because our allogeneic T cell product candidates are based on new technologies and will require the creation of inventory of mass-produced, off-the-shelf product, they will require extensive research and development and have substantial manufacturing and processing costs. In addition, costs to treat patients with relapsed or refractory cancer and to treat potential side effects that may result from our product candidates can be significant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. For instance, the FDA placed our clinical trials on hold in October 2021, which suspended our clinical programs prior to resolution of the hold in January 2022. Even if we succeed in advancing our clinical trials and commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a pipeline of allogeneic T cell product candidates that are engineered from healthy donor T cells to express CARs and are intended for use in any patient with certain cancers. Advancing these novel product candidates creates significant challenges for us, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">manufacturing our product candidates to our or regulatory specifications and in a timely manner to support our clinical trials, and, if approved, commercialization;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sourcing clinical and, if approved, commercial supplies for the raw materials used to manufacture our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">understanding and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately affect our ability to produce product in a reliable and consistent manner and treat certain patients;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">educating medical personnel regarding the potential side effect profile of our product candidates, if approved, such as the potential adverse side effects related to cytokine release syndrome (CRS), neurotoxicity, graft-versus-host disease (GvHD), prolonged cytopenia, aplastic anemia and neutropenic sepsis;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">using medicines to preempt or manage adverse side effects of our product candidates and such medicines may be difficult to source or costly or may not adequately control the side effects and/or may have other safety risks or a detrimental impact on the efficacy of the treatment;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">conditioning patients with chemotherapy and ALLO-647 or other lymphodepletion agents in advance of administering our product candidates, which may be difficult to source, costly or increase the risk of infections and other adverse side effects;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining regulatory approval, as the FDA and other regulatory authorities have limited experience with development of allogeneic T cell therapies for cancer; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gene-editing is a relatively new technology, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cellectis&#8217;s TALEN technology involves a relatively new approach to gene editing, using sequence-specific DNA-cutting enzymes, or nucleases, to perform precise and stable modifications in the DNA of living-cells and organisms. Although Cellectis has generated nucleases for many specific gene sequences, it has not created nucleases for all gene sequences that we may seek to target, and Cellectis may not agree to or have difficulty creating nucleases for other gene sequences that we may seek to target, which could limit the usefulness of this technology. This technology may also not be shown to be effective in clinical studies that Cellectis, we or other licensees of Cellectis technology may conduct, or may be associated with safety issues that may negatively affect our development programs. For instance, gene-editing may create unintended changes to the DNA such as a non-target site gene-editing, a large deletion, or a DNA translocation, any of which could lead to oncogenesis. In our ALPHA2 trial, we observed a chromosomal abnormality, and the FDA placed our clinical trials on hold following this observation. While our investigation concluded that gene editing was not responsible for the chromosomal abnormality and the hold was resolved, we may discover future abnormalities caused by gene editing or other factors that would impact our development plans. The gene editing of our product candidates may also not be successful in limiting the risk of GvHD or premature rejection by the patient.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the gene-editing industry is rapidly developing, and our competitors may introduce new technologies that render our technology obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates. As competitors use or develop new technologies, any failures of such technology could adversely impact our program. We also may be placed at a competitive disadvantage, and competitive pressures may force us to implement new technologies at a substantial cost. In addition, our competitors may have greater financial, technical and personnel resources that allow them to enjoy technological advantages and may in the future allow them to implement new technologies before we can. We cannot be certain that we will be able to implement technologies on a timely basis or at a cost that is acceptable to us. If we are unable to maintain technological advancements consistent with industry standards, our operations and financial condition may be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 global pandemic has and is adversely impacting our business, including our preclinical studies and clinical trials.*</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or other outbreaks could adversely impact our business. As a result of the COVID-19 pandemic, or similar pandemics, and government response to pandemics, we have and may in the future experience disruptions that could severely impact our business, preclinical studies and clinical trials, including: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">halting or suspending enrollment in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays or difficulties in enrolling and retaining patients in our clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">interruption of key clinical trial activities, such as obtaining laboratory materials for collecting patient samples, clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increased adverse events and deaths in our clinical trials due to COVID-19 related infections, which may result in increased complications due to immune suppression from our lymphodepletion regimen;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or being forced to quarantine; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays or disruptions in preclinical experiments and investigational new drug application-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations and vendors; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">interruption of, or delays in receiving, supplies of our raw materials or product candidates from our suppliers and contract manufacturing organizations (CMOs) due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, or due to prioritization of production for COVID-19 specific therapies or vaccines;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">limitations on employee resources that would otherwise be focused on advancing our business, including because of sickness of employees or their families, including executive officers and other key employees, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">other disruptions to employee productivity, such as due to limited in person contact and reduction in employee morale.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local government response to the pandemic has included "shelter in place", "stay at home" and similar types of orders, which have limited travel and business operations in our locations, the location of our clinical trial sites, and the location of key vendors. The effects of our work-from-home policies and future government orders may increase risks associated with cybersecurity, disrupt our business and delay our development programs, regulatory and commercialization timelines. We continue to closely monitor the COVID-19 situation and may face several challenges or disruptions related to increasing onsite presence, including re-integration challenges by our employees and distractions to management related to such transition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while the long-term economic impact and the duration of the COVID-19 pandemic may be difficult to predict, the pandemic has resulted in, and may in the future result in, significant disruption of global financial markets, which could reduce our ability to access capital and could negatively affect our liquidity and the liquidity and stability of markets for our common stock. Market and economic deterioration could also adversely impact our portfolio of corporate and government bonds.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The extent to which the pandemic may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, the rise of new variants or subvariants that could be more contagious and virulent, travel restrictions and actions to contain the pandemic or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily reliant on our partners for access to TALEN gene editing technology for the manufacturing and development of our product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A critical aspect to manufacturing allogeneic T cell product candidates involves gene editing the healthy donor T cells in an effort to avoid GvHD and to limit the patient&#8217;s immune system from attacking the allogeneic T cells. GvHD results when allogeneic T cells start recognizing the patient&#8217;s normal tissue as foreign. We use Cellectis&#8217;s TALEN gene-editing technology to inactivate a gene coding for TCR&#945;, a key component of the natural antigen receptor of T cells, to cause the engineered T cells to be incapable of recognizing foreign antigens. Accordingly, when injected into a patient, the intent is for the engineered T cell not to recognize the tissue of the patient as foreign and thus avoid attacking the patient&#8217;s tissue. In addition, we use TALEN gene editing to inactivate the CD52 gene in donor T cells, which codes for the target of an anti-CD52 monoclonal antibody. Anti-CD52 monoclonal antibodies deplete CD52 expressing T cells in patients while sparing therapeutic allogeneic T cells lacking CD52. By administering an anti-CD52 antibody prior to infusing our product candidates, we believe we have the potential to reduce the likelihood of a patient&#8217;s immune system from rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which the engineered allogeneic T cells can actively target and destroy the cancer cells. However, the antibody may not have the benefits that we anticipate and could have adverse effects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on an agreement with Cellectis for rights to use TALEN technology for 15 select cancer targets, including BCMA, FLT3, CD70, DLL3 and other targets included in our pipeline. We also rely on Cellectis, through our agreement with Servier, for rights to UCART19, ALLO-501 and ALLO-501A. Any other gene-editing technology used to research and develop product candidates directed at targets not covered by our existing agreements with Cellectis and Servier will require significant investment and time for advancement. In addition, the Cellectis gene-editing technology may fail to produce viable product candidates. Moreover, both Servier and Cellectis may terminate our respective agreements in the event of a material breach of the agreements, or upon certain insolvency events. Cellectis has challenged and may in the future challenge certain performance by Servier, such as its development of products licensed under the Cellectis-Servier Agreement in ALL, and any failure by those parties to resolve such matters may have an adverse impact on us. If our agreements were terminated or we required other gene editing technology, such a license or technology may not be available to us on reasonable terms, or at all, and advancing other gene editing technology would require significant resources. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servier&#8217;s Discontinuation of its involvement in the development of CD19 Products may have adverse consequences.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On September 15, 2022, Servier sent a notice of discontinuation of its involvement in the development of all CD19 Products pursuant to the Servier Agreement. Despite there being no obligation under the terms of the Servier Agreement to do so, Servier believes that we had to exercise the Ex-US Option within a limited timeframe that passed. Servier also communicated to us that it believes it does not have to contribute to development costs 90 days from its notice of discontinuation, pending our exercise of the Ex-US Option. We disagree with these assertions relating to both the maintenance of the Ex-US Option as well as contribution to development costs during our consideration of the Ex-US Option. Any failure of Servier to fulfill its obligations may be harmful to us, and while we would intend to vigorously pursue our rights and remedies to enforce our contractual rights, any legal outcome for such enforcement action is inherently uncertain, will add to our costs and divert management time.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Servier also licenses certain rights to the CD19 Products from Cellectis and sublicenses those rights to us. Cellectis has challenged certain performance by Servier and has also challenged the ability of Servier to grant a world-wide sublicense. Servier&#8217;s Discontinuation and any subsequent actions may further strain the relationship between Servier and Cellectis, as well as between us and Cellectis. Any failure to resolve Cellectis challenges could have a significant adverse impact on our business, financial condition and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research, development and manufacturing efforts on our engineered allogeneic T cell therapy and our future success depends on the successful development of this therapeutic approach. We are in the early stages of developing our platform and we have experienced significant development challenges, such as with the prior clinical hold by the FDA, and there can be no assurance that any development problems we have now or experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial facilities or partners, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. For instance, it will take additional time and expense to transfer the Alloy process to our manufacturing facility and meet regulatory conditions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, since we are in the early stages of clinical development, we do not know all the doses to be evaluated in pivotal trials or, if approved, commercially. Finding a suitable dose for our cell therapy product candidates as well as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALLO-647 may delay our anticipated clinical development timelines. In addition, our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also advancing product candidates against unexplored targets and with new technology. For example, we are advancing ALLO-316 against a target, CD70, that has not been validated by any autologous CAR T therapies. ALLO-316 may have limited efficacy or have off-target toxicities. Since CD70 is found on activated T cells, ALLO-316 may also cause fratricide resulting in the loss of ALLO-316 cells or depletion of host T cells increasing the risk of infections. In addition, our ALLO-605 product candidate is our first TurboCAR candidate that is designed to mimic cytokine signaling selectively within CAR T cells. Our TurboCAR product candidates may be more difficult to manufacture, which could delay development timelines, or not demonstrate any of the benefits that we expect. Our TurboCAR product candidates have the potential to be more potent, which in turn may also increase the risk of adverse events, such as CRS and neurotoxicity. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical study requirements of the FDA, European Medicines Agency (EMA) and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. We face additional challenges in obtaining regulatory approval for ALLO-647, which we use as part of our lymphodepletion regimen, and for which we would seek to obtain approval concurrently with approval of a CAR T cell product candidate. Approvals by the EMA and FDA for existing autologous CAR T therapies, such as Kymriah and Yescarta, may not be indicative of what these regulators may require for approval of our therapies. Also, while we expect reduced variability in our products candidates compared to autologous products, we do not have significant clinical data supporting any benefit of lower variability and the use of healthy donor material may create separate variability challenges for us. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the autologous CAR T therapies that have previously been approved. For instance, allogeneic product candidates may result in GvHD or chromosomal abnormalities not experienced with autologous products. Additionally, any Phase 2 trial results, such as in the ALPHA2 trial, may not be representative of Phase 1 results, which were based on limited patients. Even if we collect promising initial clinical data of our product candidates, longer-term data may reveal new adverse events or responses that are not durable. Unexpected clinical outcomes would significantly impact our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is highly dependent on the success of our lead product candidates. If we are unable to advance clinical development, obtain approval of and successfully commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and future success depends on our ability to advance clinical development, obtain regulatory approval of, and then successfully commercialize, our lead product candidates, including ALLO-501A. Because ALLO-501A and ALLO-715 are among the first allogeneic products to be evaluated in the clinic, the failure of any such product candidate, or the failure of other allogeneic T cell therapies, including for reasons due to safety, efficacy or durability, may impede our ability to develop our product candidates, and significantly influence physicians&#8217; and regulators&#8217; opinions in regard to the viability of our entire pipeline of allogeneic T cell therapies. For instance, all of our clinical trials were put on clinical hold due to an observation in the ALPHA2 trial. While the clinical hold has been resolved, we could be subject to a clinical hold in the future due to unexpected observations, adverse patient outcomes or other issues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates, including our lead product candidates, will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. In addition, because our other product candidates are based on similar technology as our lead product candidates, if any of the lead product candidates encounters additional safety issues, efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that have halted and could in the future halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unacceptable severity and prevalence of side effects or unexpected characteristics. Approved autologous CAR T therapies and those under development have shown frequent rates of CRS, neurotoxicity, serious infections, prolonged cytopenia and hypogammaglobulinemia, and adverse events have resulted in the death of patients. We expect similar adverse events for allogeneic CAR T product candidates.  Other adverse events could also emerge in autologous CAR T therapies over time. For instance, patients who received an autologous anti-BCMA CAR T cell therapy have experienced neurocognitive and hypokinetic movement disorder with features of Parkinson's disease that emerged months after treatment and may have been due to BCMA expression within the brain. Our anti-BCMA product candidates have the risk of causing similar adverse events.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our allogeneic CAR T cell product candidates may also cause unique adverse events related to the differences between the donor and patients, such as GvHD or infusion reactions. In addition, we utilize a lymphodepletion regimen, which generally includes fludarabine, cyclophosphamide and ALLO-647, that may cause serious adverse events. For instance, because the regimen will cause a transient and sometimes prolonged immune suppression, patients will have an increased risk of infection, such as to COVID-19, that may be unable to be cleared by the patient and ultimately lead to other serious adverse events or death. Our lymphodepletion regimen has caused and may also cause prolonged cytopenia and aplastic anemia. We are also exploring various dosing strategies for lymphodepletion in our clinical trials, such as higher and lower dosing of ALLO-647 in combination with fludarabine and/or cyclophosphamide, which may increase the risk of serious adverse events.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our and Servier's clinical trials of allogeneic CAR T product candidates, the most common severe or life threatening adverse events resulted from serious infections, prolonged cytopenia, prolonged pancytopenia, hypokalemia, multiple organ dysfunction syndrome, neutropenic sepsis and aplastic anemia. As reported, patients have died from adverse events and future patients may also experience toxicity resulting in death.  For additional safety data, please see "Business--Product Pipeline and Development Strategy" in our Annual Report. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we treat and re-treat more patients with our product candidates in our clinical trials, new less common side effects may also emerge.  For instance, we observed a chromosomal abnormality that led to a previous clinical hold on our clinical trials. While our investigation concluded that the chromosomal abnormality had no clinical significance and was unrelated to our manufacturing process, our manufacturing process includes gene engineering by using lentivirus and TALEN nucleases that may in the future cause insertion, deletion, or chromosomal translocation that may result in allogeneic CAR T cells to proliferate uncontrollably and adverse events.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may combine the use of our product candidates with other investigational therapies that may cause separate adverse events or events related to the combination. For instance, we previously enrolled a combination of ALLO-715 and nirogacestat, a gamma secretase inhibitor, in a cohort in the UNIVERSAL trial. The most common adverse events relating to nirogacestat in prior trials have included diarrhea, nausea, fatigue, hypophosphatemia, vomiting, rash, cough, decreased appetite, pyrexia and hypokalemia. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we are able to proceed with clinical development, if unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Any data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell therapy are not normally encountered in the general patient population and by medical personnel. We have trained and expect to have to train medical personnel using CAR T cell product candidates to understand the side effect profile of our product candidates for both our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, including in any post-approval studies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for any trials that may be completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish initial, interim or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For instance, we have published preliminary data from the ALPHA trial, the ALPHA2 trial and UNIVERSAL trial, however such results are preliminary in nature, do not bear statistical significance and should not be viewed as predictive of ultimate success. It is possible that such results will not continue or may not be repeated in any clinical trial of anti-CD19 or anti-BCMA CAR T cell product candidates or our other product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to submit INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to submit INDs for additional product candidates in the future. We cannot be sure that submission of an IND or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials. The manufacturing of allogeneic CAR T cell therapy remains an emerging and evolving field. Accordingly, we expect CMC related topics, including product specification, will be a focus of IND reviews, which may delay the clearance of INDs or IND amendments. For instance, if we introduce changes to the manufacturing of our product candidates, regulatory authorities may require additional studies or clinical data to support the changes, which could delay our clinical trial timelines. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, IND amendment or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we submitted a standalone cross-reference IND for ALLO-647, which is being used as part of lymphodepletion in all our clinical trials. While our IND has been accepted, we have to update the IND for any new IND or IND amendment relating to our allogeneic CAR T cell product candidates. Any regulatory issues related to the review of our ALLO-647 IND updates or to the development of ALLO-647 could delay development of our allogeneic CAR T cell product candidates and significantly affect our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if our trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical studies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials, including the validation and deployment of release assays;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulty sourcing healthy donor material of sufficient quality and in sufficient quantity to meet our development needs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in reaching a consensus with regulatory agencies on study design;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in obtaining required institutional review board (IRB) approval at each clinical study site;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in recruiting suitable patients to participate in our clinical studies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulty collaborating with patient groups and investigators;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure by our CROs, other third parties or us to adhere to clinical study requirements;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure to perform in accordance with the FDA&#8217;s good clinical practice (GCP) requirements or applicable regulatory guidelines in other countries;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays or failures in the transfer of manufacturing processes to any CMO or our own manufacturing facility or any other development or commercialization partner for the manufacture of product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in having patients complete participation in a study or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">patients dropping out of a study;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of clinical studies of our product candidates being greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials, including due to suppliers prioritizing COVID-19 specific treatments or vaccines; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing, including due to our  CMOs or other vendors prioritizing COVID-19 specific treatments or vaccines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may also increase the risk of certain of the events described above and delay our development timelines. Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, as we transition manufacturing of certain of our product candidates from our CMO to our manufacturing facility, we will be required to meet certain regulatory conditions, such as establishing comparability with the product candidates manufactured at our CMO, and our inability to meet such conditions would result in investment of additional resources, a delay in using our manufacturing facility for production and extend our clinical trial timelines. Similar conditions may apply if we make manufacturing or formulation changes to our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Monitoring and managing toxicities in patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our clinical trials of our product candidates, we contract or will contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using our product candidates, if approved, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of our product candidates may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. For example, as we</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progress the ALPHA2 and EXPAND trials, we may face enrollment challenges, including an unwillingness of sites to participate, the exclusion of patients with certain disease characteristics or the ineligibility of patients that have received prior autologous CAR T therapies, which continue to gain adoption. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The COVID-19 pandemic, including the travel and business restrictions imposed by government authorities in response to the pandemic, have resulted in, and may continue to cause, reduced enrollment and may also create challenges to related clinical trial activities. The enrollment of patients may be more difficult, such as due to the perceptions of the safety of our clinical trials due to the previous clinical hold, and will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the patient eligibility criteria defined in the protocol;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the proximity of patients to study sites;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the design of the trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to obtain and maintain patient consents; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the competition from approved products and from product candidates in other clinical trials; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we only need to conduct a limited number of manufacturing runs to generate clinical supply, the diversity of our supply is limited during clinical trials. As a result, some patients may have antibodies to certain donor specific antigens that may interact with our product candidates, which would render the patients ineligible for treatment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials will also compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites are also being used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As our clinical trials require conditioning patients with chemotherapy, including agents such as cyclophosphamide and fludarabine, and ALLO-647, our ability to enroll may be impacted by the shortage of the agents used for conditioning. For instance, the FDA has reported a shortage of fludarabine and any failure or delays by us or by our clinical trial sites to obtain sufficient quantities of fludarabine may delay our ability to enroll and treat patients in our clinical trials.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, monoclonal antibodies, hematopoietic cell transplantation as well as autologous CAR T cell therapies, rather than enroll patients in our clinical trial, including if our product candidates have or are perceived to have additional safety or efficacy risks or if using our product candidates may affect insurance coverage of conventional therapies. For instance, the development of autologous CAR T cell therapies continues to rapidly advance, and, more recently, Janssen Pharmaceutical Companies of Johnson &amp; Johnson announced the FDA approval of an autologous CAR T cell therapy for the treatment of adults with R/R multiple myeloma, Gilead Sciences announced the FDA approval of an autologous CAR T cell therapy for the initial treatment of R/R LBCL and Bristol Myers Squibb announced the FDA approval of an autologous CAR T cell therapy for R/R LBCL after one prior therapy. We also may experience risks associated with a new class of therapies, bispecific antibodies, which have recently been approved for multiple myeloma and are expected to be approved for LBCL. The compelling results and related approvals impact our ability to enroll patients with R/R multiple myeloma or R/R LBCL in our clinical trials. Moreover, patients eligible for allogeneic CAR T cell therapies but ineligible for autologous CAR T cell therapies due to aggressive cancer and inability to wait for autologous CAR T cell therapies may be at greater risk for complications and death from therapy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA often approves new therapies initially only for use in patients with R/R metastatic disease. We expect to initially seek approval of our product candidates in this setting. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment. There is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials, including potentially comparative trials against approved therapies. We are also targeting a similar patient population as autologous CAR T product candidates, including approved autologous CAR T products. Our therapies may not be as safe and effective as autologous CAR T therapies and may only be approved for patients who are ineligible for autologous CAR T therapy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of both the number of patients who have the cancers we are targeting, as well as the subset of patients with these cancers in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we expect ALLO-501A to initially target a small patient population that suffers from R/R NHL. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our development strategy relies on incorporating an anti-CD52 monoclonal antibody as part of the lymphodepletion preconditioning regimen prior to infusing allogeneic CAR T cell product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize an anti-CD52 monoclonal antibody as part of a lymphodepletion regimen to be infused prior to infusing our product candidates. While we believe an anti-CD52 antibody may be able to reduce the likelihood of a patient&#8217;s immune system rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which such engineered allogeneic T cells can actively target and destroy cancer cells, the antibody may not have the benefits that we anticipate and could have adverse effects. For instance, our lymphodepletion regimen, including using an anti-CD52 antibody, will cause a transient and sometimes prolonged immune suppression that is associated with an increased risk of infection, such as to COVID-19, that may be unable to be cleared by the patient and ultimately lead to other serious adverse events or death.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the prior CALM and PALL trials, a commercially available monoclonal antibody, alemtuzumab, that binds CD52 was used. Alemtuzumab is known to have risk of causing certain adverse events. In 2020, the EMA completed a pharmacovigilance review of alemtuzumab in the context of the treatment of multiple sclerosis following reports of immune-mediated conditions and problems affecting the heart and blood vessels, including fatal cases. The EMA recommended that alemtuzumab should not be used in patients with certain heart, circulation or bleeding disorders or in patients who have autoimmune disorders other than multiple sclerosis. The EMA also recommended that alemtuzumab only be given in a hospital with ready access to intensive care facilities and specialists who can manage serious adverse reactions. Based on the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommendations, we have added relevant new safety information to certain of our clinical trial documentation, including informed consent forms. Our product candidates will also continue to be administered at specialized centers, which are experienced at managing patients with advanced malignancies as well as toxicities associated with immunomodulatory therapies. We will continue to monitor any new safety information that will be reported or added to the product labels of alemtuzumab. If the EMA or other regulatory agencies further limit the use of alemtuzumab or anti-CD52 antibodies, our clinical program would be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To secure our own readily available source of anti-CD52 antibody, we are developing our own monoclonal anti-CD52 antibody, ALLO-647, which we use in our clinical trials. ALLO-647 may cause serious adverse events that alemtuzumab may cause, including fatal adverse events, immune thrombocytopenia, glomerular nephropathies, thyroid disorders, autoimmune cytopenias, autoimmune hepatitis, hemophagocytic lymphohistiocytosis, acquired hemophilia and infections, stroke, and progressive multifocal leukoencephalopathy. In addition, we are exploring various dosing strategies for lymphodepletion in our clinical trials, such as higher and lower dosing of ALLO-647 in combination with fludarabine and cyclophosphamide, which may increase the risk of serious adverse events. See "Business--Product Pipeline and Development Strategy" in our Annual Report for information on safety events.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully develop and manufacture ALLO-647 in the timeframe we anticipate, or at all, or if regulatory authorities do not approve the use of ALLO-647 in combination with our allogeneic T cell product candidates, we may be unable to source alemtuzumab and our engineered allogeneic T cell product candidates may be less effective, which could result in delays in our product development efforts and/or the commercial potential of our product candidates.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may fail to successfully manufacture our product candidates, operate our own manufacturing facility, or obtain regulatory approval to utilize or commercialize from our manufacturing facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to achieve clinical or commercial manufacturing and cell processing on our own or at a CMO, including mass-producing off-the-shelf product to satisfy demands for any of our product candidates. While we believe the manufacturing and processing approaches are appropriate to support our clinical product development, we have limited experience in managing the allogeneic T cell engineering process, and our allogeneic processes may be more difficult or more expensive than the approaches taken by our competitors. We cannot be sure that the manufacturing processes employed by us or the technologies that we incorporate for manufacturing will result in consistent T cell production that will be safe and effective.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease for approximately 118,000 square feet to develop a state-of-the-art cell therapy manufacturing facility in Newark, California. We decided to initiate the Phase 2 trial of ALLO-501A with material manufactured utilizing the Alloy process at our CMO, rather than material manufactured at our manufacturing facility that did not use the Alloy process, and may subsequently transition the Alloy process to our manufacturing facility during the course of our Phase 2 trials. This approach remains subject to FDA review, and may ultimately result in increased costs and delays in conducting the ALPHA2 trial and EXPAND trial, submitting a biologics license application (BLA) or gaining FDA approval of ALLO-501A. In addition, we may be unable to manufacture additional Alloy material at the CMO or transition the Alloy manufacturing process to our manufacturing facility for ALLO-501A as well as for our other product candidates, which could delay our clinical trials. Similar conditions may apply if we make manufacturing or formulation changes to our product candidates. In addition, any process or raw material change could introduce unacceptable product variability and impact our ability to manufacture on a consistent and reproducible basis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also do not yet have sufficient information to reliably estimate the cost of the clinical and commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. In addition, the ultimate clinical and any commercial dose and treatment regimen will affect our ability to scale and our costs per dose. For instance, because ALLO-715 may require a higher dose than ALLO-501A, it is possible that it may be more difficult to scale ALLO-715 production to meet any demand. As a result, we may never be able to develop a commercially viable product. The commercial manufacturing facility we build will also require FDA approval, which we may never obtain. Even if approved, we would be subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP, and other government regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations. The application of new regulatory guidelines or parameters, such as those related to release testing, may also adversely affect our ability to manufacture our product candidates. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities, such supply may have to be discarded and our manufacturing facility may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or any of our vendors may fail to manage the logistics of storing and shipping our raw materials and product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in the inability to manufacture product, the loss of usable product or prevent or delay the delivery of product candidates to patients.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience manufacturing difficulties due to resource constraints or as a result of labor disruptions, such as due to a COVID-19 outbreak, or disputes. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a company, we have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company, we have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces or be on favorable terms. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product that receives regulatory approval in the United States or in other markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to globally develop our product candidates. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">differing regulatory requirements in foreign countries;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">differing standards for the conduct of clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States and shipping the product candidate to the patient abroad;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">import and export requirements and restrictions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulties staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">business interruptions resulting from the COVID-19 pandemic or other natural or man-made disasters, including earthquakes, tsunamis, fires or other medical epidemics, or geo-political actions, including war and terrorism.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our collaborations with Servier and Cellectis, each based in France, our collaboration with Notch Therapeutics Inc. (Notch), based in Canada, and our joint venture for China, Taiwan, South Korea and Singapore with Overland Pharmaceuticals (CY) Inc., may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry, and the immuno-oncology industry specifically, is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, engineered T cells face significant competition from multiple companies. Success of other therapies could impact our regulatory strategy and delay or prevent regulatory approval of our product candidates. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional information regarding our competition, see &#8220;Item 1. Business&#8212;Competition&#8221; in our Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Executive Chair, our President and Chief Executive Officer, our Chief Financial Officer, our Executive Vice President of Research &amp; Development, our Chief Technical Officer, and our General Counsel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct substantially all of our operations at our facilities in the San Francisco Bay area. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We experienced higher attrition in 2021 than previous years and ongoing attrition may lead to higher costs for hiring and retention, diversion of management time to address retention matters and disrupt the business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock unit (RSU) awards that vest over time. The value to employees of stock options and RSU awards that vest over time have been significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. While we completed an option exchange program in July 2022 to alleviate the significant number of employee options that are underwater, the program excluded certain senior officers and new options granted under the program will only have value for employees if our stock price increases over time. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 1, 2022, we had 356 full-time employees. As our development, manufacturing and commercialization plans and strategies develop, we have rapidly expanded our employee base and expect to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.   Our ability to build our organization and manage our employees has also been affected by the COVID-19 pandemic, as many of our staff are working from home on a part-time or full-time basis. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. We may also be subject to penalties or other liabilities if we mis-classify employees as consultants. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring and retaining employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop, manufacture and commercialize our product candidates and, accordingly, may not achieve our research, development, manufacturing and commercialization goals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form or seek additional strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form or seek additional strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we license products or new technologies or acquire businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. For instance, our agreements with Cellectis, Servier, Notch and Antion require significant research and development that may not result in the development and commercialization of product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of acquired assets or other strategic transactions.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, including our acquisition of CAR T cell assets from Pfizer, licenses with Cellectis, Servier, Notch, Antion, joint venture with Overland Pharmaceuticals (CY) Inc. and any future strategic transactions depends on the risks and uncertainties involved including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unanticipated liabilities related to acquired companies or joint ventures;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">retention of key employees;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">inability of our strategic partners to access suitable capital;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disruption in or termination of our relationships with collaborators or suppliers as a result of such a transaction; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">possible write-offs or impairment charges relating to acquired businesses or joint ventures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries. For instance, our joint venture with Overland Pharmaceuticals (CY) Inc. may face difficulties manufacturing, such as from changes in raw materials or processes due to local regulations, or delivering our licensed product candidates in China, Taiwan, South Korea or Singapore, which could prevent any development or commercialization of our licensed product candidates in the region. The joint venture will also require significant operational and financial support in the future by us or third parties, and any future financing of the joint venture would increase our expenses or dilute our ownership in the joint venture. We may also face unknown liabilities due to supporting our joint venture, such as due to any misuse of materials supplied to our joint venture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to spend a substantial amount of capital in the development and manufacture of our product candidates. We will need substantial additional financing to develop our products and implement our operating plans. In particular, we will require substantial additional financing to enable commercial production of our products and initiate and complete registrational trials for multiple products in multiple regions. Further, if approved, we will require significant additional capital in order to launch and commercialize our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had $637.3 million in cash and cash equivalents and investments. Changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may also need to raise additional capital sooner than we currently anticipate if we choose to expand more rapidly than we presently plan. In any event, we will require additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and our stock price has faced extreme volatility. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations under the agreements. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our security measures, or those of our CROs, CMOs, collaborators, contractors, consultants or other third parties upon whom we rely, are compromised or the security, confidentiality, integrity or availability of our information technology, software, services, networks, communications or data is compromised, limited or fails, we could experience a material adverse impact.*</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may collect, process, store and transmit proprietary, confidential and sensitive information, including personal data (including health information), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties. We may also share or receive sensitive information with our partners, CROs, CMOs, or other third parties. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our internal computer systems and those of our CROs, CMOs, collaborators, contractors, consultants or other third parties are vulnerable to damage from computer viruses, unauthorized access, cybersecurity threats, and telecommunication and electrical failures. In addition, the COVID-19 pandemic has intensified our dependence on information technology systems as many of our critical business activities are currently being conducted remotely. Our remote workforce poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises. Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce and distribute our product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cyberattacks could include, but are not limited to, the deployment of harmful malware (including as a result of advanced persistent threat intrusions), denial-of-service (such as credential stuffing), credential harvesting, social engineering attacks (including through phishing attacks), viruses, ransomware, supply chain attacks, personnel misconduct or error and other similar threats. We may also be the subject of software bugs, server malfunction, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures or other similar issues. In particular, ransomware attacks are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, disruptions to our clinical trials, loss of data (including data related to clinical trials), significant expense to restore data or systems, reputational loss and the diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach to our information technology systems or the third-party information technology systems that support us and our services. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption.  A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information.  A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to manufacture or deliver our product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may expend significant resources, or modify our business activities and operations, including our clinical trial activities, in an effort to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures or use industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We have experienced attempts to compromise our information technology systems or otherwise cause a security incident, but, to our knowledge, such attempts have been unsuccessful. In addition, from time to time, our vendors inform us of security incidents. To date, our review of such incidents as reported to us did not reveal material information being lost, Allogene-specific security vulnerabilities or provide any useful information or insight into our systems or environment. However, we may not have all information related to such incidents and future incidents could have an adverse impact on our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may be unable to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate exploitable critical vulnerabilities, if any, in our information technology systems, our efforts may not be successful.  Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. We may also face heightened physical and information technology risks due to our sharing office space with other tenants at certain of our sites. Any failure to prevent or mitigate security incidents or improper access to, use of, or disclosure of our clinical data or patients&#8217; personal data could result in significant liability under state, federal, and international law and may cause a material adverse impact to our reputation, affect our ability to conduct our clinical trials and potentially disrupt our business. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data protection laws, privacy policies and data protection obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may also experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that the limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or adequately mitigate liabilities arising out of our privacy and security practices, or that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, statutory, regulatory and policy changes, and business disruptions, such as those caused by the COVID-19 pandemic. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the business disruptions caused by the COVID-19 pandemic or cybersecurity attacks described above, our operations, and those of our CMOs, CROs, clinical trial sites and other contractors and consultants, could be subject to other disruptions, including those caused by earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, tsunamis, typhoons, fires, extreme weather conditions, medical epidemics, wars and other geopolitical conflicts (such as Russia military action against Ukraine) and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to manufacture our product candidates could be disrupted if our operations or those of our suppliers are affected by a man-made or natural disaster or other business interruption. Our corporate headquarters and manufacturing facility are located in California near major earthquake faults and fire and flood zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire and flood zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire, flood or other natural disaster.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of identifiable patient information, price reporting, false claims and provider transparency. If our operations are found to be in violation of any of these laws that apply to us, we may be subject to significant civil, criminal and administrative penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing privacy laws, regulations and standards as well as policies, contracts and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to enforcement or litigation (that could result in fines or penalties), a disruption of clinical trials or commercialization of products, reputational harm, or other adverse business effects.*</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, use, generate, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share personal data and other sensitive information, including, but not limited to, proprietary and confidential business information, trade secrets, intellectual property, and information we collect about patients in connection with clinical trials. Accordingly, we are, or may become, subject to numerous federal, state, local and international data privacy and security laws, regulations, guidance, and industry standards as well as external and internal privacy and security policies, contracts and other obligations that apply to our processing of personal data and the processing of personal data on our behalf.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws and other similar laws (e.g., wiretapping laws). For example, the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), and their respective implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH, through its implementing regulations, makes certain of HIPAA&#8217;s privacy and security standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity&#8217;s workforce, that creates, receives, maintains or transmits protected health information for or on behalf of a covered entity for a function or activity regulated by HIPAA as well as their covered subcontractors.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the California Consumer Privacy Act (CCPA) creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households.  The CCPA requires covered companies to provide new disclosures to California consumers, affords California residents certain rights related to their personal data, including the right to opt-out of certain sales of personal data, and allow for a new cause of action for certain data breaches. Although there are limited exemptions for clinical trial data under the CCPA, as our business progresses, the CCPA may become applicable and significantly impact our business activities and exemplifies the vulnerability of our business to evolving regulatory environment related to personal data and protected health information.  Furthermore, it is anticipated that the California Privacy Rights Act of 2020 (CPRA), effective January 1, 2023, will expand the CCPA&#8217;s requirements, including applying to personal information of business representatives and employees and establishing a new regulatory agency to implement and enforce the law.  In addition, other states have enacted or proposed data privacy laws. For example, Virginia passed the Consumer Data Protection Act, Colorado passed the Colorado Privacy Act, Connecticut passed the Act Concerning Personal Data Privacy and Online Monitoring, and Utah passed the Consumer Privacy Act, all of which become effective in 2023. Additionally, several states and localities have enacted statutes banning or restricting the collection of biometric information. Moreover, data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate compliance efforts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, there are an increasing number of laws, regulations and industry standards concerning privacy, data protection, information security and cross-border personal data transfers. For example, the European Union&#8217;s General Data Protection Regulation (EU GDPR), the United Kingdom&#8217;s GDPR (UK GDPR), and China&#8217;s Personal Information Protection Law (PIPL) impose strict requirements for processing personal data. Failure to comply with the requirements of the EU GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. If we cannot implement a valid compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or other foreign jurisdictions. The inability to import personal data to the United States could significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties that are subject to such cross-border data transfer or localization laws; or requiring us to increase our personal data processing capabilities and infrastructure in foreign jurisdictions at significant expenses. Further, individuals may initiate litigation related to processing of their personal data. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, privacy advocates and industry groups have proposed, and may propose, standards with which we are legally or contractually bound to comply.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. As a result, preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors, consultants or other third parties that process personal data on our behalf. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we endeavor to comply with all applicable privacy and security obligations, we may at times fail to do so or may be perceived to have failed to do so.  Moreover, despite our efforts, we may not be successful in achieving compliance if our employees, third-party collaborators, service providers, contractors or consultants fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party service provider to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others. If we fail, or are perceived to have failed, to address or comply with obligations related to data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits and inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; temporary or permanent bans on all or some processing of personal data; orders to destroy or not use personal data; and imprisonment of company officials.  Any of these events could have a material adverse effect on our reputation, business, or financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">decreased demand for our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injury to our reputation;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">initiation of investigations by regulators;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">exhaustion of any available insurance and our capital resources;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability to commercialize any product candidate; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a decline in our share price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. While we have obtained and expect to obtain clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current law, federal net operating losses incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal net operating losses in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. As a result of our IPO in October 2018 and private placements and other transactions that have occurred since our incorporation, we may have experienced an &#8220;ownership change&#8221;. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. We anticipate incurring significant additional net losses for the foreseeable future, and our ability to utilize net operating loss carryforwards associated with any such losses to offset future taxable income may be limited to the extent we incur future ownership changes. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials under agreements with us. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practices (GCPs), which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to manufacture and store our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.*</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are manufactured in the United States by our CMOs, and we manage all other aspects of the supply, including planning, CMO oversight, disposition and distribution logistics. For example, in the past, Servier was responsible for UCART19 manufacturing, and experienced UCART19 supply issues that limited its ability to recruit new patients. There can be no assurance that we will not experience supply or manufacturing issues in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have long-term agreements in place with CMOs for the manufacture of our cell therapies or of ALLO-647. If we are unable to contract with CMOs on acceptable terms or at all, our clinical development program would be delayed and our business would be significantly harmed. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have built our own manufacturing facility for cell therapies, the transition of manufacturing to our own facility will require significant investment and that we meet certain regulatory conditions, which may delay or extend our clinical trial timelines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to achieve manufacturing and processing and may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for any of our product candidates. Our clinical supply is also limited to small quantities and any latent defects discovered in our supply could significantly delay our development timelines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our actual and potential future reliance on a limited number of third-party manufacturers exposes us to the following risks:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our third-party manufacturers could breach or terminate their agreement with us.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Our current and potential future CMOs may also be required to shut down in response to the spread of COVID-19 or they may prioritize manufacturing for COVID-19 therapies or vaccines. In addition, our CMOs have certain responsibilities for storage of raw materials and in the past have lost or failed to adequately store our raw materials.  We also rely on third parties to store our released product candidates, and any failure to adequately store our product candidates could result in significant delay to our development timelines. Any additional or future damage or loss of raw materials or product candidates could materially impact our ability to manufacture and supply our product candidates. Each of these risks could delay our clinical trials, the approval, if any of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on T cells from healthy donors to manufacture our product candidates, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike autologous CAR T companies, we are reliant on receiving healthy donor material to manufacture our product candidates. Healthy donor T cells vary in type and quality, and this variation makes producing standardized product candidates more difficult and makes the development and commercialization pathway of those product candidates more uncertain. We have developed a screening process designed to enhance the quality and consistency of T cells used in the manufacture of our CAR T cell product candidates, but our screening process may fail to identify suitable donor material and we may discover unacceptable variability with the material after production. We may also have to update our specifications for new risks that may emerge, such as to screen for new viruses or chromosomal abnormalities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have strict specifications for donor material, which include specifications required by regulatory authorities. If we are unable to identify and obtain donor material that satisfy specifications, agree with regulatory authorities on appropriate specifications, or address variability in donor T cells, there may be inconsistencies in the product candidates we produce or we may be unable to initiate or continue clinical trials on the timelines we expect, which could harm our reputation and adversely impact our business and prospects. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, vendors have and are facing challenges in obtaining donor material during the COVID-19 pandemic. While we have donor material on hand, if the COVID-19 pandemic continues and as a result our vendors are unable to secure donor material, or our vendors are unable to secure donor material for other reasons, we may no longer have sufficient donor material to manufacture our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.*</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require many specialty raw materials, including viral vectors that deliver the CAR sequence and electroporation technology, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. We do not have contracts with many of the suppliers, and we may not be able to contract with them on acceptable terms, or at all. Many suppliers curtailed their operations during the COVID-19 pandemic, focused their operations on supporting COVID-19 therapies and vaccines, or have faced higher attrition, and our ability and the ability of our suppliers to source raw materials has been impacted. Accordingly, we may experience higher costs or delays in receiving, or fail to secure entirely, key raw materials to support clinical or commercial manufacturing. Certain raw materials also require third-party testing, and some of the testing service companies may not have capacity or be able to conduct the testing that we request.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also face competition for supplies from other cell therapy companies.  Such competition may make it difficult for us to secure raw materials or the testing of such materials on commercially reasonable terms or in a timely manner.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier, including to meet any regulatory requirements for such qualification, could result in additional costs, delays, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. For instance, we have had and may continue to have environmental notice of violations at our manufacturing facility. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. In addition, we have commenced shipment of certain materials to our joint venture with Overland Pharmaceuticals (CY) Inc. in China and any violation by our joint venture in the use, manufacture, storage, handling and disposal under foreign law may subject us to additional liability. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a BLA from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding CMC matters for the product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogeneic T cell therapies for cancer. We may also request clinical trial initiation or regulatory approval of future CAR-based product candidates by target, regardless of cancer type or origin, which the FDA may have difficulty accepting. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have previously experienced a delay in our clinical trials due to a clinical hold, and may experience future delays in completing planned clinical trials for a variety of reasons, including delays related to:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">obtaining regulatory authorization to begin a trial, if applicable;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the availability of financial resources to commence and complete the planned trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">obtaining approval at each clinical trial site by an independent IRB;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">obtaining regulatory and other approvals to modify the conduct of a clinical trial;</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">recruiting suitable patients to participate in a trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial prior to treatment, or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">addressing any patient safety concerns that arise during the course of a trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">adding new clinical trial sites; or</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">manufacturing sufficient quantities of qualified materials under cGMPs, releasing product in accordance with specifications, and delivering product candidates for use in clinical trials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter future delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by any Data Safety Monitoring Committee. The FDA&#8217;s review of our data of our clinical trials may, depending on the data, also result in the delay, suspension or termination of one or more of our clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are developing novel CAR T cell immunotherapy product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and the FDA has recently issued draft guidance relevant to our product candidates, including relating to CMC matters, manufacturing at a single versus multiple sites and clinical study design. Depending on the ultimate guidance that is approved, this guidance could delay our clinical development and increase our costs. Guidance from regulatory authorities may also continue to change in the future. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies (OTAT), formerly known as the Office of Cellular, Tissue and Gene Therapies (OCTGT), within its Center for Biologics Evaluation and Research (CBER) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the EU a special committee called the Committee for Advanced Therapies (CAT) was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. In this regard, on May 28, 2014, the EMA issued a recommendation that UCART19 be considered a gene therapy product under Regulation (EC) No 1394/2007 on ATMPs. We believe our other product candidates may receive a similar recommendation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAR T cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. We expect ongoing FDA feedback on our trials, some of which may lead to changes in the trials, which could cause future delays to our trials. In addition, even if we believe the results are sufficiently compelling, such as for both the ALPHA2 trial and EXPAND trial, the FDA could ultimately require longer-term follow-up results, additional data from our clinical trials or additional trials that could delay or prevent our first BLA submission. The FDA may require that we conduct a comparative trial against an approved therapy including potentially an approved autologous T cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. We believe </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our accelerated approval strategy is warranted given the limited alternatives for patients with R/R cancers, but the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the inability to resolve any future clinical hold;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain regulatory approval for ALLO-647 in a timely manner or at all, which could delay any approval or commercialization of our allogeneic T cell product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we are concurrently developing ALLO-647 to be used as part of the lymphodepletion regimen for our allogeneic CAR T cell product candidates, mapping a co-development path for dual approval of ALLO-647 and any of our CAR T cell product candidates and coordinating concurrent review with different divisions of the FDA create additional regulatory uncertainty for us and may delay the development of our product candidates. We expect the Center for Drug Evaluation and Research division of the FDA to exercise authority over the regulatory approval of ALLO-647 while the CBER division will oversee the regulatory approval of our allogeneic CAR T cell product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we expect regulatory authorities will require us to demonstrate the safety of ALLO-647 and its contribution to the overall benefit to risk ratio of the lymphodepletion regimen through a randomized study with a cohort of patients that do not receive ALLO-647. We plan to assess ALLO-647 in a separate registrational trial, the EXPAND trial, that we are working to initiate. We cannot be certain when or whether we will be able to successfully initiate and enroll the EXPAND trial in a timely manner or that the outcome of this study will support FDA approval. For instance, enrolling two studies, ALPHA2 and EXPAND, that target the same indication may delay enrollment completion, and difference in data between the trials would introduce other regulatory review complications that would adversely impact both trials. Any delays to ALLO-647 approval could delay any approval or commercialization of our allogeneic CAR T cell product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regenerative Medicine Advanced Therapy designation and Fast Track designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-715 and ALLO-501A and fast track designation (FTD) for ALLO-605 and ALLO-316. There is no assurance that we will be able to obtain RMAT designation or FTD for any of our additional product candidates. RMAT designation and FTD do not change the FDA&#8217;s standards for product approval, and there is no assurance that such designation will result in expedited review or approval or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation and FTD can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA granted orphan drug designation to ALLO-605 and ALLO-715 for the treatment of multiple myeloma. We plan to seek orphan drug designation for additional product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products, but may never receive such designations. Some of our product candidates target indications that are not orphan indications. In addition, even with orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gene-editing technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. Given the previous clinical hold involved a chromosomal abnormality, our manufacturing or gene editing may be further scrutinized or may be viewed as unsafe, even though our investigation found that the abnormality was not related to our manufacturing or gene editing. In particular, our success will depend upon physicians specializing in our targeted diseases prescribing our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, given the novel nature of gene-editing and cell therapy technologies, governments may place import, export or other restrictions in order to retain control or limit the use of the technologies. For instance, any limits on exporting certain of our technology to China may adversely affect Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by us and Overland Pharmaceuticals (CY) Inc. Increased negative public opinion or more restrictive government regulations either in the United States or internationally, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for such product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affordable Care Act) to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty and could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect physicians in the large bone marrow transplant centers to be particularly important to the market acceptance of our products and we may not be able to educate them on the benefits of using our product candidates for many reasons. For example, certain of the product candidates that we will be developing target a cell surface marker that may be present on cancer cells as well as non-cancerous cells. It is possible that our product candidates may kill these non-cancerous cells, which may result in unacceptable side effects, including death. Additional factors will influence whether our product candidates are accepted in the market, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the clinical indications for which our product candidates are approved;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the potential and perceived advantages of our product candidates over alternative treatments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the prevalence and severity of any side effects;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">limitations or warnings contained in the labeling approved by the FDA;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the timing of market introduction of our product candidates as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the cost of treatment in relation to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business could be negatively impacted by environmental, social and corporate governance (ESG) matters or our</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">reporting of such matters.*</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increasing focus from certain investors, employees, partners, and other stakeholders concerning ESG matters. While we have internal efforts directed at ESG matters and preparations for any increased required future disclosures, we may be perceived to be not acting responsibly in connection with these matters, which could negatively impact us. Moreover, the SEC has recently proposed, and may continue to propose, certain mandated ESG reporting requirements, such as the SEC&#8217;s proposed rules designed to enhance and standardize climate-related disclosures, which, if finally approved, would significantly increase our compliance and reporting costs and may also result in disclosures that certain investors or other stakeholders deem to negatively impact our reputation or that harm our stock price. In addition, we currently do not report our environmental emissions, and lack of reporting could result in certain investors declining to invest in our common stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. We depend substantially on our license agreements with Pfizer, Servier and Cellectis. These licenses may be terminated upon certain conditions. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. For example, we are dependent on our license with Cellectis for gene-editing technology that is necessary to produce our engineered T cells. In addition, we are reliant on Servier in-licensing from Cellectis some of the intellectual property rights they are licensing to us, including certain intellectual property rights relating to ALLO-501 and ALLO-501A. To the extent these licensors fail to meet their obligations under their license agreements, which we are not in control of, we may lose the benefits of our license agreements with these licensors. For instance, Cellectis has challenged and may in the future challenge certain performance by Servier, such as its development of products licensed under the Cellectis-Servier Agreement in ALL, and any failure by those parties to resolve such matters may have an adverse impact on us. In the future, we may also enter into additional license agreements that are material to the development of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those related to:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trade secret protection and license agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive collaboration with Servier to develop and commercialize certain anti-CD19 allogeneic T cell product candidates, including ALLO-501A, and we hold the commercial rights to these product candidates in the United States. We also have an exclusive worldwide license from Cellectis to its TALEN gene-editing technology for the development of allogeneic T cell product candidates directed against 15 different cancer antigens. Our collaboration with Servier gives us access to TALEN gene-editing technology for all product candidates under the Servier Agreement. Certain intellectual property which is covered by these agreements may have been developed with funding from the U.S. government. If so, our rights in this intellectual property may be subject to certain research and other rights of the government.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional patent applications have been filed, and we anticipate additional patent applications will be filed, both in the United States and in other countries, as appropriate. However, we cannot predict:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">if and when patents will issue;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Composition of matter patents for biological and pharmaceutical products such as CAR-based product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the patentability, validity, enforceability or scope thereof, for example through inter partes review (IPR) post-grant review or ex parte reexamination before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions, which may result in such patents being cancelled, narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. United States patent applications containing or that at any time contained a claim not entitled to a priority date before March 16, 2013 are subject to the &#8220;first to file&#8221; system implemented by the America Invents Act (2011).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This first to file system will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For United States applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the United States patent laws, including new procedures for challenging patent applications and issued patents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees, Allogene Overland and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. Although we require all of our employees to assign their inventions to us, and require all of our employees and key consultants who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. For example, we plan to transfer technology to Allogene Overland or its affiliates in certain developing countries, and we cannot be certain that we or Allogene Overland or any of its affiliates will be able to protect or enforce any proprietary rights in these countries. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may sue us. We are aware of several U.S. patents held by third parties that may be considered by those third parties to be relevant to cell-based therapies. Generally, conducting clinical trials and other development activities in the United </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States is not considered an act of infringement. If and when any of our product candidates is approved by the FDA, third parties may then seek to enforce their patents by filing a patent infringement lawsuit against us. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. We may not be able to prove in litigation that any patent enforced against us is invalid.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may be alleged to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own, that we believe will facilitate the development of our product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put one or more of our pending patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include IPR, ex parte re-examination and post grant review in the United States, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to protect our intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries where Allogene Overland or its affiliates may do business, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us or Allogene Overland or any of its affiliates to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock following our IPO in October 2018 has been and is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the commencement, enrollment or results of our clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adverse results or delays in clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our failure to commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adverse regulatory decisions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adverse developments concerning the manufacture or supply of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to establish collaborations if needed;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unanticipated serious safety concerns related to immuno-oncology or related to the use of our product candidates or pre-conditioning regimen;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">introduction of new products or services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the status of one or more of our license or collaboration agreements, including any material disputes, amendments or terminations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to effectively manage our growth;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the size and growth of our initial cancer target markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to successfully treat additional types of cancers or at different stages;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our cash position;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the market valuations of similar companies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ineffectiveness of our disclosure controls or internal controls;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disagreements with our auditor or termination of an auditor engagement;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">significant business disruptions caused by natural or man-made disasters, such as the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general political and economic conditions; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements. We are required, pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting.  We are also required to have our auditors formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 on an annual basis.  Complying with Section 404 requires a rigorous compliance program as well as adequate time and resources. We may not be able to complete our internal control evaluation, testing and any required remediation in a timely fashion. Additionally, if we or our auditors identify one or more material weaknesses in our internal control over financial reporting, we will not be able to assert that our internal controls are effective. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2021, we implemented a new enterprise resource planning (ERP) system, which required the investment of significant financial and human resources. We plan to continue to implement new ERP modules, which we also expect will require significant resources. Any failure to maintain or implement new or improved internal controls related to our ERP system or otherwise could result in material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence and could cause the trading price of our common stock to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain any future cash flow or earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a requirement that special meetings of stockholders be called only by the chair of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market, economic and geo-political conditions may have serious adverse consequences on our business, financial condition and stock price.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global credit and financial markets have experienced extreme volatility and disruptions in the past.  These disruptions have resulted and may continue to result in severely diminished liquidity and credit availability, high inflation, declines in consumer confidence, declines in economic growth, and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment, higher inflation, or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Our portfolio of corporate and government bonds would also be adversely impacted.  Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn or rising inflation, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other international and geo-political events could also have a serious adverse impact on our business. For instance, in February 2022, Russia initiated military action against Ukraine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In response, the United States and certain other countries</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">imposed significant sanctions and trade actions against Russia and could impose further sanctions, trade restrictions, and other retaliatory actions. While we cannot predict the broader consequences, the conflict and retaliatory and counter-retaliatory actions could materially adversely affect global trade, currency exchange rates, inflation, regional economies, and the global economy, which in turn may increase our costs, disrupt our supply chain, impair our ability to raise or access additional capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition, and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, including by any of our directors, officers or larger shareholders, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock could be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if the clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="iad69808f292f43f6bbc63337efb1d90e_112"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iad69808f292f43f6bbc63337efb1d90e_121"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of document</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000173728722000039/allo-20220617x8kxexhibit31.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on June 17, 2022)</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm">3.1,</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000173728722000039/allo-20220617x8kxexhibit31.htm">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518290441/d548088dex41.htm">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on October 2, 2018).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex42.htm">Investors Rights Agreement, dated April 6, 2018, as amended September 5, 2018, by and among the Registrant and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20220930xex311.htm">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20220930xex312.htm">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20220930xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document. </span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q has been formatted in Inline XBRL.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="iad69808f292f43f6bbc63337efb1d90e_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad69808f292f43f6bbc63337efb1d90e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 2, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ David Chang</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 2, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Eric Schmidt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Schmidt, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>allo-20220930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ide3f1cbd71a549fa8ac0473a7089ace1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Chang, M.D., Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Allogene Therapeutics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; David Chang</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>allo-20220930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1d0c5a94cb6f447b8677f95aea43ca2c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Schmidt, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Allogene Therapeutics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Eric Schmidt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Schmidt, Ph.D.<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>allo-20220930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i72a1854413a3460dad8c8d90ececd00c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002&#160;</font></div><div style="margin-top:12pt;text-indent:47.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David Chang, M.D., Ph.D., President and Chief Executive Officer of the Company, and I, Eric Schmidt, Ph.D., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;&#160;</font></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)&#59; and&#160;</font></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.&#160;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; David Chang</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Eric Schmidt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Schmidt, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:12pt;text-indent:47.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liability of Section&#160;18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>allo-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3bc7a964-10eb-47e7-910c-f5ea785aeb6d,g:304a2d5e-50f8-4210-a420-41588b836a7a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:allo="http://allogene.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://allogene.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://allogene.com/role/DescriptionofBusiness">
        <link:definition>0000007 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://allogene.com/role/FairValueMeasurements">
        <link:definition>0000009 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://allogene.com/role/FinancialInstruments">
        <link:definition>0000010 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://allogene.com/role/BalanceSheetComponents">
        <link:definition>0000011 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://allogene.com/role/LicenseandCollaborationAgreements">
        <link:definition>0000012 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://allogene.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestments" roleURI="http://allogene.com/role/EquityMethodInvestments">
        <link:definition>0000014 - Disclosure - Equity Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://allogene.com/role/StockBasedCompensation">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://allogene.com/role/RelatedPartyTransactions">
        <link:definition>0000016 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://allogene.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://allogene.com/role/NetLossPerShare">
        <link:definition>0000018 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://allogene.com/role/SubsequentEvents">
        <link:definition>0000019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://allogene.com/role/FairValueMeasurementsTables">
        <link:definition>0000021 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://allogene.com/role/FinancialInstrumentsTables">
        <link:definition>0000022 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://allogene.com/role/BalanceSheetComponentsTables">
        <link:definition>0000023 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://allogene.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000024 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://allogene.com/role/StockBasedCompensationTables">
        <link:definition>0000025 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://allogene.com/role/NetLossPerShareTables">
        <link:definition>0000026 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://allogene.com/role/DescriptionofBusinessDetails">
        <link:definition>0000027 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>0000028 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail">
        <link:definition>0000029 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails">
        <link:definition>0000030 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetails" roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails">
        <link:definition>0000031 - Disclosure - Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsDetails" roleURI="http://allogene.com/role/BalanceSheetComponentsDetails">
        <link:definition>0000032 - Disclosure - Balance Sheet Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsDetails" roleURI="http://allogene.com/role/LicenseandCollaborationAgreementsDetails">
        <link:definition>0000033 - Disclosure - License and Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000034 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseLiabilitiesDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails">
        <link:definition>0000035 - Disclosure - Commitments and Contingencies - Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseCostsDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails">
        <link:definition>0000036 - Disclosure - Commitments and Contingencies - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails">
        <link:definition>0000037 - Disclosure - Commitments and Contingencies - Undiscounted Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsDetails" roleURI="http://allogene.com/role/EquityMethodInvestmentsDetails">
        <link:definition>0000038 - Disclosure - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>0000039 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>0000040 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsDetails" roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails">
        <link:definition>0000041 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsActivityDetails" roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails">
        <link:definition>0000042 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpenseDetails" roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails">
        <link:definition>0000043 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000044 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://allogene.com/role/NetLossPerShareDetails">
        <link:definition>0000045 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://allogene.com/role/SubsequentEventsDetails">
        <link:definition>0000046 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="allo_ServierMember" abstract="true" name="ServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_ResearchCollaborationAndLicenseAgreementMember" abstract="true" name="ResearchCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_CollaborationArrangementExpense" abstract="false" name="CollaborationArrangementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AreaOfOperatingLease" abstract="false" name="AreaOfOperatingLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" abstract="false" name="ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_AreaOfOffice" abstract="false" name="AreaOfOffice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_TwoRiverConsultingLLCMember" abstract="true" name="TwoRiverConsultingLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_LiabilitiesLesseeTableTextBlock" abstract="false" name="LiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="allo_MilestoneTypeDomain" abstract="true" name="MilestoneTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_AggregatePotentialMilestoneReceivable" abstract="false" name="AggregatePotentialMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AllogeneOverlandMember" abstract="true" name="AllogeneOverlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="allo_NotchTherapeuticsIncMember" abstract="true" name="NotchTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_BellcoCapitalLLCMember" abstract="true" name="BellcoCapitalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_StockOptionGrantedPeriod" abstract="false" name="StockOptionGrantedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember" abstract="true" name="AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_EquityInvestmentBasisDomain" abstract="true" name="EquityInvestmentBasisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_UpfrontAndQuarterlyCashPayments" abstract="false" name="UpfrontAndQuarterlyCashPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ConsultingAgreementsMember" abstract="true" name="ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_ClinicalRegulatoryAndCommercialMilestoneMember" abstract="true" name="ClinicalRegulatoryAndCommercialMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" abstract="false" name="AggregatePotentialRegulatoryAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_UniversityOfTexasMDAndersonCancerCenterMember" abstract="true" name="UniversityOfTexasMDAndersonCancerCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_RoyaltyObligationPeriodFromDateOfFirstSale" abstract="false" name="RoyaltyObligationPeriodFromDateOfFirstSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="allo_AntionCollaborationAgreementMilestoneAchievementOneMember" abstract="true" name="AntionCollaborationAgreementMilestoneAchievementOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="allo_PaymentsCommencingJanuary2021Member" abstract="true" name="PaymentsCommencingJanuary2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_NewarkMember" abstract="true" name="NewarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_RegulatoryMilestoneMember" abstract="true" name="RegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_AreaOfNewOfficeBuilding" abstract="false" name="AreaOfNewOfficeBuilding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="allo_CollaborationAgreementCommittedFunding" abstract="false" name="CollaborationAgreementCommittedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CollaborativeArrangementRightsAndObligationsMilestonePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CollaborationAgreementUpfrontPayment" abstract="false" name="CollaborationAgreementUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_TwoThousandEighteenPlanMember" abstract="true" name="TwoThousandEighteenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_RelatedPartyTransactionMonthlyPaymentsInArrears" abstract="false" name="RelatedPartyTransactionMonthlyPaymentsInArrears" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_TenantImprovementAllowanceUtilizedToDate" abstract="false" name="TenantImprovementAllowanceUtilizedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AggregatePotentialMilestonePayments" abstract="false" name="AggregatePotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ComputerEquipmentAndPurchasedSoftwareMember" abstract="true" name="ComputerEquipmentAndPurchasedSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_AggregatePotentialMilestonePayable" abstract="false" name="AggregatePotentialMilestonePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CellectisSAMember" abstract="true" name="CellectisSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_OverlandPharmaceuticalsIncMember" abstract="true" name="OverlandPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_LeaseOneAmendedMember" abstract="true" name="LeaseOneAmendedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_SubleaseAgreementMember" abstract="true" name="SubleaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_EarlyExerciseOfStockOptionsMember" abstract="true" name="EarlyExerciseOfStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_CurrentAccruedAndOtherLiabilitiesMember" abstract="true" name="CurrentAccruedAndOtherLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_AdditionalAreaOfNewOfficeBuilding" abstract="false" name="AdditionalAreaOfNewOfficeBuilding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="allo_RelatedPartyTransactionCompensationPercentage" abstract="false" name="RelatedPartyTransactionCompensationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="allo_CostMethodInvestmentTransactionCosts" abstract="false" name="CostMethodInvestmentTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_LeaseTwoMember" abstract="true" name="LeaseTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_AntionCollaborationAgreementMilestoneAchievementTwoMember" abstract="true" name="AntionCollaborationAgreementMilestoneAchievementTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_FounderSharesOfCommonStockMember" abstract="true" name="FounderSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_JointVentureCapitalSupportPayments" abstract="false" name="JointVentureCapitalSupportPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CashEquivalentsAndShortTermInvestments" abstract="false" name="CashEquivalentsAndShortTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_VotingInterestMember" abstract="true" name="VotingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_ReductionToResearchAndDevelopmentExpense" abstract="false" name="ReductionToResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_IncomeLossFromCostMethodInvestment" abstract="false" name="IncomeLossFromCostMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" abstract="false" name="OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="allo_LesseeFinanceLeasePaymentUponContractTermination" abstract="false" name="LesseeFinanceLeasePaymentUponContractTermination" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement" abstract="false" name="PaymentsToAcquireInvestmentsUponMilestoneAchievement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_PaymentTermsAxis" abstract="true" name="PaymentTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_SalesMilestoneMember" abstract="true" name="SalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_EquityInvestmentBasisAxis" abstract="true" name="EquityInvestmentBasisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_PercentageOfDevelopmentCostPayableByTheCompany" abstract="false" name="PercentageOfDevelopmentCostPayableByTheCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="allo_LicenseAndCollaborationAgreementMember" abstract="true" name="LicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_PaymentsCommencingJanuary2022Member" abstract="true" name="PaymentsCommencingJanuary2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_PreClinicalDevelopmentMilestoneMember" abstract="true" name="PreClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_NumberOfOptionsToExtendLease" abstract="false" name="NumberOfOptionsToExtendLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_PfizerIncMember" abstract="true" name="PfizerIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" abstract="false" name="MaximumPaymentsRequiredPerProductAgainstSelectedTarget" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AccruedAndOtherLiabilitiesCurrent" abstract="false" name="AccruedAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="allo_MilestoneTypeAxis" abstract="true" name="MilestoneTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_TenantImprovementAllowance" abstract="false" name="TenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_LicenseAgreementsTextBlock" abstract="false" name="LicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="allo_DevelopmentAndSalesMember" abstract="true" name="DevelopmentAndSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_PaymentTermsDomain" abstract="true" name="PaymentTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_AntionCollaborationAgreementMember" abstract="true" name="AntionCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_AssetContributionAgreementMember" abstract="true" name="AssetContributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" abstract="false" name="NumberOfSharesAsPercentageOfCommonSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" abstract="false" name="PercentageOfDevelopmentCostPayableByCollaborationPartner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>allo-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3bc7a964-10eb-47e7-910c-f5ea785aeb6d,g:304a2d5e-50f8-4210-a420-41588b836a7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="allo-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f57919ea-16ad-4c16-be7e-169e09cd27c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38e9f6ff-2615-4900-97b7-9a10f2ec874d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f57919ea-16ad-4c16-be7e-169e09cd27c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38e9f6ff-2615-4900-97b7-9a10f2ec874d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_64de8b98-34f8-4c80-82d7-ebcce4665fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f57919ea-16ad-4c16-be7e-169e09cd27c0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_64de8b98-34f8-4c80-82d7-ebcce4665fc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7b43090b-5758-41b9-9f92-9dc81804b3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f57919ea-16ad-4c16-be7e-169e09cd27c0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7b43090b-5758-41b9-9f92-9dc81804b3f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_088dc1c0-c2f3-4d2e-a943-f346abcf81bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_92866537-d60a-4595-854b-ee0edbad65d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_088dc1c0-c2f3-4d2e-a943-f346abcf81bd" xlink:to="loc_us-gaap_LiabilitiesCurrent_92866537-d60a-4595-854b-ee0edbad65d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_908ef6ea-28ea-4954-9772-8dc2c638795e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_088dc1c0-c2f3-4d2e-a943-f346abcf81bd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_908ef6ea-28ea-4954-9772-8dc2c638795e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5ebeb359-dd1c-4af2-a854-d6ca43fca105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_088dc1c0-c2f3-4d2e-a943-f346abcf81bd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5ebeb359-dd1c-4af2-a854-d6ca43fca105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_116a1cea-90f5-4338-aa95-be7704ae9083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fbf738bc-4ed0-4fb6-9fdc-3675d93f37f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_116a1cea-90f5-4338-aa95-be7704ae9083" xlink:to="loc_us-gaap_PreferredStockValue_fbf738bc-4ed0-4fb6-9fdc-3675d93f37f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cc5dba3c-9f36-4eb0-a8e2-30635d119bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_116a1cea-90f5-4338-aa95-be7704ae9083" xlink:to="loc_us-gaap_CommonStockValue_cc5dba3c-9f36-4eb0-a8e2-30635d119bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e4c82ba4-e666-421e-bcb4-d8522054a7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_116a1cea-90f5-4338-aa95-be7704ae9083" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e4c82ba4-e666-421e-bcb4-d8522054a7ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32778590-405c-4580-a0e8-f158adec9a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_116a1cea-90f5-4338-aa95-be7704ae9083" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32778590-405c-4580-a0e8-f158adec9a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f83a8e99-4295-4aab-b846-646ef1e1ae67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_116a1cea-90f5-4338-aa95-be7704ae9083" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f83a8e99-4295-4aab-b846-646ef1e1ae67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e73af39-37a3-47e2-8ae0-6f41bf3d96d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d1b6a7cc-4c42-4edd-a189-b9de8e2704fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e73af39-37a3-47e2-8ae0-6f41bf3d96d7" xlink:to="loc_us-gaap_Liabilities_d1b6a7cc-4c42-4edd-a189-b9de8e2704fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7d30fe5f-5c3e-4d47-974d-2707e49baa43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e73af39-37a3-47e2-8ae0-6f41bf3d96d7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7d30fe5f-5c3e-4d47-974d-2707e49baa43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c013fed6-c61d-4f86-80b6-93c824773a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3e73af39-37a3-47e2-8ae0-6f41bf3d96d7" xlink:to="loc_us-gaap_StockholdersEquity_c013fed6-c61d-4f86-80b6-93c824773a53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f0c189e0-8913-4d5e-aff3-235d3fb1a0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_906aa9d9-4321-4602-b990-c7896af8ff06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0c189e0-8913-4d5e-aff3-235d3fb1a0ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_906aa9d9-4321-4602-b990-c7896af8ff06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_3c7aa9a2-3d0a-476f-bf02-13aaf17f4688" xlink:href="allo-20220930.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0c189e0-8913-4d5e-aff3-235d3fb1a0ba" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_3c7aa9a2-3d0a-476f-bf02-13aaf17f4688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_487e68e7-d283-4817-9d69-ba54cc721e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f0c189e0-8913-4d5e-aff3-235d3fb1a0ba" xlink:to="loc_us-gaap_AccountsPayableCurrent_487e68e7-d283-4817-9d69-ba54cc721e2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_457f947a-dbed-40a9-a385-83642dc24a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ae59c8ed-f637-41bf-a49b-08d5150c85ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_457f947a-dbed-40a9-a385-83642dc24a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ae59c8ed-f637-41bf-a49b-08d5150c85ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7f2e787a-1d82-46a0-b1a1-38c4da9596a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_457f947a-dbed-40a9-a385-83642dc24a9e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7f2e787a-1d82-46a0-b1a1-38c4da9596a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ad06bd46-3e3b-4fc8-84cf-65403be163a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_457f947a-dbed-40a9-a385-83642dc24a9e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ad06bd46-3e3b-4fc8-84cf-65403be163a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_305ccf94-6610-4d99-b415-fb0b207a1a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_457f947a-dbed-40a9-a385-83642dc24a9e" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_305ccf94-6610-4d99-b415-fb0b207a1a7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_53a3566e-af75-4ae9-ae2a-a9582ef9f304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_457f947a-dbed-40a9-a385-83642dc24a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_53a3566e-af75-4ae9-ae2a-a9582ef9f304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a9b66538-916b-4f65-9b45-e7916d247e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_457f947a-dbed-40a9-a385-83642dc24a9e" xlink:to="loc_us-gaap_AssetsCurrent_a9b66538-916b-4f65-9b45-e7916d247e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_34201dc0-d3f7-446f-8d6e-01502015b36a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_457f947a-dbed-40a9-a385-83642dc24a9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_34201dc0-d3f7-446f-8d6e-01502015b36a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5587286-72ca-4ab7-917b-3c6f532b2950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_45422706-0ae3-4232-bd01-c37c476629dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5587286-72ca-4ab7-917b-3c6f532b2950" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_45422706-0ae3-4232-bd01-c37c476629dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_50ef4914-a8da-4a2a-a518-0c220f1e553e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5587286-72ca-4ab7-917b-3c6f532b2950" xlink:to="loc_us-gaap_InterestAndOtherIncome_50ef4914-a8da-4a2a-a518-0c220f1e553e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c443460-a863-4175-aeee-b8d9e1cb3b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7720de10-490d-4d15-9fac-b596a138e893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6c443460-a863-4175-aeee-b8d9e1cb3b64" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7720de10-490d-4d15-9fac-b596a138e893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1e43ed1d-da64-4da9-b562-32c995adbd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6c443460-a863-4175-aeee-b8d9e1cb3b64" xlink:to="loc_us-gaap_OperatingExpenses_1e43ed1d-da64-4da9-b562-32c995adbd63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e9fad032-e67d-4bf3-a255-0d59ab31f605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_34f56d2f-d3e6-455c-8ff5-6bd33c10ed2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e9fad032-e67d-4bf3-a255-0d59ab31f605" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_34f56d2f-d3e6-455c-8ff5-6bd33c10ed2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f67e0d36-d9e0-4f89-985c-6f168a24c97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e9fad032-e67d-4bf3-a255-0d59ab31f605" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f67e0d36-d9e0-4f89-985c-6f168a24c97b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a617474b-5deb-4322-86d3-717ba66648eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_71077b02-cdc6-4e8a-8c30-98060c67d182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a617474b-5deb-4322-86d3-717ba66648eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_71077b02-cdc6-4e8a-8c30-98060c67d182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2fc68b53-70f0-481a-9cf6-6207b0399f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a617474b-5deb-4322-86d3-717ba66648eb" xlink:to="loc_us-gaap_NetIncomeLoss_2fc68b53-70f0-481a-9cf6-6207b0399f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f6e60826-e364-4794-9f56-2cddd4b99762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c3772380-c3aa-415a-841e-e3f56030f203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f6e60826-e364-4794-9f56-2cddd4b99762" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c3772380-c3aa-415a-841e-e3f56030f203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_30952d75-de9c-4136-8693-025c57569bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f6e60826-e364-4794-9f56-2cddd4b99762" xlink:to="loc_us-gaap_OperatingIncomeLoss_30952d75-de9c-4136-8693-025c57569bb6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="allo-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_63176381-1f96-4120-ac3b-f7441d47e29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_63176381-1f96-4120-ac3b-f7441d47e29c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_4491e97f-1e9a-40c5-ba0a-a678279bd4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_OperatingLeaseExpense_4491e97f-1e9a-40c5-ba0a-a678279bd4a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_52e4995d-f67b-4fc1-88f3-15f9756bcd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_52e4995d-f67b-4fc1-88f3-15f9756bcd03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_16cc7136-ffe4-472a-ab6b-28d642051d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_16cc7136-ffe4-472a-ab6b-28d642051d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3dcad291-1d90-45b2-9cf7-f75b86798a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_Depreciation_3dcad291-1d90-45b2-9cf7-f75b86798a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_faef3ecc-a6eb-41be-8206-9d1269fba626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_faef3ecc-a6eb-41be-8206-9d1269fba626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ad6254ed-e14a-42cb-b8ac-80e3d5f16ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ad6254ed-e14a-42cb-b8ac-80e3d5f16ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1cdb8c16-db0e-4690-9645-ed152580b95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_ProfitLoss_1cdb8c16-db0e-4690-9645-ed152580b95b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_c069becb-8258-4427-9b3f-3ec02321d011" xlink:href="allo-20220930.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_c069becb-8258-4427-9b3f-3ec02321d011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8146c2a2-ae8e-4b37-891f-80f9b7d3b5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_ShareBasedCompensation_8146c2a2-ae8e-4b37-891f-80f9b7d3b5c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c7872d7c-7f6f-4365-9bde-0919e0cd44ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c7872d7c-7f6f-4365-9bde-0919e0cd44ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a28f703c-eed2-44f9-9f66-fcd09ad77587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4eeb079-fd0d-4986-a2a8-1498008b5b52" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a28f703c-eed2-44f9-9f66-fcd09ad77587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c504c3a-ed86-4327-afcb-1f9b0410f5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43106846-0a1c-49ad-9508-160b57af9646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c504c3a-ed86-4327-afcb-1f9b0410f5cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43106846-0a1c-49ad-9508-160b57af9646" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e0961853-6a40-476e-9e3a-8647544e5ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c504c3a-ed86-4327-afcb-1f9b0410f5cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e0961853-6a40-476e-9e3a-8647544e5ec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3aa55285-f237-4e0b-a561-82294352833f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c504c3a-ed86-4327-afcb-1f9b0410f5cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3aa55285-f237-4e0b-a561-82294352833f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9a6ea1a-3105-4237-9ea5-8028555ba72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bf3e1a5f-db66-409b-8ccd-1063609aeefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9a6ea1a-3105-4237-9ea5-8028555ba72c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bf3e1a5f-db66-409b-8ccd-1063609aeefc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_54f30103-44b6-47e8-b2d5-27a1b9f07de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9a6ea1a-3105-4237-9ea5-8028555ba72c" xlink:to="loc_us-gaap_ProceedsFromStockPlans_54f30103-44b6-47e8-b2d5-27a1b9f07de7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7420c108-66a9-415d-8e5c-0695d85627ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d345cabd-3b1d-412a-a505-6b567d0a333b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7420c108-66a9-415d-8e5c-0695d85627ea" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d345cabd-3b1d-412a-a505-6b567d0a333b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6fe9c8d7-195a-4fee-8643-20edf5a0bc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7420c108-66a9-415d-8e5c-0695d85627ea" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6fe9c8d7-195a-4fee-8643-20edf5a0bc5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12b8e34c-a33b-4bb6-8032-4302dbb45045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7420c108-66a9-415d-8e5c-0695d85627ea" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12b8e34c-a33b-4bb6-8032-4302dbb45045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ad553d44-9e2b-4d82-9a6b-8fff73a25266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7420c108-66a9-415d-8e5c-0695d85627ea" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ad553d44-9e2b-4d82-9a6b-8fff73a25266" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0f9c66e1-5739-44c4-9795-bb83d192cb62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_497e9f64-84b8-4cef-9771-e0b0cad65038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0f9c66e1-5739-44c4-9795-bb83d192cb62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_497e9f64-84b8-4cef-9771-e0b0cad65038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9fb610bd-6ce7-44c6-a2c4-ba68c72deb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0f9c66e1-5739-44c4-9795-bb83d192cb62" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9fb610bd-6ce7-44c6-a2c4-ba68c72deb4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d700925f-f0bc-45e7-bc8d-218d44bea685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0f9c66e1-5739-44c4-9795-bb83d192cb62" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d700925f-f0bc-45e7-bc8d-218d44bea685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_524b8c05-5736-46f1-bca6-e3dcce91fd6d" xlink:href="allo-20220930.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f1041531-5b0a-4ff1-9b0c-b68e61a41892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_524b8c05-5736-46f1-bca6-e3dcce91fd6d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f1041531-5b0a-4ff1-9b0c-b68e61a41892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ddd90028-04e8-4604-99a0-9e214b301ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_524b8c05-5736-46f1-bca6-e3dcce91fd6d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ddd90028-04e8-4604-99a0-9e214b301ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_8f14c93b-a632-44d3-aa89-e3ff1d596187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_524b8c05-5736-46f1-bca6-e3dcce91fd6d" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_8f14c93b-a632-44d3-aa89-e3ff1d596187" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#BalanceSheetComponentsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_74397779-8b38-483f-be1a-b94c77718ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4e8f78aa-048a-4509-9697-fe24118ba0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_74397779-8b38-483f-be1a-b94c77718ef2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4e8f78aa-048a-4509-9697-fe24118ba0ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f33ca5ca-0523-4403-9696-e95145d96edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_74397779-8b38-483f-be1a-b94c77718ef2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f33ca5ca-0523-4403-9696-e95145d96edc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7057de29-c4db-4739-a7fc-1e7e761c9905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82e6f48c-3586-4af8-bfd3-212788fc171a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7057de29-c4db-4739-a7fc-1e7e761c9905" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82e6f48c-3586-4af8-bfd3-212788fc171a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_01945e79-8a11-4c15-ab80-1095d63becf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7057de29-c4db-4739-a7fc-1e7e761c9905" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_01945e79-8a11-4c15-ab80-1095d63becf5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_3c92a8b5-14c5-4aad-bedb-ae5be845a775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bac42b17-0499-4fb6-840c-07c717f07516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_3c92a8b5-14c5-4aad-bedb-ae5be845a775" xlink:to="loc_us-gaap_OperatingLeaseCost_bac42b17-0499-4fb6-840c-07c717f07516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_1e785072-4d1d-408d-aad8-d43aa5efdec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_3c92a8b5-14c5-4aad-bedb-ae5be845a775" xlink:to="loc_us-gaap_VariableLeaseCost_1e785072-4d1d-408d-aad8-d43aa5efdec7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e26e7d1-2192-4d92-852e-9ec0d3028ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9dee0e6e-fbe0-4def-a3f5-5228c7398305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e26e7d1-2192-4d92-852e-9ec0d3028ae0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9dee0e6e-fbe0-4def-a3f5-5228c7398305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f95844f2-7c06-4454-a389-a85bb531df85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e26e7d1-2192-4d92-852e-9ec0d3028ae0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f95844f2-7c06-4454-a389-a85bb531df85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c4e0c0d3-a2d0-4714-9d69-68dd9b214520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e26e7d1-2192-4d92-852e-9ec0d3028ae0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c4e0c0d3-a2d0-4714-9d69-68dd9b214520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9a977130-64f0-41e5-8442-99fa32c4c73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e26e7d1-2192-4d92-852e-9ec0d3028ae0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9a977130-64f0-41e5-8442-99fa32c4c73d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_5b04b1c3-77c7-49bb-9002-75f43604b693" xlink:href="allo-20220930.xsd#allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e26e7d1-2192-4d92-852e-9ec0d3028ae0" xlink:to="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_5b04b1c3-77c7-49bb-9002-75f43604b693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_50326f91-d2eb-4411-82d8-a5ac5e022f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e26e7d1-2192-4d92-852e-9ec0d3028ae0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_50326f91-d2eb-4411-82d8-a5ac5e022f44" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>allo-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3bc7a964-10eb-47e7-910c-f5ea785aeb6d,g:304a2d5e-50f8-4210-a420-41588b836a7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="allo-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i4b9c7170e73d43e8b0dd95db98a5a6db_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_188e83da-56f8-42d7-9a62-154da02a698d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_188e83da-56f8-42d7-9a62-154da02a698d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f557af01-45d4-438f-b851-e2af57faff85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f557af01-45d4-438f-b851-e2af57faff85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36c6f360-4d54-483b-a649-e793ee71653f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockholdersEquity_36c6f360-4d54-483b-a649-e793ee71653f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9e2bb3f-79a9-45e8-8e80-4028bc5e2dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9e2bb3f-79a9-45e8-8e80-4028bc5e2dcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad06fd53-7397-448e-8254-157eb9e434e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad06fd53-7397-448e-8254-157eb9e434e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_b5729420-1926-4b0d-80a8-b7d31ee444ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_b5729420-1926-4b0d-80a8-b7d31ee444ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_694d4f56-4c41-4b77-8204-eace57a87521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_694d4f56-4c41-4b77-8204-eace57a87521" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7b4eb712-a3a8-4284-999c-46b292565ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7b4eb712-a3a8-4284-999c-46b292565ef3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3ddba568-d1f7-4b7e-8924-bd687633f234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3ddba568-d1f7-4b7e-8924-bd687633f234" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f5ace83-b0e2-49e2-a3e7-47800db44cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_NetIncomeLoss_8f5ace83-b0e2-49e2-a3e7-47800db44cfa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_40b64036-bd88-4aac-80f0-490ed98a5d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_40b64036-bd88-4aac-80f0-490ed98a5d65" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c0e9edff-fe0b-4210-ac75-ca47fdf26b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5c15453e-2cf3-4283-ae23-88b8703df849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bb8bcae3-042a-48de-931b-5675cefcec61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_188e83da-56f8-42d7-9a62-154da02a698d" xlink:to="loc_us-gaap_StatementTable_bb8bcae3-042a-48de-931b-5675cefcec61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4736af49-2689-460d-9f59-8381979068a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bb8bcae3-042a-48de-931b-5675cefcec61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4736af49-2689-460d-9f59-8381979068a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4736af49-2689-460d-9f59-8381979068a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4736af49-2689-460d-9f59-8381979068a9" xlink:to="loc_us-gaap_EquityComponentDomain_4736af49-2689-460d-9f59-8381979068a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4736af49-2689-460d-9f59-8381979068a9" xlink:to="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dfba86c9-baeb-490a-90b3-51ace22351f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:to="loc_us-gaap_CommonStockMember_dfba86c9-baeb-490a-90b3-51ace22351f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_da4081ac-1044-4163-ae78-cf79ed9795ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_da4081ac-1044-4163-ae78-cf79ed9795ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cf1ab50e-e68a-4b14-83a9-409f09a40847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:to="loc_us-gaap_RetainedEarningsMember_cf1ab50e-e68a-4b14-83a9-409f09a40847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3ce3e8fc-6d60-40da-ae41-542ba850c5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3ce3e8fc-6d60-40da-ae41-542ba850c5e9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20220930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" id="i6d3cad74192b4056b150b357a1e08729_FairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68295e4b-ea16-450c-9431-7475a31190a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b9ce8c99-920a-431b-97d4-400e302bb347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68295e4b-ea16-450c-9431-7475a31190a4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b9ce8c99-920a-431b-97d4-400e302bb347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_264ded88-2ff1-43f0-b272-419b5e2ca5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68295e4b-ea16-450c-9431-7475a31190a4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_264ded88-2ff1-43f0-b272-419b5e2ca5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f13d6f36-ae16-462f-9bb8-0513d6b9ba05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68295e4b-ea16-450c-9431-7475a31190a4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f13d6f36-ae16-462f-9bb8-0513d6b9ba05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_58ab95e8-57ae-42e5-8598-a657b4bc6619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f13d6f36-ae16-462f-9bb8-0513d6b9ba05" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_58ab95e8-57ae-42e5-8598-a657b4bc6619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_58ab95e8-57ae-42e5-8598-a657b4bc6619_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_58ab95e8-57ae-42e5-8598-a657b4bc6619" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_58ab95e8-57ae-42e5-8598-a657b4bc6619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc46eaa1-d02f-49ac-a413-995dae599b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_58ab95e8-57ae-42e5-8598-a657b4bc6619" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc46eaa1-d02f-49ac-a413-995dae599b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c9e5d632-4f55-45ca-9e45-2fe71372836d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc46eaa1-d02f-49ac-a413-995dae599b4d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c9e5d632-4f55-45ca-9e45-2fe71372836d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6455bae8-09c8-4d84-8c20-658f30162a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f13d6f36-ae16-462f-9bb8-0513d6b9ba05" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6455bae8-09c8-4d84-8c20-658f30162a33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6455bae8-09c8-4d84-8c20-658f30162a33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6455bae8-09c8-4d84-8c20-658f30162a33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6455bae8-09c8-4d84-8c20-658f30162a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e0abd6c-0300-4078-acad-afba198480e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6455bae8-09c8-4d84-8c20-658f30162a33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e0abd6c-0300-4078-acad-afba198480e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_153b293e-5d5b-4016-a3e5-8c3ab60a0b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e0abd6c-0300-4078-acad-afba198480e6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_153b293e-5d5b-4016-a3e5-8c3ab60a0b64" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="allo-20220930.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="extended" id="i4b6286f4180643a49c5f7e0a4164dc59_FairValueMeasurementsFinancialAssetsandLiabilitiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_01a4f66e-8341-448b-af01-125696165244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0dd9e4d8-e090-47dd-bfdb-f27133c74b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_01a4f66e-8341-448b-af01-125696165244" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0dd9e4d8-e090-47dd-bfdb-f27133c74b95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_01a4f66e-8341-448b-af01-125696165244" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63dc1980-a058-4981-90b3-d21f204ce3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63dc1980-a058-4981-90b3-d21f204ce3c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_63dc1980-a058-4981-90b3-d21f204ce3c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63dc1980-a058-4981-90b3-d21f204ce3c9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_63dc1980-a058-4981-90b3-d21f204ce3c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f142bf1-818e-4653-9fee-97c025c52d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63dc1980-a058-4981-90b3-d21f204ce3c9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f142bf1-818e-4653-9fee-97c025c52d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_768afa1a-c920-445b-a027-b5756679e14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f142bf1-818e-4653-9fee-97c025c52d78" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_768afa1a-c920-445b-a027-b5756679e14b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d750f10-dc39-4a12-ab63-0cd3a00b1c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d750f10-dc39-4a12-ab63-0cd3a00b1c75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d750f10-dc39-4a12-ab63-0cd3a00b1c75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d750f10-dc39-4a12-ab63-0cd3a00b1c75" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d750f10-dc39-4a12-ab63-0cd3a00b1c75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d750f10-dc39-4a12-ab63-0cd3a00b1c75" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b4ed4ad3-0dfb-4d65-862f-ccdbf53added" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b4ed4ad3-0dfb-4d65-862f-ccdbf53added" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_71d1c05a-95dd-4c19-9da0-3ef42ac2eca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_71d1c05a-95dd-4c19-9da0-3ef42ac2eca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8d38e679-19bd-41a6-b58c-51812207e160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8d38e679-19bd-41a6-b58c-51812207e160" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_bc2c425d-7e88-4f5a-aa42-559014b5b87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_bc2c425d-7e88-4f5a-aa42-559014b5b87d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bc2c425d-7e88-4f5a-aa42-559014b5b87d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_bc2c425d-7e88-4f5a-aa42-559014b5b87d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bc2c425d-7e88-4f5a-aa42-559014b5b87d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_bc2c425d-7e88-4f5a-aa42-559014b5b87d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f555a545-3421-4491-898c-6c6a22e5c0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f555a545-3421-4491-898c-6c6a22e5c0d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6b66ca91-5197-44c8-ba50-955d69be3299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_CommercialPaperMember_6b66ca91-5197-44c8-ba50-955d69be3299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_b5350546-1087-435d-acf5-d3304bc23623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_b5350546-1087-435d-acf5-d3304bc23623" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0b7becb9-d965-452c-9a5d-6e54b7fe638d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0b7becb9-d965-452c-9a5d-6e54b7fe638d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fc6f7bfe-e6c0-48ca-9821-0fd2feb285b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fc6f7bfe-e6c0-48ca-9821-0fd2feb285b2" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i2fd90fc7986f4d1faa1355fec0673598_FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_32065377-40b8-4f11-8053-52417fd51bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_32065377-40b8-4f11-8053-52417fd51bdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d2afe14b-5899-424a-a1d3-366c42bf3601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d2afe14b-5899-424a-a1d3-366c42bf3601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e3248754-7d9e-4349-9b3c-cbd3aa73587f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e3248754-7d9e-4349-9b3c-cbd3aa73587f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b292ff2b-bb79-4301-9cb2-b3e7aa294851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b292ff2b-bb79-4301-9cb2-b3e7aa294851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_de052570-80f2-479f-8c19-b7743ebf89e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_de052570-80f2-479f-8c19-b7743ebf89e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d39eb2b1-15d6-4f44-b461-6fa89594303d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d39eb2b1-15d6-4f44-b461-6fa89594303d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6b3a63d7-48be-4a99-8ded-c70f16626c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6b3a63d7-48be-4a99-8ded-c70f16626c17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_70d00c17-ea2b-4d63-98c1-cab83334895d" xlink:href="allo-20220930.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_70d00c17-ea2b-4d63-98c1-cab83334895d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_76094200-73b9-4ec3-b2e7-7baeb6cf1718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_76094200-73b9-4ec3-b2e7-7baeb6cf1718" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_42acc2ec-dcdb-4350-baa5-e6d4ac24374c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_76094200-73b9-4ec3-b2e7-7baeb6cf1718" xlink:to="loc_us-gaap_FinancialInstrumentAxis_42acc2ec-dcdb-4350-baa5-e6d4ac24374c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_42acc2ec-dcdb-4350-baa5-e6d4ac24374c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_42acc2ec-dcdb-4350-baa5-e6d4ac24374c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_42acc2ec-dcdb-4350-baa5-e6d4ac24374c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_42acc2ec-dcdb-4350-baa5-e6d4ac24374c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2edd0197-a81b-4bc4-acdf-2ac5c63cc8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2edd0197-a81b-4bc4-acdf-2ac5c63cc8df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_08cbf6ad-b235-4f60-b12d-0836c7b6a844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_CommercialPaperMember_08cbf6ad-b235-4f60-b12d-0836c7b6a844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ad700f20-c03b-4bf1-a3de-676b09d01e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ad700f20-c03b-4bf1-a3de-676b09d01e29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d7bc7fc1-067a-447c-beed-fab1fc90fa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d7bc7fc1-067a-447c-beed-fab1fc90fa7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_50cf6cde-3a76-4462-a045-830db9d351c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_50cf6cde-3a76-4462-a045-830db9d351c1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#BalanceSheetComponentsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="extended" id="i06d123c11e1c48a2b0df12c41258e637_BalanceSheetComponentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fd38a7bd-6444-489d-a3e1-ae67a4cdac48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fd38a7bd-6444-489d-a3e1-ae67a4cdac48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f922d0f4-3c38-4b41-a8cc-fe452181a6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f922d0f4-3c38-4b41-a8cc-fe452181a6e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9516d247-6f7d-4913-9baa-667ff3fa3cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9516d247-6f7d-4913-9baa-667ff3fa3cdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_502f8520-0c71-4632-a624-3b594f10759f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_502f8520-0c71-4632-a624-3b594f10759f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_608cfd72-9809-4562-ba62-bb6b235fbe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_502f8520-0c71-4632-a624-3b594f10759f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_608cfd72-9809-4562-ba62-bb6b235fbe3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_608cfd72-9809-4562-ba62-bb6b235fbe3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_608cfd72-9809-4562-ba62-bb6b235fbe3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_608cfd72-9809-4562-ba62-bb6b235fbe3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_608cfd72-9809-4562-ba62-bb6b235fbe3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d1858c6b-04bf-4a43-a0ec-f695ac0aa707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d1858c6b-04bf-4a43-a0ec-f695ac0aa707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_f8e0036d-399d-41ea-bf57-a7b83b446097" xlink:href="allo-20220930.xsd#allo_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_allo_LaboratoryEquipmentMember_f8e0036d-399d-41ea-bf57-a7b83b446097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_24e83747-86b3-4e97-a800-f02b9978f9f6" xlink:href="allo-20220930.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_24e83747-86b3-4e97-a800-f02b9978f9f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8e9e4a83-b6b0-4320-8320-775a43a9d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8e9e4a83-b6b0-4320-8320-775a43a9d33e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_86650964-ee1f-4004-a600-6cda226e9220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_us-gaap_ConstructionInProgressMember_86650964-ee1f-4004-a600-6cda226e9220" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#LicenseandCollaborationAgreementsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended" id="i40bc6f18e1a0474694f2f1410d08d4df_LicenseandCollaborationAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_654a814d-87a7-4ad6-b94d-d141a2e81d8a" xlink:href="allo-20220930.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_AggregatePotentialMilestonePayments_654a814d-87a7-4ad6-b94d-d141a2e81d8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_8904430d-53fc-4119-856b-b5dc733ddb35" xlink:href="allo-20220930.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_8904430d-53fc-4119-856b-b5dc733ddb35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_4c285cb2-3816-400b-b830-0e180c25626d" xlink:href="allo-20220930.xsd#allo_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_MilestonePayments_4c285cb2-3816-400b-b830-0e180c25626d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_6ca8a2b5-f8a9-4e88-a9be-68cb6cee62d0" xlink:href="allo-20220930.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_6ca8a2b5-f8a9-4e88-a9be-68cb6cee62d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_5412fe35-3ea9-4295-85f5-e82bc34ad417" xlink:href="allo-20220930.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_5412fe35-3ea9-4295-85f5-e82bc34ad417" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6944be5e-e2b5-4391-8045-b3bf3d725742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6944be5e-e2b5-4391-8045-b3bf3d725742" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_c5935c21-ba7c-44ac-a7f0-289ab5cc47e9" xlink:href="allo-20220930.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_c5935c21-ba7c-44ac-a7f0-289ab5cc47e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_e64593b1-20ae-4f3e-ac76-b1c2ae8aee8c" xlink:href="allo-20220930.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_e64593b1-20ae-4f3e-ac76-b1c2ae8aee8c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable_fa8f91cd-5d88-4f84-8eb8-4be6565e1a84" xlink:href="allo-20220930.xsd#allo_AggregatePotentialMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_AggregatePotentialMilestoneReceivable_fa8f91cd-5d88-4f84-8eb8-4be6565e1a84" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_67e26a23-15d1-4d43-92a8-0b1370fb6821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_67e26a23-15d1-4d43-92a8-0b1370fb6821" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_f43cd47e-6931-4999-a026-c715d7564bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_DueFromRelatedParties_f43cd47e-6931-4999-a026-c715d7564bc2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment_21bfb7e1-45e7-421e-97da-f8da09f1aa31" xlink:href="allo-20220930.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_CollaborationAgreementUpfrontPayment_21bfb7e1-45e7-421e-97da-f8da09f1aa31" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d0f9499e-caf1-4484-be42-5d84edaaa72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d0f9499e-caf1-4484-be42-5d84edaaa72e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_62977d4e-32c5-4bc4-a952-475cfc3838db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_62977d4e-32c5-4bc4-a952-475cfc3838db" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7ef0f0dd-b6da-4460-825c-67af8daff735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7ef0f0dd-b6da-4460-825c-67af8daff735" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable_ff2e2e45-37d5-4a29-b51b-7b30d6b31d7e" xlink:href="allo-20220930.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_AggregatePotentialMilestonePayable_ff2e2e45-37d5-4a29-b51b-7b30d6b31d7e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationArrangementExpense_f03e3585-e68b-4bff-942a-934aca891f3a" xlink:href="allo-20220930.xsd#allo_CollaborationArrangementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_CollaborationArrangementExpense_f03e3585-e68b-4bff-942a-934aca891f3a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementTerm_7f8858a6-5040-41cd-8ff3-732887b18861" xlink:href="allo-20220930.xsd#allo_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_CollaborationAgreementTerm_7f8858a6-5040-41cd-8ff3-732887b18861" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementCommittedFunding_1a75b518-d896-4818-b20f-a476df8caa65" xlink:href="allo-20220930.xsd#allo_CollaborationAgreementCommittedFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_CollaborationAgreementCommittedFunding_1a75b518-d896-4818-b20f-a476df8caa65" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UpfrontAndQuarterlyCashPayments_e887c873-b15f-48cd-9ae4-3b92400b1e33" xlink:href="allo-20220930.xsd#allo_UpfrontAndQuarterlyCashPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_UpfrontAndQuarterlyCashPayments_e887c873-b15f-48cd-9ae4-3b92400b1e33" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_JointVentureCapitalSupportPayments_3d9dd166-629e-45dd-9fdf-516466759dd5" xlink:href="allo-20220930.xsd#allo_JointVentureCapitalSupportPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_JointVentureCapitalSupportPayments_3d9dd166-629e-45dd-9fdf-516466759dd5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a01a086-7558-4c2b-8d4b-fb317ae8033f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a01a086-7558-4c2b-8d4b-fb317ae8033f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ReductionToResearchAndDevelopmentExpense_7588a32e-52c7-471f-9ac8-03da393a8797" xlink:href="allo-20220930.xsd#allo_ReductionToResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_ReductionToResearchAndDevelopmentExpense_7588a32e-52c7-471f-9ac8-03da393a8797" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_767c7743-1625-426c-9007-37872cbdabc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_767c7743-1625-426c-9007-37872cbdabc5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement_adb53222-ac0d-4606-a989-e02f9003bf13" xlink:href="allo-20220930.xsd#allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement_adb53222-ac0d-4606-a989-e02f9003bf13" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eff0adc7-5507-4314-b681-219ceb5fdd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eff0adc7-5507-4314-b681-219ceb5fdd88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_eff0adc7-5507-4314-b681-219ceb5fdd88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eff0adc7-5507-4314-b681-219ceb5fdd88" xlink:to="loc_us-gaap_RelatedPartyDomain_eff0adc7-5507-4314-b681-219ceb5fdd88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eff0adc7-5507-4314-b681-219ceb5fdd88" xlink:to="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_2742bef6-24ef-48f5-9a69-d0cfe833582b" xlink:href="allo-20220930.xsd#allo_PfizerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:to="loc_allo_PfizerIncMember_2742bef6-24ef-48f5-9a69-d0cfe833582b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember_c820e3fb-31a7-415b-9d3d-d6d81b14b213" xlink:href="allo-20220930.xsd#allo_CellectisSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:to="loc_allo_CellectisSAMember_c820e3fb-31a7-415b-9d3d-d6d81b14b213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember_e1534e22-2a3d-46b3-b582-076e28c7e2d4" xlink:href="allo-20220930.xsd#allo_ServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:to="loc_allo_ServierMember_e1534e22-2a3d-46b3-b582-076e28c7e2d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_5e2412eb-c2ba-464a-89a7-7c52ae4988be" xlink:href="allo-20220930.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:to="loc_allo_NotchTherapeuticsIncMember_5e2412eb-c2ba-464a-89a7-7c52ae4988be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeAxis_e79c5fbe-defe-4d6b-b602-33a8981a7b33" xlink:href="allo-20220930.xsd#allo_MilestoneTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_allo_MilestoneTypeAxis_e79c5fbe-defe-4d6b-b602-33a8981a7b33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain_e79c5fbe-defe-4d6b-b602-33a8981a7b33_default" xlink:href="allo-20220930.xsd#allo_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_MilestoneTypeAxis_e79c5fbe-defe-4d6b-b602-33a8981a7b33" xlink:to="loc_allo_MilestoneTypeDomain_e79c5fbe-defe-4d6b-b602-33a8981a7b33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain_ab32a4ac-b36b-487f-a872-9ef917e80510" xlink:href="allo-20220930.xsd#allo_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_MilestoneTypeAxis_e79c5fbe-defe-4d6b-b602-33a8981a7b33" xlink:to="loc_allo_MilestoneTypeDomain_ab32a4ac-b36b-487f-a872-9ef917e80510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DevelopmentAndSalesMember_fab83e06-412b-475d-9646-c8b0ea2af757" xlink:href="allo-20220930.xsd#allo_DevelopmentAndSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_MilestoneTypeDomain_ab32a4ac-b36b-487f-a872-9ef917e80510" xlink:to="loc_allo_DevelopmentAndSalesMember_fab83e06-412b-475d-9646-c8b0ea2af757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_dd86367a-4462-4249-81e5-1f0aaa48f9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_dd86367a-4462-4249-81e5-1f0aaa48f9a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_dd86367a-4462-4249-81e5-1f0aaa48f9a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_dd86367a-4462-4249-81e5-1f0aaa48f9a0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_dd86367a-4462-4249-81e5-1f0aaa48f9a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_dd86367a-4462-4249-81e5-1f0aaa48f9a0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_b4822502-18ef-4d33-b657-54c1e0a71193" xlink:href="allo-20220930.xsd#allo_AssetContributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_AssetContributionAgreementMember_b4822502-18ef-4d33-b657-54c1e0a71193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember_6c2293ea-dd3c-4cce-b5db-286074480b79" xlink:href="allo-20220930.xsd#allo_RegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_RegulatoryMilestoneMember_6c2293ea-dd3c-4cce-b5db-286074480b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember_4a51e26f-0795-4be3-8353-7f41c381a8b8" xlink:href="allo-20220930.xsd#allo_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_SalesMilestoneMember_4a51e26f-0795-4be3-8353-7f41c381a8b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_23620a27-32c9-4a64-8e5a-c2eb98d28a1e" xlink:href="allo-20220930.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_23620a27-32c9-4a64-8e5a-c2eb98d28a1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_3b2b79ba-735d-4980-b754-69191df6fca8" xlink:href="allo-20220930.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_3b2b79ba-735d-4980-b754-69191df6fca8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2cf20ae9-5660-411c-9263-988a2ec75af1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_srt_RangeAxis_2cf20ae9-5660-411c-9263-988a2ec75af1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2cf20ae9-5660-411c-9263-988a2ec75af1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2cf20ae9-5660-411c-9263-988a2ec75af1" xlink:to="loc_srt_RangeMember_2cf20ae9-5660-411c-9263-988a2ec75af1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0807ae67-9719-4457-9b23-0a90e611a6e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2cf20ae9-5660-411c-9263-988a2ec75af1" xlink:to="loc_srt_RangeMember_0807ae67-9719-4457-9b23-0a90e611a6e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aad69618-b0e5-4754-80cf-5550ed84fdd2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0807ae67-9719-4457-9b23-0a90e611a6e1" xlink:to="loc_srt_MinimumMember_aad69618-b0e5-4754-80cf-5550ed84fdd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f11ea37c-6d75-4d4f-9dc0-867f32225ef5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0807ae67-9719-4457-9b23-0a90e611a6e1" xlink:to="loc_srt_MaximumMember_f11ea37c-6d75-4d4f-9dc0-867f32225ef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8cf13146-ef3c-4bc2-b449-9df39ad12903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8cf13146-ef3c-4bc2-b449-9df39ad12903" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8cf13146-ef3c-4bc2-b449-9df39ad12903_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8cf13146-ef3c-4bc2-b449-9df39ad12903" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8cf13146-ef3c-4bc2-b449-9df39ad12903_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8cf13146-ef3c-4bc2-b449-9df39ad12903" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_9a7e926a-96b9-4fd3-ac8d-4da71638a588" xlink:href="allo-20220930.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_9a7e926a-96b9-4fd3-ac8d-4da71638a588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_58bba4e3-a401-416a-9798-95e644a4b966" xlink:href="allo-20220930.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_58bba4e3-a401-416a-9798-95e644a4b966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_e29ec54c-6819-4862-8518-2d5eb68a9b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_us-gaap_CorporateJointVentureMember_e29ec54c-6819-4862-8518-2d5eb68a9b70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntionCollaborationAgreementMember_e2f0c6ee-3d41-4537-ad2e-3c5769624089" xlink:href="allo-20220930.xsd#allo_AntionCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_AntionCollaborationAgreementMember_e2f0c6ee-3d41-4537-ad2e-3c5769624089" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntionCollaborationAgreementMilestoneAchievementOneMember_0097cd01-b29e-4e9c-85d0-84a45aa01011" xlink:href="allo-20220930.xsd#allo_AntionCollaborationAgreementMilestoneAchievementOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_AntionCollaborationAgreementMilestoneAchievementOneMember_0097cd01-b29e-4e9c-85d0-84a45aa01011" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember_9cda867f-3473-4aaf-9fa1-e41d6f888afb" xlink:href="allo-20220930.xsd#allo_AntionCollaborationAgreementMilestoneAchievementTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember_9cda867f-3473-4aaf-9fa1-e41d6f888afb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_69bbb273-10fa-40f1-8ef3-c40bc4e1f414" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_69bbb273-10fa-40f1-8ef3-c40bc4e1f414" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_69bbb273-10fa-40f1-8ef3-c40bc4e1f414_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_69bbb273-10fa-40f1-8ef3-c40bc4e1f414" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_69bbb273-10fa-40f1-8ef3-c40bc4e1f414_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ab50f8d2-563e-4727-99ce-439c5d9a762b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_69bbb273-10fa-40f1-8ef3-c40bc4e1f414" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ab50f8d2-563e-4727-99ce-439c5d9a762b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_17107611-5134-4206-a755-0e7c04b87658" xlink:href="allo-20220930.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ab50f8d2-563e-4727-99ce-439c5d9a762b" xlink:to="loc_allo_NotchTherapeuticsIncMember_17107611-5134-4206-a755-0e7c04b87658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember_d3b6d7a6-1633-4d0c-ac0d-962b38731fb2" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ab50f8d2-563e-4727-99ce-439c5d9a762b" xlink:to="loc_allo_AllogeneOverlandMember_d3b6d7a6-1633-4d0c-ac0d-962b38731fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a0088986-394a-445a-b4c9-305f32c91f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a0088986-394a-445a-b4c9-305f32c91f97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a0088986-394a-445a-b4c9-305f32c91f97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a0088986-394a-445a-b4c9-305f32c91f97" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a0088986-394a-445a-b4c9-305f32c91f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c1b295d3-2ab2-4103-8cde-a703665b5aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a0088986-394a-445a-b4c9-305f32c91f97" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c1b295d3-2ab2-4103-8cde-a703665b5aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c0bacf85-65c4-4ecd-a4d6-f415e4856ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c1b295d3-2ab2-4103-8cde-a703665b5aec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c0bacf85-65c4-4ecd-a4d6-f415e4856ecd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2ddc8d05-eab8-4b99-9b33-d1706fb6b6eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_srt_CounterpartyNameAxis_2ddc8d05-eab8-4b99-9b33-d1706fb6b6eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ddc8d05-eab8-4b99-9b33-d1706fb6b6eb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2ddc8d05-eab8-4b99-9b33-d1706fb6b6eb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ddc8d05-eab8-4b99-9b33-d1706fb6b6eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2ddc8d05-eab8-4b99-9b33-d1706fb6b6eb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember_5b11fe35-51c6-4ffb-b8d8-fd338694ab08" xlink:href="allo-20220930.xsd#allo_UniversityOfTexasMDAndersonCancerCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:to="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember_5b11fe35-51c6-4ffb-b8d8-fd338694ab08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember_5cadaac8-50af-4cca-ab8e-e62125ff79c8" xlink:href="allo-20220930.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:to="loc_allo_OverlandPharmaceuticalsIncMember_5cadaac8-50af-4cca-ab8e-e62125ff79c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_de8e8154-8cd1-46f3-8d6b-1f657280d006" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:to="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_de8e8154-8cd1-46f3-8d6b-1f657280d006" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2370f734-fa97-4cce-b087-ca39a446823c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_dei_LegalEntityAxis_2370f734-fa97-4cce-b087-ca39a446823c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2370f734-fa97-4cce-b087-ca39a446823c_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2370f734-fa97-4cce-b087-ca39a446823c" xlink:to="loc_dei_EntityDomain_2370f734-fa97-4cce-b087-ca39a446823c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_dc7553e2-aa4e-49ba-b482-aaedf6684a2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2370f734-fa97-4cce-b087-ca39a446823c" xlink:to="loc_dei_EntityDomain_dc7553e2-aa4e-49ba-b482-aaedf6684a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember_580226fa-cb5b-4eba-9330-2bfc1d06098b" xlink:href="allo-20220930.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_dc7553e2-aa4e-49ba-b482-aaedf6684a2b" xlink:to="loc_allo_OverlandPharmaceuticalsIncMember_580226fa-cb5b-4eba-9330-2bfc1d06098b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis_7a80c562-8c98-43dd-a180-99706e0e9db8" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_allo_EquityInvestmentBasisAxis_7a80c562-8c98-43dd-a180-99706e0e9db8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_7a80c562-8c98-43dd-a180-99706e0e9db8_default" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_EquityInvestmentBasisAxis_7a80c562-8c98-43dd-a180-99706e0e9db8" xlink:to="loc_allo_EquityInvestmentBasisDomain_7a80c562-8c98-43dd-a180-99706e0e9db8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_2dbd25ef-6e4b-4997-87cf-f6a6ac22c938" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_EquityInvestmentBasisAxis_7a80c562-8c98-43dd-a180-99706e0e9db8" xlink:to="loc_allo_EquityInvestmentBasisDomain_2dbd25ef-6e4b-4997-87cf-f6a6ac22c938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember_b9d426c4-dbd5-4320-b85a-8c474a29f6c7" xlink:href="allo-20220930.xsd#allo_VotingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_EquityInvestmentBasisDomain_2dbd25ef-6e4b-4997-87cf-f6a6ac22c938" xlink:to="loc_allo_VotingInterestMember_b9d426c4-dbd5-4320-b85a-8c474a29f6c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73f4dc36-fd75-479a-8135-3619bdea279e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73f4dc36-fd75-479a-8135-3619bdea279e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_73f4dc36-fd75-479a-8135-3619bdea279e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73f4dc36-fd75-479a-8135-3619bdea279e" xlink:to="loc_us-gaap_ClassOfStockDomain_73f4dc36-fd75-479a-8135-3619bdea279e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45996788-3c5d-43d1-a8f4-63e2db40d0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73f4dc36-fd75-479a-8135-3619bdea279e" xlink:to="loc_us-gaap_ClassOfStockDomain_45996788-3c5d-43d1-a8f4-63e2db40d0b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_5fcafefe-4c60-4e62-80a9-129813556336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45996788-3c5d-43d1-a8f4-63e2db40d0b9" xlink:to="loc_us-gaap_PreferredStockMember_5fcafefe-4c60-4e62-80a9-129813556336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_57bfb3b1-db72-47bf-9606-f7a921e63a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_57bfb3b1-db72-47bf-9606-f7a921e63a7e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_57bfb3b1-db72-47bf-9606-f7a921e63a7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_57bfb3b1-db72-47bf-9606-f7a921e63a7e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_57bfb3b1-db72-47bf-9606-f7a921e63a7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_36820f46-5cc1-4adc-bb47-56602b41c9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_57bfb3b1-db72-47bf-9606-f7a921e63a7e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_36820f46-5cc1-4adc-bb47-56602b41c9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CurrentAccruedAndOtherLiabilitiesMember_9a71d276-7746-4938-b05d-f683ee3b6af6" xlink:href="allo-20220930.xsd#allo_CurrentAccruedAndOtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_36820f46-5cc1-4adc-bb47-56602b41c9fc" xlink:to="loc_allo_CurrentAccruedAndOtherLiabilitiesMember_9a71d276-7746-4938-b05d-f683ee3b6af6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i4415d5641ccd4871be55bf18486a37ca_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_11f9ef3f-adb3-44ad-92d3-3213af896618" xlink:href="allo-20220930.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_AreaOfNewOfficeBuilding_11f9ef3f-adb3-44ad-92d3-3213af896618" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_edfcfa50-264a-4110-9b98-9f2fe0dbe756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_edfcfa50-264a-4110-9b98-9f2fe0dbe756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0783af7c-4d01-4ac3-b3a4-935f7ad7b748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0783af7c-4d01-4ac3-b3a4-935f7ad7b748" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_4d1933fc-4773-4b14-9d8c-033ee2253f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_TenantImprovements_4d1933fc-4773-4b14-9d8c-033ee2253f3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AdditionalAreaOfNewOfficeBuilding_0e8daaed-ac81-4f63-b6b5-ad0c3a6bba3e" xlink:href="allo-20220930.xsd#allo_AdditionalAreaOfNewOfficeBuilding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_AdditionalAreaOfNewOfficeBuilding_0e8daaed-ac81-4f63-b6b5-ad0c3a6bba3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowance_74049379-2b47-4772-a880-63bb5c96d86f" xlink:href="allo-20220930.xsd#allo_TenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_TenantImprovementAllowance_74049379-2b47-4772-a880-63bb5c96d86f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOperatingLease_32df2c14-d3bf-4ed0-b33e-6ef1b2291d4d" xlink:href="allo-20220930.xsd#allo_AreaOfOperatingLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_AreaOfOperatingLease_32df2c14-d3bf-4ed0-b33e-6ef1b2291d4d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfOptionsToExtendLease_ffb4be65-9dac-4ecf-b172-1aa13fae8f78" xlink:href="allo-20220930.xsd#allo_NumberOfOptionsToExtendLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_NumberOfOptionsToExtendLease_ffb4be65-9dac-4ecf-b172-1aa13fae8f78" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowanceUtilizedToDate_05d1e22a-4d76-4c28-8156-ee8b3b6a5e5f" xlink:href="allo-20220930.xsd#allo_TenantImprovementAllowanceUtilizedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_TenantImprovementAllowanceUtilizedToDate_05d1e22a-4d76-4c28-8156-ee8b3b6a5e5f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0b55e255-6b80-4afc-ac26-2dea1ae73984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0b55e255-6b80-4afc-ac26-2dea1ae73984" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9390f475-14aa-4059-ac0c-c767278babee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_OperatingLeasePayments_9390f475-14aa-4059-ac0c-c767278babee" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_248f361d-eab9-405b-9135-edbda745f5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_248f361d-eab9-405b-9135-edbda745f5bc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_be8c38ae-3996-4ea1-977d-221e0f322e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_be8c38ae-3996-4ea1-977d-221e0f322e42" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_16c7f299-618e-40e9-b06f-dbae38a57aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_16c7f299-618e-40e9-b06f-dbae38a57aa0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeFinanceLeasePaymentUponContractTermination_6deb6770-f9a3-4192-aa76-60c443648153" xlink:href="allo-20220930.xsd#allo_LesseeFinanceLeasePaymentUponContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_LesseeFinanceLeasePaymentUponContractTermination_6deb6770-f9a3-4192-aa76-60c443648153" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_0b639dea-5c05-4503-b4dc-03342812650b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_0b639dea-5c05-4503-b4dc-03342812650b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_36ed7a25-4247-4b89-90af-095bde352f10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:to="loc_srt_StatementGeographicalAxis_36ed7a25-4247-4b89-90af-095bde352f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_36ed7a25-4247-4b89-90af-095bde352f10_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_36ed7a25-4247-4b89-90af-095bde352f10" xlink:to="loc_srt_SegmentGeographicalDomain_36ed7a25-4247-4b89-90af-095bde352f10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_89419fdb-7405-43cb-87cb-d4adf1bb7d18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_36ed7a25-4247-4b89-90af-095bde352f10" xlink:to="loc_srt_SegmentGeographicalDomain_89419fdb-7405-43cb-87cb-d4adf1bb7d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember_ee0bf8f0-b02a-40c3-a7c6-706316e0671d" xlink:href="allo-20220930.xsd#allo_NewarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_89419fdb-7405-43cb-87cb-d4adf1bb7d18" xlink:to="loc_allo_NewarkMember_ee0bf8f0-b02a-40c3-a7c6-706316e0671d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ecec3e35-a1dd-4336-8b07-2f68f0b03241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:to="loc_us-gaap_CreditFacilityAxis_ecec3e35-a1dd-4336-8b07-2f68f0b03241" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ecec3e35-a1dd-4336-8b07-2f68f0b03241_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ecec3e35-a1dd-4336-8b07-2f68f0b03241" xlink:to="loc_us-gaap_CreditFacilityDomain_ecec3e35-a1dd-4336-8b07-2f68f0b03241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e3452542-3d61-423c-ae63-4402aed5d34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ecec3e35-a1dd-4336-8b07-2f68f0b03241" xlink:to="loc_us-gaap_CreditFacilityDomain_e3452542-3d61-423c-ae63-4402aed5d34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_8b39472f-fd72-4a8d-a09c-e9a58640dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e3452542-3d61-423c-ae63-4402aed5d34a" xlink:to="loc_us-gaap_LetterOfCreditMember_8b39472f-fd72-4a8d-a09c-e9a58640dc87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_d8a19067-af6a-47bf-93ac-bc96bbbf63b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:to="loc_us-gaap_LeaseContractualTermAxis_d8a19067-af6a-47bf-93ac-bc96bbbf63b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_d8a19067-af6a-47bf-93ac-bc96bbbf63b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_d8a19067-af6a-47bf-93ac-bc96bbbf63b4" xlink:to="loc_us-gaap_LeaseContractualTermDomain_d8a19067-af6a-47bf-93ac-bc96bbbf63b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_837caa0e-80ff-4fa4-b5ee-c3ed19faf329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_d8a19067-af6a-47bf-93ac-bc96bbbf63b4" xlink:to="loc_us-gaap_LeaseContractualTermDomain_837caa0e-80ff-4fa4-b5ee-c3ed19faf329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseOneAmendedMember_e6cda722-4ad0-4648-8ccd-0f2c9534fc9a" xlink:href="allo-20220930.xsd#allo_LeaseOneAmendedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_837caa0e-80ff-4fa4-b5ee-c3ed19faf329" xlink:to="loc_allo_LeaseOneAmendedMember_e6cda722-4ad0-4648-8ccd-0f2c9534fc9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseTwoMember_b0c32293-457c-436f-9972-e0e1ea4041b5" xlink:href="allo-20220930.xsd#allo_LeaseTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_837caa0e-80ff-4fa4-b5ee-c3ed19faf329" xlink:to="loc_allo_LeaseTwoMember_b0c32293-457c-436f-9972-e0e1ea4041b5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#EquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/EquityMethodInvestmentsDetails" xlink:type="extended" id="id1c24821e54d4f20afd1e8fef656d302_EquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_138a0625-0b8c-4e53-8643-40d9ed1e7ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_138a0625-0b8c-4e53-8643-40d9ed1e7ecf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts_013ff43e-2f09-4831-9b48-8dfba22a5118" xlink:href="allo-20220930.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_allo_CostMethodInvestmentTransactionCosts_013ff43e-2f09-4831-9b48-8dfba22a5118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_31ed80a7-5363-47b4-a528-1c7c9547071c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_31ed80a7-5363-47b4-a528-1c7c9547071c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_6904ded7-da0e-4d6e-adb5-bf020bab3a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_6904ded7-da0e-4d6e-adb5-bf020bab3a18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4dfaaa4c-4ad5-4189-a35b-1dd3c609121a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4dfaaa4c-4ad5-4189-a35b-1dd3c609121a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_d045ead2-9402-46f7-ba30-208160513df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_d045ead2-9402-46f7-ba30-208160513df8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ccedbdfb-38f8-422c-9582-8990236fecef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ccedbdfb-38f8-422c-9582-8990236fecef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec503ccd-9cb0-41ef-808a-24f8f58d2e8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ccedbdfb-38f8-422c-9582-8990236fecef" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec503ccd-9cb0-41ef-808a-24f8f58d2e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ec503ccd-9cb0-41ef-808a-24f8f58d2e8a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec503ccd-9cb0-41ef-808a-24f8f58d2e8a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ec503ccd-9cb0-41ef-808a-24f8f58d2e8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c64c263c-f429-420b-82f7-15342b5dd53b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec503ccd-9cb0-41ef-808a-24f8f58d2e8a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c64c263c-f429-420b-82f7-15342b5dd53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_e0660392-76ea-4097-a7ad-fc25dc8da5ba" xlink:href="allo-20220930.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c64c263c-f429-420b-82f7-15342b5dd53b" xlink:to="loc_allo_NotchTherapeuticsIncMember_e0660392-76ea-4097-a7ad-fc25dc8da5ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember_9c0564ae-f872-433b-8e46-14bf327eb0f3" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c64c263c-f429-420b-82f7-15342b5dd53b" xlink:to="loc_allo_AllogeneOverlandMember_9c0564ae-f872-433b-8e46-14bf327eb0f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis_7f47ff36-b15f-4bed-897b-a27ee6e78a1e" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ccedbdfb-38f8-422c-9582-8990236fecef" xlink:to="loc_allo_EquityInvestmentBasisAxis_7f47ff36-b15f-4bed-897b-a27ee6e78a1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_7f47ff36-b15f-4bed-897b-a27ee6e78a1e_default" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_EquityInvestmentBasisAxis_7f47ff36-b15f-4bed-897b-a27ee6e78a1e" xlink:to="loc_allo_EquityInvestmentBasisDomain_7f47ff36-b15f-4bed-897b-a27ee6e78a1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_16e65ce7-e91b-4845-8568-c24181a2d4bf" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_EquityInvestmentBasisAxis_7f47ff36-b15f-4bed-897b-a27ee6e78a1e" xlink:to="loc_allo_EquityInvestmentBasisDomain_16e65ce7-e91b-4845-8568-c24181a2d4bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember_d2ab623d-0554-4283-9e39-f22b7a5192ba" xlink:href="allo-20220930.xsd#allo_VotingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_EquityInvestmentBasisDomain_16e65ce7-e91b-4845-8568-c24181a2d4bf" xlink:to="loc_allo_VotingInterestMember_d2ab623d-0554-4283-9e39-f22b7a5192ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="id2a5ea188fd743aa9c97f738cbf74fac_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_1301cf69-9bcc-4d24-a469-a8621557786c" xlink:href="allo-20220930.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_1301cf69-9bcc-4d24-a469-a8621557786c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod_e563e0da-a758-48a7-aefa-d12f4b050480" xlink:href="allo-20220930.xsd#allo_StockOptionGrantedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_StockOptionGrantedPeriod_e563e0da-a758-48a7-aefa-d12f4b050480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_c1306317-6e72-45db-94e4-3957a39b9de4" xlink:href="allo-20220930.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_c1306317-6e72-45db-94e4-3957a39b9de4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_04457a39-dc3d-4372-8cc6-3f7c007be1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_04457a39-dc3d-4372-8cc6-3f7c007be1dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6d491bf2-7b79-41cd-a8b3-ccf54baaef07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6d491bf2-7b79-41cd-a8b3-ccf54baaef07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees_3d0a483a-2d40-4e54-8b64-6fdc841e5ec2" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees_3d0a483a-2d40-4e54-8b64-6fdc841e5ec2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions_3abe6374-4389-46d3-afbd-79c8fb1c5a38" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions_3abe6374-4389-46d3-afbd-79c8fb1c5a38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding_7c617783-6feb-4ee4-8704-66fec725ac99" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding_7c617783-6feb-4ee4-8704-66fec725ac99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ea328f8-c836-4373-9b70-32e8eaeb14e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ea328f8-c836-4373-9b70-32e8eaeb14e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3cce7fce-2543-450d-b312-9ce4fec0aff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3cce7fce-2543-450d-b312-9ce4fec0aff8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a6181d2e-2042-4d24-ac36-7c4d269125d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a6181d2e-2042-4d24-ac36-7c4d269125d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_315c4c4d-1356-4988-8b47-1522a89962f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_315c4c4d-1356-4988-8b47-1522a89962f6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4380b61-b94c-4d32-b8af-84393478e508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4380b61-b94c-4d32-b8af-84393478e508" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d8b8e75e-9541-4091-a05b-4ab32cb61411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d8b8e75e-9541-4091-a05b-4ab32cb61411" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_98030a97-5901-4cda-b9fd-6ec4734133c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_98030a97-5901-4cda-b9fd-6ec4734133c9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c714a43-e9ad-40db-8c71-a085c14578d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c714a43-e9ad-40db-8c71-a085c14578d5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e0063f1-0d74-41c1-85ec-99d1257857d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e0063f1-0d74-41c1-85ec-99d1257857d2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50a4d8d1-db64-450c-84b3-1fc3ac016268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50a4d8d1-db64-450c-84b3-1fc3ac016268" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_a19afc78-5d1a-4544-b4da-8d0865f7f693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_a19afc78-5d1a-4544-b4da-8d0865f7f693" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a06233d-c7cc-4039-91e8-eab6634a8bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a06233d-c7cc-4039-91e8-eab6634a8bb7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_91dbb64b-b2cc-4283-9f8c-ad125036e7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_91dbb64b-b2cc-4283-9f8c-ad125036e7e3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_02ae6f59-cfb9-45bc-a96d-9c4cde92ad51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_02ae6f59-cfb9-45bc-a96d-9c4cde92ad51" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_143f2ba7-6064-4f80-a63d-17bfe42a5360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_143f2ba7-6064-4f80-a63d-17bfe42a5360" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_06d22d8d-d57c-4689-a4da-761691752797" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_143f2ba7-6064-4f80-a63d-17bfe42a5360" xlink:to="loc_srt_RangeAxis_06d22d8d-d57c-4689-a4da-761691752797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_06d22d8d-d57c-4689-a4da-761691752797_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_06d22d8d-d57c-4689-a4da-761691752797" xlink:to="loc_srt_RangeMember_06d22d8d-d57c-4689-a4da-761691752797_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d45d93f-c857-4a50-a7ac-49fa7b4098c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_06d22d8d-d57c-4689-a4da-761691752797" xlink:to="loc_srt_RangeMember_7d45d93f-c857-4a50-a7ac-49fa7b4098c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b6388ed-92ca-41fc-b020-fc03378d9b2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7d45d93f-c857-4a50-a7ac-49fa7b4098c2" xlink:to="loc_srt_MaximumMember_8b6388ed-92ca-41fc-b020-fc03378d9b2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6bfa9344-fbf7-4d1f-a848-6a512a38d0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_143f2ba7-6064-4f80-a63d-17bfe42a5360" xlink:to="loc_us-gaap_AwardTypeAxis_6bfa9344-fbf7-4d1f-a848-6a512a38d0c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6bfa9344-fbf7-4d1f-a848-6a512a38d0c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6bfa9344-fbf7-4d1f-a848-6a512a38d0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6bfa9344-fbf7-4d1f-a848-6a512a38d0c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_597d679d-f560-4580-a4d4-14e0e713f19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6bfa9344-fbf7-4d1f-a848-6a512a38d0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_597d679d-f560-4580-a4d4-14e0e713f19b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9ea2b4fc-8a30-45e4-a931-0e4a64511983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_597d679d-f560-4580-a4d4-14e0e713f19b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9ea2b4fc-8a30-45e4-a931-0e4a64511983" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6c6b0aff-cf38-449c-99c2-d914038f7256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_597d679d-f560-4580-a4d4-14e0e713f19b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6c6b0aff-cf38-449c-99c2-d914038f7256" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="if6e7ddfd776a4f3982a4bbe46a8c9230_StockBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6c5b598c-6021-4b79-bd47-e267280ebbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6c5b598c-6021-4b79-bd47-e267280ebbbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dd11f144-e9ae-4342-8eef-7dd0b22d4b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dd11f144-e9ae-4342-8eef-7dd0b22d4b46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b220c6c8-fbc8-427b-8cdc-c1d31ba075d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b220c6c8-fbc8-427b-8cdc-c1d31ba075d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ec2f6ff4-ee79-40c2-b4d0-3b5e659fe173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ec2f6ff4-ee79-40c2-b4d0-3b5e659fe173" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod_3102ad6b-a588-4698-8b8a-8d097bf6b916" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod_3102ad6b-a588-4698-8b8a-8d097bf6b916" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross_949e2397-f036-4f82-8020-630563bc5209" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross_949e2397-f036-4f82-8020-630563bc5209" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9692a775-e597-4396-914b-5fa62c07df66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_98383da1-aa3c-41a0-a8fc-8102efc82450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_98383da1-aa3c-41a0-a8fc-8102efc82450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_348a1702-337b-4ec0-b6fd-ebfa700bac54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_348a1702-337b-4ec0-b6fd-ebfa700bac54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_05e757e3-95bf-41d3-84b4-3632860ce574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_05e757e3-95bf-41d3-84b4-3632860ce574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c3d8109-cd79-47fc-a7c3-23434d5bc250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c3d8109-cd79-47fc-a7c3-23434d5bc250" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_de9ede23-a30f-4340-b1e3-1f7954094b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_de9ede23-a30f-4340-b1e3-1f7954094b4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c59147c6-7afe-4a60-a447-f97ba392ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c59147c6-7afe-4a60-a447-f97ba392ad44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice_b2295fca-3d00-4764-9fcd-8fa4208afa1f" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice_b2295fca-3d00-4764-9fcd-8fa4208afa1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice_e2f98297-03bf-4cbb-87f5-e39d566f493d" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice_e2f98297-03bf-4cbb-87f5-e39d566f493d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8faaadee-8a98-481b-a61e-e172a0acac11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1fc68703-49c3-43c3-b4f5-21c8ef5f1727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1fc68703-49c3-43c3-b4f5-21c8ef5f1727" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b3ce3433-319c-4f7b-b3ab-24e2e079240c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b3ce3433-319c-4f7b-b3ab-24e2e079240c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e5f7538-5fa8-454c-a213-1c3072cdafd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e5f7538-5fa8-454c-a213-1c3072cdafd6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d04c3fb2-c118-43b5-8294-bda13b1840ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d04c3fb2-c118-43b5-8294-bda13b1840ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3a918104-125a-4082-a0a1-0b035fbcf84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3a918104-125a-4082-a0a1-0b035fbcf84b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61239952-9b76-45e0-8e83-1463b34b9122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61239952-9b76-45e0-8e83-1463b34b9122" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fbc6ffa6-3162-45db-a32e-4129f344a670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fbc6ffa6-3162-45db-a32e-4129f344a670" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c2de9298-9456-4741-91eb-6142f2a92df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c2de9298-9456-4741-91eb-6142f2a92df0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5956c62-d398-439e-af50-afbcb786c3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5956c62-d398-439e-af50-afbcb786c3f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f3108fc9-566d-4f46-95c8-b1d51e7460a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5956c62-d398-439e-af50-afbcb786c3f9" xlink:to="loc_us-gaap_AwardTypeAxis_f3108fc9-566d-4f46-95c8-b1d51e7460a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3108fc9-566d-4f46-95c8-b1d51e7460a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f3108fc9-566d-4f46-95c8-b1d51e7460a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3108fc9-566d-4f46-95c8-b1d51e7460a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bec9d753-8c1c-4c40-ac8e-0b6bd9838be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f3108fc9-566d-4f46-95c8-b1d51e7460a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bec9d753-8c1c-4c40-ac8e-0b6bd9838be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_46ca78ab-c6ba-4822-a8f9-4dadcb3e8020" xlink:href="allo-20220930.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bec9d753-8c1c-4c40-ac8e-0b6bd9838be4" xlink:to="loc_allo_TwoThousandEighteenPlanMember_46ca78ab-c6ba-4822-a8f9-4dadcb3e8020" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="extended" id="ibc1c60123c1e46a1a4a77f42ac5c0cca_StockBasedCompensationValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c21e7c55-4a3e-42ac-a490-d3d4ab7706ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c21e7c55-4a3e-42ac-a490-d3d4ab7706ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1d870d7e-8b37-4317-bb6b-366a8d26ec8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1d870d7e-8b37-4317-bb6b-366a8d26ec8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e088b1f8-b7e0-495c-be99-dd43456bb030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e088b1f8-b7e0-495c-be99-dd43456bb030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2de5f0e9-5f98-429e-9a87-6272819083a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2de5f0e9-5f98-429e-9a87-6272819083a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3458e91c-bf9a-495a-a481-6d28ae6fa9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3458e91c-bf9a-495a-a481-6d28ae6fa9c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e609899c-b381-4bf7-abda-9be0cf48d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e609899c-b381-4bf7-abda-9be0cf48d4bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7a5d8a6-90dc-408b-8154-6d2c9728aa38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7a5d8a6-90dc-408b-8154-6d2c9728aa38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ab4bbf67-b869-4306-9602-2527ea277a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7a5d8a6-90dc-408b-8154-6d2c9728aa38" xlink:to="loc_us-gaap_AwardTypeAxis_ab4bbf67-b869-4306-9602-2527ea277a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab4bbf67-b869-4306-9602-2527ea277a14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ab4bbf67-b869-4306-9602-2527ea277a14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab4bbf67-b869-4306-9602-2527ea277a14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89494449-bf4e-4d47-8344-e78099d9db1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ab4bbf67-b869-4306-9602-2527ea277a14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89494449-bf4e-4d47-8344-e78099d9db1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_d7f80ca0-5436-482d-885f-68787e1df563" xlink:href="allo-20220930.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89494449-bf4e-4d47-8344-e78099d9db1d" xlink:to="loc_allo_TwoThousandEighteenPlanMember_d7f80ca0-5436-482d-885f-68787e1df563" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_127ae8ab-e647-42e1-bdb8-b5ed9c16a775" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7a5d8a6-90dc-408b-8154-6d2c9728aa38" xlink:to="loc_srt_RangeAxis_127ae8ab-e647-42e1-bdb8-b5ed9c16a775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_127ae8ab-e647-42e1-bdb8-b5ed9c16a775_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_127ae8ab-e647-42e1-bdb8-b5ed9c16a775" xlink:to="loc_srt_RangeMember_127ae8ab-e647-42e1-bdb8-b5ed9c16a775_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_998ccd8c-1f2e-4cbb-b61d-b33428c60c44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_127ae8ab-e647-42e1-bdb8-b5ed9c16a775" xlink:to="loc_srt_RangeMember_998ccd8c-1f2e-4cbb-b61d-b33428c60c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e2b3aeb-8996-496d-9a08-de17519ed02b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_998ccd8c-1f2e-4cbb-b61d-b33428c60c44" xlink:to="loc_srt_MinimumMember_5e2b3aeb-8996-496d-9a08-de17519ed02b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1bfb7867-f21a-4d06-9a7c-ce8ea7dd4c92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_998ccd8c-1f2e-4cbb-b61d-b33428c60c44" xlink:to="loc_srt_MaximumMember_1bfb7867-f21a-4d06-9a7c-ce8ea7dd4c92" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i46399633110a42fb975a19281c5ed51b_StockBasedCompensationRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8cd9ece9-b5c8-45f6-9604-08dfafac393f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8cd9ece9-b5c8-45f6-9604-08dfafac393f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6dfbbdd5-4b94-4273-8467-f59e1f8d1f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6dfbbdd5-4b94-4273-8467-f59e1f8d1f7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8903ecad-341d-4181-9cb0-3aa7858f09b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8903ecad-341d-4181-9cb0-3aa7858f09b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2617dd9c-2885-4f65-a3b0-a91940efac7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2617dd9c-2885-4f65-a3b0-a91940efac7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7930e4ca-a99d-4321-a74d-d5c4e6ede421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1b20cf71-b911-4d18-b712-167de36acc17" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1b20cf71-b911-4d18-b712-167de36acc17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3d163052-f716-49fc-b6f5-4a6cb7b4310c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3d163052-f716-49fc-b6f5-4a6cb7b4310c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e1b2358-d270-4145-b93b-c733513d472b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e1b2358-d270-4145-b93b-c733513d472b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_28141368-8490-4667-ab24-283547af1e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_28141368-8490-4667-ab24-283547af1e1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_411ba744-48a6-4b88-ae16-05faf7642d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_411ba744-48a6-4b88-ae16-05faf7642d6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb6c2c5f-66d6-4768-9333-e75d758ef0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_92a3f4a8-7cf9-4a40-b67e-0d9fef824cdb" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_92a3f4a8-7cf9-4a40-b67e-0d9fef824cdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_f0830f43-210f-4438-af37-0b7f0346da47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_f0830f43-210f-4438-af37-0b7f0346da47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_97ee5553-6f82-49d9-bfa4-a55924be321c" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_97ee5553-6f82-49d9-bfa4-a55924be321c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_3eeff8d5-2b3c-4977-81f0-c5125c7d0979" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_3eeff8d5-2b3c-4977-81f0-c5125c7d0979" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6f40bb16-c11d-44e8-a72c-5f9e104acddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6f40bb16-c11d-44e8-a72c-5f9e104acddf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_e6592c83-9e20-459c-9063-6a41c0f5bdd5" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_e6592c83-9e20-459c-9063-6a41c0f5bdd5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b6f646c-ae2a-4c09-bffc-8505c47ed471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b6f646c-ae2a-4c09-bffc-8505c47ed471" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f19a901d-04d7-4ed4-9f65-2ffd36a6bf22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b6f646c-ae2a-4c09-bffc-8505c47ed471" xlink:to="loc_us-gaap_AwardTypeAxis_f19a901d-04d7-4ed4-9f65-2ffd36a6bf22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f19a901d-04d7-4ed4-9f65-2ffd36a6bf22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f19a901d-04d7-4ed4-9f65-2ffd36a6bf22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f19a901d-04d7-4ed4-9f65-2ffd36a6bf22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70e42a17-98e0-4755-bebe-8fb3c137fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f19a901d-04d7-4ed4-9f65-2ffd36a6bf22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70e42a17-98e0-4755-bebe-8fb3c137fed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2cb5c6ab-4c3c-44dc-b71b-3b84520096d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70e42a17-98e0-4755-bebe-8fb3c137fed9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2cb5c6ab-4c3c-44dc-b71b-3b84520096d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended" id="i03ec48a7a5d547e39108ed210ce66c36_StockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fc5cf116-22f7-4fb9-b9f1-1596a6ca4884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c2e7d7f-8d67-40a1-8e61-1cc523fc2b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fc5cf116-22f7-4fb9-b9f1-1596a6ca4884" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c2e7d7f-8d67-40a1-8e61-1cc523fc2b40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89b2f741-65ee-4912-8f37-8159c9151f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fc5cf116-22f7-4fb9-b9f1-1596a6ca4884" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89b2f741-65ee-4912-8f37-8159c9151f12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_310a91db-403f-440e-9355-bea245ee51ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89b2f741-65ee-4912-8f37-8159c9151f12" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_310a91db-403f-440e-9355-bea245ee51ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_310a91db-403f-440e-9355-bea245ee51ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_310a91db-403f-440e-9355-bea245ee51ef" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_310a91db-403f-440e-9355-bea245ee51ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f7eb7263-9183-4117-bfbd-89ba27ea1f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_310a91db-403f-440e-9355-bea245ee51ef" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f7eb7263-9183-4117-bfbd-89ba27ea1f08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1bf182f1-2788-4bf4-b422-f3e8e943656a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f7eb7263-9183-4117-bfbd-89ba27ea1f08" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1bf182f1-2788-4bf4-b422-f3e8e943656a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_66779950-b880-4ae8-8c28-e9c7cde3f11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f7eb7263-9183-4117-bfbd-89ba27ea1f08" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_66779950-b880-4ae8-8c28-e9c7cde3f11f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i90852d69490f4918aef7732ade752fbb_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44ea5524-0b93-436a-93a2-1a23bee7197a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44ea5524-0b93-436a-93a2-1a23bee7197a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_ab4ef959-1eae-4291-8cb5-9e4111e9fe7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_ab4ef959-1eae-4291-8cb5-9e4111e9fe7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOffice_534649db-74d1-4936-90a1-d34bb3818d69" xlink:href="allo-20220930.xsd#allo_AreaOfOffice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_allo_AreaOfOffice_534649db-74d1-4936-90a1-d34bb3818d69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_2493c7a3-c536-46f2-a2fd-ba0cd97f5f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_2493c7a3-c536-46f2-a2fd-ba0cd97f5f4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5efa47f-c55b-4f64-b54d-04ad59600f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5efa47f-c55b-4f64-b54d-04ad59600f25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bcf344fa-72cf-404a-b7fa-548af33cfad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_OperatingLeaseLiability_bcf344fa-72cf-404a-b7fa-548af33cfad9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts_92bb85b8-97f0-42c8-8e9b-ca61320f0c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_RelatedPartyCosts_92bb85b8-97f0-42c8-8e9b-ca61320f0c88" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_72533848-fd30-487f-b549-bb7238012d66" xlink:href="allo-20220930.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_72533848-fd30-487f-b549-bb7238012d66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_658cfc0a-fafc-47d7-bbc7-87f3095a74ce" xlink:href="allo-20220930.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_658cfc0a-fafc-47d7-bbc7-87f3095a74ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2397717f-ddbd-430e-9277-e12f5da05979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2397717f-ddbd-430e-9277-e12f5da05979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2397717f-ddbd-430e-9277-e12f5da05979_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2397717f-ddbd-430e-9277-e12f5da05979" xlink:to="loc_us-gaap_RelatedPartyDomain_2397717f-ddbd-430e-9277-e12f5da05979_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_de5a43f8-b7e1-4e82-b4ce-8505767a5d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2397717f-ddbd-430e-9277-e12f5da05979" xlink:to="loc_us-gaap_RelatedPartyDomain_de5a43f8-b7e1-4e82-b4ce-8505767a5d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember_02176d1d-fa8d-45f0-884d-7d30878f4b15" xlink:href="allo-20220930.xsd#allo_BellcoCapitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_de5a43f8-b7e1-4e82-b4ce-8505767a5d6e" xlink:to="loc_allo_BellcoCapitalLLCMember_02176d1d-fa8d-45f0-884d-7d30878f4b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLLCMember_2710b127-be35-4105-8a17-ad9a0a82e36f" xlink:href="allo-20220930.xsd#allo_TwoRiverConsultingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_de5a43f8-b7e1-4e82-b4ce-8505767a5d6e" xlink:to="loc_allo_TwoRiverConsultingLLCMember_2710b127-be35-4105-8a17-ad9a0a82e36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_6bdd1c19-ec43-416b-81f0-a7b7899709fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_6bdd1c19-ec43-416b-81f0-a7b7899709fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6bdd1c19-ec43-416b-81f0-a7b7899709fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6bdd1c19-ec43-416b-81f0-a7b7899709fd" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6bdd1c19-ec43-416b-81f0-a7b7899709fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e1dd35e0-9fc4-43bf-acbe-76985dd63948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6bdd1c19-ec43-416b-81f0-a7b7899709fd" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e1dd35e0-9fc4-43bf-acbe-76985dd63948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubleaseAgreementMember_caa89e9c-cff4-4a5e-a201-5da9c53b7a2f" xlink:href="allo-20220930.xsd#allo_SubleaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e1dd35e0-9fc4-43bf-acbe-76985dd63948" xlink:to="loc_allo_SubleaseAgreementMember_caa89e9c-cff4-4a5e-a201-5da9c53b7a2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember_d189d076-5471-45c8-a875-2c32096c9371" xlink:href="allo-20220930.xsd#allo_ConsultingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e1dd35e0-9fc4-43bf-acbe-76985dd63948" xlink:to="loc_allo_ConsultingAgreementsMember_d189d076-5471-45c8-a875-2c32096c9371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89f52269-dae7-4227-951d-bf57b8bc0b5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_srt_RangeAxis_89f52269-dae7-4227-951d-bf57b8bc0b5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_89f52269-dae7-4227-951d-bf57b8bc0b5b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_89f52269-dae7-4227-951d-bf57b8bc0b5b" xlink:to="loc_srt_RangeMember_89f52269-dae7-4227-951d-bf57b8bc0b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0e186e4-8df4-4dc7-9e4f-f027f82f6320" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_89f52269-dae7-4227-951d-bf57b8bc0b5b" xlink:to="loc_srt_RangeMember_c0e186e4-8df4-4dc7-9e4f-f027f82f6320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76e5a354-ebbf-4438-8bac-4f9ff40205c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c0e186e4-8df4-4dc7-9e4f-f027f82f6320" xlink:to="loc_srt_MaximumMember_76e5a354-ebbf-4438-8bac-4f9ff40205c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsAxis_20abda87-c7b8-428c-8518-77a0ed55a1f5" xlink:href="allo-20220930.xsd#allo_PaymentTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_allo_PaymentTermsAxis_20abda87-c7b8-428c-8518-77a0ed55a1f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain_20abda87-c7b8-428c-8518-77a0ed55a1f5_default" xlink:href="allo-20220930.xsd#allo_PaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_PaymentTermsAxis_20abda87-c7b8-428c-8518-77a0ed55a1f5" xlink:to="loc_allo_PaymentTermsDomain_20abda87-c7b8-428c-8518-77a0ed55a1f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain_74d017c4-46fb-41e6-a199-814c31498595" xlink:href="allo-20220930.xsd#allo_PaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_PaymentTermsAxis_20abda87-c7b8-428c-8518-77a0ed55a1f5" xlink:to="loc_allo_PaymentTermsDomain_74d017c4-46fb-41e6-a199-814c31498595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2021Member_5a89ef08-80f0-46ee-b6ba-347a1e1584fd" xlink:href="allo-20220930.xsd#allo_PaymentsCommencingJanuary2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_PaymentTermsDomain_74d017c4-46fb-41e6-a199-814c31498595" xlink:to="loc_allo_PaymentsCommencingJanuary2021Member_5a89ef08-80f0-46ee-b6ba-347a1e1584fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2022Member_2d3b26f7-c7a8-4d31-a990-6694df363045" xlink:href="allo-20220930.xsd#allo_PaymentsCommencingJanuary2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_PaymentTermsDomain_74d017c4-46fb-41e6-a199-814c31498595" xlink:to="loc_allo_PaymentsCommencingJanuary2022Member_2d3b26f7-c7a8-4d31-a990-6694df363045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a1683078-f95e-4afe-a183-944032fb93a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_srt_CounterpartyNameAxis_a1683078-f95e-4afe-a183-944032fb93a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a1683078-f95e-4afe-a183-944032fb93a3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a1683078-f95e-4afe-a183-944032fb93a3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a1683078-f95e-4afe-a183-944032fb93a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b82ea3f-1434-469f-a6da-7f6569ba84d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a1683078-f95e-4afe-a183-944032fb93a3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b82ea3f-1434-469f-a6da-7f6569ba84d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_0f3af2cc-d7a9-4319-9732-cd8e2c7e120f" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b82ea3f-1434-469f-a6da-7f6569ba84d8" xlink:to="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_0f3af2cc-d7a9-4319-9732-cd8e2c7e120f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#NetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended" id="iadb20116b26e4c8ba1881c3be0b42196_NetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c6e5aa73-a1f0-4e64-b319-6e024606337f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_421f0243-439f-43d3-9149-34bda1edf402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c6e5aa73-a1f0-4e64-b319-6e024606337f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_421f0243-439f-43d3-9149-34bda1edf402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7fca5a7a-0345-4905-b527-ecbefd487c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c6e5aa73-a1f0-4e64-b319-6e024606337f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7fca5a7a-0345-4905-b527-ecbefd487c8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65edc510-ec97-4ecd-b888-8c4045f593e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7fca5a7a-0345-4905-b527-ecbefd487c8e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65edc510-ec97-4ecd-b888-8c4045f593e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65edc510-ec97-4ecd-b888-8c4045f593e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65edc510-ec97-4ecd-b888-8c4045f593e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65edc510-ec97-4ecd-b888-8c4045f593e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65edc510-ec97-4ecd-b888-8c4045f593e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4cd108cd-5cdd-4a57-85f3-55461c376f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4cd108cd-5cdd-4a57-85f3-55461c376f32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3b787ca6-a183-4792-a502-915fdb9edbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3b787ca6-a183-4792-a502-915fdb9edbbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a4d65fff-cf3d-43dd-abfe-db9e8724e477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_us-gaap_EmployeeStockMember_a4d65fff-cf3d-43dd-abfe-db9e8724e477" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember_c8d95efc-973f-43d0-97d0-69e27bb92bd0" xlink:href="allo-20220930.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_allo_FounderSharesOfCommonStockMember_c8d95efc-973f-43d0-97d0-69e27bb92bd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_e01a949e-4403-4572-ad52-d5132ae0b3df" xlink:href="allo-20220930.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_e01a949e-4403-4572-ad52-d5132ae0b3df" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended" id="ie983beed933a43df98c8e3bbff330e7d_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_678279b0-d178-4e96-b454-8fc082535344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment_5a44d99c-09c4-4a1e-91b7-d4b6dcb7dcba" xlink:href="allo-20220930.xsd#allo_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_678279b0-d178-4e96-b454-8fc082535344" xlink:to="loc_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment_5a44d99c-09c4-4a1e-91b7-d4b6dcb7dcba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_32c4cbbe-c464-4fc2-ba17-c5bf83ff7572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_678279b0-d178-4e96-b454-8fc082535344" xlink:to="loc_us-gaap_SubsequentEventTable_32c4cbbe-c464-4fc2-ba17-c5bf83ff7572" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_826dadb9-8b1f-4376-a0c3-cc5d9d7428e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_32c4cbbe-c464-4fc2-ba17-c5bf83ff7572" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_826dadb9-8b1f-4376-a0c3-cc5d9d7428e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_826dadb9-8b1f-4376-a0c3-cc5d9d7428e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_826dadb9-8b1f-4376-a0c3-cc5d9d7428e9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_826dadb9-8b1f-4376-a0c3-cc5d9d7428e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4cb3dd00-f927-4f63-ae78-00451246d70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_826dadb9-8b1f-4376-a0c3-cc5d9d7428e9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4cb3dd00-f927-4f63-ae78-00451246d70f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_13305039-7012-467c-8925-aa2c663c1f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4cb3dd00-f927-4f63-ae78-00451246d70f" xlink:to="loc_us-gaap_SubsequentEventMember_13305039-7012-467c-8925-aa2c663c1f65" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_a14dceef-5699-443a-8f66-7bf9d2a8783c" xlink:href="allo-20220930.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_a14dceef-5699-443a-8f66-7bf9d2a8783c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>allo-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3bc7a964-10eb-47e7-910c-f5ea785aeb6d,g:304a2d5e-50f8-4210-a420-41588b836a7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_allo_ReductionToResearchAndDevelopmentExpense_0489e8b7-63e8-4256-9029-2b250fe4121a_terseLabel_en-US" xlink:label="lab_allo_ReductionToResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to research and development expense</link:label>
    <link:label id="lab_allo_ReductionToResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_allo_ReductionToResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to Research and Development Expense</link:label>
    <link:label id="lab_allo_ReductionToResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_allo_ReductionToResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ReductionToResearchAndDevelopmentExpense" xlink:href="allo-20220930.xsd#allo_ReductionToResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ReductionToResearchAndDevelopmentExpense" xlink:to="lab_allo_ReductionToResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cb18a991-d8d5-45e7-940c-4f8cc2f8689c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bd7d899c-3370-4475-b524-320d9fc28f35_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_db46aac7-dc6d-49fd-9a23-80a78a34c792_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_431a7c4a-ffea-4d2f-b0da-8c4319fea32f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_de62a3e7-86c1-4bcd-a30e-318fa939170e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f79ca3bd-9df7-454e-80c2-4f4d6e2660ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_731ddb8b-2a79-43e6-bab1-c2d375bd590a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestoneTypeAxis_b0bdb952-e92b-459c-8d11-7b134647f573_terseLabel_en-US" xlink:label="lab_allo_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_allo_MilestoneTypeAxis_label_en-US" xlink:label="lab_allo_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_allo_MilestoneTypeAxis_documentation_en-US" xlink:label="lab_allo_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeAxis" xlink:href="allo-20220930.xsd#allo_MilestoneTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestoneTypeAxis" xlink:to="lab_allo_MilestoneTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a170aac3-20f7-43b4-be3e-23006c25c054_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PfizerIncMember_7dba7d80-dc7e-4c9d-98da-9a03898984cb_terseLabel_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_allo_PfizerIncMember_label_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc [Member]</link:label>
    <link:label id="lab_allo_PfizerIncMember_documentation_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember" xlink:href="allo-20220930.xsd#allo_PfizerIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PfizerIncMember" xlink:to="lab_allo_PfizerIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c26a8ea0-0c47-4998-af6d-c5608aa13953_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_9e75e84c-c8cb-44c0-9f0f-c098aeda4a81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f70cf11-9618-41df-ab71-99025383ad56_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_043844e8-0ca9-491e-97b6-559b9d7df40c_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_4c11692e-ef1b-4279-a1fb-b7182f3fb5c5_terseLabel_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised stock options subject to future vesting</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_label_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercise Of Stock Options [Member]</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_documentation_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember" xlink:href="allo-20220930.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EarlyExerciseOfStockOptionsMember" xlink:to="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3cb7df90-7419-42db-b45f-c359d8f0fba9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_10030e1c-17aa-484b-92bf-f98030bfd004_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_48829e33-0895-471e-bf59-f136fb46e012_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_622459d4-7127-4bdd-a7b8-c1a57df4dca7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a802a6ab-8ea9-47ee-8c65-9e7d15e29e46_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78a27f82-c14f-4d7e-9621-b9355f8734a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_292a673b-3d24-432e-937d-fab56f9b6b90_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LeaseTwoMember_444d68b0-c251-4676-be0d-3a862a8e8daa_terseLabel_en-US" xlink:label="lab_allo_LeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Two</link:label>
    <link:label id="lab_allo_LeaseTwoMember_label_en-US" xlink:label="lab_allo_LeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Two [Member]</link:label>
    <link:label id="lab_allo_LeaseTwoMember_documentation_en-US" xlink:label="lab_allo_LeaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseTwoMember" xlink:href="allo-20220930.xsd#allo_LeaseTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LeaseTwoMember" xlink:to="lab_allo_LeaseTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0444f94f-8a3b-4324-b943-1f2bbccb474c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_86d85ea9-4d44-4bd1-9921-e646fd36e142_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected exercise barrier (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_dd4bc683-7c21-45e4-8c46-6935fb24358a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a0405745-39e7-47ac-afa6-9dafc7e457f4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b9b7005f-6324-4c32-9913-6b607004e53d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92eb97c9-26b7-4be5-8479-b6e4bcf16a80_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_99786f64-0c08-455b-a136-093d9f066937_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_5e0a76d1-29fb-43b3-a0ab-71f25c24bf5e_terseLabel_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:href="allo-20220930.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:to="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f9008ae3-d1bd-4baf-ae95-b6642910f540_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9dfcc4ee-fe01-4f78-b080-cb68028ae994_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_f34bbba5-d235-4db3-92ac-1f111bafaa32_terseLabel_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and purchased software</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_label_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Purchased Software [Member]</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_documentation_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and purchased software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:href="allo-20220930.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:to="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_dec5c1ac-716d-43b8-8e68-7660e9a79226_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees_f8aa783a-26a1-4d2d-9bbd-50b662e7b25a_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange offer, number of employees</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Employees</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_81112d12-5619-45c4-bc51-9e92ed053c8d_terseLabel_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, upfront payment</link:label>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_label_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment" xlink:href="allo-20220930.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationAgreementUpfrontPayment" xlink:to="lab_allo_CollaborationAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_a4ea8018-437c-4d86-b2f6-6d91229d1bfd_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockOptionGrantedPeriod_e5b43605-ab92-43a4-a536-6202f8867e99_terseLabel_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option grant period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_label_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Granted Period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_documentation_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option granted period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod" xlink:href="allo-20220930.xsd#allo_StockOptionGrantedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockOptionGrantedPeriod" xlink:to="lab_allo_StockOptionGrantedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_83c5f867-5dd5-44b8-b286-2e16ff453988_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_bae0d2fb-ab9e-4eaf-8167-db767911f676_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan modification, incremental cost</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e971db1a-c614-4efc-91a8-2107caf8d4aa_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_d1159581-84f1-4649-ac7e-c4771c526713_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_23b68064-21c4-4da3-a545-6ac0a842f8c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aa3bc68e-d53e-4995-b868-c91b0f9fe543_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_88300767-44bc-4dd1-9aec-e5eaeb70c3c4_terseLabel_en-US" xlink:label="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label id="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="allo-20220930.xsd#allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_5a5c47a0-84fc-47e0-acbf-c99d3d17f087_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_402c8290-9265-4bf7-97b5-a4e6eefc0d42_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining 6 months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_98cc3207-2bb0-4dae-8497-9ba36bd4ad27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c39dfd7b-3e9b-432f-b302-6ad6e2a764f5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ec748d5b-6020-441d-91c0-b3d949d43430_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_bc9214e1-1b80-4eda-959d-6ca9b286c0b9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected shares to be purchased under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_37701523-eb51-4618-8c92-215dbcac86c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20bd071b-146b-467d-82e2-c7624a616ed8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_BellcoCapitalLLCMember_180e6b1f-a0b2-4028-a17b-caa3f1a7e001_terseLabel_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_label_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital L L C [Member]</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_documentation_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember" xlink:href="allo-20220930.xsd#allo_BellcoCapitalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_BellcoCapitalLLCMember" xlink:to="lab_allo_BellcoCapitalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cad0567a-ed33-4ab1-99f8-ff6d7ce7edde_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_db9ddad9-47be-4df2-8b2b-3c2eb14df3e3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b1edaf9a-8c4e-4bd5-b605-e7ee50a77410_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ac8544ad-0883-4604-9130-5d42ee07e1b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_62e68d29-23b1-472d-b8f6-67c7ed391ed3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_7c63d14b-e7c5-41cd-b336-ddea6a00698a_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting life, vested and expected to vest (in years)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_8f3c1ee4-8e79-48d7-9c1b-7a6e384e59c2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentTermsDomain_d7474e19-4caa-46e8-ac26-320c0512bcad_terseLabel_en-US" xlink:label="lab_allo_PaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Domain]</link:label>
    <link:label id="lab_allo_PaymentTermsDomain_label_en-US" xlink:label="lab_allo_PaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Domain]</link:label>
    <link:label id="lab_allo_PaymentTermsDomain_documentation_en-US" xlink:label="lab_allo_PaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain" xlink:href="allo-20220930.xsd#allo_PaymentTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentTermsDomain" xlink:to="lab_allo_PaymentTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c4a62085-e78f-4a85-aec4-fe3116bfc896_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8092786c-feae-430b-9cac-29e0898d4ed6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3f176b14-0375-48c5-aefa-ae39092e9d33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_db65cfbc-0342-45d8-8d3a-a5647b50978f_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_458e7a42-dead-4427-bbf8-5ac40ac1c264_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Payable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable" xlink:href="allo-20220930.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestonePayable" xlink:to="lab_allo_AggregatePotentialMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_947ce69d-59cc-4296-8d73-f548b713ba15_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for amounts related to tenant improvement allowances</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyCosts_16ad1705-f6fb-40f1-a4c9-b70bd4381e98_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party costs</link:label>
    <link:label id="lab_us-gaap_RelatedPartyCosts_label_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyCosts" xlink:to="lab_us-gaap_RelatedPartyCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9df13bba-3d98-4edc-ad6c-2bdf1a62ee2f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e2f47b02-7241-4ad3-abdb-2601a8f83b75_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationArrangementExpense_33c2d57f-c645-4e19-a774-7ea7f5e1f8d5_terseLabel_en-US" xlink:label="lab_allo_CollaborationArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration arrangement, expense</link:label>
    <link:label id="lab_allo_CollaborationArrangementExpense_label_en-US" xlink:label="lab_allo_CollaborationArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Expense</link:label>
    <link:label id="lab_allo_CollaborationArrangementExpense_documentation_en-US" xlink:label="lab_allo_CollaborationArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationArrangementExpense" xlink:href="allo-20220930.xsd#allo_CollaborationArrangementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationArrangementExpense" xlink:to="lab_allo_CollaborationArrangementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c7ccd31-1a88-4124-8525-3e075882f6f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f9f350a6-997b-4f6f-b85c-ea197db56ab8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1d70ec8-b97b-4413-853e-6b8ee6487612_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_fb967110-36cd-4a0d-812b-69d558be606e_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization/accretion on investment securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_596e5c4f-7794-428d-a186-77e5a0ec6998_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_801aa88a-71b5-4fb1-8327-e06d83769dfd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0919d742-6a2c-470a-a97e-7aecfc0c0d25_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_561ba981-9e2d-4cb8-ae6e-70107a51482b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2fc03c57-ff75-4792-9061-4391a26948ae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_58271719-ce18-4a3d-834c-a5c9f75b0302_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_37eb15d9-5c84-4634-94f2-464355160589_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5fd3393b-dea1-4e1b-a6e6-2762216ef9d9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6a3af740-7e00-4cae-80b7-e363b982c433_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce13b576-36ee-4b93-9bc4-9734fbdef7f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a8b3ae95-9be2-4519-9ae2-e47c618bfe47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LesseeFinanceLeasePaymentUponContractTermination_02d3b937-f71e-4117-96ac-057e815a603c_terseLabel_en-US" xlink:label="lab_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination payment</link:label>
    <link:label id="lab_allo_LesseeFinanceLeasePaymentUponContractTermination_label_en-US" xlink:label="lab_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Payment Upon Contract Termination</link:label>
    <link:label id="lab_allo_LesseeFinanceLeasePaymentUponContractTermination_documentation_en-US" xlink:label="lab_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Payment Upon Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:href="allo-20220930.xsd#allo_LesseeFinanceLeasePaymentUponContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:to="lab_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ba8f5278-623f-49a2-92f8-d936aed7c440_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5c827766-d79b-4801-8333-2f52c15c5d6f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_b2620cdd-1464-4734-b21b-fecfc507197a_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Payments</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments" xlink:href="allo-20220930.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestonePayments" xlink:to="lab_allo_AggregatePotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9c52fed4-0577-4aea-88be-8036b11992b1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1f3fb674-6c56-41f6-8fbd-f50a532898dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_4005b433-2906-4747-a0a4-3276ad51820b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestoneTypeDomain_efee6b18-ddb8-4370-8a6a-caec56c493b3_terseLabel_en-US" xlink:label="lab_allo_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_allo_MilestoneTypeDomain_label_en-US" xlink:label="lab_allo_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_allo_MilestoneTypeDomain_documentation_en-US" xlink:label="lab_allo_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain" xlink:href="allo-20220930.xsd#allo_MilestoneTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestoneTypeDomain" xlink:to="lab_allo_MilestoneTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_3b015100-fb89-4f90-afa7-1ad11172ba2b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6681a04f-3d9c-419e-a702-55e8ccec97ed_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_101619d6-2839-491d-9052-70d334410236_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_82206a0c-2d2b-46d3-a39d-ea0f6575b7bc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_17c28c9c-a38b-48f6-b33f-24f8bbb6f741_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e6f70abc-a45d-4e90-9ba8-fc71f63b3f14_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_95e16a6d-d403-4377-bb8d-5616ecc5b269_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_00634245-f716-44b2-86f0-a811a1aea953_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction compensation percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Compensation Percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction compensation percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage" xlink:href="allo-20220930.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionCompensationPercentage" xlink:to="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_07194cb8-0a42-4429-9903-351deaa64c47_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_94434922-e981-480e-8cb2-05be8f204e46_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5ed76fd9-021c-46bf-b851-f0a2cb5e9ee8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec750d1a-8a03-4c73-b5b3-0ed7da593437_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_448630b6-29ff-4747-a734-fc561091c209_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_b6a99dd0-d044-4346-b251-e020e0e646b3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f97f714f-cf41-4035-b497-05ffc1c17101_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_21001c31-a721-4704-b486-4882215a42c6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f0acd098-c57d-414b-9f5c-aacec8737470_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b97109e0-7c37-4032-b7f2-588368eecf91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Stock Option Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_4ba6e6ef-f244-43f4-9fd4-0ee376edb562_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_e0a869b6-53ed-4864-82dd-4eaa9e657d2e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c036f301-73ed-4a9e-ac0a-57626ba7fac7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_444bce13-8775-48b9-bb02-9eb9549d7e78_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercised common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24bce0b1-0fab-4119-a4d2-abcbe5051dea_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation expense, weighted average recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ad57bd76-57c8-4c16-8e7e-672b3e291064_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentsCommencingJanuary2022Member_c9ff8340-5c23-4218-b926-e05dc56ebb0f_terseLabel_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2022</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2022Member_label_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2022 [Member]</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2022Member_documentation_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2022Member" xlink:href="allo-20220930.xsd#allo_PaymentsCommencingJanuary2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentsCommencingJanuary2022Member" xlink:to="lab_allo_PaymentsCommencingJanuary2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_8b516360-8e00-40e6-864b-edd3a13fbc26_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under the employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e23476dd-02f9-46ff-b3d8-e8d75ab8453c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3061a83d-581e-406f-8f79-01a78a9772be_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LiabilitiesLesseeTableTextBlock_c90c324a-4279-45a0-a43b-8b8b740cade6_terseLabel_en-US" xlink:label="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Liabilities</link:label>
    <link:label id="lab_allo_LiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_allo_LiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LiabilitiesLesseeTableTextBlock" xlink:href="allo-20220930.xsd#allo_LiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LiabilitiesLesseeTableTextBlock" xlink:to="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_65137c27-5ced-455a-aa13-48b575690bfe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_271b28bd-b6c7-43e2-a863-2cd9a37b9e86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EquityInvestmentBasisAxis_ac8b22c1-476c-44a0-a1df-baaa94ce1785_terseLabel_en-US" xlink:label="lab_allo_EquityInvestmentBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Axis]</link:label>
    <link:label id="lab_allo_EquityInvestmentBasisAxis_label_en-US" xlink:label="lab_allo_EquityInvestmentBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Axis]</link:label>
    <link:label id="lab_allo_EquityInvestmentBasisAxis_documentation_en-US" xlink:label="lab_allo_EquityInvestmentBasisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EquityInvestmentBasisAxis" xlink:to="lab_allo_EquityInvestmentBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TenantImprovementAllowanceUtilizedToDate_33b69010-2780-41dc-a9d6-11eb061ab662_terseLabel_en-US" xlink:label="lab_allo_TenantImprovementAllowanceUtilizedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance utilized to date</link:label>
    <link:label id="lab_allo_TenantImprovementAllowanceUtilizedToDate_label_en-US" xlink:label="lab_allo_TenantImprovementAllowanceUtilizedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance, Utilized To Date</link:label>
    <link:label id="lab_allo_TenantImprovementAllowanceUtilizedToDate_documentation_en-US" xlink:label="lab_allo_TenantImprovementAllowanceUtilizedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance, Utilized To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowanceUtilizedToDate" xlink:href="allo-20220930.xsd#allo_TenantImprovementAllowanceUtilizedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TenantImprovementAllowanceUtilizedToDate" xlink:to="lab_allo_TenantImprovementAllowanceUtilizedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_27e4066c-ae16-4b61-8cf1-3d9bd7eee86b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_05634127-3224-4274-89be-b48159ed8b0c_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_f5daacfa-eb68-4c8e-8b10-bc924be3fcb8_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_622c27ec-179a-4e97-8a62-8e9952caac6a_terseLabel_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc.</link:label>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_label_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_documentation_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember" xlink:href="allo-20220930.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NotchTherapeuticsIncMember" xlink:to="lab_allo_NotchTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment_b595a701-fb15-40ea-b736-19da8c57d8da_terseLabel_en-US" xlink:label="lab_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, milestone payment</link:label>
    <link:label id="lab_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment_label_en-US" xlink:label="lab_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:label id="lab_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment_documentation_en-US" xlink:label="lab_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:href="allo-20220930.xsd#allo_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:to="lab_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e254fb18-bc41-4850-aebf-98648fb6ac60_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LeaseOneAmendedMember_cabce6e6-e552-4510-a964-f5504c37b028_terseLabel_en-US" xlink:label="lab_allo_LeaseOneAmendedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease One, Amended</link:label>
    <link:label id="lab_allo_LeaseOneAmendedMember_label_en-US" xlink:label="lab_allo_LeaseOneAmendedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease One, Amended [Member]</link:label>
    <link:label id="lab_allo_LeaseOneAmendedMember_documentation_en-US" xlink:label="lab_allo_LeaseOneAmendedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease One, Amended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseOneAmendedMember" xlink:href="allo-20220930.xsd#allo_LeaseOneAmendedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LeaseOneAmendedMember" xlink:to="lab_allo_LeaseOneAmendedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d892fcca-ac34-4edc-a672-d3a98314c7ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4ad31cf1-4c7f-4a18-a6b2-c01fb5aabb4f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_4d7b6401-1396-420d-b011-9bc0c43c8b85_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_dd5a8a09-b03d-4744-921b-4461d401a25a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1cd98ced-03f9-45ac-bae4-3488c01481a9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c8422968-996e-4e82-85f3-ae1831ed9441_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8e9138b4-b70c-459f-a688-8c186d424aff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_40d23aec-9c2d-4af1-b609-6f23e6cbf336_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3c034907-55c5-4ceb-a50b-c26ec999f9b1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentsCommencingJanuary2021Member_a99f1f1d-5203-4856-9b48-458989ca87e7_terseLabel_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2021</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2021Member_label_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2021 [Member]</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2021Member_documentation_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2021Member" xlink:href="allo-20220930.xsd#allo_PaymentsCommencingJanuary2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentsCommencingJanuary2021Member" xlink:to="lab_allo_PaymentsCommencingJanuary2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_d71e688e-b82b-4bfc-ab25-864294cdfe94_terseLabel_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office and laboratory (in square feet)</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_label_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of New Office Building</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_documentation_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of new office building.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding" xlink:href="allo-20220930.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfNewOfficeBuilding" xlink:to="lab_allo_AreaOfNewOfficeBuilding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_beed2cee-7633-43f5-964d-a3df1ed8f34a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-Based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b3d6a402-41f9-409b-99b6-6aa9664694e0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AllogeneOverlandMember_39f263fb-9ead-4a5c-9f6f-e7e3f4842cf7_terseLabel_en-US" xlink:label="lab_allo_AllogeneOverlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene Overland</link:label>
    <link:label id="lab_allo_AllogeneOverlandMember_label_en-US" xlink:label="lab_allo_AllogeneOverlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene Overland [Member]</link:label>
    <link:label id="lab_allo_AllogeneOverlandMember_documentation_en-US" xlink:label="lab_allo_AllogeneOverlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene Overland</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AllogeneOverlandMember" xlink:to="lab_allo_AllogeneOverlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_729442d3-8c12-47b7-b156-a9d3682378c3_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_479193a0-6bad-4780-b9c1-1e3e13468e11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_676dbb68-e59d-442e-a11a-8b605a6b9652_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_350ec3b5-df89-44e8-928e-885a00f43107_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units subject to vesting</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_eb55f4da-f278-4e8d-bf91-20de9be90843_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c664f87d-3034-470e-a241-1544f0d69d4b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_a347dd3a-9eff-44fd-8ed8-10507a1a0d4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AntionCollaborationAgreementMember_c4e6e0ef-ec3a-445e-8c8f-2e1d90fb3a1e_terseLabel_en-US" xlink:label="lab_allo_AntionCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antion Collaboration Agreement</link:label>
    <link:label id="lab_allo_AntionCollaborationAgreementMember_label_en-US" xlink:label="lab_allo_AntionCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antion Collaboration Agreement [Member]</link:label>
    <link:label id="lab_allo_AntionCollaborationAgreementMember_documentation_en-US" xlink:label="lab_allo_AntionCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antion Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntionCollaborationAgreementMember" xlink:href="allo-20220930.xsd#allo_AntionCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AntionCollaborationAgreementMember" xlink:to="lab_allo_AntionCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_45eba58c-aefa-45ac-b4b5-e16da8bab757_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d821902e-bf4b-469a-b181-8446a1002d61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e0d13f37-241d-4324-8d58-da61c06ddf64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_22e5a0de-0b5b-4429-9935-2c79c040a4ba_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_af2c6921-4e49-4b9a-8b5b-ea91f3c023ad_terseLabel_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development cost payable by collaboration partner</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_label_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By Collaboration Partner</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_documentation_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:href="allo-20220930.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:to="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_bd423851-8c6a-4cb3-9b9a-b2ea3701d39c_terseLabel_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Liabilities Current</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent" xlink:href="allo-20220930.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent" xlink:to="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_275cbff6-a5f2-4647-83e6-b9e6584b8abb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6ed8d1e3-9403-46e3-a947-c9b1957ddcc2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f5dced8b-5ef7-454b-9933-db2b865fa580_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7b44ca43-dfe3-4c41-a757-dcbf42247e9d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_194710bc-4c23-482a-a3c4-0c67e0916dc4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f062824d-a8fa-4a4d-b739-44fcdfc25b37_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5c78ff2c-cbb6-4e4b-8066-94514c3142bd_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_4cc8bf2c-15e0-4f21-8f42-3866ec742f2d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d140f415-ccec-407f-ace6-d1c9062a71db_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5f7aee5-5790-4199-acd7-6677d69cc232_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_88413b9d-6fe0-4350-bfc0-f3dbd240db74_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AssetContributionAgreementMember_e7783a45-7e0d-4c9a-9a6a-2196bd8174b2_verboseLabel_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Contribution Agreement</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_label_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Contribution Agreement [Member]</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_documentation_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset contribution agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember" xlink:href="allo-20220930.xsd#allo_AssetContributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AssetContributionAgreementMember" xlink:to="lab_allo_AssetContributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_28d1c68a-b509-4b9a-afb2-f6a0df88c996_terseLabel_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_label_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Text Block]</link:label>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAgreementsTextBlock" xlink:href="allo-20220930.xsd#allo_LicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAgreementsTextBlock" xlink:to="lab_allo_LicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_72dbb5f3-b073-4913-9a5a-44191ca95066_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable from available-fore-sale investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_87cb17e5-8bae-4186-95ee-8d1aa9149374_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b701e1b4-959e-4aea-bf92-468fe664d190_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_5237374f-dcd8-4bc3-ae26-a9490184e1f5_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_47f0ac6b-c330-41f5-b259-fb158cc46d4f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0b7add9c-d1b0-4f45-9fc4-de14b13fbe82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_887df2b1-964e-4d62-9d42-cba6ec5881ae_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_26b3173d-9173-4be2-8e71-81544171cd6e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_5ad16be1-3fc3-4db4-98df-0fc3ce4c0c63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity Under Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_59c27e38-52bb-45a0-b279-e5ba0c4ac8bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_2ea6e520-35a5-4dc7-b921-39cb9836b238_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_10ba83fa-c987-4489-a57d-40c29d03ba6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_ed83e511-fd25-4ecd-9371-d45e18a57001_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, option to extend term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_10904115-ee97-4e7a-9240-d95dc2473953_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationAgreementCommittedFunding_4f092d50-34d6-435d-9be1-2a87bab4c54c_terseLabel_en-US" xlink:label="lab_allo_CollaborationAgreementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding</link:label>
    <link:label id="lab_allo_CollaborationAgreementCommittedFunding_label_en-US" xlink:label="lab_allo_CollaborationAgreementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Committed Funding</link:label>
    <link:label id="lab_allo_CollaborationAgreementCommittedFunding_documentation_en-US" xlink:label="lab_allo_CollaborationAgreementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Committed Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementCommittedFunding" xlink:href="allo-20220930.xsd#allo_CollaborationAgreementCommittedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationAgreementCommittedFunding" xlink:to="lab_allo_CollaborationAgreementCommittedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_94e72521-6450-4156-9a90-ace5bf244254_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_0a9c81d9-c12e-434d-bba3-f229263c5a0d_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5769cd79-4d58-4f0c-9194-47730ba5fd00_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EquityInvestmentBasisDomain_c118828c-8dd5-44cd-bf05-10b8d96e1765_terseLabel_en-US" xlink:label="lab_allo_EquityInvestmentBasisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Domain]</link:label>
    <link:label id="lab_allo_EquityInvestmentBasisDomain_label_en-US" xlink:label="lab_allo_EquityInvestmentBasisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Domain]</link:label>
    <link:label id="lab_allo_EquityInvestmentBasisDomain_documentation_en-US" xlink:label="lab_allo_EquityInvestmentBasisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EquityInvestmentBasisDomain" xlink:to="lab_allo_EquityInvestmentBasisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2493c6b9-6bca-43cd-858a-c4a2f1b44cbf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_618a5e10-a4cf-48d9-8d2e-cda34735bff5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AdditionalAreaOfNewOfficeBuilding_656c1fc5-88c9-4c9c-a07f-55645e46c9df_terseLabel_en-US" xlink:label="lab_allo_AdditionalAreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of office and laboratory (in square feet)</link:label>
    <link:label id="lab_allo_AdditionalAreaOfNewOfficeBuilding_label_en-US" xlink:label="lab_allo_AdditionalAreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Area of New Office Building</link:label>
    <link:label id="lab_allo_AdditionalAreaOfNewOfficeBuilding_documentation_en-US" xlink:label="lab_allo_AdditionalAreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Area of New Office Building</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AdditionalAreaOfNewOfficeBuilding" xlink:href="allo-20220930.xsd#allo_AdditionalAreaOfNewOfficeBuilding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AdditionalAreaOfNewOfficeBuilding" xlink:to="lab_allo_AdditionalAreaOfNewOfficeBuilding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f79f2a0f-991f-4392-8615-f428aefee45f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_a6641901-1455-421c-9e70-314e73e4a9db_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction monthly payment in arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Monthly Payments In Arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction monthly payments in arrears.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:href="allo-20220930.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:to="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_UpfrontAndQuarterlyCashPayments_13f09fba-7094-4c7e-ab4b-3f18c60b09d3_terseLabel_en-US" xlink:label="lab_allo_UpfrontAndQuarterlyCashPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and quarterly cash payments</link:label>
    <link:label id="lab_allo_UpfrontAndQuarterlyCashPayments_label_en-US" xlink:label="lab_allo_UpfrontAndQuarterlyCashPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Quarterly Cash Payments</link:label>
    <link:label id="lab_allo_UpfrontAndQuarterlyCashPayments_documentation_en-US" xlink:label="lab_allo_UpfrontAndQuarterlyCashPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Quarterly Cash Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UpfrontAndQuarterlyCashPayments" xlink:href="allo-20220930.xsd#allo_UpfrontAndQuarterlyCashPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_UpfrontAndQuarterlyCashPayments" xlink:to="lab_allo_UpfrontAndQuarterlyCashPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_50467dbc-bfac-4d9e-8328-8cea94c98297_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_bfcdd4cf-c229-49ba-937f-0340d6606e9c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9d797810-d847-4b9d-9b7d-ec7f15103a43_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7208170c-1aa0-42a6-9c00-d4d8bee01317_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_a350410e-af4f-453c-90e1-d83fb04946af_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a27094c1-04ef-4041-a962-73b5781c9b5c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5774633d-858b-4ce5-8f88-e6b36247747d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b4337a9c-8a85-433a-9416-1a2220ca0f8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4c97de8c-4d1c-40e9-9b4e-915826174c43_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9c9d764f-d991-406b-b319-605c1d9d9398_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod_e4af907e-9242-48aa-a80b-877027b7269b_negatedTerseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, option exchange, options cancelled (in shares)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2ffe6086-1af5-4173-bd34-5bdf02f83b58_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfOffice_4cb07e5e-a104-4729-b535-027f9c94b9f8_terseLabel_en-US" xlink:label="lab_allo_AreaOfOffice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space (in square feet)</link:label>
    <link:label id="lab_allo_AreaOfOffice_label_en-US" xlink:label="lab_allo_AreaOfOffice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Office</link:label>
    <link:label id="lab_allo_AreaOfOffice_documentation_en-US" xlink:label="lab_allo_AreaOfOffice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOffice" xlink:href="allo-20220930.xsd#allo_AreaOfOffice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfOffice" xlink:to="lab_allo_AreaOfOffice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_35d917cd-c844-41c5-8080-c51a408ff110_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_JointVentureCapitalSupportPayments_837bb11e-0c02-47a1-8d8b-c10ebc6ac4e9_terseLabel_en-US" xlink:label="lab_allo_JointVentureCapitalSupportPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture capital support payments</link:label>
    <link:label id="lab_allo_JointVentureCapitalSupportPayments_label_en-US" xlink:label="lab_allo_JointVentureCapitalSupportPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture Capital Support Payments</link:label>
    <link:label id="lab_allo_JointVentureCapitalSupportPayments_documentation_en-US" xlink:label="lab_allo_JointVentureCapitalSupportPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture Capital Support Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_JointVentureCapitalSupportPayments" xlink:href="allo-20220930.xsd#allo_JointVentureCapitalSupportPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_JointVentureCapitalSupportPayments" xlink:to="lab_allo_JointVentureCapitalSupportPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0a23f87f-2547-4426-b55f-46312501cc06_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cc5751df-8fc6-4ab8-abc4-350041cec2d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_fcd5c383-afa2-48c5-adec-f1de72a4a423_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_59010142-e72c-42cd-be7a-538c963fd5f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationAgreementTerm_18f0a3f3-c112-49b3-aa48-d7aff15dea49_terseLabel_en-US" xlink:label="lab_allo_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_allo_CollaborationAgreementTerm_label_en-US" xlink:label="lab_allo_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term</link:label>
    <link:label id="lab_allo_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_allo_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementTerm" xlink:href="allo-20220930.xsd#allo_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationAgreementTerm" xlink:to="lab_allo_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_29690945-4bce-4115-b31d-0541ef2c3d5a_verboseLabel_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember" xlink:href="allo-20220930.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAndCollaborationAgreementMember" xlink:to="lab_allo_LicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_227cd665-4348-4d0a-a106-4b57d84b5f75_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized&#160;Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8d161f87-f3a6-4da5-90cc-fbc3aa53d421_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_56adb682-b8a9-4ff0-86bc-00a6127c41b9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ConsultingAgreementsMember_08ff80e5-cbc1-4398-9c07-b5ed93034880_terseLabel_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreements</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_label_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_documentation_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember" xlink:href="allo-20220930.xsd#allo_ConsultingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ConsultingAgreementsMember" xlink:to="lab_allo_ConsultingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_65efece1-2467-4ec1-8023-45fc72da06b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_2e79e83f-cf39-4940-83dc-b03ddfc30a3f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SalesMilestoneMember_936fa1c9-87df-4a2e-b8cc-4aed4f564047_terseLabel_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_label_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_documentation_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember" xlink:href="allo-20220930.xsd#allo_SalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SalesMilestoneMember" xlink:to="lab_allo_SalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_438c3a72-79d5-43ac-a51b-7f96147a067d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f5a2ec07-32ef-46ba-8317-7c2c9a61e7bf_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_91dcd06d-6fdd-4764-b72c-41abf5c8f1e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity Under Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f79cb764-9036-4e5c-bced-76aeaa0a77a2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0b5f77fa-d34d-4a03-b183-a3ccfd972b30_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a64794ba-c80c-4271-a409-1773f479f38e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b3c3bc98-2808-4b25-b333-f0b2f42f32c5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cfffd0b1-9548-4859-a8f9-550402d12ba3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cb4bae99-9682-430e-96af-d5052c9613d7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_862c3512-fa33-4502-bbf7-1da231443b15_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_02307084-8ff0-4f6c-a255-3dbdb56c262c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-Based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d72a04b4-6c4e-480a-8693-03289b1912c0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_5829747a-3b7a-4f8e-bbe7-2bde72bcc69a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49ce8dff-1129-4624-8b3b-18969f543627_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7091fdcf-78d9-49ae-964f-2094159cb6c0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfOperatingLease_48175a57-71d9-423a-935e-01a238eab8e4_terseLabel_en-US" xlink:label="lab_allo_AreaOfOperatingLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of operating lease (in square feet)</link:label>
    <link:label id="lab_allo_AreaOfOperatingLease_label_en-US" xlink:label="lab_allo_AreaOfOperatingLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Operating Lease</link:label>
    <link:label id="lab_allo_AreaOfOperatingLease_documentation_en-US" xlink:label="lab_allo_AreaOfOperatingLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOperatingLease" xlink:href="allo-20220930.xsd#allo_AreaOfOperatingLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfOperatingLease" xlink:to="lab_allo_AreaOfOperatingLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_e2265454-06e6-45c7-baf0-b60c06a9f230_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, unvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6b70c830-b5dd-4acf-a963-360ca1bfe580_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_52aadf2e-4549-44a4-8076-1b070e811bd1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2db51205-b9d2-4c28-9213-cd12caad7290_terseLabel_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payments required per product against selected target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_label_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Payments Required Per Product Against Selected Target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_documentation_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payments required per product against selected target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:href="allo-20220930.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:to="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6a397af6-3fcd-4a54-a201-d7d5b8f1173f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_32b9faaf-c00f-4384-afbf-28d495d60627_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c911fed2-5350-4ea7-8405-b6dcb8236bc4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d260a31b-db41-487f-81f1-84e863b49e0b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_00187f06-8346-4e60-bc28-0ced88bb4a23_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0f8afaa1-ce1d-4124-a407-e52a850bc059_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used in computing net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a0e6eb11-c4c5-4a97-a6c4-22422ddf7199_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cc9859e8-549e-4ee8-8d36-1b0a7be9876c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_560d73f8-b63d-4fdc-bc4d-e1a0d1b44976_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_da55bd9b-be30-48dc-ac00-1523e8958683_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b7d94ac0-7615-46a0-acef-ff69303bec6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_03ee75af-c2f9-424e-8f50-d5626ac1981c_negatedTerseLabel_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of loss from equity method investment</link:label>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_label_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Cost Method Investment</link:label>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_documentation_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Cost Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment" xlink:href="allo-20220930.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_IncomeLossFromCostMethodInvestment" xlink:to="lab_allo_IncomeLossFromCostMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_202f63fe-9426-4516-926f-0dadce9f2513_terseLabel_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_label_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_documentation_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:href="allo-20220930.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:to="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9788ecc2-e3a3-4f85-b4e5-20104f5b249a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: 400,000,000 shares authorized as of September 30, 2022 and 200,000,000 shares authorized as of December 31, 2021; 144,031,588 and 142,623,065 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_a8c9ed24-d992-4281-9481-953151e64ecf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d27dcb15-3ee8-4286-b3ec-f3b827435e25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e7f95562-e359-4c0d-a2d6-d0b6a1ee4e68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_a3dfcafd-c9bc-4108-9c89-efa3a1610391_terseLabel_en-US" xlink:label="lab_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene Overland, Allogene Overland BioPharm (HK) Limited</link:label>
    <link:label id="lab_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_label_en-US" xlink:label="lab_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene Overland, Allogene Overland BioPharm (HK) Limited [Member]</link:label>
    <link:label id="lab_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_documentation_en-US" xlink:label="lab_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene Overland, Allogene Overland BioPharm (HK) Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember" xlink:to="lab_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice_2850d4d8-95d5-4249-ab58-32c143a056d9_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, option exchange options granted (in dollars per share)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants In Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants In Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_912f8471-e76f-4350-9bf9-6bc13372b93f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TenantImprovementAllowance_8f442f38-b41a-4393-8492-e1cccdefb320_terseLabel_en-US" xlink:label="lab_allo_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements</link:label>
    <link:label id="lab_allo_TenantImprovementAllowance_label_en-US" xlink:label="lab_allo_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance</link:label>
    <link:label id="lab_allo_TenantImprovementAllowance_documentation_en-US" xlink:label="lab_allo_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowance" xlink:href="allo-20220930.xsd#allo_TenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TenantImprovementAllowance" xlink:to="lab_allo_TenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2ee3fd4d-04cc-45f8-b74b-ea36df69ce97_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e48fbb0-48c9-4dc4-bf8d-16eec7fb760a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b71e110-8c7e-4108-b83f-ee55e9fe2e62_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8f22e288-eed3-4020-93d5-ed2e1cceaa0c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_33fd8e22-a27b-4481-b87f-56f50f8be7d3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c6290c0f-f0bd-4c91-a39e-abb058323c07_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dc561431-8746-4aec-968b-2bdc91683ffc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_390e5fb9-3d3b-477c-a0b2-eac174622acc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_72f3793d-b079-4610-babf-a228c0c1bfd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_addc4b58-ceb4-4874-9f6d-53e5b7fc9593_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting life, unvested (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_89d9b595-2bdf-4ac0-9042-c50bc21d2b26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_9806d3d5-aa81-45c8-8d2a-e9272e6921ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1de2a76d-a95a-40d2-a842-6b294d555d16_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_422f2597-dc35-4eeb-90e7-8a6eb7e9d0c7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_cdcd3ec3-e7bf-4109-9f12-153606177da9_terseLabel_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founders' shares of common stock subject to future vesting</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_label_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder Shares Of Common Stock [Member]</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_documentation_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder shares of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember" xlink:href="allo-20220930.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_FounderSharesOfCommonStockMember" xlink:to="lab_allo_FounderSharesOfCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c33e8f89-aeab-40fc-96af-a88ca3407a83_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_06342792-038e-46db-9258-2f33e79fa033_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6d621890-5eae-48a3-82a6-e7b21f5eda7b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AntionCollaborationAgreementMilestoneAchievementOneMember_8de48474-1f5e-48f1-9d5c-75ef79e4c025_terseLabel_en-US" xlink:label="lab_allo_AntionCollaborationAgreementMilestoneAchievementOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antion Collaboration Agreement, Milestone Achievement One</link:label>
    <link:label id="lab_allo_AntionCollaborationAgreementMilestoneAchievementOneMember_label_en-US" xlink:label="lab_allo_AntionCollaborationAgreementMilestoneAchievementOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antion Collaboration Agreement, Milestone Achievement One [Member]</link:label>
    <link:label id="lab_allo_AntionCollaborationAgreementMilestoneAchievementOneMember_documentation_en-US" xlink:label="lab_allo_AntionCollaborationAgreementMilestoneAchievementOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antion Collaboration Agreement, Milestone Achievement One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntionCollaborationAgreementMilestoneAchievementOneMember" xlink:href="allo-20220930.xsd#allo_AntionCollaborationAgreementMilestoneAchievementOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AntionCollaborationAgreementMilestoneAchievementOneMember" xlink:to="lab_allo_AntionCollaborationAgreementMilestoneAchievementOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_8dbb7a20-1a54-485b-8e95-0481e78b91a4_terseLabel_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_label_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone [Member]</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_documentation_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:href="allo-20220930.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:to="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ba1db551-c46e-4de3-afbc-a13751c7fcb9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_8917b5f9-cf06-4091-94bf-a20aa3b6591c_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f46b16d-3333-4a5c-b8ee-67246e1a7ce2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized&#160;Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d7b06dcf-c99c-4195-b470-d675a5061a02_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a024a0ba-c798-4099-836a-74802ffb9643_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_VotingInterestMember_30291d1c-1926-4fef-9671-03e3c13d98e9_terseLabel_en-US" xlink:label="lab_allo_VotingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Interest</link:label>
    <link:label id="lab_allo_VotingInterestMember_label_en-US" xlink:label="lab_allo_VotingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Interest [Member]</link:label>
    <link:label id="lab_allo_VotingInterestMember_documentation_en-US" xlink:label="lab_allo_VotingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember" xlink:href="allo-20220930.xsd#allo_VotingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_VotingInterestMember" xlink:to="lab_allo_VotingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_5b708c69-3018-48b6-b8e8-69730c311429_terseLabel_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Significant Accounting Policies Policy [Policy Text Block]</link:label>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:href="allo-20220930.xsd#allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:to="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7767683d-da63-4bcc-b3cc-b12357010c8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_OverlandPharmaceuticalsIncMember_600e5ed4-72a2-4be9-8e98-bd7aba854f7f_terseLabel_en-US" xlink:label="lab_allo_OverlandPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overland Pharmaceuticals Inc.</link:label>
    <link:label id="lab_allo_OverlandPharmaceuticalsIncMember_label_en-US" xlink:label="lab_allo_OverlandPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overland Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_allo_OverlandPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_allo_OverlandPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overland Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember" xlink:href="allo-20220930.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OverlandPharmaceuticalsIncMember" xlink:to="lab_allo_OverlandPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_77793c4d-c4ca-426f-a749-c7c09c72a6d8_terseLabel_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember" xlink:href="allo-20220930.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PreClinicalDevelopmentMilestoneMember" xlink:to="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_e562bd3d-b6d4-4b0d-a9a8-5dd97060ce7e_terseLabel_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development costs payable by the Company</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_label_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By The Company</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_documentation_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By The Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:href="allo-20220930.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:to="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_3bebf0e2-5a5f-4ed4-919a-ed20f0cbcfdc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_211de807-1e44-4d66-b766-d343fd594ad0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_218ce85e-451a-4f73-baef-b49b642daab2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a55a0e17-a725-411a-9896-c4f049bd6a23_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9eba87f-990e-44a5-8049-9a0c59c903a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_25d02535-2058-4bfc-9436-9f56388b68f0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding_29507682-9f88-4e2f-a1e9-03ac57f19815_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange offer, percentage of total shares outstanding</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Percentage Of Total Shares Outstanding</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Percentage Of Total Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a3f5111a-e9e9-4e3e-b9ae-710c96d926f4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_a62fadd6-08f9-4511-9c1c-040edd331906_terseLabel_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend lease</link:label>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_label_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Lease</link:label>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_documentation_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfOptionsToExtendLease" xlink:href="allo-20220930.xsd#allo_NumberOfOptionsToExtendLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfOptionsToExtendLease" xlink:to="lab_allo_NumberOfOptionsToExtendLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_46175883-c01c-4a93-bd4c-46b0cfed9d75_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e3594191-f575-4b00-8ee8-61e9ee78b4ff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d3915b1f-3178-443e-9b14-aebcf0c03a60_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0a997f6b-ea84-4b63-a8f0-7bbb005bd2b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_36ff15af-52ab-4358-b4a2-6464840a02c3_terseLabel_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_label_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting L L C [Member]</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_documentation_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLLCMember" xlink:href="allo-20220930.xsd#allo_TwoRiverConsultingLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoRiverConsultingLLCMember" xlink:to="lab_allo_TwoRiverConsultingLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f1d9031f-fda5-4926-8eea-1cfeeed5bf15_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_470afe6b-e8a3-4d1f-8b2a-974ffa6acaaf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4dd313cb-5d73-4f68-945b-e1c8179b3801_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b8b178ed-3dc6-44c3-93f7-cd25ce2007cb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ff3953cf-21c7-4bb8-a9aa-4a05ed4282f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f339d0ee-7d28-434a-a78d-547487695994_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_132b921d-0170-457f-bff3-e2958b103b3c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_078279fb-c0fb-4f47-b254-8f5571812cef_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7ef10465-0dda-4dba-88dc-88e97ff555e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f199066d-00bf-43a0-8a15-9729f9e5f416_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_3b06d2ed-8cb6-40ba-be92-5c5f71ee1d10_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_378f2aff-4489-4824-b769-931a58123fab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5ca1feeb-9e56-4cac-b8ef-0fd1e6b0676a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_72cabbd8-d5c7-4440-b9b1-6f3198b82323_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a56253f-f30a-42ae-bb35-6d82f42074ee_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_786a6966-4aea-4b1e-8acc-99d123e9fec3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bb7f52fb-e616-4381-be95-65aa01a25908_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4e99a3c2-513a-45b8-9d56-d205942e98d8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e4ca09b8-62d7-4c89-8e6c-00133746cfbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_df65dc62-7b45-42fb-b21b-56cdbe34a6f1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_8c93c093-6a9e-49af-8184-db565083ec52_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining contractual maturities of available-for-sale securities (in years)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NewarkMember_04debc1c-914a-4f14-84a4-7fac541c2ae8_terseLabel_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark</link:label>
    <link:label id="lab_allo_NewarkMember_label_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark [Member]</link:label>
    <link:label id="lab_allo_NewarkMember_documentation_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember" xlink:href="allo-20220930.xsd#allo_NewarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NewarkMember" xlink:to="lab_allo_NewarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LaboratoryEquipmentMember_665deff4-4fa1-471e-b63c-aff876429804_terseLabel_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember" xlink:href="allo-20220930.xsd#allo_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LaboratoryEquipmentMember" xlink:to="lab_allo_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5365bb13-adc1-48dd-97d7-6523b8ac51f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis and Level of Inputs Used in Such Measurements by Major Security Type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_41288b01-aa48-49a2-b0e0-c1a651b0a418_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_17e246ff-3aad-47b3-ad94-6de739c4eaed_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2c371f42-8622-4ca0-aa2f-abaee203289a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_db2e93ab-5b47-46ee-a55d-b9a42014a057_terseLabel_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost</link:label>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_label_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investment, Transaction Costs</link:label>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_documentation_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investment, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts" xlink:href="allo-20220930.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CostMethodInvestmentTransactionCosts" xlink:to="lab_allo_CostMethodInvestmentTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f8ca8196-d073-4197-915c-67faa05e4a68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_ec7656a9-8f64-4d4d-9433-246814ed79f5_totalLabel_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_documentation_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments" xlink:href="allo-20220930.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments" xlink:to="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_db515217-98a8-44c6-9a56-ae703f4e2f49_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3e720f8e-939e-4619-9eb1-fbd142b84237_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_33378e0a-0b83-4e5c-97f8-b84046e4ff36_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_DevelopmentAndSalesMember_36dbc60d-dc8d-4a7b-96b4-9283dfe3fa69_terseLabel_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Sales</link:label>
    <link:label id="lab_allo_DevelopmentAndSalesMember_label_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Sales [Member]</link:label>
    <link:label id="lab_allo_DevelopmentAndSalesMember_documentation_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DevelopmentAndSalesMember" xlink:href="allo-20220930.xsd#allo_DevelopmentAndSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DevelopmentAndSalesMember" xlink:to="lab_allo_DevelopmentAndSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7c636898-5e88-48be-9799-8fbba79f64f9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ba27d8dc-0a40-4dd1-b03d-2d36e67199e0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8a76a44f-274f-49f9-994f-2273c5d3cfbd_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_f2d6dd2a-7217-40c8-9305-2c0e9227ee59_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_319405bf-f65d-4021-a60c-68a260fab113_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c8e7d52-9341-4352-95ef-269738591c61_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice_4102e0e4-77c5-4ce8-bdf0-77bc69ff18ed_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, option exchange options cancelled (in dollars per share)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_c571fa45-fcf2-4604-b31c-69417260041b_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b164fe49-585c-465a-b2c3-731e0b0fcdcf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_693b3478-68b7-4266-a8a2-a90924f8b1bd_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_06d3df35-76d2-4914-b01f-1110b8a53a55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_299300dc-1e8b-473f-b963-3da3e9152df8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_7be0fd39-cc2e-4652-acc6-3f894e7fc502_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_cfe0284a-852d-4ec3-8d56-ca8c7b67e700_terseLabel_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_label_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Plan [Member]</link:label>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_documentation_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember" xlink:href="allo-20220930.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoThousandEighteenPlanMember" xlink:to="lab_allo_TwoThousandEighteenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_07bff1b4-1268-493f-9cf4-10f3c47e9b10_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f31c1f5b-9ad1-4479-8c60-0733bd2caa2e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used in computing net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_aac946a7-76a6-4af1-8987-480c31a9b2de_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5c7b016a-c1c4-485f-bbbc-3c0fbbe9ecbc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2d045d36-89a2-4632-8279-59165f035e7d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1fccc8ef-7167-482b-bc51-689c1e53b99b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Notes 6 and 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a29e8532-aec4-498d-bb12-d91566d0802b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3a618f95-fa21-40aa-ac37-5a2137956f01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b79859d-1194-46f2-87e6-0845f53a9d5e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e32d8575-ffa1-45f1-bb92-9dfb4e797fdc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_57987e09-8f84-4735-bf91-6f6075bf82e7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of September 30, 2022 and December 31, 2021; no shares were issued and outstanding as of September 30, 2022 and December 31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CellectisSAMember_061161cc-bd1d-4808-be6f-34eab4fab2cc_terseLabel_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis</link:label>
    <link:label id="lab_allo_CellectisSAMember_label_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis S A [Member]</link:label>
    <link:label id="lab_allo_CellectisSAMember_documentation_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis S.A..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember" xlink:href="allo-20220930.xsd#allo_CellectisSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CellectisSAMember" xlink:to="lab_allo_CellectisSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_4a637961-be5d-4b97-9e41-15fad7068538_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_9cc596d3-0528-4821-ac40-1e65d7d7e086_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0930ada3-a715-4abe-9bc8-6ca5dbf8bdea_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ba043a13-5c44-4653-9b88-6f15d08f3e53_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue - related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_3e57e62b-e3c4-4db0-831a-013210fb5bac_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6d83656b-eb10-4283-8afd-43f4e6cc351f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_94bccae4-6bc3-499e-aed9-25a643cf9708_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7804d92d-5ba4-4470-92f0-3e4a08b18dd9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_06a0d4ce-c53f-4993-9132-08a34717f51b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ae185385-b715-416d-9b30-5f1ff0850677_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b457df34-314a-4089-876f-187fa0520747_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_49e52d49-7096-41b8-aa63-0a96b1b6da50_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions_ae310468-ae15-4eee-8700-a9fa6afb12db_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange offer, number of options accepted for cancellation (in shares)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Options</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentTermsAxis_0fbeb4aa-a021-4e5f-88b5-ac712c022eea_terseLabel_en-US" xlink:label="lab_allo_PaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Axis]</link:label>
    <link:label id="lab_allo_PaymentTermsAxis_label_en-US" xlink:label="lab_allo_PaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Axis]</link:label>
    <link:label id="lab_allo_PaymentTermsAxis_documentation_en-US" xlink:label="lab_allo_PaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsAxis" xlink:href="allo-20220930.xsd#allo_PaymentTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentTermsAxis" xlink:to="lab_allo_PaymentTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1c3e4cb-5d2e-42e1-b5c8-36cd4fb625b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_27bafc16-f276-4f2b-b0f2-f62ade8b0b1a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_9a1e93c7-8692-4099-8dd4-c42c8a7e7d33_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_145707ad-c0b2-45c2-865a-7adc443e596f_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0c45bc98-f34c-4878-985c-0bcdfdb7d341_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_8d6b8be5-3f2e-4199-9468-0d3dc484a4d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Leasing Costs, Commissions, and Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:to="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement_28a75d03-967b-4508-9ac8-7c9bc26b3b2b_terseLabel_en-US" xlink:label="lab_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for investments upon milestone achievement</link:label>
    <link:label id="lab_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement_label_en-US" xlink:label="lab_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments Upon Milestone Achievement</link:label>
    <link:label id="lab_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement_documentation_en-US" xlink:label="lab_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments Upon Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement" xlink:href="allo-20220930.xsd#allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement" xlink:to="lab_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_229e6a52-b527-41f1-862c-7ab2a25002ac_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cc622337-7e68-43cb-88cb-acc12cb5f58a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e9f2c9b5-1e62-4acf-91ac-8e97b3cf5d6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_13dc9c99-a441-4a77-b367-d41d84ece88d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_6cd64134-3ff9-413c-ae21-c4fe45bff34e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e5383cba-2769-4209-b435-7316b7fbc3a6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4d3f1503-1551-42dd-8eeb-ff38d3964f60_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_914a5fae-c090-4a4f-8ede-a11e6e1ceb60_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_680fff81-88c5-4882-988c-44db6b4d0e32_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting life, granted (in years)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4790aaf8-363c-4714-bdc8-39226a26ed9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_51ca32f3-1e7f-40ad-9710-13c2af3ec95b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_038f8f5c-3e6b-4b43-a582-723e439200fe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_978b0d9a-e298-4f85-a608-fe5ac0bcad62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_51bedb31-549b-4d8c-ac91-251f34fe487b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SubleaseAgreementMember_4d7e8873-eb8c-4ae2-9997-4a08161774a0_terseLabel_en-US" xlink:label="lab_allo_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement</link:label>
    <link:label id="lab_allo_SubleaseAgreementMember_label_en-US" xlink:label="lab_allo_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement [Member]</link:label>
    <link:label id="lab_allo_SubleaseAgreementMember_documentation_en-US" xlink:label="lab_allo_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubleaseAgreementMember" xlink:href="allo-20220930.xsd#allo_SubleaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SubleaseAgreementMember" xlink:to="lab_allo_SubleaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_e0c00e77-64a0-4324-bd4f-82082094b451_terseLabel_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation period from date of first sale</link:label>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_label_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation Period From Date Of First Sale</link:label>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_documentation_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation Period From Date Of First Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:href="allo-20220930.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:to="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4da77036-2de9-4923-98cb-a0e875e92012_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3c417227-5403-483a-b61c-d0d7d2a9f009_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_8aa426e6-d002-418b-a88e-04f1ec15022b_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a969cb69-be6f-4ed7-bdb4-2efd96e772be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_63384e8d-c936-47c6-8bdd-b6d4187ce3a5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Lease Payments Under Lease Liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_17817988-705a-4634-a3d2-9754db3f716b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember_c677b59f-b03c-40ec-840d-b83c86380f50_terseLabel_en-US" xlink:label="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Texas MD Anderson Cancer Center</link:label>
    <link:label id="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember_label_en-US" xlink:label="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Texas MD Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember_documentation_en-US" xlink:label="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Texas MD Anderson Cancer Center</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:href="allo-20220930.xsd#allo_UniversityOfTexasMDAndersonCancerCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:to="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b4ce5a75-c7e9-4002-9bae-700243b27175_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestonePayments_dd4c2048-e200-4d3c-a780-8eb91eb5f8ef_terseLabel_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_allo_MilestonePayments_label_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_allo_MilestonePayments_documentation_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments" xlink:href="allo-20220930.xsd#allo_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestonePayments" xlink:to="lab_allo_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_eb86c1f3-698d-4938-8918-5029e10fb070_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_19c07c5f-f424-4f06-9edd-f350b1612605_terseLabel_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cost recoveries</link:label>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_label_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Direct Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_abafb8ac-8605-49e5-b994-a60a9894172a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_386c45f4-57ae-4976-b728-10e253268b14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_ab249f26-7c7e-458a-a979-aca728611d72_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_abbf1036-847c-4176-80af-6d7a1a24a390_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3b142e21-4d3f-43aa-a6ca-5e0ec2f6aa8d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_eade7bfa-e596-405f-8374-f8099874b8d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_be2e216e-aefd-4d8c-b2fa-81264691e5f1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CurrentAccruedAndOtherLiabilitiesMember_ea3a1100-0ac9-4873-8972-3e2d5c87758b_terseLabel_en-US" xlink:label="lab_allo_CurrentAccruedAndOtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Accrued and Other Liabilities</link:label>
    <link:label id="lab_allo_CurrentAccruedAndOtherLiabilitiesMember_label_en-US" xlink:label="lab_allo_CurrentAccruedAndOtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Accrued and Other Liabilities [Member]</link:label>
    <link:label id="lab_allo_CurrentAccruedAndOtherLiabilitiesMember_documentation_en-US" xlink:label="lab_allo_CurrentAccruedAndOtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Accrued and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CurrentAccruedAndOtherLiabilitiesMember" xlink:href="allo-20220930.xsd#allo_CurrentAccruedAndOtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CurrentAccruedAndOtherLiabilitiesMember" xlink:to="lab_allo_CurrentAccruedAndOtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_d0f94c5b-6806-40d3-a9f3-64257d0f7692_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone receivable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Receivable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable" xlink:href="allo-20220930.xsd#allo_AggregatePotentialMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestoneReceivable" xlink:to="lab_allo_AggregatePotentialMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross_e3e3198e-20e2-4f37-8143-bbaf0d4e26e0_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, option exchange, options granted (in shares)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants in Period, Gross</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b3ec3e1a-b3e7-4ce9-8b12-8a7741a2f084_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_e0974943-62dc-41d8-babc-b2f75bf7fcce_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_09ce8322-1985-4960-976f-6b6eef7cdacb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2c685124-f910-4065-9eb6-c080efd13e95_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_db99b0b1-5d22-4cf4-a899-49697588791f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c0e6319-dcdb-4404-9933-6f83ccfbc651_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_499a7b78-1e8e-4faa-91e8-675b4ec98415_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_758b7310-bccc-4a98-8880-3a434c8d60b6_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_33e303f0-0128-4a91-89f1-89b5b494c153_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_99775eaa-a653-4844-89a4-86ac80c5940c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b1249b39-d5ff-44a3-922e-b2dff0c47e0e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_f1625af5-e69c-427d-bccd-bd7104376423_terseLabel_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares as percentage of common shares outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_label_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_documentation_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares as percentage of common shares outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:href="allo-20220930.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:to="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember_df2c9709-1708-44dc-b322-a8db34d8bb0a_terseLabel_en-US" xlink:label="lab_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antion Collaboration Agreement, Milestone Achievement Two</link:label>
    <link:label id="lab_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember_label_en-US" xlink:label="lab_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antion Collaboration Agreement, Milestone Achievement Two [Member]</link:label>
    <link:label id="lab_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember_documentation_en-US" xlink:label="lab_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antion Collaboration Agreement, Milestone Achievement Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember" xlink:href="allo-20220930.xsd#allo_AntionCollaborationAgreementMilestoneAchievementTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember" xlink:to="lab_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_489e43f1-83c2-4d1c-927b-4c433c3ecd57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3e46a549-5403-4cdf-8471-a85b6c9dc168_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_148fe9c5-d968-48bd-b530-52b3a375aae0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ServierMember_8dd927e6-6ed0-4446-abe9-86933bffd81d_verboseLabel_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_allo_ServierMember_label_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier [Member]</link:label>
    <link:label id="lab_allo_ServierMember_documentation_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember" xlink:href="allo-20220930.xsd#allo_ServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ServierMember" xlink:to="lab_allo_ServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_0783edd0-63e6-4f8e-8666-f1a81f99bbe2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a7386f08-94a3-4e82-9701-6224d48ab0cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_2a731b9d-d057-4eea-88f2-6a4ad7e13d13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of stock in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_dc282197-b04b-445a-af37-058cde92a9ba_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for additional investment in interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2e57c53-ddb1-4b7b-a326-e52591e04a9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_df4452ec-f19b-4a78-8405-95060d20204d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_0bfe4e3c-0a12-4bd2-8a94-09d5be768c8a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_216c65d2-2989-4882-9686-91440f5d191f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_f0d5ab63-eab4-4045-a01d-beb4c3a2a660_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_ea04e4fb-70a0-4e7d-b36e-1ca62b02b3ed_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancellable purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_5e44d934-9c69-48fd-aee2-b222623a58d1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_05d07980-ce09-4ea9-a62a-0ea8b18441a6_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_baad5a99-907e-4b23-a58f-eb03f9544fee_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest in Notch</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_cc1da209-ad7d-4c6d-ba66-3ee15b6539d4_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential regulatory and development milestones</link:label>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_label_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Regulatory And Development Milestones</link:label>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential regulatory and development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:href="allo-20220930.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:to="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RegulatoryMilestoneMember_7595c39d-3df3-404f-9ca9-676e3f5518fc_terseLabel_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_label_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone [Member]</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember" xlink:href="allo-20220930.xsd#allo_RegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RegulatoryMilestoneMember" xlink:to="lab_allo_RegulatoryMilestoneMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>allo-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:3bc7a964-10eb-47e7-910c-f5ea785aeb6d,g:304a2d5e-50f8-4210-a420-41588b836a7a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5f5666df-3ba5-4a2a-9727-3609136be80b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_DocumentType_5f5666df-3ba5-4a2a-9727-3609136be80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d5a0c7ac-65db-4eea-bc9a-605e8a8c697b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_DocumentQuarterlyReport_d5a0c7ac-65db-4eea-bc9a-605e8a8c697b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_13e08750-4c0d-4917-bb55-5f34bbfa719a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_DocumentPeriodEndDate_13e08750-4c0d-4917-bb55-5f34bbfa719a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b909c99b-1a23-4e83-823e-bd6c51be90af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_DocumentTransitionReport_b909c99b-1a23-4e83-823e-bd6c51be90af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3def1e90-0d0d-4d41-8ac5-85d333bece73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityFileNumber_3def1e90-0d0d-4d41-8ac5-85d333bece73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1d9aa297-596c-4b5b-918a-26237fc2e55d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityRegistrantName_1d9aa297-596c-4b5b-918a-26237fc2e55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c816b877-2049-481d-a4b0-d0c5fd956318" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c816b877-2049-481d-a4b0-d0c5fd956318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f7fa73d2-7303-41e4-8697-e3746873d100" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityTaxIdentificationNumber_f7fa73d2-7303-41e4-8697-e3746873d100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0378d2f0-73a5-4d62-8add-1110adbd283c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityAddressAddressLine1_0378d2f0-73a5-4d62-8add-1110adbd283c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_164c13cc-976b-4548-83ea-ddc030be9e6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityAddressCityOrTown_164c13cc-976b-4548-83ea-ddc030be9e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d3ee4458-4aaf-4194-bf4b-65846add0bca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityAddressStateOrProvince_d3ee4458-4aaf-4194-bf4b-65846add0bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b12f99e4-cb60-4b2b-9f21-c840e79f5dc0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityAddressPostalZipCode_b12f99e4-cb60-4b2b-9f21-c840e79f5dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9d42db69-ac99-42e1-9ce3-b98811ea5e0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_CityAreaCode_9d42db69-ac99-42e1-9ce3-b98811ea5e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_51987918-1f44-4f2f-b266-543967a5e39e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_LocalPhoneNumber_51987918-1f44-4f2f-b266-543967a5e39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a9be1746-4d98-48aa-a90f-7b37cb02ffa4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_Security12bTitle_a9be1746-4d98-48aa-a90f-7b37cb02ffa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_99e0f551-4a88-4ba7-9d27-d64b751fe3c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_TradingSymbol_99e0f551-4a88-4ba7-9d27-d64b751fe3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_003c2aa9-ae8c-49d5-ac0f-815c7e414a0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_SecurityExchangeName_003c2aa9-ae8c-49d5-ac0f-815c7e414a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e5ff405e-4d80-4930-bde4-c76d5085b748" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityCurrentReportingStatus_e5ff405e-4d80-4930-bde4-c76d5085b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fadcc901-cd6b-4082-9827-b91227b79be1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityInteractiveDataCurrent_fadcc901-cd6b-4082-9827-b91227b79be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5f83e395-e07d-47fb-a374-2b4d9a229d1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityFilerCategory_5f83e395-e07d-47fb-a374-2b4d9a229d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_33be8af1-3173-4f66-a553-d3b7dffcb4fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntitySmallBusiness_33be8af1-3173-4f66-a553-d3b7dffcb4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_55a1198b-6ecb-4845-8174-0a6162509b46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityEmergingGrowthCompany_55a1198b-6ecb-4845-8174-0a6162509b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_13a283f1-6538-47ff-a056-e23bdd0be2af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityShellCompany_13a283f1-6538-47ff-a056-e23bdd0be2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f3a16238-eb85-490d-827b-2d0b271344dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f3a16238-eb85-490d-827b-2d0b271344dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b4f46ecf-767c-4776-82d8-2877b91014cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_CurrentFiscalYearEndDate_b4f46ecf-767c-4776-82d8-2877b91014cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f0fe759e-508a-4409-bc26-5a0d26c24e72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_AmendmentFlag_f0fe759e-508a-4409-bc26-5a0d26c24e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_be0f4195-6fe0-4775-825a-044a6af6184a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_EntityCentralIndexKey_be0f4195-6fe0-4775-825a-044a6af6184a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2f060bdb-a92a-4ace-b19f-444f6b94dad0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_DocumentFiscalYearFocus_2f060bdb-a92a-4ace-b19f-444f6b94dad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9ecf06a6-c361-4736-a321-e8f83cf5bfbe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac3482a-f7fa-4f2c-9fb8-02c9dc6cb829" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9ecf06a6-c361-4736-a321-e8f83cf5bfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="allo-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_05531431-c0ce-4dd4-a435-42cb1bed8508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_05531431-c0ce-4dd4-a435-42cb1bed8508" xlink:to="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_be163ab4-fb11-404e-ac25-e7411e59fa04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:to="loc_us-gaap_AssetsCurrentAbstract_be163ab4-fb11-404e-ac25-e7411e59fa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93f5fd23-55ed-42bc-8467-40da9b26856f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_be163ab4-fb11-404e-ac25-e7411e59fa04" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93f5fd23-55ed-42bc-8467-40da9b26856f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_89eaebbb-6d06-4439-b072-6b34bba3c7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_be163ab4-fb11-404e-ac25-e7411e59fa04" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_89eaebbb-6d06-4439-b072-6b34bba3c7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_86deb9bd-fbbe-460e-8be1-84aad2bf4003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_be163ab4-fb11-404e-ac25-e7411e59fa04" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_86deb9bd-fbbe-460e-8be1-84aad2bf4003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_210ed8bb-9a0d-4877-8f4c-26f5a61f1f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_be163ab4-fb11-404e-ac25-e7411e59fa04" xlink:to="loc_us-gaap_AssetsCurrent_210ed8bb-9a0d-4877-8f4c-26f5a61f1f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_98429307-abf4-4ad3-bf4f-bbc79484a482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_98429307-abf4-4ad3-bf4f-bbc79484a482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c7b732b-bdbd-4676-8520-c70d883ec740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c7b732b-bdbd-4676-8520-c70d883ec740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7fcfa241-ac68-40f0-8070-82904b644aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7fcfa241-ac68-40f0-8070-82904b644aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0602a92f-86e6-4d76-83cf-13f4e08e0eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0602a92f-86e6-4d76-83cf-13f4e08e0eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b3e17cfb-ff0b-4bad-b61b-b90bb82fb1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b3e17cfb-ff0b-4bad-b61b-b90bb82fb1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9a2a6c31-05f9-4880-8182-ca9111b2c441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_9a2a6c31-05f9-4880-8182-ca9111b2c441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9ad4debb-6736-49c7-9a5c-bcb9f5a7c014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_039fb8eb-01d3-4c68-826a-91f04f791590" xlink:to="loc_us-gaap_Assets_9ad4debb-6736-49c7-9a5c-bcb9f5a7c014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0103dd21-72c4-4650-a6a7-c14547e3dd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_05531431-c0ce-4dd4-a435-42cb1bed8508" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0103dd21-72c4-4650-a6a7-c14547e3dd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bab94fa8-a6b0-438a-9e2c-3a730262e9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0103dd21-72c4-4650-a6a7-c14547e3dd6d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bab94fa8-a6b0-438a-9e2c-3a730262e9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3e4400cc-a458-4a81-a66b-7f471d59618a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bab94fa8-a6b0-438a-9e2c-3a730262e9a7" xlink:to="loc_us-gaap_AccountsPayableCurrent_3e4400cc-a458-4a81-a66b-7f471d59618a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_ee651727-5884-4464-8d0a-790a46ddf1d0" xlink:href="allo-20220930.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bab94fa8-a6b0-438a-9e2c-3a730262e9a7" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_ee651727-5884-4464-8d0a-790a46ddf1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2d864d8a-f020-4a4a-b011-21eb85eec0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bab94fa8-a6b0-438a-9e2c-3a730262e9a7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2d864d8a-f020-4a4a-b011-21eb85eec0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3360fdf9-9690-47f7-8046-321571f1ad29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bab94fa8-a6b0-438a-9e2c-3a730262e9a7" xlink:to="loc_us-gaap_LiabilitiesCurrent_3360fdf9-9690-47f7-8046-321571f1ad29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9459f523-98c9-4a03-9865-41cf9f82ad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0103dd21-72c4-4650-a6a7-c14547e3dd6d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9459f523-98c9-4a03-9865-41cf9f82ad3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7d1109bf-f236-4919-9aca-6393e8fdde61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0103dd21-72c4-4650-a6a7-c14547e3dd6d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7d1109bf-f236-4919-9aca-6393e8fdde61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d0d3de51-dc71-4a23-bdf6-0a9f5a0ae562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0103dd21-72c4-4650-a6a7-c14547e3dd6d" xlink:to="loc_us-gaap_Liabilities_d0d3de51-dc71-4a23-bdf6-0a9f5a0ae562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a69d5751-787a-4b4a-9801-cda2a41a4db1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0103dd21-72c4-4650-a6a7-c14547e3dd6d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a69d5751-787a-4b4a-9801-cda2a41a4db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3432c5c3-00fb-4a02-8049-4e66d749ff35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0103dd21-72c4-4650-a6a7-c14547e3dd6d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3432c5c3-00fb-4a02-8049-4e66d749ff35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a305e76f-1537-4c02-8007-afb9ac5eb3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3432c5c3-00fb-4a02-8049-4e66d749ff35" xlink:to="loc_us-gaap_PreferredStockValue_a305e76f-1537-4c02-8007-afb9ac5eb3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_99414a7b-0599-4076-9140-c6155a7d334b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3432c5c3-00fb-4a02-8049-4e66d749ff35" xlink:to="loc_us-gaap_CommonStockValue_99414a7b-0599-4076-9140-c6155a7d334b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f142ebde-4dbc-4aa0-873f-5c323c464e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3432c5c3-00fb-4a02-8049-4e66d749ff35" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f142ebde-4dbc-4aa0-873f-5c323c464e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0d7136b4-83bb-43bb-a2cd-068773d1961a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3432c5c3-00fb-4a02-8049-4e66d749ff35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0d7136b4-83bb-43bb-a2cd-068773d1961a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e8a6e1fb-3993-4364-ab42-37e316f71518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3432c5c3-00fb-4a02-8049-4e66d749ff35" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e8a6e1fb-3993-4364-ab42-37e316f71518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_adc2f06f-0505-43db-8b20-ea25c9131c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3432c5c3-00fb-4a02-8049-4e66d749ff35" xlink:to="loc_us-gaap_StockholdersEquity_adc2f06f-0505-43db-8b20-ea25c9131c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8d73e20-ffba-40d7-9136-4a1201fcaf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0103dd21-72c4-4650-a6a7-c14547e3dd6d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8d73e20-ffba-40d7-9136-4a1201fcaf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_edd872ad-15c7-44c5-a738-7d0610be0402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_824544d8-9f34-483b-9fd4-bc6c28287aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd872ad-15c7-44c5-a738-7d0610be0402" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_824544d8-9f34-483b-9fd4-bc6c28287aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3e83d753-6b04-43d0-961b-871ba42a9471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd872ad-15c7-44c5-a738-7d0610be0402" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3e83d753-6b04-43d0-961b-871ba42a9471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0149c448-542b-4f37-9d31-022d66378f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd872ad-15c7-44c5-a738-7d0610be0402" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0149c448-542b-4f37-9d31-022d66378f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0d3ab04d-3df3-42f2-986d-00c3cc901d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd872ad-15c7-44c5-a738-7d0610be0402" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0d3ab04d-3df3-42f2-986d-00c3cc901d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_33ce9a5e-45e3-4c91-b263-4df9df5c7fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd872ad-15c7-44c5-a738-7d0610be0402" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_33ce9a5e-45e3-4c91-b263-4df9df5c7fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d3bdc601-d9f3-4a92-be59-5cec8b761746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd872ad-15c7-44c5-a738-7d0610be0402" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d3bdc601-d9f3-4a92-be59-5cec8b761746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_824f408c-e0e3-4bc9-8454-f6c699775375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd872ad-15c7-44c5-a738-7d0610be0402" xlink:to="loc_us-gaap_CommonStockSharesIssued_824f408c-e0e3-4bc9-8454-f6c699775375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_932c0137-3606-4140-a593-baeff134d58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd872ad-15c7-44c5-a738-7d0610be0402" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_932c0137-3606-4140-a593-baeff134d58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4592091d-2b99-4b97-8bc0-960ff7319721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_RevenuesAbstract_4592091d-2b99-4b97-8bc0-960ff7319721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bd1d5ef1-010e-412f-96ba-c5101d06d9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_4592091d-2b99-4b97-8bc0-960ff7319721" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bd1d5ef1-010e-412f-96ba-c5101d06d9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1d90b16e-c143-486d-ab3a-f10bfbb84c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1d90b16e-c143-486d-ab3a-f10bfbb84c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6b06c680-f5be-4241-a8cd-eda057177be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1d90b16e-c143-486d-ab3a-f10bfbb84c85" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6b06c680-f5be-4241-a8cd-eda057177be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8e2e50b6-1760-4103-87ab-6960e6030a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1d90b16e-c143-486d-ab3a-f10bfbb84c85" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8e2e50b6-1760-4103-87ab-6960e6030a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_02a46f71-c867-4b9e-87e3-7146274a9614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1d90b16e-c143-486d-ab3a-f10bfbb84c85" xlink:to="loc_us-gaap_OperatingExpenses_02a46f71-c867-4b9e-87e3-7146274a9614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_71d86808-fa80-4098-b42c-033e63572b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_OperatingIncomeLoss_71d86808-fa80-4098-b42c-033e63572b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_534c433b-fe4c-4ee0-8fb5-f4b6d1136e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_534c433b-fe4c-4ee0-8fb5-f4b6d1136e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_c51aa6be-4d85-4b6c-bd56-cc1de77162a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_534c433b-fe4c-4ee0-8fb5-f4b6d1136e80" xlink:to="loc_us-gaap_InterestAndOtherIncome_c51aa6be-4d85-4b6c-bd56-cc1de77162a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_127df9c8-1003-488b-addd-d14db9546a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_534c433b-fe4c-4ee0-8fb5-f4b6d1136e80" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_127df9c8-1003-488b-addd-d14db9546a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d45c4162-88ff-42ee-abdf-03ca8f2fe539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_534c433b-fe4c-4ee0-8fb5-f4b6d1136e80" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d45c4162-88ff-42ee-abdf-03ca8f2fe539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a22cf55c-5bc5-4db1-9e96-004fab06c906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_NetIncomeLoss_a22cf55c-5bc5-4db1-9e96-004fab06c906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cfd0caf7-0e65-4934-ac2a-e7ba903bf898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cfd0caf7-0e65-4934-ac2a-e7ba903bf898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d40304c-e287-4d45-9636-34fe393d6be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cfd0caf7-0e65-4934-ac2a-e7ba903bf898" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d40304c-e287-4d45-9636-34fe393d6be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e2ec0075-5fda-4b16-8258-098703caf578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cfd0caf7-0e65-4934-ac2a-e7ba903bf898" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e2ec0075-5fda-4b16-8258-098703caf578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e751ac9a-50e3-4309-b869-1c6e487bfc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_EarningsPerShareBasic_e751ac9a-50e3-4309-b869-1c6e487bfc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b6bb33d2-3d21-48ff-ab77-2ee6bb88d034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b6bb33d2-3d21-48ff-ab77-2ee6bb88d034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9ffb9998-fd15-4128-8e8f-d56bc794a5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9ffb9998-fd15-4128-8e8f-d56bc794a5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6a7de21c-4ad8-440f-9963-1a2002b7bc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_dcb9e4ef-ed35-4e1c-a803-7b8596500fd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6a7de21c-4ad8-440f-9963-1a2002b7bc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="allo-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7ea4da90-cb23-4a47-8e6d-0b13d5344ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bb8bcae3-042a-48de-931b-5675cefcec61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7ea4da90-cb23-4a47-8e6d-0b13d5344ed7" xlink:to="loc_us-gaap_StatementTable_bb8bcae3-042a-48de-931b-5675cefcec61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4736af49-2689-460d-9f59-8381979068a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bb8bcae3-042a-48de-931b-5675cefcec61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4736af49-2689-460d-9f59-8381979068a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4736af49-2689-460d-9f59-8381979068a9" xlink:to="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dfba86c9-baeb-490a-90b3-51ace22351f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:to="loc_us-gaap_CommonStockMember_dfba86c9-baeb-490a-90b3-51ace22351f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_da4081ac-1044-4163-ae78-cf79ed9795ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_da4081ac-1044-4163-ae78-cf79ed9795ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cf1ab50e-e68a-4b14-83a9-409f09a40847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:to="loc_us-gaap_RetainedEarningsMember_cf1ab50e-e68a-4b14-83a9-409f09a40847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3ce3e8fc-6d60-40da-ae41-542ba850c5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c985318c-49a5-49d1-bcad-4267d7e16082" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3ce3e8fc-6d60-40da-ae41-542ba850c5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_188e83da-56f8-42d7-9a62-154da02a698d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bb8bcae3-042a-48de-931b-5675cefcec61" xlink:to="loc_us-gaap_StatementLineItems_188e83da-56f8-42d7-9a62-154da02a698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_188e83da-56f8-42d7-9a62-154da02a698d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f557af01-45d4-438f-b851-e2af57faff85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f557af01-45d4-438f-b851-e2af57faff85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36c6f360-4d54-483b-a649-e793ee71653f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockholdersEquity_36c6f360-4d54-483b-a649-e793ee71653f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9e2bb3f-79a9-45e8-8e80-4028bc5e2dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9e2bb3f-79a9-45e8-8e80-4028bc5e2dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad06fd53-7397-448e-8254-157eb9e434e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad06fd53-7397-448e-8254-157eb9e434e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_b5729420-1926-4b0d-80a8-b7d31ee444ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_b5729420-1926-4b0d-80a8-b7d31ee444ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_694d4f56-4c41-4b77-8204-eace57a87521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_694d4f56-4c41-4b77-8204-eace57a87521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7b4eb712-a3a8-4284-999c-46b292565ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7b4eb712-a3a8-4284-999c-46b292565ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3ddba568-d1f7-4b7e-8924-bd687633f234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3ddba568-d1f7-4b7e-8924-bd687633f234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f5ace83-b0e2-49e2-a3e7-47800db44cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_NetIncomeLoss_8f5ace83-b0e2-49e2-a3e7-47800db44cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_40b64036-bd88-4aac-80f0-490ed98a5d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_40b64036-bd88-4aac-80f0-490ed98a5d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c0e9edff-fe0b-4210-ac75-ca47fdf26b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c0e9edff-fe0b-4210-ac75-ca47fdf26b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5c15453e-2cf3-4283-ae23-88b8703df849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f62794-a6db-47cb-bca3-d29992694d40" xlink:to="loc_us-gaap_StockholdersEquity_5c15453e-2cf3-4283-ae23-88b8703df849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="allo-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdf3b0fe-c954-4f70-bbdc-2b11c67b2819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdf3b0fe-c954-4f70-bbdc-2b11c67b2819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_585dd187-77d5-493d-8a50-967fb89237ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdf3b0fe-c954-4f70-bbdc-2b11c67b2819" xlink:to="loc_us-gaap_ProfitLoss_585dd187-77d5-493d-8a50-967fb89237ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9568bdc1-2255-407d-a952-4dbc8a9d3830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9568bdc1-2255-407d-a952-4dbc8a9d3830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0ddfd4bb-09b7-4639-a249-3448dcca1cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9568bdc1-2255-407d-a952-4dbc8a9d3830" xlink:to="loc_us-gaap_ShareBasedCompensation_0ddfd4bb-09b7-4639-a249-3448dcca1cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_10a2037a-6b10-43cc-9ef1-846396b94734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9568bdc1-2255-407d-a952-4dbc8a9d3830" xlink:to="loc_us-gaap_Depreciation_10a2037a-6b10-43cc-9ef1-846396b94734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_86df2e5e-c66e-446a-a77f-9f59d2d85f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9568bdc1-2255-407d-a952-4dbc8a9d3830" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_86df2e5e-c66e-446a-a77f-9f59d2d85f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_4d12774e-fc02-4848-8542-62f5d4a42724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9568bdc1-2255-407d-a952-4dbc8a9d3830" xlink:to="loc_us-gaap_OperatingLeaseExpense_4d12774e-fc02-4848-8542-62f5d4a42724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_7fb30a92-e46b-461e-b6cd-a764b13bae1e" xlink:href="allo-20220930.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9568bdc1-2255-407d-a952-4dbc8a9d3830" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_7fb30a92-e46b-461e-b6cd-a764b13bae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d050fea-b0ba-4e69-8f70-15b0344ddd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9568bdc1-2255-407d-a952-4dbc8a9d3830" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d050fea-b0ba-4e69-8f70-15b0344ddd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e9600798-ce08-429a-8b34-15923b8796a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d050fea-b0ba-4e69-8f70-15b0344ddd48" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e9600798-ce08-429a-8b34-15923b8796a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8833c2af-59cd-479b-8986-3e2845944bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d050fea-b0ba-4e69-8f70-15b0344ddd48" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8833c2af-59cd-479b-8986-3e2845944bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_915bbbe2-5d2a-4635-84cb-a5530142a62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d050fea-b0ba-4e69-8f70-15b0344ddd48" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_915bbbe2-5d2a-4635-84cb-a5530142a62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9e18895c-4992-4193-9a2f-d983ef4a1575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d050fea-b0ba-4e69-8f70-15b0344ddd48" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9e18895c-4992-4193-9a2f-d983ef4a1575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f9d4e17e-359a-4982-8b70-a86c5b7e105e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d050fea-b0ba-4e69-8f70-15b0344ddd48" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f9d4e17e-359a-4982-8b70-a86c5b7e105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_aa202c6d-60bc-48c3-a068-33877f7756c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d050fea-b0ba-4e69-8f70-15b0344ddd48" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_aa202c6d-60bc-48c3-a068-33877f7756c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0315c2e4-39f8-4a7a-8e86-aa5fcc7b676e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9568bdc1-2255-407d-a952-4dbc8a9d3830" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0315c2e4-39f8-4a7a-8e86-aa5fcc7b676e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ebff49-44fa-48bd-97df-c37869897b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ebff49-44fa-48bd-97df-c37869897b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cd96fbf2-939d-4a3c-8489-8cc113b12c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ebff49-44fa-48bd-97df-c37869897b00" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cd96fbf2-939d-4a3c-8489-8cc113b12c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8f483bfb-e363-43ee-8d35-11c1e70ec2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ebff49-44fa-48bd-97df-c37869897b00" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8f483bfb-e363-43ee-8d35-11c1e70ec2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9dc2c127-3a5c-4ca9-a46f-0fbd2fe4f3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ebff49-44fa-48bd-97df-c37869897b00" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9dc2c127-3a5c-4ca9-a46f-0fbd2fe4f3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5069b64a-fc52-413d-a270-602074a74b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ebff49-44fa-48bd-97df-c37869897b00" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5069b64a-fc52-413d-a270-602074a74b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31b95c54-c61f-4f56-856c-8d9e5f95ed13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ebff49-44fa-48bd-97df-c37869897b00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31b95c54-c61f-4f56-856c-8d9e5f95ed13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a5d89028-ec82-43b5-a07c-61bfac361772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a5d89028-ec82-43b5-a07c-61bfac361772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c11ce35e-ac64-495b-857b-a4f841050bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a5d89028-ec82-43b5-a07c-61bfac361772" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c11ce35e-ac64-495b-857b-a4f841050bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_208dd750-9f5b-46d5-86f2-28257957097a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a5d89028-ec82-43b5-a07c-61bfac361772" xlink:to="loc_us-gaap_ProceedsFromStockPlans_208dd750-9f5b-46d5-86f2-28257957097a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f27f1ff4-f427-47aa-8156-9578b0130d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a5d89028-ec82-43b5-a07c-61bfac361772" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f27f1ff4-f427-47aa-8156-9578b0130d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2f80c34c-82e0-4c7f-8dbf-de294277c989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2f80c34c-82e0-4c7f-8dbf-de294277c989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_228a677c-1dd6-4bcf-bcb6-fbd6d302221a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_228a677c-1dd6-4bcf-bcb6-fbd6d302221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a680e31f-c89a-4a51-9e97-d239c169c5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a680e31f-c89a-4a51-9e97-d239c169c5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2f7a48d1-607b-4bb4-aeb2-61340578ac57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2f7a48d1-607b-4bb4-aeb2-61340578ac57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a3d1300c-7b8b-4e06-a263-5a8748204b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2f7a48d1-607b-4bb4-aeb2-61340578ac57" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a3d1300c-7b8b-4e06-a263-5a8748204b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_38ee0257-5d4d-436f-becd-1efa4bc0a422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3c4bd3d9-01f6-4a79-9bdb-9c7a1a80fb29" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_38ee0257-5d4d-436f-becd-1efa4bc0a422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_b5847a67-6f96-4310-a386-67875209917d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_38ee0257-5d4d-436f-becd-1efa4bc0a422" xlink:to="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_b5847a67-6f96-4310-a386-67875209917d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_9bc6ea94-4bf3-4454-871a-5b03d4ed6031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_38ee0257-5d4d-436f-becd-1efa4bc0a422" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_9bc6ea94-4bf3-4454-871a-5b03d4ed6031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="allo-20220930.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0ea323b9-145e-43cf-a64b-9b6fc78fd95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_107ff14d-e1d2-4886-98e8-fa176b786301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0ea323b9-145e-43cf-a64b-9b6fc78fd95e" xlink:to="loc_us-gaap_NatureOfOperations_107ff14d-e1d2-4886-98e8-fa176b786301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cf54cc51-a8f6-408e-a6c8-45d474e2bb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_22a8ea46-55e5-4cd5-b231-5b46b7f0105c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf54cc51-a8f6-408e-a6c8-45d474e2bb36" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_22a8ea46-55e5-4cd5-b231-5b46b7f0105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4efba553-8307-4690-a818-fc9351c7fe2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_976aaf4e-768a-4705-b000-5b744e167f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4efba553-8307-4690-a818-fc9351c7fe2a" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_976aaf4e-768a-4705-b000-5b744e167f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:type="simple" xlink:href="allo-20220930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_83462c30-2887-438e-91e3-d168ae272da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_96b70fa7-e3ff-4dad-9e7b-c84ea25f43f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_83462c30-2887-438e-91e3-d168ae272da9" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_96b70fa7-e3ff-4dad-9e7b-c84ea25f43f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="allo-20220930.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ae62f7c-fcd8-4238-998d-f2bfa0c1f20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a2e9e166-e2c4-4dc4-9e5c-d4986f3f0ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ae62f7c-fcd8-4238-998d-f2bfa0c1f20f" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a2e9e166-e2c4-4dc4-9e5c-d4986f3f0ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="allo-20220930.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_7048dd34-6732-4fbb-8ee9-3a4238b6e755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAgreementsTextBlock_143fe202-dbb6-4687-b6f9-b3ae15d78723" xlink:href="allo-20220930.xsd#allo_LicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7048dd34-6732-4fbb-8ee9-3a4238b6e755" xlink:to="loc_allo_LicenseAgreementsTextBlock_143fe202-dbb6-4687-b6f9-b3ae15d78723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa6a3d9b-dc1e-4144-979b-ab08c9fa8510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c76aeff8-35ad-4dd7-9b26-3168ca6f56d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa6a3d9b-dc1e-4144-979b-ab08c9fa8510" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c76aeff8-35ad-4dd7-9b26-3168ca6f56d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestments" xlink:type="simple" xlink:href="allo-20220930.xsd#EquityMethodInvestments"/>
  <link:presentationLink xlink:role="http://allogene.com/role/EquityMethodInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d2c9ebde-7357-45c1-b2b2-fb88a4f79aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_540b1196-1b11-43aa-b9fb-0109a3d61a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d2c9ebde-7357-45c1-b2b2-fb88a4f79aa5" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_540b1196-1b11-43aa-b9fb-0109a3d61a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21399ce6-b5c8-49f7-b298-7a60168a2f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1f9ab5aa-b7d7-4063-8b21-00b84478c0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21399ce6-b5c8-49f7-b298-7a60168a2f89" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1f9ab5aa-b7d7-4063-8b21-00b84478c0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20220930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_51d55b2d-ec3b-4290-b3d1-7126213921f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_781bf85c-2225-4755-b00a-8a955783b699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_51d55b2d-ec3b-4290-b3d1-7126213921f1" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_781bf85c-2225-4755-b00a-8a955783b699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ffb3d80d-85e9-48a7-93a4-7472d017c256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_fb4cb064-6f7e-4a47-8a98-c61cbdfa46c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ffb3d80d-85e9-48a7-93a4-7472d017c256" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_fb4cb064-6f7e-4a47-8a98-c61cbdfa46c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:type="simple" xlink:href="allo-20220930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a2397bde-792d-4933-9df7-71e1bdcbc289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c9f8fd01-be28-47f1-9aca-6efb46d2275d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2397bde-792d-4933-9df7-71e1bdcbc289" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c9f8fd01-be28-47f1-9aca-6efb46d2275d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_13d8cdd9-2052-4659-92f7-5d4ba96cc8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_a8206d35-8247-472b-a3fb-0fe7f6db55cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_13d8cdd9-2052-4659-92f7-5d4ba96cc8a0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_a8206d35-8247-472b-a3fb-0fe7f6db55cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20220930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d97c0c94-2d8d-4e29-9e43-db860df91bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56173067-7048-4298-b5fd-60341b7b9562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d97c0c94-2d8d-4e29-9e43-db860df91bf1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56173067-7048-4298-b5fd-60341b7b9562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4c21b4a5-c5aa-48f3-8518-e612050094fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d97c0c94-2d8d-4e29-9e43-db860df91bf1" xlink:to="loc_us-gaap_UseOfEstimates_4c21b4a5-c5aa-48f3-8518-e612050094fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_ca1465bd-516e-4405-b749-8f88aab005bf" xlink:href="allo-20220930.xsd#allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d97c0c94-2d8d-4e29-9e43-db860df91bf1" xlink:to="loc_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_ca1465bd-516e-4405-b749-8f88aab005bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8a430edb-1e72-46f5-9435-b1d424909d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d97c0c94-2d8d-4e29-9e43-db860df91bf1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8a430edb-1e72-46f5-9435-b1d424909d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aa7c0fe9-cb2b-4784-967d-61ccc041a6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4152466e-ed3e-4ead-bd3b-44f6ae8d1430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aa7c0fe9-cb2b-4784-967d-61ccc041a6c5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4152466e-ed3e-4ead-bd3b-44f6ae8d1430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="allo-20220930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6f96abf1-167d-49ad-b89b-fabd4a1b0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8819e4a2-5b09-4d9b-8135-13a791f1cb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6f96abf1-167d-49ad-b89b-fabd4a1b0ffd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8819e4a2-5b09-4d9b-8135-13a791f1cb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="allo-20220930.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2c25801-0be5-494b-969e-bc51a8092f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9c612d00-9fca-48e6-a8ba-19b1c6432eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2c25801-0be5-494b-969e-bc51a8092f88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9c612d00-9fca-48e6-a8ba-19b1c6432eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6da0fd86-b1b7-4c18-8724-a50a3c7e781a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LiabilitiesLesseeTableTextBlock_422f07ee-648a-40a6-9505-4ca4c9d62145" xlink:href="allo-20220930.xsd#allo_LiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6da0fd86-b1b7-4c18-8724-a50a3c7e781a" xlink:to="loc_allo_LiabilitiesLesseeTableTextBlock_422f07ee-648a-40a6-9505-4ca4c9d62145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2cbba4ec-a062-40dc-931a-23626dd120ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6da0fd86-b1b7-4c18-8724-a50a3c7e781a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2cbba4ec-a062-40dc-931a-23626dd120ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d50c0786-484a-4e3a-9fbd-a1cf5a3459cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6da0fd86-b1b7-4c18-8724-a50a3c7e781a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d50c0786-484a-4e3a-9fbd-a1cf5a3459cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21d5f21f-123e-4f73-9235-cbfb4a85da12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_86f1dd30-26a7-4367-8ef4-4298e94fc433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21d5f21f-123e-4f73-9235-cbfb4a85da12" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_86f1dd30-26a7-4367-8ef4-4298e94fc433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4a3314db-4ead-4f47-9963-ceeef539060a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21d5f21f-123e-4f73-9235-cbfb4a85da12" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4a3314db-4ead-4f47-9963-ceeef539060a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_427f138c-4c39-4b76-bf9f-890f87c0a77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21d5f21f-123e-4f73-9235-cbfb4a85da12" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_427f138c-4c39-4b76-bf9f-890f87c0a77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_934c772b-9a34-4d09-8545-51f7ed9cf04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21d5f21f-123e-4f73-9235-cbfb4a85da12" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_934c772b-9a34-4d09-8545-51f7ed9cf04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="allo-20220930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_077512d3-19e8-4ede-b856-6cd051732ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c32c92bb-d163-4018-ac0d-f09543b6ce74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_077512d3-19e8-4ede-b856-6cd051732ac2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c32c92bb-d163-4018-ac0d-f09543b6ce74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_905be2d5-d39c-452f-905f-0b40b5e01c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_52e95722-3adf-42df-b6f1-9e95d3c2d234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_905be2d5-d39c-452f-905f-0b40b5e01c34" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_52e95722-3adf-42df-b6f1-9e95d3c2d234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4cdba065-c08d-4383-bdde-fff320a14017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_905be2d5-d39c-452f-905f-0b40b5e01c34" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4cdba065-c08d-4383-bdde-fff320a14017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20220930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cab2ba9e-66df-4ab9-8c83-b3bdd6df4275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f13d6f36-ae16-462f-9bb8-0513d6b9ba05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cab2ba9e-66df-4ab9-8c83-b3bdd6df4275" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f13d6f36-ae16-462f-9bb8-0513d6b9ba05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_58ab95e8-57ae-42e5-8598-a657b4bc6619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f13d6f36-ae16-462f-9bb8-0513d6b9ba05" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_58ab95e8-57ae-42e5-8598-a657b4bc6619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc46eaa1-d02f-49ac-a413-995dae599b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_58ab95e8-57ae-42e5-8598-a657b4bc6619" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc46eaa1-d02f-49ac-a413-995dae599b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c9e5d632-4f55-45ca-9e45-2fe71372836d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc46eaa1-d02f-49ac-a413-995dae599b4d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c9e5d632-4f55-45ca-9e45-2fe71372836d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6455bae8-09c8-4d84-8c20-658f30162a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f13d6f36-ae16-462f-9bb8-0513d6b9ba05" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6455bae8-09c8-4d84-8c20-658f30162a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e0abd6c-0300-4078-acad-afba198480e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6455bae8-09c8-4d84-8c20-658f30162a33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e0abd6c-0300-4078-acad-afba198480e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_153b293e-5d5b-4016-a3e5-8c3ab60a0b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e0abd6c-0300-4078-acad-afba198480e6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_153b293e-5d5b-4016-a3e5-8c3ab60a0b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68295e4b-ea16-450c-9431-7475a31190a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f13d6f36-ae16-462f-9bb8-0513d6b9ba05" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68295e4b-ea16-450c-9431-7475a31190a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b9ce8c99-920a-431b-97d4-400e302bb347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68295e4b-ea16-450c-9431-7475a31190a4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b9ce8c99-920a-431b-97d4-400e302bb347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_264ded88-2ff1-43f0-b272-419b5e2ca5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68295e4b-ea16-450c-9431-7475a31190a4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_264ded88-2ff1-43f0-b272-419b5e2ca5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="allo-20220930.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_330cf468-7543-4c7b-a101-1b5fdd9f3330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_330cf468-7543-4c7b-a101-1b5fdd9f3330" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63dc1980-a058-4981-90b3-d21f204ce3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63dc1980-a058-4981-90b3-d21f204ce3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f142bf1-818e-4653-9fee-97c025c52d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63dc1980-a058-4981-90b3-d21f204ce3c9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f142bf1-818e-4653-9fee-97c025c52d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_768afa1a-c920-445b-a027-b5756679e14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f142bf1-818e-4653-9fee-97c025c52d78" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_768afa1a-c920-445b-a027-b5756679e14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d750f10-dc39-4a12-ab63-0cd3a00b1c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d750f10-dc39-4a12-ab63-0cd3a00b1c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d750f10-dc39-4a12-ab63-0cd3a00b1c75" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b4ed4ad3-0dfb-4d65-862f-ccdbf53added" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b4ed4ad3-0dfb-4d65-862f-ccdbf53added" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_71d1c05a-95dd-4c19-9da0-3ef42ac2eca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_71d1c05a-95dd-4c19-9da0-3ef42ac2eca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8d38e679-19bd-41a6-b58c-51812207e160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30e79f33-f7d1-4f80-a391-e346e978ce79" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8d38e679-19bd-41a6-b58c-51812207e160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_bc2c425d-7e88-4f5a-aa42-559014b5b87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_bc2c425d-7e88-4f5a-aa42-559014b5b87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_bc2c425d-7e88-4f5a-aa42-559014b5b87d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f555a545-3421-4491-898c-6c6a22e5c0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f555a545-3421-4491-898c-6c6a22e5c0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6b66ca91-5197-44c8-ba50-955d69be3299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_CommercialPaperMember_6b66ca91-5197-44c8-ba50-955d69be3299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_b5350546-1087-435d-acf5-d3304bc23623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_b5350546-1087-435d-acf5-d3304bc23623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0b7becb9-d965-452c-9a5d-6e54b7fe638d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0b7becb9-d965-452c-9a5d-6e54b7fe638d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fc6f7bfe-e6c0-48ca-9821-0fd2feb285b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f692435-216f-4a22-9b4f-a4ff9219e3c4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fc6f7bfe-e6c0-48ca-9821-0fd2feb285b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_01a4f66e-8341-448b-af01-125696165244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_efea55ff-ed31-496c-9e2a-95387cac7a45" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_01a4f66e-8341-448b-af01-125696165244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0dd9e4d8-e090-47dd-bfdb-f27133c74b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_01a4f66e-8341-448b-af01-125696165244" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0dd9e4d8-e090-47dd-bfdb-f27133c74b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_48795462-6e52-4805-be8e-465b01856d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_76094200-73b9-4ec3-b2e7-7baeb6cf1718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_48795462-6e52-4805-be8e-465b01856d7b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_76094200-73b9-4ec3-b2e7-7baeb6cf1718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_42acc2ec-dcdb-4350-baa5-e6d4ac24374c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_76094200-73b9-4ec3-b2e7-7baeb6cf1718" xlink:to="loc_us-gaap_FinancialInstrumentAxis_42acc2ec-dcdb-4350-baa5-e6d4ac24374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_42acc2ec-dcdb-4350-baa5-e6d4ac24374c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2edd0197-a81b-4bc4-acdf-2ac5c63cc8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2edd0197-a81b-4bc4-acdf-2ac5c63cc8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_08cbf6ad-b235-4f60-b12d-0836c7b6a844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_CommercialPaperMember_08cbf6ad-b235-4f60-b12d-0836c7b6a844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ad700f20-c03b-4bf1-a3de-676b09d01e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ad700f20-c03b-4bf1-a3de-676b09d01e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d7bc7fc1-067a-447c-beed-fab1fc90fa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d7bc7fc1-067a-447c-beed-fab1fc90fa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_50cf6cde-3a76-4462-a045-830db9d351c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c216abe2-2cb4-426b-959c-10adaa4f5cae" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_50cf6cde-3a76-4462-a045-830db9d351c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_76094200-73b9-4ec3-b2e7-7baeb6cf1718" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_32065377-40b8-4f11-8053-52417fd51bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_32065377-40b8-4f11-8053-52417fd51bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d2afe14b-5899-424a-a1d3-366c42bf3601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d2afe14b-5899-424a-a1d3-366c42bf3601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e3248754-7d9e-4349-9b3c-cbd3aa73587f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e3248754-7d9e-4349-9b3c-cbd3aa73587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b292ff2b-bb79-4301-9cb2-b3e7aa294851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b292ff2b-bb79-4301-9cb2-b3e7aa294851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_de052570-80f2-479f-8c19-b7743ebf89e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_de052570-80f2-479f-8c19-b7743ebf89e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d39eb2b1-15d6-4f44-b461-6fa89594303d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d39eb2b1-15d6-4f44-b461-6fa89594303d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6b3a63d7-48be-4a99-8ded-c70f16626c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6b3a63d7-48be-4a99-8ded-c70f16626c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_70d00c17-ea2b-4d63-98c1-cab83334895d" xlink:href="allo-20220930.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d94371aa-e1d7-4d8a-a9ef-942ca20ec9ac" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_70d00c17-ea2b-4d63-98c1-cab83334895d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e74207ff-e5cc-4def-929a-baa2bb2200c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_1dc38179-4d2d-4051-9218-7d08fdd723ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e74207ff-e5cc-4def-929a-baa2bb2200c4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_1dc38179-4d2d-4051-9218-7d08fdd723ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1356fc66-167f-4c8b-b748-85bb6fe4cf60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e74207ff-e5cc-4def-929a-baa2bb2200c4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1356fc66-167f-4c8b-b748-85bb6fe4cf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_0eca636d-88da-4a07-8145-fa701e4b261c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e74207ff-e5cc-4def-929a-baa2bb2200c4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_0eca636d-88da-4a07-8145-fa701e4b261c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#BalanceSheetComponentsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fa95f29a-6d0c-4152-b540-f89a9e427cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_502f8520-0c71-4632-a624-3b594f10759f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fa95f29a-6d0c-4152-b540-f89a9e427cdd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_502f8520-0c71-4632-a624-3b594f10759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_608cfd72-9809-4562-ba62-bb6b235fbe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_502f8520-0c71-4632-a624-3b594f10759f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_608cfd72-9809-4562-ba62-bb6b235fbe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_608cfd72-9809-4562-ba62-bb6b235fbe3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d1858c6b-04bf-4a43-a0ec-f695ac0aa707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d1858c6b-04bf-4a43-a0ec-f695ac0aa707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_f8e0036d-399d-41ea-bf57-a7b83b446097" xlink:href="allo-20220930.xsd#allo_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_allo_LaboratoryEquipmentMember_f8e0036d-399d-41ea-bf57-a7b83b446097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_24e83747-86b3-4e97-a800-f02b9978f9f6" xlink:href="allo-20220930.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_24e83747-86b3-4e97-a800-f02b9978f9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8e9e4a83-b6b0-4320-8320-775a43a9d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8e9e4a83-b6b0-4320-8320-775a43a9d33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_86650964-ee1f-4004-a600-6cda226e9220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88bc7643-15c8-4b00-ab21-5108b47299a4" xlink:to="loc_us-gaap_ConstructionInProgressMember_86650964-ee1f-4004-a600-6cda226e9220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_502f8520-0c71-4632-a624-3b594f10759f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fd38a7bd-6444-489d-a3e1-ae67a4cdac48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fd38a7bd-6444-489d-a3e1-ae67a4cdac48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f922d0f4-3c38-4b41-a8cc-fe452181a6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f922d0f4-3c38-4b41-a8cc-fe452181a6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9516d247-6f7d-4913-9baa-667ff3fa3cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_eecd3d64-a21f-4599-bdf8-ea76ac06dd0f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9516d247-6f7d-4913-9baa-667ff3fa3cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#LicenseandCollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_2beb7242-0298-48f7-97f9-e69f90c9d498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_2beb7242-0298-48f7-97f9-e69f90c9d498" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eff0adc7-5507-4314-b681-219ceb5fdd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eff0adc7-5507-4314-b681-219ceb5fdd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eff0adc7-5507-4314-b681-219ceb5fdd88" xlink:to="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_2742bef6-24ef-48f5-9a69-d0cfe833582b" xlink:href="allo-20220930.xsd#allo_PfizerIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:to="loc_allo_PfizerIncMember_2742bef6-24ef-48f5-9a69-d0cfe833582b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember_c820e3fb-31a7-415b-9d3d-d6d81b14b213" xlink:href="allo-20220930.xsd#allo_CellectisSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:to="loc_allo_CellectisSAMember_c820e3fb-31a7-415b-9d3d-d6d81b14b213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember_e1534e22-2a3d-46b3-b582-076e28c7e2d4" xlink:href="allo-20220930.xsd#allo_ServierMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:to="loc_allo_ServierMember_e1534e22-2a3d-46b3-b582-076e28c7e2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_5e2412eb-c2ba-464a-89a7-7c52ae4988be" xlink:href="allo-20220930.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c4b2d747-c3a1-4450-9f08-60d64dab2720" xlink:to="loc_allo_NotchTherapeuticsIncMember_5e2412eb-c2ba-464a-89a7-7c52ae4988be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeAxis_e79c5fbe-defe-4d6b-b602-33a8981a7b33" xlink:href="allo-20220930.xsd#allo_MilestoneTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_allo_MilestoneTypeAxis_e79c5fbe-defe-4d6b-b602-33a8981a7b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain_ab32a4ac-b36b-487f-a872-9ef917e80510" xlink:href="allo-20220930.xsd#allo_MilestoneTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeAxis_e79c5fbe-defe-4d6b-b602-33a8981a7b33" xlink:to="loc_allo_MilestoneTypeDomain_ab32a4ac-b36b-487f-a872-9ef917e80510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DevelopmentAndSalesMember_fab83e06-412b-475d-9646-c8b0ea2af757" xlink:href="allo-20220930.xsd#allo_DevelopmentAndSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeDomain_ab32a4ac-b36b-487f-a872-9ef917e80510" xlink:to="loc_allo_DevelopmentAndSalesMember_fab83e06-412b-475d-9646-c8b0ea2af757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_dd86367a-4462-4249-81e5-1f0aaa48f9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_dd86367a-4462-4249-81e5-1f0aaa48f9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_dd86367a-4462-4249-81e5-1f0aaa48f9a0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_b4822502-18ef-4d33-b657-54c1e0a71193" xlink:href="allo-20220930.xsd#allo_AssetContributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_AssetContributionAgreementMember_b4822502-18ef-4d33-b657-54c1e0a71193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember_6c2293ea-dd3c-4cce-b5db-286074480b79" xlink:href="allo-20220930.xsd#allo_RegulatoryMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_RegulatoryMilestoneMember_6c2293ea-dd3c-4cce-b5db-286074480b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember_4a51e26f-0795-4be3-8353-7f41c381a8b8" xlink:href="allo-20220930.xsd#allo_SalesMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_SalesMilestoneMember_4a51e26f-0795-4be3-8353-7f41c381a8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_23620a27-32c9-4a64-8e5a-c2eb98d28a1e" xlink:href="allo-20220930.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_23620a27-32c9-4a64-8e5a-c2eb98d28a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_3b2b79ba-735d-4980-b754-69191df6fca8" xlink:href="allo-20220930.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_377d51e9-84a8-4afb-bd0e-d307b36e9b88" xlink:to="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_3b2b79ba-735d-4980-b754-69191df6fca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2cf20ae9-5660-411c-9263-988a2ec75af1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_srt_RangeAxis_2cf20ae9-5660-411c-9263-988a2ec75af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0807ae67-9719-4457-9b23-0a90e611a6e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2cf20ae9-5660-411c-9263-988a2ec75af1" xlink:to="loc_srt_RangeMember_0807ae67-9719-4457-9b23-0a90e611a6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aad69618-b0e5-4754-80cf-5550ed84fdd2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0807ae67-9719-4457-9b23-0a90e611a6e1" xlink:to="loc_srt_MinimumMember_aad69618-b0e5-4754-80cf-5550ed84fdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f11ea37c-6d75-4d4f-9dc0-867f32225ef5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0807ae67-9719-4457-9b23-0a90e611a6e1" xlink:to="loc_srt_MaximumMember_f11ea37c-6d75-4d4f-9dc0-867f32225ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8cf13146-ef3c-4bc2-b449-9df39ad12903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8cf13146-ef3c-4bc2-b449-9df39ad12903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8cf13146-ef3c-4bc2-b449-9df39ad12903" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_9a7e926a-96b9-4fd3-ac8d-4da71638a588" xlink:href="allo-20220930.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_9a7e926a-96b9-4fd3-ac8d-4da71638a588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_58bba4e3-a401-416a-9798-95e644a4b966" xlink:href="allo-20220930.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_58bba4e3-a401-416a-9798-95e644a4b966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_e29ec54c-6819-4862-8518-2d5eb68a9b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_us-gaap_CorporateJointVentureMember_e29ec54c-6819-4862-8518-2d5eb68a9b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntionCollaborationAgreementMember_e2f0c6ee-3d41-4537-ad2e-3c5769624089" xlink:href="allo-20220930.xsd#allo_AntionCollaborationAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_AntionCollaborationAgreementMember_e2f0c6ee-3d41-4537-ad2e-3c5769624089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntionCollaborationAgreementMilestoneAchievementOneMember_0097cd01-b29e-4e9c-85d0-84a45aa01011" xlink:href="allo-20220930.xsd#allo_AntionCollaborationAgreementMilestoneAchievementOneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_AntionCollaborationAgreementMilestoneAchievementOneMember_0097cd01-b29e-4e9c-85d0-84a45aa01011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember_9cda867f-3473-4aaf-9fa1-e41d6f888afb" xlink:href="allo-20220930.xsd#allo_AntionCollaborationAgreementMilestoneAchievementTwoMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4bc7242-00dc-49fa-8016-c40444ad9103" xlink:to="loc_allo_AntionCollaborationAgreementMilestoneAchievementTwoMember_9cda867f-3473-4aaf-9fa1-e41d6f888afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_69bbb273-10fa-40f1-8ef3-c40bc4e1f414" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_69bbb273-10fa-40f1-8ef3-c40bc4e1f414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ab50f8d2-563e-4727-99ce-439c5d9a762b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_69bbb273-10fa-40f1-8ef3-c40bc4e1f414" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ab50f8d2-563e-4727-99ce-439c5d9a762b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_17107611-5134-4206-a755-0e7c04b87658" xlink:href="allo-20220930.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ab50f8d2-563e-4727-99ce-439c5d9a762b" xlink:to="loc_allo_NotchTherapeuticsIncMember_17107611-5134-4206-a755-0e7c04b87658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember_d3b6d7a6-1633-4d0c-ac0d-962b38731fb2" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ab50f8d2-563e-4727-99ce-439c5d9a762b" xlink:to="loc_allo_AllogeneOverlandMember_d3b6d7a6-1633-4d0c-ac0d-962b38731fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a0088986-394a-445a-b4c9-305f32c91f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a0088986-394a-445a-b4c9-305f32c91f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c1b295d3-2ab2-4103-8cde-a703665b5aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a0088986-394a-445a-b4c9-305f32c91f97" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c1b295d3-2ab2-4103-8cde-a703665b5aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c0bacf85-65c4-4ecd-a4d6-f415e4856ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c1b295d3-2ab2-4103-8cde-a703665b5aec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c0bacf85-65c4-4ecd-a4d6-f415e4856ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2ddc8d05-eab8-4b99-9b33-d1706fb6b6eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_srt_CounterpartyNameAxis_2ddc8d05-eab8-4b99-9b33-d1706fb6b6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2ddc8d05-eab8-4b99-9b33-d1706fb6b6eb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember_5b11fe35-51c6-4ffb-b8d8-fd338694ab08" xlink:href="allo-20220930.xsd#allo_UniversityOfTexasMDAndersonCancerCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:to="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember_5b11fe35-51c6-4ffb-b8d8-fd338694ab08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember_5cadaac8-50af-4cca-ab8e-e62125ff79c8" xlink:href="allo-20220930.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:to="loc_allo_OverlandPharmaceuticalsIncMember_5cadaac8-50af-4cca-ab8e-e62125ff79c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_de8e8154-8cd1-46f3-8d6b-1f657280d006" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4874f632-4900-455f-ae0c-d0b3c5f15833" xlink:to="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_de8e8154-8cd1-46f3-8d6b-1f657280d006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2370f734-fa97-4cce-b087-ca39a446823c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_dei_LegalEntityAxis_2370f734-fa97-4cce-b087-ca39a446823c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_dc7553e2-aa4e-49ba-b482-aaedf6684a2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2370f734-fa97-4cce-b087-ca39a446823c" xlink:to="loc_dei_EntityDomain_dc7553e2-aa4e-49ba-b482-aaedf6684a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember_580226fa-cb5b-4eba-9330-2bfc1d06098b" xlink:href="allo-20220930.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_dc7553e2-aa4e-49ba-b482-aaedf6684a2b" xlink:to="loc_allo_OverlandPharmaceuticalsIncMember_580226fa-cb5b-4eba-9330-2bfc1d06098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis_7a80c562-8c98-43dd-a180-99706e0e9db8" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_allo_EquityInvestmentBasisAxis_7a80c562-8c98-43dd-a180-99706e0e9db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_2dbd25ef-6e4b-4997-87cf-f6a6ac22c938" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_EquityInvestmentBasisAxis_7a80c562-8c98-43dd-a180-99706e0e9db8" xlink:to="loc_allo_EquityInvestmentBasisDomain_2dbd25ef-6e4b-4997-87cf-f6a6ac22c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember_b9d426c4-dbd5-4320-b85a-8c474a29f6c7" xlink:href="allo-20220930.xsd#allo_VotingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_EquityInvestmentBasisDomain_2dbd25ef-6e4b-4997-87cf-f6a6ac22c938" xlink:to="loc_allo_VotingInterestMember_b9d426c4-dbd5-4320-b85a-8c474a29f6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73f4dc36-fd75-479a-8135-3619bdea279e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73f4dc36-fd75-479a-8135-3619bdea279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45996788-3c5d-43d1-a8f4-63e2db40d0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73f4dc36-fd75-479a-8135-3619bdea279e" xlink:to="loc_us-gaap_ClassOfStockDomain_45996788-3c5d-43d1-a8f4-63e2db40d0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_5fcafefe-4c60-4e62-80a9-129813556336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45996788-3c5d-43d1-a8f4-63e2db40d0b9" xlink:to="loc_us-gaap_PreferredStockMember_5fcafefe-4c60-4e62-80a9-129813556336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_57bfb3b1-db72-47bf-9606-f7a921e63a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_57bfb3b1-db72-47bf-9606-f7a921e63a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_36820f46-5cc1-4adc-bb47-56602b41c9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_57bfb3b1-db72-47bf-9606-f7a921e63a7e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_36820f46-5cc1-4adc-bb47-56602b41c9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CurrentAccruedAndOtherLiabilitiesMember_9a71d276-7746-4938-b05d-f683ee3b6af6" xlink:href="allo-20220930.xsd#allo_CurrentAccruedAndOtherLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_36820f46-5cc1-4adc-bb47-56602b41c9fc" xlink:to="loc_allo_CurrentAccruedAndOtherLiabilitiesMember_9a71d276-7746-4938-b05d-f683ee3b6af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d93bdbbf-f431-4696-944e-e982c1f6c438" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_654a814d-87a7-4ad6-b94d-d141a2e81d8a" xlink:href="allo-20220930.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_AggregatePotentialMilestonePayments_654a814d-87a7-4ad6-b94d-d141a2e81d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_8904430d-53fc-4119-856b-b5dc733ddb35" xlink:href="allo-20220930.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_8904430d-53fc-4119-856b-b5dc733ddb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_4c285cb2-3816-400b-b830-0e180c25626d" xlink:href="allo-20220930.xsd#allo_MilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_MilestonePayments_4c285cb2-3816-400b-b830-0e180c25626d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_6ca8a2b5-f8a9-4e88-a9be-68cb6cee62d0" xlink:href="allo-20220930.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_6ca8a2b5-f8a9-4e88-a9be-68cb6cee62d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_5412fe35-3ea9-4295-85f5-e82bc34ad417" xlink:href="allo-20220930.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_5412fe35-3ea9-4295-85f5-e82bc34ad417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6944be5e-e2b5-4391-8045-b3bf3d725742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6944be5e-e2b5-4391-8045-b3bf3d725742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_c5935c21-ba7c-44ac-a7f0-289ab5cc47e9" xlink:href="allo-20220930.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_c5935c21-ba7c-44ac-a7f0-289ab5cc47e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_e64593b1-20ae-4f3e-ac76-b1c2ae8aee8c" xlink:href="allo-20220930.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_e64593b1-20ae-4f3e-ac76-b1c2ae8aee8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable_fa8f91cd-5d88-4f84-8eb8-4be6565e1a84" xlink:href="allo-20220930.xsd#allo_AggregatePotentialMilestoneReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_AggregatePotentialMilestoneReceivable_fa8f91cd-5d88-4f84-8eb8-4be6565e1a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_67e26a23-15d1-4d43-92a8-0b1370fb6821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_67e26a23-15d1-4d43-92a8-0b1370fb6821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_f43cd47e-6931-4999-a026-c715d7564bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_DueFromRelatedParties_f43cd47e-6931-4999-a026-c715d7564bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment_21bfb7e1-45e7-421e-97da-f8da09f1aa31" xlink:href="allo-20220930.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_CollaborationAgreementUpfrontPayment_21bfb7e1-45e7-421e-97da-f8da09f1aa31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d0f9499e-caf1-4484-be42-5d84edaaa72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d0f9499e-caf1-4484-be42-5d84edaaa72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_62977d4e-32c5-4bc4-a952-475cfc3838db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_62977d4e-32c5-4bc4-a952-475cfc3838db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7ef0f0dd-b6da-4460-825c-67af8daff735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7ef0f0dd-b6da-4460-825c-67af8daff735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable_ff2e2e45-37d5-4a29-b51b-7b30d6b31d7e" xlink:href="allo-20220930.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_AggregatePotentialMilestonePayable_ff2e2e45-37d5-4a29-b51b-7b30d6b31d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationArrangementExpense_f03e3585-e68b-4bff-942a-934aca891f3a" xlink:href="allo-20220930.xsd#allo_CollaborationArrangementExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_CollaborationArrangementExpense_f03e3585-e68b-4bff-942a-934aca891f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementTerm_7f8858a6-5040-41cd-8ff3-732887b18861" xlink:href="allo-20220930.xsd#allo_CollaborationAgreementTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_CollaborationAgreementTerm_7f8858a6-5040-41cd-8ff3-732887b18861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementCommittedFunding_1a75b518-d896-4818-b20f-a476df8caa65" xlink:href="allo-20220930.xsd#allo_CollaborationAgreementCommittedFunding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_CollaborationAgreementCommittedFunding_1a75b518-d896-4818-b20f-a476df8caa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UpfrontAndQuarterlyCashPayments_e887c873-b15f-48cd-9ae4-3b92400b1e33" xlink:href="allo-20220930.xsd#allo_UpfrontAndQuarterlyCashPayments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_UpfrontAndQuarterlyCashPayments_e887c873-b15f-48cd-9ae4-3b92400b1e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_JointVentureCapitalSupportPayments_3d9dd166-629e-45dd-9fdf-516466759dd5" xlink:href="allo-20220930.xsd#allo_JointVentureCapitalSupportPayments"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_JointVentureCapitalSupportPayments_3d9dd166-629e-45dd-9fdf-516466759dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a01a086-7558-4c2b-8d4b-fb317ae8033f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a01a086-7558-4c2b-8d4b-fb317ae8033f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ReductionToResearchAndDevelopmentExpense_7588a32e-52c7-471f-9ac8-03da393a8797" xlink:href="allo-20220930.xsd#allo_ReductionToResearchAndDevelopmentExpense"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_ReductionToResearchAndDevelopmentExpense_7588a32e-52c7-471f-9ac8-03da393a8797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_767c7743-1625-426c-9007-37872cbdabc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_767c7743-1625-426c-9007-37872cbdabc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement_adb53222-ac0d-4606-a989-e02f9003bf13" xlink:href="allo-20220930.xsd#allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_509b3b66-e843-4729-b284-dc81ff32494d" xlink:to="loc_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement_adb53222-ac0d-4606-a989-e02f9003bf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa9d9d49-f9c1-4cb0-aaf6-3f51c8f44379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa9d9d49-f9c1-4cb0-aaf6-3f51c8f44379" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_36ed7a25-4247-4b89-90af-095bde352f10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:to="loc_srt_StatementGeographicalAxis_36ed7a25-4247-4b89-90af-095bde352f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_89419fdb-7405-43cb-87cb-d4adf1bb7d18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_36ed7a25-4247-4b89-90af-095bde352f10" xlink:to="loc_srt_SegmentGeographicalDomain_89419fdb-7405-43cb-87cb-d4adf1bb7d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember_ee0bf8f0-b02a-40c3-a7c6-706316e0671d" xlink:href="allo-20220930.xsd#allo_NewarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_89419fdb-7405-43cb-87cb-d4adf1bb7d18" xlink:to="loc_allo_NewarkMember_ee0bf8f0-b02a-40c3-a7c6-706316e0671d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ecec3e35-a1dd-4336-8b07-2f68f0b03241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:to="loc_us-gaap_CreditFacilityAxis_ecec3e35-a1dd-4336-8b07-2f68f0b03241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e3452542-3d61-423c-ae63-4402aed5d34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ecec3e35-a1dd-4336-8b07-2f68f0b03241" xlink:to="loc_us-gaap_CreditFacilityDomain_e3452542-3d61-423c-ae63-4402aed5d34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_8b39472f-fd72-4a8d-a09c-e9a58640dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e3452542-3d61-423c-ae63-4402aed5d34a" xlink:to="loc_us-gaap_LetterOfCreditMember_8b39472f-fd72-4a8d-a09c-e9a58640dc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_d8a19067-af6a-47bf-93ac-bc96bbbf63b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:to="loc_us-gaap_LeaseContractualTermAxis_d8a19067-af6a-47bf-93ac-bc96bbbf63b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_837caa0e-80ff-4fa4-b5ee-c3ed19faf329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_d8a19067-af6a-47bf-93ac-bc96bbbf63b4" xlink:to="loc_us-gaap_LeaseContractualTermDomain_837caa0e-80ff-4fa4-b5ee-c3ed19faf329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseOneAmendedMember_e6cda722-4ad0-4648-8ccd-0f2c9534fc9a" xlink:href="allo-20220930.xsd#allo_LeaseOneAmendedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_837caa0e-80ff-4fa4-b5ee-c3ed19faf329" xlink:to="loc_allo_LeaseOneAmendedMember_e6cda722-4ad0-4648-8ccd-0f2c9534fc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LeaseTwoMember_b0c32293-457c-436f-9972-e0e1ea4041b5" xlink:href="allo-20220930.xsd#allo_LeaseTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_837caa0e-80ff-4fa4-b5ee-c3ed19faf329" xlink:to="loc_allo_LeaseTwoMember_b0c32293-457c-436f-9972-e0e1ea4041b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dce41d44-cd57-44dd-b308-71650193e562" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_11f9ef3f-adb3-44ad-92d3-3213af896618" xlink:href="allo-20220930.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_AreaOfNewOfficeBuilding_11f9ef3f-adb3-44ad-92d3-3213af896618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_edfcfa50-264a-4110-9b98-9f2fe0dbe756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_edfcfa50-264a-4110-9b98-9f2fe0dbe756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0783af7c-4d01-4ac3-b3a4-935f7ad7b748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0783af7c-4d01-4ac3-b3a4-935f7ad7b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_4d1933fc-4773-4b14-9d8c-033ee2253f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_TenantImprovements_4d1933fc-4773-4b14-9d8c-033ee2253f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AdditionalAreaOfNewOfficeBuilding_0e8daaed-ac81-4f63-b6b5-ad0c3a6bba3e" xlink:href="allo-20220930.xsd#allo_AdditionalAreaOfNewOfficeBuilding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_AdditionalAreaOfNewOfficeBuilding_0e8daaed-ac81-4f63-b6b5-ad0c3a6bba3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowance_74049379-2b47-4772-a880-63bb5c96d86f" xlink:href="allo-20220930.xsd#allo_TenantImprovementAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_TenantImprovementAllowance_74049379-2b47-4772-a880-63bb5c96d86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOperatingLease_32df2c14-d3bf-4ed0-b33e-6ef1b2291d4d" xlink:href="allo-20220930.xsd#allo_AreaOfOperatingLease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_AreaOfOperatingLease_32df2c14-d3bf-4ed0-b33e-6ef1b2291d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfOptionsToExtendLease_ffb4be65-9dac-4ecf-b172-1aa13fae8f78" xlink:href="allo-20220930.xsd#allo_NumberOfOptionsToExtendLease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_NumberOfOptionsToExtendLease_ffb4be65-9dac-4ecf-b172-1aa13fae8f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowanceUtilizedToDate_05d1e22a-4d76-4c28-8156-ee8b3b6a5e5f" xlink:href="allo-20220930.xsd#allo_TenantImprovementAllowanceUtilizedToDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_TenantImprovementAllowanceUtilizedToDate_05d1e22a-4d76-4c28-8156-ee8b3b6a5e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0b55e255-6b80-4afc-ac26-2dea1ae73984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0b55e255-6b80-4afc-ac26-2dea1ae73984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9390f475-14aa-4059-ac0c-c767278babee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_OperatingLeasePayments_9390f475-14aa-4059-ac0c-c767278babee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_248f361d-eab9-405b-9135-edbda745f5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_248f361d-eab9-405b-9135-edbda745f5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_be8c38ae-3996-4ea1-977d-221e0f322e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_be8c38ae-3996-4ea1-977d-221e0f322e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_16c7f299-618e-40e9-b06f-dbae38a57aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_16c7f299-618e-40e9-b06f-dbae38a57aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeFinanceLeasePaymentUponContractTermination_6deb6770-f9a3-4192-aa76-60c443648153" xlink:href="allo-20220930.xsd#allo_LesseeFinanceLeasePaymentUponContractTermination"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_allo_LesseeFinanceLeasePaymentUponContractTermination_6deb6770-f9a3-4192-aa76-60c443648153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_0b639dea-5c05-4503-b4dc-03342812650b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3bcb6ceb-9e39-47e4-a06c-f7c8cc980e48" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_0b639dea-5c05-4503-b4dc-03342812650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4541b438-f3e3-4057-8ec7-833e8dfc83e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_dc059414-cb5b-463c-b4ba-66a2994f88fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4541b438-f3e3-4057-8ec7-833e8dfc83e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_dc059414-cb5b-463c-b4ba-66a2994f88fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a67dff3e-5516-4205-aedc-1097a9f409c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4541b438-f3e3-4057-8ec7-833e8dfc83e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a67dff3e-5516-4205-aedc-1097a9f409c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_589fad22-be21-4d9d-ac97-5bbf956e2d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4541b438-f3e3-4057-8ec7-833e8dfc83e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_589fad22-be21-4d9d-ac97-5bbf956e2d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cae0d929-e632-4177-9038-8f99b39cc5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4541b438-f3e3-4057-8ec7-833e8dfc83e8" xlink:to="loc_us-gaap_OperatingLeaseLiability_cae0d929-e632-4177-9038-8f99b39cc5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c59bb26-63bd-4d94-96c5-8d044413b188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d3f11932-1307-44a2-a32c-77c38d3d2969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c59bb26-63bd-4d94-96c5-8d044413b188" xlink:to="loc_us-gaap_OperatingLeaseCost_d3f11932-1307-44a2-a32c-77c38d3d2969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_3f06003f-f671-48e8-8f5b-01ffbae589ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c59bb26-63bd-4d94-96c5-8d044413b188" xlink:to="loc_us-gaap_VariableLeaseCost_3f06003f-f671-48e8-8f5b-01ffbae589ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_e7579284-58b8-45a6-a17e-40d5cbbea98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8c59bb26-63bd-4d94-96c5-8d044413b188" xlink:to="loc_us-gaap_LeaseCost_e7579284-58b8-45a6-a17e-40d5cbbea98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_887e65cb-35c4-4fdd-adc5-d160c2003725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_887e65cb-35c4-4fdd-adc5-d160c2003725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e2a4fe48-14a2-46df-87b4-bcdfd97db800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e2a4fe48-14a2-46df-87b4-bcdfd97db800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b89d398f-7fc5-46f2-ad61-ac120a9c261a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b89d398f-7fc5-46f2-ad61-ac120a9c261a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f61eee12-22e5-4cda-9184-4aeeda01ae37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f61eee12-22e5-4cda-9184-4aeeda01ae37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b052bbe6-4874-4010-ac7a-1b1796f4daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b052bbe6-4874-4010-ac7a-1b1796f4daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_d6af0af5-76ff-44db-aab8-7f94b1759144" xlink:href="allo-20220930.xsd#allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:to="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_d6af0af5-76ff-44db-aab8-7f94b1759144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_efbb516c-3ca5-45ce-8b17-45113b38bc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_efbb516c-3ca5-45ce-8b17-45113b38bc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0feef688-d818-4194-a594-9cd366d16cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0feef688-d818-4194-a594-9cd366d16cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ad05c6bd-a62b-4703-be5b-f89eb38b0a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5da78dc6-6b49-4035-bccb-7448edf9e356" xlink:to="loc_us-gaap_OperatingLeaseLiability_ad05c6bd-a62b-4703-be5b-f89eb38b0a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#EquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/EquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3ab12bf8-2bea-4787-a9a7-f8b266d33b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ccedbdfb-38f8-422c-9582-8990236fecef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3ab12bf8-2bea-4787-a9a7-f8b266d33b46" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ccedbdfb-38f8-422c-9582-8990236fecef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec503ccd-9cb0-41ef-808a-24f8f58d2e8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ccedbdfb-38f8-422c-9582-8990236fecef" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec503ccd-9cb0-41ef-808a-24f8f58d2e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c64c263c-f429-420b-82f7-15342b5dd53b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ec503ccd-9cb0-41ef-808a-24f8f58d2e8a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c64c263c-f429-420b-82f7-15342b5dd53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_e0660392-76ea-4097-a7ad-fc25dc8da5ba" xlink:href="allo-20220930.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c64c263c-f429-420b-82f7-15342b5dd53b" xlink:to="loc_allo_NotchTherapeuticsIncMember_e0660392-76ea-4097-a7ad-fc25dc8da5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember_9c0564ae-f872-433b-8e46-14bf327eb0f3" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c64c263c-f429-420b-82f7-15342b5dd53b" xlink:to="loc_allo_AllogeneOverlandMember_9c0564ae-f872-433b-8e46-14bf327eb0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis_7f47ff36-b15f-4bed-897b-a27ee6e78a1e" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ccedbdfb-38f8-422c-9582-8990236fecef" xlink:to="loc_allo_EquityInvestmentBasisAxis_7f47ff36-b15f-4bed-897b-a27ee6e78a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_16e65ce7-e91b-4845-8568-c24181a2d4bf" xlink:href="allo-20220930.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_EquityInvestmentBasisAxis_7f47ff36-b15f-4bed-897b-a27ee6e78a1e" xlink:to="loc_allo_EquityInvestmentBasisDomain_16e65ce7-e91b-4845-8568-c24181a2d4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember_d2ab623d-0554-4283-9e39-f22b7a5192ba" xlink:href="allo-20220930.xsd#allo_VotingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_EquityInvestmentBasisDomain_16e65ce7-e91b-4845-8568-c24181a2d4bf" xlink:to="loc_allo_VotingInterestMember_d2ab623d-0554-4283-9e39-f22b7a5192ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ccedbdfb-38f8-422c-9582-8990236fecef" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_138a0625-0b8c-4e53-8643-40d9ed1e7ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_138a0625-0b8c-4e53-8643-40d9ed1e7ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts_013ff43e-2f09-4831-9b48-8dfba22a5118" xlink:href="allo-20220930.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_allo_CostMethodInvestmentTransactionCosts_013ff43e-2f09-4831-9b48-8dfba22a5118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_31ed80a7-5363-47b4-a528-1c7c9547071c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_31ed80a7-5363-47b4-a528-1c7c9547071c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_6904ded7-da0e-4d6e-adb5-bf020bab3a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_6904ded7-da0e-4d6e-adb5-bf020bab3a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4dfaaa4c-4ad5-4189-a35b-1dd3c609121a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4dfaaa4c-4ad5-4189-a35b-1dd3c609121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_d045ead2-9402-46f7-ba30-208160513df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b263e6a7-0b8f-460d-a10b-1a4b954b6114" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_d045ead2-9402-46f7-ba30-208160513df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5b6da46-b8a4-4156-851b-4a27f275389b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_143f2ba7-6064-4f80-a63d-17bfe42a5360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5b6da46-b8a4-4156-851b-4a27f275389b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_143f2ba7-6064-4f80-a63d-17bfe42a5360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_06d22d8d-d57c-4689-a4da-761691752797" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_143f2ba7-6064-4f80-a63d-17bfe42a5360" xlink:to="loc_srt_RangeAxis_06d22d8d-d57c-4689-a4da-761691752797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d45d93f-c857-4a50-a7ac-49fa7b4098c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_06d22d8d-d57c-4689-a4da-761691752797" xlink:to="loc_srt_RangeMember_7d45d93f-c857-4a50-a7ac-49fa7b4098c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b6388ed-92ca-41fc-b020-fc03378d9b2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7d45d93f-c857-4a50-a7ac-49fa7b4098c2" xlink:to="loc_srt_MaximumMember_8b6388ed-92ca-41fc-b020-fc03378d9b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6bfa9344-fbf7-4d1f-a848-6a512a38d0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_143f2ba7-6064-4f80-a63d-17bfe42a5360" xlink:to="loc_us-gaap_AwardTypeAxis_6bfa9344-fbf7-4d1f-a848-6a512a38d0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_597d679d-f560-4580-a4d4-14e0e713f19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6bfa9344-fbf7-4d1f-a848-6a512a38d0c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_597d679d-f560-4580-a4d4-14e0e713f19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9ea2b4fc-8a30-45e4-a931-0e4a64511983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_597d679d-f560-4580-a4d4-14e0e713f19b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9ea2b4fc-8a30-45e4-a931-0e4a64511983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6c6b0aff-cf38-449c-99c2-d914038f7256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_597d679d-f560-4580-a4d4-14e0e713f19b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6c6b0aff-cf38-449c-99c2-d914038f7256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_143f2ba7-6064-4f80-a63d-17bfe42a5360" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_1301cf69-9bcc-4d24-a469-a8621557786c" xlink:href="allo-20220930.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_1301cf69-9bcc-4d24-a469-a8621557786c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod_e563e0da-a758-48a7-aefa-d12f4b050480" xlink:href="allo-20220930.xsd#allo_StockOptionGrantedPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_StockOptionGrantedPeriod_e563e0da-a758-48a7-aefa-d12f4b050480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_c1306317-6e72-45db-94e4-3957a39b9de4" xlink:href="allo-20220930.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_c1306317-6e72-45db-94e4-3957a39b9de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_04457a39-dc3d-4372-8cc6-3f7c007be1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_04457a39-dc3d-4372-8cc6-3f7c007be1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6d491bf2-7b79-41cd-a8b3-ccf54baaef07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6d491bf2-7b79-41cd-a8b3-ccf54baaef07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees_3d0a483a-2d40-4e54-8b64-6fdc841e5ec2" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees_3d0a483a-2d40-4e54-8b64-6fdc841e5ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions_3abe6374-4389-46d3-afbd-79c8fb1c5a38" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions_3abe6374-4389-46d3-afbd-79c8fb1c5a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding_7c617783-6feb-4ee4-8704-66fec725ac99" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding_7c617783-6feb-4ee4-8704-66fec725ac99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ea328f8-c836-4373-9b70-32e8eaeb14e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ea328f8-c836-4373-9b70-32e8eaeb14e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3cce7fce-2543-450d-b312-9ce4fec0aff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3cce7fce-2543-450d-b312-9ce4fec0aff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a6181d2e-2042-4d24-ac36-7c4d269125d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a6181d2e-2042-4d24-ac36-7c4d269125d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_315c4c4d-1356-4988-8b47-1522a89962f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_315c4c4d-1356-4988-8b47-1522a89962f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4380b61-b94c-4d32-b8af-84393478e508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4380b61-b94c-4d32-b8af-84393478e508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d8b8e75e-9541-4091-a05b-4ab32cb61411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d8b8e75e-9541-4091-a05b-4ab32cb61411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_98030a97-5901-4cda-b9fd-6ec4734133c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_98030a97-5901-4cda-b9fd-6ec4734133c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c714a43-e9ad-40db-8c71-a085c14578d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c714a43-e9ad-40db-8c71-a085c14578d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e0063f1-0d74-41c1-85ec-99d1257857d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e0063f1-0d74-41c1-85ec-99d1257857d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50a4d8d1-db64-450c-84b3-1fc3ac016268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50a4d8d1-db64-450c-84b3-1fc3ac016268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_a19afc78-5d1a-4544-b4da-8d0865f7f693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_a19afc78-5d1a-4544-b4da-8d0865f7f693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a06233d-c7cc-4039-91e8-eab6634a8bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a06233d-c7cc-4039-91e8-eab6634a8bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_91dbb64b-b2cc-4283-9f8c-ad125036e7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_91dbb64b-b2cc-4283-9f8c-ad125036e7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_02ae6f59-cfb9-45bc-a96d-9c4cde92ad51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2133dc29-f54a-4762-99d7-37fa56401954" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_02ae6f59-cfb9-45bc-a96d-9c4cde92ad51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f9b23608-5127-4476-9593-d67c83fc8297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5956c62-d398-439e-af50-afbcb786c3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f9b23608-5127-4476-9593-d67c83fc8297" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5956c62-d398-439e-af50-afbcb786c3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f3108fc9-566d-4f46-95c8-b1d51e7460a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5956c62-d398-439e-af50-afbcb786c3f9" xlink:to="loc_us-gaap_AwardTypeAxis_f3108fc9-566d-4f46-95c8-b1d51e7460a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bec9d753-8c1c-4c40-ac8e-0b6bd9838be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f3108fc9-566d-4f46-95c8-b1d51e7460a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bec9d753-8c1c-4c40-ac8e-0b6bd9838be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_46ca78ab-c6ba-4822-a8f9-4dadcb3e8020" xlink:href="allo-20220930.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bec9d753-8c1c-4c40-ac8e-0b6bd9838be4" xlink:to="loc_allo_TwoThousandEighteenPlanMember_46ca78ab-c6ba-4822-a8f9-4dadcb3e8020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5956c62-d398-439e-af50-afbcb786c3f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6c5b598c-6021-4b79-bd47-e267280ebbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6c5b598c-6021-4b79-bd47-e267280ebbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dd11f144-e9ae-4342-8eef-7dd0b22d4b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dd11f144-e9ae-4342-8eef-7dd0b22d4b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b220c6c8-fbc8-427b-8cdc-c1d31ba075d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b220c6c8-fbc8-427b-8cdc-c1d31ba075d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ec2f6ff4-ee79-40c2-b4d0-3b5e659fe173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ec2f6ff4-ee79-40c2-b4d0-3b5e659fe173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod_3102ad6b-a588-4698-8b8a-8d097bf6b916" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod_3102ad6b-a588-4698-8b8a-8d097bf6b916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross_949e2397-f036-4f82-8020-630563bc5209" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross_949e2397-f036-4f82-8020-630563bc5209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9692a775-e597-4396-914b-5fa62c07df66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4466086b-a5b3-4d9d-9ee0-6fa940e01d96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9692a775-e597-4396-914b-5fa62c07df66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_98383da1-aa3c-41a0-a8fc-8102efc82450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_98383da1-aa3c-41a0-a8fc-8102efc82450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_348a1702-337b-4ec0-b6fd-ebfa700bac54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_348a1702-337b-4ec0-b6fd-ebfa700bac54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_05e757e3-95bf-41d3-84b4-3632860ce574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_05e757e3-95bf-41d3-84b4-3632860ce574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c3d8109-cd79-47fc-a7c3-23434d5bc250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c3d8109-cd79-47fc-a7c3-23434d5bc250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_de9ede23-a30f-4340-b1e3-1f7954094b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_de9ede23-a30f-4340-b1e3-1f7954094b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c59147c6-7afe-4a60-a447-f97ba392ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c59147c6-7afe-4a60-a447-f97ba392ad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice_b2295fca-3d00-4764-9fcd-8fa4208afa1f" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice_b2295fca-3d00-4764-9fcd-8fa4208afa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice_e2f98297-03bf-4cbb-87f5-e39d566f493d" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice_e2f98297-03bf-4cbb-87f5-e39d566f493d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8faaadee-8a98-481b-a61e-e172a0acac11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_243a5e0d-4236-4445-bb5f-203cbbb4381c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8faaadee-8a98-481b-a61e-e172a0acac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1fc68703-49c3-43c3-b4f5-21c8ef5f1727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1fc68703-49c3-43c3-b4f5-21c8ef5f1727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b3ce3433-319c-4f7b-b3ab-24e2e079240c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b3ce3433-319c-4f7b-b3ab-24e2e079240c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e5f7538-5fa8-454c-a213-1c3072cdafd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e5f7538-5fa8-454c-a213-1c3072cdafd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d04c3fb2-c118-43b5-8294-bda13b1840ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d04c3fb2-c118-43b5-8294-bda13b1840ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3a918104-125a-4082-a0a1-0b035fbcf84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3a918104-125a-4082-a0a1-0b035fbcf84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61239952-9b76-45e0-8e83-1463b34b9122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61239952-9b76-45e0-8e83-1463b34b9122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fbc6ffa6-3162-45db-a32e-4129f344a670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fbc6ffa6-3162-45db-a32e-4129f344a670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c2de9298-9456-4741-91eb-6142f2a92df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccc26118-c7e5-4626-bb47-0f613b8264bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c2de9298-9456-4741-91eb-6142f2a92df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a79e5691-14cd-4eb1-aaf9-df7a08014935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7a5d8a6-90dc-408b-8154-6d2c9728aa38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a79e5691-14cd-4eb1-aaf9-df7a08014935" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7a5d8a6-90dc-408b-8154-6d2c9728aa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ab4bbf67-b869-4306-9602-2527ea277a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7a5d8a6-90dc-408b-8154-6d2c9728aa38" xlink:to="loc_us-gaap_AwardTypeAxis_ab4bbf67-b869-4306-9602-2527ea277a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89494449-bf4e-4d47-8344-e78099d9db1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ab4bbf67-b869-4306-9602-2527ea277a14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89494449-bf4e-4d47-8344-e78099d9db1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_d7f80ca0-5436-482d-885f-68787e1df563" xlink:href="allo-20220930.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89494449-bf4e-4d47-8344-e78099d9db1d" xlink:to="loc_allo_TwoThousandEighteenPlanMember_d7f80ca0-5436-482d-885f-68787e1df563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_127ae8ab-e647-42e1-bdb8-b5ed9c16a775" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7a5d8a6-90dc-408b-8154-6d2c9728aa38" xlink:to="loc_srt_RangeAxis_127ae8ab-e647-42e1-bdb8-b5ed9c16a775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_998ccd8c-1f2e-4cbb-b61d-b33428c60c44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_127ae8ab-e647-42e1-bdb8-b5ed9c16a775" xlink:to="loc_srt_RangeMember_998ccd8c-1f2e-4cbb-b61d-b33428c60c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e2b3aeb-8996-496d-9a08-de17519ed02b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_998ccd8c-1f2e-4cbb-b61d-b33428c60c44" xlink:to="loc_srt_MinimumMember_5e2b3aeb-8996-496d-9a08-de17519ed02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1bfb7867-f21a-4d06-9a7c-ce8ea7dd4c92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_998ccd8c-1f2e-4cbb-b61d-b33428c60c44" xlink:to="loc_srt_MaximumMember_1bfb7867-f21a-4d06-9a7c-ce8ea7dd4c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7a5d8a6-90dc-408b-8154-6d2c9728aa38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c21e7c55-4a3e-42ac-a490-d3d4ab7706ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c21e7c55-4a3e-42ac-a490-d3d4ab7706ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1d870d7e-8b37-4317-bb6b-366a8d26ec8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1d870d7e-8b37-4317-bb6b-366a8d26ec8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e088b1f8-b7e0-495c-be99-dd43456bb030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e088b1f8-b7e0-495c-be99-dd43456bb030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2de5f0e9-5f98-429e-9a87-6272819083a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2de5f0e9-5f98-429e-9a87-6272819083a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3458e91c-bf9a-495a-a481-6d28ae6fa9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3458e91c-bf9a-495a-a481-6d28ae6fa9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e609899c-b381-4bf7-abda-9be0cf48d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3d94f0-c196-481a-9e2e-11401e01b8b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e609899c-b381-4bf7-abda-9be0cf48d4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3ae76bd-6271-46a3-a0cb-3215f9baf881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b6f646c-ae2a-4c09-bffc-8505c47ed471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3ae76bd-6271-46a3-a0cb-3215f9baf881" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b6f646c-ae2a-4c09-bffc-8505c47ed471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f19a901d-04d7-4ed4-9f65-2ffd36a6bf22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b6f646c-ae2a-4c09-bffc-8505c47ed471" xlink:to="loc_us-gaap_AwardTypeAxis_f19a901d-04d7-4ed4-9f65-2ffd36a6bf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70e42a17-98e0-4755-bebe-8fb3c137fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f19a901d-04d7-4ed4-9f65-2ffd36a6bf22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70e42a17-98e0-4755-bebe-8fb3c137fed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2cb5c6ab-4c3c-44dc-b71b-3b84520096d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70e42a17-98e0-4755-bebe-8fb3c137fed9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2cb5c6ab-4c3c-44dc-b71b-3b84520096d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b6f646c-ae2a-4c09-bffc-8505c47ed471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8cd9ece9-b5c8-45f6-9604-08dfafac393f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8cd9ece9-b5c8-45f6-9604-08dfafac393f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6dfbbdd5-4b94-4273-8467-f59e1f8d1f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6dfbbdd5-4b94-4273-8467-f59e1f8d1f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8903ecad-341d-4181-9cb0-3aa7858f09b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8903ecad-341d-4181-9cb0-3aa7858f09b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2617dd9c-2885-4f65-a3b0-a91940efac7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2617dd9c-2885-4f65-a3b0-a91940efac7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7930e4ca-a99d-4321-a74d-d5c4e6ede421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4069222d-8c58-460e-a701-feaa2d72778a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7930e4ca-a99d-4321-a74d-d5c4e6ede421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1b20cf71-b911-4d18-b712-167de36acc17" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1b20cf71-b911-4d18-b712-167de36acc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3d163052-f716-49fc-b6f5-4a6cb7b4310c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3d163052-f716-49fc-b6f5-4a6cb7b4310c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e1b2358-d270-4145-b93b-c733513d472b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e1b2358-d270-4145-b93b-c733513d472b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_28141368-8490-4667-ab24-283547af1e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_28141368-8490-4667-ab24-283547af1e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_411ba744-48a6-4b88-ae16-05faf7642d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_411ba744-48a6-4b88-ae16-05faf7642d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb6c2c5f-66d6-4768-9333-e75d758ef0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b7aa8cb-d5e2-4900-9c64-ed6c3362ccc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb6c2c5f-66d6-4768-9333-e75d758ef0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_92a3f4a8-7cf9-4a40-b67e-0d9fef824cdb" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_92a3f4a8-7cf9-4a40-b67e-0d9fef824cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_f0830f43-210f-4438-af37-0b7f0346da47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_f0830f43-210f-4438-af37-0b7f0346da47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_97ee5553-6f82-49d9-bfa4-a55924be321c" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_97ee5553-6f82-49d9-bfa4-a55924be321c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_3eeff8d5-2b3c-4977-81f0-c5125c7d0979" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_3eeff8d5-2b3c-4977-81f0-c5125c7d0979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6f40bb16-c11d-44e8-a72c-5f9e104acddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6f40bb16-c11d-44e8-a72c-5f9e104acddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_e6592c83-9e20-459c-9063-6a41c0f5bdd5" xlink:href="allo-20220930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279df5db-3fca-489d-98f9-47fcfd6ba8e0" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_e6592c83-9e20-459c-9063-6a41c0f5bdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#StockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8a44385-f27d-4d0f-accc-dba529f7d46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89b2f741-65ee-4912-8f37-8159c9151f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8a44385-f27d-4d0f-accc-dba529f7d46a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89b2f741-65ee-4912-8f37-8159c9151f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_310a91db-403f-440e-9355-bea245ee51ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89b2f741-65ee-4912-8f37-8159c9151f12" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_310a91db-403f-440e-9355-bea245ee51ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f7eb7263-9183-4117-bfbd-89ba27ea1f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_310a91db-403f-440e-9355-bea245ee51ef" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f7eb7263-9183-4117-bfbd-89ba27ea1f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1bf182f1-2788-4bf4-b422-f3e8e943656a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f7eb7263-9183-4117-bfbd-89ba27ea1f08" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1bf182f1-2788-4bf4-b422-f3e8e943656a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_66779950-b880-4ae8-8c28-e9c7cde3f11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f7eb7263-9183-4117-bfbd-89ba27ea1f08" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_66779950-b880-4ae8-8c28-e9c7cde3f11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fc5cf116-22f7-4fb9-b9f1-1596a6ca4884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89b2f741-65ee-4912-8f37-8159c9151f12" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fc5cf116-22f7-4fb9-b9f1-1596a6ca4884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c2e7d7f-8d67-40a1-8e61-1cc523fc2b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fc5cf116-22f7-4fb9-b9f1-1596a6ca4884" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c2e7d7f-8d67-40a1-8e61-1cc523fc2b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_fbaea5e2-aaad-4a7b-b6c6-93167a576ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_fbaea5e2-aaad-4a7b-b6c6-93167a576ac4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2397717f-ddbd-430e-9277-e12f5da05979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2397717f-ddbd-430e-9277-e12f5da05979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_de5a43f8-b7e1-4e82-b4ce-8505767a5d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2397717f-ddbd-430e-9277-e12f5da05979" xlink:to="loc_us-gaap_RelatedPartyDomain_de5a43f8-b7e1-4e82-b4ce-8505767a5d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember_02176d1d-fa8d-45f0-884d-7d30878f4b15" xlink:href="allo-20220930.xsd#allo_BellcoCapitalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_de5a43f8-b7e1-4e82-b4ce-8505767a5d6e" xlink:to="loc_allo_BellcoCapitalLLCMember_02176d1d-fa8d-45f0-884d-7d30878f4b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLLCMember_2710b127-be35-4105-8a17-ad9a0a82e36f" xlink:href="allo-20220930.xsd#allo_TwoRiverConsultingLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_de5a43f8-b7e1-4e82-b4ce-8505767a5d6e" xlink:to="loc_allo_TwoRiverConsultingLLCMember_2710b127-be35-4105-8a17-ad9a0a82e36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_6bdd1c19-ec43-416b-81f0-a7b7899709fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_6bdd1c19-ec43-416b-81f0-a7b7899709fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e1dd35e0-9fc4-43bf-acbe-76985dd63948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6bdd1c19-ec43-416b-81f0-a7b7899709fd" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e1dd35e0-9fc4-43bf-acbe-76985dd63948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubleaseAgreementMember_caa89e9c-cff4-4a5e-a201-5da9c53b7a2f" xlink:href="allo-20220930.xsd#allo_SubleaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e1dd35e0-9fc4-43bf-acbe-76985dd63948" xlink:to="loc_allo_SubleaseAgreementMember_caa89e9c-cff4-4a5e-a201-5da9c53b7a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember_d189d076-5471-45c8-a875-2c32096c9371" xlink:href="allo-20220930.xsd#allo_ConsultingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e1dd35e0-9fc4-43bf-acbe-76985dd63948" xlink:to="loc_allo_ConsultingAgreementsMember_d189d076-5471-45c8-a875-2c32096c9371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89f52269-dae7-4227-951d-bf57b8bc0b5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_srt_RangeAxis_89f52269-dae7-4227-951d-bf57b8bc0b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0e186e4-8df4-4dc7-9e4f-f027f82f6320" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_89f52269-dae7-4227-951d-bf57b8bc0b5b" xlink:to="loc_srt_RangeMember_c0e186e4-8df4-4dc7-9e4f-f027f82f6320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76e5a354-ebbf-4438-8bac-4f9ff40205c0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c0e186e4-8df4-4dc7-9e4f-f027f82f6320" xlink:to="loc_srt_MaximumMember_76e5a354-ebbf-4438-8bac-4f9ff40205c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsAxis_20abda87-c7b8-428c-8518-77a0ed55a1f5" xlink:href="allo-20220930.xsd#allo_PaymentTermsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_allo_PaymentTermsAxis_20abda87-c7b8-428c-8518-77a0ed55a1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain_74d017c4-46fb-41e6-a199-814c31498595" xlink:href="allo-20220930.xsd#allo_PaymentTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_PaymentTermsAxis_20abda87-c7b8-428c-8518-77a0ed55a1f5" xlink:to="loc_allo_PaymentTermsDomain_74d017c4-46fb-41e6-a199-814c31498595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2021Member_5a89ef08-80f0-46ee-b6ba-347a1e1584fd" xlink:href="allo-20220930.xsd#allo_PaymentsCommencingJanuary2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_PaymentTermsDomain_74d017c4-46fb-41e6-a199-814c31498595" xlink:to="loc_allo_PaymentsCommencingJanuary2021Member_5a89ef08-80f0-46ee-b6ba-347a1e1584fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2022Member_2d3b26f7-c7a8-4d31-a990-6694df363045" xlink:href="allo-20220930.xsd#allo_PaymentsCommencingJanuary2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_PaymentTermsDomain_74d017c4-46fb-41e6-a199-814c31498595" xlink:to="loc_allo_PaymentsCommencingJanuary2022Member_2d3b26f7-c7a8-4d31-a990-6694df363045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a1683078-f95e-4afe-a183-944032fb93a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_srt_CounterpartyNameAxis_a1683078-f95e-4afe-a183-944032fb93a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b82ea3f-1434-469f-a6da-7f6569ba84d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a1683078-f95e-4afe-a183-944032fb93a3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b82ea3f-1434-469f-a6da-7f6569ba84d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_0f3af2cc-d7a9-4319-9732-cd8e2c7e120f" xlink:href="allo-20220930.xsd#allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b82ea3f-1434-469f-a6da-7f6569ba84d8" xlink:to="loc_allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember_0f3af2cc-d7a9-4319-9732-cd8e2c7e120f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_92d5a235-d96f-437a-ab55-3e292ce9840a" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44ea5524-0b93-436a-93a2-1a23bee7197a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44ea5524-0b93-436a-93a2-1a23bee7197a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_ab4ef959-1eae-4291-8cb5-9e4111e9fe7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_ab4ef959-1eae-4291-8cb5-9e4111e9fe7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOffice_534649db-74d1-4936-90a1-d34bb3818d69" xlink:href="allo-20220930.xsd#allo_AreaOfOffice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_allo_AreaOfOffice_534649db-74d1-4936-90a1-d34bb3818d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_2493c7a3-c536-46f2-a2fd-ba0cd97f5f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_2493c7a3-c536-46f2-a2fd-ba0cd97f5f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5efa47f-c55b-4f64-b54d-04ad59600f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5efa47f-c55b-4f64-b54d-04ad59600f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bcf344fa-72cf-404a-b7fa-548af33cfad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_OperatingLeaseLiability_bcf344fa-72cf-404a-b7fa-548af33cfad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts_92bb85b8-97f0-42c8-8e9b-ca61320f0c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_us-gaap_RelatedPartyCosts_92bb85b8-97f0-42c8-8e9b-ca61320f0c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_72533848-fd30-487f-b549-bb7238012d66" xlink:href="allo-20220930.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_72533848-fd30-487f-b549-bb7238012d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_658cfc0a-fafc-47d7-bbc7-87f3095a74ce" xlink:href="allo-20220930.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ae8ed319-a451-4f17-9864-3676ab3ecbb1" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_658cfc0a-fafc-47d7-bbc7-87f3095a74ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4890bed6-5cc7-4a60-ac0c-e26a1b5bc6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7fca5a7a-0345-4905-b527-ecbefd487c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4890bed6-5cc7-4a60-ac0c-e26a1b5bc6e1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7fca5a7a-0345-4905-b527-ecbefd487c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65edc510-ec97-4ecd-b888-8c4045f593e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7fca5a7a-0345-4905-b527-ecbefd487c8e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65edc510-ec97-4ecd-b888-8c4045f593e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_65edc510-ec97-4ecd-b888-8c4045f593e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4cd108cd-5cdd-4a57-85f3-55461c376f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4cd108cd-5cdd-4a57-85f3-55461c376f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3b787ca6-a183-4792-a502-915fdb9edbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3b787ca6-a183-4792-a502-915fdb9edbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a4d65fff-cf3d-43dd-abfe-db9e8724e477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_us-gaap_EmployeeStockMember_a4d65fff-cf3d-43dd-abfe-db9e8724e477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember_c8d95efc-973f-43d0-97d0-69e27bb92bd0" xlink:href="allo-20220930.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_allo_FounderSharesOfCommonStockMember_c8d95efc-973f-43d0-97d0-69e27bb92bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_e01a949e-4403-4572-ad52-d5132ae0b3df" xlink:href="allo-20220930.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5902dc-4829-470a-8869-ed7d46587211" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_e01a949e-4403-4572-ad52-d5132ae0b3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c6e5aa73-a1f0-4e64-b319-6e024606337f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7fca5a7a-0345-4905-b527-ecbefd487c8e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c6e5aa73-a1f0-4e64-b319-6e024606337f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_421f0243-439f-43d3-9149-34bda1edf402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c6e5aa73-a1f0-4e64-b319-6e024606337f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_421f0243-439f-43d3-9149-34bda1edf402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="allo-20220930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ba5558ed-e6fb-4bfc-9d83-fba59ed241fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_32c4cbbe-c464-4fc2-ba17-c5bf83ff7572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ba5558ed-e6fb-4bfc-9d83-fba59ed241fe" xlink:to="loc_us-gaap_SubsequentEventTable_32c4cbbe-c464-4fc2-ba17-c5bf83ff7572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_826dadb9-8b1f-4376-a0c3-cc5d9d7428e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_32c4cbbe-c464-4fc2-ba17-c5bf83ff7572" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_826dadb9-8b1f-4376-a0c3-cc5d9d7428e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4cb3dd00-f927-4f63-ae78-00451246d70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_826dadb9-8b1f-4376-a0c3-cc5d9d7428e9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4cb3dd00-f927-4f63-ae78-00451246d70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_13305039-7012-467c-8925-aa2c663c1f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4cb3dd00-f927-4f63-ae78-00451246d70f" xlink:to="loc_us-gaap_SubsequentEventMember_13305039-7012-467c-8925-aa2c663c1f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_678279b0-d178-4e96-b454-8fc082535344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_32c4cbbe-c464-4fc2-ba17-c5bf83ff7572" xlink:to="loc_us-gaap_SubsequentEventLineItems_678279b0-d178-4e96-b454-8fc082535344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment_5a44d99c-09c4-4a1e-91b7-d4b6dcb7dcba" xlink:href="allo-20220930.xsd#allo_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_678279b0-d178-4e96-b454-8fc082535344" xlink:to="loc_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment_5a44d99c-09c4-4a1e-91b7-d4b6dcb7dcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810324624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,210,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810044160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 74,357<span></span>
</td>
<td class="nump">$ 173,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">477,872<span></span>
</td>
<td class="nump">283,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">16,832<span></span>
</td>
<td class="nump">14,021<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">569,061<span></span>
</td>
<td class="nump">471,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">85,108<span></span>
</td>
<td class="nump">352,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">85,245<span></span>
</td>
<td class="nump">58,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">114,442<span></span>
</td>
<td class="nump">122,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">10,292<span></span>
</td>
<td class="nump">10,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">9,378<span></span>
</td>
<td class="nump">5,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="nump">14,046<span></span>
</td>
<td class="nump">18,005<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">887,572<span></span>
</td>
<td class="nump">1,038,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,045<span></span>
</td>
<td class="nump">10,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">36,938<span></span>
</td>
<td class="nump">37,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,872<span></span>
</td>
<td class="nump">48,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, non-current</a></td>
<td class="nump">96,706<span></span>
</td>
<td class="nump">69,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,033<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">147,611<span></span>
</td>
<td class="nump">122,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Notes 6 and 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of September 30, 2022 and December 31, 2021; no shares were issued and outstanding as of September 30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 400,000,000 shares authorized as of September 30, 2022 and 200,000,000 shares authorized as of December 31, 2021; 144,031,588 and 142,623,065 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,893,908<span></span>
</td>
<td class="nump">1,822,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,141,133)<span></span>
</td>
<td class="num">(903,348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(12,958)<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">739,961<span></span>
</td>
<td class="nump">916,406<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 887,572<span></span>
</td>
<td class="nump">$ 1,038,634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810290512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">144,031,588<span></span>
</td>
<td class="nump">142,623,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">144,031,588<span></span>
</td>
<td class="nump">142,623,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810380864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 38,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">63,641<span></span>
</td>
<td class="nump">58,720<span></span>
</td>
<td class="nump">180,968<span></span>
</td>
<td class="nump">166,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,897<span></span>
</td>
<td class="nump">18,999<span></span>
</td>
<td class="nump">58,303<span></span>
</td>
<td class="nump">54,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">82,538<span></span>
</td>
<td class="nump">77,719<span></span>
</td>
<td class="nump">239,271<span></span>
</td>
<td class="nump">220,337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(82,489)<span></span>
</td>
<td class="num">(77,670)<span></span>
</td>
<td class="num">(239,075)<span></span>
</td>
<td class="num">(181,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses</a></td>
<td class="num">(1,661)<span></span>
</td>
<td class="num">(909)<span></span>
</td>
<td class="num">(519)<span></span>
</td>
<td class="num">(1,766)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(659)<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(83,148)<span></span>
</td>
<td class="num">(78,186)<span></span>
</td>
<td class="num">(237,785)<span></span>
</td>
<td class="num">(182,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale investments</a></td>
<td class="num">(1,486)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(10,391)<span></span>
</td>
<td class="num">(666)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (84,634)<span></span>
</td>
<td class="num">$ (78,250)<span></span>
</td>
<td class="num">$ (248,176)<span></span>
</td>
<td class="num">$ (182,803)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (1.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (1.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per share, basic (in shares)</a></td>
<td class="nump">143,661,721<span></span>
</td>
<td class="nump">137,025,698<span></span>
</td>
<td class="nump">142,809,469<span></span>
</td>
<td class="nump">134,690,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">143,661,721<span></span>
</td>
<td class="nump">137,025,698<span></span>
</td>
<td class="nump">142,809,469<span></span>
</td>
<td class="nump">134,690,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489805709040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,474,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,079,617<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 1,725,552<span></span>
</td>
<td class="num">$ (646,343)<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale investments</a></td>
<td class="num">(369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(369)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,470,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">1,069,779<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">1,749,097<span></span>
</td>
<td class="num">(679,358)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,474,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,079,617<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">1,725,552<span></span>
</td>
<td class="num">(646,343)<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)</a></td>
<td class="nump">293,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (182,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale investments</a></td>
<td class="num">(666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,439,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">969,942<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">1,798,678<span></span>
</td>
<td class="num">(828,480)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,470,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">1,069,779<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">1,749,097<span></span>
</td>
<td class="num">(679,358)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs</a></td>
<td class="nump">3,214<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">21,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(70,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale investments</a></td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,120,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">1,023,812<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">1,774,298<span></span>
</td>
<td class="num">(750,294)<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(78,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale investments</a></td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,439,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 969,942<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">1,798,678<span></span>
</td>
<td class="num">(828,480)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">142,623,065<span></span>
</td>
<td class="nump">142,623,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 916,406<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">1,822,179<span></span>
</td>
<td class="num">(903,348)<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(79,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale investments</a></td>
<td class="num">(6,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,682)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,569,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 855,230<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">1,847,534<span></span>
</td>
<td class="num">(983,198)<span></span>
</td>
<td class="num">(9,249)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">142,623,065<span></span>
</td>
<td class="nump">142,623,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 916,406<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">1,822,179<span></span>
</td>
<td class="num">(903,348)<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (237,785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale investments</a></td>
<td class="num">$ (10,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">144,031,588<span></span>
</td>
<td class="nump">144,031,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 739,961<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">1,893,908<span></span>
</td>
<td class="num">(1,141,133)<span></span>
</td>
<td class="num">(12,958)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,569,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">855,230<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">1,847,534<span></span>
</td>
<td class="num">(983,198)<span></span>
</td>
<td class="num">(9,249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(74,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale investments</a></td>
<td class="num">(2,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,223)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,723,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">801,949<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">1,871,262<span></span>
</td>
<td class="num">(1,057,985)<span></span>
</td>
<td class="num">(11,472)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">21,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(83,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale investments</a></td>
<td class="num">$ (1,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,486)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">144,031,588<span></span>
</td>
<td class="nump">144,031,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 739,961<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 1,893,908<span></span>
</td>
<td class="num">$ (1,141,133)<span></span>
</td>
<td class="num">$ (12,958)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810570464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (237,785)<span></span>
</td>
<td class="num">$ (182,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">66,354<span></span>
</td>
<td class="nump">58,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">11,227<span></span>
</td>
<td class="nump">6,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization/accretion on investment securities</a></td>
<td class="nump">2,735<span></span>
</td>
<td class="nump">5,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash rent expense</a></td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">2,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_IncomeLossFromCostMethodInvestment', window );">Share of loss from equity method investment</a></td>
<td class="nump">3,959<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,811)<span></span>
</td>
<td class="num">(2,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(3,211)<span></span>
</td>
<td class="num">(991)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,930<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(1,388)<span></span>
</td>
<td class="nump">6,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">466<span></span>
</td>
<td class="num">(38,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(2,092)<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(158,423)<span></span>
</td>
<td class="num">(139,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,499)<span></span>
</td>
<td class="num">(20,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of stock in equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,938)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">260,379<span></span>
</td>
<td class="nump">645,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(200,318)<span></span>
</td>
<td class="num">(474,801)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">56,562<span></span>
</td>
<td class="nump">134,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">8,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">2,461<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,904<span></span>
</td>
<td class="nump">11,641<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(98,957)<span></span>
</td>
<td class="nump">6,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; beginning of period</a></td>
<td class="nump">183,606<span></span>
</td>
<td class="nump">192,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; end of period</a></td>
<td class="nump">84,649<span></span>
</td>
<td class="nump">199,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease liability</a></td>
<td class="nump">31,361<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="num">(6,605)<span></span>
</td>
<td class="num">(4,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Cash received for amounts related to tenant improvement allowances</a></td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_IncomeLossFromCostMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Cost Method Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_IncomeLossFromCostMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810321584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is an immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company had cash and cash equivalents and investments of $637.3 million as of September&#160;30, 2022. Since inception through September&#160;30, 2022, the Company has incurred cumulative net losses of $1.1 billion. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). </span></div>The Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition and operations. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If business conditions, financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489815389792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of stockholders&#8217; equity as of September&#160;30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended December&#160;31, 2021, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 23, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the accounting policies during the three and nine months ended September&#160;30, 2022, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued or effective that are expected to have a material impact on the Company's condensed financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489895298736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs including quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets or liabilities as of September&#160;30, 2022 and as of December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:&#160;</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,034&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Included within cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489812654576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial InstrumentsThe fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,812)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,719&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,515)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,205&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,156)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,034&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022,&#160;the remaining contractual maturities of available-for-sale securities were less than 2 years. There have been no significant realized losses on available-for-sale securities for the periods presented. As of September&#160;30, 2022, unrealized losses on available-for-sale securities are not attributed to credit risk. The Company believes that it is more likely than not that investments in an unrealized loss position will be held until maturity and all interest and principal will be received. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company&#8217;s available-for-sale securities are due to market factors. As of September&#160;30, 2022 and December&#160;31, 2021, securities with a fair value of $153.7 million and zero, respectively, were in a continuous net unrealized loss position for more than 12 months. To date, the Company has not recorded any impairment charges on available-for-sale securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the Company recognized $1.5 million and $1.9 million, respectively, of accrued interest receivable from available-for-sale securities within prepaid expenses and other current assets on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489895324768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet ComponentsProperty and Equipment, Net<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and purchased software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,030&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489816222320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_LicenseAgreementsTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Contribution Agreement with Pfizer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets, including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $30.0 million or $60.0 million, depending on the target, with aggregate potential regulatory and development milestones of up to $840.0 million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $325.0 million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three and nine months ended September&#160;30, 2022 or 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) 12 years from the first sale of such product in such country.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Cellectis</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $185.0 million per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to $2.8 billion. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalties are payable, on a licensed-product-by-licensed-product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs the Company incurred in connection with this agreement were recognized as research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, zero costs were incurred related to the achievement of a clinical development milestone under this agreement. For the three and nine months ended September&#160;30, 2021, $5.0 million and $10.0 million, respectively, in costs were incurred related to the achievement of a clinical development milestone under this agreement. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreement with Servier</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19, ALLO-501 and ALLO-501A in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for 60% of the specified development costs and Servier is responsible for the remaining 40% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $137.5 million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $78.0 million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $42.0 million and &#8364;70.5 million ($69.1 million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $3.8 million and $20.4 million, respectively, of net cost recoveries under the cost-sharing terms of the Servier Agreement as a reduction to research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded $5.1 million and $13.2 million, respectively, of net cost recoveries. As of September&#160;30, 2022 and December&#160;31, 2021, amounts due from Servier of $4.3 million and $4.1 million, respectively, were recorded in other current assets in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, Servier sent a notice of discontinuation (Discontinuation) of its involvement in the development of all licensed products directed against CD19, including UCART19, ALLO-501 and ALLO-501A (collectively, CD19 Products), pursuant to the Servier Agreement. Servier&#8217;s Discontinuation provides the Company with the right to elect a license to the CD19 Products outside of the United States (Ex-US Option) and does not otherwise affect the Company's current exclusive license for the development and commercialization of CD19 Products in the United States. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Notch</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $10.0&#160;million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. In addition, Allogene made a $5.0&#160;million investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, an Allogene representative serves on the Notch Board of Directors. In February 2021, the Company made an additional $15.9 million investment in Notch's Series A preferred stock. In October 2021, the Company made an additional $1.8&#160;million investment in Notch's common stock. Immediately following this transaction, the Company's share in Notch was 23.0% on a voting interest basis. The Company did not have a controlling interest in Notch as of September&#160;30, 2022, and continued to account for its investment in Notch as an equity method investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Notch Agreement, Notch will be eligible to receive up to $7.25&#160;million upon achieving certain agreed research milestones, up to $4.0&#160;million per exclusive target upon achieving certain pre-clinical development milestones, and up to $283.0&#160;million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three and nine months ended September&#160;30, 2022, the Company recorded $1.0 million and $2.8 million, respectively, in collaboration costs as research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded $0.8 million and $3.9 million, respectively, in collaboration costs as research and development expenses.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Strategic Alliance with The University of Texas MD Anderson Cancer Center</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2020, the Company entered into a strategic five-year collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The Company and MD Anderson are collaborating on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company has committed up to $15.0&#160;million of funding for the duration of the agreement. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance. The Company made an upfront payment of $3.0&#160;million to MD Anderson in the year ended December 31, 2020. The Company is obligated to make further payments to MD Anderson each year upon the anniversary of the agreement </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective date through the duration of the agreement term. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, among other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $0.2 million and $1.1 million in collaboration costs as research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded $0.4 million and $0.8 million, respectively, in collaboration costs as research and development expenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture and License Agreement with Allogene Overland Biopharm (CY) Limited </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, the Company entered into a License Agreement with Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by the Company and Overland Pharmaceuticals (CY) Inc. (Overland), pursuant to a Share Purchase Agreement, dated December 14, 2020, for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore (the JV Territory). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Share Purchase Agreement, the Company acquired Seed Preferred Shares in Allogene Overland representing 49% of Allogene Overland's outstanding stock as partial consideration for the License Agreement, and Overland acquired Seed Preferred Shares representing 51% of Allogene Overland's outstanding stock for $117.0&#160;million in upfront and certain quarterly cash payments, to support operations of Allogene Overland. As of September&#160;30, 2022, the Company and Overland are the sole equity holders in Allogene Overland. The Company received $40&#160;million from Allogene Overland as partial consideration for the License Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the License Agreement, the Company granted Allogene Overland an exclusive license to develop, manufacture and commercialize certain allogeneic CAR T cell candidates directed at four targets, BCMA, CD70, FLT3, and DLL3, in the JV Territory. As consideration, the Company would also be entitled to additional regulatory milestone payments of up to $40.0&#160;million and, subject to certain conditions, tiered low-to-mid single-digit sales royalties. Subsequent to entering into the License Agreement, Allogene Overland assigned the License Agreement to a wholly-owned subsidiary, Allogene Overland BioPharm (HK) Limited. On April 1, 2022, Allogene Overland HK assigned the License Agreement to Allogene Overland Biopharm (PRC) Co., Limited.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promises that the Company concluded were distinct performance obligations in the License Agreement included: (1) the license of intellectual property and delivery of know-how, (2) the manufacturing license, related know-how and support, (3) if and when available know-how developed in future periods, and (4) participation in the joint steering committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Fixed consideration exists in the form of the upfront payment. Regulatory milestones and royalties were considered variable consideration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. Milestone fees were constrained and not included in the transaction price due to the uncertainties of research and development. The Company re-evaluates the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The shares of Series Seed Preferred Stock were accounted for as part of the Company&#8217;s joint venture and equity method accounting upon formation of the joint venture, and as such, were excluded from the transaction price. The Company determined that the initial transaction price consists of the upfront payment of $40.0&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price allocated to the license of intellectual property and delivery of know-how will be recognized upon grant of license and delivery of know-how. The transaction price allocated to (i) the manufacturing license, related know-how and support services, (ii) if and when available know-how developed in future periods, and (iii) participation in the joint steering committee, will be recognized over time as the services are delivered. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received in advance are recorded as deferred revenue and will be recognized as the performance obligations are satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that Allogene Overland is a variable interest entity as of September&#160;30, 2022 and December 31, 2021. The Company does not have the power to independently direct the activities which most significantly affect Allogene Overland's economic performance. Accordingly, the Company did not consolidate Allogene Overland because the Company determined that it was not the primary beneficiary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recognized less than $0.1&#160;million and $0.2 million of collaboration revenue, respectively. For the three and nine months ended September&#160;30, 2021, the Company recognized less than $0.1&#160;million and $38.4 million, respectively, of collaboration revenue, primarily related to the license of intellectual property and delivery of the know-how performance obligation which was delivered in the first quarter of 2021. For the three and nine months ended September&#160;30, 2022, the Company recorded $0.3 million and $0.6 million, respectively, of net cost recoveries under the terms of the license agreement as a reduction to research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded zero net cost recoveries. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and License Agreement with Antion </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2022, the Company entered into an exclusive collaboration and global license agreement (Antion Collaboration and License Agreement) with Antion Biosciences SA (Antion) for Antion&#8217;s miRNA technology (miCAR), to advance multiplex gene silencing as an additional tool to develop next generation allogeneic CAR T products. Pursuant to the agreement, Antion will exclusively collaborate with the Company on oncology products for a defined period. The Company will also have exclusive worldwide rights to commercialize products incorporating Antion technology developed during the collaboration. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Antion Collaboration and License Agreement includes an exclusive research collaboration to conduct research and development of the use of Antion&#8217;s proprietary technologies to produce certain products for a defined period, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint steering committee. The Company will reimburse Antion's costs incurred in accordance with such plan and budget. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Antion Collaboration and License Agreement, the Company made an upfront payment to Antion of $3.5 million in return for a license to access Antion's technology in order to conduct research pursuant to the agreement. The upfront payment was fully recognized as research and development expense as the license had no foreseeable alternative future use. In addition, the Company made a $3.0 million investment in Antion's preferred stock and is expected to make an additional $3.0&#160;million investment in Antion's preferred stock upon achievement of an agreed milestone. The Company accounts for its investment in Antion's preferred stock as an equity investment measured at cost less any impairment. In connection with this investment, a Company representative was appointed to Antion&#8217;s Board of Directors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Antion Collaboration and License Agreement, Antion will be eligible to receive up to $35.3 million for four products upon achievement of certain development and regulatory milestones. For each additional product, Antion will be eligible to receive $2.0 million upon achievement of a regulatory milestone. Antion is also entitled to receive a low single-digit royalty on the Company&#8217;s sales of licensed products, subject to certain reductions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $0.6 million and $4.5 million in research and development expenses related to the upfront payment and collaboration costs, of which $0.5 million is recorded in accrued and other liabilities as of September&#160;30, 2022. The Company's total equity investment in Antion was $3.0 million as of September&#160;30, 2022 and is recognized in other long-term assets in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489812654576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into an operating lease agreement (HQ Lease) for office and laboratory space which consists of approximately 68,000 square feet located in South San Francisco, California. The lease term was 127 months beginning August 2018 through February 2029 with an option to extend the term for seven years which was not reasonably assured of exercise. The Company has made certain tenant improvements, including the addition of laboratory space, and has received $5.0 million of tenant improvement allowances. The rent payments began on March 1, 2019 after an abatement period. In December 2021, the Company amended its lease agreement to lease an additional 47,566 square feet of office and laboratory space in South San Francisco, California, as part of the same building as the Company&#8217;s current headquarters. The lease term commenced in April 2022 and is for a period of 120 months. The rent payments for the expansion premises began in August 2022 after an abatement period. The lease term for the existing premises was also extended and the lease for both the existing and expansion premises will expire on March 31, 2032 with an option to extend the term for eight years which is not reasonably assured of exercise. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an operating lease agreement for office and laboratory space which consists of 14,943 square feet located in South San Francisco, California. The lease term was 124 months beginning November 2018 through February 2029, with an option to extend the term for another seven years which was not reasonably assured of exercise. The Company has made certain tenant improvements, including the upgrading of current office and laboratory space with a </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease incentive allowance of $0.8 million. Rent payments began in November 2018. In December 2021, the Company amended its lease agreement to extend the term of the lease to be co-terminus with the HQ Lease. The lease term will expire March 31, 2032 with an option to extend the term for eight years which is not reasonably assured of exercise. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease term is 188 months beginning November 2020 through July 2036. Upon certain conditions, the Company has two ten-year options to extend the lease, both of which are not reasonably assured of exercise. The Company has received $3.0 million of tenant improvement allowances for costs related to the design and construction of certain Company improvements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains letters of credit for the benefit of landlords which is disclosed as restricted cash in the condensed consolidated balance sheets. Restricted cash related to letters of credit due to landlords was $6.0 million as of September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_090f2506-4094-4262-920e-2e1663730d2d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_c2737ca9-b04a-4d28-a3da-5b7ccec47c9f">Current portion included in accrued and other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,831&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,537&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,129&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,944&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the nine months ended September&#160;30, 2022 was $2.6 million and was included in net cash used in operating activities in our condensed consolidated statements of cash flows. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undiscounted future lease payments under the lease agreements as of September&#160;30, 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2022 (remaining 6 months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our estimated incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was&#160;6.19%. As of&#160;September&#160;30, 2022, the weighted average remaining lease term for our operating leases is&#160;10.21 years.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, the Company entered into a Solar Power Purchase and Energy Services Agreement for the installation and operation of a solar photovoltaic generating system and battery energy storage system at the Company's cell therapy manufacturing facility in Newark, California. The agreement has a term of 20 years and commenced in September 2022. The Company is obligated to pay for electricity generated from the system at an agreed rate for the duration of the agreement term. Termination of the agreement by the Company will result in a termination payment due of approximately $4.3 million. In connection with the agreement, the Company maintains a letter of credit for the benefit of the service provider in the amount of $4.3 million which is disclosed as restricted cash in the condensed consolidated balance sheets as of September&#160;30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into certain license agreements for intellectual property which is used as part of our development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of September&#160;30, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into contracts in the normal course of business that includes arrangements with clinical research organizations, vendors for preclinical research and vendors for manufacturing. These agreements generally allow for cancellation with notice. As of September&#160;30, 2022, the Company had non-cancellable purchase commitments of $0.4 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489815262288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investment</a></td>
<td class="text">Equity Method Investments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notch Therapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the execution of the Notch Agreement (see Note 6), the Company also entered into a Share Purchase Agreement with the Company acquiring shares of Notch&#8217;s Series Seed convertible preferred stock for a total investment cost of $5.1&#160;million which includes transaction costs of $0.1&#160;million, resulting in a 25% ownership interest in Notch. In February 2021, the Company made a $15.9 million investment in Notch's Series A preferred stock. Immediately following this transaction, the Company's share in Notch was 20.7% on a voting interest basis. In October 2021, the Company made an additional $1.8&#160;million investment in Notch's common stock. Immediately following this transaction, the Company's share in Notch was 23.0% on a voting interest basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s total equity investment in Notch as of September&#160;30, 2022 and December&#160;31, 2021 was $14.0 million and $18.0 million, respectively, and the Company accounted for the investment using the equity method of accounting. During the three and nine months ended September&#160;30, 2022 and 2021, the Company recognized its share of Notch's net loss under the other expenses caption within the condensed consolidated statement of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allogene Overland </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the execution of the License Agreement with Allogene Overland (see Note 6), the Company also entered into a Share Purchase Agreement and Shareholders' Agreement with the joint venture company acquiring shares of Allogene Overland&#8217;s Seed Preferred Shares representing a 49% ownership interest in exchange for entering into a License Agreement which had a carrying value of zero. The Company accounts for its investment in Allogene Overland as an equity method investment at carrying value. The Company's total equity investment in Allogene Overland was zero as of September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s equity investment in Allogene Overland as of September&#160;30, 2022 and December&#160;31, 2021 had a zero carryover basis. Therefore, the Company did not account for its share of losses incurred by Allogene Overland. See Note 6 for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489815211184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company adopted its 2018 Equity Incentive Plan (Prior 2018 Plan). The Prior 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s Board of Directors and consultants of the Company under terms and provisions established by the Company&#8217;s Board of Directors. In September 2018, the Board of Directors adopted a new amended and restated 2018 Equity Incentive Plan as a successor to and continuation of the Prior 2018 Plan, which became effective in October 2018 (the 2018 Plan), which authorized additional shares for issuance and provided for an automatic annual increase to the number of shares issuable under the 2018 Plan by an amount equal to 5% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed 10 years. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than 100% of the fair market value of the Company&#8217;s common stock on the grant date. Options granted typically vest over a four-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there were 12,035,820 shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Exchange program</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, the Company commenced an offer to exchange certain eligible options held by eligible employees of the Company for new options (the Exchange Offer). The Exchange Offer expired on July 19, 2022. Pursuant to the Exchange Offer, 199 eligible holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of 3,666,600 shares of the Company&#8217;s common stock, representing approximately 93.5% of the total shares of common stock underlying the eligible options. On July 19, 2022, immediately following the expiration of the Exchange Offer, the Company granted new options to purchase 3,666,600 shares of common stock, pursuant to the terms of the Exchange Offer and the 2018 Plan. The exercise price of the new options granted pursuant to the Exchange Offer was $13.31 per share, which was the closing price of the common stock on the Nasdaq Global Select Market on the grant date of the new options. The new options are subject to a new three-year vesting schedule, vesting in equal annual installments over the vesting term. Each new option has a maximum term of seven years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange of stock options was treated as a modification for accounting purposes. The incremental expense of $5.2&#160;million for the new options was calculated using a lattice option pricing model. The incremental expense and the unamortized expense remaining on the exchanged options as of the modification date will be recognized over the new three-year service period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes option activity under the 2018 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:42.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contract<br/>Term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,239,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,627,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled under the Option Exchange</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,666,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted under the Option Exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,666,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,122,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,657,219&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,122,447&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on September&#160;30, 2022. For the nine months ended September&#160;30, 2022, the estimated weighted-average grant-date fair value of employee options granted was $9.99 per share. As of September&#160;30, 2022, there was $96.7&#160;million of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of 2 years, 324 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:67.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.195%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 - 6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27 - 6.08</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.82% - 73.39%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.73% - 70.80%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61% - 3.49%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 1.16%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the new options granted under the Option Exchange program was estimated at the date of grant using a lattice option pricing model with the following assumptions: expected volatility of 73.74%, expected risk-free rate of 3.06%, expected dividends of 0% and expected exercise barrier of 2.57.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected exercise barrier - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The modified options are assumed to be exercised upon vesting and when the ratio of stock market price to exercise price reaches 2.57, or expiration, whichever is earlier.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes restricted stock unit activity under the 2018 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant Date Fair<br/>Value per<br/>Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,108,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,108,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there was $85.0&#160;million of unrecognized stock-based compensation related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 2 years, 240 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercised Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows certain of its employees and its directors to exercise options granted under the Prior 2018 Plan and the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the non-current portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. During the nine months ended September 30, 2022 and 2021, zero and 293,594 options were early exercised. As of September&#160;30, 2022 and December&#160;31, 2021 there was $1.9 million and $2.9 million, respectively, recorded in accrued and other liabilities and $1.1 million and $2.5 million, respectively, recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed consolidated financial statements since the exercise date but the shares which are subject to future vesting conditions are not included in the calculation of earnings per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489815372608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a license agreement with Allogene Overland, a corporate joint venture entity and related party (see Note 6). The license agreement was subsequently assigned to a wholly-owned subsidiary of Allogene Overland, Allogene Overland BioPharm (HK) Limited. On April 1, 2022, Allogene Overland HK assigned the License Agreement to Allogene Overland Biopharm (PRC) Co., Limited. During the three and nine months ended September&#160;30, 2022, the Company recognized less than $0.1 million and $0.2 million of collaboration revenue under this arrangement, respectively. During the three and nine months ended September&#160;30, 2021, the Company recognized less than $0.1 million and $38.4 million, respectively, of collaboration revenue under this arrangement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022, the Company recorded $0.3 million and $0.6 million, respectively, of net cost recoveries under the terms of the license agreement as a reduction to research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded zero net cost recoveries under the terms of the license agreement. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for 1,293 square feet of office space in Los Angeles, California for a three year term. On April 1, 2020, Bellco Capital Advisors Inc. assumed all rights, title, interests and obligations under the sublease from Bellco Capital LLC. In November 2021, the sublease was extended to June 30, 2025. The sublease was amended, effective in July 2022, to move to a nearby location, with office space of 737 square feet. The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is a trustee of the Belldegrun Family Trust, which controls Bellco Capital Advisors Inc. The total right of use asset and associated liability recorded related to this related party lease was $0.2&#160;million and $0.3&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a services agreement with Two River, LLC (Two River), a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chair of the board of directors, and a director of the Company to provide various managerial, clinical development, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $0.1 million and $0.6 million for the three and nine months ended September&#160;30, 2022, respectively. The costs incurred for services provided under this agreement were $0.2 million and $0.4 million for the three and nine months ended September&#160;30, 2021, respectively.</span></div>In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $38,583 per month in arrears commencing January 2021 and $40,217 per month in arrears commencing January 2022. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to 60% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The costs incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $0.2 million and $0.6 million for the three and nine months ended September&#160;30, 2022, respectively. The costs incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $0.2 million and $0.6 million for the three and nine months ended September&#160;30, 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810797408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company has a history of losses and expects to record a loss in 2022. The Company continues to maintain a full valuation allowance against its net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489895118000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,122,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,109,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units subject to vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,108,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,393,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected shares to be purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Founders' shares of common stock subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,143,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,865,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489815327440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn October 6, 2022, the Company announced the initiation of the Phase 2 clinical trial of ALLO-501A (the ALPHA2 trial) in patients with relapsed/refractory large B-cell lymphoma. The Company is also in the process of initiating the EXPAND trial, which is intended to demonstrate the contribution of ALLO-647 to the lymphodepletion regimen. In accordance with the Servier Agreement, the Company is required to make a milestone payment of $8.0&#160;million upon first dosing of the first patient in a Phase 2 clinical trial. The milestone payment is expected to be recognized in the fourth quarter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489816085264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of stockholders&#8217; equity as of September&#160;30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended December&#160;31, 2021, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 23, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the accounting policies during the three and nine months ended September&#160;30, 2022, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued or effective that are expected to have a material impact on the Company's condensed financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489895118000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis and Level of Inputs Used in Such Measurements by Major Security Type</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:&#160;</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,034&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Included within cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489815187392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Fair Value and Amortized Cost</a></td>
<td class="text">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,812)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,719&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,515)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,205&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,156)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,034&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489815216992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and purchased software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,030&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489816095520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_LiabilitiesLesseeTableTextBlock', window );">Schedule of Lease Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_090f2506-4094-4262-920e-2e1663730d2d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_c2737ca9-b04a-4d28-a3da-5b7ccec47c9f">Current portion included in accrued and other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,831&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,537&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,129&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,944&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Lease Payments Under Lease Liability</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undiscounted future lease payments under the lease agreements as of September&#160;30, 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2022 (remaining 6 months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810371424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under Plan</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes option activity under the 2018 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:42.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contract<br/>Term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,239,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,627,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled under the Option Exchange</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,666,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted under the Option Exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,666,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,122,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,657,219&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,122,447&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Stock Option Valuation Assumptions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:67.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.195%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 - 6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27 - 6.08</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.82% - 73.39%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.73% - 70.80%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61% - 3.49%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 1.16%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity Under Plan</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes restricted stock unit activity under the 2018 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant Date Fair<br/>Value per<br/>Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,108,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,108,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489815281664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Shares</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,122,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,109,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units subject to vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,108,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,393,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected shares to be purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Founders' shares of common stock subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,143,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,865,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489816192256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="nump">$ 637,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 1,141,133<span></span>
</td>
<td class="nump">$ 903,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489809510976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - Fair Value, Measurements, Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 582,205,000<span></span>
</td>
<td class="nump">$ 752,034,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489805347456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities (Detail) - Fair Value, Measurements, Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 582,205,000<span></span>
</td>
<td class="nump">$ 752,034,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">19,225,000<span></span>
</td>
<td class="nump">115,867,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">17,987,000<span></span>
</td>
<td class="nump">58,976,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">168,517,000<span></span>
</td>
<td class="nump">223,474,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">332,334,000<span></span>
</td>
<td class="nump">303,016,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">44,142,000<span></span>
</td>
<td class="nump">50,701,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">351,559,000<span></span>
</td>
<td class="nump">418,883,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">19,225,000<span></span>
</td>
<td class="nump">115,867,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">332,334,000<span></span>
</td>
<td class="nump">303,016,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">230,646,000<span></span>
</td>
<td class="nump">333,151,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">17,987,000<span></span>
</td>
<td class="nump">58,976,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">168,517,000<span></span>
</td>
<td class="nump">223,474,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">44,142,000<span></span>
</td>
<td class="nump">50,701,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489805265584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 594,719<span></span>
</td>
<td class="nump">$ 754,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(12,515)<span></span>
</td>
<td class="num">(2,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">582,205<span></span>
</td>
<td class="nump">752,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">19,225<span></span>
</td>
<td class="nump">115,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">477,872<span></span>
</td>
<td class="nump">283,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">85,108<span></span>
</td>
<td class="nump">352,179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CashEquivalentsAndShortTermInvestments', window );">Total cash equivalents and investments</a></td>
<td class="nump">582,205<span></span>
</td>
<td class="nump">752,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">19,225<span></span>
</td>
<td class="nump">115,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">19,225<span></span>
</td>
<td class="nump">115,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">17,995<span></span>
</td>
<td class="nump">58,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">17,987<span></span>
</td>
<td class="nump">58,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">172,278<span></span>
</td>
<td class="nump">224,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(3,761)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">168,517<span></span>
</td>
<td class="nump">223,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">339,145<span></span>
</td>
<td class="nump">304,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(6,812)<span></span>
</td>
<td class="num">(1,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">332,334<span></span>
</td>
<td class="nump">303,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">46,076<span></span>
</td>
<td class="nump">51,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(1,934)<span></span>
</td>
<td class="num">(374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 44,142<span></span>
</td>
<td class="nump">$ 50,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489816188480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Maximum remaining contractual maturities of available-for-sale securities (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Net unrealized loss position</a></td>
<td class="nump">$ 153,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest receivable from available-fore-sale investments</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL121698322-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267856-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810337984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 149,030<span></span>
</td>
<td class="nump">$ 146,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(34,588)<span></span>
</td>
<td class="num">(23,361)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">114,442<span></span>
</td>
<td class="nump">122,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">108,412<span></span>
</td>
<td class="nump">108,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">31,443<span></span>
</td>
<td class="nump">29,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember', window );">Computer equipment and purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">5,033<span></span>
</td>
<td class="nump">4,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">3,976<span></span>
</td>
<td class="nump">3,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489799712160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 14, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,641,000<span></span>
</td>
<td class="nump">$ 58,720,000<span></span>
</td>
<td class="nump">$ 180,968,000<span></span>
</td>
<td class="nump">$ 166,193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,046,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,046,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments for additional investment in interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,938,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="nump">38,438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments for investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,318,000<span></span>
</td>
<td class="nump">474,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=allo_UniversityOfTexasMDAndersonCancerCenterMember', window );">University Of Texas MD Anderson Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationAgreementUpfrontPayment', window );">Collaboration agreement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationAgreementCommittedFunding', window );">Committed funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember', window );">Allogene Overland, Allogene Overland BioPharm (HK) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Net cost recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">38,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ReductionToResearchAndDevelopmentExpense', window );">Reduction to research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | University Of Texas MD Anderson Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationArrangementExpense', window );">Collaboration arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments for additional investment in interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Voting Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember', window );">Allogene Overland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember', window );">Allogene Overland | Overland Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Allogene Overland | Overland Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_UpfrontAndQuarterlyCashPayments', window );">Upfront and quarterly cash payments</a></td>
<td class="nump">$ 117,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_JointVentureCapitalSupportPayments', window );">Joint venture capital support payments</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Allogene Overland | Allogene Overland, Allogene Overland BioPharm (HK) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationAgreementUpfrontPayment', window );">Collaboration agreement, upfront payment</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMember', window );">Antion Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationAgreementUpfrontPayment', window );">Collaboration agreement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationArrangementExpense', window );">Collaboration arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMember', window );">Antion Collaboration Agreement | Current Accrued and Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationArrangementExpense', window );">Collaboration arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMember', window );">Antion Collaboration Agreement | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments for investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement', window );">Payments for investments upon milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMilestoneAchievementOneMember', window );">Antion Collaboration Agreement, Milestone Achievement One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMilestoneAchievementTwoMember', window );">Antion Collaboration Agreement, Milestone Achievement Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_RoyaltyObligationPeriodFromDateOfFirstSale', window );">Royalty obligation period from date of first sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones', window );">Aggregate potential regulatory and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget', window );">Maximum payments required per product against selected target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Pre-Clinical Development Milestone | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Development and Sales | Maximum | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostPayableByTheCompany', window );">Percentage of development costs payable by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner', window );">Percentage of development cost payable by collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Net cost recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">$ 20,400,000<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestoneReceivable', window );">Aggregate potential milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestoneReceivable', window );">Aggregate potential milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationArrangementExpense', window );">Collaboration arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborationAgreementUpfrontPayment', window );">Collaboration agreement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Pre-Clinical Development Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Clinical, Regulatory, and Commercial Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory and development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialRegulatoryAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationAgreementCommittedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Committed Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationAgreementCommittedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_JointVentureCapitalSupportPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint Venture Capital Support Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_JointVentureCapitalSupportPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payments required per product against selected target.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Investments Upon Milestone Achievement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Development Cost Payable By Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfDevelopmentCostPayableByCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfDevelopmentCostPayableByTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Development Cost Payable By The Company</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfDevelopmentCostPayableByTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ReductionToResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction to Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ReductionToResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RoyaltyObligationPeriodFromDateOfFirstSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation Period From Date Of First Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RoyaltyObligationPeriodFromDateOfFirstSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_UpfrontAndQuarterlyCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and Quarterly Cash Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_UpfrontAndQuarterlyCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=allo_UniversityOfTexasMDAndersonCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=allo_UniversityOfTexasMDAndersonCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_EquityInvestmentBasisAxis=allo_VotingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_EquityInvestmentBasisAxis=allo_VotingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=allo_OverlandPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=allo_OverlandPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=allo_OverlandPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=allo_OverlandPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=allo_CurrentAccruedAndOtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=allo_CurrentAccruedAndOtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMilestoneAchievementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMilestoneAchievementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMilestoneAchievementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMilestoneAchievementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489805401904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178; </div>
<div>renewal</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of office and laboratory (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,943<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">124 months<span></span>
</td>
<td class="text">127 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AdditionalAreaOfNewOfficeBuilding', window );">Additional area of office and laboratory (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_TenantImprovementAllowance', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_LesseeFinanceLeasePaymentUponContractTermination', window );">Termination payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Non-cancellable purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=allo_LeaseOneAmendedMember', window );">Lease One, Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=allo_LeaseTwoMember', window );">Lease Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=allo_NewarkMember', window );">Newark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">188 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AreaOfOperatingLease', window );">Area of operating lease (in square feet) | ft&#178;</a></td>
<td class="nump">118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_NumberOfOptionsToExtendLease', window );">Number of options to extend lease | renewal</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_TenantImprovementAllowanceUtilizedToDate', window );">Tenant improvement allowance utilized to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AdditionalAreaOfNewOfficeBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Area of New Office Building</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AdditionalAreaOfNewOfficeBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfNewOfficeBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of new office building.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfNewOfficeBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LesseeFinanceLeasePaymentUponContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Payment Upon Contract Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LesseeFinanceLeasePaymentUponContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfOptionsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options to extend lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfOptionsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_TenantImprovementAllowanceUtilizedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement Allowance, Utilized To Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_TenantImprovementAllowanceUtilizedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=allo_LeaseOneAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=allo_LeaseOneAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=allo_LeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=allo_LeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=allo_NewarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=allo_NewarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810277808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in accrued and other current liabilities</a></td>
<td class="nump">$ 5,831<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">96,706<span></span>
</td>
<td class="nump">69,929<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 102,537<span></span>
</td>
<td class="nump">$ 73,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489816035504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3,177<span></span>
</td>
<td class="nump">$ 1,853<span></span>
</td>
<td class="nump">$ 8,476<span></span>
</td>
<td class="nump">$ 5,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 3,793<span></span>
</td>
<td class="nump">$ 2,301<span></span>
</td>
<td class="nump">$ 9,944<span></span>
</td>
<td class="nump">$ 6,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810629856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Undiscounted Future Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining 6 months)</a></td>
<td class="nump">$ 2,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">12,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">12,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">12,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">12,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">2027 and thereafter</a></td>
<td class="nump">90,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">143,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(40,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 102,537<span></span>
</td>
<td class="nump">$ 73,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489805230880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2019</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments for additional investment in interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,938,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,046,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire interest in Notch</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CostMethodInvestmentTransactionCosts', window );">Transaction cost</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments for additional investment in interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Voting Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember', window );">Allogene Overland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CostMethodInvestmentTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Method Investment, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CostMethodInvestmentTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_EquityInvestmentBasisAxis=allo_VotingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_EquityInvestmentBasisAxis=allo_VotingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489804929280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 19, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 21, 2022 </div>
<div>employee </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding', window );">Number of shares as percentage of common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,035,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Plan modification, incremental cost</a></td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Expected exercise barrier (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">293,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees', window );">Exchange offer, number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions', window );">Exchange offer, number of options accepted for cancellation (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,666,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding', window );">Exchange offer, percentage of total shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, options granted (in shares) | shares</a></td>
<td class="nump">3,666,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock based compensation expense, weighted average recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 324 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Expected risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Expected exercise barrier (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock based compensation expense, weighted average recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 240 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_StockOptionGrantedPeriod', window );">Stock option grant period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate', window );">Option exercise price as percentage of fair value of common stock on grate date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares as percentage of common shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option exercise price as percentage of fair value of common stock on grate date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Percentage Of Total Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockOptionGrantedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option granted period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockOptionGrantedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489805438592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(293,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance (in shares)</a></td>
<td class="nump">10,239,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, options granted (in shares)</a></td>
<td class="nump">8,627,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, options exercised (in shares)</a></td>
<td class="num">(174,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, options forfeited (in shares)</a></td>
<td class="num">(569,697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod', window );">Number of options, option exchange, options cancelled (in shares)</a></td>
<td class="num">(3,666,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross', window );">Number of options, option exchange, options granted (in shares)</a></td>
<td class="nump">3,666,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance (in shares)</a></td>
<td class="nump">18,122,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,239,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">13,657,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, vested and expected to vest (in shares)</a></td>
<td class="nump">18,122,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 21.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options granted (in dollars per share)</a></td>
<td class="nump">9.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options exercised (in dollars per share)</a></td>
<td class="nump">2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options forfeited (in dollars per share)</a></td>
<td class="nump">24.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, option exchange options cancelled (in dollars per share)</a></td>
<td class="nump">26.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, option exchange options granted (in dollars per share)</a></td>
<td class="nump">13.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">13.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contract term, outstanding (in years)</a></td>
<td class="text">8 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, exercisable (in years)</a></td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, vested and expected to vest (in years)</a></td>
<td class="text">8 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, balance</a></td>
<td class="nump">$ 25,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">24,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 25,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants In Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489805422768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">70.82%<span></span>
</td>
<td class="nump">69.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">73.39%<span></span>
</td>
<td class="nump">70.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk-free interest rate, minimum</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk-free interest rate, maximum</a></td>
<td class="nump">3.49%<span></span>
</td>
<td class="nump">1.16%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489810095040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Unit - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, beginning balance (in shares)</a></td>
<td class="nump">4,261,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted (in shares)</a></td>
<td class="nump">3,316,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units, vested (in shares)</a></td>
<td class="num">(991,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units, forfeited (in shares)</a></td>
<td class="num">(476,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, ending balance (in shares)</a></td>
<td class="nump">6,108,670<span></span>
</td>
<td class="nump">4,261,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Restricted stock units, vested and expected to vest (in shares)</a></td>
<td class="nump">6,108,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 26.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, granted (in dollars per share)</a></td>
<td class="nump">9.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, vested (in dollars per share)</a></td>
<td class="nump">27.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, forfeited (in dollars per share)</a></td>
<td class="nump">22.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, ending balance (in dollars per share)</a></td>
<td class="nump">17.41<span></span>
</td>
<td class="nump">$ 26.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 17.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining vesting life, unvested (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 8 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining vesting life, granted (in years)</a></td>
<td class="text">1 year 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining vesting life, vested and expected to vest (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value, unvested</a></td>
<td class="nump">$ 65,974<span></span>
</td>
<td class="nump">$ 63,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 65,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489799698784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 21,148<span></span>
</td>
<td class="nump">$ 20,856<span></span>
</td>
<td class="nump">$ 66,354<span></span>
</td>
<td class="nump">$ 58,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">11,016<span></span>
</td>
<td class="nump">10,074<span></span>
</td>
<td class="nump">35,068<span></span>
</td>
<td class="nump">28,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 10,132<span></span>
</td>
<td class="nump">$ 10,782<span></span>
</td>
<td class="nump">$ 31,286<span></span>
</td>
<td class="nump">$ 30,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489798200688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">$ 196,000<span></span>
</td>
<td class="nump">$ 38,438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,030,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,129,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember', window );">Allogene Overland, Allogene Overland BioPharm (HK) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">38,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Net cost recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_AreaOfOffice', window );">Area of office space (in square feet) | ft&#178;</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Sublease, term of contract (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Payments Commencing January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears', window );">Related party transaction monthly payment in arrears</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Payments Commencing January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears', window );">Related party transaction monthly payment in arrears</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_RelatedPartyTransactionCompensationPercentage', window );">Related party transaction compensation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember', window );">Two River | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfOffice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of office.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfOffice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction compensation percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction monthly payments in arrears.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionMonthlyPaymentsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489813024176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">25,143,966<span></span>
</td>
<td class="nump">17,865,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">18,122,447<span></span>
</td>
<td class="nump">10,109,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units subject to vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">6,108,670<span></span>
</td>
<td class="nump">3,393,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Expected shares to be purchased under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">750,317<span></span>
</td>
<td class="nump">276,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember', window );">Founders' shares of common stock subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,028,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember', window );">Early exercised stock options subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">162,532<span></span>
</td>
<td class="nump">1,057,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140489809573184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 06, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Collaborative arrangement, rights and obligations, milestone payment</a></td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborativeArrangementRightsAndObligationsMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborativeArrangementRightsAndObligationsMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>allo-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:allo="http://allogene.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="allo-20220930.xsd" xlink:type="simple"/>
    <context id="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0782ce963cba40ac97e2f2e475fbde26_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i851ceebb52594744ab16edeb67e8db95_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iecc019de3c544aa08930db1891672917_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia16e1786ad8b4304b2dea68bd40ec715_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2768721624b646e4b4102030fc534111_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62204640c1dd4c7e84683bae3464411b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90fc78fa954a4298bce5f60606ef9a4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idab67126ce664974bc2dd9963d5c3ba0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i660319721ce344d8a0b9154850955702_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i568599dba7e143dfae2ed582eab3cff3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4c2e5335e0bc41c785958fd6330aacc7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i328d6792e081436fa76276a9678f424c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic0adaff1a464431da2afd3e58a0fc274_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic900f2b82bd74b6ab94b987c5117fc3a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia8c5743ca8a348359d46ddb287076e9d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i67020356c6204f40b4841f871a50d053_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i66ea312ec5214b9caacbbb7ac02ee5ff_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0b1e6139112545ef9da1ebd8710ab2f1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib1e087f2a6e34ff89eb1651f147dcc07_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i53bc2cfd3e704820a725a843f0e2fdf8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i666c9e4e34704eb890ea456c2f944a0d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i25f5c9a7d2bc4d3ca5014da4f40097b1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i00e354ae71e34ceea20c3c9ba63e8763_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i45581b958f3f4670b5c86820707bb668_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if440df8de9ff4378a42f14411ea24199_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ice884c5236d74ae4aed903a5266a526b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic2ed3bf5b05643c09d7e7b6060b8df59_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i29d45c7d7a79444cbab51b762db8a92a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7e40da32cd9649fda45dd94c8886a401_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib52a77f5cfce4da693d48878535ff579_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia7e4663ddd5e4d3fb00c03d8227b3e83_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3fc217acd2be43718fb7e4ed4c014def_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3533121d864f4c0583c7555923834700_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8448819002f446acb79abaf404098bfb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4c0e6ec7e054c1da14d802766b50abf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibefeee67a5174cca8fc8c95afe569cb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27bc23f568da4811a9958f2effaa11a7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i52c6c38d96b3496c83a3c3f4292c5f08_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i60949035a3624cc68a5f08899693ed89_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3285731b68de4e41ad0c1865ada7997c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i36b261d41d814a7cb5646538703fecb1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i656fbffbeb434eb49eeae23b018e4fe7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i93a49ed55a0642638b964d93a55082ef_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i027d2deea89848eba3b25676ffe40a68_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie3c3681993a340ce9e153807ca820af8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i96a08f54165449009616a55b4debdf18_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1192f2bcfd174e4e87c6a48a6b229311_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b441d0ab9104d6f906ea50fc1740b98_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1ced53064cd42a28878d18228552b20_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9545d58a43c140a2a6a71474a6ee1920_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia77b5caccc864c93a8578007ada8f202_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i470e7ef6e8484f10a411d5c0a26a3342_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i970726c2db304fcbb4d9a0c045073a76_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i66f164bd81e042c9bdbbf51049d8b187_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if2793cc8b4294f6aa53a79a343ce1cd5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie199bf4d5f3d4388984d9af23f496b4a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e8df77f75814bb3bd276293c61def27_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia8ff97a82a1149f0a766b4dd2aeb2039_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i44eb82ada8fc4b7aac17b9def190f34b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i66c9685093544f8e9743c24c6b40e4fc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i96730d707ea04cf892c0873970a6389c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie730bc1281e742289f7b14d42eff7b48_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic59dec0676034b50b7ad0a219c00b9ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16d0ead330c24d62aeb2da5efcc4a64a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1e54a3337efd4d039762b588776fa199_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib0b727b1deb0471d88a053257c9a4611_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib0e1772a9a774e75a2d532c1fa03dfd9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibd4d50cd1236423f81f303edc85b5416_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibcdb27b9bd024ba9aa1c201ba5aa6171_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2c83b117241041978e86a79078e74505_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1c093d5bad964a0cb856275d022daf5c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib9e4e9b1f287486c97e5fdc273885d36_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i67e850a333e249b0925d51da049c0000_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia80be28ab7b844ffac2c1c656f493915_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i00b938fa488644558a07b02468cca245_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i41d843d66f73450085167330c08fa8f4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7957a6a04a864f12ad0b9fd205fb2027_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1a8d37d4b41e43ae8b50608fce513cf9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5a332d398be94f8283d48f49a486acd4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ided01fd1fae3479a887f1df9839cb3c9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iae16a63b5e8d410aaea9422f95a58df3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6229e7a19925408a883eeb53268596c3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifb1e9f69fd5145b2a82d1c99cf574c36_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia7be2e87e35f4e328aca6856dd8c331c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iecb03622518f4a8aa208f441ff5ed3e5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia9664a6d74d14cd2b0e6999a7746fbb3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8b39ce52bb534d8ab364d55d7a5a4845_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b26963b040c464ab654260f9b024c8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9196dc684bfe4858b5edf3e1ffd737c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08414a6efbee44f99241e34feca223cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib21f092a53bd4a75b19b5ea1f96f0dca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaac26891f51c43f698aa0fcfa42259de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5742857dc7946a285456adb1db7f9b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19e46bf35fc4476db2f52c28e5fdfe66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87f1616b693e482bbe1bc2c39cb50669_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cc072cc86b04dd09d83c1d2c3602144_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d45516c51f84306a30498bb283d1dae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia22fda346a3b44f58bf392876c6af2d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie368da95aed94f39a8028a7fe3264ca2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac7b7966b0834b118a6dddf7f31e7efc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iceda1e0793a444bfbea8f6f96fc85ca1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d0b55b1ab65461dbc838d478634fbc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a6f4571309a4989846c43edc13b9607_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifba287fafeb24922afb0bd5704ca7f09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43eb4f2c71bd40acade960ac4537414f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i274296360e7f471b817e447bda912e0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9eadb3f0fcf547ddab8ff0ef26f06f52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a34f9b02232491b96689d6036cda254_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8c3e4c35b6d4a5fa0398b1187be86ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67454b2a010e4042ac9e965a1600e8a8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5f21a84a447d4ac69ec3d11a73e75977_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id75fdfd77e0748c8bb330bc88f7cea38_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i495066fc809c46088689104229f96bd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc8586da0577480cb7a0240005555a9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bbc0838fe244d26ba01e286b31789de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb2b5f01151e42a08a9681956bf850f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32d24e7b9e4e46139098c072d28e3b8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5db76501bbc74787965531c11d212d58_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i08b3bb83a6f447df99a6eb708011d28b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie09d16f1562c4ea7a6206e6000a0d8c9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5f488c95563e4fc0abd6053e7cdbcef3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26accf762170429ebb2cfab586faf0e3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i86caf7b4d7f94d6a815a266b3f51ee53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icda10573477f47fda5d385ccafcf2a6b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic6c9232fcc104c6894737b6331f6e04d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf1f3fff4077416faac3922039ac158c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic4d4d159174f4bfea30e39a7ea47463f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba32805724354181ae04c6b3cacb4be2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7dddb67349574083921a243e6e892161_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6aade5c20f2244a3ade2b713c171949b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ief48337bd67341b9bb41f73b0b3c18f3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7eb2b0edcdf44e7894b474bef1a2f72c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9534ed89959b476bb3c61a21f111f0ac_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic8ccb9c3e12e4bfbbafab7c1c5ed2261_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ida71502c322b490db719e60631ed9186_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i12d3205699d44a1595452c484f84725b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:DevelopmentAndSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5cd514b962e246c6931c985ac1c2ec04_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibd1dcad80d4e4790ae883499a22385cc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5454ce81effa43ec82d692544d01340c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i82036ec2aaa24cc88e17cb24559ae7cd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8cc896b3a0a744c0b48d522995094a4c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i72513027aa40456ea894b7c240d9529e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4eeda0f2399347eba9a1d3c03cd7ed64_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d882b41ba7546aaa56039ced1a10287_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6dbfd0aa1f5c4f6d8ac7bf09374fbbcb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id7323529b23b45e7b1f3558682b81cd8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic72e6bbd73b24d50b42d5a271012c22c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i664e2401aa7b4ff9b1bca0d363df47d4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e4f3d045a2243009dac024b2e80a3ca_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic983cd690af84de59565ffe50d5f5432_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58179b3cdca14b9aa3417426bdb601bb_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="i66aa59ed9c4048298f0a3a33feba7cc5_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="i3871a5c9adb14fedb9c83c1425f51c54_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ie8a195a8a56445a3999166ac9339894c_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i44b0b5f2e18c49b2991662b317cd0227_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:EquityInvestmentBasisAxis">allo:VotingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i36321bc5549f4fdf84b022c72c2623e0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i25e249ab3ca0464995456f2a93a352ff_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6b6f12ac8d143eda9f281cbcc802324_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ClinicalRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7bb1c70c0e2a408eba7c119e0cecf3a3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i190dbd12ad724f999de964f8944f43f9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7aa0b52e31cb47caa5b6de4a921c9b55_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb0223ba204941ab82cb484b7e33f56a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia9bf9785d75b4721b9ff6232ef70d39b_D20201006-20201006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-06</endDate>
        </period>
    </context>
    <context id="iee875a3ae84d46ed987a1b307db20e6e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3240a374c5ab440e8b5e1aabbdba7c25_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iff52c9c9567540af853d7d4e7492d0ca_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if7f6257251904aeda6581f6bfc8b2065_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93f8ae51b31a40de91e52c6738e4e6d5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib9fc1bf30b194863ae80b306bfcfbb2f_I20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="if2742005271e46328201e1c4c09f2efc_I20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">allo:OverlandPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="iae425c05634344d4904101d51eef4cc6_D20201214-20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:OverlandPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="i717e3fb1a0d945d5851037cc406f873a_D20201214-20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="i5d1cf8a7bcb44874baee49aa53e9d5ce_I20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8499187e402947009dcd0f43cd08b023_I20220105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="ib00af316994b480e903873475c1e0166_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia7b7af3feeda4ecd91976cd1a7640903_I20220105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMilestoneAchievementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="i7bbcb65830e9469e8584561b4ed503d6_I20220105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMilestoneAchievementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="i7ab46440194c44e0abc3230ea0acaa11_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0599d7f096e54faa830326a4b07be324_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i12798b13b2e34a1f8b05f08a0a198299_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:CurrentAccruedAndOtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia1861d08a2de4faebc1dfeee012e2263_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:CurrentAccruedAndOtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:AntionCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0db19e8474cf4b47a8a2c996ea80614d_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="i6c0fcddb98e0438fbee11a2250f1b7bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">allo:LeaseOneAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87ee1a949aa34bb7bc017891ce79e050_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ic1bb308e19ad469187b256dd69806dce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">allo:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e8ea8f25c7b4bfb9cf53b843eb1b98b_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="ica7aec93cbca455f9d73fe168f4f412b_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="id1877d8c1c9d40b58cdc5a256ab21b2b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i285646cc47ee4e0781be1e398f978e9a_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i936368d1ad874c5791721226f6432723_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i186cd8de8d9844958fcbdfb4ccfb61ed_D20191101-20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-01</endDate>
        </period>
    </context>
    <context id="i1b45cc2e745b42e9b32d37a59ae969d4_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:EquityInvestmentBasisAxis">allo:VotingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i1492a2fea02e4f998d775344e68d1e5f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7b00d6b5fecd421bb33ba50571717267_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ed593580aad4f18a35e79239d80c7d7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8da13d9ff1754a2f85537e5c6a6528e9_I20220621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-21</instant>
        </period>
    </context>
    <context id="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-19</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="ib2ab7bde48b24a23bcc9d3eec9a88153_I20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-19</instant>
        </period>
    </context>
    <context id="i2930cb3944834b138006d0840c8071b9_D20220719-20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2022-07-19</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="i335a2face5cf44a58769ff4969fb2cc1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87b1b7f6f25749da9e0c6010a3a596c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i80967c9edd9c4b2c9d93991aba2977e3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie0ac5f114f4b4675aa3371c31e9a9f93_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf9b3aebda244d37a641882195bc9a25_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic91b0bb6bd0945bbac49f373c6dce054_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i11560b36616e4aaeba3be6911de62405_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id11744c3dcc0478fbe1ac19d5b674e5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f197f101d1c490f9238233b8c06f878_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0cf5a81c459045259eb6e048191ed8b9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6627a5e0bcb745a7bcf2b1a0bcfb8913_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9b8c2dddec8a42c2a41bd9069f28fb76_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3949326941ae44ad8b85a5116571b2d9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb04d23e1b334eea8232a278c94030b1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f95a2fe74e8495c8a44a351002ab5f1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i692e53151ed54db2bcad88681554f8e5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i657be91ad1cf4834ae3e495d97c6b831_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0b0292c40a9540d5afb21ac604de6b00_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide3d377e6ef446be87bcdb339dfc0b9b_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i55782e475b6a49e68f013ee57e855017_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i10cdf1fbcbd24042b88e39c59ceb0185_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i6835c65c40e448ee9cdf956aa442f14c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2f07bcc60d124644b17029e7a86498b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i244e669df12d499393987c604e57d35f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i70d6feb00c574d04aecd098830cbbe99_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i311fa2e0db8b4c88adb07d7473de0631_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3f691c5f7eea4a9b9059a123b37ca9aa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ffebc0cc88b45c683f02d07c9da34b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48fcbfbc97c948488803f2fa246b65ec_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i83ba27cde25d42a1bcb8d43b98591e86_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i71270f28c9f44b26884a7a3c29b0a8c6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iad6cc93503974700a19e1ba725f39da7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9b84fdd9ca2b4e34a5b489c6cfd75f6b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3537c96671a47618355dfe9daa3ab84_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c288bc903b4445db1aca2a0589bff15_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie2735eb3759f4c978a3d46ef79aa58c4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i09654a2f64fc4baea96c1b7e18d63c05_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia29bfb086dc54826adc5a81036ef756f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i168b193cba9e427089753a5b30b8c90f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i774d91333c954992bc09c9a46d392ded_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a0727775830468a9e27ab2c44c1b6ff_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1d3e864f70414a80bc0964777b022263_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf062f962ee04c1fad713216e1f06041_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6b6de817bdd944afad54fb6f862dd4cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i34c392be59f54e6f9714301ddcb1bc63_I20221006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-06</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewal">
        <measure>allo:renewal</measure>
    </unit>
    <unit id="employee">
        <measure>allo:employee</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl8yLTEtMS0xLTM4MzQz_f8de3c3a-05ea-4f4d-ba67-7801c75b24ee">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl8zLTEtMS0xLTM4MzQz_b6467e34-9d64-4d1e-b954-4a9a906496e8">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl80LTEtMS0xLTM4MzQz_ab029bca-7167-427f-88ae-bb9a09c2c900">0001737287</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl81LTEtMS0xLTM4MzQz_ff1220d3-fa56-4566-a698-dd170424ec18">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80L2ZyYWc6YTM0NzRiOWQ3YThiNGE2NWI3MmJiMjdhYzc3NjIyYTgvdGFibGU6NzFmMDE2MDJjYTA2NDUzZGI0MWFjMDM5OWY0OTA0MjIvdGFibGVyYW5nZTo3MWYwMTYwMmNhMDY0NTNkYjQxYWMwMzk5ZjQ5MDQyMl82LTEtMS0xLTM4MzQz_39b583d2-01ca-4d82-8afd-628002b0488f">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_090f2506-4094-4262-920e-2e1663730d2d">http://allogene.com/20220930#AccruedAndOtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_c2737ca9-b04a-4d28-a3da-5b7ccec47c9f">http://allogene.com/20220930#AccruedAndOtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzIw_c44218f9-29db-471d-95d1-fd85bbb016c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YTY0YWQ3OTI0MThkNDVhYWJlNzMyMWE5MmU3MTBjYTMvdGFibGVyYW5nZTphNjRhZDc5MjQxOGQ0NWFhYmU3MzIxYTkyZTcxMGNhM18wLTAtMS0xLTM4MzQz_4aad8fb9-5128-4869-bbbc-589f81b6c31a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yNDU_e95ffc29-bd16-4ce5-9d1c-6c2522d3137a">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6NzM3NzkwZmQ4Y2U2NDEzYzhiN2IwNzMwNzEyZDAwZTcvdGFibGVyYW5nZTo3Mzc3OTBmZDhjZTY0MTNjOGI3YjA3MzA3MTJkMDBlN18wLTAtMS0xLTM4MzQz_17e9bb21-b27c-441a-9e67-a4a4f114cf42">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzEx_fea6aeb3-ae9e-4dd5-b526-c1993a6b8b1c">001-38693</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV80MjE_74764728-7de0-4b94-844b-c566af9b221b">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YTFiODIwZmU3MmFhNDA1YmFlYjMyMTRlMDg1OTdlNzYvdGFibGVyYW5nZTphMWI4MjBmZTcyYWE0MDViYWViMzIxNGUwODU5N2U3Nl8wLTAtMS0xLTM4MzQz_16f09e21-6b35-49eb-b411-7a78d93e5da6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YTFiODIwZmU3MmFhNDA1YmFlYjMyMTRlMDg1OTdlNzYvdGFibGVyYW5nZTphMWI4MjBmZTcyYWE0MDViYWViMzIxNGUwODU5N2U3Nl8wLTItMS0xLTM4MzQz_e4dca1a3-9e67-44bc-bf6f-51b40570cc55">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzEy_1615e505-66d2-4dbf-b921-05d19adde96e">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE1_e3f48eef-545d-408c-894a-35205344db7b">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzEz_66f6f547-c157-4a6f-96ce-ca929c810d28">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE2_8e2adc5d-dfa8-48dd-8c2b-7faf5a6fbf0c">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV83MTI_172bab56-ee7b-4138-9110-d42daeb29ea5">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE0_f266a9a8-4204-4dd2-82c2-54cd81a8b784">457-2700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YzhmZjNhOTU3YjM0NDhiY2FkMTc0YjdjYThjNDY4M2MvdGFibGVyYW5nZTpjOGZmM2E5NTdiMzQ0OGJjYWQxNzRiN2NhOGM0NjgzY18xLTAtMS0xLTM4MzQz_2dc2c1f5-c63f-465b-ac51-a518da7b6046">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YzhmZjNhOTU3YjM0NDhiY2FkMTc0YjdjYThjNDY4M2MvdGFibGVyYW5nZTpjOGZmM2E5NTdiMzQ0OGJjYWQxNzRiN2NhOGM0NjgzY18xLTItMS0xLTM4MzQz_dcf4d226-6abd-46d2-9bc4-66a7ba00de6a">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6YzhmZjNhOTU3YjM0NDhiY2FkMTc0YjdjYThjNDY4M2MvdGFibGVyYW5nZTpjOGZmM2E5NTdiMzQ0OGJjYWQxNzRiN2NhOGM0NjgzY18xLTQtMS0xLTM4MzQz_9f5db61c-7dbd-453b-9b02-414d7384dffc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzI1_df043de1-229f-4b47-b6de-3f54a976b21b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE3_9022b18d-e775-4a77-a1fd-2dd70158bca3">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6MmI4ZGI2OTNiOWZiNDQ1MzgyZmM4MjJjNzEyNzZmMTcvdGFibGVyYW5nZToyYjhkYjY5M2I5ZmI0NDUzODJmYzgyMmM3MTI3NmYxN18wLTAtMS0xLTM4MzQz_5cec9b27-0929-4354-bb85-b2311d4d577c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6MmI4ZGI2OTNiOWZiNDQ1MzgyZmM4MjJjNzEyNzZmMTcvdGFibGVyYW5nZToyYjhkYjY5M2I5ZmI0NDUzODJmYzgyMmM3MTI3NmYxN18xLTQtMS0xLTM4MzQz_ed251bbb-fe9d-4adb-9530-4e2ed7d706e6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGFibGU6MmI4ZGI2OTNiOWZiNDQ1MzgyZmM4MjJjNzEyNzZmMTcvdGFibGVyYW5nZToyYjhkYjY5M2I5ZmI0NDUzODJmYzgyMmM3MTI3NmYxN18yLTEtMS0xLTM4MzQz_7d9bb09f-8d2e-4f3c-8286-29dc80235771">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMzE5_33dd9c14-1c73-4f42-8af3-ce1e386bdf60">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0782ce963cba40ac97e2f2e475fbde26_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xL2ZyYWc6MzhkZWEyZmNjNzE3NDc2Mzk1NDM5MTkwOTZiYWNkN2UvdGV4dHJlZ2lvbjozOGRlYTJmY2M3MTc0NzYzOTU0MzkxOTA5NmJhY2Q3ZV8yMjQz_d6f10165-fb95-48f5-9ac6-4e440ce9c813"
      unitRef="shares">144210154</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMy0xLTEtMS0zODM0Mw_801a670a-c699-409d-958a-f5530cf2bcb0"
      unitRef="usd">74357000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMy0zLTEtMS0zODM0Mw_70c41522-cc1a-4b9b-993c-8c5196417aa1"
      unitRef="usd">173314000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNC0xLTEtMS0zODM0Mw_588ac64c-73d3-4ddf-9e6f-53ce2d1eb4fe"
      unitRef="usd">477872000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNC0zLTEtMS0zODM0Mw_0be2bb55-3755-409c-913b-476cff29cd17"
      unitRef="usd">283988000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNS0xLTEtMS0zODM0Mw_2d7a46a5-3220-446c-af6e-df2a985dc8e4"
      unitRef="usd">16832000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNS0zLTEtMS0zODM0Mw_55e9e4cb-53ed-4048-97c6-89e0e59863b2"
      unitRef="usd">14021000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNi0xLTEtMS0zODM0Mw_e32cc850-2675-4028-ab25-0e4d2aede48f"
      unitRef="usd">569061000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNi0zLTEtMS0zODM0Mw_636e2eba-fdd7-4fc2-a6e5-35a52a5225b3"
      unitRef="usd">471323000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNy0xLTEtMS0zODM0Mw_3147246b-c08e-4e75-93d5-401280face62"
      unitRef="usd">85108000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfNy0zLTEtMS0zODM0Mw_71241424-43ab-4d92-a6ce-77a180408b03"
      unitRef="usd">352179000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfOC0xLTEtMS0zODM0Mw_63b64c55-803a-470a-9149-ffe4def53fe2"
      unitRef="usd">85245000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfOC0zLTEtMS0zODM0Mw_a55b49d4-a577-411e-8303-85ebb730236f"
      unitRef="usd">58030000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfOS0xLTEtMS0zODM0Mw_e1e2ebe2-213d-4beb-a413-d2ca37de51d4"
      unitRef="usd">114442000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfOS0zLTEtMS0zODM0Mw_f2c201a8-cea5-4a64-8b1e-a0246d1c80cc"
      unitRef="usd">122990000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTAtMS0xLTEtMzgzNDM_004bcc86-7913-493c-bee9-0a01bb3b966e"
      unitRef="usd">10292000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTAtMy0xLTEtMzgzNDM_b945f89b-cac0-4b4e-95e3-399d961752ad"
      unitRef="usd">10292000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTEtMS0xLTEtMzgzNDM_aa652073-fea7-4d91-baf7-6ed1c4ab3d95"
      unitRef="usd">9378000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTEtMy0xLTEtMzgzNDM_67a50cb3-f3ab-4825-9714-de3b1debbb50"
      unitRef="usd">5815000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTItMS0xLTEtMzgzNDM_2afefa32-38dd-41a2-88d8-9d9ce4f6a293"
      unitRef="usd">14046000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTItMy0xLTEtMzgzNDM_b6707882-fcf6-4066-9668-76500ee691df"
      unitRef="usd">18005000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTMtMS0xLTEtMzgzNDM_313af2ad-6319-4841-81c9-0e6c088d0971"
      unitRef="usd">887572000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTMtMy0xLTEtMzgzNDM_889efd0d-2847-42f1-8e0d-7c6b9d5d2c76"
      unitRef="usd">1038634000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTYtMS0xLTEtMzgzNDM_eecdf4f3-cd65-4441-839f-7b120306d8ff"
      unitRef="usd">11045000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTYtMy0xLTEtMzgzNDM_45e06c86-8131-4ee3-ae41-917673482e46"
      unitRef="usd">10255000</us-gaap:AccountsPayableCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTctMS0xLTEtMzgzNDM_48388e6f-e0cf-4ad4-86f6-b44bd9824c13"
      unitRef="usd">36938000</allo:AccruedAndOtherLiabilitiesCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTctMy0xLTEtMzgzNDM_49bf68aa-ad6f-4fc3-800a-0c474af30eaa"
      unitRef="usd">37496000</allo:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTgtMS0xLTEtMzgzNDM_c7fec969-34e4-40ff-aba2-cb7d80002639"
      unitRef="usd">889000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTgtMy0xLTEtMzgzNDM_001249ce-b25a-4ec7-9ff0-e171a23b3fc3"
      unitRef="usd">423000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTktMS0xLTEtMzgzNDM_95837fe6-b207-4e57-9dae-0fb80a66daeb"
      unitRef="usd">48872000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMTktMy0xLTEtMzgzNDM_093174a5-33b0-4ea1-8cfb-4adf843b5624"
      unitRef="usd">48174000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjAtMS0xLTEtMzgzNDM_27d84ebd-9ffc-4910-8db6-68aebb32e270"
      unitRef="usd">96706000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjAtMy0xLTEtMzgzNDM_6d2e6dc8-5f1c-4329-90a8-d9c7c0338f04"
      unitRef="usd">69929000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjEtMS0xLTEtMzgzNDM_af381973-55b1-4a27-a26d-d6ff93b75a73"
      unitRef="usd">2033000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjEtMy0xLTEtMzgzNDM_0f99c5b2-2e1a-4d9e-ae8b-00c3b3abe1f2"
      unitRef="usd">4125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjItMS0xLTEtMzgzNDM_68187c54-252e-4d0d-87f2-00d0deef4c06"
      unitRef="usd">147611000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjItMy0xLTEtMzgzNDM_1e841012-1224-4a6e-8ec6-6600e9a6818e"
      unitRef="usd">122228000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjMtMS0xLTEtMzgzNDM_becf93cb-5a65-4f91-a115-7ae5b936a561"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjMtMy0xLTEtMzgzNDM_0c977842-8945-4a11-b309-438463fe2026"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml8yMQ_c0d5ed3c-e6bc-49d8-86fa-cae5dbf2a483"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml8yMQ_c33e9cc0-8e82-4fe2-9e31-9c25c27545ef"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml8zNQ_0cc1e859-6333-4401-9a1d-153dd9fbf1fb"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml8zNQ_731caa5f-b755-484e-8644-bf704bdec1d4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml85OQ_456c9786-b7d4-44e5-b804-d16efadf91bf"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml85OQ_b205d5cf-9626-47bc-b313-dbfa6ae17aa5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml85OQ_b91398ab-a5eb-4413-a51c-b57dd4661bfd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjo2Y2RjN2EzZTVhYzM0YzJlODI1MmNkOTkxZWE0OGU2Ml85OQ_f4734302-5542-4ec6-9738-31411683201d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMS0xLTEtMzgzNDM_75fef5bb-20f7-42b0-9cb0-34c9548e93ea"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjUtMy0xLTEtMzgzNDM_fb9063d0-50f2-4d6a-bfff-729420fdcc34"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xOA_6eac5942-623b-4185-bcb1-7423e7f87338"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xOA_e2541893-9b82-4d9a-99b7-6f8f8886bdcc"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8zMg_e8434ae2-f299-42d9-bc12-ebd7883dba90"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl83Nw_30bb18d6-9cc0-4463-a3a8-b1c26c48589b"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xMjM_aca6960a-0208-42ff-8bcc-665a4ff7935d"
      unitRef="shares">144031588</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xMjM_fda5f1e0-545d-4e25-a106-182add89ca42"
      unitRef="shares">144031588</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xMzA_c24ca4b7-f700-4b52-b190-4fee2552898b"
      unitRef="shares">142623065</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMC0xLTEtMzgzNDMvdGV4dHJlZ2lvbjpjMTE4MGM0ZmJmYTA0ZmQwYTdmZWY1YWMzNmYwNjhhMl8xMzA_c88814ee-0eaa-4de3-89e0-8499a011c231"
      unitRef="shares">142623065</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMS0xLTEtMzgzNDM_4b117b5c-1198-48fe-8133-b1ce169a8a23"
      unitRef="usd">144000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjYtMy0xLTEtMzgzNDM_f9db70e3-00e2-4b4e-8ab6-774ac959ec04"
      unitRef="usd">142000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjctMS0xLTEtMzgzNDM_641758eb-e3bb-4810-81c1-90220c9988ff"
      unitRef="usd">1893908000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjctMy0xLTEtMzgzNDM_795838e1-cb51-4ccf-ab5d-cb7b17c48b30"
      unitRef="usd">1822179000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjgtMS0xLTEtMzgzNDM_ddb96c39-036a-4e4c-9349-7bdfa3b06a57"
      unitRef="usd">-1141133000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjgtMy0xLTEtMzgzNDM_cd31e605-0bbf-438f-af94-c3d6b47b50ed"
      unitRef="usd">-903348000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjktMS0xLTEtMzgzNDM_6f9b42f2-5032-4b7a-9d05-3e1b95cf7a8c"
      unitRef="usd">-12958000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMjktMy0xLTEtMzgzNDM_c87e16c4-0f87-480d-9ef4-49e61eab0b0a"
      unitRef="usd">-2567000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMzAtMS0xLTEtMzgzNDM_59aecf22-862d-48f7-942c-612bea8501f8"
      unitRef="usd">739961000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMzAtMy0xLTEtMzgzNDM_5c033c2a-2b65-4997-8356-95793006a522"
      unitRef="usd">916406000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMzEtMS0xLTEtMzgzNDM_ee031887-1730-4fa2-894b-b330518ce755"
      unitRef="usd">887572000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xNi9mcmFnOmNhNTgxMWRjNzM4YjQxZGNhZGMxZmM5MDg0YmNjNDNhL3RhYmxlOmUyZjIxMTRhMmIyNjRhNzg5OTI0NDAwMjc0MzNjNGNkL3RhYmxlcmFuZ2U6ZTJmMjExNGEyYjI2NGE3ODk5MjQ0MDAyNzQzM2M0Y2RfMzEtMy0xLTEtMzgzNDM_c33e2645-8fb0-4ba6-9cfb-3329a8dcdfdc"
      unitRef="usd">1038634000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMi0xLTEtMS0zODM0Mw_7c3f28fc-442b-46fe-a969-41de9745ae42"
      unitRef="usd">49000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMi0zLTEtMS0zODM0Mw_e2d80ecb-cfbd-49a1-abd9-ced135bf4da3"
      unitRef="usd">49000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMi01LTEtMS0zODM0Mw_ae5b05bc-d0c2-447f-9774-47328286305e"
      unitRef="usd">196000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMi03LTEtMS0zODM0Mw_ed4b9c49-39fd-4067-ae11-832a94ae7352"
      unitRef="usd">38438000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNC0xLTEtMS0zODM0Mw_d26149e0-03c5-4e88-9ddc-f07f84ef0f8b"
      unitRef="usd">63641000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNC0zLTEtMS0zODM0Mw_865eb2a8-a053-4ecd-a6ac-8843c9a0cf4d"
      unitRef="usd">58720000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNC01LTEtMS0zODM0Mw_11a9fddd-ce90-4a32-a610-62460fc0bfec"
      unitRef="usd">180968000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNC03LTEtMS0zODM0Mw_ad974330-c7c8-4334-b413-c2b48335dec6"
      unitRef="usd">166193000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNS0xLTEtMS0zODM0Mw_528a6580-46a9-4d03-9a8a-f3e5455a12b1"
      unitRef="usd">18897000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNS0zLTEtMS0zODM0Mw_58caea82-efe8-4205-b865-8d095afd68b1"
      unitRef="usd">18999000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNS01LTEtMS0zODM0Mw_676f3a87-7feb-47d3-82f9-d252f1c7fbee"
      unitRef="usd">58303000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNS03LTEtMS0zODM0Mw_d281ea3c-f8cb-4136-8534-058606f31abc"
      unitRef="usd">54144000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNi0xLTEtMS0zODM0Mw_4defc37a-34ee-45d5-a539-d6f905ef3f34"
      unitRef="usd">82538000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNi0zLTEtMS0zODM0Mw_2294dfe1-3be3-4d18-b7cb-510e4d84d8c7"
      unitRef="usd">77719000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNi01LTEtMS0zODM0Mw_9dc5ee44-d621-4059-83a9-befc3366fcbd"
      unitRef="usd">239271000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNi03LTEtMS0zODM0Mw_52ea863d-f63f-4656-9030-8ec8f7a89a20"
      unitRef="usd">220337000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNy0xLTEtMS0zODM0Mw_c6f7f332-77bc-4b40-8c2a-f4864e67528a"
      unitRef="usd">-82489000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNy0zLTEtMS0zODM0Mw_676159d4-a361-49d6-948d-a122804daa1a"
      unitRef="usd">-77670000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNy01LTEtMS0zODM0Mw_8ef7065f-ff4f-451e-a1ff-6dfd5deaa6ca"
      unitRef="usd">-239075000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfNy03LTEtMS0zODM0Mw_00aacdd3-01d6-4d15-942e-f7231664a9d4"
      unitRef="usd">-181899000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfOS0xLTEtMS0zODM0Mw_48a53041-caa5-4f25-bc58-006a403a7bfd"
      unitRef="usd">1002000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfOS0zLTEtMS0zODM0Mw_0485b00f-58ba-4f2e-96af-083e50553217"
      unitRef="usd">393000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfOS01LTEtMS0zODM0Mw_3d18867d-9be8-478f-af59-7b86e2453b14"
      unitRef="usd">1809000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfOS03LTEtMS0zODM0Mw_9c6e2abe-a13c-4a85-b228-0326773d225d"
      unitRef="usd">1528000</us-gaap:InterestAndOtherIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTAtMS0xLTEtMzgzNDM_21dca4e4-2c22-453b-aa6a-8fb5f62d2b24"
      unitRef="usd">-1661000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTAtMy0xLTEtMzgzNDM_0ea2692a-a71d-4ae6-8b21-c59b02288b70"
      unitRef="usd">-909000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTAtNS0xLTEtMzgzNDM_8e21bb2e-89bb-48ea-8681-ce4da42aa32b"
      unitRef="usd">-519000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTAtNy0xLTEtMzgzNDM_cc64e808-0838-4cad-9a02-e92286fd38f8"
      unitRef="usd">-1766000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTEtMS0xLTEtMzgzNDM_4ae8f7f4-32d6-4f8c-ad07-c055ec79bdd1"
      unitRef="usd">-659000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTEtMy0xLTEtMzgzNDM_375e5e7a-ee65-4bd1-9902-056680d5eb8a"
      unitRef="usd">-516000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTEtNS0xLTEtMzgzNDM_2bddd2a0-7159-47d6-bedb-0959e58911ea"
      unitRef="usd">1290000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTEtNy0xLTEtMzgzNDM_2687f901-3057-4e10-a6a1-3f9df8db8137"
      unitRef="usd">-238000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTItMS0xLTEtMzgzNDM_bf287306-f171-49e2-a1c3-cadee2aca150"
      unitRef="usd">-83148000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTItMy0xLTEtMzgzNDM_82130f46-a9a8-4e4a-9faf-3925e6d6c3e3"
      unitRef="usd">-78186000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTItNS0xLTEtMzgzNDM_61fff86e-2abc-4d51-8a17-bd302c3bbe4b"
      unitRef="usd">-237785000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTItNy0xLTEtMzgzNDM_9e935801-2083-4968-8b80-3329973e7cd6"
      unitRef="usd">-182137000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTQtMS0xLTEtMzgzNDM_df3b76b8-7f27-43ad-8727-852bb3a115cc"
      unitRef="usd">-1486000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTQtMy0xLTEtMzgzNDM_d43238aa-5bf8-4aec-807b-6f83d2c72b1c"
      unitRef="usd">-64000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTQtNS0xLTEtMzgzNDM_0c29a7d7-c65b-4927-a8cb-ca6732423d9b"
      unitRef="usd">-10391000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTQtNy0xLTEtMzgzNDM_05c38180-7e51-4097-898f-e1232cfb17af"
      unitRef="usd">-666000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTUtMS0xLTEtMzgzNDM_ba0b95ab-857d-41d7-9501-d7de713e75b1"
      unitRef="usd">-84634000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTUtMy0xLTEtMzgzNDM_5174755d-3dbc-4efe-af53-d8d67aa40b51"
      unitRef="usd">-78250000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTUtNS0xLTEtMzgzNDM_ff757873-f6aa-49f1-9b0f-0bdc1b728696"
      unitRef="usd">-248176000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTUtNy0xLTEtMzgzNDM_79a0c2e5-29c6-4fce-9417-662bebe3b50c"
      unitRef="usd">-182803000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtMS0xLTEtMzgzNDM_cf2788e1-c4ee-48fb-bfd8-01bdb4f651f5"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtMS0xLTEtMzgzNDM_e3198f39-847e-4db6-80b6-c218e6b195ce"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtMy0xLTEtMzgzNDM_79658dbb-f35b-489d-b692-25785d4aa9f6"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtMy0xLTEtMzgzNDM_b4c9fb0b-10bd-4764-acb0-55052b09f980"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtNS0xLTEtMzgzNDM_958916e7-7234-4dba-8851-59d823328030"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtNS0xLTEtMzgzNDM_d2d472ed-0132-48b4-9396-6932f664c5a0"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtNy0xLTEtMzgzNDM_baf9c3ad-d448-49c1-b7a3-f166af4c3784"
      unitRef="usdPerShare">-1.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTYtNy0xLTEtMzgzNDM_cd220fd0-729a-447b-bf33-434e2beda2b3"
      unitRef="usdPerShare">-1.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctMS0xLTEtMzgzNDM_8c326c88-5699-4f9c-8e12-90610a5e310b"
      unitRef="shares">143661721</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctMS0xLTEtMzgzNDM_97cc9aae-7b95-44e7-b55d-04f4d6abcd27"
      unitRef="shares">143661721</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctMy0xLTEtMzgzNDM_6ccdee17-94a0-4eb2-8e51-38c168ecff13"
      unitRef="shares">137025698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctMy0xLTEtMzgzNDM_e01b3850-6be4-4965-a7fe-8647dfb8d72f"
      unitRef="shares">137025698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctNS0xLTEtMzgzNDM_99c4b472-2be1-437d-93cc-b07d285e6a23"
      unitRef="shares">142809469</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctNS0xLTEtMzgzNDM_d5a84cab-adba-4cb2-be94-89bf67dc5f64"
      unitRef="shares">142809469</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctNy0xLTEtMzgzNDM_2fe66ecc-64d4-4356-bd8a-fb5115a2e335"
      unitRef="shares">134690310</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8xOS9mcmFnOmJhYmI4ZWNkODJlOTQwNjg5OTIxODI0YjViYjI1YmQwL3RhYmxlOmYzOTQxMGUzYzkyOTRhM2JiNzBkYWM2MmEzOGVjOGExL3RhYmxlcmFuZ2U6ZjM5NDEwZTNjOTI5NGEzYmI3MGRhYzYyYTM4ZWM4YTFfMTctNy0xLTEtMzgzNDM_3701c443-7d19-4f97-8aa2-6d84050d5b1b"
      unitRef="shares">134690310</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia16e1786ad8b4304b2dea68bd40ec715_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi0xLTEtMS0zODc2Ng_63cfb356-77af-4b5a-b905-2db7028a22e1"
      unitRef="shares">142623065</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia16e1786ad8b4304b2dea68bd40ec715_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi0zLTEtMS0zODc2Ng_81a9e926-62f1-4ac3-83b8-a40ae3b9e454"
      unitRef="usd">142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2768721624b646e4b4102030fc534111_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi01LTEtMS0zODc2Ng_7f6b648c-2232-477c-90a7-a60754536183"
      unitRef="usd">1822179000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62204640c1dd4c7e84683bae3464411b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi03LTEtMS0zODc2Ng_b46cdf0a-860c-4145-99b7-d8528fd80bce"
      unitRef="usd">-903348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90fc78fa954a4298bce5f60606ef9a4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi05LTEtMS0zODc2Ng_ddcf9411-e5d5-4c1d-be06-a22c7b786b61"
      unitRef="usd">-2567000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMi0xMS0xLTEtMzg3NjY_170eead4-3e14-4ec3-a27b-3bf0dec9fb3b"
      unitRef="usd">916406000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idab67126ce664974bc2dd9963d5c3ba0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMy0xLTEtMS0zODc2Ng_9384444b-a4a6-46d0-ab85-94cc5d859903"
      unitRef="shares">715961</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idab67126ce664974bc2dd9963d5c3ba0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMy0zLTEtMS0zODc2Ng_fc29fba1-7d43-4c62-9e4c-1cfedbecb529"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMy01LTEtMS0zODc2Ng_a4ae9fcb-558b-4329-b42c-ec9a28f2d5c7"
      unitRef="usd">282000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMy0xMS0xLTEtMzg3NjY_e00702df-3512-4fda-bb09-c42474718b83"
      unitRef="usd">283000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNC01LTEtMS0zODc2Ng_022de0f7-5d9c-41bb-96b0-5458e7b99b0e"
      unitRef="usd">1228000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNC0xMS0xLTEtMzg3NjY_3b3eeeb8-a447-4f3a-a4d0-5602ae067c44"
      unitRef="usd">1228000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNS01LTEtMS0zODc2Ng_4df1d782-ad47-4fd6-8f97-8270e83e8c6e"
      unitRef="usd">22315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNS0xMS0xLTEtMzg3NjY_bf967e9d-fbf8-44e9-89cb-ed664f6ce33b"
      unitRef="usd">22315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idab67126ce664974bc2dd9963d5c3ba0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNi0xLTEtMS0zODc2Ng_432f174e-a1dc-47fa-8d76-7905118825d8"
      unitRef="shares">230876</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i32c991a1bf9740f4b3a4ecb9b23a75a4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNi01LTEtMS0zODc2Ng_ac7e1670-3a2f-4cef-88f2-f38d48ed9b8a"
      unitRef="usd">1530000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNi0xMS0xLTEtMzg3NjY_c9ffe7c1-593f-4199-a80e-22be09e1f3ed"
      unitRef="usd">1530000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="i660319721ce344d8a0b9154850955702_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNy03LTEtMS0zODc2Ng_6a3ba58c-c0b3-4341-ab93-74162f678af3"
      unitRef="usd">-79850000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfNy0xMS0xLTEtMzg3NjY_27853ef2-464a-4694-bbbd-060309a01ead"
      unitRef="usd">-79850000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i568599dba7e143dfae2ed582eab3cff3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOC05LTEtMS0zODc2Ng_a536bad7-7433-486e-aae2-3b9b9e5397b9"
      unitRef="usd">-6682000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2953bb916cbe47119dda99d3ee80722f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOC0xMS0xLTEtMzg3NjY_be3536c4-4055-4e9d-b906-75a834ee9c64"
      unitRef="usd">-6682000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4c2e5335e0bc41c785958fd6330aacc7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS0xLTEtMS0zODc2Ng_d770bd41-9868-4e40-9ee5-0ec3fd7b8282"
      unitRef="shares">143569902</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4c2e5335e0bc41c785958fd6330aacc7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS0zLTEtMS0zODc2Ng_d9aeb180-6757-4925-8e4a-a7ad89e483e6"
      unitRef="usd">143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i328d6792e081436fa76276a9678f424c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS01LTEtMS0zODc2Ng_445bca50-33e5-4e81-9511-a9dd14ce6e7a"
      unitRef="usd">1847534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0adaff1a464431da2afd3e58a0fc274_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS03LTEtMS0zODc2Ng_78cc6048-1f49-4acb-a99f-eb40b381c2ed"
      unitRef="usd">-983198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic900f2b82bd74b6ab94b987c5117fc3a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS05LTEtMS0zODc2Ng_0eab4895-fb72-48c4-ab50-1e52f05c4196"
      unitRef="usd">-9249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8c5743ca8a348359d46ddb287076e9d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfOS0xMS0xLTEtMzg3NjY_dfc10d45-6a6b-446c-b813-c38ba055c8b6"
      unitRef="usd">855230000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i67020356c6204f40b4841f871a50d053_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTAtMS0xLTEtMzg3NjY_ec6d69e9-8621-424b-8422-5d63e3306430"
      unitRef="shares">153269</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i67020356c6204f40b4841f871a50d053_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTAtMy0xLTEtMzg3NjY_2d53ca3b-4d6d-4fd1-b645-995e04d8f93d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i66ea312ec5214b9caacbbb7ac02ee5ff_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTAtNS0xLTEtMzg3NjY_9c33bc7b-0bf0-4255-8aef-882707076825"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTAtMTEtMS0xLTM4NzY2_c07f5c65-298e-4393-80e2-ff3101253997"
      unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i66ea312ec5214b9caacbbb7ac02ee5ff_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTEtNS0xLTEtMzg3NjY_5645f377-dda6-4f7e-b9aa-1b6f9e9b2900"
      unitRef="usd">813000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTEtMTEtMS0xLTM4NzY2_341639a2-1c58-42cf-a1ae-f64592c6ed92"
      unitRef="usd">813000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i66ea312ec5214b9caacbbb7ac02ee5ff_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTItNS0xLTEtMzg3NjY_dffac374-4a4c-4c2d-93ec-d801603b02ee"
      unitRef="usd">22891000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTItMTEtMS0xLTM4NzY2_aec5c181-e7cb-4700-bd32-2f89214b6c2a"
      unitRef="usd">22891000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTMtMTEtMS0xLTM4NzY2_083ebb50-4cfd-426f-a306-86b45329b799"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="i0b1e6139112545ef9da1ebd8710ab2f1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTQtNy0xLTEtMzg3NjY_a77e1ea8-5c46-4a6c-ba4a-4271f5950c30"
      unitRef="usd">-74787000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTQtMTEtMS0xLTM4NzY2_559b876b-1ec9-4fe4-98bd-a4bb552f1ad4"
      unitRef="usd">-74787000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib1e087f2a6e34ff89eb1651f147dcc07_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTUtOS0xLTEtMzg3NjY_a43c8797-93f1-4243-b76d-b1088a15ac8b"
      unitRef="usd">-2223000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9f2e0f5d3e894c73a612c8bf11adbe35_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTUtMTEtMS0xLTM4NzY2_6c3a554e-6ecf-4325-a4fb-f56c9061a9e8"
      unitRef="usd">-2223000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i53bc2cfd3e704820a725a843f0e2fdf8_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtMS0xLTEtMzg3NjY_f9549b6a-affa-4833-b495-917407ff8604"
      unitRef="shares">143723171</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i53bc2cfd3e704820a725a843f0e2fdf8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtMy0xLTEtMzg3NjY_ac7374ff-9a2b-451b-a498-c07ad75229d6"
      unitRef="usd">144000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i666c9e4e34704eb890ea456c2f944a0d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtNS0xLTEtMzg3NjY_1a1b3c60-4061-4f4a-8e3e-ad86bb4f94db"
      unitRef="usd">1871262000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25f5c9a7d2bc4d3ca5014da4f40097b1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtNy0xLTEtMzg3NjY_5f4fd556-327a-44e6-b2db-a2a2b1cfe592"
      unitRef="usd">-1057985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00e354ae71e34ceea20c3c9ba63e8763_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtOS0xLTEtMzg3NjY_7ad63d10-2e4e-4e85-9ff5-fd262ebee8e2"
      unitRef="usd">-11472000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45581b958f3f4670b5c86820707bb668_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTYtMTEtMS0xLTM4NzY2_105fa0ba-3551-41ec-ad2b-0c0af33e6ecc"
      unitRef="usd">801949000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if440df8de9ff4378a42f14411ea24199_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTctMS0xLTEtMzg3NjY_d36e2120-5690-4a14-bac4-2fab951ccb65"
      unitRef="shares">177678</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTctNS0xLTEtMzg3NjY_38fbef60-edf5-4d1c-a90a-60c53ad25e03"
      unitRef="usd">135000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTctMTEtMS0xLTM4NzY2_e31c76cd-878d-4cff-b965-3c080b59f10d"
      unitRef="usd">135000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTgtNS0xLTEtMzg3NjY_52e1dad7-3fdc-489e-a34d-7ecdbd7726e5"
      unitRef="usd">432000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTgtMTEtMS0xLTM4NzY2_af9e5a27-bb70-40e9-927d-379d837ec046"
      unitRef="usd">432000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTktNS0xLTEtMzg3NjY_a31d6639-07d4-41f3-b76f-ee13f9610b07"
      unitRef="usd">21148000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMTktMTEtMS0xLTM4NzY2_593567ef-d77f-499a-97aa-5a92791deeee"
      unitRef="usd">21148000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if440df8de9ff4378a42f14411ea24199_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjAtMS0xLTEtMzg3NjY_3400a7cc-34c0-477c-a9ea-542ffd189f10"
      unitRef="shares">130739</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic2b7ef9cb6694223860650e57b305b46_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjAtNS0xLTEtMzg3NjY_b87c4915-85f5-4c1d-9be5-abc2d8da0b5a"
      unitRef="usd">931000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjAtMTEtMS0xLTM4NzY2_05946377-3e0a-4696-96c7-03bb6f08d439"
      unitRef="usd">931000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="ice884c5236d74ae4aed903a5266a526b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjEtNy0xLTEtMzg3NjY_4d225eac-5526-40a1-86d3-62fd7bce8bff"
      unitRef="usd">-83148000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjEtMTEtMS0xLTM4NzY2_e901d96c-3821-4b62-8627-066ce1bca989"
      unitRef="usd">-83148000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic2ed3bf5b05643c09d7e7b6060b8df59_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjItOS0xLTEtMzg3NjY_965ee2bd-32b6-49a2-a91a-e523f5c83e38"
      unitRef="usd">-1486000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjItMTEtMS0xLTM4NzY2_f5a1eeb5-acf6-44b9-9eab-384cf5f9d9a6"
      unitRef="usd">-1486000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i29d45c7d7a79444cbab51b762db8a92a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtMS0xLTEtMzg3NjY_5d782182-39a2-40f9-b893-5104454251fc"
      unitRef="shares">144031588</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i29d45c7d7a79444cbab51b762db8a92a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtMy0xLTEtMzg3NjY_21c8d871-7e07-4bdc-8cb5-3d13da1b2515"
      unitRef="usd">144000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e40da32cd9649fda45dd94c8886a401_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtNS0xLTEtMzg3NjY_c21b5bda-b1c2-491b-927c-f636bf568ad2"
      unitRef="usd">1893908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib52a77f5cfce4da693d48878535ff579_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtNy0xLTEtMzg3NjY_239c4dd1-cd4d-4cf3-8da9-90740b871afc"
      unitRef="usd">-1141133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7e4663ddd5e4d3fb00c03d8227b3e83_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtOS0xLTEtMzg3NjY_e1c1cce6-0b39-409e-92d5-91ef3d87721a"
      unitRef="usd">-12958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmE3YzUyMWMzNjY1ZTQxZTE4OTI1ZDQxMDIwYTFkZTdiL3RhYmxlcmFuZ2U6YTdjNTIxYzM2NjVlNDFlMTg5MjVkNDEwMjBhMWRlN2JfMjMtMTEtMS0xLTM4NzY2_9d4edd1a-24d3-4796-9bf5-794854c2d0b0"
      unitRef="usd">739961000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3fc217acd2be43718fb7e4ed4c014def_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi0xLTEtMS0zODc4Mg_4d8972cd-27ef-4e9d-90cd-dd235bee52ae"
      unitRef="shares">140474305</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3fc217acd2be43718fb7e4ed4c014def_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi0zLTEtMS0zODc4Mg_b16d5c39-fd6b-4bc9-a690-4bc8b2533653"
      unitRef="usd">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3533121d864f4c0583c7555923834700_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi01LTEtMS0zODc4Mg_20cb49b6-e364-4eef-8f38-de9598e0fd8d"
      unitRef="usd">1725552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8448819002f446acb79abaf404098bfb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi03LTEtMS0zODc4Mg_3a85a4be-d43f-44e5-9e98-71968bac8f00"
      unitRef="usd">-646343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic4c0e6ec7e054c1da14d802766b50abf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi05LTEtMS0zODc4Mg_904ecfa3-59bb-47f5-8137-37024a23fbf9"
      unitRef="usd">268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibefeee67a5174cca8fc8c95afe569cb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMi0xMS0xLTEtMzg3ODI_730a2245-0c24-4ae1-a4ba-14d8940a3827"
      unitRef="usd">1079617000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i27bc23f568da4811a9958f2effaa11a7_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMy0xLTEtMS0zODc4Mg_f3adc966-3804-4ec3-9c88-052c68e84054"
      unitRef="shares">897744</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i27bc23f568da4811a9958f2effaa11a7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMy0zLTEtMS0zODc4Mg_687a0bcd-8662-4944-b6f3-f2e81fec849d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMy01LTEtMS0zODc4Mg_df995052-7dca-4d34-9909-140b7fe54b92"
      unitRef="usd">4059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMy0xMS0xLTEtMzg3ODI_c2e08ac3-3c91-4cef-bd59-2b3f4702cc53"
      unitRef="usd">4060000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNC01LTEtMS0zODc4Mg_e9abd7d3-63a9-4faf-949f-a6cd871e8fc2"
      unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNC0xMS0xLTEtMzg3ODI_3dc38bd8-b22d-4420-8e40-a619252255a4"
      unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNS01LTEtMS0zODc4Mg_90932875-e608-4c29-97d0-7f490e82c754"
      unitRef="usd">16792000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNS0xMS0xLTEtMzg3ODI_56681308-d2ed-45b8-b86c-d4e101d78132"
      unitRef="usd">16792000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i27bc23f568da4811a9958f2effaa11a7_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNi0xLTEtMS0zODc4Mg_3e1c83cf-b7f4-4bcb-a995-7e386e344c6c"
      unitRef="shares">98026</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3e2b3bf34bbd47449c0c5d197d13a0d3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNi01LTEtMS0zODc4Mg_7abd7f3d-dad5-46be-8b3c-3289cd3ad350"
      unitRef="usd">1984000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNi0xMS0xLTEtMzg3ODI_3ca10999-69a7-458d-b790-5c61eeddad03"
      unitRef="usd">1984000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="i52c6c38d96b3496c83a3c3f4292c5f08_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNy03LTEtMS0zODc4Mg_5f09d0eb-f39d-43e6-93fe-61587abdb30a"
      unitRef="usd">-33015000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfNy0xMS0xLTEtMzg3ODI_8313ba3a-4306-4655-91ed-206ac76dba1b"
      unitRef="usd">-33015000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i60949035a3624cc68a5f08899693ed89_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOC05LTEtMS0zODc4Mg_d6fc7055-91a7-4aa1-9829-3171004b5816"
      unitRef="usd">-369000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i07f7830d65664e0bb1f2a646267a226b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOC0xMS0xLTEtMzg3ODI_781b329a-c52a-4975-801a-03c2f553c57a"
      unitRef="usd">-369000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3285731b68de4e41ad0c1865ada7997c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS0xLTEtMS0zODc4Mg_14a74129-3b14-4fdb-8e37-3f421f6b3d66"
      unitRef="shares">141470075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3285731b68de4e41ad0c1865ada7997c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS0zLTEtMS0zODc4Mg_57cd33f0-6d8b-458b-8156-05717e824304"
      unitRef="usd">141000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36b261d41d814a7cb5646538703fecb1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS01LTEtMS0zODc4Mg_34ed6594-cfad-45e0-b9af-d049ca646956"
      unitRef="usd">1749097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i656fbffbeb434eb49eeae23b018e4fe7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS03LTEtMS0zODc4Mg_a66395da-c3ac-4258-a372-c531bb5b12ff"
      unitRef="usd">-679358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i93a49ed55a0642638b964d93a55082ef_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS05LTEtMS0zODc4Mg_f65f87c8-0bdf-4f6a-85a9-80cd03277b2b"
      unitRef="usd">-101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i027d2deea89848eba3b25676ffe40a68_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfOS0xMS0xLTEtMzg3ODI_42b7cd2a-38b3-4900-a087-c9b66af93d00"
      unitRef="usd">1069779000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie3c3681993a340ce9e153807ca820af8_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTAtMS0xLTEtMzg3ODI_4c4c6e7c-e4cf-4ba0-9d52-245f0854b566"
      unitRef="shares">650656</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie3c3681993a340ce9e153807ca820af8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTAtMy0xLTEtMzg3ODI_c3cdd465-7b2b-4f6b-9615-b9d8c74c6407"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i96a08f54165449009616a55b4debdf18_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTAtNS0xLTEtMzg3ODI_af5305ab-2b0e-4c62-8d68-12ca656db7c7"
      unitRef="usd">3213000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTAtMTEtMS0xLTM4Nzgy_aaf61626-b244-486c-8843-13b0273e8c43"
      unitRef="usd">3214000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i96a08f54165449009616a55b4debdf18_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTEtNS0xLTEtMzg3ODI_96ef8838-03a0-4430-988f-5879f476b8dd"
      unitRef="usd">854000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTEtMTEtMS0xLTM4Nzgy_38a9302b-5d68-4a99-9976-e7c48e7a6166"
      unitRef="usd">854000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i96a08f54165449009616a55b4debdf18_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTItNS0xLTEtMzg3ODI_de7a1f9e-02ed-4326-a4d7-7bf4369394eb"
      unitRef="usd">21134000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTItMTEtMS0xLTM4Nzgy_48cc2767-e8e9-4281-a27e-94f473bf0bd0"
      unitRef="usd">21134000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTMtMTEtMS0xLTM4Nzgy_ac71aa4d-50ce-4eee-a220-5a2ae0bd20ac"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="i1192f2bcfd174e4e87c6a48a6b229311_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTQtNy0xLTEtMzg3ODI_997a750a-eaf0-4bed-a3c2-b086ebe2f9d8"
      unitRef="usd">-70936000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTQtMTEtMS0xLTM4Nzgy_f87d3a30-5f53-4b43-a3c1-b1a5440040f3"
      unitRef="usd">-70936000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0b441d0ab9104d6f906ea50fc1740b98_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTUtOS0xLTEtMzg3ODI_64e94043-e2b0-42db-ac1e-8630a0e930cc"
      unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib33700f6bac34102a47e4ae1d8a010bf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTUtMTEtMS0xLTM4Nzgy_8bf8f975-6ef8-4bb0-8d3b-0debe83cab0b"
      unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic1ced53064cd42a28878d18228552b20_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtMS0xLTEtMzg3ODI_e171da23-7f9b-4217-afe8-4a26c6d26305"
      unitRef="shares">142120731</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic1ced53064cd42a28878d18228552b20_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtMy0xLTEtMzg3ODI_628c3414-5d51-4e83-8b83-b5506f972121"
      unitRef="usd">142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9545d58a43c140a2a6a71474a6ee1920_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtNS0xLTEtMzg3ODI_4c25de49-8076-499f-819e-9930b1dbeb39"
      unitRef="usd">1774298000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia77b5caccc864c93a8578007ada8f202_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtNy0xLTEtMzg3ODI_53f71ed2-0f7e-4235-a8c2-d9546dc9dfee"
      unitRef="usd">-750294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i470e7ef6e8484f10a411d5c0a26a3342_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtOS0xLTEtMzg3ODI_715437f4-d072-48a1-8149-77395d1fc9dc"
      unitRef="usd">-334000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i970726c2db304fcbb4d9a0c045073a76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTYtMTEtMS0xLTM4Nzgy_c99c1bb7-2df4-45de-bc0a-aa5f8735f9f3"
      unitRef="usd">1023812000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i66f164bd81e042c9bdbbf51049d8b187_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTctMS0xLTEtMzg3ODI_a751fc46-c3b1-4600-8211-bc0ab5e35f54"
      unitRef="shares">229918</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTctNS0xLTEtMzg3ODI_19b8dcde-952f-4544-9128-db09c302a27b"
      unitRef="usd">750000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTctMTEtMS0xLTM4Nzgy_8aaeb8fb-7bdb-4107-b515-5bdd511cb8c5"
      unitRef="usd">750000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTgtNS0xLTEtMzg3ODI_a468d556-4ff1-40c4-aad5-fdd9359e8e38"
      unitRef="usd">1142000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTgtMTEtMS0xLTM4Nzgy_501212f7-aaa5-46b4-b62b-5a62ae4d2bfe"
      unitRef="usd">1142000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTktNS0xLTEtMzg3ODI_2dce8238-797d-4707-ac6d-10eb90a7be7c"
      unitRef="usd">20856000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMTktMTEtMS0xLTM4Nzgy_2b82cd82-770f-41d4-ab81-91a0d6a66b26"
      unitRef="usd">20856000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i66f164bd81e042c9bdbbf51049d8b187_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjAtMS0xLTEtMzg3ODI_ed7e6a1b-ee46-4783-b254-4298aac27ec2"
      unitRef="shares">89180</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6f94f8f77f5e4ddab976d7edc80e99c8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjAtNS0xLTEtMzg3ODI_06f5e595-c018-4d24-9786-94171cca5f12"
      unitRef="usd">1632000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjAtMTEtMS0xLTM4Nzgy_b3dc893a-3f87-415b-83e7-83fbd4b8f4b5"
      unitRef="usd">1632000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="if2793cc8b4294f6aa53a79a343ce1cd5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjEtNy0xLTEtMzg3ODI_be506cb9-6757-49c2-bbf1-2f88b5276b84"
      unitRef="usd">-78186000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjEtMTEtMS0xLTM4Nzgy_feef81a5-b240-4a81-9310-b828186d43ff"
      unitRef="usd">-78186000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie199bf4d5f3d4388984d9af23f496b4a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjItOS0xLTEtMzg3ODI_69ea448a-2425-4a43-9850-72abc67f6947"
      unitRef="usd">-64000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjItMTEtMS0xLTM4Nzgy_d34e38ec-6b0f-429b-9848-de22588b7cb8"
      unitRef="usd">-64000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9e8df77f75814bb3bd276293c61def27_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtMS0xLTEtMzg3ODI_f0b3636b-45ca-42f3-bd64-42afdb61fdbe"
      unitRef="shares">142439829</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9e8df77f75814bb3bd276293c61def27_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtMy0xLTEtMzg3ODI_7b472dd1-cc89-4ae1-9f19-87a539df9453"
      unitRef="usd">142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8ff97a82a1149f0a766b4dd2aeb2039_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtNS0xLTEtMzg3ODI_c59460ab-6d28-411c-b23d-ca2d28a625d6"
      unitRef="usd">1798678000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44eb82ada8fc4b7aac17b9def190f34b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtNy0xLTEtMzg3ODI_af9faf6b-7cb8-4adf-94fe-68c4f32d700f"
      unitRef="usd">-828480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66c9685093544f8e9743c24c6b40e4fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtOS0xLTEtMzg3ODI_76e7d0f7-bc70-439f-be76-2d32762150a2"
      unitRef="usd">-398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96730d707ea04cf892c0873970a6389c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yMi9mcmFnOmE1ZDdmMjNiMGRmMTQwYjhiMWE2ODljNGUyYjkzNzBhL3RhYmxlOmM5NTJlMzM1ZTlmMjQyMjQ4YWRiMzkxMGNkNmU4OWU1L3RhYmxlcmFuZ2U6Yzk1MmUzMzVlOWYyNDIyNDhhZGIzOTEwY2Q2ZTg5ZTVfMjMtMTEtMS0xLTM4Nzgy_115b2605-865c-41b8-9c2a-5a14a5c338a3"
      unitRef="usd">969942000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMy0xLTEtMS0zODM0Mw_28c7e70b-7679-47d0-bbad-bb500d8be9a4"
      unitRef="usd">-237785000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMy0zLTEtMS0zODM0Mw_9f46dcc5-a28e-433e-9d8a-db4b4d42c0f7"
      unitRef="usd">-182137000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNS0xLTEtMS0zODM0Mw_0656494c-ae38-489f-bd0c-daf3ad1fdfd3"
      unitRef="usd">66354000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNS0zLTEtMS0zODM0Mw_328d7caf-aa86-4130-b8dc-34d91475ac53"
      unitRef="usd">58782000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNi0xLTEtMS0zODM0Mw_77bf2c3f-5714-4102-9a24-d706eb788974"
      unitRef="usd">11227000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNi0zLTEtMS0zODM0Mw_342edce3-f185-4957-863a-6e73ad740c61"
      unitRef="usd">6212000</us-gaap:Depreciation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNy0xLTEtMS0zODM0Mw_8a632ee5-267e-481b-a3a8-70c9b6ee8b44"
      unitRef="usd">-2735000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfNy0zLTEtMS0zODM0Mw_cef7afe4-53b1-4721-bfab-fe5b937bb4c1"
      unitRef="usd">-5361000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfOC0xLTEtMS0zODM0Mw_bf2fc6e1-7f8e-4612-b286-194e8b121d67"
      unitRef="usd">2193000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfOC0zLTEtMS0zODM0Mw_8d4419a8-04ec-407b-a049-b086a1b98d39"
      unitRef="usd">2622000</us-gaap:OperatingLeaseExpense>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfOS0xLTEtMS0zODM0Mw_a0344c03-3468-426f-894c-0388ba8dd106"
      unitRef="usd">-3959000</allo:IncomeLossFromCostMethodInvestment>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfOS0zLTEtMS0zODM0Mw_b5ce206f-8896-4cf0-b73c-80ecc8c912ad"
      unitRef="usd">-1766000</allo:IncomeLossFromCostMethodInvestment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTEtMS0xLTEtMzgzNDM_97710cee-8685-4867-b0a3-6b6eec9fc2fc"
      unitRef="usd">2811000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTEtMy0xLTEtMzgzNDM_176e4597-f51b-499f-8ca2-0413baa97dcd"
      unitRef="usd">2153000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTItMS0xLTEtMzgzNDM_6f05a0ba-1dfe-453c-9900-a287d04afbce"
      unitRef="usd">3211000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTItMy0xLTEtMzgzNDM_35411dd0-3ad4-4a97-84b7-4350f23b0e24"
      unitRef="usd">991000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTMtMS0xLTEtMzgzNDM_6a2dc69c-db28-4230-91fb-ef546863fa66"
      unitRef="usd">1930000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTMtMy0xLTEtMzgzNDM_9fbcc9c7-3a60-4100-a192-0bb17d075cba"
      unitRef="usd">1277000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTQtMS0xLTEtMzgzNDM_4b39b6c0-4bbf-49b5-8145-7896a0b84fa7"
      unitRef="usd">-1388000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTQtMy0xLTEtMzgzNDM_10f61a6a-9cb8-4563-9853-a31a7ed6e74f"
      unitRef="usd">6420000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTUtMS0xLTEtMzgzNDM_a14b369e-9501-4d6e-8bff-8a6f91e466b7"
      unitRef="usd">466000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTUtMy0xLTEtMzgzNDM_bd6f7792-1558-476c-8316-7b1513d570ec"
      unitRef="usd">-38627000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTYtMS0xLTEtMzgzNDM_8c13543e-7370-4b94-9bd6-ace07ab20f60"
      unitRef="usd">-2092000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTYtMy0xLTEtMzgzNDM_ca12d2b3-dc62-4484-a402-1aa54a36bc76"
      unitRef="usd">2092000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTctMS0xLTEtMzgzNDM_614612f2-3813-42bb-bd74-79f2656588c1"
      unitRef="usd">-158423000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTctMy0xLTEtMzgzNDM_57d71e17-7107-4fb5-bc08-f015d85b23d7"
      unitRef="usd">-139376000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTktMS0xLTEtMzgzNDM_34bfb1b5-4b2b-4f82-a6ad-26afb61518dd"
      unitRef="usd">3499000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMTktMy0xLTEtMzgzNDM_5b2a0d54-c58c-4e8b-ae76-673b4771b741"
      unitRef="usd">20710000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjAtMS0xLTEtMzgzNDM_1e950e39-805e-43b5-8b1f-9266a8431894"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjAtMy0xLTEtMzgzNDM_52171e7f-f301-401c-b1f4-ebe3783ff833"
      unitRef="usd">15938000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjEtMS0xLTEtMzgzNDM_f601f681-788f-4259-b39b-caec6acf3280"
      unitRef="usd">260379000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjEtMy0xLTEtMzgzNDM_63a313ce-e441-49ef-85a4-d774203eee28"
      unitRef="usd">645854000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjItMS0xLTEtMzgzNDM_769970e7-754c-4a0d-aedb-d8caf846e976"
      unitRef="usd">200318000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjItMy0xLTEtMzgzNDM_5e96f7d6-5376-4392-a9b5-8f4bef23f5e5"
      unitRef="usd">474801000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjMtMS0xLTEtMzgzNDM_572dbfff-c13a-4cb4-bacd-0ceeb16cfe01"
      unitRef="usd">56562000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjMtMy0xLTEtMzgzNDM_c2cc0b87-2269-4896-b43b-d82b7880851d"
      unitRef="usd">134405000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjUtMS0xLTEtMzgzNDM_c686a5e8-4f8e-4940-8b96-f0f6b7f3bf84"
      unitRef="usd">443000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjUtMy0xLTEtMzgzNDM_a656ed77-17fe-4ce9-99ec-3965475b3024"
      unitRef="usd">8024000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjYtMS0xLTEtMzgzNDM_7d4e743f-3ddc-4a25-8c2d-0eb2643cd732"
      unitRef="usd">2461000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjYtMy0xLTEtMzgzNDM_2430274a-e86d-4201-bee9-d33edf08a109"
      unitRef="usd">3617000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjctMS0xLTEtMzgzNDM_b7056c8c-e8b8-4fc3-b9d5-afc6ef6c594a"
      unitRef="usd">2904000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjctMy0xLTEtMzgzNDM_6eb5acfa-7f19-47c3-90dd-900e23522b5a"
      unitRef="usd">11641000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjgtMS0xLTEtMzgzNDM_d88f7e5e-01ee-49d8-8161-12168e6ae5ca"
      unitRef="usd">-98957000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjgtMy0xLTEtMzgzNDM_fdada77e-75c7-4661-a934-b9a6cce87a24"
      unitRef="usd">6670000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjktMS0xLTEtMzgzNDM_130e89fe-e599-430d-9624-57df910b9ed4"
      unitRef="usd">183606000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibefeee67a5174cca8fc8c95afe569cb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMjktMy0xLTEtMzgzNDM_4dd84f02-6cf8-4207-8184-c2150a12b327"
      unitRef="usd">192800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzAtMS0xLTEtMzgzNDM_013e6a44-6bfd-4b94-9d41-b6e402ba8805"
      unitRef="usd">84649000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i96730d707ea04cf892c0873970a6389c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzAtMy0xLTEtMzgzNDM_ab061cf3-0adf-4021-b35b-7d845d51b06d"
      unitRef="usd">199470000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzItMS0xLTEtMzgzNDM_c941c333-408d-46f6-b691-77379589ef35"
      unitRef="usd">31361000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzItMy0xLTEtMzgzNDM_8b8e27af-66a2-4fb6-b3d1-f23068794794"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzYtMS0xLTEtMzgzNDM_dce8d531-d210-47db-9184-751799a40bc6"
      unitRef="usd">6605000</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
    <us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzYtMy0xLTEtMzgzNDM_eafca573-76b8-42a4-b029-360e4234daa0"
      unitRef="usd">4058000</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzctMS0xLTEtMzgzNDM_3103417f-0622-4f8c-8152-936e41e5928b"
      unitRef="usd">325000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8yNS9mcmFnOjk5ZDcyY2ZiMmZiNDQ5MTY5YjhjNzk3Nzk4YWVkODBhL3RhYmxlOjhkZjVmMjg0ODRhODQ4MzRiMGQ0M2YyMThjNjJhMzNiL3RhYmxlcmFuZ2U6OGRmNWYyODQ4NGE4NDgzNGIwZDQzZjIxOGM2MmEzM2JfMzctMy0xLTEtMzgzNDM_70ab137a-9aaf-4706-8f93-0f077e776223"
      unitRef="usd">1111000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:NatureOfOperations
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zMS9mcmFnOjFiZjJhZGViZTczZjRlYTFhMGFmZjM5NGQ1YmI1Y2YwL3RleHRyZWdpb246MWJmMmFkZWJlNzNmNGVhMWEwYWZmMzk0ZDViYjVjZjBfMjU1OA_df1f4d11-64b1-47c2-bc01-35edaf8d97fc">Description of Business&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is an immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Need for Additional Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#x2019;s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates.    &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company had cash and cash equivalents and investments of $637.3 million as of September&#160;30, 2022. Since inception through September&#160;30, 2022, the Company has incurred cumulative net losses of $1.1 billion. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). &lt;/span&gt;&lt;/div&gt;The Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition and operations. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If business conditions, financial markets and/or the overall economy are impacted for an extended period, the Company&#x2019;s results may be adversely affected.</us-gaap:NatureOfOperations>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zMS9mcmFnOjFiZjJhZGViZTczZjRlYTFhMGFmZjM5NGQ1YmI1Y2YwL3RleHRyZWdpb246MWJmMmFkZWJlNzNmNGVhMWEwYWZmMzk0ZDViYjVjZjBfODky_a185f8f9-9dcb-43be-ba32-00393a15fe51"
      unitRef="usd">637300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zMS9mcmFnOjFiZjJhZGViZTczZjRlYTFhMGFmZjM5NGQ1YmI1Y2YwL3RleHRyZWdpb246MWJmMmFkZWJlNzNmNGVhMWEwYWZmMzk0ZDViYjVjZjBfOTgz_3c90995c-b47b-4d75-b494-4fb847821e4f"
      unitRef="usd">-1100000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzU5OA_1ab7e878-752f-4247-bc88-663982176484">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#x2019;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of stockholders&#x2019; equity as of September&#160;30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and related notes for the year ended December&#160;31, 2021, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February 23, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the accounting policies during the three and nine months ended September&#160;30, 2022, as compared to the significant accounting policies described in Note 1 of the &#x201c;Notes to Financial Statements&#x201d; in the Company&#x2019;s audited financial statements included in its Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements issued or effective that are expected to have a material impact on the Company's condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzU5MQ_9434650c-16b2-4dcf-9fd0-4606437db053">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#x2019;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of stockholders&#x2019; equity as of September&#160;30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and related notes for the year ended December&#160;31, 2021, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February 23, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzU5NQ_cf295076-ccc8-455f-a82b-d34c109a4a7d">Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <allo:ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzYwMQ_980c2a06-7203-482a-93dd-3f257aa1effa">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the accounting policies during the three and nine months ended September&#160;30, 2022, as compared to the significant accounting policies described in Note 1 of the &#x201c;Notes to Financial Statements&#x201d; in the Company&#x2019;s audited financial statements included in its Annual Report.&lt;/span&gt;&lt;/div&gt;</allo:ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNC9mcmFnOmYzNDMyMzA1MTM1NDRhZTBhNzhhODg1MjIwNTZmNjI4L3RleHRyZWdpb246ZjM0MzIzMDUxMzU0NGFlMGE3OGE4ODUyMjA1NmY2MjhfMzYwMg_6b1bae21-eb3e-46a5-aabe-6ad76546b23a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements issued or effective that are expected to have a material impact on the Company's condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfODg3_f5a38763-7987-493b-a728-f22d0ac0cbd0">Fair Value Measurements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs including quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets or liabilities as of September&#160;30, 2022 and as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Included within cash and cash equivalents on the Company&#x2019;s condensed consolidated balance sheets&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie730bc1281e742289f7b14d42eff7b48_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfNTE4_1af78d78-56a9-41cb-964e-aa8a879b578d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic59dec0676034b50b7ad0a219c00b9ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfNTE4_4d138bcf-1f8e-42d9-b64f-465382638db3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic59dec0676034b50b7ad0a219c00b9ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfNTE4_df1ab980-ce90-46dd-a578-7ed6f388b1c6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie730bc1281e742289f7b14d42eff7b48_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfNTE4_f2dc2491-bddb-4cbb-a9ce-e11c090a221d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RleHRyZWdpb246ZDViMTNmYzdmZjVjNDdlYzg3YTUxMGNjMmU5ZjA0MTVfODg4_7a4a6e0c-b133-478b-9fe0-a33250f07eb9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Included within cash and cash equivalents on the Company&#x2019;s condensed consolidated balance sheets&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i16d0ead330c24d62aeb2da5efcc4a64a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNC0xLTEtMS0zODM0Mw_8a68b493-a92a-4e69-9e37-4bafd069ae12"
      unitRef="usd">19225000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1e54a3337efd4d039762b588776fa199_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNC0zLTEtMS0zODM0Mw_f0ed939a-e2a3-43cc-80ed-9f438a83b6ba"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0b727b1deb0471d88a053257c9a4611_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNC01LTEtMS0zODM0Mw_523074ee-1a04-4aef-b0e4-e58f5f52ef19"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0e1772a9a774e75a2d532c1fa03dfd9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNC03LTEtMS0zODM0Mw_91ff7a48-8550-4a47-b1d9-55934760cef4"
      unitRef="usd">19225000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibd4d50cd1236423f81f303edc85b5416_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNS0xLTEtMS0zODM0Mw_c211334e-754a-439d-9ea9-2e5c4b1d48ab"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibcdb27b9bd024ba9aa1c201ba5aa6171_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNS0zLTEtMS0zODM0Mw_d5f48a4c-b0dc-4fa8-a583-b16328547a4c"
      unitRef="usd">17987000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2c83b117241041978e86a79078e74505_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNS01LTEtMS0zODM0Mw_fb2addd4-f6f6-4bd6-8d12-8c1020274146"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c093d5bad964a0cb856275d022daf5c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNS03LTEtMS0zODM0Mw_a97f58a7-a2d8-4a01-8733-8e5a42ec354e"
      unitRef="usd">17987000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib9e4e9b1f287486c97e5fdc273885d36_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNi0xLTEtMS0zODM0Mw_a12f61ab-d8ae-4a55-a4c1-fb0d3f3e8a07"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i67e850a333e249b0925d51da049c0000_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNi0zLTEtMS0zODM0Mw_bf3be695-e2b8-4813-b07d-fc13751effe0"
      unitRef="usd">168517000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia80be28ab7b844ffac2c1c656f493915_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNi01LTEtMS0zODM0Mw_6ab9946d-1dc3-4111-87dd-8a23dcaaa458"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i00b938fa488644558a07b02468cca245_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNi03LTEtMS0zODM0Mw_ddb87d09-5333-4a2d-829c-cabcc28d5909"
      unitRef="usd">168517000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i41d843d66f73450085167330c08fa8f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNy0xLTEtMS0zODM0Mw_2d134654-ea07-4642-a5b8-cf5ecce40cb7"
      unitRef="usd">332334000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7957a6a04a864f12ad0b9fd205fb2027_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNy0zLTEtMS0zODM0Mw_6912594e-d3e8-4eaa-89b1-9d92ac5b0fb6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1a8d37d4b41e43ae8b50608fce513cf9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNy01LTEtMS0zODM0Mw_0bdc19a1-a41b-499b-9027-691b0cca385b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a332d398be94f8283d48f49a486acd4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfNy03LTEtMS0zODM0Mw_0e96148f-df4b-4dbf-a9c9-8f5191907af7"
      unitRef="usd">332334000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ided01fd1fae3479a887f1df9839cb3c9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOC0xLTEtMS0zODM0Mw_94b85661-14ee-455a-bfb3-c947d65a3dff"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iae16a63b5e8d410aaea9422f95a58df3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOC0zLTEtMS0zODM0Mw_7a4492e8-0d04-4739-85df-5135505675f3"
      unitRef="usd">44142000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6229e7a19925408a883eeb53268596c3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOC01LTEtMS0zODM0Mw_80f69e96-bc82-4069-bff0-8b6e2fe0d303"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifb1e9f69fd5145b2a82d1c99cf574c36_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOC03LTEtMS0zODM0Mw_671039bb-1cd0-4128-87b6-a9861c4ad46e"
      unitRef="usd">44142000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia7be2e87e35f4e328aca6856dd8c331c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOS0xLTEtMS0zODM0Mw_1778e48c-5749-4cf5-8939-ae6cfe3b0ccc"
      unitRef="usd">351559000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecb03622518f4a8aa208f441ff5ed3e5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOS0zLTEtMS0zODM0Mw_665b0f4e-e999-4aea-9ce0-a6f5a3701fe8"
      unitRef="usd">230646000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie730bc1281e742289f7b14d42eff7b48_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOS01LTEtMS0zODM0Mw_5b978b47-4f75-4446-9ef3-659aaa61c796"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia9664a6d74d14cd2b0e6999a7746fbb3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmNlNGJhNTlkOGZmODQ4ZmQ4MWY1OGMzYmQ1ZDc1ZjliL3RhYmxlcmFuZ2U6Y2U0YmE1OWQ4ZmY4NDhmZDgxZjU4YzNiZDVkNzVmOWJfOS03LTEtMS0zODM0Mw_02ad9d08-3529-45a4-9b65-58a42a452b66"
      unitRef="usd">582205000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b39ce52bb534d8ab364d55d7a5a4845_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNC0xLTEtMS0zODM0Mw_56ad2f68-72ac-4b89-8c3f-1bd32eae6f9f"
      unitRef="usd">115867000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3b26963b040c464ab654260f9b024c8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNC0zLTEtMS0zODM0Mw_552fe46d-93b4-4dbb-97be-c0e266b8acd6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9196dc684bfe4858b5edf3e1ffd737c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNC01LTEtMS0zODM0Mw_c8c27b22-4028-4280-a4d1-a1108ef244e5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i08414a6efbee44f99241e34feca223cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNC03LTEtMS0zODM0Mw_c0ee4776-5f6a-4771-8fc1-160afa371079"
      unitRef="usd">115867000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib21f092a53bd4a75b19b5ea1f96f0dca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNS0xLTEtMS0zODM0Mw_e92a8f91-4498-4486-a361-2bd74c88457c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaac26891f51c43f698aa0fcfa42259de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNS0zLTEtMS0zODM0Mw_a15fd14e-e54a-4c67-9f98-76398327f417"
      unitRef="usd">58976000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia5742857dc7946a285456adb1db7f9b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNS01LTEtMS0zODM0Mw_a8a03cc8-5d61-42ed-a6bd-eb1401e8571a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i19e46bf35fc4476db2f52c28e5fdfe66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNS03LTEtMS0zODM0Mw_10343387-ae7d-452b-9aa9-ae9c21c430fe"
      unitRef="usd">58976000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i87f1616b693e482bbe1bc2c39cb50669_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNi0xLTEtMS0zODM0Mw_2a5d7a02-0cad-4228-bd55-7cd163330342"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0cc072cc86b04dd09d83c1d2c3602144_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNi0zLTEtMS0zODM0Mw_d37a00b8-2592-4028-b272-3c6d7ffc7cda"
      unitRef="usd">223474000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d45516c51f84306a30498bb283d1dae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNi01LTEtMS0zODM0Mw_20c0d7a1-937f-4e8f-9241-873ad5f974dd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia22fda346a3b44f58bf392876c6af2d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNi03LTEtMS0zODM0Mw_7b7f3549-dc2c-4e24-97aa-306f072279a3"
      unitRef="usd">223474000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie368da95aed94f39a8028a7fe3264ca2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNy0xLTEtMS0zODM0Mw_d5c986ba-c811-4002-af64-6508be3a4b3d"
      unitRef="usd">303016000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iac7b7966b0834b118a6dddf7f31e7efc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNy0zLTEtMS0zODM0Mw_27f64fed-59f3-4d64-9416-577be7286c87"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iceda1e0793a444bfbea8f6f96fc85ca1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNy01LTEtMS0zODM0Mw_36f6c2cb-326c-4097-8b98-67ce650bb05d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d0b55b1ab65461dbc838d478634fbc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfNy03LTEtMS0zODM0Mw_97c8eb86-25a9-4932-89a3-12d3eb0acc68"
      unitRef="usd">303016000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6a6f4571309a4989846c43edc13b9607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOC0xLTEtMS0zODM0Mw_2589974f-d833-4e08-a1a1-005667cec027"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifba287fafeb24922afb0bd5704ca7f09_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOC0zLTEtMS0zODM0Mw_e8b64642-6de2-4c20-9594-57b26ae5e49b"
      unitRef="usd">50701000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i43eb4f2c71bd40acade960ac4537414f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOC01LTEtMS0zODM0Mw_169303dc-2671-441d-bae6-46d8cf729587"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i274296360e7f471b817e447bda912e0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOC03LTEtMS0zODM0Mw_90aa988a-a1e6-46d9-a2d6-ce9a46568bcd"
      unitRef="usd">50701000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9eadb3f0fcf547ddab8ff0ef26f06f52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOS0xLTEtMS0zODM0Mw_c592071d-5632-4ad9-a5dd-2edaf3267322"
      unitRef="usd">418883000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0a34f9b02232491b96689d6036cda254_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOS0zLTEtMS0zODM0Mw_7a8b6951-98b5-4aea-8352-ffb4822cac2b"
      unitRef="usd">333151000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic59dec0676034b50b7ad0a219c00b9ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOS01LTEtMS0zODM0Mw_7e2b6718-e813-4f8c-b90b-aaa250cf48fc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8c3e4c35b6d4a5fa0398b1187be86ac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV8zNy9mcmFnOmQ1YjEzZmM3ZmY1YzQ3ZWM4N2E1MTBjYzJlOWYwNDE1L3RhYmxlOmI2NDFiNGM2YTNkNDQ5ODM4YTc5Mzc4MWRmNDYzM2JhL3RhYmxlcmFuZ2U6YjY0MWI0YzZhM2Q0NDk4MzhhNzkzNzgxZGY0NjMzYmFfOS03LTEtMS0zODM0Mw_3f4f5a82-1c0c-4100-91a7-25ffdf425704"
      unitRef="usd">752034000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMTMxOA_55fb60a7-46f5-43b3-89ac-35d497b0a48e">Financial InstrumentsThe fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022,&#160;the remaining contractual maturities of available-for-sale securities were less than 2 years. There have been no significant realized losses on available-for-sale securities for the periods presented. As of September&#160;30, 2022, unrealized losses on available-for-sale securities are not attributed to credit risk. The Company believes that it is more likely than not that investments in an unrealized loss position will be held until maturity and all interest and principal will be received. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company&#x2019;s available-for-sale securities are due to market factors. As of September&#160;30, 2022 and December&#160;31, 2021, securities with a fair value of $153.7 million and zero, respectively, were in a continuous net unrealized loss position for more than 12 months. To date, the Company has not recorded any impairment charges on available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Company recognized $1.5 million and $1.9 million, respectively, of accrued interest receivable from available-for-sale securities within prepaid expenses and other current assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMTMxOQ_dea5ecaa-253b-4249-8f7d-a3a6e1c9edcb">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of September&#160;30, 2022 and as of December&#160;31, 2021 are presented in the following tables:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i67454b2a010e4042ac9e965a1600e8a8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMy0xLTEtMS0zODM0Mw_8119b529-7ff9-42d7-a070-fb595a8733e0"
      unitRef="usd">19225000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i67454b2a010e4042ac9e965a1600e8a8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMy0zLTEtMS0zODM0Mw_d07fd6e3-e1ef-4352-acb5-6ebaad22b4a7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i67454b2a010e4042ac9e965a1600e8a8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMy01LTEtMS0zODM0Mw_e11a4cea-d866-4c9b-9289-16a4f9437809"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67454b2a010e4042ac9e965a1600e8a8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMy03LTEtMS0zODM0Mw_a1e313bd-2a69-46cd-bb13-f6340ee2b7cc"
      unitRef="usd">19225000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5f21a84a447d4ac69ec3d11a73e75977_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNC0xLTEtMS0zODM0Mw_c9ed3365-ee9c-4e59-81e1-5d170e708f3f"
      unitRef="usd">17995000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f21a84a447d4ac69ec3d11a73e75977_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNC0zLTEtMS0zODM0Mw_3c0e85a3-e452-4ed6-89e6-3b10e850cdca"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f21a84a447d4ac69ec3d11a73e75977_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNC01LTEtMS0zODM0Mw_8e9f408c-64ed-4614-843f-8e526bd1eb1e"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f21a84a447d4ac69ec3d11a73e75977_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNC03LTEtMS0zODM0Mw_d9cf1da9-6fa6-4ad1-9312-3337ff18d384"
      unitRef="usd">17987000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNS0xLTEtMS0zODM0Mw_e7dc47f7-eb75-43fc-9174-76bb6790739f"
      unitRef="usd">172278000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNS0zLTEtMS0zODM0Mw_136198c4-dee4-46fe-9747-c6a525399350"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNS01LTEtMS0zODM0Mw_0882fe56-916c-4c48-a7f2-4e882a5ddb0c"
      unitRef="usd">3761000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e870dec21e44bb0b1fbeaf64c17b496_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNS03LTEtMS0zODM0Mw_2f4aebe1-09a1-494e-a077-04a7f13304eb"
      unitRef="usd">168517000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNi0xLTEtMS0zODM0Mw_6ac1f5f9-525a-4e14-b18b-e380c124d7f5"
      unitRef="usd">339145000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNi0zLTEtMS0zODM0Mw_eb496ca4-a665-4102-8b7e-75ef7781f374"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNi01LTEtMS0zODM0Mw_de072650-0c04-4be4-81f6-c0bde699500e"
      unitRef="usd">6812000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f608a19cf3e4ad8b08006d63b40d4c4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNi03LTEtMS0zODM0Mw_371a3f2a-5895-4116-8294-293444888f9f"
      unitRef="usd">332334000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id75fdfd77e0748c8bb330bc88f7cea38_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNy0xLTEtMS0zODM0Mw_0ed438b2-5ee8-43dd-b0f4-80ac1e709386"
      unitRef="usd">46076000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id75fdfd77e0748c8bb330bc88f7cea38_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNy0zLTEtMS0zODM0Mw_4cfe6240-633a-4804-a1a6-7d9cb4a90448"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id75fdfd77e0748c8bb330bc88f7cea38_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNy01LTEtMS0zODM0Mw_532d5e87-2912-4b14-8895-ad9ba6c3da6d"
      unitRef="usd">1934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id75fdfd77e0748c8bb330bc88f7cea38_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfNy03LTEtMS0zODM0Mw_3ff2faf8-5129-4297-b83f-4c43c18d1890"
      unitRef="usd">44142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfOC0xLTEtMS0zODM0Mw_9e82ccb9-0bbc-49c3-bc30-6d079a556c7e"
      unitRef="usd">594719000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfOC0zLTEtMS0zODM0Mw_303b8a5f-df83-40d5-8d92-f0eb56043cee"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfOC01LTEtMS0zODM0Mw_62b7dbf9-3a38-4c31-acf3-2cd71e545d0a"
      unitRef="usd">12515000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfOC03LTEtMS0zODM0Mw_755faf1f-736d-4b1c-ab40-53d9cad7a13f"
      unitRef="usd">582205000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMTEtNy0xLTEtMzgzNDM_7c2c2735-e0a9-4189-a6af-a0dd4c27f9b8"
      unitRef="usd">19225000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMTItNy0xLTEtMzgzNDM_2cc853f5-6b94-4784-9b29-6bec8bec05b2"
      unitRef="usd">477872000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMTMtNy0xLTEtMzgzNDM_46ae0b87-4cbd-4255-afe2-361e5d0db8c0"
      unitRef="usd">85108000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOmY3NTExYTFhM2Y1YTQ3ODViN2UwYjIxNzFlMWRkN2JhL3RhYmxlcmFuZ2U6Zjc1MTFhMWEzZjVhNDc4NWI3ZTBiMjE3MWUxZGQ3YmFfMTQtNy0xLTEtMzgzNDM_6469591d-5b80-4318-b6b4-afd01632a5a4"
      unitRef="usd">582205000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i495066fc809c46088689104229f96bd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMy0xLTEtMS0zODM0Mw_b59efb7f-13ec-47f0-a977-38535adeb8ac"
      unitRef="usd">115867000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i495066fc809c46088689104229f96bd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMy0zLTEtMS0zODM0Mw_5833c2b8-6817-4ad0-bc32-4e0d9bbcea3c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i495066fc809c46088689104229f96bd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMy01LTEtMS0zODM0Mw_210788bb-a97b-4603-8fe5-043e59035ab3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i495066fc809c46088689104229f96bd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMy03LTEtMS0zODM0Mw_f8cd23ce-a8bd-44a3-986c-331c2a35de3b"
      unitRef="usd">115867000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icc8586da0577480cb7a0240005555a9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNC0xLTEtMS0zODM0Mw_119be231-5fea-4f13-871e-31aae17664a1"
      unitRef="usd">58981000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icc8586da0577480cb7a0240005555a9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNC0zLTEtMS0zODM0Mw_80cc290c-1c6d-41e5-9db6-bf0cd8a6ee1e"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icc8586da0577480cb7a0240005555a9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNC01LTEtMS0zODM0Mw_92523ef2-2c85-4cc6-9d74-b4da28cafba5"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc8586da0577480cb7a0240005555a9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNC03LTEtMS0zODM0Mw_d0501603-dfdb-4272-9355-02c3029fc499"
      unitRef="usd">58976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4bbc0838fe244d26ba01e286b31789de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNS0xLTEtMS0zODM0Mw_ad7e7fb4-4752-42a5-b50a-888c1814b702"
      unitRef="usd">224092000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4bbc0838fe244d26ba01e286b31789de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNS0zLTEtMS0zODM0Mw_0f0f43c8-4541-419a-87dd-105011ac9ff8"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4bbc0838fe244d26ba01e286b31789de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNS01LTEtMS0zODM0Mw_b1418c78-ab74-4bad-8016-b9e9de1c63de"
      unitRef="usd">647000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bbc0838fe244d26ba01e286b31789de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNS03LTEtMS0zODM0Mw_04f1d7d6-d7a0-479f-b3d3-c191940799aa"
      unitRef="usd">223474000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icb2b5f01151e42a08a9681956bf850f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNi0xLTEtMS0zODM0Mw_0e56991c-6f52-46ea-9610-b36c73e79f01"
      unitRef="usd">304142000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icb2b5f01151e42a08a9681956bf850f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNi0zLTEtMS0zODM0Mw_4c17ceec-4ce8-40b1-9c12-cf053a0647a3"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icb2b5f01151e42a08a9681956bf850f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNi01LTEtMS0zODM0Mw_96c7db82-e073-4e4a-9aa0-af72b40acec5"
      unitRef="usd">1128000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb2b5f01151e42a08a9681956bf850f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNi03LTEtMS0zODM0Mw_5776c58f-c89f-4d92-be09-65e2e21a1c8b"
      unitRef="usd">303016000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i32d24e7b9e4e46139098c072d28e3b8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNy0xLTEtMS0zODM0Mw_62a66028-1894-48a0-af0b-0da3d7403263"
      unitRef="usd">51075000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i32d24e7b9e4e46139098c072d28e3b8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNy0zLTEtMS0zODM0Mw_8edc6bc4-68a1-4da9-a54b-6694fc2d25a3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i32d24e7b9e4e46139098c072d28e3b8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNy01LTEtMS0zODM0Mw_825a5423-88ab-41c2-835c-92312719dd6c"
      unitRef="usd">374000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32d24e7b9e4e46139098c072d28e3b8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfNy03LTEtMS0zODM0Mw_6431ce3e-578e-4443-ab7d-355d6a64d2f8"
      unitRef="usd">50701000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfOC0xLTEtMS0zODM0Mw_1e5bc7b1-c7eb-486b-82aa-a26604016e32"
      unitRef="usd">754157000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfOC0zLTEtMS0zODM0Mw_fbfcb829-ab14-4598-8761-f8ef671047af"
      unitRef="usd">33000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfOC01LTEtMS0zODM0Mw_93981a90-ad21-45fe-bbec-8c0e0e60496a"
      unitRef="usd">2156000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfOC03LTEtMS0zODM0Mw_4d22b42e-b36a-4730-9532-7b8d19d280d1"
      unitRef="usd">752034000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMTEtNy0xLTEtMzgzNDM_3ae5ab2d-dd4e-4d98-ad17-e8ec65d24f1a"
      unitRef="usd">115867000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMTItNy0xLTEtMzgzNDM_d5ad9e89-5633-42d9-9c48-a73abec1885d"
      unitRef="usd">283988000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMTMtNy0xLTEtMzgzNDM_bd34b449-915a-40f3-974c-adcbefaccb61"
      unitRef="usd">352179000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RhYmxlOjM5M2ViOTlmODdmNTRjZjZiMjlhMTRkMjIxZWZjYTZiL3RhYmxlcmFuZ2U6MzkzZWI5OWY4N2Y1NGNmNmIyOWExNGQyMjFlZmNhNmJfMTQtNy0xLTEtMzgzNDM_ab9bdccb-86b1-48d0-95a0-6137ac57062c"
      unitRef="usd">752034000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMzEw_70a93e3e-c21e-49f5-a513-b2e05fed3a7b">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfOTMx_5d2227ff-eecd-4251-a9c6-53f9dc61991a"
      unitRef="usd">153700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfOTM4_6751046e-e524-45cf-8884-57e678af8245"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMTE2Ng_38585da8-e298-4fb9-a100-80283b6f0a51"
      unitRef="usd">1500000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80MC9mcmFnOmVhNzE2MjIzMjNhZjRiOWZiMjA3NTliZDkyMGYxNTUyL3RleHRyZWdpb246ZWE3MTYyMjMyM2FmNGI5ZmIyMDc1OWJkOTIwZjE1NTJfMzI5ODUzNDg4NDY2NA_9dc45d2f-7568-4e4e-b9a9-b20b9b442b44"
      unitRef="usd">1900000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RleHRyZWdpb246OTdkM2NhOWFiZjI3NGZkOWJlYmQ5N2I5NTg3NmMyYWZfMTIw_062d5c4d-53e4-44e5-8d06-a2fc7bd79e36">Balance Sheet ComponentsProperty and Equipment, Net&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and Equipment consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RleHRyZWdpb246OTdkM2NhOWFiZjI3NGZkOWJlYmQ5N2I5NTg3NmMyYWZfMTIx_81da32de-4b4e-4796-9bd7-2fc0fd207b43">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and Equipment consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5db76501bbc74787965531c11d212d58_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfMi0xLTEtMS0zODM0Mw_c1135cbd-67f4-474f-9fbb-b78ec48d7105"
      unitRef="usd">108412000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i08b3bb83a6f447df99a6eb708011d28b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfMi0zLTEtMS0zODM0Mw_e059214e-9b1b-406f-b6d9-5033fbd0fab3"
      unitRef="usd">108353000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie09d16f1562c4ea7a6206e6000a0d8c9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfMy0xLTEtMS0zODM0Mw_65e83944-75b0-44da-8111-1c05a7deacdd"
      unitRef="usd">31443000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5f488c95563e4fc0abd6053e7cdbcef3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfMy0zLTEtMS0zODM0Mw_e36fc403-0b3d-4dbb-8642-0c4fbf0e361e"
      unitRef="usd">29666000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i26accf762170429ebb2cfab586faf0e3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNC0xLTEtMS0zODM0Mw_6f870673-8e56-4ee4-819a-9582182903ff"
      unitRef="usd">5033000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i86caf7b4d7f94d6a815a266b3f51ee53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNC0zLTEtMS0zODM0Mw_7652e680-6b00-40e0-b6f2-437ef6bb89e9"
      unitRef="usd">4373000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icda10573477f47fda5d385ccafcf2a6b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNS0xLTEtMS0zODM0Mw_14067bb4-7470-42a4-84c3-9e603e030340"
      unitRef="usd">3976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic6c9232fcc104c6894737b6331f6e04d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNS0zLTEtMS0zODM0Mw_dffead09-d01e-46a0-a6ef-761d94cef228"
      unitRef="usd">3920000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaf1f3fff4077416faac3922039ac158c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNi0xLTEtMS0zODM0Mw_4885d4d7-12e2-4076-b88a-d73e9c567640"
      unitRef="usd">166000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic4d4d159174f4bfea30e39a7ea47463f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNi0zLTEtMS0zODM0Mw_b398b895-dd22-40e6-b1dc-f55c26af4305"
      unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNy0xLTEtMS0zODM0Mw_6fe69f10-9b0b-4c98-a9f2-05c748432144"
      unitRef="usd">149030000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfNy0zLTEtMS0zODM0Mw_ec7d354c-624e-4273-b723-f90658f94fc3"
      unitRef="usd">146351000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfOC0xLTEtMS0zODM0Mw_7a3b4320-3395-4e27-8476-5cc8c095e43b"
      unitRef="usd">34588000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfOC0zLTEtMS0zODM0Mw_56417fea-11e3-4f34-b22d-a90c2ac1dcb2"
      unitRef="usd">23361000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfOS0xLTEtMS0zODM0Mw_1d1cd343-9c40-4b6e-9d59-5e80315f84da"
      unitRef="usd">114442000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80My9mcmFnOjk3ZDNjYTlhYmYyNzRmZDliZWJkOTdiOTU4NzZjMmFmL3RhYmxlOjY3NmUwMTllZjhjMDRlZGQ4NzNhMjlkNzMyZjY4MzBkL3RhYmxlcmFuZ2U6Njc2ZTAxOWVmOGMwNGVkZDg3M2EyOWQ3MzJmNjgzMGRfOS0zLTEtMS0zODM0Mw_2916a23e-ebe0-4b9c-ada2-2d7f7cbf975e"
      unitRef="usd">122990000</us-gaap:PropertyPlantAndEquipmentNet>
    <allo:LicenseAgreementsTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjg1OTU_de499512-8eb1-40e4-8d7c-59dbb5bfd2f2">License and Collaboration Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Contribution Agreement with Pfizer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets, including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $30.0 million or $60.0 million, depending on the target, with aggregate potential regulatory and development milestones of up to $840.0 million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $325.0 million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three and nine months ended September&#160;30, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#x2019;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) 12 years from the first sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Collaboration and License Agreement with Cellectis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#x2019;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $185.0 million per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to $2.8 billion. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#x2019;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#x2019;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The royalties are payable, on a licensed-product-by-licensed-product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#x2019; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#x2019; prior written notice in the event of the other party&#x2019;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs the Company incurred in connection with this agreement were recognized as research and development expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022, zero costs were incurred related to the achievement of a clinical development milestone under this agreement. For the three and nine months ended September&#160;30, 2021, $5.0 million and $10.0 million, respectively, in costs were incurred related to the achievement of a clinical development milestone under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreement with Servier&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19, ALLO-501 and ALLO-501A in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for 60% of the specified development costs and Servier is responsible for the remaining 40% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#x2019;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#x2019;s sole expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $137.5 million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $78.0 million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $42.0 million and &#x20ac;70.5 million ($69.1 million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#x2019;s election not to pursue such rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#x2019;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#x2019;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022, the Company recorded $3.8 million and $20.4 million, respectively, of net cost recoveries under the cost-sharing terms of the Servier Agreement as a reduction to research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded $5.1 million and $13.2 million, respectively, of net cost recoveries. As of September&#160;30, 2022 and December&#160;31, 2021, amounts due from Servier of $4.3 million and $4.1 million, respectively, were recorded in other current assets in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2022, Servier sent a notice of discontinuation (Discontinuation) of its involvement in the development of all licensed products directed against CD19, including UCART19, ALLO-501 and ALLO-501A (collectively, CD19 Products), pursuant to the Servier Agreement. Servier&#x2019;s Discontinuation provides the Company with the right to elect a license to the CD19 Products outside of the United States (Ex-US Option) and does not otherwise affect the Company's current exclusive license for the development and commercialization of CD19 Products in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Collaboration and License Agreement with Notch&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#x2019;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#x2019;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#x2019;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#x2019;s election, following the joint development committee&#x2019;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#x2019;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $10.0&#160;million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. In addition, Allogene made a $5.0&#160;million investment in Notch&#x2019;s series seed convertible preferred stock, resulting in Allogene having a 25% ownership interest in Notch&#x2019;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, an Allogene representative serves on the Notch Board of Directors. In February 2021, the Company made an additional $15.9 million investment in Notch's Series A preferred stock. In October 2021, the Company made an additional $1.8&#160;million investment in Notch's common stock. Immediately following this transaction, the Company's share in Notch was 23.0% on a voting interest basis. The Company did not have a controlling interest in Notch as of September&#160;30, 2022, and continued to account for its investment in Notch as an equity method investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Notch Agreement, Notch will be eligible to receive up to $7.25&#160;million upon achieving certain agreed research milestones, up to $4.0&#160;million per exclusive target upon achieving certain pre-clinical development milestones, and up to $283.0&#160;million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#x2019;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#x2019;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#x2019;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#x2019; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#x2019;s insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the three and nine months ended September&#160;30, 2022, the Company recorded $1.0 million and $2.8 million, respectively, in collaboration costs as research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded $0.8 million and $3.9 million, respectively, in collaboration costs as research and development expenses.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Strategic Alliance with The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 6, 2020, the Company entered into a strategic five-year collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The Company and MD Anderson are collaborating on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, the Company has committed up to $15.0&#160;million of funding for the duration of the agreement. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance. The Company made an upfront payment of $3.0&#160;million to MD Anderson in the year ended December 31, 2020. The Company is obligated to make further payments to MD Anderson each year upon the anniversary of the agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effective date through the duration of the agreement term. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, among other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022, the Company recorded $0.2 million and $1.1 million in collaboration costs as research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded $0.4 million and $0.8 million, respectively, in collaboration costs as research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joint Venture and License Agreement with Allogene Overland Biopharm (CY) Limited &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2020, the Company entered into a License Agreement with Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by the Company and Overland Pharmaceuticals (CY) Inc. (Overland), pursuant to a Share Purchase Agreement, dated December 14, 2020, for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore (the JV Territory). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Share Purchase Agreement, the Company acquired Seed Preferred Shares in Allogene Overland representing 49% of Allogene Overland's outstanding stock as partial consideration for the License Agreement, and Overland acquired Seed Preferred Shares representing 51% of Allogene Overland's outstanding stock for $117.0&#160;million in upfront and certain quarterly cash payments, to support operations of Allogene Overland. As of September&#160;30, 2022, the Company and Overland are the sole equity holders in Allogene Overland. The Company received $40&#160;million from Allogene Overland as partial consideration for the License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the License Agreement, the Company granted Allogene Overland an exclusive license to develop, manufacture and commercialize certain allogeneic CAR T cell candidates directed at four targets, BCMA, CD70, FLT3, and DLL3, in the JV Territory. As consideration, the Company would also be entitled to additional regulatory milestone payments of up to $40.0&#160;million and, subject to certain conditions, tiered low-to-mid single-digit sales royalties. Subsequent to entering into the License Agreement, Allogene Overland assigned the License Agreement to a wholly-owned subsidiary, Allogene Overland BioPharm (HK) Limited. On April 1, 2022, Allogene Overland HK assigned the License Agreement to Allogene Overland Biopharm (PRC) Co., Limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Promises that the Company concluded were distinct performance obligations in the License Agreement included: (1) the license of intellectual property and delivery of know-how, (2) the manufacturing license, related know-how and support, (3) if and when available know-how developed in future periods, and (4) participation in the joint steering committee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Fixed consideration exists in the form of the upfront payment. Regulatory milestones and royalties were considered variable consideration.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. Milestone fees were constrained and not included in the transaction price due to the uncertainties of research and development. The Company re-evaluates the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The shares of Series Seed Preferred Stock were accounted for as part of the Company&#x2019;s joint venture and equity method accounting upon formation of the joint venture, and as such, were excluded from the transaction price. The Company determined that the initial transaction price consists of the upfront payment of $40.0&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price allocated to the license of intellectual property and delivery of know-how will be recognized upon grant of license and delivery of know-how. The transaction price allocated to (i) the manufacturing license, related know-how and support services, (ii) if and when available know-how developed in future periods, and (iii) participation in the joint steering committee, will be recognized over time as the services are delivered. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received in advance are recorded as deferred revenue and will be recognized as the performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that Allogene Overland is a variable interest entity as of September&#160;30, 2022 and December 31, 2021. The Company does not have the power to independently direct the activities which most significantly affect Allogene Overland's economic performance. Accordingly, the Company did not consolidate Allogene Overland because the Company determined that it was not the primary beneficiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022, the Company recognized less than $0.1&#160;million and $0.2 million of collaboration revenue, respectively. For the three and nine months ended September&#160;30, 2021, the Company recognized less than $0.1&#160;million and $38.4 million, respectively, of collaboration revenue, primarily related to the license of intellectual property and delivery of the know-how performance obligation which was delivered in the first quarter of 2021. For the three and nine months ended September&#160;30, 2022, the Company recorded $0.3 million and $0.6 million, respectively, of net cost recoveries under the terms of the license agreement as a reduction to research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded zero net cost recoveries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration and License Agreement with Antion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2022, the Company entered into an exclusive collaboration and global license agreement (Antion Collaboration and License Agreement) with Antion Biosciences SA (Antion) for Antion&#x2019;s miRNA technology (miCAR), to advance multiplex gene silencing as an additional tool to develop next generation allogeneic CAR T products. Pursuant to the agreement, Antion will exclusively collaborate with the Company on oncology products for a defined period. The Company will also have exclusive worldwide rights to commercialize products incorporating Antion technology developed during the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Antion Collaboration and License Agreement includes an exclusive research collaboration to conduct research and development of the use of Antion&#x2019;s proprietary technologies to produce certain products for a defined period, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint steering committee. The Company will reimburse Antion's costs incurred in accordance with such plan and budget. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Antion Collaboration and License Agreement, the Company made an upfront payment to Antion of $3.5 million in return for a license to access Antion's technology in order to conduct research pursuant to the agreement. The upfront payment was fully recognized as research and development expense as the license had no foreseeable alternative future use. In addition, the Company made a $3.0 million investment in Antion's preferred stock and is expected to make an additional $3.0&#160;million investment in Antion's preferred stock upon achievement of an agreed milestone. The Company accounts for its investment in Antion's preferred stock as an equity investment measured at cost less any impairment. In connection with this investment, a Company representative was appointed to Antion&#x2019;s Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Antion Collaboration and License Agreement, Antion will be eligible to receive up to $35.3 million for four products upon achievement of certain development and regulatory milestones. For each additional product, Antion will be eligible to receive $2.0 million upon achievement of a regulatory milestone. Antion is also entitled to receive a low single-digit royalty on the Company&#x2019;s sales of licensed products, subject to certain reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022, the Company recorded $0.6 million and $4.5 million in research and development expenses related to the upfront payment and collaboration costs, of which $0.5 million is recorded in accrued and other liabilities as of September&#160;30, 2022. The Company's total equity investment in Antion was $3.0 million as of September&#160;30, 2022 and is recognized in other long-term assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</allo:LicenseAgreementsTextBlock>
    <allo:AggregatePotentialMilestonePayments
      contextRef="iba32805724354181ae04c6b3cacb4be2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfODE2_1ce516fc-5f8d-4c2d-bca0-ba9cde10da35"
      unitRef="usd">30000000</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i7dddb67349574083921a243e6e892161_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfODIy_27b1de97-438d-44ed-8925-8f798643c735"
      unitRef="usd">60000000</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialRegulatoryAndDevelopmentMilestones
      contextRef="i7dddb67349574083921a243e6e892161_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfOTIz_ca732ee9-acae-49e0-87d6-07fabe84d1c3"
      unitRef="usd">840000000</allo:AggregatePotentialRegulatoryAndDevelopmentMilestones>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i6aade5c20f2244a3ade2b713c171949b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM3Nw_5504a56c-924c-46ba-b741-1ec16608f49c"
      unitRef="usd">325000000</allo:AggregatePotentialMilestonePayments>
    <allo:MilestonePayments
      contextRef="ief48337bd67341b9bb41f73b0b3c18f3_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OQ_4a8c8003-acdb-40a8-a3d2-f357d737823b"
      unitRef="usd">0</allo:MilestonePayments>
    <allo:MilestonePayments
      contextRef="i7eb2b0edcdf44e7894b474bef1a2f72c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OQ_529931ef-b245-4939-8b07-10826e9437a5"
      unitRef="usd">0</allo:MilestonePayments>
    <allo:MilestonePayments
      contextRef="i6aade5c20f2244a3ade2b713c171949b_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OQ_b2cfbe39-8bef-43fa-b8ec-03c3ddfc8f96"
      unitRef="usd">0</allo:MilestonePayments>
    <allo:MilestonePayments
      contextRef="i9534ed89959b476bb3c61a21f111f0ac_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OQ_c6921256-134f-4a75-8a9f-30523e683cff"
      unitRef="usd">0</allo:MilestonePayments>
    <allo:RoyaltyObligationPeriodFromDateOfFirstSale
      contextRef="ic8ccb9c3e12e4bfbbafab7c1c5ed2261_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjMzNA_90541c57-be94-4119-a530-cbf7e3162479">P12Y</allo:RoyaltyObligationPeriodFromDateOfFirstSale>
    <allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget
      contextRef="ida71502c322b490db719e60631ed9186_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfNDYxMg_5a33e303-4009-4586-b946-46563eb829e6"
      unitRef="usd">185000000</allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i12d3205699d44a1595452c484f84725b_D20220101-20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfNDc1Mw_d46ea29a-d5cc-46d4-899c-14e8862c1a8b"
      unitRef="usd">2800000000</allo:AggregatePotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5cd514b962e246c6931c985ac1c2ec04_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfODM0Mw_665c2643-8766-464a-b729-8abba1ebf7fd"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibd1dcad80d4e4790ae883499a22385cc_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfODM0Mw_ca9f3608-967c-4ef1-8664-58522dd04c13"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5454ce81effa43ec82d692544d01340c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMTkyOQ_551f3a56-2c84-46f2-9081-5b2c581a749e"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i82036ec2aaa24cc88e17cb24559ae7cd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMTkzMw_4b1de15e-e6a2-49c2-bb16-b18dca16913b"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpense>
    <allo:PercentageOfDevelopmentCostPayableByTheCompany
      contextRef="i8cc896b3a0a744c0b48d522995094a4c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTA5Mjg_fa1a73f0-de73-4582-93e7-287fa1613e49"
      unitRef="number">0.60</allo:PercentageOfDevelopmentCostPayableByTheCompany>
    <allo:PercentageOfDevelopmentCostPayableByCollaborationPartner
      contextRef="i8cc896b3a0a744c0b48d522995094a4c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTEwMTE_9256614c-a9d0-4c50-bdee-061dc578e749"
      unitRef="number">0.40</allo:PercentageOfDevelopmentCostPayableByCollaborationPartner>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i72513027aa40456ea894b7c240d9529e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTE2NTI_77b232e6-c694-4dcb-a23e-3f96866b328d"
      unitRef="usd">137500000</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i4eeda0f2399347eba9a1d3c03cd7ed64_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTE3ODQ_3b636ac4-eda9-460f-b65f-57841ce62ae2"
      unitRef="usd">78000000</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestoneReceivable
      contextRef="i3d882b41ba7546aaa56039ced1a10287_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTIyNDQ_5cea55d5-b4e5-4ee4-af38-be73cf907764"
      unitRef="usd">42000000</allo:AggregatePotentialMilestoneReceivable>
    <allo:AggregatePotentialMilestoneReceivable
      contextRef="i6dbfd0aa1f5c4f6d8ac7bf09374fbbcb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTIyNTE_05bd45b0-9b83-4e6a-8f49-a4d8e2ce1b87"
      unitRef="eur">70500000</allo:AggregatePotentialMilestoneReceivable>
    <allo:AggregatePotentialMilestoneReceivable
      contextRef="i6dbfd0aa1f5c4f6d8ac7bf09374fbbcb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTIyNTU_163e576d-f3cb-402e-ab2e-03c4031c22a1"
      unitRef="usd">69100000</allo:AggregatePotentialMilestoneReceivable>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="id7323529b23b45e7b1f3558682b81cd8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM1ODg_5abc8c25-c96f-435b-afde-d8c9eff7e531"
      unitRef="usd">3800000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i8cc896b3a0a744c0b48d522995094a4c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM1OTU_40efdada-e10b-433f-8c3b-f0e0a85bfd4a"
      unitRef="usd">20400000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="ic72e6bbd73b24d50b42d5a271012c22c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM3OTI_988f6e27-cca4-41d3-a377-cc5ceae7cc4f"
      unitRef="usd">5100000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i664e2401aa7b4ff9b1bca0d363df47d4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM3OTk_6c1f4f72-880d-43a3-ac75-cd6a123cebab"
      unitRef="usd">13200000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:DueFromRelatedParties
      contextRef="i8e4f3d045a2243009dac024b2e80a3ca_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM4ODY_65f96134-09b0-4f33-b0d0-1304cf9dfe78"
      unitRef="usd">4300000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="ic983cd690af84de59565ffe50d5f5432_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTM4OTM_0f8bd1df-3bf6-4b78-8c37-a6a355fa4999"
      unitRef="usd">4100000</us-gaap:DueFromRelatedParties>
    <allo:CollaborationAgreementUpfrontPayment
      contextRef="i58179b3cdca14b9aa3417426bdb601bb_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTU4MjA_d3efe371-2df4-487a-80d3-38681e4a1b7f"
      unitRef="usd">10000000</allo:CollaborationAgreementUpfrontPayment>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i66aa59ed9c4048298f0a3a33feba7cc5_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTU5Njc_c7275cb8-a235-442f-aa84-de4d035bff19"
      unitRef="usd">5000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i66aa59ed9c4048298f0a3a33feba7cc5_I20191101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTYwNjQ_fba75af2-dd51-4a65-b91a-d71985e00be6"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i3871a5c9adb14fedb9c83c1425f51c54_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTYzMzg_0b50eb7b-6015-4dde-bcc1-d20e6b37aa01"
      unitRef="usd">15900000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie8a195a8a56445a3999166ac9339894c_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY0Mzc_d1c2fe8f-59f4-4f5b-998b-b31982e25ae7"
      unitRef="usd">1800000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i44b0b5f2e18c49b2991662b317cd0227_I20211031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY1NDk_ba6689e7-8ef8-4ec8-b9de-b4dfd79c226b"
      unitRef="number">0.230</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <allo:AggregatePotentialMilestonePayable
      contextRef="i36321bc5549f4fdf84b022c72c2623e0_I20220930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY3OTk_8916d27a-b094-426e-bf1c-4baae65a5d77"
      unitRef="usd">7250000</allo:AggregatePotentialMilestonePayable>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i25e249ab3ca0464995456f2a93a352ff_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY4NTk_84a38748-7659-4e6f-a8a4-0f49d19a154c"
      unitRef="usd">4000000</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="ib6b6f12ac8d143eda9f281cbcc802324_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTY5NTM_73f4a9cc-031b-45a9-8997-87bc475dcfb6"
      unitRef="usd">283000000</allo:AggregatePotentialMilestonePayments>
    <allo:CollaborationArrangementExpense
      contextRef="i7bb1c70c0e2a408eba7c119e0cecf3a3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTg1MTk_bb62045b-8725-423c-97f0-990ddd161ef6"
      unitRef="usd">1000000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="i190dbd12ad724f999de964f8944f43f9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTg1MjY_67d92a62-1c73-4388-9707-f2eb8aabbf63"
      unitRef="usd">2800000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="i7aa0b52e31cb47caa5b6de4a921c9b55_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTg2NTQ_8ec9060b-4126-4b7c-95a0-b4654be5b441"
      unitRef="usd">800000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="ibb0223ba204941ab82cb484b7e33f56a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTg2NjE_99d6d665-8fcd-4f9d-b2e5-c719a4cbe73b"
      unitRef="usd">3900000</allo:CollaborationArrangementExpense>
    <allo:CollaborationAgreementTerm
      contextRef="ia9bf9785d75b4721b9ff6232ef70d39b_D20201006-20201006"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjg1OTE_338e6a90-18a5-4da7-8015-a11d996e889d">P5Y</allo:CollaborationAgreementTerm>
    <allo:CollaborationAgreementCommittedFunding
      contextRef="ia9bf9785d75b4721b9ff6232ef70d39b_D20201006-20201006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTkyODk_fa04c7e8-5ffe-4a1b-856f-c8afd4c1dd7b"
      unitRef="usd">15000000</allo:CollaborationAgreementCommittedFunding>
    <allo:CollaborationAgreementUpfrontPayment
      contextRef="iee875a3ae84d46ed987a1b307db20e6e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMTk1MDk_5c54ddfb-4b53-45cb-b72d-adaf6a38047d"
      unitRef="usd">3000000</allo:CollaborationAgreementUpfrontPayment>
    <allo:CollaborationArrangementExpense
      contextRef="i3240a374c5ab440e8b5e1aabbdba7c25_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjAzODU_6b203226-568a-49af-8059-386e14d37727"
      unitRef="usd">200000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="iff52c9c9567540af853d7d4e7492d0ca_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjAzOTI_241b3f4d-575e-4654-9031-3ae98bbc64f4"
      unitRef="usd">1100000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="if7f6257251904aeda6581f6bfc8b2065_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMTk0NA_0f8461f5-6e37-4c28-b7c4-0222123a1b89"
      unitRef="usd">400000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="i93f8ae51b31a40de91e52c6738e4e6d5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjA1MDU_5ed97c6d-3002-4248-856d-5969919f6b47"
      unitRef="usd">800000</allo:CollaborationArrangementExpense>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib9fc1bf30b194863ae80b306bfcfbb2f_I20201214"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjEyNTQ_3daad150-ebbb-435c-9014-81fcb4a70b4a"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if2742005271e46328201e1c4c09f2efc_I20201214"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjE0MDc_174661ba-8a0a-4483-9f57-9ab9a59e8730"
      unitRef="number">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <allo:UpfrontAndQuarterlyCashPayments
      contextRef="iae425c05634344d4904101d51eef4cc6_D20201214-20201214"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjE0NTU_63924da3-d005-4af2-89ba-810f37aec128"
      unitRef="usd">117000000</allo:UpfrontAndQuarterlyCashPayments>
    <allo:JointVentureCapitalSupportPayments
      contextRef="iae425c05634344d4904101d51eef4cc6_D20201214-20201214"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjE2NzE_04c29abe-028c-4a22-98ae-e4d76ec89054"
      unitRef="usd">40000000</allo:JointVentureCapitalSupportPayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i717e3fb1a0d945d5851037cc406f873a_D20201214-20201214"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjIxMDk_77a2828c-16cb-4809-808e-1d4b1e8c4f96"
      unitRef="usd">40000000</allo:AggregatePotentialMilestonePayments>
    <allo:CollaborationAgreementUpfrontPayment
      contextRef="i5d1cf8a7bcb44874baee49aa53e9d5ce_I20201214"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjQwMTg_3721af02-96e3-4e9d-b16a-17f067446830"
      unitRef="usd">40000000</allo:CollaborationAgreementUpfrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMTk5OQ_5ca8f499-5558-4c4b-80bf-0698b3b0ea0c"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjUyODk_c501bd90-a6c5-466b-8ac4-b31ac0810044"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjUzOTM_325ea679-ebad-4b93-a5a1-7d9bf327a330"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjU0MDA_4c2ca9ad-b2e3-42e3-b5a8-4e70af542233"
      unitRef="usd">38400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMzI5ODUzNDkxMjA0MA_7da459d2-8cd1-403d-8811-063d64c0f6e9"
      unitRef="usd">300000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjU2NjA_52b0e83a-13e0-4a42-a6ef-db290d969310"
      unitRef="usd">600000</us-gaap:RecoveryOfDirectCosts>
    <allo:ReductionToResearchAndDevelopmentExpense
      contextRef="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjU4NDQ_52657244-4853-405e-82b4-3c7abe4de04b"
      unitRef="usd">0</allo:ReductionToResearchAndDevelopmentExpense>
    <allo:ReductionToResearchAndDevelopmentExpense
      contextRef="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjU4NDQ_c30bfd29-878d-470e-9b57-c1b4637e4a3b"
      unitRef="usd">0</allo:ReductionToResearchAndDevelopmentExpense>
    <allo:CollaborationAgreementUpfrontPayment
      contextRef="i8499187e402947009dcd0f43cd08b023_I20220105"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjcxMDQ_083add54-482e-433a-964e-02687c8601b3"
      unitRef="usd">3500000</allo:CollaborationAgreementUpfrontPayment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ib00af316994b480e903873475c1e0166_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjczODQ_c0aa879b-3470-4472-b7b5-f2530c77650c"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireInvestments>
    <allo:PaymentsToAcquireInvestmentsUponMilestoneAchievement
      contextRef="ib00af316994b480e903873475c1e0166_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjc0NjQ_5145b74f-dd1c-412f-af06-470c92124815"
      unitRef="usd">3000000</allo:PaymentsToAcquireInvestmentsUponMilestoneAchievement>
    <allo:AggregatePotentialMilestonePayable
      contextRef="ia7b7af3feeda4ecd91976cd1a7640903_I20220105"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjc4ODE_fedd4053-3167-48cc-886d-93180b09b1b9"
      unitRef="usd">35300000</allo:AggregatePotentialMilestonePayable>
    <allo:AggregatePotentialMilestonePayable
      contextRef="i7bbcb65830e9469e8584561b4ed503d6_I20220105"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgwMzM_8f7be2ee-a8f9-42c7-965c-a27d16063fa1"
      unitRef="usd">2000000</allo:AggregatePotentialMilestonePayable>
    <allo:CollaborationArrangementExpense
      contextRef="i7ab46440194c44e0abc3230ea0acaa11_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgyNjc_e32488e5-4c96-48b3-ad39-bc4311cba7cd"
      unitRef="usd">600000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="i0599d7f096e54faa830326a4b07be324_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgyNzQ_298faa38-058d-4f8a-a37a-245ab88bf122"
      unitRef="usd">4500000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="i12798b13b2e34a1f8b05f08a0a198299_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgzNzk_52f26ba4-9435-4114-9cf2-d6f97552210d"
      unitRef="usd">500000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="ia1861d08a2de4faebc1dfeee012e2263_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjgzNzk_9a66aa7e-835c-4f6c-b422-59c5f7bc8ccf"
      unitRef="usd">500000</allo:CollaborationArrangementExpense>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ib00af316994b480e903873475c1e0166_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80Ni9mcmFnOjk4ODM4NDY3NTJhNTQyMjdhMmJhZTE1MWZiZGNhMGFiL3RleHRyZWdpb246OTg4Mzg0Njc1MmE1NDIyN2EyYmFlMTUxZmJkY2EwYWJfMjg0ODk_c0aa879b-3470-4472-b7b5-f2530c77650c"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM4MQ_190f87e0-68a1-4464-b74f-df6bb873dc8c">Commitments and Contingencies&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Company entered into an operating lease agreement (HQ Lease) for office and laboratory space which consists of approximately 68,000 square feet located in South San Francisco, California. The lease term was 127 months beginning August 2018 through February 2029 with an option to extend the term for seven years which was not reasonably assured of exercise. The Company has made certain tenant improvements, including the addition of laboratory space, and has received $5.0 million of tenant improvement allowances. The rent payments began on March 1, 2019 after an abatement period. In December 2021, the Company amended its lease agreement to lease an additional 47,566 square feet of office and laboratory space in South San Francisco, California, as part of the same building as the Company&#x2019;s current headquarters. The lease term commenced in April 2022 and is for a period of 120 months. The rent payments for the expansion premises began in August 2022 after an abatement period. The lease term for the existing premises was also extended and the lease for both the existing and expansion premises will expire on March 31, 2032 with an option to extend the term for eight years which is not reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an operating lease agreement for office and laboratory space which consists of 14,943 square feet located in South San Francisco, California. The lease term was 124 months beginning November 2018 through February 2029, with an option to extend the term for another seven years which was not reasonably assured of exercise. The Company has made certain tenant improvements, including the upgrading of current office and laboratory space with a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lease incentive allowance of $0.8 million. Rent payments began in November 2018. In December 2021, the Company amended its lease agreement to extend the term of the lease to be co-terminus with the HQ Lease. The lease term will expire March 31, 2032 with an option to extend the term for eight years which is not reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, the Company entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease term is 188 months beginning November 2020 through July 2036. Upon certain conditions, the Company has two ten-year options to extend the lease, both of which are not reasonably assured of exercise. The Company has received $3.0 million of tenant improvement allowances for costs related to the design and construction of certain Company improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains letters of credit for the benefit of landlords which is disclosed as restricted cash in the condensed consolidated balance sheets. Restricted cash related to letters of credit due to landlords was $6.0 million as of September&#160;30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_090f2506-4094-4262-920e-2e1663730d2d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_c2737ca9-b04a-4d28-a3da-5b7ccec47c9f"&gt;Current portion included in accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities for the nine months ended September&#160;30, 2022 was $2.6 million and was included in net cash used in operating activities in our condensed consolidated statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The undiscounted future lease payments under the lease agreements as of September&#160;30, 2022 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;2022 (remaining 6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our estimated incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was&#160;6.19%. As of&#160;September&#160;30, 2022, the weighted average remaining lease term for our operating leases is&#160;10.21 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, the Company entered into a Solar Power Purchase and Energy Services Agreement for the installation and operation of a solar photovoltaic generating system and battery energy storage system at the Company's cell therapy manufacturing facility in Newark, California. The agreement has a term of 20 years and commenced in September 2022. The Company is obligated to pay for electricity generated from the system at an agreed rate for the duration of the agreement term. Termination of the agreement by the Company will result in a termination payment due of approximately $4.3 million. In connection with the agreement, the Company maintains a letter of credit for the benefit of the service provider in the amount of $4.3 million which is disclosed as restricted cash in the condensed consolidated balance sheets as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into certain license agreements for intellectual property which is used as part of our development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of September&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company enters into contracts in the normal course of business that includes arrangements with clinical research organizations, vendors for preclinical research and vendors for manufacturing. These agreements generally allow for cancellation with notice. As of September&#160;30, 2022, the Company had non-cancellable purchase commitments of $0.4 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <allo:AreaOfNewOfficeBuilding
      contextRef="i0db19e8474cf4b47a8a2c996ea80614d_I20180831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTk4_9bfd60f6-e7a5-4f06-b896-f242449e9a40"
      unitRef="sqft">68000</allo:AreaOfNewOfficeBuilding>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i0db19e8474cf4b47a8a2c996ea80614d_I20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjc2_e12e555b-1def-435b-a76c-a68c18507796">P127M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i0db19e8474cf4b47a8a2c996ea80614d_I20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzQx_b3365129-44ca-4adb-9874-c3e02fcf0dd7">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:TenantImprovements
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTAx_718cf183-5136-477f-bcc9-8bec7c8ff4fb"
      unitRef="usd">5000000</us-gaap:TenantImprovements>
    <allo:AdditionalAreaOfNewOfficeBuilding
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNjc2_9ae59f0b-09d1-44f1-9aa4-091f54ed8374"
      unitRef="sqft">47566</allo:AdditionalAreaOfNewOfficeBuilding>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6c0fcddb98e0438fbee11a2250f1b7bd_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfODg4_7e1ac45d-2a97-43b3-a5e0-1e682663479e">P120M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6c0fcddb98e0438fbee11a2250f1b7bd_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTE2Ng_091b3dbf-f406-4c7d-a590-8f71085ad72e">P8Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:AreaOfNewOfficeBuilding
      contextRef="i87ee1a949aa34bb7bc017891ce79e050_I20181031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTMzNg_6786abf8-44cf-450b-9e21-3418f027e1f7"
      unitRef="sqft">14943</allo:AreaOfNewOfficeBuilding>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i87ee1a949aa34bb7bc017891ce79e050_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTQxNA_7f878595-3262-44f7-82f2-e87e1a331f58">P124M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i87ee1a949aa34bb7bc017891ce79e050_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTQ4OA_88a2867c-4894-4e0d-ab18-6a462f6cef15">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:TenantImprovementAllowance
      contextRef="i87ee1a949aa34bb7bc017891ce79e050_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTY4Ng_e36a6738-171c-4164-8c73-0c612d08cfc5"
      unitRef="usd">800000</allo:TenantImprovementAllowance>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic1bb308e19ad469187b256dd69806dce_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMTkxMg_4c90edb1-945d-444c-8548-115e27c71af0">P8Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:AreaOfOperatingLease
      contextRef="i0e8ea8f25c7b4bfb9cf53b843eb1b98b_D20190201-20190228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjA0MA_55a15781-4e54-4e8f-8649-4e3977b2bdea"
      unitRef="sqft">118000</allo:AreaOfOperatingLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ica7aec93cbca455f9d73fe168f4f412b_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjE1NA_d7cb74b5-9528-48d1-acc0-ab98146f6864">P188M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <allo:NumberOfOptionsToExtendLease
      contextRef="i0e8ea8f25c7b4bfb9cf53b843eb1b98b_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjIyMw_561223b2-8a02-42c4-b744-9b2bf38642ef"
      unitRef="renewal">2</allo:NumberOfOptionsToExtendLease>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ica7aec93cbca455f9d73fe168f4f412b_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM3NQ_2d3045e4-c1a7-4d5a-97c2-a9df379610c9">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:TenantImprovementAllowanceUtilizedToDate
      contextRef="id1877d8c1c9d40b58cdc5a256ab21b2b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjM0Mg_2b7243fc-92f3-4bfa-b022-1bd4b4132a17"
      unitRef="usd">3000000</allo:TenantImprovementAllowanceUtilizedToDate>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjY3OQ_ba40c7a5-e2b3-4221-b39d-1e7f914891d5"
      unitRef="usd">6000000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMjY3OQ_d49df4d7-6460-4d8d-837c-b9fd38262958"
      unitRef="usd">6000000</us-gaap:LettersOfCreditOutstandingAmount>
    <allo:LiabilitiesLesseeTableTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM3Nw_589e2150-0e0d-4290-b53e-58a941948b6c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_090f2506-4094-4262-920e-2e1663730d2d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0wLTEtMS0zODM0Mw_c2737ca9-b04a-4d28-a3da-5b7ccec47c9f"&gt;Current portion included in accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</allo:LiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi0yLTEtMS0zODM0Mw_0656954e-07df-4e73-8df5-a0f50cecfc19"
      unitRef="usd">5831000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMi00LTEtMS0zODM0Mw_48ebcfa3-df0f-4c1c-bce5-f661f35ab0de"
      unitRef="usd">3200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMy0yLTEtMS0zODM0Mw_ee872195-3691-4ccd-bf1b-c6acbb6da049"
      unitRef="usd">96706000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfMy00LTEtMS0zODM0Mw_f46daf91-a236-49b2-b69e-bded397359a0"
      unitRef="usd">69929000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfNC0yLTEtMS0zODM0Mw_14f6a0e9-71ca-4ae8-a193-d60fbaac41ad"
      unitRef="usd">102537000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjYxMDY2OTczMWRiYjRkMTA5ZWIwNjE0OTMyNWZhZTIzL3RhYmxlcmFuZ2U6NjEwNjY5NzMxZGJiNGQxMDllYjA2MTQ5MzI1ZmFlMjNfNC00LTEtMS0zODM0Mw_6769cb80-e53b-46ed-a06e-4220c502b00f"
      unitRef="usd">73129000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM4MA_72a9b440-30e9-46bb-9df9-355263139341">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMi0yLTEtMS0zODM0Mw_0d4535b5-8a40-4cda-9fe3-84d61162e5a8"
      unitRef="usd">3177000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMi00LTEtMS0zODM0Mw_d6233f70-38fb-4ba3-883e-e5c1d4141bf5"
      unitRef="usd">1853000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMi02LTEtMS0zODM0Mw_e3798551-b401-4854-8836-78759b8e0e65"
      unitRef="usd">8476000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMi04LTEtMS0zODM0Mw_258871d1-de6b-4aa2-b75e-511df5798243"
      unitRef="usd">5568000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMy0yLTEtMS0zODM0Mw_dfe7979c-d2b5-4763-af67-b9ab74e9330f"
      unitRef="usd">616000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMy00LTEtMS0zODM0Mw_c08c09bf-bd92-46aa-8e0e-5b231617a5d0"
      unitRef="usd">448000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMy02LTEtMS0zODM0Mw_cbeab18b-ec2b-4049-9e51-f40998095f92"
      unitRef="usd">1468000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfMy04LTEtMS0zODM0Mw_073708e0-78a9-4a45-9384-07c98e7ac012"
      unitRef="usd">979000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfNC0yLTEtMS0zODM0Mw_b88721f6-b8c9-4d78-88a9-7b4d978ea21e"
      unitRef="usd">3793000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfNC00LTEtMS0zODM0Mw_1d86c074-66a1-4619-b18d-5396761a6d3c"
      unitRef="usd">2301000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfNC02LTEtMS0zODM0Mw_d1d2da8f-dccf-42bc-a2d7-3f97e4215e2a"
      unitRef="usd">9944000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOjkzNGQ0MjY2ZmYwYzRiNmU5MGYxYzI3NDM2MThmZWYzL3RhYmxlcmFuZ2U6OTM0ZDQyNjZmZjBjNGI2ZTkwZjFjMjc0MzYxOGZlZjNfNC04LTEtMS0zODM0Mw_69c86198-8372-4ba0-bd5e-64a020981388"
      unitRef="usd">6547000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzAyMg_e99167dc-f363-428b-b190-dfc4a674a339"
      unitRef="usd">2600000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM3OA_c7e02eed-3f00-4865-beb6-7de2fa962867">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The undiscounted future lease payments under the lease agreements as of September&#160;30, 2022 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;2022 (remaining 6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfMS0yLTEtMS0zODM0Mw_f859d183-9164-435a-ab8f-6351409dd5ca"
      unitRef="usd">2943000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfMi0yLTEtMS0zODM0Mw_1dc32f49-826b-4ac4-aefa-d6f0b8facaa0"
      unitRef="usd">12065000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfMy0yLTEtMS0zODM0Mw_d6d4f2d5-4a32-434d-a173-547de204aebb"
      unitRef="usd">12464000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfNC0yLTEtMS0zODM0Mw_d14e09b4-0fc9-463f-a103-0502f28600d0"
      unitRef="usd">12636000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfNS0yLTEtMS0zODM0Mw_601d2dd7-3602-40a1-af90-f1fa27bec105"
      unitRef="usd">12819000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <allo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfNi0yLTEtMS0zODM0Mw_52fcaa79-ccdb-4343-ba2a-257170a8b3ad"
      unitRef="usd">90492000</allo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfNy0yLTEtMS0zODM0Mw_b0cd8426-34bb-49ac-8c4f-d9536d287e12"
      unitRef="usd">143419000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfOC0yLTEtMS0zODM0Mw_8db7da96-5137-4be7-a243-c8aacd3b2d2c"
      unitRef="usd">40882000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RhYmxlOmUxZmQyOGFhMTllNjRiZTliMTIxMDM2Y2IyYzViZTBkL3RhYmxlcmFuZ2U6ZTFmZDI4YWExOWU2NGJlOWIxMjEwMzZjYjJjNWJlMGRfOS0yLTEtMS0zODM0Mw_95033e32-7f0c-4535-bd45-c70f43ee00ef"
      unitRef="usd">102537000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzU0Nw_830ae212-c293-435b-ba8f-40c90fd93ac9"
      unitRef="number">0.0619</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzYzMQ_b1d43b1d-f9c5-4247-8e62-5b12423a3aa2">P10Y2M15D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i285646cc47ee4e0781be1e398f978e9a_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfMzk2MA_bf15d468-9147-45bf-8909-8eedf10e0ed1">P20Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <allo:LesseeFinanceLeasePaymentUponContractTermination
      contextRef="i285646cc47ee4e0781be1e398f978e9a_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNDI1Mw_a3913d31-3413-4fc4-b493-f25c82a7f918"
      unitRef="usd">4300000</allo:LesseeFinanceLeasePaymentUponContractTermination>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i936368d1ad874c5791721226f6432723_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNDM4OQ_14309dcf-bfd7-4338-b20a-7fb7453d9ed4"
      unitRef="usd">4300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV80OS9mcmFnOmNjZTEwM2MyNTEyMzQ1NDBiMGY1YjYwZDMzODhkZmJhL3RleHRyZWdpb246Y2NlMTAzYzI1MTIzNDU0MGIwZjViNjBkMzM4OGRmYmFfNTM3Mg_d59d4f01-f5f6-4e88-943a-7a9e40292c5e"
      unitRef="usd">400000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTk2NQ_9099e2f3-8f4b-49c9-a3b8-7311ef699306">Equity Method Investments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Notch Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the execution of the Notch Agreement (see Note 6), the Company also entered into a Share Purchase Agreement with the Company acquiring shares of Notch&#x2019;s Series Seed convertible preferred stock for a total investment cost of $5.1&#160;million which includes transaction costs of $0.1&#160;million, resulting in a 25% ownership interest in Notch. In February 2021, the Company made a $15.9 million investment in Notch's Series A preferred stock. Immediately following this transaction, the Company's share in Notch was 20.7% on a voting interest basis. In October 2021, the Company made an additional $1.8&#160;million investment in Notch's common stock. Immediately following this transaction, the Company's share in Notch was 23.0% on a voting interest basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s total equity investment in Notch as of September&#160;30, 2022 and December&#160;31, 2021 was $14.0 million and $18.0 million, respectively, and the Company accounted for the investment using the equity method of accounting. During the three and nine months ended September&#160;30, 2022 and 2021, the Company recognized its share of Notch's net loss under the other expenses caption within the condensed consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allogene Overland &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the execution of the License Agreement with Allogene Overland (see Note 6), the Company also entered into a Share Purchase Agreement and Shareholders' Agreement with the joint venture company acquiring shares of Allogene Overland&#x2019;s Seed Preferred Shares representing a 49% ownership interest in exchange for entering into a License Agreement which had a carrying value of zero. The Company accounts for its investment in Allogene Overland as an equity method investment at carrying value. The Company's total equity investment in Allogene Overland was zero as of September&#160;30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s equity investment in Allogene Overland as of September&#160;30, 2022 and December&#160;31, 2021 had a zero carryover basis. Therefore, the Company did not account for its share of losses incurred by Allogene Overland. See Note 6 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i186cd8de8d9844958fcbdfb4ccfb61ed_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMzA1_0e6c10d3-02cc-4404-9e3d-94c95e8470c2"
      unitRef="usd">5100000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <allo:CostMethodInvestmentTransactionCosts
      contextRef="i186cd8de8d9844958fcbdfb4ccfb61ed_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMzQ0_2ca59cd5-92ee-4ed6-8d1f-093857f27359"
      unitRef="usd">100000</allo:CostMethodInvestmentTransactionCosts>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i66aa59ed9c4048298f0a3a33feba7cc5_I20191101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMzYz_a8f88573-53c8-4b12-80e6-20bb2c71cd98"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i3871a5c9adb14fedb9c83c1425f51c54_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfNDMy_1cab1103-de1f-4271-b9da-175157dfc14b"
      unitRef="usd">15900000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1b45cc2e745b42e9b32d37a59ae969d4_I20210228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfNTU2_0e429964-e1f9-4752-8370-51ab837352eb"
      unitRef="number">0.207</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ie8a195a8a56445a3999166ac9339894c_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfNjM1_d1c2fe8f-59f4-4f5b-998b-b31982e25ae7"
      unitRef="usd">1800000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i44b0b5f2e18c49b2991662b317cd0227_I20211031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfNzQ3_ba6689e7-8ef8-4ec8-b9de-b4dfd79c226b"
      unitRef="number">0.230</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfODQ1_7edc75e4-8151-4c1f-a353-e8244a14b9cf"
      unitRef="usd">14000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfODUy_20022319-2957-499a-ac72-5235a4fb0373"
      unitRef="usd">18000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib9fc1bf30b194863ae80b306bfcfbb2f_I20201214"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTQ0NQ_8f860595-0178-4025-a377-bb7e4cee67b5"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="ib9fc1bf30b194863ae80b306bfcfbb2f_I20201214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTU0Nw_7f3bd603-6af7-4a35-93e1-d7fda0244154"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i1492a2fea02e4f998d775344e68d1e5f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTcyNQ_a62ad43a-ec11-4e53-87f9-35083d22e668"
      unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i7b00d6b5fecd421bb33ba50571717267_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTcyNQ_dd0818d5-c4e6-4a00-b2f1-79dd63ebb677"
      unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i1492a2fea02e4f998d775344e68d1e5f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTgyMA_0e31affc-2cc1-442b-bc36-0f876c09938d"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i7b00d6b5fecd421bb33ba50571717267_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81Mi9mcmFnOmQwMjIyMDNlYWNmYzQ3MjI5ZTNlN2E3YWVhNjRhNTAwL3RleHRyZWdpb246ZDAyMjIwM2VhY2ZjNDcyMjllM2U3YTdhZWE2NGE1MDBfMTgyMA_ed20d06d-c5f5-4511-9b50-2470440fb2a3"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ3MA_61de9ef5-f9cd-4a54-8646-53fe5a972f81">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company adopted its 2018 Equity Incentive Plan (Prior 2018 Plan). The Prior 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#x2019;s Board of Directors and consultants of the Company under terms and provisions established by the Company&#x2019;s Board of Directors. In September 2018, the Board of Directors adopted a new amended and restated 2018 Equity Incentive Plan as a successor to and continuation of the Prior 2018 Plan, which became effective in October 2018 (the 2018 Plan), which authorized additional shares for issuance and provided for an automatic annual increase to the number of shares issuable under the 2018 Plan by an amount equal to 5% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed 10 years. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than 100% of the fair market value of the Company&#x2019;s common stock on the grant date. Options granted typically vest over a four-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, there were 12,035,820 shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Exchange program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 21, 2022, the Company commenced an offer to exchange certain eligible options held by eligible employees of the Company for new options (the Exchange Offer). The Exchange Offer expired on July 19, 2022. Pursuant to the Exchange Offer, 199 eligible holders elected to exchange, and the Company accepted for cancellation, eligible options to purchase an aggregate of 3,666,600 shares of the Company&#x2019;s common stock, representing approximately 93.5% of the total shares of common stock underlying the eligible options. On July 19, 2022, immediately following the expiration of the Exchange Offer, the Company granted new options to purchase 3,666,600 shares of common stock, pursuant to the terms of the Exchange Offer and the 2018 Plan. The exercise price of the new options granted pursuant to the Exchange Offer was $13.31 per share, which was the closing price of the common stock on the Nasdaq Global Select Market on the grant date of the new options. The new options are subject to a new three-year vesting schedule, vesting in equal annual installments over the vesting term. Each new option has a maximum term of seven years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exchange of stock options was treated as a modification for accounting purposes. The incremental expense of $5.2&#160;million for the new options was calculated using a lattice option pricing model. The incremental expense and the unamortized expense remaining on the exchanged options as of the modification date will be recognized over the new three-year service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes option activity under the 2018 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contract&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,239,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,627,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(569,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled under the Option Exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,666,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted under the Option Exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,666,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,122,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,657,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,122,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market on September&#160;30, 2022. For the nine months ended September&#160;30, 2022, the estimated weighted-average grant-date fair value of employee options granted was $9.99 per share. As of September&#160;30, 2022, there was $96.7&#160;million of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of 2 years, 324 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.82% - 73.39%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.73% - 70.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61% - 3.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 1.16%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the new options granted under the Option Exchange program was estimated at the date of grant using a lattice option pricing model with the following assumptions: expected volatility of 73.74%, expected risk-free rate of 3.06%, expected dividends of 0% and expected exercise barrier of 2.57.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected exercise barrier - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The modified options are assumed to be exercised upon vesting and when the ratio of stock market price to exercise price reaches 2.57, or expiration, whichever is earlier.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes restricted stock unit activity under the 2018 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant Date Fair&lt;br/&gt;Value per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Vesting Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,316,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(991,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,108,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,108,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, there was $85.0&#160;million of unrecognized stock-based compensation related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 2 years, 240 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#x2019; common stock was as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Early Exercised Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allows certain of its employees and its directors to exercise options granted under the Prior 2018 Plan and the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#x2019;s lapsing repurchase right upon termination of employment or service on the Company&#x2019;s Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the non-current portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. During the nine months ended September 30, 2022 and 2021, zero and 293,594 options were early exercised. As of September&#160;30, 2022 and December&#160;31, 2021 there was $1.9 million and $2.9 million, respectively, recorded in accrued and other liabilities and $1.1 million and $2.5 million, respectively, recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed consolidated financial statements since the exercise date but the shares which are subject to future vesting conditions are not included in the calculation of earnings per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfODgx_7446c473-bf2c-43e7-b96a-27d9de8a2aa8"
      unitRef="number">0.05</allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding>
    <allo:StockOptionGrantedPeriod
      contextRef="i2ed593580aad4f18a35e79239d80c7d7_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA2Mg_9c1d40ef-e5f6-482e-81b6-6c1ce372fae0">P10Y</allo:StockOptionGrantedPeriod>
    <allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate
      contextRef="i2ed593580aad4f18a35e79239d80c7d7_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTE5NQ_615e697a-49f6-4291-a08b-6da8133baaac"
      unitRef="number">1</allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ2Mw_a19e1a81-077c-4d12-8afd-ae4d12c2b013">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ2NA_c1d0408e-25b5-4132-a1f5-2a171c9b6862">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTUyMQ_d97677e4-832a-473f-8149-d3b573fbe508"
      unitRef="shares">12035820</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees
      contextRef="i8da13d9ff1754a2f85537e5c6a6528e9_I20220621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDcyMQ_7cf1228b-486d-4296-ab4c-28f8ad47a832"
      unitRef="employee">199</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions
      contextRef="i8da13d9ff1754a2f85537e5c6a6528e9_I20220621"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDY4MA_e01f15fb-6c02-41b9-b69d-a76d516eac2c"
      unitRef="shares">3666600</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding
      contextRef="i8da13d9ff1754a2f85537e5c6a6528e9_I20220621"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDcwMQ_fcef03f8-8c57-4e14-b5f4-9278de41e0b6"
      unitRef="number">0.935</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDY2OA_fefc5b7a-4b8f-49d7-a88e-e3e5c917e3dc"
      unitRef="shares">3666600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib2ab7bde48b24a23bcc9d3eec9a88153_I20220719"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDY5Mg_ee46b2ea-0f78-4d29-bc83-4d1079ff0e65"
      unitRef="usdPerShare">13.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDc0OQ_6392a3dc-eeb9-493a-b0a5-60c020f0b3b5">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMjE5OTAyMzI3NDcwOA_c32c9417-9c3f-4863-9cd6-49d464225926">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i2930cb3944834b138006d0840c8071b9_D20220719-20220719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDcwOA_7cbadd4f-06ca-491a-8d2a-164cfe482001"
      unitRef="usd">5200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8cf8a832b35e4e2ba9e6e0b0d64b1ebb_D20220719-20220719"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NDc1MA_c9c1fc86-0568-4ba7-b4c9-2d35e6c2ba7b">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ2NQ_0f0e86d0-902c-4616-b53e-f543b136156f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes option activity under the 2018 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contract&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,239,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,627,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(569,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled under the Option Exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,666,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted under the Option Exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,666,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,122,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,657,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,122,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i335a2face5cf44a58769ff4969fb2cc1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfMy0xLTEtMS0zODM0Mw_9e05601b-ec6a-471c-aec0-b05f49adebdf"
      unitRef="shares">10239167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i335a2face5cf44a58769ff4969fb2cc1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfMy0zLTEtMS0zODM0Mw_ce4ab3d4-b894-4351-bbe5-cfc51d80a0e2"
      unitRef="usdPerShare">21.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i87b1b7f6f25749da9e0c6010a3a596c8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfMy01LTEtMS0zODM0Mw_64ebb216-64d5-437c-98e4-14f0fb47c3ec">P7Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i335a2face5cf44a58769ff4969fb2cc1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfMy03LTEtMS0zODM0Mw_e0a22089-1567-4e68-9a51-10143eeb5c7b"
      unitRef="usd">26223000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNC0xLTEtMS0zODM0Mw_f3d18bc1-7f25-4479-bf71-461440e937a8"
      unitRef="shares">8627428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNC0zLTEtMS0zODM0Mw_0316cf08-c245-457f-a9a0-600dc0754d0a"
      unitRef="usdPerShare">9.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNS0xLTEtMS00MDExNA_7f8a9b62-c164-4eb7-84d8-61d72e9a57a3"
      unitRef="shares">174451</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNS0zLTEtMS00MDEzMw_a5388822-379c-49b2-98d5-153f3e845c48"
      unitRef="usdPerShare">2.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNS0xLTEtMS0zODM0Mw_60bc21d8-efd9-4f48-b537-264d2d497116"
      unitRef="shares">569697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNS0zLTEtMS0zODM0Mw_7e1e06d3-b0fb-487a-9042-5c8fd3056a31"
      unitRef="usdPerShare">24.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNi0xLTEtMS0zODM0Mw_d65233ca-29e6-4d9a-bfae-7be856bb746b"
      unitRef="shares">3666600</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNi0zLTEtMS0zODM0Mw_22d17b83-672c-4973-93a2-c11cf3f2161e"
      unitRef="usdPerShare">26.82</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC0xLTEtMS00MDEyMg_40014646-25f1-4c65-88e1-e070c98492ed"
      unitRef="shares">3666600</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC0zLTEtMS00MDE0MQ_39206546-0d05-41ac-9ffa-e8806983dfd5"
      unitRef="usdPerShare">13.31</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNy0xLTEtMS0zODM0Mw_264b9b00-047a-4626-815b-55fec3f5bd82"
      unitRef="shares">18122447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNy0zLTEtMS0zODM0Mw_8ff15cc4-0f98-4e53-bdb5-d873a0e654e5"
      unitRef="usdPerShare">12.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNy01LTEtMS0zODM0Mw_c2abf7fa-45c7-4d1d-976a-4b86713da34d">P8Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfNy03LTEtMS0zODM0Mw_d4ace53c-bf26-4f57-afb4-3a139d4a48d2"
      unitRef="usd">25996000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC0xLTEtMS0zODM0Mw_6e607e30-4497-4b31-99e4-06de83c0019e"
      unitRef="shares">13657219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC0zLTEtMS0zODM0Mw_fce1a325-53d4-4feb-b64c-c33e236ae191"
      unitRef="usdPerShare">13.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC01LTEtMS0zODM0Mw_727c76aa-7de6-40e3-8e90-1dd43a795c99">P8Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOC03LTEtMS0zODM0Mw_2acc81e8-2f0f-4756-895b-feb86d8b9287"
      unitRef="usd">24715000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOS0xLTEtMS0zODM0Mw_0390bed6-4318-4973-a205-2790890de87c"
      unitRef="shares">18122447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOS0zLTEtMS0zODM0Mw_c50a8852-e190-425b-ba08-e51ecd582543"
      unitRef="usdPerShare">12.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOS01LTEtMS0zODM0Mw_989927f7-696b-4034-b985-92ad406d7fb3">P8Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i8a25b95829da41bdbe9eba6c9e59ed51_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjIxMWRiNDdkNmJmMzQ2ZmNhZWZkZjg1MWFjYzY5ZTEzL3RhYmxlcmFuZ2U6MjExZGI0N2Q2YmYzNDZmY2FlZmRmODUxYWNjNjllMTNfOS03LTEtMS0zODM0Mw_d0542444-6df8-495f-947a-5df6f0cb21fd"
      unitRef="usd">25996000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMjA4MQ_751ab59d-79e2-4878-a302-2d0514164c8a"
      unitRef="usdPerShare">9.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i80967c9edd9c4b2c9d93991aba2977e3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMjExNQ_a26aabce-32ab-4633-8065-5b703cdcb25a"
      unitRef="usd">96700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMjI2Mw_4967237b-0d5e-4479-a321-e482921a94b1">P2Y324D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ2Nw_c1550b35-d1b5-4947-bc5a-4680b493da86">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.82% - 73.39%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.73% - 70.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61% - 3.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 1.16%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie0ac5f114f4b4675aa3371c31e9a9f93_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMi0xLTEtMS0zODM0My90ZXh0cmVnaW9uOjY1ZWRkMjcxYmU1MjQ2ZjRhN2RlYzY5NGI0ZGM5ZDU0XzQ_2f4a7f5c-ec78-467e-a3d0-2b5650af6610">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibf9b3aebda244d37a641882195bc9a25_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMi0xLTEtMS0zODM0My90ZXh0cmVnaW9uOjY1ZWRkMjcxYmU1MjQ2ZjRhN2RlYzY5NGI0ZGM5ZDU0Xzk_506c0257-c3cc-4110-b378-307c765009f5">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic91b0bb6bd0945bbac49f373c6dce054_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMi0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjIyOTNkNzQxNTQyMzRlYWFiOGJiNmI4YjZkNTUwYmJiXzQ_c9626c87-2793-456e-8735-39535676f5dd">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i11560b36616e4aaeba3be6911de62405_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMi0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjIyOTNkNzQxNTQyMzRlYWFiOGJiNmI4YjZkNTUwYmJiXzk_caf241d4-ba22-4b6e-8415-2c4c3cfd4df0">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMy0xLTEtMS0zODM0My90ZXh0cmVnaW9uOmQ4ZjVjOGJiYzAzNjQ3ZTA4NjU0MGIyNTM5MTI5OTU1XzQ_22371e3c-2e1f-4a0e-baad-e6067f5e69ef"
      unitRef="number">0.7082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMy0xLTEtMS0zODM0My90ZXh0cmVnaW9uOmQ4ZjVjOGJiYzAzNjQ3ZTA4NjU0MGIyNTM5MTI5OTU1Xzk_e25c1465-ad02-4654-b933-82dbff0c5970"
      unitRef="number">0.7339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMy0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjU1MmMxMjFlYjcxODRhN2FiNWY1Nzk4YjcwZmY4OGU3XzQ_4f9d9fe3-2b8e-44b9-99e0-2a937be700e5"
      unitRef="number">0.6973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfMy0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjU1MmMxMjFlYjcxODRhN2FiNWY1Nzk4YjcwZmY4OGU3Xzk_758ff83d-d5b4-4299-bcb1-e0eeaa6c0644"
      unitRef="number">0.7080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNC0xLTEtMS0zODM0My90ZXh0cmVnaW9uOjg2ZWYzNzMwZTAxMzRmMDE4ZWFkY2VjYzY3OTdkOWZlXzQ_5e3dfd33-4e66-4a95-a964-c5e50017920c"
      unitRef="number">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNC0xLTEtMS0zODM0My90ZXh0cmVnaW9uOjg2ZWYzNzMwZTAxMzRmMDE4ZWFkY2VjYzY3OTdkOWZlXzk_35130cc6-29c5-4ac9-a349-a1244ee9be41"
      unitRef="number">0.0349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNC0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjc5NzVmOWRhMTc1MTRkZjg5ZmMyNjRkZmVhZDA2MTk5XzQ_31047be7-1afc-4f28-a57b-bd668edb033b"
      unitRef="number">0.0060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNC0zLTEtMS0zODM0My90ZXh0cmVnaW9uOjc5NzVmOWRhMTc1MTRkZjg5ZmMyNjRkZmVhZDA2MTk5Xzk_c40e445a-239f-45ff-ab7e-24ed1872fedd"
      unitRef="number">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ice1dbb356b5946d994e58ee58305e689_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNS0xLTEtMS0zODM0Mw_c181017a-f4b0-48fc-a816-59d6e0d4746e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id799c2b4dc4d4302b726b093aa657ecb_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjU5MTMzODFlNDU3ZDQ3MWQ4NWEyMjFkMTJlODNjMDllL3RhYmxlcmFuZ2U6NTkxMzM4MWU0NTdkNDcxZDg1YTIyMWQxMmU4M2MwOWVfNS0zLTEtMS0zODM0Mw_bbbe9dfb-48d8-46b8-9704-0e5a668910c6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY1Mw_7282c949-d55f-419e-959b-96a389fdad4a"
      unitRef="number">0.7374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY3NA_43f51916-1554-4b20-9eb9-09081d85109a"
      unitRef="number">0.0306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8a467bae2ac743c285409d16a7582a1e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY2OQ_937ad984-17f8-4b3b-804f-73e2a8dbcd79"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i80967c9edd9c4b2c9d93991aba2977e3_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY2MQ_e4b8c9de-f963-4824-9083-f2f6bdef97c1"
      unitRef="usdPerShare">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMzYzMA_31d2fa78-1196-4137-8534-32a7766e79f3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMTA5OTUxMTY0NjY0Nw_8af81088-71ef-44bb-92a6-f0d72cca23d7"
      unitRef="usdPerShare">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ3Mg_fa2643f2-a0af-48ba-9776-3695906b7197">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes restricted stock unit activity under the 2018 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average Grant Date Fair&lt;br/&gt;Value per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Vesting Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,316,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(991,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,108,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,108,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id11744c3dcc0478fbe1ac19d5b674e5c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfMy0xLTEtMS0zODM0Mw_8d9807e8-35b4-425d-a0fb-b66f3abdd19e"
      unitRef="shares">4261108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id11744c3dcc0478fbe1ac19d5b674e5c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfMy0zLTEtMS0zODM0Mw_0e034100-9d17-4ba3-96d8-e71fcf7f90f9"
      unitRef="usdPerShare">26.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i7f197f101d1c490f9238233b8c06f878_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfMy01LTEtMS0zODM0Mw_d36a359c-9b0d-4c2a-aa7b-a75ebd8e3f54">P1Y8M19D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="id11744c3dcc0478fbe1ac19d5b674e5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfMy03LTEtMS0zODM0Mw_8a42ac3b-43cd-4cd9-b1a1-b8867d598d5f"
      unitRef="usd">63576000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNC0xLTEtMS0zODM0Mw_660e4dc6-eaa6-406f-a433-9686b5c0d57d"
      unitRef="shares">3316499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNC0zLTEtMS0zODM0Mw_511679c2-54a4-4510-abe5-c5c4db93c8c8"
      unitRef="usdPerShare">9.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNC01LTEtMS0zODM0Mw_692e41d3-d2a5-48c1-8a12-aed87c65a7f6">P1Y10M20D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNS0xLTEtMS0zODM0Mw_78938a94-dd83-4809-86b3-14dc78cb8b41"
      unitRef="shares">991967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNS0zLTEtMS0zODM0Mw_d26ebcea-c0b8-4a2b-9e10-05f635ac05a1"
      unitRef="usdPerShare">27.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNi0xLTEtMS0zODM0Mw_b0066b28-b258-4029-9031-003829531c32"
      unitRef="shares">476970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNi0zLTEtMS0zODM0Mw_0e0fb1e7-87af-45dc-86c2-af45d82ec38e"
      unitRef="usdPerShare">22.24</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNy0xLTEtMS0zODM0Mw_a86133cd-1f87-46e5-8480-be35837d3863"
      unitRef="shares">6108670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNy0zLTEtMS0zODM0Mw_f8f2c9fd-1f63-4b96-8e03-381fff5aeec4"
      unitRef="usdPerShare">17.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNy01LTEtMS0zODM0Mw_471f826e-edac-449e-ade7-1bf4118b8fff">P1Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfNy03LTEtMS0zODM0Mw_d8a0b853-1f28-4e40-b150-189f9864bad7"
      unitRef="usd">65974000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfOC0xLTEtMS0zODM0Mw_eccbde8c-bc7a-4284-9d2c-4598e69cae61"
      unitRef="shares">6108670</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfOC0zLTEtMS0zODM0Mw_dd06b095-2240-4435-9177-3f3d64c6d572"
      unitRef="usdPerShare">17.41</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfOC01LTEtMS0zODM0Mw_01feeb33-b8c2-4a11-9d70-69a3c4656cc2">P1Y8M12D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue
      contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOjhlYzU2OGU4N2I4MDQyM2I5NjJiYWM5MWNlMzkyYzI4L3RhYmxlcmFuZ2U6OGVjNTY4ZTg3YjgwNDIzYjk2MmJhYzkxY2UzOTJjMjhfOC03LTEtMS0zODM0Mw_263c4e1f-48e9-4a3a-a4c7-fa659ecf4266"
      unitRef="usd">65974000</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i0cf5a81c459045259eb6e048191ed8b9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMzc2Mw_8451fe74-d866-4fb4-9643-dad87e994987"
      unitRef="usd">85000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfMzkyMA_ab5a7bbf-4fa0-4bf3-9d88-23db14445637">P2Y240D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTQ3MQ_e2a2c51b-bdeb-4d84-9f5f-d999da20cb44">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#x2019; common stock was as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6627a5e0bcb745a7bcf2b1a0bcfb8913_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMi0xLTEtMS0zODM0Mw_2154825e-d706-4621-843b-0c2371536437"
      unitRef="usd">11016000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b8c2dddec8a42c2a41bd9069f28fb76_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMi0zLTEtMS0zODM0Mw_ee273737-e5ec-4192-88e5-8e4e717309e0"
      unitRef="usd">10074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3949326941ae44ad8b85a5116571b2d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMi01LTEtMS0zODM0Mw_30bf4ce6-e889-4476-b318-6310cad7f310"
      unitRef="usd">35068000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb04d23e1b334eea8232a278c94030b1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMi03LTEtMS0zODM0Mw_9a9ad789-b9ac-4163-9a78-7aa7e0c82b3c"
      unitRef="usd">28494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1f95a2fe74e8495c8a44a351002ab5f1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMy0xLTEtMS0zODM0Mw_49d9ba35-43d4-4755-b223-2182b505f577"
      unitRef="usd">10132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i692e53151ed54db2bcad88681554f8e5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMy0zLTEtMS0zODM0Mw_d6e85cc9-701e-4400-b3b3-8611adffdeb6"
      unitRef="usd">10782000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i657be91ad1cf4834ae3e495d97c6b831_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMy01LTEtMS0zODM0Mw_6111ffad-0a15-46ac-80a0-4c22848686a1"
      unitRef="usd">31286000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b0292c40a9540d5afb21ac604de6b00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfMy03LTEtMS0zODM0Mw_731e1cd5-c34e-4a8d-b391-ec774f5b949c"
      unitRef="usd">30288000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfNC0xLTEtMS0zODM0Mw_e9b912f7-4835-4b5d-8a7f-ef0f7a49e7fc"
      unitRef="usd">21148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i782928e2b7fc4da0a12104d331ce01f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfNC0zLTEtMS0zODM0Mw_b3222a3a-875d-4813-ac88-b87fd187ffbe"
      unitRef="usd">20856000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfNC01LTEtMS0zODM0Mw_56278697-c423-4b38-9971-42e38634d530"
      unitRef="usd">66354000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RhYmxlOmQxOGIyNTFkMmYwYzQxYjc4YjNjYWRiMDliMjIxMTRhL3RhYmxlcmFuZ2U6ZDE4YjI1MWQyZjBjNDFiNzhiM2NhZGIwOWIyMjExNGFfNC03LTEtMS0zODM0Mw_3649baf6-d4b6-4bc1-9a42-84d85bed6c7b"
      unitRef="usd">58782000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNDkzNw_869282b9-1ef1-4e59-a858-ba7b3e5ab32a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNDk0NA_797a82a6-d9f9-4a3a-a6f9-4d73ec2f6f34"
      unitRef="shares">293594</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTAwMw_dd38eef2-aa60-48ed-825b-32a34302f9dd"
      unitRef="usd">1900000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTAxMA_34b72b29-7c5c-413b-85c4-8d9d0ffe9b0b"
      unitRef="usd">2900000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i851ceebb52594744ab16edeb67e8db95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTA3NA_c6e7f384-df8e-4c4a-8425-779295bc5951"
      unitRef="usd">1100000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="iecc019de3c544aa08930db1891672917_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81NS9mcmFnOmFmOTA3Y2FmOWVkZDRkMjVhOGEyMjU2ZGFlZTUxMGQxL3RleHRyZWdpb246YWY5MDdjYWY5ZWRkNGQyNWE4YTIyNTZkYWVlNTEwZDFfNTA4MQ_b86d618d-57ca-4ce3-9ea6-96a47bd9e9c7"
      unitRef="usd">2500000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTY0OTI2NzQ0NTkxMg_4f64c0ff-bfc1-45ea-b9ac-1b82039ae256">Related Party Transactions&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a license agreement with Allogene Overland, a corporate joint venture entity and related party (see Note 6). The license agreement was subsequently assigned to a wholly-owned subsidiary of Allogene Overland, Allogene Overland BioPharm (HK) Limited. On April 1, 2022, Allogene Overland HK assigned the License Agreement to Allogene Overland Biopharm (PRC) Co., Limited. During the three and nine months ended September&#160;30, 2022, the Company recognized less than $0.1 million and $0.2 million of collaboration revenue under this arrangement, respectively. During the three and nine months ended September&#160;30, 2021, the Company recognized less than $0.1 million and $38.4 million, respectively, of collaboration revenue under this arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022, the Company recorded $0.3 million and $0.6 million, respectively, of net cost recoveries under the terms of the license agreement as a reduction to research and development expenses. For the three and nine months ended September&#160;30, 2021, the Company recorded zero net cost recoveries under the terms of the license agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sublease Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for 1,293 square feet of office space in Los Angeles, California for a three year term. On April 1, 2020, Bellco Capital Advisors Inc. assumed all rights, title, interests and obligations under the sublease from Bellco Capital LLC. In November 2021, the sublease was extended to June 30, 2025. The sublease was amended, effective in July 2022, to move to a nearby location, with office space of 737 square feet. The Company&#x2019;s executive chairman, Arie Belldegrun, M.D., FACS, is a trustee of the Belldegrun Family Trust, which controls Bellco Capital Advisors Inc. The total right of use asset and associated liability recorded related to this related party lease was $0.2&#160;million and $0.3&#160;million at September&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consulting Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into a services agreement with Two River, LLC (Two River), a firm affiliated with the Company&#x2019;s President and Chief Executive Officer, the Company&#x2019;s Executive Chair of the board of directors, and a director of the Company to provide various managerial, clinical development, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $0.1 million and $0.6 million for the three and nine months ended September&#160;30, 2022, respectively. The costs incurred for services provided under this agreement were $0.2 million and $0.4 million for the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#x2019;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $38,583 per month in arrears commencing January 2021 and $40,217 per month in arrears commencing January 2022. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to 60% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The costs incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $0.2 million and $0.6 million for the three and nine months ended September&#160;30, 2022, respectively. The costs incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $0.2 million and $0.6 million for the three and nine months ended September&#160;30, 2021, respectively.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzQyMQ_7a99ce65-e25c-4831-a792-6db5e2fcecac"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzQzMg_486aca37-4706-4758-92dd-3ef8c9b907f1"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfNjY2_939f0e9a-766d-47a0-9c39-41535958f2f2"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfNjcz_4c2ca9ad-b2e3-42e3-b5a8-4e70af542233"
      unitRef="usd">38400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i94c627bfaf8744c1a65d0e3fdd0917ab_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzQxMg_df9d1e84-a3aa-469b-9282-9223785f5398"
      unitRef="usd">300000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="ic67ef4db97074fb08d0d143abb0afd08_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfNzk2_52b0e83a-13e0-4a42-a6ef-db290d969310"
      unitRef="usd">600000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i1e00ae47df7f44719a56dda76afad07b_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfOTgw_413ea916-22ea-4798-b7c6-51fade0ceb7d"
      unitRef="usd">0</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="ie616468f0d064a2ba51759d0b7ccff08_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfOTgw_457d4764-8a82-45a0-bae2-a309a9303f87"
      unitRef="usd">0</us-gaap:RecoveryOfDirectCosts>
    <allo:AreaOfOffice
      contextRef="ide3d377e6ef446be87bcdb339dfc0b9b_D20181201-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTE1Ng_92308ae3-0750-40df-bf1f-12a8c4a5e4f4"
      unitRef="sqft">1293</allo:AreaOfOffice>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="i55782e475b6a49e68f013ee57e855017_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzU5Mw_84a50560-ca37-4692-9893-f37d0c37322b">P3Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <allo:AreaOfOffice
      contextRef="i10cdf1fbcbd24042b88e39c59ceb0185_D20220701-20220731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzM4Mg_c75606ce-6e69-43bc-851e-49413b5b88d3"
      unitRef="sqft">737</allo:AreaOfOffice>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6835c65c40e448ee9cdf956aa442f14c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTY5NQ_418582ec-1498-4d46-a0a0-d51122cdea6d"
      unitRef="usd">200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6835c65c40e448ee9cdf956aa442f14c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTY5NQ_d0cca3bb-1c74-43fe-9183-83b28a85d3ac"
      unitRef="usd">200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2f07bcc60d124644b17029e7a86498b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTcwMg_6349bb82-8eef-460d-a10e-559f00985239"
      unitRef="usd">300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2f07bcc60d124644b17029e7a86498b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMTcwMg_f39da07c-dd46-4f60-ae92-0f7e6c7e04f1"
      unitRef="usd">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RelatedPartyCosts
      contextRef="i244e669df12d499393987c604e57d35f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjE5Nw_0abf1efb-3a20-45e5-81a5-3e8b670071dc"
      unitRef="usd">100000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="i70d6feb00c574d04aecd098830cbbe99_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjIwNA_5677b936-c8dd-4f27-a345-9e08f7973b9b"
      unitRef="usd">600000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="i311fa2e0db8b4c88adb07d7473de0631_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjMxNg_8e67978a-f581-4e1a-a1f6-3b3b62637213"
      unitRef="usd">200000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="i3f691c5f7eea4a9b9059a123b37ca9aa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzI5ODUzNDg4NzM5MA_ac42250c-8b7e-4ee3-8e45-e7a45bcbf968"
      unitRef="usd">400000</us-gaap:RelatedPartyCosts>
    <allo:RelatedPartyTransactionMonthlyPaymentsInArrears
      contextRef="i5ffebc0cc88b45c683f02d07c9da34b6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjg4Nw_69e7de88-ca77-42e7-beec-79f1ccc48435"
      unitRef="usd">38583</allo:RelatedPartyTransactionMonthlyPaymentsInArrears>
    <allo:RelatedPartyTransactionMonthlyPaymentsInArrears
      contextRef="i48fcbfbc97c948488803f2fa246b65ec_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMjkzOQ_c5050c5e-5353-44dd-93be-8f5fafe71ccf"
      unitRef="usd">40217</allo:RelatedPartyTransactionMonthlyPaymentsInArrears>
    <allo:RelatedPartyTransactionCompensationPercentage
      contextRef="i83ba27cde25d42a1bcb8d43b98591e86_D20180801-20180831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzA4Nw_b83ede72-a2c6-46ab-b335-b84387c9f7a1"
      unitRef="number">0.60</allo:RelatedPartyTransactionCompensationPercentage>
    <us-gaap:RelatedPartyCosts
      contextRef="i71270f28c9f44b26884a7a3c29b0a8c6_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzM3MQ_91e42e41-2e1e-45c7-9020-9c5c38819eff"
      unitRef="usd">200000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="iad6cc93503974700a19e1ba725f39da7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzM3OA_b5c2d1aa-4bd9-4dda-b863-e04a450ff7ed"
      unitRef="usd">600000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="i9b84fdd9ca2b4e34a5b489c6cfd75f6b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzUzNw_31cfe62c-8cd3-4404-ba4e-9a4ef333f76a"
      unitRef="usd">200000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="ib3537c96671a47618355dfe9daa3ab84_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV81OC9mcmFnOmRkMmMxNjE5NWFmNDQ3Yjk5NWI5ZGFhNjA0ZGRmODlkL3RleHRyZWdpb246ZGQyYzE2MTk1YWY0NDdiOTk1YjlkYWE2MDRkZGY4OWRfMzU0NA_5f3c8059-c19c-45f7-80f5-a6cce3dfd7b8"
      unitRef="usd">600000</us-gaap:RelatedPartyCosts>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82MS9mcmFnOjA3YWNkNWYxNzdjODRkYWE5OWVkNDQ5NDQ4N2IwNDg5L3RleHRyZWdpb246MDdhY2Q1ZjE3N2M4NGRhYTk5ZWQ0NDk0NDg3YjA0ODlfMTk5_33a33ba7-f8bb-4889-b0d8-9f86134000bc">Income TaxesThe Company has a history of losses and expects to record a loss in 2022. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RleHRyZWdpb246ZTRiY2Y2YjdiODc5NGQ4YzlmMWY2YTViY2VhYzYwNzlfMjIw_4f9e082a-567d-436d-a487-ad98b2367d75">Net Loss Per Share&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,122,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,109,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units subject to vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,108,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,393,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected shares to be purchased under Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Founders' shares of common stock subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,028,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,143,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,865,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RleHRyZWdpb246ZTRiY2Y2YjdiODc5NGQ4YzlmMWY2YTViY2VhYzYwNzlfMjIx_23e7c00a-9077-4436-8745-fd769a1dfa60">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,122,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,109,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units subject to vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,108,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,393,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected shares to be purchased under Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Founders' shares of common stock subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,028,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,143,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,865,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4c288bc903b4445db1aca2a0589bff15_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfMi0xLTEtMS0zODM0Mw_d2f1ec89-890d-452b-8722-a588b3fd7ddd"
      unitRef="shares">18122447</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie2735eb3759f4c978a3d46ef79aa58c4_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfMi0zLTEtMS0zODM0Mw_04d77178-93f7-451a-b399-359d952f3130"
      unitRef="shares">10109169</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i09654a2f64fc4baea96c1b7e18d63c05_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfMy0xLTEtMS0zODM0Mw_179194de-3a82-45ff-918a-d3348db2e987"
      unitRef="shares">6108670</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia29bfb086dc54826adc5a81036ef756f_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfMy0zLTEtMS0zODM0Mw_6b94b365-d205-4b2d-b3ec-93da5fb5a079"
      unitRef="shares">3393604</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i168b193cba9e427089753a5b30b8c90f_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNC0xLTEtMS0zODM0Mw_f6aac80e-9475-4341-8c44-c7e93315da1f"
      unitRef="shares">750317</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i774d91333c954992bc09c9a46d392ded_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNC0zLTEtMS0zODM0Mw_fa89e086-1fd7-4429-b518-fef0e9a4e53d"
      unitRef="shares">276253</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0a0727775830468a9e27ab2c44c1b6ff_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNS0xLTEtMS0zODM0Mw_8e2e59e9-a432-49ee-a8c7-8be37a302e35"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d3e864f70414a80bc0964777b022263_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNS0zLTEtMS0zODM0Mw_74e77177-fd15-4941-848f-f48a2ef88092"
      unitRef="shares">3028848</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf062f962ee04c1fad713216e1f06041_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNi0xLTEtMS0zODM0Mw_ba74e022-2ae2-45b7-ba06-ba160fd603f5"
      unitRef="shares">162532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6b6de817bdd944afad54fb6f862dd4cc_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNi0zLTEtMS0zODM0Mw_d9213852-b68e-401a-a192-e32de542da92"
      unitRef="shares">1057793</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNy0xLTEtMS0zODM0Mw_414a54af-9678-4699-bcfe-ba3313b81fb2"
      unitRef="shares">25143966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie182671a51e24dd481498ceb5cd578ef_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82NC9mcmFnOmU0YmNmNmI3Yjg3OTRkOGM5ZjFmNmE1YmNlYWM2MDc5L3RhYmxlOmMzMzZhOWQyNjc5NjQyMTI5ZWJiMGQzNGFhYzdhYTdlL3RhYmxlcmFuZ2U6YzMzNmE5ZDI2Nzk2NDIxMjllYmIwZDM0YWFjN2FhN2VfNy0zLTEtMS0zODM0Mw_f87abf66-38d0-46bc-9f2f-aff1a6756093"
      unitRef="shares">17865667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82Ny9mcmFnOjQwYmE2NGFiZTUyMDRhYTk4MmJlNzc4YWQ3MmQ5MGNkL3RleHRyZWdpb246NDBiYTY0YWJlNTIwNGFhOTgyYmU3NzhhZDcyZDkwY2RfMTExMg_ddde992e-987a-4483-9e60-16f971f30caa">Subsequent EventsOn October 6, 2022, the Company announced the initiation of the Phase 2 clinical trial of ALLO-501A (the ALPHA2 trial) in patients with relapsed/refractory large B-cell lymphoma. The Company is also in the process of initiating the EXPAND trial, which is intended to demonstrate the contribution of ALLO-647 to the lymphodepletion regimen. In accordance with the Servier Agreement, the Company is required to make a milestone payment of $8.0&#160;million upon first dosing of the first patient in a Phase 2 clinical trial. The milestone payment is expected to be recognized in the fourth quarter.</us-gaap:SubsequentEventsTextBlock>
    <allo:CollaborativeArrangementRightsAndObligationsMilestonePayment
      contextRef="i34c392be59f54e6f9714301ddcb1bc63_I20221006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFkNjk4MDhmMjkyZjQzZjZiYmM2MzMzN2VmYjFkOTBlL3NlYzphZDY5ODA4ZjI5MmY0M2Y2YmJjNjMzMzdlZmIxZDkwZV82Ny9mcmFnOjQwYmE2NGFiZTUyMDRhYTk4MmJlNzc4YWQ3MmQ5MGNkL3RleHRyZWdpb246NDBiYTY0YWJlNTIwNGFhOTgyYmU3NzhhZDcyZDkwY2RfMTA5OTUxMTYzMzM4OA_1b772efd-475b-44e2-b2b4-bb6f7f0d6d29"
      unitRef="usd">8000000</allo:CollaborativeArrangementRightsAndObligationsMilestonePayment>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M@TU&.4RQ#P1E _#Y7$KS-+&=1M-91G\ 4$L#!!0    ( ,*"8E75\NI<X04
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M"S^O\HR>LIWB(6<">\J .)]'9<#S*6!/&1 (]Y1!@4=[RC*#(K+81T "#_;
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M2P8EE:A)%9::;8JA$!RWN8'[C0;>%]RA<@94-8FJIK#4;.\,9^#/[X#@4/=
MQH6[UGDX1;19J)!AX#$HK*RV#08?\#-U0'"@:*>4>M<AU X(5#6)JJ9.#HCM
MV,$7?+ZD ^)P51RP[@VK1]^0@P2#4T:X=TN'2C!0U126FFVI(1@\M@/BM(T
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M/VE7&_Q"@B17!L]=[#S=*<WC1R_GL]/70<"#=<-(H5.*A5D0CJTBL+(8!\I
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M=POY*-\QR\Y.M%H2[;3AS7WX5+TU@A/2%>7::D@%[.S9>R&9+ 2KR)4T5K?
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M?^&&EY]<JP"8F8;[ZW>U"CIRNT+Y[2%DBSY)) +;638'H:^_+WQ$,7"7391
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MK.F_@MH9T'VEE'W<N #CGVKU"U!+ P04    " #"@F)5.?  <GD@  "->P
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MO<+M"MEVH)HR@=OI'+8OJKY4]=)]4R (0'!-. #P0$. RNA%E6U:4'YMM\U
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M?'8>;0@\>:U*9(:5Z"*>!UK5#?#1O%*X);$+X PHZW&(Q P!V.!R )1!2X(
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M2U62'PS\([G;"3N:JN@UM[R8B-]RX_ERIJ TPH:Q&_LGG1Y#06::"O[L47V
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MQ0?@^T73=/87W,#]!>X7_P]02P,$%     @ PH)B5262UZ-K"@  ]QT  !D
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M_G3<8\:_9O0?"IV[5WL+710Z=8]TU2P,+<#O2ZV+^@,I:-[U7OT;4$L#!!0
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M?$OU(^'*$WIY$VS.I^*I#7C&YK\I?M2 (P/<GUGD7MU0@/HS:?0O4$L#!!0
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MF7P#W8AZ=70&#E#;75GOE6HBL57;I3(-+>N)\,U7\S29?=>(E[4T!;W\01N
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MA"Q;\=KGGJ3'8CB9#*I EC )I%>*449Y(KDR+6I/H4J]UA2?'M0WJF0IPHL
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MR]E)9S)\?K8?Y*/ GY*7;N,W!4]FQGP.BS?I26<0 +'BQ <+ O\6/&6E@B'
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MVZZ",H :&S8(^Z@./^,IGKGCJY0P_@N'T3:+ Z@&8U5W I."CLOQSXZG/%P
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M7+/!Z7$"-@[8>/"F#4-M83R-R+"MZ9^$E@U(OS3&;P\<8/>7F_P 4$L#!!0
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MFV;O9"2R.D17-H>!H-0V_9>?&C]\R8%9<V#&N),B1OE21GEQYMU&>-H-:?3
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M-#A/8@]4=_?H%D8V[GN_D 9O#^ZQP.L:5]8![2LIS6YA$_07P-E_4$L#!!0
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M."YX;6S-5M%NVC 4_14KFZ9.8DU("%0=1&I!U2JU4U74[F':@TDN8-6Q,]M
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M<(D?&J!L +Z?2VFV$]O+ZD^7Y#=02P,$%     @ PH)B58T>,F]2!P  Y48
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M,CB[0"+5]N!V8F3EVMA*&FR*;EC@LP7*&N!^+J793FQG[!_"Y#=02P,$%
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MXVZ3?T^+SZNMCX/U<_FP6/RV_B2]_.'%^?HA%;-B4JV-O/[?I^*BF,W65/U
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M^Z="X,_@FSNC_J%/#@NT-8IJ M4DJL6HEJ!:BFH9JBE4TZAF4,U2FGMAJ*9
MVGD&!=(.6B!%M0C5!*I)5(M1+4&U%-4R5%.HIE'-H)JE-#>+F@)IYZ0"Z78
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MSZ:IWLAT6SX:Y2Z5,HW+EQO! Y$5&ZCO5VDJ']\4"9HG!"W^!5!+ P04
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MX<N*L.JI4'4$+<J[<$F%O%G+9B)?5\ 40,ZO*!7[C@K0O->"/U!+ P04
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M-N=IWD$=?Q)"OC3R /5O'J;_ 5!+ P04    " #"@F)5B'M'2KD(  #F10
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MM(J/9#L%COT1(!LA14+WP\.AJC_Z\"6)1#A4A4N]<=HG[U1ZSAF]/W?9$V&
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M-9 $N#90SY>,R:>.GJ"^EHE_ %!+ P04    " #"@F)5"=4&1[P$  !2%P
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M5%H+-GFALJ_0(E]%+3?*BE-QMQ X'JTX21^N%B+5&5J22NP_AE4%KU#R*$>
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MEXOWG"UY5@3(]U=I*IY7B@+[YY7._@-02P,$%     @ PH)B530+6MA !
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MWQ!HYX#G&Z7LWG"M,7QLZ5]02P,$%     @ PH)B54O;IA)N P  KA8   T
M  !X;"]S='EL97,N>&ULW5C=;MHP%'Z5*%VG5IH:0M9 5D#:D"I-VJ9*[<7N
M*D,<L.0XF3$=]'+/LZ?:D\PGSA_4!]%>K#!0B7T^G^]\Y_CDKX.%6G-Z.Z=4
M.:N4B\70G2N5?_"\Q71.4[*XR'(J-))D,B5*3^7,6^22DG@!3BGWNIU.Z*6$
M"7<T$,OT.E4+9YHMA1JZ46URS.%S/'3]\+WK&+IQ%M.A>W_V]L<R4U=O'',\
M>7=RTKD_O]JVGQ7 N>M922_W(+WH='!B #'R<#_R7=P8=6^3NEA^JHF,XRGF
MUK>XZ2B-)TPPY\B>SI]?OS<3:N738!4]0M[K[%6K':7"B'UKRJV$,<>NO59M
MUW)_O+*!1X,D$TT?!ZXQ:':24N>!\*$[)IQ-) .OA*2,KXVY"X9IQC/I*'T"
MZ7 ^6!:/!O;-#,ZMDB=E(I-%;!/!_$[*Y5M -0.!C/-:8-<UAM$@)TI1*:[U
MI%A<&)] 3CF^6^=:X4R2M=^]=!N'XJ"#3#(94UF'\=W*-!IPFH <R69S.*HL
M]P!4*DOU(&9DE@E2:*@\RH&FG5+.;^'"\SW9X%XEK7TK^DC40RVH'!H:,P'^
M-IOA;M.&+^)U<O:0J4]+G8XHYM"A]$;2A*V*^2JI!6#L/LY.\IRO/W(V$RDU
MR>\=<#0@E9\SSR1[U-&@5:;:0*7K/%"IV+1M^2E)?D=7JFJG58)K[AZAYG];
MYQD55!+>%JU[_Y"K_&+%0>^U)!=7E6W!5HWET\2AB[P\!I'A,8@\BI[L'X/(
MZ A$]E[MJOD<D?XQB.P>OLC@,%O2*Y\I6P^N&X^MM=6!UX.A^PU>-G@3U)DL
M&5=,E+,YBV,JGCR]:GI%)OIE?(-?KX]I0I9<W=7@T&W&7VG,EFE4K[J!0I2K
MFO$72$\_"E?O)CH6$S%=T7A<3N5L4@P=/=!1RP\X;"/7Q<>.8#X&LR. 87$P
M!9B/\<+B_$_Y]-%\#(9IZUN1/NK31WV,EPT9%U\LCMTGTA][IE$4!&&(570\
MMBH88W4+0_BSLV':P .+ Y&>5VM\M_$.V=T'V)[NZA L4[P3L4SQ6@-BKQMX
M1)%]M[$XX('M M8[$-\>!WK*[A,$L*N8-NP,QI$HPA#H17N/AB%2G1"^]OW!
MSI(@B"([ IA=01!@")R-.((I  T8$@3%?7#K?N15]RFO^0_UZ"]02P,$%
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MGH^_+Q\G.^_X'6<'?^P6OU!+ P04    " #"@F)5)OJ'I[4!  #<&P  $P
M %M#;VYT96YT7U1Y<&5S72YX;6S-F<UNPC 0A%\%Y8J(L9W2'P&7MM>60U_
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M?];]U)M_ E!+ 0(4 Q0    ( ,*"8E4'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ PH)B54VIX-?M
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ PH)B59E<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #"@F)5#*%ZJ^D%  #N'@
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ PH)B57SX"7 Z!@  KAD  !@              ("!*PX  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,*"8E7&131V @,
M &4*   8              " @9L4  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " #"@F)5U?+J7.$%   ,&P  &               @('3
M%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ PH)B55+T
MZ9ND#@  PI8  !@              ("!ZAT  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( ,*"8E6&$%+?0@<  !\?   8
M  " @<0L  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #"
M@F)5O-B)OF(%  !J#   &               @($\-   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ PH)B522K)\S.!@  B1,  !@
M         ("!U#D  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( ,*"8E415W^69P0  (,+   8              " @=A   !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #"@F)5.,ZYT-(%  #@#@
M&0              @(%U10  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( ,*"8E4I'_S\'@,  +4&   9              " @7Y+  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ PH)B53GP ')Y
M(   C7L  !D              ("!TTX  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " #"@F)5)9+7HVL*  #W'0  &0
M@(&#;P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,*"
M8E43/+H;X@0  #(-   9              " @25Z  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ PH)B55]-]M<Y#@  $"D  !D
M         ("!/G\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " #"@F)5_Z>]C<0%  "Q#P  &0              @(&NC0  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,*"8E7_)7OH6P(  #T%
M   9              " @:F3  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ PH)B59%OK2)& P  " <  !D              ("!.Y8
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #"@F)5F7XB
MU3$#  #Q!@  &0              @(&XF0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( ,*"8E51./HV_P8  #85   9
M  " @2"=  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MPH)B5>Q6_./F P  PPD  !D              ("!5J0  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " #"@F)52E2*CQL$   ,"@  &0
M            @(%SJ   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( ,*"8E75&Y>?) ,  )0&   9              " @<6L  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ PH)B5<MRN9\E!
M20H  !D              ("!(+   'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " #"@F)5A1D#P,P%  #0#@  &0              @(%\
MM   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,*"8E7Y
M.<!>6P,  !,'   9              " @7^Z  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ PH)B59, RY&( @  (@8  !D
M     ("!$;X  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,*"8E6J,NMZ! 0  !D4   9              "
M@5'4  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ PH)B
M5>.8V6_N&P  L/L! !D              ("!C-@  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " #"@F)5]NGL9M8'   M2   &0
M        @(&Q]   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( ,*"8E7V%?Z&YP(   P(   9              " @;[\  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ PH)B557GBI7_ @  NPD
M !D              ("!W/\  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " #"@F)52'*_"#T#  "("P  &0              @($2 P$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,*"8E5P[_^!
ME 4  /\P   9              " @88& 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ PH)B58A[1TJY"   YD4  !D
M ("!40P! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #"
M@F)54JOQ]#P&  !T*0  &0              @(%!%0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,*"8E7G".5AO ,  *(1   9
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M970T-2YX;6Q02P$"% ,4    " #"@F)5TFNZ42<"  #D!   &0
M    @($"-0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M ,*"8E5+VZ82;@,  *X6   -              "  6 W 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ PH)B59>*NQS     $P(   L              ( !
M^3H! %]R96QS+RYR96QS4$L! A0#%     @ PH)B54.'@7SV P   Q\   \
M             ( !XCL! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,*"
M8E7]+-6EK@$  ,$;   :              "  05  0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,*"8E4F^H>GM0$  -P;   3
M          "  >M! 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     V #8
*L0X  -%# 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>267</ContextCount>
  <ElementCount>273</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Equity Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/EquityMethodInvestments</Role>
      <ShortName>Equity Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://allogene.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/FinancialInstruments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/BalanceSheetComponents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/CommitmentsandContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/NetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/DescriptionofBusiness</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Balance Sheet Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsDetails</Role>
      <ShortName>Balance Sheet Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/BalanceSheetComponentsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - License and Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseandCollaborationAgreementsDetails</Role>
      <ShortName>License and Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Commitments and Contingencies - Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Commitments and Contingencies - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Commitments and Contingencies - Undiscounted Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Undiscounted Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/EquityMethodInvestmentsDetails</Role>
      <ShortName>Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/EquityMethodInvestments</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/RelatedPartyTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/NetLossPerShareTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="allo-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/SubsequentEvents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="allo-20220930.htm">allo-20220930.htm</File>
    <File>allo-20220930.xsd</File>
    <File>allo-20220930_cal.xml</File>
    <File>allo-20220930_def.xml</File>
    <File>allo-20220930_lab.xml</File>
    <File>allo-20220930_pre.xml</File>
    <File>allo-20220930xex311.htm</File>
    <File>allo-20220930xex312.htm</File>
    <File>allo-20220930xex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="670">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "allo-20220930.htm": {
   "axisCustom": 3,
   "axisStandard": 22,
   "contextCount": 267,
   "dts": {
    "calculationLink": {
     "local": [
      "allo-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "allo-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "allo-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "allo-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 447,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 51,
   "keyStandard": 222,
   "memberCustom": 35,
   "memberStandard": 27,
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://allogene.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Financial Instruments",
     "role": "http://allogene.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Balance Sheet Components",
     "role": "http://allogene.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - License and Collaboration Agreements",
     "role": "http://allogene.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "role": "http://allogene.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Equity Method Investments",
     "role": "http://allogene.com/role/EquityMethodInvestments",
     "shortName": "Equity Method Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stock-Based Compensation",
     "role": "http://allogene.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Related Party Transactions",
     "role": "http://allogene.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Income Taxes",
     "role": "http://allogene.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Net Loss Per Share",
     "role": "http://allogene.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Subsequent Events",
     "role": "http://allogene.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://allogene.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Financial Instruments (Tables)",
     "role": "http://allogene.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://allogene.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://allogene.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://allogene.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Description of Business (Details)",
     "role": "http://allogene.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ia9664a6d74d14cd2b0e6999a7746fbb3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LiabilitiesFairValueDisclosure",
       "us-gaap:AssetsFairValueDisclosure",
       "us-gaap:AssetsFairValueDisclosure",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie730bc1281e742289f7b14d42eff7b48_I20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ia9664a6d74d14cd2b0e6999a7746fbb3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)",
     "role": "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ib0e1772a9a774e75a2d532c1fa03dfd9_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)",
     "role": "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails",
     "shortName": "Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Financial Instruments - Additional Information (Details)",
     "role": "http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Balance Sheet Components (Details)",
     "role": "http://allogene.com/role/BalanceSheetComponentsDetails",
     "shortName": "Balance Sheet Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - License and Collaboration Agreements (Details)",
     "role": "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
     "shortName": "License and Collaboration Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "iee875a3ae84d46ed987a1b307db20e6e_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "allo:CollaborationAgreementUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i87ee1a949aa34bb7bc017891ce79e050_I20181031",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "allo:AreaOfNewOfficeBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i87ee1a949aa34bb7bc017891ce79e050_I20181031",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "allo:AreaOfNewOfficeBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "allo:LiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Commitments and Contingencies - Lease Liabilities (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "allo:LiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Commitments and Contingencies - Lease Costs (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails",
     "shortName": "Commitments and Contingencies - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Commitments and Contingencies - Undiscounted Future Lease Payments (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Undiscounted Future Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i851ceebb52594744ab16edeb67e8db95_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Equity Method Investments (Details)",
     "role": "http://allogene.com/role/EquityMethodInvestmentsDetails",
     "shortName": "Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i186cd8de8d9844958fcbdfb4ccfb61ed_D20191101-20191101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ice1dbb356b5946d994e58ee58305e689_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ice1dbb356b5946d994e58ee58305e689_D20220101-20220930",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "id11744c3dcc0478fbe1ac19d5b674e5c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ic7e410828c494779bafe7d703d4f1cc2_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i84c78919b72c4471b2a04d675a8d6fbf_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Related Party Transactions (Details)",
     "role": "http://allogene.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i10cdf1fbcbd24042b88e39c59ceb0185_D20220701-20220731",
      "decimals": "0",
      "lang": "en-US",
      "name": "allo:AreaOfOffice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Net Loss Per Share (Details)",
     "role": "http://allogene.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i34c392be59f54e6f9714301ddcb1bc63_I20221006",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "allo:CollaborativeArrangementRightsAndObligationsMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Subsequent Events (Details)",
     "role": "http://allogene.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i34c392be59f54e6f9714301ddcb1bc63_I20221006",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "allo:CollaborativeArrangementRightsAndObligationsMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i3fc217acd2be43718fb7e4ed4c014def_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "i27bc23f568da4811a9958f2effaa11a7_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Description of Business",
     "role": "http://allogene.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://allogene.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Fair Value Measurements",
     "role": "http://allogene.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220930.htm",
      "contextRef": "ie88adfbe95e64adaaa8c942f817c4630_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 71,
   "tag": {
    "allo_AccruedAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Liabilities Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AdditionalAreaOfNewOfficeBuilding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Area of New Office Building",
        "label": "Additional Area of New Office Building",
        "terseLabel": "Additional area of office and laboratory (in square feet)"
       }
      }
     },
     "localname": "AdditionalAreaOfNewOfficeBuilding",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AggregatePotentialMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential milestone payable",
        "label": "Aggregate Potential Milestone Payable",
        "terseLabel": "Aggregate potential milestone payable"
       }
      }
     },
     "localname": "AggregatePotentialMilestonePayable",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential milestone payments.",
        "label": "Aggregate Potential Milestone Payments",
        "terseLabel": "Aggregate potential milestone payments"
       }
      }
     },
     "localname": "AggregatePotentialMilestonePayments",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential milestone receivable.",
        "label": "Aggregate Potential Milestone Receivable",
        "terseLabel": "Aggregate potential milestone receivable"
       }
      }
     },
     "localname": "AggregatePotentialMilestoneReceivable",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialRegulatoryAndDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential regulatory and development milestones.",
        "label": "Aggregate Potential Regulatory And Development Milestones",
        "terseLabel": "Aggregate potential regulatory and development milestones"
       }
      }
     },
     "localname": "AggregatePotentialRegulatoryAndDevelopmentMilestones",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allogene Overland, Allogene Overland BioPharm (HK) Limited",
        "label": "Allogene Overland, Allogene Overland BioPharm (HK) Limited [Member]",
        "terseLabel": "Allogene Overland, Allogene Overland BioPharm (HK) Limited"
       }
      }
     },
     "localname": "AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AllogeneOverlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allogene Overland",
        "label": "Allogene Overland [Member]",
        "terseLabel": "Allogene Overland"
       }
      }
     },
     "localname": "AllogeneOverlandMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AntionCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antion Collaboration Agreement",
        "label": "Antion Collaboration Agreement [Member]",
        "terseLabel": "Antion Collaboration Agreement"
       }
      }
     },
     "localname": "AntionCollaborationAgreementMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AntionCollaborationAgreementMilestoneAchievementOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antion Collaboration Agreement, Milestone Achievement One",
        "label": "Antion Collaboration Agreement, Milestone Achievement One [Member]",
        "terseLabel": "Antion Collaboration Agreement, Milestone Achievement One"
       }
      }
     },
     "localname": "AntionCollaborationAgreementMilestoneAchievementOneMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AntionCollaborationAgreementMilestoneAchievementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antion Collaboration Agreement, Milestone Achievement Two",
        "label": "Antion Collaboration Agreement, Milestone Achievement Two [Member]",
        "terseLabel": "Antion Collaboration Agreement, Milestone Achievement Two"
       }
      }
     },
     "localname": "AntionCollaborationAgreementMilestoneAchievementTwoMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AreaOfNewOfficeBuilding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of new office building.",
        "label": "Area Of New Office Building",
        "terseLabel": "Area of office and laboratory (in square feet)"
       }
      }
     },
     "localname": "AreaOfNewOfficeBuilding",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AreaOfOffice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of office.",
        "label": "Area Of Office",
        "terseLabel": "Area of office space (in square feet)"
       }
      }
     },
     "localname": "AreaOfOffice",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AreaOfOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of operating lease.",
        "label": "Area Of Operating Lease",
        "terseLabel": "Area of operating lease (in square feet)"
       }
      }
     },
     "localname": "AreaOfOperatingLease",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AssetContributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset contribution agreement.",
        "label": "Asset Contribution Agreement [Member]",
        "verboseLabel": "Asset Contribution Agreement"
       }
      }
     },
     "localname": "AssetContributionAgreementMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_BellcoCapitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bellco Capital LLC.",
        "label": "Bellco Capital L L C [Member]",
        "terseLabel": "Bellco"
       }
      }
     },
     "localname": "BellcoCapitalLLCMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CashEquivalentsAndShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments",
        "totalLabel": "Total cash equivalents and investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestments",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CellectisSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cellectis S.A..",
        "label": "Cellectis S A [Member]",
        "terseLabel": "Cellectis"
       }
      }
     },
     "localname": "CellectisSAMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in significant accounting policies.",
        "label": "Changes In Significant Accounting Policies Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_ClinicalRegulatoryAndCommercialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical, Regulatory, and Commercial Milestone",
        "label": "Clinical, Regulatory, and Commercial Milestone [Member]",
        "terseLabel": "Clinical, Regulatory, and Commercial Milestone"
       }
      }
     },
     "localname": "ClinicalRegulatoryAndCommercialMilestoneMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CollaborationAgreementCommittedFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Committed Funding",
        "label": "Collaboration Agreement, Committed Funding",
        "terseLabel": "Committed funding"
       }
      }
     },
     "localname": "CollaborationAgreementCommittedFunding",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Term",
        "label": "Collaboration Agreement, Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment",
        "label": "Collaboration Agreement, Upfront Payment",
        "terseLabel": "Collaboration agreement, upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CollaborationArrangementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Expense",
        "label": "Collaboration Arrangement, Expense",
        "terseLabel": "Collaboration arrangement, expense"
       }
      }
     },
     "localname": "CollaborationArrangementExpense",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CollaborativeArrangementRightsAndObligationsMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment",
        "terseLabel": "Collaborative arrangement, rights and obligations, milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayment",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ComputerEquipmentAndPurchasedSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and purchased software.",
        "label": "Computer Equipment And Purchased Software [Member]",
        "terseLabel": "Computer equipment and purchased software"
       }
      }
     },
     "localname": "ComputerEquipmentAndPurchasedSoftwareMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting agreements.",
        "label": "Consulting Agreements [Member]",
        "terseLabel": "Consulting Agreements"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CostMethodInvestmentTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Method Investment, Transaction Costs",
        "label": "Cost Method Investment, Transaction Costs",
        "terseLabel": "Transaction cost"
       }
      }
     },
     "localname": "CostMethodInvestmentTransactionCosts",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CurrentAccruedAndOtherLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Accrued and Other Liabilities",
        "label": "Current Accrued and Other Liabilities [Member]",
        "terseLabel": "Current Accrued and Other Liabilities"
       }
      }
     },
     "localname": "CurrentAccruedAndOtherLiabilitiesMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_DevelopmentAndSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Sales [Member]",
        "label": "Development And Sales [Member]",
        "terseLabel": "Development and Sales"
       }
      }
     },
     "localname": "DevelopmentAndSalesMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_EarlyExerciseOfStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercise of stock options.",
        "label": "Early Exercise Of Stock Options [Member]",
        "terseLabel": "Early exercised stock options subject to future vesting"
       }
      }
     },
     "localname": "EarlyExerciseOfStockOptionsMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_EquityInvestmentBasisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment Basis",
        "label": "Equity Investment Basis [Axis]",
        "terseLabel": "Equity Investment Basis [Axis]"
       }
      }
     },
     "localname": "EquityInvestmentBasisAxis",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_EquityInvestmentBasisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment Basis [Domain]",
        "label": "Equity Investment Basis [Domain]",
        "terseLabel": "Equity Investment Basis [Domain]"
       }
      }
     },
     "localname": "EquityInvestmentBasisDomain",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_FounderSharesOfCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder shares of common stock.",
        "label": "Founder Shares Of Common Stock [Member]",
        "terseLabel": "Founders' shares of common stock subject to future vesting"
       }
      }
     },
     "localname": "FounderSharesOfCommonStockMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_IncomeLossFromCostMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Cost Method Investment",
        "label": "Income (Loss) from Cost Method Investment",
        "negatedTerseLabel": "Share of loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromCostMethodInvestment",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_JointVentureCapitalSupportPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture Capital Support Payments",
        "label": "Joint Venture Capital Support Payments",
        "terseLabel": "Joint venture capital support payments"
       }
      }
     },
     "localname": "JointVentureCapitalSupportPayments",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment member.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LeaseOneAmendedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease One, Amended",
        "label": "Lease One, Amended [Member]",
        "terseLabel": "Lease One, Amended"
       }
      }
     },
     "localname": "LeaseOneAmendedMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LeaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Two.",
        "label": "Lease Two [Member]",
        "terseLabel": "Lease Two"
       }
      }
     },
     "localname": "LeaseTwoMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LesseeFinanceLeasePaymentUponContractTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance Lease, Payment Upon Contract Termination",
        "label": "Lessee, Finance Lease, Payment Upon Contract Termination",
        "terseLabel": "Termination payment"
       }
      }
     },
     "localname": "LesseeFinanceLeasePaymentUponContractTermination",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Payments Due After Year Four",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_LiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, Lessee",
        "label": "Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Lease Liabilities"
       }
      }
     },
     "localname": "LiabilitiesLesseeTableTextBlock",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_LicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements text block.",
        "label": "License Agreements [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsTextBlock",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreement.",
        "label": "License And Collaboration Agreement [Member]",
        "verboseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payments required per product against selected target.",
        "label": "Maximum Payments Required Per Product Against Selected Target",
        "terseLabel": "Maximum payments required per product against selected target"
       }
      }
     },
     "localname": "MaximumPaymentsRequiredPerProductAgainstSelectedTarget",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_MilestoneTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Type [Axis]",
        "label": "Milestone Type [Axis]",
        "terseLabel": "Milestone Type [Axis]"
       }
      }
     },
     "localname": "MilestoneTypeAxis",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_MilestoneTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Milestone Type [Axis]",
        "label": "Milestone Type [Domain]",
        "terseLabel": "Milestone Type [Domain]"
       }
      }
     },
     "localname": "MilestoneTypeDomain",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NewarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Newark [Member]",
        "label": "Newark [Member]",
        "terseLabel": "Newark"
       }
      }
     },
     "localname": "NewarkMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NotchTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notch Therapeutics, Inc.",
        "label": "Notch Therapeutics, Inc. [Member]",
        "terseLabel": "Notch Therapeutics, Inc."
       }
      }
     },
     "localname": "NotchTherapeuticsIncMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NumberOfOptionsToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options to extend lease.",
        "label": "Number Of Options To Extend Lease",
        "terseLabel": "Number of options to extend lease"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendLease",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares as percentage of common shares outstanding.",
        "label": "Number Of Shares As Percentage Of Common Shares Outstanding",
        "terseLabel": "Number of shares as percentage of common shares outstanding"
       }
      }
     },
     "localname": "NumberOfSharesAsPercentageOfCommonSharesOutstanding",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise price as percentage of fair value of common stock on grate date.",
        "label": "Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date",
        "terseLabel": "Option exercise price as percentage of fair value of common stock on grate date"
       }
      }
     },
     "localname": "OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_OverlandPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overland Pharmaceuticals Inc.",
        "label": "Overland Pharmaceuticals Inc. [Member]",
        "terseLabel": "Overland Pharmaceuticals Inc."
       }
      }
     },
     "localname": "OverlandPharmaceuticalsIncMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PaymentTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Terms",
        "label": "Payment Terms [Axis]",
        "terseLabel": "Payment Terms [Axis]"
       }
      }
     },
     "localname": "PaymentTermsAxis",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_PaymentTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Terms",
        "label": "Payment Terms [Domain]",
        "terseLabel": "Payment Terms [Domain]"
       }
      }
     },
     "localname": "PaymentTermsDomain",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PaymentsCommencingJanuary2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Commencing January 2021",
        "label": "Payments Commencing January 2021 [Member]",
        "terseLabel": "Payments Commencing January 2021"
       }
      }
     },
     "localname": "PaymentsCommencingJanuary2021Member",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PaymentsCommencingJanuary2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Commencing January 2022",
        "label": "Payments Commencing January 2022 [Member]",
        "terseLabel": "Payments Commencing January 2022"
       }
      }
     },
     "localname": "PaymentsCommencingJanuary2022Member",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PaymentsToAcquireInvestmentsUponMilestoneAchievement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Investments Upon Milestone Achievement",
        "label": "Payments to Acquire Investments Upon Milestone Achievement",
        "terseLabel": "Payments for investments upon milestone achievement"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestmentsUponMilestoneAchievement",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_PercentageOfDevelopmentCostPayableByCollaborationPartner": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Development Cost Payable By Related Party",
        "label": "Percentage Of Development Cost Payable By Collaboration Partner",
        "terseLabel": "Percentage of development cost payable by collaboration partner"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostPayableByCollaborationPartner",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PercentageOfDevelopmentCostPayableByTheCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Development Cost Payable By The Company",
        "label": "Percentage Of Development Cost Payable By The Company",
        "terseLabel": "Percentage of development costs payable by the Company"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostPayableByTheCompany",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PreClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Clinical Development Milestone [Member]",
        "label": "Pre-Clinical Development Milestone [Member]",
        "terseLabel": "Pre-Clinical Development Milestone"
       }
      }
     },
     "localname": "PreClinicalDevelopmentMilestoneMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ReductionToResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction to Research and Development Expense",
        "label": "Reduction to Research and Development Expense",
        "terseLabel": "Reduction to research and development expense"
       }
      }
     },
     "localname": "ReductionToResearchAndDevelopmentExpense",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_RegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone member.",
        "label": "Regulatory Milestone [Member]",
        "terseLabel": "Regulatory Milestone"
       }
      }
     },
     "localname": "RegulatoryMilestoneMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RelatedPartyTransactionCompensationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction compensation percentage.",
        "label": "Related Party Transaction Compensation Percentage",
        "terseLabel": "Related party transaction compensation percentage"
       }
      }
     },
     "localname": "RelatedPartyTransactionCompensationPercentage",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_RelatedPartyTransactionMonthlyPaymentsInArrears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction monthly payments in arrears.",
        "label": "Related Party Transaction Monthly Payments In Arrears",
        "terseLabel": "Related party transaction monthly payment in arrears"
       }
      }
     },
     "localname": "RelatedPartyTransactionMonthlyPaymentsInArrears",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ResearchCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreement.",
        "label": "Research Collaboration And License Agreement [Member]",
        "terseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RoyaltyObligationPeriodFromDateOfFirstSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation Period From Date Of First Sale",
        "label": "Royalty Obligation Period From Date Of First Sale",
        "terseLabel": "Royalty obligation period from date of first sale"
       }
      }
     },
     "localname": "RoyaltyObligationPeriodFromDateOfFirstSale",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone member.",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales Milestone"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ServierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Servier.",
        "label": "Servier [Member]",
        "verboseLabel": "Servier"
       }
      }
     },
     "localname": "ServierMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining vesting life, granted (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Restricted stock units, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Employees",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Employees",
        "terseLabel": "Exchange offer, number of employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfEmployees",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Options",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Number Of Options",
        "terseLabel": "Exchange offer, number of options accepted for cancellation (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferNumberOfOptions",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Percentage Of Total Shares Outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Exchange Offer, Percentage Of Total Shares Outstanding",
        "terseLabel": "Exchange offer, percentage of total shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExchangeOfferPercentageOfTotalSharesOutstanding",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period",
        "negatedTerseLabel": "Number of options, option exchange, options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriod",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Option Exchange, Cancellations In Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, option exchange options cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeCancellationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants in Period, Gross",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants in Period, Gross",
        "terseLabel": "Number of options, option exchange, options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodGross",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants In Period, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Option Exchange, Grants In Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, option exchange options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionExchangeGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining vesting life, vested and expected to vest (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_StockOptionGrantedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option granted period.",
        "label": "Stock Option Granted Period",
        "terseLabel": "Stock option grant period"
       }
      }
     },
     "localname": "StockOptionGrantedPeriod",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_SubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Agreement [Member]",
        "label": "Sublease Agreement [Member]",
        "terseLabel": "Sublease Agreement"
       }
      }
     },
     "localname": "SubleaseAgreementMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for tenant improvements.",
        "label": "Tenant Improvement Allowance",
        "terseLabel": "Allowance for tenant improvements"
       }
      }
     },
     "localname": "TenantImprovementAllowance",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_TenantImprovementAllowanceUtilizedToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Improvement Allowance, Utilized To Date",
        "label": "Tenant Improvement Allowance, Utilized To Date",
        "terseLabel": "Tenant improvement allowance utilized to date"
       }
      }
     },
     "localname": "TenantImprovementAllowanceUtilizedToDate",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_TwoRiverConsultingLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two River Consulting LLC [Member]",
        "label": "Two River Consulting L L C [Member]",
        "terseLabel": "Two River"
       }
      }
     },
     "localname": "TwoRiverConsultingLLCMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TwoThousandEighteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen plan.",
        "label": "Two Thousand Eighteen Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenPlanMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_UniversityOfTexasMDAndersonCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University Of Texas MD Anderson Cancer Center",
        "label": "University Of Texas MD Anderson Cancer Center [Member]",
        "terseLabel": "University Of Texas MD Anderson Cancer Center"
       }
      }
     },
     "localname": "UniversityOfTexasMDAndersonCancerCenterMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_UpfrontAndQuarterlyCashPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and Quarterly Cash Payments",
        "label": "Upfront and Quarterly Cash Payments",
        "terseLabel": "Upfront and quarterly cash payments"
       }
      }
     },
     "localname": "UpfrontAndQuarterlyCashPayments",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_VotingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voting Interest",
        "label": "Voting Interest [Member]",
        "terseLabel": "Voting Interest"
       }
      }
     },
     "localname": "VotingInterestMember",
     "nsuri": "http://allogene.com/20220930",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r31",
      "r33",
      "r79",
      "r80",
      "r211",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r210",
      "r218",
      "r241",
      "r242",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r403",
      "r445",
      "r447",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r210",
      "r218",
      "r241",
      "r242",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r403",
      "r445",
      "r447",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r186",
      "r191",
      "r192",
      "r193",
      "r194",
      "r210",
      "r218",
      "r231",
      "r241",
      "r242",
      "r274",
      "r275",
      "r276",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r403",
      "r445",
      "r447",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r186",
      "r191",
      "r192",
      "r193",
      "r194",
      "r210",
      "r218",
      "r231",
      "r241",
      "r242",
      "r274",
      "r275",
      "r276",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r403",
      "r445",
      "r447",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r32",
      "r33",
      "r79",
      "r80",
      "r211",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r137",
      "r138",
      "r228",
      "r230",
      "r446",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r137",
      "r138",
      "r228",
      "r230",
      "r446",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r369"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r8",
      "r183"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r38",
      "r39",
      "r40",
      "r435",
      "r452",
      "r453"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r37",
      "r40",
      "r46",
      "r47",
      "r48",
      "r82",
      "r83",
      "r84",
      "r313",
      "r358",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r287",
      "r288",
      "r289",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r244",
      "r291",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r75",
      "r125",
      "r128",
      "r134",
      "r165",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r309",
      "r314",
      "r332",
      "r367",
      "r369",
      "r419",
      "r433"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r22",
      "r75",
      "r165",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r309",
      "r314",
      "r332",
      "r367",
      "r369"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized\u00a0Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized\u00a0Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r144",
      "r173"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r141",
      "r145",
      "r173",
      "r422"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r143",
      "r173"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r6",
      "r143",
      "r173"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Long-term investments",
        "verboseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r5",
      "r71"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r71",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash \u2014 end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash \u2014 beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r333"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r74",
      "r75",
      "r97",
      "r98",
      "r99",
      "r101",
      "r103",
      "r111",
      "r112",
      "r113",
      "r165",
      "r197",
      "r202",
      "r203",
      "r204",
      "r208",
      "r209",
      "r216",
      "r217",
      "r220",
      "r221",
      "r223",
      "r332",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r424",
      "r439"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Notes 6 and 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r195",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r369"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value: 400,000,000 shares authorized as of September 30, 2022 and 200,000,000 shares authorized as of December 31, 2021; 144,031,588 and 142,623,065 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45",
      "r50",
      "r426",
      "r443"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r225",
      "r226",
      "r229"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r149",
      "r173",
      "r174",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Accrued interest receivable from available-fore-sale investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Maximum remaining contractual maturities of available-for-sale securities (in years)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r153",
      "r176",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Net unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-Based Arrangements, Liability, Current",
        "terseLabel": "Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-Based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Other long term liabilities, related to shares held by employees and directors that were subject to repurchase"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r69",
      "r181"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r246",
      "r247",
      "r280",
      "r281",
      "r284",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r15",
      "r77",
      "r200",
      "r202",
      "r203",
      "r207",
      "r208",
      "r209",
      "r362",
      "r423",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r51",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r95",
      "r97",
      "r101",
      "r102",
      "r103",
      "r107",
      "r108",
      "r322",
      "r323",
      "r427",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r51",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r97",
      "r101",
      "r102",
      "r103",
      "r107",
      "r108",
      "r322",
      "r323",
      "r427",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock based compensation expense, weighted average recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Expected shares to be purchased under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r48",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r110",
      "r167",
      "r223",
      "r224",
      "r287",
      "r288",
      "r289",
      "r300",
      "r301",
      "r321",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r358",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r324",
      "r325",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis and Level of Inputs Used in Such Measurements by Major Security Type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r324",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r212",
      "r214",
      "r215",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r325",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r212",
      "r232",
      "r233",
      "r238",
      "r240",
      "r325",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r212",
      "r214",
      "r215",
      "r232",
      "r233",
      "r238",
      "r240",
      "r325",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r212",
      "r214",
      "r215",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r325",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r212",
      "r214",
      "r215",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r329",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r159",
      "r160",
      "r161",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r177",
      "r178",
      "r179",
      "r180",
      "r213",
      "r222",
      "r320",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r185",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r68",
      "r404"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Net amortization/accretion on investment securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Equity method investment"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r354",
      "r356"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Lease Payments Under Lease Liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (remaining 6 months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, option to extend term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Sublease, term of contract (in years)"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r24",
      "r75",
      "r129",
      "r165",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r310",
      "r314",
      "r315",
      "r332",
      "r367",
      "r368"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r75",
      "r165",
      "r332",
      "r369",
      "r421",
      "r437"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r26",
      "r75",
      "r165",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r310",
      "r314",
      "r315",
      "r332",
      "r367",
      "r368",
      "r369"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r114",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r41",
      "r43",
      "r48",
      "r49",
      "r70",
      "r75",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r93",
      "r94",
      "r100",
      "r125",
      "r127",
      "r130",
      "r133",
      "r135",
      "r165",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r323",
      "r332",
      "r425",
      "r442"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r125",
      "r127",
      "r130",
      "r133",
      "r135"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r348",
      "r356"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails",
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion included in accrued and other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, non-current",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails",
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r345",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r353",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r352",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r35",
      "r36",
      "r38"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "verboseLabel": "Net unrealized loss on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred.",
        "label": "Payments for Leasing Costs, Commissions, and Tenant Improvements",
        "negatedTerseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "PaymentsForLeasingCostsCommissionsAndTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r60",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "terseLabel": "Cash received for amounts related to tenant improvement allowances"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchase of stock in equity method investment",
        "verboseLabel": "Payments for additional investment in interest"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://allogene.com/role/EquityMethodInvestmentsDetails",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Payments to acquire interest in Notch"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments",
        "terseLabel": "Payments for investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r369"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value: 10,000,000 shares authorized as of September 30, 2022 and December 31, 2021; no shares were issued and outstanding as of September 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r64",
      "r286"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r58",
      "r59",
      "r142"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r41",
      "r43",
      "r48",
      "r65",
      "r75",
      "r85",
      "r93",
      "r94",
      "r125",
      "r127",
      "r130",
      "r133",
      "r135",
      "r165",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r308",
      "r311",
      "r312",
      "r316",
      "r317",
      "r323",
      "r332",
      "r428"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r7",
      "r182"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r184",
      "r369",
      "r432",
      "r438"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails",
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r11",
      "r420",
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Non-cancellable purchase commitments"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecoveryOfDirectCosts": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.",
        "label": "Recovery of Direct Costs",
        "terseLabel": "Net cost recoveries"
       }
      }
     },
     "localname": "RecoveryOfDirectCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyCosts": {
     "auth_ref": [
      "r53",
      "r77",
      "r200",
      "r202",
      "r203",
      "r207",
      "r208",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.",
        "label": "Related Party Costs",
        "terseLabel": "Related party costs"
       }
      }
     },
     "localname": "RelatedPartyCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r239",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r239",
      "r361",
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "verboseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r239",
      "r361",
      "r364",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "verboseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r359",
      "r360",
      "r362",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r294",
      "r405",
      "r468"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r9",
      "r72",
      "r455"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Unit",
        "verboseLabel": "Restricted stock units subject to vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r224",
      "r369",
      "r436",
      "r451",
      "r453"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r167",
      "r287",
      "r288",
      "r289",
      "r300",
      "r301",
      "r321",
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r123",
      "r124",
      "r126",
      "r131",
      "r132",
      "r136",
      "r137",
      "r139",
      "r227",
      "r228",
      "r406"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue - related party"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r351",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r148",
      "r150",
      "r154",
      "r155",
      "r156",
      "r157",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r278",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r1",
      "r75",
      "r163",
      "r165",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity Under Plan"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r243",
      "r245",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r250",
      "r266",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity Under Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule Stock Option Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Restricted stock units, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Restricted stock units, unvested, ending balance (in shares)",
        "periodStartLabel": "Restricted stock units, unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average fair value at date of grant per share, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining vesting life, unvested (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Restricted stock units, vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Expected exercise barrier (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Expected risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Expected risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Expected risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grants in period, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, ending balance (in shares)",
        "periodStartLabel": "Number of options, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-average exercise price, beginning balance (in dollars per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Plan modification, incremental cost"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-average exercise price, options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value, unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Vesting of early exercised common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r73",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r74",
      "r75",
      "r97",
      "r98",
      "r99",
      "r101",
      "r103",
      "r111",
      "r112",
      "r113",
      "r165",
      "r197",
      "r202",
      "r203",
      "r204",
      "r208",
      "r209",
      "r216",
      "r217",
      "r220",
      "r221",
      "r223",
      "r332",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r30",
      "r46",
      "r47",
      "r48",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r110",
      "r167",
      "r223",
      "r224",
      "r287",
      "r288",
      "r289",
      "r300",
      "r301",
      "r321",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r358",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Other Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Other Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r110",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r13",
      "r14",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r223",
      "r224",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of options, options exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r13",
      "r14",
      "r223",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r223",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r19",
      "r20",
      "r75",
      "r140",
      "r165",
      "r332",
      "r369"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r340",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r340",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r340",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r340",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r370",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r151",
      "r152",
      "r159",
      "r160",
      "r161",
      "r213",
      "r222",
      "r320",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "verboseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r78",
      "r232",
      "r240",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r349",
      "r356"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r96",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of shares used in computing net loss per share, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r95",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares used in computing net loss per share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL121698322-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r469": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r470": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r471": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r472": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r473": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r474": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r475": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r476": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r477": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r478": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r479": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r480": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r481": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001737287-22-000083-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-22-000083-xbrl.zip
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MFF5XSK.#R1,(D!*%["ES&H!!0MH@<21,GFFQ-C MU'.>(3Z6D,2<82Z@#Z;
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M;:!9D@\\(YA$+EC#1AZO%TX#>*J=1>6AEN1<R[6!:=$^\(SPR:6%5*[OSJ5
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MB<K:T3('E9RK:-H*8F8<MSY*YI!.BV# <26"E$&#!&$FL[9E60%=QD6 /]V
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M?D!L=0C!*:185FI!# X%%%"$HXH&?U6T$ML?%ELXJ\1V7F*K $*4GI'$F!#
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MS]A:1[-_'M%:2N!8*1&9(!1 .Y&2==1Y(($K'E(N<KK.@>.?2K26$*.-(O%
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MBS#[@ H]W>]U!8$>P31&\C.R?T"_V;\"XU_=0;/S?@=?N(=GS&(ZKS2R=9T
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M:+W22#B#LYKDFC+$!)(3%,$Y BD04_X [0K"O(0]+B(AZ'+HD'020E,+4H4
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M+XCRR$0??.H>''>'?72DMIOOC]'=ZKQ&KZHD3I71CCJ=5&)2"QL@US57R.2
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M^MMM" TTH*\,Z#-&B#0JJ60(4M(*T$<.SA4CA"FM+8LJ^=IPI_@R)D@#^@8
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MS*<TMND/V\SEX%Q CT: \(D#2A/!R1# ,Q.%+?(FL;!RNJ'CTJR9VS@PL7C
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MW=L$\7EK9TE\7V'VS,/[-SH\2U>@NQD^BT!Y-BV9@RBV#7$P$67QZ[0 ES
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M6V_.!5Z"RSF9P$$Y610G=P[(L@1"^,1<XEFFV#_%N?4E$/OI='#XI>4QVQE
M;G'^)J8FIB:F.R6FA:;Y:B:Y,X*')!&C)5;L,X56,:>48>(:)MD5LRZ+QGER
M%(Y?I[JSK-E<*[.YWLU-]-4D/2D;(# O 25R(.\D&.1:9&TLY3K9R V+5)>8
M<]EPW.BVB6DYNEV!!]SH]H;I=L[%%<8JF;( U$CEAT/PWD=@19<R1XPGBOWB
MV]:A?ZE#?'8T3N7*WZ?8^<:#@EUZ0Z/#NED>"H)@4G R&!W5&9I=(5#KUV]Q
MV":F)J8FIB:F)J8>B&D1VUOI.N0W>C*)HXR9DDA169'(RY"S_';;N]O4_MFB
M]H^F^(,+@^+[X_&S8DX\2^%L/#H=I<G' N-BBSS-S^EM,]M79;8_?3BW#(24
MU)ZB 8-2 EJ=@,H1 .F==TE)9[S;V=5#?<G$R867@30&Z",#K,_[;@S00P:8
M;PI(LI! 0$"F%&!M#_".:3"*K,247-#8*PK8HK2TN12]_Z;#;K$%#/9H' X&
MD@\'%7K+I*F76V#4/X9;K$\ @RC*3*K$?$ >3+%YE,U12\F(0ICN\KE.>\##
M;DYA5STS;0EX>G8Z.:6C>OM:#\"2Y/1LK@<@&L-\1 [.:ENX"1FXE!2P%&2.
MQEMA15VU+8=*NZ%CJQJ+W9NU92M,(MP9!I@W<;X-_M=;Y=6LCT4 /KNT(CI*
MGEL&VB@#Z(0"FY" #$7K$EJ9= ?P!NP&[,MZ3FS4QHG$;#DC.I/1PFARVMB,
M L,RP&X^Q\I0/S?L Y4/I!A(F:K+88N"5YP#%=^38T@ZF:Z/Q*(9*HD-^W<&
M^XL$+@*C2#ESJCO6)8\D*,=RH"RQ'(3!J\'?%A'?!@O,5F@9&X)F:(%G=( 4
M?"$ ER%Y9%Y:7HRVN+/KK!QRM\S.]0;_[82_8RR+X@+Z:-!K\@Z]LR8416)R
MD-3@WR_XSZ8>6"*/UBG(W@A &Q#(%YN )R4R4\51<\7T=T.!KH'_+H!_ >R3
M#<J@#&1)%A]1N8@Z1B^L848G%YO=WPO(S^4:8@Z<152@27M U &\Y1*"M)Z8
M4L'Z@GFKU% LWPEW4]!O=80]W<V]N?G;Q;(;VK#"=4H'+1CF8CRC19ZMX<7%
MCDQ=U'#@10972]9V<_>,+?>>/SB=6WL6=-2N#FG3@@,*]&!1"%!1RR0ETU@$
MN<N5' H];R.U*JT-Q?@E_6C+ ;RM,+P%++^;:8^(JIBKLA@]4<<ZWYB#U\40
M<DXEAM%F)^,*MG,W%/<8Q3J1Y"(%)3AZ%XB"]]Y08"(EE7-#<>]0O#^CD5V0
MT@?C@?G,BD96"BQU4[!$\3R+[VF%VMD52V<L&HQ;97L34Q/3AHII :7HLD@L
MJRB3=1B,),U%L#YS3K%6IC:EV#NEN#>-XQ?%N(?[[U^(/P,S606M0#B; *63
M8%D2D+/DC LEG3-%*RX]4GSS:H@W*6:W_NW<FSO-H V=:&)J8MH*GWEM*T2;
M%;& %?%XSK56&E66QD",I &S2> =$7"OLTO."\?8SJ[EJZH$;G!OK-S$U,2T
M:6*Z5=^Z*<]^*,\Y%UPBU]*1 !Z4!10A W%*D(M6=2+H%)WHF_;<^K5>*]VP
MO;G1P!:T;6)J8MH&Y[EM_]P<(^')G(<=<Z8@#0(2!L @(CB9 D3+"N2EKZ>B
MV_YI7:M#V31::.S=Q-3$M U.=E.RFZ1DYSQQ*N96X)9#,L$#&L; 1RE 9.NJ
M&::#H!YJV2T:JG5#.[8W-X38(KU-3$U,34Q-3$U,34Q-3!OF(*U@OVT>O4T1
MWJ?Q<7-X%G)X]N8='F9E\G5P!X8< 87.0))IL-JCDL)YX]P'7+?TXX9LM]W<
MV$T+L34Q-3$U,=TI,2TR.(UYGC27CG.A4*7L(O'DHS6<D1>97\,@:^L6;];L
M^OET?V:> !F3>"(+*J &I#I)B>KB16%X5DZQ4&>#&!P::_JQMJ$!N?'MUHAI
M$;Y=@0/<^/:F^7;.S57*>6NT!YZ" \P)P5D?@; XOZJH38K8+\)M/:ZWOM]V
M<P-\+0[;Q-3$U,34Q-3$U#<Q+6)\>YZ8-5F03A)SMBYYKA7/'$T,@9EO-[[;
M=LO^V>V_GCZ=*7HGE,$:9\#)W,U0E>"-CN YLY:XHN*)[>R*H1#SK7$+3YEO
M%-!'"EB?_]THH(\4,.>ZZR!)*4R@4\B 4JCBM6</6>G@F.;DDNT5!VQ1:OIK
M&VY_/#M* \F66'![_MWOS#:,2T? *^F#"'7]E6%H!2,C%%F4F2618[;G"S&^
M/OF]+;A=)SF]F)OQGIU"YS4!Y4R 5A;[!)T"QPTR4PQ6S7"ZX=8(.>1F53T#
MO5F(L\(\PIVA@'D;Y]OPWS;<K@/ALYG:8G*:XGJ"(^$!%??%^G 6BO-)T2@A
M7.Q6W*YJ:'1#]E8A6^MBI"9,$@NRD[>.)<)BN(KL$(G%99#=O([5P7ZVVYX3
M]S)H!E@\#,",!#;)!!2M]AZ+]*+O=MP:/A1ZZ<7U#?P; _Y%8A="914<F2A\
MP"CKTF2.D>H2&.:,YU>CORVYO!T:F-'^*F..2FF0PA3['I,&+V(Q 42Q!GC(
M2=7!7'S(E!DZ.S\B>^'*@<8 V\4 C"6ID)+AQ00HMX,$"S(X3UHF:[1L#- S
M!IC-0!0K7\O(&8ABQ=5E]\6YSUE!CD7M)Y^2394!^!#-O!70X+^%\%\ _:B4
MY=XIFV5&;9A7P>KBWQMFO-=Z*;^^@7Z%3O]LSH$SE8EY JE4,?]Y"L7R+_X_
M"XRRE$FG$'9V+>-#=\E^ZYX:_ZVBL*>;;C<WD;M8FB,CLIAM3$6#HC264&2.
MR'DQBY [=Y[*-1>I7-<VW?:0+L-<%B1*G007#)1V#) X0CGD"")347X\!*]5
ML9&,&6IC>]1#W(HU6EG=UHAI ;,T"&]2=@66VJ$0TFJF%4O*>,F41_T5'FY;
MVVZ><F?CT])FG[)FD&)Q1C'R8J Z1J!94+*8JBHQ62A7+KVUK>&XT6T34Q/3
MAHII :UH,1CKN/-&!$3#O2"&41M%-NKL<].*O=.*<W&;)'DP.D2PQL8ZTBB#
M=UJ!#,PRKUSF+/9-+=Y0N>@FA676O\QT<WO7VXB!)J8FIJWPFML^MCZ8$2_G
MEYF*Q"-% S+' &A= I(8P:00?31&Z*1V=E&NJNRKP;VQ<A-3$].FB>E6G>NF
M//NA/.=7J&27% D#WIM:/YT<.&$B2..BE46',M1]TYY;OS]EI<M,-S<<V**V
M34Q-3-O@/+<]:YMC)/PUYV&3Y%%KZ8"9B( \=W-=,J3$97::,\_,SJ[@0XZM
M8&C3:*&Q=Q-3$],V.-E-R6Z2DIT?>NRDTL7L@FA,!G2.P!DB4%0<<L=C2MW*
M\+YIV2V:GW1#RTRW,(38AP:"*]>1?6U:>Z.KK]'5JP=S702RG! R(8#$P "-
MJ26MJ;!5$7*.W-;BG5J[PX9&KJKGJN4*^FUM-C'UA8]ON8O@"YLAFY6X$.W.
MAF*\-0$=5V!5[20(/(+S20'Y(**-Q+RBG5TG^[3NOF&Y46X34Q-33S7CC782
M-,VX,H=D;C>R<JBE,2 3(T#M-#@=###IO<[,1I2N;ZIQZRL9EMJ+O+EAX!:M
M;V)J8FIBNE-B6F327DBVV%U*2!T-4BK_BXY)4D+K^L-?P^AJ>SIOUN1Z/#=O
M$Z,0*E$ 540&R(B#U5&"%CD:7T3L<][9M?+2C%5;^--;(#>^W0@Q+<*W*W!R
M&]_>--_.-\P[QF-Q:D$6@ )Z+0KABN+B:AT2]X&<=?TBW-8N?^M[D3<WB-=B
MK4U,34Q-3$U,34Q]$]-"P0Z1HO19>:8TRL!<-,EXS33S-F;UM4*XMA1UH^SV
M)W-;"9Q6*0D?00JO 1T)(,<)DA(RJV!EDK;N)4&KEU]*T"B@CQ2P/O^[44 ?
M*6#.=<^*>$I> 85<. "] Y?(%T\>0U;914>Z5QRP1:GIK^U%?I9.3M-KG\;+
M+4<^OP'GFR&F(8G[LMS^>'Q6,/AA.\0:5JQ\B'_TJM;FTJX X2*J8*(AXQ Q
M>/**>Z-%]):<H/,M*U]O!EAB>_(YF;%&9M<@L[VYVG\53?%1K !931EDV8&W
M3H+B#%&A4#R';LOJD$D^5'95[4JK0];U2?$#LE:9F%CJBU[]+;].'E^,G=X&
M=_SW2L_ =6_-AO+I)2LKOXE,VRKJ=9#D3')<\&"C-1Q,8@;0QP V%/M/1BXC
M%0= <;625=0K!$:CQ9Y00*/%I6C1)&21I C1:70Y$JH8'09KK29D?!E:;%[R
MZCASMKLI".Z5CP2>AV)8.N[K,+H 64OML]*68K? MQB;0\=NQ*QLS-F8<].9
M<Y% I5>"C,DJY) PDG8RHK7&*JER5L9=39UM!?+M<.BLW2E=P!@YA(C=4@T)
M-I(#QPPR7PQ2ZISS(<?RCY3+EPDU^FSTV>CSG#ZIF)Y:RQBC*O0ILV<L,!FM
M$,;+9&6CSY[1YVRN-O' 0T@:F)<.D+E43-"HP/&4BQR-$9P*?8JA4RLHL6S<
MV;ASJ[ESD12YXB$E7PQ0Y= @DN<ZQ>2U239ZIYK3W@_&G$MMNXBI&)P$HF@\
M0%,;KXNW#L:A51A$9)[M[!KIADXOW7S= ^+L,N/_/*UU%1<%V9^4G7_R7B&5
MXST^1][NO_SXG[N?UW'?\9>M@8RZ=[Q?)UV.PI?I251Z>GZ0!A3JB'TZ>E=W
MV!T=GY;/HW%Y^&@P*M?Z<DR'@Q,:G];U=J<':9(*A]%9')UVL_EK-\%T2O]1
M=\JH/IQ'1W041N6%D]/R0%? ?Z_GLNC5R\YEA.*>446R)\>3;@KI_7$ZI-/1
MF_3=WZ-X>G"A8CYYX3D?L(\O(5_D<G9Z]4MN\'!^\2C*F1:/3WX>C#_VM+Q,
MX,>)_@+*Y5KOT^'?]&ZR\\_/OM+KT1',W,+9;W_E=\QY;=]Q2K-%[1Z/NZFS
M]PNMIW']JW)-U)MK&1R,JSWR7R.*VEEFLW BH\S:^Z"EE"9ESZ-CZ4]3"*1J
M@4H-#ZLITS7JT.YEDMPH%KVJ;JH[J _^\Y^G/SS>?SQX_K^/?WGPT^-?GS]Y
M^&PX>++_<'&.N^EK?_B!L!]^2MC//M!T%>6G!F17C6^^&TP-R3Y\OP4UW#]^
MO=!6_[.)5__DJ"C=X[/RKG$R'*2W(55[[J!3T*^+77@Z6?QKW9RJZVS$C[JI
M,TK+S3RDDTFZ?_'+=W$T.3FD=_='1]T-Z%[TW6L:ORPT?J[0*H7/%D[6SYL^
M_9'=[[$IPY_7;9Y_\OG3][JG9BSLZ7/"W;..7_DTNW?U<U]Z6W?/V&][UR\_
MA]:N_%K-/2;TAERKO6>YV9!KY>R>E&)3+E;<XT)NRL6R MJKG_[T;<^+N6?L
M:\FZ2-[E@<"O-G6XN3^])$@WI<);"DE=7O<]K1N>:ODKZ[S+?1@?_SU;\_W5
M>_+EEVW&_?FX.:)3>'5]!(R.NM_/ETBTNW;)70OA[/79834GNUOU*.51&)VV
M6_7U6]5U,$W/UZ=M3(-I']/@'[63:2ZSTFYD<3Z/3\]!>HG+TCT^X[9<K0HX
M+J,*/DD?73?RVO-;.^TH^=*AN_87OD-W[4'GDEUVW-8] *8/;62/4CCO(N-=
M%QE;9CO,&IK$^CF0^=(F,9E#X3 *4?B$TG";O4F8(@;&,:;<Y0)9,=5Y:Q+[
M8EIP3^T___&PO"O_X_EA>>W/[\H_^.+W7T9[[_]ZN_?#_E_[KW_%I[__RN?2
M@N__XGNO?RW7\]OAT]]?O-M_]*3\<W#PQP]/WC]]_OCO%^)G\<?SE^J/Y[_E
MO=%Y$<4S]O[IHX![+__$:)T1(8*H*ZTPN0B.E?^,44CE4U*"4FU_8$,T.)1,
MK6@J\QI:P-;2&[]>_%]&D;<*_^O71BS\_3>4]^8+(+Z-].Y0,]>-D=G[&3+S
M7$<5I(,<M0?TP0%IQ^IOU@LEI5:R([-&8HW$[CB)%31PP:/5F MQ*2N#44HY
M(:W$8D$O0V+;7\5U8PS'9QA.L.#1>0U):BSF6K'9;):VW%ZGG$TL1QMKUX 1
M:JB4:#S7>&X+>6ZQB4YH+7>,B8RH*7CCR%-&ALQ9G_W51-<J_6^#\>0,XTFR
MBM GB"B+@XI)@4O.@N%.VW+2;69L9U>C'DI<IDNJ45VCNAY2W2+C*XL=EW0*
M)C%5-TY2\48M$T9KKQCYYI?>&(>I&0YS#%/()$$Y7_Q2DQ58+@U(PP22D-EG
MM[,K]-*=\HW$&HEM-HGYE%-*VI#B!D,@FX,-3E%.2KO@;?-+>\%P;S^=-??T
MT9,_C60D!"I@013'E!*'8K415!WDD)&TPE3'E!DWU-QL"M'=T'3-3=J+43>F
M=IG4XUQN25>C-:E@&YR=E%_3VS0.HTGW[/3AXY,JX,F CN*@[LFH[3OER5^>
M_;K,MHS-70>TX!A.XT.=/JUM)+2<DW/*9E$./U'Y+],-).:,3P<2<R:_FFJ]
M8NWM-.W:/?ET*K''YZ*,+0&[,N9\-Y> S9)B<%J#M*Q&](($%ZP%ID30-EDL
MQOS.KG5F:%8V@Z[M_KIUL%\R(W(YI"^VW_H*G#<C:!$HSZ8?M37$?(A@M:YC
MT1#!ZRRA"-'RG()%5X/S#<3;"V*9A)<^2_0^UN$(+K"@(G<F<DDLRIL <7-S
M5H;PV?1;S(64BV8&$P,!1HG@''/%RV'>%!<5O1,[NSADRC64;QC*VS;5)J8F
MIEO0F<QD8R6+6FF-B7G/LR"-6FA#XF+'>-.9FZ(SYT*#021FJ?BU,C@.&%(&
M'Y6#8BEE-$R$4*ORBM+42]?EK1#F;2/N'*9_^QB]2S0^?/<AV!<_"P2V';AM
M%UP34Q/3IGK<-1#NJ;!:;7--1Y-N\-"#\9B.7G;#9_[][N.?_$3OZD,/_J9Q
M/+<J*DNF^.1H:G1\3Z-Q9WCP9D<L8$?L/YSSO9,C'TV4H"4YP$P9'+H,I$/=
MWY)L#L7W-GQ5Q?T-[8V4FYB:F#9-3+?J>3?=V0O=.>>#RQBD]=&"%R("HF!@
M$[*B/+D32@BE"/NF/&^Z]N8VP-J%HZ"#0_6A/T!FF<6V&\A9+:C;Q-3$M W>
M\\>%]9/GQQ]'E-7I9$^.SN>276XE_)+^[VPT&9VF9VG\9A32U ;X)87CET?=
MNW2F0 O5K\Q,>#;G8COFI+!&0=+, @;AH)P$!B:C8\F*8&HM&M=#XY9N+6VL
MT,B[B:F):4/%=)M>=M.Q&Z1CYUSQ<@HLET6_1I&**ZY\<<JM#A QE2,037E2
M]%#)WG0^_#9 _?CUR>'QNY3..U=.SL;AH$!H<')(W^:1;V$4L0]=*A=RZO[H
MIW,I_52$-&FM*BNCKOE9@3+Q8&7(X(M#4(=J>:B"!I.DU4DB!AUV=IT=,J%[
M%$=L:8.6W=D:,?6U%^%*2F[&Y H9>39@8VI)1)81(D4%J'T"ZV4 *:P+45*4
MBM6N:V>7;AUL2&^$W,34Q+2A8NIK/T+3FS?BR<S50P3BS#D'VI$!5#86I\8Q
M4$'SE&)1ITSV3W'>A8J(_70Z.#R>7+W38SOCR2WLW\34Q-3$=*?$M,@<WSH.
M)T@;G?82G0Y6D@PRHW BJ,SL-:RR*P;Z%HTS76%6%Y@ULVME9M>[N5F^14XN
MLN0A2Q<!9=+@9$Z@N;(UE.$EHYU=*8>,S^^9N?XHWX;C1K=-3,O1[0J<X$:W
M-TRW<UZNE5QZDE2HEFE K10XGF*1F*9@=/3$?;_XMG7=7^H0GQV-4[GR]REV
MOO&@8)?>T.BPKJ"'@B"8%)P,1D=UOF97%]1Z\%LHMHFIB:F)J8FIB:D'8EK$
M]M;,H6-2D=0"0]"6:H##.J>=3-&Z;[>]NQ7NGVUO_VB*/[@P*+X_'C\KYL2S
M%,[&H]-1FGRL-RZVR-/\G-XVRWP!R_SIP[F%(%'G8%AGCM?T$Q$'9X4#R4TY
M+NB5Y;H8YGI^BN3""XT:Q/L(\?6YUPWBMP/Q^8T8EGLI'$%0HGC@SBBPC!,P
M&4162@9EJ$<8OZ'<\NGQR=KA:2Z%Y[_IL%M; 8,]&H>#@>3#0<76,HGFY184
M72J56TV^+U;U+X551G*O;4R8D%-D@5NM*))QSH1N5\]UBOT?=M,#NQ*8:8'_
MT[/3R2D=U=O7*OI71E+/YBKZ.9)!7@T/SQ$P1P\VU<5D&07/VLNH=5V8S8=H
MV)"9^2CAM\7\U["WYP-N5ID06"_^>U=[<_T%90M__PWEO4NJZK^)]-J6Q=63
MV>SZ#65"E#(ST-'Z6M-7R(PK#4P9;I(5*!EV9-9(K)'8'2<Q[87F$7FTU00(
M7A7?4TEKF,PI>+X,B;6$[LH8;K;=1V**6CF$D*FVCB<&WE&&R-"%&CYPJIIK
M0X-NR-S22Q8;SS6>ZR'/+11*5SK[G'WR6,#CT:5$24C/N$V8D[F:Z*X(KS7&
M6ROCS58,DM;2J4@0) 5 H2R0- *"*B:X5YZ+G'=VM7%#J>:W9R]<PM*HKE%=
MG[[X(E3G)!5ZBTH1TRBTM-YIC.51I9@5*:^$ZAJ;+<)FLVF_K%6V)EA@/F;
MK FL(@>6A<BD,,8+7^PW-N^A-B9K3+;13+9(;E28*&(QU*RS:),GZ8721N><
MD)&VS3GM!;G-)3Q1>!.B("BJ1P(ZQH"8-1"<UYJRDY%UPRB8=D-C5K4@<^U$
MUTJ2Y\!<>]F[7.IQ_FSSU^#LI/QZL16L/CM]^'@ZW7] 1W'PYN,2L5^>_7HW
M"Y472[,F&:2VW!533B(+R26NI&4FD!6,\D7G&U[4BFC)EAFNML2&Q):%O<:&
MQ.</3N>8,V#0R01(&(I=Z(F!BTJ P%KXI]"KFH;5B@VU:I/5M@;M\Z;/DE!?
MR2K49@4MAN5W,]M.98@1M8+JS%4?SX/37(%WT093<([,%"NHH7A[4>QTL7NS
M0JX55C.XR%^34AYC*GX_OQ$4-T=G=1#?GU'7E)5DBCP(SQ(42 NP45O@(E!1
MT+&X007B<BBX;##?,)BW=IHFIB:F6U":7DK#6#&7*$CD3!":A)1XM,0X\[DI
MS<U2FGO3U$=1G'NX__[ENS^)<K&#A 8O$ 'KR@-K40*7G@DCDPTHIUKS+H_<
MVX#HWV\?(WB)QH?O/@3\XF?!P"4B>YL[8J5-PFEB:F+:"I^[K3+N@R'Q>,[[
M=CIE:Z4%)HD!HF3@K,V@K'$9C?8VQIU=JY:V(AK<&RLW,34Q;:B8;M7W;LJS
M'\ISS@N7EIQDPH.J$6LDY\ YHR&9@#89*F:3[IOVO NK![N(%'1XJ%[T!\S<
ML;6#+:[;Q-3$M W^<UM2O#EVPI,Y)SL64X!GEX!U2XJET$ 8#1B?46HG'2:_
MLROXD,L^1>L;+33V;F)J8NJIDEVYG]V4["8IV3EG'&T(PF@#R28'*"P'$B:!
MPXQ&^LQ\9#W4LG=A#=W%7L;S#I:3\\V,@Y-#^C:??',#B2W>V\34Q-3$U,34
MQ-3$U,2T83[2"K9OY]';%.%]&A\WGV<AGV?ODC+@8#@11E L),"44O%Y! -%
M@E)Q> 2C\ '7+0EYHS!=:O?VYD9P6J"MB:F)J8GI3HEID=%RG#N1A0\Y<H,)
MDS5!$UK27@@G.;^&3=:6P=ZLY?7SZ?[,8 +G#!G%"!)E!NB+14LR"/#,ZN23
MR"[:G5W#AD[.SQAI:Z=Z"^3&MQLAID7X=@4^<./;F^;;.4\W6Q,ER>+:9B4+
MX:*LA,O!<U)8#@FR+/M%N*W9]=:W;V]NC*^%8IN8FIB:F)J8FICZ)J:%5O-Z
M1!X9>5<L[*BS8SJ18CEP@\R[ZU3"M]6\?3+-?SU].E/=KC$Y9,4>3\(S0!$]
M4. );)$EL>0D"V%G5\CY\6T+S^%O&.\CQM?G8#>,WQ+&Y]QOZ[/-=>MVG1=1
MW.^"=!NE!Q:33U8&\LSW".0WE%_NP_[M'\^.TD"R)=9OGW_WN[U^._"0HI),
M8X@H2%AK;.16"*N4\(*=[\GX^CCXMG[[9DCJQ=S@]\0-CR0DF.Q\,42X <JI
M]N4+'70417:JKJP50R[8T,A5C8WNS7:@K^0$UDL O:N_N?YVH(6__X82W[SI
M]FVLU_9OKX/-9C+,6MAJ3B.HJ#A@,;+ ^O+#*\6*'VT$%[QCL\9BC<7N-HLY
MA04DEE &CHP$:3(<#9).B;OE6*PE=5='<;-S$3 (%1/6E8U& SJ7P7*7P#G)
M/(\^>>FZ#=P&A\+-;Z1M1->(;O.);I%0&QGC5: 0@BTFFY-DE;&,&8ID<R&Y
MJYFN;>"^'<J;L>J4S(:G*(!EDXJ/*A60#0)BT6$Z!A=S2CN[1K%">/-=Z@O7
ML32N:US7IR^^"->A8<FDK)-%BYDS0LZC"L6^TR0EKH;K&ITM1&>SN3_#%4J3
M$2(S M 2+Q9<,>B,D4Y%G@NAA9U=><G C49EC<HVFLH6\4]-08<.(GK), ?O
M,3IB@:%B1I+1S3_M![O-93V#<X%[;T#$PG%8G%7P10$!D<K62)5=+3KF0R;D
MT/*-B<2URN2>+N'>W'J1Q9*M6F>NT4?+$T,1G(_>9\49NF@]M^:\8L1<5(RX
MMH2[U]09YG*Q9%2Q_E!#D)X#:L; "LX[^O0J%>I4N+,KA!LZOG1@KU6'M4+=
M)J:E3%2='6:;C<DJ88SDG='1I!@L2\4(LE]AY+8K_>8I=S:;PIVW,103U2F1
MB[&*"(X+"]$S%R03)(SO0HN-;C<,QXUNFYB:F&Y!*QHKG+!)>%-LV4B,>*UC
MCU+RD!C/K&G%WFG%^<IUHN1M]F"*EPE8I 5><07*QZ@X#]X&U3>U>-/CT38@
M0+/^/<F;.PVC#2UI8FIBV@JO>6VK'EN>:%4VQLLYSYM0VZB4!LR9 [* 0!05
MY!B=5"[9)&U-$ZVN6+NQ02/M)J8FIDT3TZWZWDVW;H!NG?/?%2N"%]D4E4H*
M4'L$K^O*9=*"BM4E?$[]4ZYW8:O32K<L;VX\L85]FYB:F+;!^VX+(#?'4OAK
MS@L7,20KI 7C3 0TK)@,04?@+'G'R/ADZAPJ-K1J?D)LHX5^TT)C[R:F)J9M
M<,.;DMTD)3OGC@MO18A6@#$L _*(0-YR<)Q8U*2U%[J'6O8N+!Q;^9;E+8PS
M]J$=X<H]B=?<(=%Z$J[!7:\>S,^'*\ZA)NXA)=3%0:C#E(1"0.$L41 F!;&S
M:]V0VZ6+@5IF82,LSR:FOA#S+;<D7'-W;3,GEZ/DV9@-TT6XRBD(C%O *!"<
ML1H<<L-#()6YJ,D=+?N4W&E0;XS<Q-3$U%/%>:-="TUQWHPO,QN'\;(80DX2
MR&P-(%<>K$RF_,@^HK<9O>J?YKP+91%+[7W?W)AR"_TW,34Q-3'=*3$M,L\P
M"^-D"-:C<)@UD9)D'$F4(?$0U37,LK:'^&;MKL=S\UM]4DP'[T ;5<PN5U>^
M^UPDEJWU2ACM+>[L&COD=IDUQ W(C6^;F);CVQ6XP8UO;YIOY_>^%]_3<E+@
M!3) JJ4&DC/P5MC"L1%ESOTBW-:\?^M[WS<WS->BL4U,34Q-3$U,34Q]$],B
MQG?BSOF,46593#1KG:TSS[.0&9WV2-]N?+>=T+=BFC^9W_ON$B%: H%"%<L<
M)3BK&!A!/FB3M4.SLZM7L/JA0;R/$%^??]T@?DL0G_.^H\0D;0J@?:WV%\X7
MC*.%F(10UGH3O.T/QF\HN]R'K>_/TLEI>NW3>+G5[^<WX'SCQ#2D<%^6VQ^/
MSPK&/FR=N-N[X5VRL=:A&F4Y>B]]%$8+)X/F,65ASO>W?+TMH.V&OQDFVYNK
M_<_,2RVU!U2!"I%E"3[J6OM/.7K-RX\TW0V/T@V+9EM1[]+JD+7NM59?22S<
M,H7TKLKG^GNO5G^#-I1;+UF,]4W$VM;/KX,P9Q+=QJ,1,7((P;KBW24.+G,'
MUI"2+F:'2JYD_7PCRD:4C2B_MO?9YNP,64&<H\N,C-8>8Q24O&#2+4.4+7V]
M.A:=[6\*RJ%FY$%'80$Y#^"%+">>1'F M%!1=QONG1UJLZI%6(U+&Y?>,2Y=
M:+$T)E^8-!92#>@-4>#&NV)P<L>R1'\UF2ZP6+JQZ@I9=<8VI>PRY>+,U_!C
ML4UC!H<Y@;8!LQ31,)9W=JVP0[RDDW_AHJ!&IXU.&YU>W:>O@]-6%;Y4B-DF
M9U &@:$8J"QA#BNAT\:8"S'F;*[6Z&0BRP9\, Q0N@P^&0TBRAIQX8J1V-F5
M;MX";6S9V+*QY>HBGMI(5@P4DXAAR-:)P*R1SC#2TKHOD&4S.6\T'#J;">=<
M>:&9 JM5*)Y\,3Q=$ 2*.)(*4EJ2.[M.NZ';HIAHEU'_YVFMM[@HQ/ZDW/R3
M]PJI'/+Q.?YV_^7'_]S]O'[[CK]L#934O>/].BYS%+Y,4J*2U/.#-*!0Y_33
MT;NZ2>_H^+1\'HW+PT>#4;G6EV,Z')S0^+0NV3L]2)-4F(S.XNBT&_!?NPBF
MH_Z/NH-&]>$\.J*C,"HOG)R6![K"_7M7WIWS"T)QSZCR-4Z.)]W<SOOC=$BG
MHS?IN[]'\?3@@E4_>>$Y!-C'EY O%W%V^O^S]^9-;21+^^A74?#^XO[.B5 Q
MM2^>$T0P8/LP=R3&-AY?^,=1JQ'6PBL)V_#I;U9+8I$ @Q'00$W$, PM=5=7
M53[YY%*95W_E 5?BVGGG<^<8SOW,HZW0V 9I--:)&IHX \O6><D84S$Y$@R.
MGZE8F7UI?WAVVN-+1&X8[5=D$[S@*]O];H]'*[]=F(=>IX_FYGU^RJZ<F)3N
M;6(F0 3J:3"LBKN^ OB+P_PI&).MS5@:^\.LM__GYTND0,0R3F;AV<@JOSK"
M8M<N6_[SRV.'7V"%*@BG%QG@ VW;A52C:MNN__77]MO7[=>-G?^^?K_^]^N/
M.UL;'YJ-K?;&U>)=E[%OG&+5QGFL^G"*4-4:V=%^XTUW\'U4A_>Y)9C_Z^,,
MF/_]%$>_U0?],CB"NX;1Z0M4+.,,\"MF V/LVL-1?#7[Y??0&1UV[?&K3K^Z
M;_6EWZ="--42&>+F4_;R7$PNGZ'?*IX@X#1C</KDZ>75ZM(<4YM<4P"C[.K+
M>)5<>>VZVQ*R*HGYI=M>?TW<TV#IS0;TDZS,GV9:FX6/7F(M3W;XPUB%YD:Y
MFFWX2Z,%']L?-5X#'H6+.9L7;(&[3M$Y+\=5%L%U2:[UFSPP@NF5":VW>=L7
M-67D-INJWB7/;_;.E0Y/68<WTG#0:PP.8V9P8-QDN_M;=2S@U4WVT55SL9P-
M]LN'3)8_PB==@&U^4]RN_MJ=RV'4[45O[9"M@TOU9J]VJZ.&6MN07#0B2FZ#
MM59[PVG21'DNV>0<$L5D<@Z)WB(0]?=PD#KCIU/DH_UAZEP]^"KV-OWQ+MWK
MM'I[G?;F.]':V16[!_L'[9.O#/[ENY_^^;J]><ZY>K#_=>_@'QC7%[R]^7Y_
M>_,=;YV\[[3>OLO//&[MP'</_MR'47;FG:O;;]_WVI]VC_-WVF]?\_;FEY/V
MVZWO>YOY_;9^;+^%]^N]/FG1/]-IGND'?+*]V<*M[Y^I]BHJ[)"2RB"N D;.
MV0 _!,9!P\I:#OJ-J:;2XK%J?#Q*B*E 4GU>[7:GGS65BEA!(N4A<$VXT3XZ
MX8-0.J;IT4AR^Z.1!9+N!9).YB#))"Z#]P)9JB/BC$5D@K8H..YXX-3CI%;6
M8)6;A*EZ0-*SHON7B^"YUF&-\: QC"!TOM.-C?Z4\N6_YM]]M@N.L@.PTU^^
M45 7ZG^?!'^B;.@J%?7>$O7I0?V8L_"P;'DN$R$?9/UCOE=?T4[+TDZG1PK.
MM!.60G+#/;*1:<1USN8*V*-@$[.!I) "6UF3LLG$XLG\ARQQ>2^DN8CR\EAF
M$>4'%N5YHLFH#LK;A "')>*$Y<J6P2/&@R%<">OS,4NAP?1=5E91C<CF4V$9
MF_$0R&:G$H>&[8>&[0U@<">_3C7N5"+HJ>#3LJG&^64HJ+0T5.HL$ RE7**>
M)204X8!*F")C*4=!81F=TMHH#N8O:5*Z:/T^9!F_7R,8CU[CZZD(\+()1A'@
M>Q+@!5K!:0P^,I2(%H@;H9"6S"(9%5@(BF,O"5@(34H>MSO4'5G%T_9=Y$#E
M>2+QF_5^&"NA'/3/5<)NC$YKW!6WQH,' ;=.UV%2A!!6;?W<HFVGS<[(PW2/
MU_OA[V'L=8YZ!=J6!FV+T4)M):,Q"@2J*2+020Y99C52V!LG8]2.YVAA4['%
M6&'Q?3P;>;^W"%N1]\>5]WDJXV-2-D6.!',$<44)<LDZE*)PABGGN <J(YI,
MDAK)^PMSD+0'?50%W8:9K\0?V7D8BV/DH1PCV[,0YU_1CN+KR?075%H6*FUO
M++ 0EVCR,A*D4DX0D(0B1[5$Q'!@((22(%5F(<2P&AE8Q4%2.Q92!/EA!7F>
M7NC .3%@/V >/>)8@3F!N4$.:VF),SHPDP59TN(I>;PLCQR8S(?VJB2?*M4_
M5D4/&KTXWA^$<\Z2XB%Y, ^)[78'K\XZ,[R!9=D8C,:M:DG.S*@"7TN#K\54
M$(L9YQXSQ+C4B%.9D,Z9(9AI[:P.@6"YLL::1BRKHGGQAM10MI?N#2FR_?"R
M/4]-8/DBQ5FBM9&(^X214\PCC:/W -Z$VE 5CY6+G4^+Y^.!I'1CW_:_P-TN
M)AJ/1G$\JC)%NAWK.MV2='SC_4;%I$A)C=?\[V$\M)TP\W--%GJ0FU8U_-&P
M<H%-=L#+(J,/?&AOWFWOA]EFWHR3_V[UIZNT&5.$-0E38WJ]'ZKV8NO5 A7]
MM;1#-*<%TZJJDR?MS=9GHQ3! !M(RYR%H*4"L]HR)'.<SIOD:?+9MM9DT77_
ME(_U%3&_-P=9$?,:B/GQ13$G2D8NC$))$(>X,<!8O:4(<\*<M48%'RI?N%CT
MA3_EHW)/A:Y4@M#H#OI?T#@.>W?A)D_6J5\S;E(M27O0G]+%@E++1JFM!3(B
M$Q86.XM(2!%Q 8:T,1CG$[XJ8&Z3\S%[RNB=R$@)UM58KN^?C%PAUT5T;R>Z
M<P2#"4Y("!@Q&SCBP"B0YDXAS@1.E#D,Z[FR9DQ-!/>%>4/6?94.-VH<VN-<
MC?%E.3WJQ2MF:_'W9"D*HU@>++46&86EP4OC47"YN1ME&!F2'(I)<*DE2U96
MS=U@'6ODGR\^CMK%WHI4/Z94SY$- X: -UX!V9 XGWT$$X$8BK!S! P%);RS
M6:JINO/1Q^+2N /G&![%<$G@Y5R\K7@X'N.TU"7@E9?JK[-UF?EFSY(=SZX5
M;%L>MKU;8"S<,>.D!UAS+B%NG$"@K@12VDB+G>;)YK)F3:;OT@BL^$!>.%DI
M\OY8\CX?F<%)$BLM,E6C5"$9,EHP9!FQ*@89%4_Y&#BG=[90BO_DUXO+3"*7
MC6'\%OM'Q7_RB/Z3W+@GC^139[R_<32"68G#&5K5IPOITX"CCPOTPQ(@(-)$
M9 2L$0?\0=JEA+25R9#(I71 /WBMTAF+NZ1^49@;VQX_$>="/98HZW/4PP69
ME#(4$2& >BCID69$(N6(( R6&D>_LL9T4UY20JIDA3Q\5DAQG-3,<3(72RY&
MT[T@U^X"2]&>,,%91(KE7NG.<&0 S9#U$2OK*-A4.*>S8;-X(K0X2>HJY?5R
MDA39?B#9GF,EWA(:J&,H>$D1YYHCRS&0%&L%MTPZK^15LOT\'"),U9N6M&_2
MON$N+I*;M?M[&J!6#^H"2Y8;\?T]''SKA!C^./X(2P<8-UNX]=-U*^"V/'#S
MB_DH)->A210Q31CBU#GD@N)(F42ED$+K7"F+"-WD= F9^#?NF_E4_"XO%AGN
MS2-3D.&1D&&.]@@5%(E$(46P0CPY@9S'&B5,1-#"419RW)>9)E.+SM>:(<.S
M:G1UL[ZVD_(VI:_MO?>U?2I5!_X^&OI]FX^>#U+C<)@Y\OBXRH;*=9$.7UXA
MI$<]W_6W/:Z:TNT,UCU,_S#^/5V1O[NVJA/[>K8H1<TM3\U]72# C+OD""@W
M[J@#-:<ILM(&1*5-3A)!= CYB!<WB\60RGGS9R':RW;=%=%^)-&>9[".6AP$
M1UYHCW*-562CDD@JYKA2Q"D.MBW%36"X]9#M%U8':<9(,B$9Y::<V7>WU"*-
M+R+T<._4Y'6U)/-UW.;L[]3Y$0,ZB<-! :[; -?!^@(G(;"6.#*#-!:YDW1.
MN78D(4.EM)HSH@U?6?M__D=30G^O4<RA!!6?'#6YD6@78G)'^9XG)I0H$E5"
MB>6<1DP\ O'F*+K(E&8I:<:RT[UI6$W.5+PT5\EP ',7IIXTD(-I*ZU,5,X8
MR0LKU?>HE&2Z(+FF;.MT.:HR7A-  ZMJPW:[H^VT_LUVNOG(ZYO!\ / U(?3
M1F@%U)8':HN%^Y+$)$E-D-(Z(4Z%0?GD&/(V>FE]8E3G%"B)FTR5NM+/6/:7
MSEF*[-=.]N<(C626$>8CBIP#H3$Q(2UL[OVK.,4LQDCURIKDHJD%KY'LOV!_
MRUUIS,NPO^[=M5)LKGN!J,52?DH:HW!42 GN$;<X(!N#0T%[FS27T519G!CH
M":F)T57<*4_.G5+$^;[$>=Z%$HU,*D@DF)*(,T.1K4I3).YBHBR)*%;6N.)-
MC9]AB;\GDY%].$WC:[CC2S.22E;VXSM7KLBXW)HM5\FXO ],6ZP-*!0-#C8V
M\H19Q+WC"/9^0+D=@B/2IXASUV+9%/+.)TU*/O;SPH1E,YN""8^$"?.'SZCW
MV&F%*)4&\=S4RW&6S1;JE-98"Y+[>3'>Y%@\"5!X@:G8J=.W?5]2L4LJ]J7Q
MQ<YH= 3[HW++^4&O-^A/LZ&.#N'7^",.?>=\DM3@, MWB3X^2O1Q:[I8VZEJ
M,#SZV(=]O@5_Z(-DYQ9"U9__L* N-P:]W%?(YO'FU,\1?*Q[E.?]0U['[<DR
M%A5Y*Q6Y6"'*2RVMB#HG;T?$#<=(.]"3"2?I5&(N:;ZRQOGB\<42='PV(G^?
M0<=[$/E"F9>(!W.4V4HA8U *$96;]OAHD#'1(V:DX$HXAG/G#]V$_]0($5Y:
M*/*&#"B+6F.\'QNQ=]@=',<XO7 X"V4>@I2]K !F79A0A6@5R!4\6QZ>+=:6
M4H%'Q5E"+(0<N:0":4\#PM%1R9D/BM%<?X;+Q4!'R05_-J)\GPRGB/(]B?(<
M-:$<R(?B%D4M ^* O,A%X">!L1@2UA;6+1\VE>3.?4)*X')Y@<O+_'<E</GX
M;.2*(,6;V7*5(,5]P-IB$2FGL)!>>X"UW#(@>8:<"0+9Y&5,T@O#;68H!B_+
MXBIQRV<""0\4MRR0<-^0,)\1#FMH?;)()6(05P )!H< /W"D3% *EU?6"&E*
M?F>KI80ME\A]]FW_2\SG\#,+:DZX4#Z2_PW$(3=LS?6"AG$T'G;\&-A1OGX7
M]\MSPKUZ5-;,\)?_?7VV:.]/URM?6.^'BW\X]\F_X<7S0>#YVL-3)_;K'Y/]
M\=Z.X^N4HB\53):(HE\6B%70.JDH(L(DYM!6T$@321"A1.HH;10>4-3HIA%W
M:8AP*UE\0@ZAYP0NCTFJ"J0\84B9(V8I@+91*B(EO$)< II8PS@8;%:"V&AE
M<W1,-J5:5GNWFO&RRYU3=>9E&S=F8HUI39B&BU\Z_7[V6.5:CY4$EG2AJ^#2
M>TQ,B,P+SJW%&O P.*(-D8H:HCYO990DE)%[1,D">LL#O<4BCX3AJ$V** H#
MUBBL+S*2<B142(9@9V( T".:-24NC>2>KZB[F&*,4@$U4MQ[JY,'LTO8%(7,
M[4XK4<=%U)^2J,_Q&R"\FB=,D?1)YQ"; I-)<^0I$=@2ZAC-9<L-;6I\9X93
MO_R?9\9C(ER[DL'<H_E7MZG[/_?T[L\%V+4@^9"<$U08KH#&.2)CB$ZJJ(,S
MH@+V&T04"[#7 ]A/%HMB8L*BM)PCZ5*8MM@+G" G(\?46:VQ6%G3O"GYG<M+
M/26'6$'!@H)3%#12@6FCL(H6<Z _AGJL%3,*6\FT\1-+MJ#@4T+!^>1VAR7Q
MB2%L0T( ? " 3#BD@/6*( A<SN=!C6GRXL"KRWG0]J"/*EJ[O)X\BS%O!O,?
M!D>N&Y=P$O2F#H5[&.(+,(3>Y]_1(*&C46S8T2B.&P,WMO"YJGMEG(9$,I V
MNCE:<MIH^_@N^9_/4\<_2TV^]%3):LMMIX^CN)[WV_9TNVWU9_&W-X/A:8N]
MO_*>F_47/BX*?7D*?;$N'2PK\8PQT.4:S!J9)%@TAB"EF#)"FY@8F#6,--ES
M/-Y1X.MYPM>R,Q"6!E^E2\FO(]><*:*=CE39A*2T-#<(!>1B@:!$&99:&:[J
MV:7D!1@<'XX.#[LQEZ&TW4;HC'QW,#H:QCN9&G6Q)^[3:'@JIZ>K D.'%LSP
M;"+8'KS9> 2F0\ZIFM@0^<AT#W 05CUO@QQ$N6A)7'*$J2CCIZ.,:U'%&I1N
MUK4P8QN#T7BT,>CU.J-1KG"QW@\[L6_[XZU>/D@72T7<):OCQ6/BP4<=!",H
M *%"7 6'3 Y\*T&4,99CYV65V'=)G;BG7-ZZH-8S1:W[*M9=4.LQ46O.B(@V
M>2L40TKFHZ/4<N0P-8A)'#EE'+057EGC32QJ4I3_A54JK)CF,/K8^18OLLUA
M[-J<KS,>-,:5T#0Z9U+3L-WNX'LNZ7-SEGG3!,2Z3='-\?JR-ZPU7M>$9)XO
M53(!Z/79]BH ?"L 7CR[SPAFG*B$L*39BZ,]TD109)B,G$1AJ'8K:XPNJ[AP
MC=*B"Q(]3R2Z1^)X+1(5GKA$F)KCB0I;1YBRR%B;P+K%$NED&,()*Q65 O#*
M+7.;A"RKG,#2R.)OX]R1$/X;.M_6_@,_9H_NV>&73G^25T,O(DNN+1J'RQ8U
M@F>R5MWQ56<,3_/72Q_-TK>S'QO6^T$/1G.<TU?Z@S$\SP[AS_U&!\;Z96B[
MC4,[K#R-X_TXBB"B]BATJI3N03_$_FCR6Y4^5#'':5DE^.)H#'^H9&SU=)GF
M9VLZ($Y75>;,AX-1)Z_NJXJ' CO]_7LGC/=G<''NBY,E>87/OF(=#.)H?/57
M'G EKIUW<7$VSO_,HZV0Q 9I--:)&IHX2](Y+QEC*B9'@L'Q<VZ]./W2_G#V
M!H?V2T1N&.U79!.\X"O;_6Z/1RN_7=RAL#WGYGU^RJZ<F)3N;6(FD@+0.AA6
ME79?565"\Z=@3+8V8VGL#[-"^I^?+Y$"$<L@D85G(^NRJBNC7;ML^>L!(%>%
MGZIMN_[77]MO7[=?-W;^^_K]^M^O/^YL;7QH-K;:&U>+=UW&WJZ0#8S:C5/0
MVC@/6F].0>O#*6@MOM3-)).1E9^LJLY(-U%$*+/-5XRLGGH,.GF XU=H\K='
MFB^R.E&OO_9S2NO:1SUXNE^"13E7#2JW"X[;:9H:4)7>?DSZ==(ZI5]O.GM
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M)*-:<& :'MB$:AJMBA0_7RFF7C-'B**<8$Z,TE%+JPR&7Q07^*KN=D4//[0
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MD+\&_2_+42!/Q.9XEO=X\5G;#ZU VH.^+SIDV3JDM:!#N+01.ZT0]RX@3H5
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MUF!D R4 BBDBYZ)'VN.((W!"(_-A J"#B[D MT[N*9!8(+%.+UX#1"Q^S <
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M/6<ZW?!7@F^5)UOE_6CVX/&OS_;WGNS >CXF&K"7G54'G-_9G,#O)V8,[S7
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MAL/;,GH9GP[#"%O?)IU^,!@"2^XE_&5VZI?= :39A=_V)@C3>EV3F/+0P2[
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M"S(6!<F7HKI-<"7[55C9*/5K$&MW/O7NHMOK@<Z"AWS, *B!0RU4=R4F^A&
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M/]T8#P;$>TU!:S>VS;33?=NY=K_;^SKGL[B7G;T"52X!R!4[ONP4NX_]_AZ
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M\VDG_EFO[!49TP\\3O^RU?&WZ>6=<6ZK*1N6=&.U\YS?\Z/I3=)NF^RDF\L
M3!V^:\3K\RFMRN1);;O@&;N=W[J?ZDE6,^03/G5'L[$_2';-=0MYK;N=URO4
MY*A5$)]2W4/*G<]/@(=]-,-N.OZYITX/[&Y/@]_H-#I?Y^$W3QAJL3^F/.%
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MX;?8=OA]&&NYQPZ_UT9Y%Z/8,G(O2\V9!V%#@RUC&549O8LFB! ?8D?@C$U
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M#7&.4^AH&KG$MJ,D=:4X'X5?FA_^!;KVO&<N?^GVTQ+31?^JR;@.=V)\[V/
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M8?K?9MA-Z0,;>2(WJ.;XL8LV[MR=UIQ'2RIM!<_-!<]R>96/H=*5=L1S6Q"
M4(*86%;$:F,K&;00F,Y6L@VAU?VGVOYTO'7GWILM;WTA;RWZ9QQ5CFH;B?6:
M$UD:0]!:(87E@I6L,H6GCYY*N:%*W_+6]^<R6,%;6S1]9XRWZ#%P-N L1TN"
MXX"FJ=1$AX+A+&6M%=5%U!P=HW)3-+UEO>_/DMVJM2_DKD5;E5:BHJ#(2*6,
M!EM5%D0+)0FMG%:A,HXRX"X E=O>(P^D@#>7[K:R[[]A-LW/7 3W5;?FA]$
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MI[4W7>Z01OT28PEQ:-N=V0#)2E5@5E5 7:TJ<(?$;O%F)47P<J0(EE5AY-K
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M5/,=B]#<R^[8(]C=="BGE*1;1:NOPL53P,7D8\(L::1]/J85"4=.)(X,53J
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MHD)Q$RPL:1Z6M%R%51CI=5UHDXRKV)6)_D I:C?.[4EP8!P7&-E.C@K0%Z8
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MN'OQ)3Y_--C-'LS"$3,.AH1,( IQ9QDR,F@4%4D^J61P,F\VJ%QG5U5R?,9
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MB/\>P5\[<!M@]@?=BC%:H%@P F<(:%W>T(#KVJ%M^V=Y 5C0QKF/&O]J]_X
M"G7<^,?__.\_&[^WC]O#'*;;Z38V3_KM3H.,:T;-__1__G>J+=#VW^NV;T[:
M#BU<^,23ZHE_?/SUG]#OZVL7SYW:CA@6W?C\BVLV)A94MIJ,Y%3MH+S_E'ES
M]TX.G.%>4N6231J\>T^L% %'ED* N:VLN^F<P9PG5\^/=_W>\;AN[&>PIE]'
M V"6L?_V6^:]\/Z;@T'>, N[]MOS\-I^^*)RO@UM^W3>VCK@L+"<@0>GK#$^
M2H%@]?#Y% %!%GQ[)(,3D28?O?5O-O!#.OA> O/BP1F%%4\.ZX #X<PZAVT*
M6-^4R;>RCQ]D'^>9=&AIO64*\2+0JX1&AH: 6$S ]IS!*I%L'_/))!/[ $SU
ME]:[?C5>DWW^=O9A)^&8RQ&![\0V\L#81B+&-G(5DDKY#)6Q0H9@E;3)!JS<
M3>G]*]M]+-MM'>W1?<-,PM%8I*0,8*T6(^.909P()HP %S#1!T:S*(D$<IMP
MP. %46<%4<($[)3W*=5H=DT2W<HB'L\B_/D^]]1GL37D:&0EL1@Y837B4<%J
M(SBEC+W98'I]P9;L%2'*.^+970KG/06O?U<GSCP(<2RAVR<FBSZ7O#S;254Z
M52GQMYH@MUCN<XPA)!-(U!Q99BWBTCB4DUS@7Y0I+9)@1F< 94M-!U<6<%N(
M//]*]P5U.&IF$6$1(YZSA:V,"05'#0Y&FJ+"B]?GS[9=@Y#=.(1A'@P+*L!H
MY#V;B[S.O)TS&.<USCOON90B_#",*N,I^S2+R\:4PK?=DI)W?QQ;0!(+COTX
M7K@@.^L65KR$J7@_VH!W=@].]SD8KC5$(DHC@)8R&@'[DD@0Z/R(?70JW.U@
MQ/=QNM5H?M=H"A6XDAQI"PL/%\#AG8V 20P;"SW-4JZXO3"M<AZ@O@>&UANW
M8F[/+?;\9SZ;8:<#CLM]SN!RW)GH:^/.@_'+E7#SOV*GXWN-7^ND[M]__[7Q
MC^JS?Y9\\:LS</^=AK,RW)$%IE2$E9%SZ:)6S@?'F G)8V<*PA,-3<Z8D/]P
M.3]ELO65CTK\O-F/=B?MI 0V]SR2:G_\_M=;TCK8-Y1A;<%IPTH -\$A[WZ1
MA BUVG,K(D_\S099HV8!(QW\>Y1S(U($$(!)WBO=W0 ;]OEL0N/WWJ"Q"4Y:
M)P[6P$8Z;1B';ML6R["-ZW8^A5":PFHOG,P:*WFE@"4H"A6U$+A*41J;P.5U
MX'=PV7O]G9.87<?NP>_95G<!A7;2V-=?X@+V/]X_^22:I_L:QAD+B5$5AY0&
MW!%M&$I,!>R98I2Z-QL5[<M%[&=W*@O,S^W- /6;@8?-\'=[D#.%MKM^/>_1
MP.]#/MI4G?T (QFVAYVXEK$FYIKB5891SW7:![9*Q;E86B9 E/J]XP5 5([A
MM&!)&N^GU23T L" !(/!5;P5L.VW$9#9FK"*^I33]+5@9OG2M49,J6+BV<9_
M&W7.QJYZ#[CPW[':_^I"/[FS1CFN60A\P<M+,P1FS%WPD6 ?8&8Z[P+EF%.G
M=63&"P/T"R:#F'7DU>WQ\;5"X"7WO,G!/?<*YH'T$<DH#>+,>:1%UNHU.>57
M0)\']F9#,74M&%;6,WL,+7Z+?E3LQA_:-D 06,4F$*9BO"$>]$?P07-]:WVM
M\6[SUS]A&F0O;=@?#88QCDG4Q;6-=X4,-';S!6MU3ENVF'ZO,[A^ZN76#8M>
M7G7H"NX]RL1L,  @+P+\ **^77:$QSF!4V[;5&I@B<5=WCR^F#%W"5)(S827
MPG,<.=<Q&C!V(Z2UG--$N+]MSO)EY/^87V\G?1K$',Q])JFF3Y )(UH?P,G3
M A9=C_*Y)\0#E\AF =L@"*'4AVCEW9R\QQG222[Q:C"O&4Q8MV$Q=PX1KSC@
M6(K($,V09HZ"VR<"JW:=YW<5KSBS?M_@(TT8>+R7.!!X$\X=49B:J*R68&9.
MW#;9?&4$=S("?PJ+F63<. <^?C[+!+P.!V0)CD@(DS V6E!F[C2C'V<P5R!]
M^R%-X Y;K#P*&9]Y M)N(_!UG,!Q]BIB7F4+S#MK-\WKX3T./\YD$MPVFK,T
MD1IP"0>C3DGWG\1JEEP48KM;.2HW!VHJ$8'!;(;@[FFO\1'&J[]6A6LF?_]G
M3A5,P$L;%MR"3L7^RD\6:2K\ 2/?#F4O <SCU\-V3%E?HR:XE6/17UOXTXO+
M?LT\>,QLW5BE87*BI-(DL),/QE>.WWA*/.%OVV_W1H,&]*\]@)ZUG;6&A][+
MNB;3VQEK,[6EUO+1N]ZH6VP@/VWJ6,FX Q?),.20YR ?",EGF$*):$RNK]L4
M+FU77PQ"/B!SIQ64\RBE =^/!FX,@_]IE?7DHU"!B1M5A1=LWUWDA*^V[JY&
MW'S_TWUL72(Q.<0LQ3DI7"!-K$ L:B<!5A0)#YV_IW"0"9QZ[(7B 7,;?8#E
M6C/LG8OFQDJLJQ&_[XAOG[8V]X54RADFD=<AP!I+%;*,"V0BUDD9Q9QQUV_7
M3K12[I7R<3D[[P>C#2,D61IQ<-IQGP^@.*R"XHJ%B"4C]\B_6]G>K6P/GG&P
MKZ,$"],6):&SY FQ0-F31,PQ)ZEDBA)V0S;H7=&&)6F(%T @H^4V9YP*8X'#
M.Z9R8I>]1W[=:L3O'GT4S<U]ZSFE GNDG8HP^I'E*O4"@8?%A?,N&5F2@ZY.
MI?L.Y+F>S5][=G4Y\NP6GY&Z^<P34.K-T<%H,+R95/L+AV&&5E?QUO7&'Z/^
M8&2[$Y6S1;^8;(S4V'VAZS9!]?$PUNU8FSJR#+YSGDZQG,7>ZJ]/AX2+#%QU
M2KDTJS<:-CKY#$N]"5$]L#0F%(FQ0K"[MG,V@&6CO$AM U>IM+G1 #I^ -Q\
M_*=&X=+QH#I(=-++ASLS?^Z=9'6P##PY)Z ^,IW:^1 Y\'A;G[]I^\:OFQ\;
MN] %G4X1T[$G9W6SSNH#ZK9JT9C]SU\^:4JM*C8>O6-[5O5ZV0S*0P&]7>>4
MUCT\B)-.OSSR6;!L/$YW@5.1@+IY[&'M=%QXJ5G"-(#+#HX[XT[.P.ELL&0J
MM:5LU%QQ@+.9YW/G[ ];-/ &V]U-8 :V?TNH?74;/4< L:?[TD05HM;(6Z5R
MJK)"+D:/E$G$>\\U9R*G*J\)O6"S.Y_J+S!:!%NJ[LXUAF  ?)Y1OUG G?Y9
MI0IUUT68ZP3P[KP!.X%V:*TQ2Q28&)=.BNAO+T.WLIJ'LYJOYSL?]KW L"2+
MB 03#'$./H%A+B*=1+(I*C"=]&:#XS4 R.^R&GIIV[ "K\Z@MY9C<Y6VY\#W
M8PWD\&4-3D6U$V[2&:\,-FM@V-,<3<G/A/\_SA&.QN@D@_J51@G##I1@5DJ(
M.4N5#Y&*P*DE0$)TX. !:6%(U+)*RL&Z3LK!^C*:T=M8Y;1^S!^QGQ4I[,'%
MKC2BK\WNSC<S6CG-8HB*(DN]S 4E'7*,">0 IC3 1%*YH*3$<S;WG^.5TA[
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MH^HR^6*"TXO1]A*<7F%0%(^72\YUX!2_ R=XHIS<K\2'WS6,Q%M6A1&'K25
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MDZ>$$:F^*E2OWL<1.O)Y"%%%-A[/X22/)1$;?+QZ_^__Z^+D] 66TQ$8*U^
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ME[B!T$<+J0L/;KA46?I+F#+F9_2D3*J(.3,.XCY-"@FM1I7Y8Y6[72/@9F5
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M*NZ,.5?&W6#4I0/GX.0VZ+C6,"65XUTM?1K[6_BYGT8(6,+3&:8%=BM"+]A
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M]S;K:[RM'!^TM!X4HFC7?&NG<E,F[72*["Z!&V3DX6T@+>53L\<4 %CC1_%
M:K:CJ4V=,G$AJ5#9\K-.<T0Z[M?+8>T>:NW,4L5%OEQR3P]Q\&B!AIE_J)FW
M+"/M3K"M/G@,UV_V)#5MT 1B3S"WBD9"?J"M4].>M\-R/M1R.D5D7N<:Q[9!
MOP+-&+*3.)J@<%Z,LTC"54"9^"\,L3A6$X<!AC5\C#4D3AN"Q((30NS=!;&
M<6@]ZH9@470&>2>I1X^+*]>%QA7U2P@X&#6LZ4.M*5/HE%47DFI-/3(#FZ^)
M EBZ'U--JX9PA@5[L$VX^2+QKUA32MR8H'5,(TN)KD:+4[]FCB$*DS0F[(O;
M6:>4'<OH]K[B\/90L9D?C"^W"7)//R#%1;08=OOCN:L$K4PFW"YSN<2<IF9F
M)0UK@K5%=&MA+W1Q"B99J'ZI\7_'*_M7#^UB(#!Y88 RG@% +=L3](TQ_^.^
MS\OA:!=)\Q(B7@6A(TR6LO";(B?;T((^_"::3#!,0NT?!T%[<)_7BV:$%A;.
M6#;Z43%OHF4P)4CMRO^&3*"%I P,DJID<11I6J\!'5JU+F7$Z22WOVCN-@!$
M>H_KG(;5DCY\(09NG+9\X)K$^9>*X\X52V%MH_DX>'^<++ ;C7+(=K994'24
MS*\X<W%23HITC#41XURH[&SAG7M N%5WV<I?NF877@FL.!1)'C##?6RKTYMS
MA(%IQ 2AI8AFE!;-KK0&["[=+!LTK9$0V6-'$HKOM"H=G7GI$V3EG,!882=9
MN\8)J2),RTU<+AC2P_HFQP<S#)U.+XZ$-EE:$E9'J8WY>_O][=(-,L:!$"'"
M@&T-B+=B-" N0#%#$+)+NQ:V02F' ;K(:R(1%[B<Z5[[9X?#:#QR!?<0[">^
MH\KS@[0E<H9*LDYG)E>V+H1ZT5U;"L NE.36J7AUUWDH6' +%HZ&@H7M&,MC
M,PU^(X%SZUJOYE[.5*P8AP6\Q.8!B="&8F.;N%0Z5/:@G'TM30#0'6;GIDHF
M'J*0B I8[SCP&F0FT#R1Z>7.S&$.[1G2I+F5ZMTG4W]K^EZ26M/SK4D!PCU8
M;/=1 RC:O:K9-Y;ZGK]7N;,MV;DEP2ZEC9\>+%VD%B6J]OF<^I]<^PLCD6N_
MX-A9(H8L;L3FO%E%_195V_XD6<V-"7ZE_8* ?9'6CIJZZ2_(]H@FD=B:0O;.
MQQ4+*#;20#$HO1:*$K",,.E:.JT-D01?38M&VP@V];G3>;,\]I<\2^!Y<Z(Z
M9T[T[C&8YHD.OH9[!WEI0&*=5PI^.PXW*#-.I #7BIEZ(I;KWE!8I)G]>C#J
M9NFTLG^<Y=2W!1G^869!.*E@UT+ZN(88R4M257W:D(Z&8/N V89=SN1)XY<&
MA;R_)ZQY5WM]-$C?T@Z28F6QH;1>F?[ITZ%U5K93?R/G?;\E.5BP,:J]CGW&
M[>VT?==$Z$!D0:U!V=<P7KA 0T*RNW3DXZ@T,\@,JF)#.M+ #C)KGV;+PS<H
MWX3H8 *)R@P*^QXD\Z5(L+EQ0[)_+;C6M@)T-% 56[/W0:D-]8P@HZD-LRR]
MZO'0F53*#^ 2VYNN$GCE0?!KJ=QU\,/"?)?7CX\V-R8 EK-5"1=H)WNSM6*0
M@;2LN+W4DV&3)-?!\C<8V<"]Q*1]GJ[H)7.HNYO2!X@ENG$[SXP3)0XUH8M;
MI IH'E1)O'/L#LJ&8;OP>=/I-+9PZ!#_'WMONMS&E64+OPKBWN]V2!%)E227
M[:K6C8Z@Z:'4;944DMR^_3,))(BT@$PX$TD:?OKOK#V=?7( *9=I$S8BNLLB
M">1PAGWVL/9:XR,J8'*HVA3,2"QH<F8U*G[*D6&0X'XP3+_/ZRM%M"=:Q [Z
MZO^].?_GE[94A'TR1*E%0@LI1TN1 N9!1H=3./Q ;B#I5(MJBL/L9L*L2X4%
M1J&G$GV:>5 !XIZB=4S'^4X[?Q6J"(M>M,@JL^+6M$QS/'6$EQ')FIPR//66
M517>*['))(E$I+@=@?&532P\HUFW(.DC[@LRG&9UU6:J]><\/QY[($EB<C,V
M+_2$I(D$T0JO"$Z8([ D&%$EP\[O,TC+]9N,@S<5# 1K[JA['Q9.>%,6Z*04
M;,O(_RNX"!6;$D<&12YKNT67G5+XQ+OU5;TS"RO\3)" '!+!8 -;^*682M52
MD=$M3WQ7G94^R949.QX)=TT_I-ZC,@L1LU_B6-$[A;.\V$K?Q-)+N8S['LEW
M1T4?Q3N!7\OK9<890=J0" #=9-V)K(22PJ<"Q2^H>]MAX"S./*QOE)RH=:2*
ML8/N\E-M\CYGI*7,Q'+F9\>)A%DZFZG-\O4>'K:G;3=(=3@:-J@BA@VVK<L3
MYOV^MU(3(L#-X,BN3PVPO]4,"(NDWPRG ;\W<&KJR4EO6]\;29JD8N',"3-*
MXE?Z5U5RC&.7T^S]1K,G&5AV.L-1D;LXD6DDT'Q[FHU[12!R_<,4FTQAQXH@
M1%N./TWHO'/'4^J-GS ^]SUQ4:;"#GW3OO6@&Z/+0=@3K)^V43B]':EM<1)@
M:5F$B22F4O"XJ/WH(#3O2DHE #B]WA,!5 *DG('"'T%N3 JDZ(*FJ]H$?Q(Q
M3H3EXYQ,&(>B:<L8L@K0+WC.>H.I0D>B:]!"%"0)H3DC' +ZRYH058[_B%FR
M#/.$#X6G='2>)$E@-9V["* V!2K3/C1H+5LDW&HQXWQL2V%,3Y8V"Z= V$N0
ML1JS=![7,E T S9?4T?YII#\&*F\X6\Y26]-30%+(I=M8J.%>9]HW'%96:'T
MV?V6(7FQO)5*24%?)J<25+*@D.;:8$1X6=5;89*6+)ED:9VH'HA=4)<*GTP_
MEXME8(QZ0F-!Q:-EO^0.=$^5ODGX$$%4EZ5/,J4.7=Q LCE&4T*2+25%",RE
MHP0'4M9_+SY1BL?N#W,_.Y@(@]!*&,M,T0K(!TXJ'N^8MLNSYV&[G+>CKZAM
M) ;22DHGG(9>%1M5@4_RW%?T&4T!SO?S=;U%)7<5GG_!H,1E^"P!X2K1THV,
M[^.I7<DS<IDLRJT3B$1IDA$0\+UI32SK)GG\OHB"EDK!!-\4@,<R/;V[I'M,
ME@.+Z&Q3CR:8-A=?+T<%#BS'+][QD,I0D+?^;E$B8B+5K87NV^I9)_'=!!+W
MR0D2]S">Y=XA<1/V]3_^[V7SE_^8W!0/Q"J_"OX[JD69'?$3SGLP7,R"17@"
M5!%AFRBZ8Y1+O=F03TPF<5/L5L#9D6F$%72.7N::>%,\#=7F%C655,P05[ S
M[%?@\8*A!=9".@UCU=!.@>2P"(]4AU.A(F26.KW9+'PF^ /;NBS@3[&8#[#>
MZ'84'1<J$L/^M<-BI5/_H<N%-;?2ECHQFX>-92)H/ADOL5/5L) >BEI40 60
MA)QXIY<CY:TFXCD0Y+5"RG4(#\,U.T:Y0=J7]8$BQF@Y,>!C9UQ/Z^.687.:
MADC'A=\M@&-@06(ZJS->62@=@[HQF_UGF**P!&=O4LWC"Y-%#G?]SWI5M6'^
M_BW?;%_83ZK<N8B*4T[F-$S;H8?=&R-'Y'$@8+LH"087Y>U?WLXV@"R$N':V
MV8=AV.39[)N24%COYB5+O?U*3Z%:T<G3X F^_>+B6]I)7Z!"7Z]GK_9 X;P+
M'M;EY:]Q]W@3XN2#:\[U?/E0A&7U,!V\'/L4 +FT@^>M5H1T1UV621RJ^Y8]
M; ,4$*$G:^MH[@E/V9\($UAEK!COH<LB_1)>BPO0Y-,SA,>D+ E'R^5K';36
MH%2C?E/JPHZMCYD?T F?:A;M<TS6^/#YD#(9=L1EM^M'W+?M2RF'YU<$3"$J
M5[;@3"+F7O4F+W=WNJ38\GQG[<>4A%JJBHKP,[;21Q3,J4DZTK(ZHEB'O+\O
MK95N!+R4-NPJEFXA?4N"W!.3+!H^@JD4Z=A)#*7'3ZKV2HJ0832?JF57MT.=
MQ1Z/V?<_"IR/%?\(JU^38$E712WPP]K>FHPC]$C=%L,8O[?WPO^1]4)L9V H
MUUVH*!J0'&^@(71D:+[W*K2^W$6KW)*9C]9 SJ_UGI.HKN%SQ&@6NYP4@N>*
M0J,S1E&_M;M86Q0?[J++3DF5DB3Y=A2MO^LNV^+'3IP,/F5I,JV9@TE@:Y9L
MNRQ2L0DFHIFS6X>#5/KY:!O&!TT?+SP$Z$[+8 J9 0Z;,X)OWQ,C8'C(JNYK
M54TE_53%,(*;;Q0[FAQTP]NJLTPNERQ);JIEIUH/O-BFJ.IUAP@$AEH9YO8+
M<"]OF.! S1%@?NTN/JUS-K\O8C9N%U9^P2*A!L\> 9Z,.>ZC>/"83](;3WTO
M/ B2ONFYIEIL+;GA7! F4XI7&WN(^'7=[;0-^O-TFRF9N.[Q'9:O>4'_4,P-
MLW=92]U](GO*ZV^EGDFK^KVV-#(?OU'^#GL\111J<;^-EZ%,M)%;,TH 41?X
M%FK685N3^]+?/-*^X)XLQKAD,HBK2IP:<]L/UE'P/D2ZHS#4RS#]Q5(@!RTK
MGC-F$@T(^@M^ G**%V$^:#51==;CHJT--R[^ELP9>=QKP.E$J3U$A-?%OHWH
MVM8\T; *NXIU;U29D Y1X_O7Y>TM)YA,F@8RA+.ONP:CES'MME.6BUJE]EIP
M/.?E@JG%&G)NP.X]=RT*,H?LPX^L&UR96/E0QN2'6=<W%K9+:-#7ADVFDN+3
M!;QB3X7LC<[=78:>DF-8#UINN=/ZZ,??44Z8$MR?/GUVGIZ.O#5@,N%7C#V[
MB,E"&$&:UW$ __,?WT8A0]0]);<<115TWML5ENST",044V]_\)/%)^'*"SVG
M(=\K=##-H$117-/)O 3%26QOI]JT4Q(8=N;U=*Y!QCX_UF;(USV2A7:'6O(5
MXHJUR*301MLJ)S2B^S#:9Q=??OI\)"FV]U*WF)V^W"TX&7R!)@PP&HJBM\#E
M?]SIKH*T1^;9!@^DVY74AOLQ@YD/AE*'3NWADA*FPX&<VO>L+GQ3\'EPW7L<
M>P8-N<6HN(KDNOP0OKD"?S$]H)@"@^&6FTU7A?VW;W?%)GR1#F;I0J VQJ(@
MKH@XT3S)VG_CY2.IW9H6%51:*3O"XDUATU:+FO0<T R)'C'J_?%]V>1]'KXC
M!&&H@:!P)HYR"&%+U'O-7-"'V9@G P3K:R>V$DJR(4RHT:2MU[H"K>V/6^[Z
MQAA3-S'M_LB5#3,V?2+PSN8R%R(2;;-  7I':SMV<^JD==LM96W4GI<C63>?
M=%":E[#LV/^*F?0P6]J5DD402%A3G1U5ER(J'^ND>J[@.9'OVG"SHG:C,A "
M6Q!^:X\AE J=^6YU=![L2^TWP!Z^./_V%;W^FW 2Q_96UV4*-\)*_R/V(WQZ
M76QVW<_=)K^4H;\D00U:(V!CA,T(KDK\&";Z0P4J:JT/&(%/SNM,83[]EM7P
M\,^?/G_*N^.K5^=.USC8!LZTU]<A\%A3(LCIL/B[\P@@I1^F9-!-2C@H37^V
M8<DT-;H F R9SQ,D7LC-Y)5\AHY3;A>*["T8U;#DP[!M6LE7J6%:%3"XU!VU
MAF6[!EMW&GXN<_2_SL.R%R<1+XMS;0.J4HHW2;@YOE6[HBTO/AK9Z4&20H>5
M'B";S<MFK@X5"O7KHF *JK*MFP4\*U;*'88SB.=D%[L/Q\+2</SB6U!<?/!5
M-,2\*LF50YRC/>^JMI;CY"+N"3Z'5%B+>$*%C$>C5LK.!V>EE3> '9;.YO[F
MAGX8NUFS+S2<P8R=X (>+O#7$US@83S+GX1!QXR%QN_!W]&R<D'%KA!AD\2I
M26(%%Z$.AX&F1GH$:#TLTJ*>=\0XP#Z%*W?35=BNMYQ%:#:26!N)FCV@,K:A
MPK$U:@'F65"+]'-A] -:$-'2GU*+D"<C! ZI,9=J!](6L FY]'BX5))C'.FY
M562[ZTUX XD\T_2EL:+H.VR8T(;RK%.C3(ZH\<()<HSC6*TZ1%*WX$\43-3B
M#'\XWY=VLAOMX:@2&Z=C.$%!7^F8 2(Y1IJALTJ5V60)""FL2T />0J.S<=[
M;Z2KJOF!$[-,?#E.JW$U?<2CYQRET[(U]9#4!^Q_,4(6!5M=:+UDM&2L'^=<
M&L-VQQWN@9=@WQCZ3>E7,PTX=JNFWES6\WV8KZ(J\VQVM0[A2=,A*U\5V_#G
ML,56)0MZ[INZ7$3W)O-.CUTB_?6JP!;=E8S:J8-#>H6[(4U)$=8*7 1T_Q:?
MR>?2;LH?#CY++G5KB6\ %0JAX0>!@RK_ AP=\K"6-<9R770?:EB+<+\UO<&^
MQQ ILQGLRII9J9!>Q1@O:G*W)26C=<1^.#C%":+!URHL/2FY<Y92+AO6ELTO
MFC7"X!/+#@&\43;O 4G[H%B/4A[E^QQ?*D]F[XIB]K^^$.:!L[,W8G3>E%NB
M6Z2;?>E24N\D)?6_]%7/JZH++_J6S!B-B3=U$/9E R@W/#;[P*0P6!(Q/$ZH
MW&3?*XV5*?OXZ91R?[%L@/E/4A!,VHSMNLX$U^6MN*-Y6-1,%;25O'NTY =7
M#A7^^QF6*;ZO029 3)\W)DH@>BB#<RA1CD#$*FE39%1.1]8Y$#XW&BY!H:70
M(DGKFA(^Q33TOX9H^.O#R X_=90ZP!@,5F&B*361IF>:P'C039'6PIV89L(#
M7E,2ICVUJR)2XT[RX=[&QM=O(Q#\J)_:ZS*/E#034WND;$E:-9+-IV41&Y1D
MP'N#S/Q<O/6P+IB@S29;K QS $<G8!/<W;,H3E OEV=AN,_:5;&.RF18;,&B
MM$M8NW!7 0 +/?>=$]J[59^35TYJ?5Q:8^&EM4?'-6<+R3R.F+Y+VK<,,>;1
MFIP#+'J2-TH;#RR7FK4RRL-%TF3W\2@=-TIA8\1XN#DG7"C=8UWG_)Z[_$-1
M6=^'[X/ZGDJ?LB):T@=0V=TI#;MB$YR6/2=M(YN?J?J61<R!QS(2E_;22TI/
MF1ICA'24R=_US/L@F!E")8[OP*]F7Q>730?&DN=/D2,G4C@.2,L*VQ)I[U;0
M&ENFV^!T^+-G?\O"T\W:'SM*KH%5&U3VZB+,2.[XK.9-ALQF L6=X,D.,Q#>
M+6\^9+,+],'53?"F:8&0(@A'C%P1WO$N>[/"\SV7F%T]!"H>DT]@VA$)2SB;
M==T9YV&I[W5Q)0SB'A8_?B7Y],3[T(H)9H+,G=:-D]M%DJK68;@\;_OP"0\R
ML6L!BH^2KFD-;)D,E5)MZ@85LB_THI% -6X"&!PGR^-3NHK(- +4N/1;V5.T
M@W2TF2).J+-Z1'&95]K*9Y<E[>8Y>A[G!5B_O!;ZHR^^/7^,O7\E1?,^(MS6
MPC#R&;A_WJUP178>>9M[,4NBG3DZ2Z,FZY8YP_Z*"]=E:Q2+P$F/Z69E]C-B
M%]P@I+Y/)GE_%*8:!%5<M.!Z]5HN I$1'FD0@5)Y-TS('-QG#$^1&R P54^(
M0N%1V'KB&#(KJAESAK_+Z8]+$TWJT5EL[4V0 &E?2/'7%:Q[.4[ *<)8[@V'
M)(:AM1)7JE1QR.?R[M8TE[+ZL?BJ:%D,]E>\V!36B->%KI;U?ASJ_0O\Y72%
M4F@I)BT=":Q==^D%X+3624IAF<(@.,$[BCUOP]4*<ZG8.&XY%5+T2^X*+2([
M\/FS3Q.)NES3*?0<=!Z9O0A.+E7)MW68&[)F5#;?37AK]EAV(^_BB$ &WIX=
MX!X?0P)F<@Y\//B3*C%F)&YDZTX97V-F#N%)=^5ZX7+G.A#>Q+ML8GPFCN<B
MX,N!B8N8SG6G7%V1VHX@/8*[&TR0]1F%Z=D*?[[  \(#\++YLNFN9E]AM\V9
MSOM<\OE-;GS[A!0$7R4#%'<$Q-!T-6%)R-UE#DQI)(E,G_-O7KT1AYS,OR/%
ME'#UH[!?#\6(O1\*0X=S?IMVQ!ERO53!XI_$B-,Z:!/X'D4](6HK^I2C_7Z^
M6!SQZX["AO+'KF@3RR3TU&AABD_;,)#4^[+VJ-PR,,&J7%9NGV5"8HL<\YK<
M7FS)4H1^\1!1G<J:Y?H",E@[%MP%WU&PI'CL?".),077&N: QZ='44RKS5T^
M>G'[LEB#6U:5TV1,$MCMSAE=5\W1+ P ^TU3-YG1!;0IT851R2>0Y_YFX#V"
M@XRWW"+$'(MP?;B,.P4X@<L'?'2GRKROS']ZJLP_C&?YTU3FX^%$)[X/VL(+
MH5;L\JU07RZD'0%-(Z@<</';<'S4S*3MJ^S5<ME'=?V,M_FV;L#;L\<&ZX??
M1/U09E&IOXV<J9;ZRQE-Y=BMZN68+\MXJ6$Z*R*2Y%7E*L9RQ3@!W"UOD/Q0
M1W+";6(GR)J#Y^M:N5VH/6#'P*HAHC42#!5RQFZ*Q=[@<.XPB9FZO"7/95]W
M4H-%KU4\"31B95D/GCK6&>F-0S'MJK/WAYN1*KN.X;+#UX[.Z_F^F*6)9!5N
M](4. : 1QKF^4H[Z97C6J!O4KLJMU=X3N5+U7@8+^EWX.JYK:JEZ'7*,)%.3
M0!,I%)'L:I8\KDVM$(?3!&DM6+T#W;@W1<X-,OVBUZZO@>E7A#D0/ [<6M^U
M24I 6FC(L1-V(?'XUF">F]J*)!_ >)EC7$%FYER>/S4&B5\G?? J6D@)D1">
ME )5SF-@A^%:YY<8RK)MNFU/F5$;ZB/)?_!3R5F@&EKXSK;CX)HR23=%(U!Y
M=86COFF;^IX#$BM$:Z"^FK );@)C-!>5=NZ.RGD(M4Z:5@JOJ9E4VF[)]%?U
MH):#%B6OT*:CG5;L3433?8.V>PCYL:^W/-8JFD2SP[G^G@3S;E4V"XY3"J\&
M1Q>#DWY 3&NDPF=TD?H5E2T]LOKEOS!=WQ>,25XD"1.DS\]8'BM^J6ZN\JK\
M.682>/HH\K&T!Y>N."_BP^$PR82*IGK<HH1-;3,O/&8JIIS1"L,3 7ZQ,7K
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MFCS[JD8ZW!G-'!.]$R*LE+!X49 WVOFQI>=>^%]D8'DHN__]1V\9-?]F^^-
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MZ*TXY\FE<L$Z4E-;L'(WP#R2$#:+8I;,ZDN49%W%':GI6 X&B:C:*'K,S&C
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MW[R%CVD-]K/_S*L.,>LS4G#Y)&/\N\B)Z.B:3^*]0+_.*(82A]!>,>D(CRD
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M>.82;BRFD%Z5Q34C:LV9*Y=]0.,O7F S37?*$M/7/ 1[^9@&\X$\7WR+<)[
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MF3RENX.]F@!,)>!8C(X^CT6$GOIVK"OH4M@\6%/I[-$W%V] #,U+AJ^0\I6
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MU)/G_ >*PQ:S11.VT.RJ*SGX1-+F&K@XZ?H:5=.V\-8?M Z>W6L[()H<I31
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MMD9O\62)7"5A^017."B7DXIL8[N3*"R-R196FCD%R!\E?"F$4X244*W1-D$
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M7:XJ&\?YG&-:>1IBZ *("?F%1IP8F35[IFXZY$@@%IAW_I4G^<J!Z1E9/'T
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MF!N]#+9\V,="75MFU]I0HD]TIWL2[%D(OH,[#[#F!X"&O",\;;9,B0;(IP1
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MF6?M+X:.<KQEP%OU.CN&_Z$E=H-_>&C^H9L=%SZR\)G'I"NFEH\E=>H;6CB
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M# A!OQ<>7VR,\T39\HWMK7?#'1:?,(O*VPUFR"92=(JFZ$<K)[I[<LV,*S0
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MBM*1I)\ZZP1KK$*.O>O@L_J\+N(Q<5RD@G!--HSI5@>UD"Q^F(QBY=@&'@Z
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MB_RZ92H@<;9U"/0MB@:Q7D&2:UY>^CB#*;%8Z2+)%C,#5:*A6"(GD,:2':9
MPA;>/K:["F.;7-^&VK\FH-M(Z,U8_7QQ<+"87T"1DB9_*Q/=6QJ"$AD]6RA
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M":3DTMH)WUA1VYK*T^9,N*4<=2^1-PW"I\/!<BYI7B=-:R4$YZD"LEFR@KJ
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MR4A9S+!$O."N=2FX%?9MLKVMF'=MXO[0>F[V/-+=+X1<HB3CHJ:!L\)J]U$
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M)?*SM9S&(X(3S(#/7!A?8C"B=8J^'M)[=D7_2:S/Z#I]N%#JXOXT(1NA%69
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MB$$S<F-T-CZB%+YUVFHE(<_0::2D7OH#3CZ/)V&&/XU'^;)U]7G&1$O-M#+
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M%712:B=B-V?]^@<?P@_?3=#C1E)JW:C@)9[4EX;#Z?L72VJ2$PQEB2!Y;9O
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M)_.;Q OPSMFH+,QPWK@W$7B-Y!;((Z0H7.<(7J$"Z;4-TD>?476"R>ZT/"U
M[5EW/11*;2V]^1]_DC=*QG.QB_B *34G&G*2]<TL,>12,B"+38S9B#SG8_$#
M5M#_9+![<.7W4*QU97N]#)^'LW"R../K".#)%\R_CB>_GM62GE?3Z=E\4H7)
MBL*P(L!&ZT'QE.FPCQ)2(E'&0 < :_WX>6,BGQPD^U5CZWDR6POKEZ_I4_V=
M-Z7@Y-Q=_84BX/$WQ.E 9A:4DP%$5G6X.,7W+AH%IN3D%$>-273S^_HA\,G
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MY7/1@.6"3^>9Q!0R2$4QH.*.@T^1@0S!.NT*\[%3VO@H-M)UWIXWTD$VT@X
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M "\1#$4$"3! BC4V-EU*B23</Y ?'.X.]W_]']\?-N";S(MUMOVW/Z _>7\
M<LLSL=[>_=L??OGZ,TS^\#_^_9_^Z5__'PC_ST^?WX'7&=\]R&T)7N62EE*
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M76_OBD\RKWCYW7HKWY;RH5@QPF+/"U,8:0\ YH&OK&L4P(A%GOH#EF$@K-P
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M!(:48X]RQ/W(O/OF\'A+^VSW$H/'5F3PT,H,'FNA+8(8!H@;!'K<XCCQ!W^
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MG(5KVB&",_FEKT#2SBEM"$VO1WKH&?.YHPVU.?)%F]XS<P[KNWWJB\=CSD6
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MT=OWG[/\"]W(YFQ5Y8O4G9I3]=];)<]O.I*NKJDK-+S+BF(5^X*Q, T@\^(
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M*Z(L+S_T$8QPJ$^JA1$DE'BZ<4#(4A]C/[2J#W%ND*61<2VC]J364MKNW<[
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M^-4(7I'QFE>=,,09%!G-[6Z/PCQ.&<Q(CB*M.4V)7P[[N5'&9@A*+K/Y<O$
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MV=PZ#3DVFVN$AK74H"%VIQ(M-] =K&]P*'LVP==1[&*'W>#T,,;!81W((H>
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MV:*2\.-RI=7,V/9/BU*'J=8Q36*A881%!@GGN67W9I P9!OD1'FDDSJ6<3^
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MN=]Y]7!]!IZKOIVD=Y\FX+WB&[ 7> +N#N;(JC,!_V!FJ_J35?4O$\"T6;?
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MOV8$1WG.$8:,D=Q&Z"+(D4)08)8FF"-&L--VV&_8L9G9[]NG)V;\"6,-&PJ
MO0:@5L&3$<)M$MQL77AH>[9P5Z T)JT/8^8'4RA"![=!AV5P\ +BA++![^H;
M&ZNJU<O,,BZ>8X?^=5DP\RE9$$&OBT2XYM_?+=>;7Y>;_U0;8TF71FK+_(0S
M%9%4:Q@S)LV>FUN7DA*82I7%5!#%S(>Z-&8-+>G83.%OB]5.MJK' "\XYD63
MB[ZJ#>_8WS7X;+L9T%',8=\V]UI_V9U^=;, JY#Y[0:\J@W8ZV2<TB?[UO?0
M@+8O^$,WL TNY]LTP.T+[HL-='L;<.#&-U5G@2]F=[PQ.V:S_GU;SN<?ERO[
MQVDDX@QK$L$\C2)+*X",#QUIR#A3*D)QE%,G6H%^Q1S;\O+KUH:5K*-=B3U0
MDYKVN71TP-]\A@9</#JVGMDUEVDH"WZWZH)*WY"N?J\3\M;M9-J%_#$ZQS@!
M':Q)C-MH'<[V[*KTB]H\+N6G'4MX@[W._GD]E3Q2-&8<)IQDD*1*098D$G+*
M2(2P[7V6.1_SN8PX-MO>D,_L%M8^IWU. #L<_(6&K6>#6_C>I;Q@+_"DR8E9
M^.>.JZ3'L^I^-!@:TH%."6^'UN_(T >FUM-#IQL-=Y#HH]?!F:+7A6_NV7]:
M;%:SQ7HF2NX(G0N68YI"B;(8$DPS2'$B8)II9GM8$I;ZA<7[DG1L:\#=P\.J
M:(<)9K6<X*4\Y.)E6Y4W<_B/IGAPG[_[Q/V8;O\$[#0.34?2^ZR,S_<_DO-'
M=?_/P]WC#N#"@%TV 4?$+0OY_7&YVMCLY/T*MYXJD:5)RBC,=4H@D41"2N(8
M1B3-,5$RHSIQ827P&--K$1B.J^"(XZG(.O'NLN0#O<L&(3B@?6\1CFB>@!$9
M%#(7Y0L-W[8'0'VV"<&!'6JC<.XQ71< ;RS C2<V5'JA'U;MNP6W6PVX7_#2
M[7#'X'=IMSW#UY5EN-Z\?IW;D^V%W"4\VIRVJMY:\@0G$38^?\YR2(A((65)
M"IG*4*R)BC3QRD)T&'-L?GPM\@040A<OQ4[L28<$0!?<W5SRP&CV;+\_+Q</
M\//L1=G6=(N'F4WB*S+ >JAU]T FD(/K,N*@KJH'!,=.I\^E_J0X=>XLCOC]
M;#-7TUAE$=*Y@C2VM;$III JCJ'F$I.(YR2*G<+%YVX^-FM2"&4/_7#T$__+
M+H_8G1#G!+UV4W$K)CW;!%\XO,AP+NG=B0GGY&:#T>!<4J/)@7/Q,QW#B5N^
M+J@M-A]>S)?/LX7ZM%%/ZVD<QUFN$(.(YS$D*A&09CJ'YB5%)%5$Z]BOM]J%
M@<;VVN[E!(6@X'<K*BAD]>V-=@E;QS!< ,3ZCJ)U LL_]'4%B5"1JTO##!MX
MNJ+L2=SHVN<[A'W>VSJ99>$(V!V)V9NLZRYBJ>0B11)*D4M(6,8A33F!-,IC
MJ56L6>JT36@?9FQ&H2%HL2LH1/4(/5S&TR%\$P2EG@U!$Z"[&J NE9V7D?*(
MRP1!;*!03$?D_((O5P%IC;=<OGJX$,M5#0ZB*M<_?6/'M,^6][=!*2[2.,UI
M#A.5YY#DW.QP,FK#X9RSC.J4V!+.#GW3#L<99\Q[WSUM7C!?S_>EFAW;J!VA
MRUF42=LR'#&"()$20XYB"2,9IRK-C)C*JW-E"'2'V$ .@V[.LI01HF&4F2^$
M:K,GI_;'*(M%(F-A-N?3%[7BRP'Q;8[7'\)?+F#K26=Y"5DW-S\ 6CTO[GN8
M"A%[8:V_@D+HQH!'H[Q->\#SJEYL$GCAX]U6LL]JO5ZN#N]M#QV^Z)K+?JHC
MF4H9,9C98P&"1 Z-6Y# 2"!%C750*O$Z$;@^Y-@LL-E:S<LGOC@56^H=D5UG
M9CH'W-W,1E@T^SX0*(2U*3-'EN2^PK66.9Q!<<<GD&UQ&'!0,^,.P+'%\;BR
MN_%1JN3Y4&=NCZ<QI@0E7$-+C&ML3X0A2Y& :<ZB%&G&,?;JT7-UQ+&9GKN'
ME2J3T#9MA(T=X74W,<% &\#"*&-0*FF'L2].X 0T+^WC#6Y=G-0_9US<+NQH
M6_;[([OUM\7<C\NYN7YMSS8WKSOR:")RE<DD,DX-P9#$]KM$F7U/2K,X3R@6
MJ1?GMNO 8[,T36:E(@VH(?F__UMN?+^_%ZE"OKLBYXEP-$8]P-NW33I"MA2T
M%ZYO7W1"&27788>U39Y@G)@HW^L[G+#<G.U;_//A3_%H+WAGC>E\7MQC_6GQ
M5:UF2_D?:O;P:*O.7XPC]Z ^_*E68K967U<SH:8$HT@A16"6B002H7+(I4;F
M1RY2JC7.W;A"QJ#,V"QJ+2MDI;! 5=*"9RON!"R?*T*14N'JYS40I>9*%MM+
MN30@K-; ^.%@;>%SW&J.84I<SK5^H*>F[V/TD,4HY;-5PS(!!\" 3PM00C,!
M-3B@0@?4\( "GQ_H8?,X&OR!'KJ!#B!_K(?/[]QS)+/=>KKZUC(.=X;[UIJ>
M.RD>BTS=-KN_?;]?%9R:K_M.$E6ZA$@RK!E)H!8Z@B1%!/(8"YA2@K,H18A@
M[K.]O3S4V-ROW_[Z_:]@4PG;Z";CMWUM@=9MPQH&L)X]C]^^@UK*1N>8@.DG
M[F@$VI*V##3H)O2ZPL?;3H<K>J(,6%\Q<O\PG]RXN6(<IT0K0F&2)\*8G81!
M'HD89C%6B",MI-!^V00#2C^^# 7'K>0:/%@E;]PXOL7SXF9+1_H,C&!;N'9U
MS4L$+-G]8"[X&\[>4%P& 24?%[M!^"GQYCOH081NZ^=Q;[:CSFU/R]7&4G9:
M=I^"SGZ:TIC'),MAFO,,DBA-(<M9!!E%-"(ZYYA+GW107P'&EB>ZD[!@G_);
MC+S!=UM1^H2TYV7!J<VC(^3>MKPK;H$,LO?P@UK5KN <F\;.]PG2L>AN(1LG
M8&=Z=I@/_+JTE.G-%AY6W"E*92QUG, LE1$D%!/($=808XQXSI*8)<D-K8RZ
M2S:V&,6%OD631@L<>V+<5*;JAN-9@QAN;MWLZIO,6,\&M]FUZ(;YN;5%T>U8
M]M.[Z :YWK*IT>UP7NEV%&" COYJV;MD;7QF>[=WYO;&N$PC2F.$I(!8Y1R2
M+-:0TS2&L62QHCB)I/;B=SP_S-@L;2TE>"[%]/0^ST/IZ&/>#%#/AFV'327A
M!%0R!O076S$(Y16>'V18WZ]5T1,/K_W3W=[[7]G&6)@ONLK<-EOD:<85TC*F
M4(C($JXD9A,J1 ICG5.B,BT2%/F\\Z=#C.U]?Z_68C4KSZ&7&OR\7<\6:NUY
M^',&2;=7_C9\>G[=2^'*/A2U>#TU)+N,0Z!7_LP @[[NEQ4\?M5;/MDA;_#^
MC^7]XW*[-M[GAR+@I1:6NZD^]-4*13EA,#>K.21*Q#"720H%RT7&TTQER*E2
M]OI08WOM(X3S@K;-(VVI'<OV%SXL0CV_^$9.4 L*:DD+M+I0-+3#YI&+%0R^
M@3*E+(R;&D95P_AL/A.*)-,)D=9LHO8[#)?KXZ3)02:.VQ7^)'0?%IO9YO7C
M;*Y6[]A&/2Q7KU.4<:TQ)Q!'J>T :[9"5&CS(]*Q()FB'#O9R0OW'YMQ+$4$
MA8R@%M*=B.X<@NW6,0 N/9M$/TB\R.A:%._$1W?N?H-1TK4HTV2E:_M8M\W,
MT7E>V4/MBRY.!)M<YS9J(J8ZQ@+KA$/*)(:$9!3F(D4097',9208BY3//L=K
M]+&][B=)(XM= [HB'60-ME7?>]O?=%O48R_4!LR7ZT;2B&U>8=L8V(R2\C+/
M-!*_&73;7_4V+SV;FY-<BWU/P%+VPR82A?CA=F.=4 NT4?,;>] ]7"=8CK=W
MW6[2L75T47YVW&#HRQ\+8U0>9\]?E7E:C1?\H*:,"4I2EL$L92DD3&.8TSR#
M)$<BQHSR2'K90^>1QV8+=R):PU;)Z-G!V1ET-Q/6"Y1]>TMEY>J9UF)[?+]>
MQ]>_?;(O5J':(3N/.VQ[8U\X3MH5>]^@XPG4O)A;)<\G>7TH.ZE/$Y%QA%,&
M!1;$V*9$0\ZY@+% FG-%E>#"ZT3*:=BQF:B2YZTHNX>G;><]SZO<@'<\OPH.
M9\]FZFHC^$KD@,=;7A"%.NYR&W38XR\O($Z.P_RN[G@\9C1AZ\?2[I7'[R4-
MB>V891F3=XP4D40DD7%J?"9F:Z?B".:1V5(F%*>)1G&B,J?B>.^1QV::C."P
M:&DUJT4'MI/E2Y'1\#?/,S5G^!V/VOH M>\3N%)F\&D/YT*"G=@E<7HO!"'>
M:(4ZIW,>=]CC.U\X3D[UO&_0S6@9,_@T*YM F2$L29(90)EAU'J*M1 B5QIF
M.+5;NXA#+A(,TYP*K)*84^I5XMDRUM@,4T/4XA4Z$!;\].MR8_Y)BS]EGF&K
M-L3=+%,@''NV1:T0AC,\#F $,C5M(PUJ7!Q4/C8G+I=T[[]4EZ?_:AZ'*8NH
MRA/CTC!E-UTTEV;3A2,H*4[25*(<14Y6X]( 8S,5M8P[5@I@I?1OPW0 XO7C
MKUNAZ7NKY(=*IVY,YU2_J2/3P0T'[\IT3IUSG9G.?N[-F[VW5N'&+,6YI@G4
M+,*0(,8@$W$&$_-CG-$DU<B+"W$@N<=F:G:G/.>KM8<IS@[T2"0\HWE")<28
MFF4BU68/G*D4HIPD.HD9E8F:/A>EE]\W;+7Y81^,8QT&/)<]+N;GZF&V6-B-
M(&?S@L;V1WIB5!S)/,F,$=',&)%$8^-8T A2J3E1&<VT%-43\V$A?_#GI=;@
M#9\65:CU0SXJ;ONH$4[^@ 'LF[G8F@D%X^%Z"#MG0_$\!))Z7!P/8:?"F]\A
M\/!=6Z,KK58K5=+\%M5[T\1X/IE"MGU73FRA7 *YIABF.D59PG4>*:<NQ2UC
MC,USW8E8GD-.P/] ?T4(@V>V B]6X+\!C"8(%?_5661LNWE<K@J2 ;8N4IG,
M4UFDZX(838!]RXK(TGLEJM_BXK?X[V"QK&_RAUHI,%NOM_8NYL/+_;1[WM6W
M-_OIQ+LM2S=.9\]+R'XFOY<S614N?RH@#MEW_2(*P?JLGXXP<%_UBRJ>]E&_
M_-$.53[O+ NTV,S6W^^JL@J48IQB(2"76-HTKAQRE6H8$\4XT8Q'PBE5XOSM
MQV:.=@)ZE*6<8M;^.M^.1-\!^EHV\!W<=2G4.47$HSCG)F0&*LAI(/37N[^&
M*L*YJ'EKX<WI5<,5VUR4^*# YO*GNG9QVEA;\$6_,W9OMFGX:W=/MKAY2E@:
M9S3%QE+9)DZ<9I J@B%.-),92O,D]B(<N#;@V*Q8*6_1-JX0V+>+TQ5XW;R5
MD*#U;/ J48M^386PAWO84MZ0'9S<D G6P.G*< /W;W)3_K1]D^-U7;=CMM_M
MYM56_MG6S39AM6CC_+EN:S^E0B0TE3%$261[+=O6<((@B%6:R$R:C5N>^NW.
MK@TY-KM22SPI2G@WN]Y"91/QWZW<92:1)U>4 _BN.Z20D/:^8;H9S0Z;)U>
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M [@;#GO_5)W>YF#8=)Z0<]$I]Z<3CB[Y07XW'CR'J)/>Y_*,NMVHFX__9?7
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MO1KV_-73J=&+$ASHRLO?/J<0]PG_7?WV][^UGZ@?VFC]][_]/U!+ P04
M" #"@F)5!&"C Z!Y  !$F04 %0   &%L;&\M,C R,C Y,S!?<')E+GAM;.R]
MV9:;1Y(F>%]/H='<CJ5\7^I459\@*66SFA+9))79,S<XYAN)2000!2 HLIZ^
MS1'[C@#\Q^]B]3F98C B"#<W^]S<S-R6?_EO7X]G/WS)R]5T,?_7'_E?V(\_
MY'E<I.G\T[_^^/O'7\#]^-_^[9_^Z5_^+X#_]>+]FQ]>+>+I<9ZO?WBYS+C.
MZ8<_INO//_P]Y=4_?BC+Q?$/?U\L_S']@@#_MOE'+Q<GWY;33Y_7/P@FQ.V?
M+O]9AFC1&P6<Y0#*9@N>LPA%9[1.8PXF_3^?_EDRA2+I#)H5!TIP!J@$ \6U
M<\%)@_;L0V?3^3_^N?XGX"K_0)N;KS9__=<?/Z_7)__\TT]__/''7[Z&Y>PO
MB^6GGP1C\J>+W_[Q_->_WOG]/^3FM[GW_J?-3R]_=36][Q?I8_E/_^O7-Q_B
MYWR,,)VOUCB/=8'5])]7FV^^641<;WC^)%T_//@;]6]P\6M0OP5<@.1_^;I*
M/_[;/_WPPQD[EHM9?I_+#_7/W]^_OEP29[/%ISS/?XF+XY_J#W]ZN2 HO,-/
ME=3-/UU_.\G_^N-J>GPRN_S>YV4N__IC_<=09<J\9'7!__OJ'_]TM?;),J\(
M+IN]OJ%OG']&7>WY=.2OZSQ/^6QO%RO,%O'&+\TJ9Q?+BW\YPY!GF^].4IY.
M-I]\%%;K)<;U1&.4R@F$8@N"*B*"+\$!$]&G:&)PPM_<=B5Y131O!+'*\2^?
M%E]^H@_^J;*B?K'AR88?=Y8[X\MN=%^<NX_TNQ-=M#$F%9 !-=#)0/!66)"&
M>2Y-R(Z%O<B^OMI-JJ_+\V@9?U@L4UZ2XKA8#I?QAFSO@O;\-WXZP25]$,3/
MTUFZ^-=5@[20U7K1@'-G8B%R?_R!=EWR<IG3FS.I/+BYS<[6I$[SYC=;2/Q_
MGN*2/G'V[7T^62S7DZ21D<Z,8'0BC9DS0H@>P3"=';IHO&TC_%L+;X4#T3\.
M]N%G)Y!XEY?31?IYGE[1%3SA,C-G-5V&D250GEL(06O01:H0"EKNL0D@;BR[
M%1QD_W#8G9>=@.'C$N>K:67\.:"#9SYZ'X"CD 1H)\$)F2$D$S4/V3,L;6Z'
M6RMO!0G5/R3VXNC(J/AYOIZNO_TRG>7?3H]#7DYDRH43A<!21712'!Q&#4XG
M*67(,5NY%QINK[@5"G2_*-B+@UU(_WW^-*U,F*]_PV/2:<DC"F]!>Q-!!1W(
MQ7((P@AI2Q19Z]0  3=7W0H%IG<4[,')+I#PFESY):FP#>,_$/_SR\7I?+W\
M]G*1\B0Z;H*SEJ2I/"C'$SG5@4%B49?DM9'<-0#&HT1LA1/;.T[:\;D+V'S$
MKZ\3L6]:IF=1BG--6'EC91)@):-[D&<%CLQCR-(JX^@GG+$&@'E@^:V@XGJ'
M2@O>=@&2HY1(!*OS/]Y,YYE/F+0NB<)H$]6]3D;059D2<,X9II"$D[$!0.Y9
M>BMP^-[!L2]/>P+&2_KR[?+CXH_YA!L5N8S$"FO(Q=;*@9/D9Z<4F61D/V?3
M$!97"V\7NF)_$E3LR-">,+&Y&M\NWRT77Z;SF"=)YJR4=J 0"RD]KR 4%<!H
MIPR!G(6X7^CBL=6W0T?'D<UFK.T)(N\6JS7._K_IR<9T"EP4[^DNC,$PLK@%
M6=Q%<(A.L6Q]T03X=@"YL?9V\.@XX-F(K2.#HVJ]HV7&#=T^*9&"\8#1DR4M
M,@<?LX3@G>,\H\YLO]#6]=6V T#'(<Z=63>RR.O;Z.S=Y\7\(@*CN7>6/&W@
M1:G*@ )!& -:26\LD2Y]WDOLMU?<3O0=AS+W8N'(XO^0X^F2H,M%^#A=S_($
M?<B<O" R?CW=9PX1T+,"-D@; Q.EH-I+_+=7W$[\'<<P]V+AR.+_N,2:??+A
MVW%8S"9T2[&B-2<SQA'A 2WX)"PDHX+5O&2YIP%P8[GM!-]QV')WYG5RZ'_^
M&C_C_%/>Q%MIC2@0Z<[*+H+R2=/M1:AU7$>;%5>XYW5_WZK;8:#CD.3>K.S"
M'7AYNJSL.GN!JY F&9RN)EF7HIC.I,@<6:Y>,@BI&K+6),V<#E:UB%G?O_IV
MT.@^!-F M5U Y/6</HW8,?V27^$:S[<U*9AB](R\F52#(\P)\(ZT7O!<"!ML
MO0J;/&O<M_IV$.D^$-F M5U I#[C+E_B.G]:++]-='&2#%T-F=D$RI8 **T"
M$<@L0B%\XBW"33<6W2YMJOL8Y.Z,[ (''XYQ-GMQNIK.\VHUJ:_V#@L'R:TD
M5I ?A%I+2#+85$H,JNSG3]ZSZ'8XZ#[:N#LCN\#!S\=Y^8FNO+\N%W^L/[]<
M')_@G."LD9-_',#D2&K-*4UV$<&9H>%&:.:#,@WP<._BV^&B^S#C_HSM A\?
M/N?9[()Z+E$X2>@V6KJJY0H@TP:RD*$&T+/8,Y'N[IK;H:'CF..>;.P"!$3X
M<4WC6,1_?/A,?%N]/5W7"H[J64^*1((N;20'I\E*9@G( @H@:"?"<JE4:O&6
M^1@-VX&DX^AD8S:/_4)Q9AS_,EU%G/V_&9<7R<1T^RE2? 6LL>1S6VMH#\F!
M<-:2Q<RXBOM!Y:&5MP-(Q_'+)BP=&19'QWF>:CKQ+S,D/+.2K?:U@,T1)Q3S
M$*(PH)$E8:)0V8J]L'!CN>T T'$<<W?F]7&#$.5+G+V>I_SU?^1ODY!949S\
M)5,RJ[ E.TAH!*84&BR&.]7"\;RU['8HZ#B2N3\S.ZG1N%)DO]!W5A-1F&$A
MD=?LB2L*8X; ?2%HDP\5O$J8]GO5>&#A[1#1<0"S!4.[PL19^='9)CQ=;,R@
M@2@-)V!+\J:EX)!=<3(6'4K8+RSQX-+;X:+CJ&4;IC9#QK_\=(>1;^@;NY5D
MD]Z;KW*B+U:+V335JOL7.*L%Y>1FY?7J)O7;UFH_^:D-BKB?1_F>U=VG*_B$
M>#+9),)5++PMOTSGM-B4 +$XJ^>ZQ!G36G(E.406ZX-'4H!*DJ,A8N A)T>6
MQB-'K> J;"!PONC9><NS]>KB.U<'[SET[:I7+M8X6JV(K5>[E/7PY ",)PDJ
M&D<WI4'PO#!5K.?:/W;-[+++FQ2,4SL^&!(N-$X#=H]X"=VD_MS5NMQ$R-Q(
M# I*X*0OF<J 46C(5G&>M2_('DNVV1TSMP@9%SK[2/9>D.S#Y@ZP\A)7GX_F
MJ?[Q\W^<3K_@C#:S.EJ_Q.7RVW3^Z6\X.\T3+XLN24C0.B<Z02&"4\;2]A+Z
M((S3YK& Z2[8V8JP'K"T%P 60TNC X@=?<$I?7N6?UDL/]".SM-8IGGU*H?U
MU=\NWJ*=SYA#"& 2,V3H2P^!60$FU%)]E-'B8X7-.RFJYY$X3L>,X6 WI(0Z
M ."[93[!:?KYZTFU6NE\O5U_)M?D.ALGSJ0<?$C$OD#6@F$9'+&4#A9B$J$H
MHJLQZ+8@:YQ>',,!K;4D.@#73>(%9V19TLGP6%L*U-I@5U0$88I&PPLOXK$4
MI;V-K'$Z=0RHF7;F[N[06*QQ=M"+[[?%/)[OT#LER)6W@ 1T4$A&*7U1((1H
MO:(CH-QCKPE#WGU75/9P_;6QX(<54 ?:Z>U)KKT+YI_>9%SE][5?X]OR.ZG>
MRL2)BC98*0*$1/J63$@#3@L&T;+DG,S1JM9AA$<)ZN&Z:P*L=FSO $/OE@O:
MSOK;NQF25I^GZIF<U.C+;[076V)!H3BI=&*08H6!8Y;^(SQ3P2B%^;$'L-WL
MIH?IZ>'^:X*@9DSO $#O,S%D&M=YX]A>4Z;,,(%>%' FUPJF>A!D+,!E49FY
MS')^[%UD%_ \1,LXS:T& $X39G< FFN>P;5-!)FYC25 *2S4PJ<$P7#2I)Z%
MX 19F$&WOK'N(V2<+EA#W%1[L[D#K+R>?R'45^VX>CT_*F4ZF^(ZKSZ<AM4T
M37%))AQM<1$WWR5E^N^+Z7S]-_KU4Q+<Q*- $R4'IDOMXN1(D7(G(*+GG <1
ME6KML^U%\#B=M0; WN'$U@%&S_A&5">5<@V=U0=KY:,E9U9'"#%X<F)M9'R8
M5YAQFFP-]NSR+$9V$ MX,\5 ^*[>)"%YDQO[>3$CIJ^J9;?^=L4:SF1*@H,E
M!)-SH!F@00N1*ZULII^9QYHZ[@*0;6D;U^\?_-%W$!%UH'FN[>M.: Z#5P4=
MT1\8*.GH"&810:*53!B1/=KAP-;5P_ PTG\88ON(H@-0'<58&V&NWN&W&D"[
MB-#*K!1C,=*IVW2H<N2C&A/ %F5YTMYPUSH<<#\EW8!I+SG?OOKV9_J(T*F)
M9'4+R].<+IY^[C)JDK/1O(YNT,[1^5)&@4L,P7J&RJ14^.T4VKM9<-LM->Y]
MUA@C W"W S7S<C'?L.3OT_7GEZ>K]>+X:E??+I^%DC,J$9,*JY.#4"$$QCD(
M7FN,<HXLM'XTV8:N<:/9 ZF@Y@+I &3W'!,I#2N)_$IO?"U%*!8<4P:DX-KR
MPC$].C^HC6$T;C![( #MR>P.7+F;CSN7X+_^2*@T^:!"@G?1$_Y9_<J0%\)C
M\<4)3(]V2][_7>T>HKJY[(:SKML*I@/%=/L2O[83FSAG/A0H8A/^X'1Z,"(8
MZ65V):5L6@<M'Z:FFYMN0&RU$44'H+JVB4EB2::L.:1H:S,Y.ADA%0,,:PR-
M8=:FM>5T;?EN[K>#./S/8G8'UURMXI^>1>=K2C+9?:19\SS6K:#Q25O:BG46
M004R\+S;=(]"@8JC2J&U]GF$G''?;@^"HU;"Z$#_/,(AJ:2(.DI@K(1Z/8MJ
M"-)%G8U)5OE29.O7W3VCW8,]\1X$58U$T0&HWEVLN]G269D$2J:S-06XEK;.
M_:M;J)E[)=#]K'.0Z;%YFCNF=-\F8^Q*N382OIO'O1>[.T#,M28UYU4UOC9+
MM0&8KGW4F37@N6(0#=<:;9)2M8;+;1K&?F ;!"M[,;H#H!REM'ECQ-D[G*;7
M\Y=X,B4;Z]JV)H4KD4.J#XXAUKD<#)R5!8AC0D9E5&[_J/\D5>,Z90.!J;$P
M.H#7^[S&Z3RGGW$Y)YMN=13CZ?'IK);4O\IE&J=TQ2=;1U@K<#(0P^I_4,0$
MS#A;YX=Y\VAWT]W2))^B:ESG;2!X-19&!_"ZMH--"*/V[EOFSWF^FG[)=;KA
M<7ZS6*U^R^NWY2-^G62')G-BG/1>TO:, @Q*@"13DIMBN7YT=.2.#[C/(7%<
M;V\HO3:@F#I X5VN33#%VMNGD!7 -.T@!7!!,,@H=/1<\NA;AY[N4C&NCS<0
MEO9D=@>AIZ><WTERR<I,&R@E8*U[MV1"UN K<L%XB5B:][)XBJ9QLW(/'<S<
M7RS-8';0EDSO-M+XG-?3B+.;6VG5G^GF$@=HUO3(G@[9N2FGY*S !'5P"2@5
M-:"5#FQBAK.0F6+M+X3A.S?=#)40K]\N-\NFC3/\+B\W+7(G3M#Y4\F!+Y+.
M)1F7]%52$**)P@EG$=O7T6U#V=CQJ\;(>3R2U40\'=A;-W=UUH3YZ'3]>;&<
M_F=.$YF=3%9+,(&I:@XP\+6\QUD>4 GTRK9^OGF<HK$#7P<%V5[BZ!1<KU>K
M4]H)X\I'I1QH)<AL+;+.):LE.D(D8Z1UQ3XV;Z$5L,ZH&3L -@*H=A!#IX"Z
MWC*>)8ET,A+(5,C9%:4.)S*)?*,H-U.+DFI=$O,$26,'OT: UJX"Z0!?UZ+#
M#U[P4L;LL<Y(T[E6I'E>QZC25ZGX5(B%)3?O</<T66/'N@;&66O!](6U._=\
MDB%%PS@D7X\->@$A:P\ZYNB"-76.ZW 8V\GF&C#V=3AL[26('C%U?LV34U(4
M<Q$RJT<C1 ^.W!0H)AKO+5F4MG6ZS .DC!O\.CR6=A! CSBZ?J=[*2+C9"E*
M4WLZU@=YU%Y"P%P*ERIIU[H7R]ZCD 8K5S\\HG85Q9^FL_TE2U>+<IZH3S_%
MFLQX[:FK/G(U"ZL^8\EAPJR[[KE]V/6A1\5+,*<8?%:Y0$ZU7#[S".B8!!N<
M]D8S5AX=7+)G]/4I\O9/LOB2YZ?YJ@&%TI[ PQ.(4'.0@K?@0JQQ%U:*E=S;
MYGTZ;]/036"U*3;N9E3LP?D.[LQS^G\A!MY7^OCSUS@[K4J[=B6A_Z7Z.!\2
M3SH7#HPS\ENX*+2[@! U)]>8F>13Z]?)'<@<%W_[X>)^D TFI YP>%G;=MX[
M^8IQ/'D6N,GU"9>,T!J'P2 1"MD@)02GHFO>$NTA8KJ)XP^JT]K(H@-0O2?Y
M$ %UY, K.D*SQ:;#Y/FN)B8P\F,<@Z)K(^Y-OTD7$W$,F;;<VI!;ARL>)6A<
MA=5(Z'>[-3:20 =P^BM9Q$N<T5Z.TO%T/JW\6=/1N]B.RR)K%@QP:QBI7#IN
MSF( 0SH^&R89BM8]]I\@:5Q]-0RD6DJA U#=8=*$"50UQ1&BJT-/2(_3!C*I
M;JZ,L J]:9YM?X>(<=\6AP'.?ISN(&WP<@-7";,3RY,C#>J@T/4.BGD'08D(
M3,ILI+8BJ,&LHRLRNGF*/HQ=M"/_>X!0Y<\Y2^;ISO'24D4E98"2523N9 :N
M! U%!9,XER:[Y@WS'Z6HFX?H88'53BH=W&BOY_19>;6^Z-)UMK$).9Z(IMIY
MR1&#@HD0DC80(T_96FX$ML;6_92,;&<WE/6=?L-[,[X#^&Q(_VTQ7]S4MA?F
M'1<V%1\=<%J[MD4.@"DE2%REX+4RZ)M;1X]2-+*-/1R<&@JB U@]O)&D=%1T
M"L"Y4L@+S9ELRE3H"H_HBBA9R]:]T/8#TW!V]W!@:L/^#BRHW_+ZFOF'0L2B
M=00=HJX5N1Q\]@884P5K=,.SUC&D&P1TDT UJ'VT.\\[ ,PV]8YG<]_I^\O:
MV>U5/OOSDG>1>!.Q6&"Y-G/S4M4)<PC9!O1,AN)\ZZ+5_:GN)O]J>-/]<-+M
MX")];,</#YP[2O__Z=DLC,L:7YX4DXQNDBR<I7.L-'@C#4A5LO0RD<DZB+/9
M@/8.7(@#8NX9D!\, #L#_TM>AD6[!+/;F[ZJ6!<Y,F8UZ))JES)NP GM@'EG
MJRE3M&VMHQ\AIP.G9#R MA)3!\;#1:..BW3Q%[B:QDFVY-)'CZ W>9F2>0C.
M>.#19.5L*)&U'FMQ+R'=I,4.>L7O+X,.;NW;FW@UG9VN<YH$$X*428"L1?.J
MNF 8K 5RP^@GSB4F6X=3'B"EFXS8@X)I%SET *>_YSKS-:<CNE[Q4_[M]#CD
MY=MR)]?W[*SX4H+WWD%)O#:C%@Y<=@62-INQPJBQ=>G[LPC<"GK^SPZ]X636
M+R#/C]?=''2#-F7!:P.UY$ I5L"3\0D<B3H1+.VQ=3G ,TG<SL=@WRDJFPCN
M3UD\<$_KG1O;:50P\%"'GT&+!)[:6_O"@$=:!=F,*I$S 3&(6B6G+&FX6N4;
MN$Q:*I53:RMZ*\+V;T9VOLC'ZHA/R'H($<E&98K\)^52!B]Y &VLCKG$')M/
M4KA)03>% (VP<+<?V<[\[N#BO*3^C"-5S2_FFS[L7Z>KB;+28%$>A'$>E&$)
M?-$>G'3<6\^,P]9O8X\2U F6=I#T0Z#9F^T=8.C6'EXMCG$ZGT3OM.2.;FJ/
M-823.!"[$BAA;+*9&^9:6_WW$M()9O87]&U7<F^N=P"=:X6BO^9J^DU2">A,
M]+4<-- &&()G04(-MV0AI.:E];/ '2+&A4P#P3Y<CKL#ESN R0-]L2\V@XHY
M(APX4XI\57(',%L'L5B?$YTCC:U;VS]*T+C1]_;P:<?]#J!TNP?V^2YBX1@T
MRY!)Y]:'@=H!&VO_?E^8KUM4K;V!^RD9-P6H/7@:\+L#U&S1P/I\8S+F.A8M
M@DFU_H0EI..@^*97&3K-HLZM3>:MB1LWG7H Q32(5#J VZ75^(:.SFOZ<C7A
MSM4^BDCN17'$G=I\&(T KLES90*-=ZV[Q-VEHI,"V(;^UVX,[@ BMY_.7\_O
MQC?>+V:S7Q;+/W"9)EH4(ZQ7@":1Q6=CJ.=,0A+>>V&\2JI]_OVS2.S$4=L1
M$7>2\8<33P?H>[3!3]':8F$<E$ZUX:LK$)SFD$7-KRA82O.2_;U[+0V&JT&!
M\)RV2\^1RLX(.]FD]=!96JZ'FJPA331%UEL\Z?->U6B4AVR]S-ERHV7K5I8[
MCD,8["(\)*;VE$!?2#IK;/?J=$D'XBP#[>R<;'[X]F33O^KGKWD9IZN<R#3-
M(@19P/KJF>B\>0.OYJ,@RT-GD>(@2'L6E>/ZBP='XG 2[.!6?6"'FXZQ]V\0
M$S,E:0E6^MJDS^6:SZC(1+&Y/LI+E5OWG'@VD>-ZG1T@M)'\>@!H/6L!-T_\
MQ[5^ZUR,2YQ_VAC/+[Y=_<H[_%:_=539>K[QO^45^>JOYV=\^06GRPUO^"1H
M*[P2##CQ&%1@"1Q#!\$FR7-6]06V-8X'VLNX-5D'A7L/:.C@5%S5-JP^+AX(
MEM_/J_>9!+*:KO.'O/PRC?F,$^]S7'R:;S[E;*3L1@Q%$RNB(ON])H8ZP11D
MC)F,>F=U\W:.0^]IW/*P0YZ2KM#1P6EYU(S[^?ADMOB6SV[+=Z?+^)F8\FZ&
M\]7$!I6#Y0)08HW&. 7$_ C*!.&%-CJ7 YDZ3Y$Z;EU$!P9/4UGV"]G-\7MP
MEQ.94D!M'"1>:GLI2[:=%PI",LX:*8MH7ENQ$Z'C5EYT ->&<NP K#>KY5W1
M= TX"8%E 8K\83ISF;9A'6,I*!5+Z\%[S^]0,%AMQ2'!M3O?.P!-LZ)>Q8)1
M3!HZ'<[5\?213/?":HI13MZA3J9Y0[J#5G4/5G%Q2*R.(NY>:K@??B*)+/N<
M2H&2&;%4< 88K8:(RI94A G#3S!Z]L/5]_]R]1RQ[/G>\/,\#?5NI2/72LL,
M(FZFRKF:)R<D.!=J[7DJ3K7/I=_IW8I_KP]7SQ%!4R =LH#L):X^_S);_#',
MH)FK3Q^^7.R!G;2O$KM<Z+(@2$85DDP>&"]UP+OUX -!T$>+'.F*(S]UJ&RK
M>^AIX!/4SWRW7'R9$N=>?/M]50.OEQUMC^)Z^N7LCK_@0$A%!E8R1%\?>8ME
M$$**( +GT=@@'&_>%N_95':2,K0O@NYQ)8845P?^!FVM3-<;3TD[G1)W%JQ-
MFU8O"<ANK)-1; GD:$L;6Y=B7ZT^+H"&EO.=N;<[,;T#N-R(H=< ^#Q.9_F&
MQ_UQ\5Q6>FT<L8Z#$)IXP&P"]%K4EH+1H4_2R=89D4/LHY.<W-8Z<'21=P#[
MBWY#-Y^%)BREDE0(P'RPH(ST@$)YD$JY%"/RF%K'].ZG9%SM.3Y"[GL/WT]<
M'8#N5::5X_2,=LY0,&D13""O6\D8P=>I8JYNPP2O;/,WC.OKCZO;N@/8SJ+I
M %:OYU_R&3,O6_(='2^6Z^E_;K936[ZLXN)T7MO7OUOFX^GI\<295$369.P8
MDT$I@X#6EDV-=!+)Z6);)V#N0.:X&9C=@71H03\?R_X,R_/\J488VL[B>5/#
M6!>]S%7BPEJ5H41&S'+*@=-*@!%%)X5*6#'8Z*;KA(R;<=D=(O<7UHCZL\;-
M)E><.QL"NEK_FM>?:__4B[,V(;]-,O0"LC*!K R>(9A(7+)&!2X#9OYD]&_+
MM<;-<.P&7D-(9E_E]G' ^L)+_ITGK5W-MDU,LY(1 @L(*AL/K@8FN Z,C-R4
MDFK=^WA[ZL9--.P&K .+M0L#\_;.R+HXP6EZ=4[/N>*_&(]4IR6O5Y/L#6/6
M.XB9U50TC^""K!GX7LC@K#?8.F%A-TI[*V-L@YLGX=E<B%W8C_>P\WS<4CQ=
M5GF<;\PY*:/  MK3C:&L#^"\,R"S<$I[I0+&X57K?:3U5@%Y(#CN+Z9.\7<4
M-T[9ZAU^VW17\,2?$+( G6IW!2,U.!4#H-:2<270B.&1=XNHWFH=#X2Y?433
MY<5,&UJ>$AU3#-/9F6USKL^O7+6KGTU\YLYY75O$D!6MN)?@411(WLE<%')M
MA[^BGT=S;S6/AT/J4(+M$L@O%_,-&_\^77]^288^F?3+BPU^FQ2?5.8V@]1D
MD"CO!%DEQ-O:>4\'FSG3K5^VGTEB;[6*!X)I.[%UB<I;-LKU$X=(D(DF@6&!
MCIV+$I 9!U(Z:XNUVL36E83/H:^WJL!QC,I=!=8!&+?/:)DPR74468'TM;L2
M6JR]&0P@ZA*C#<::UMIQ>^K&+>'K+FHTD%@[F+#UP,[.PK</I&#Y'$IMVJQ4
MJ7WG0@)O4X$HK3/>>1M8Z[RAYU,YKJMTZ,S(5N+J0(.>]TFHM>+Q/TZGRTQ[
MI6.V_E9K$>N;:<UE/]D\+,3D30E%@)<^$2-E)#_0T4T4(^<R<+HW6@-Q>^JZ
MS*QLAI/;F97#"*V+4-&=O9T54]Q^YJHEC[456 F0I:DC\7(&5P<"<1YYMBQ'
MD9HG\FY)V[C!RK'!V$)@_3Q,$AMCSFGSWOHKKL]K$S?/!&?[IN/V$F>SU=OR
M<"GCQ*<H(A<6)-;X0T0/J$P!NGV2*%D5&5OG4#8A?-Q[_=!(/KBH>S0 KA]9
MS8P/1B&46$UW+LF(%^1W&B:8)5-*!=FZ0O4Q>L8-<XZM5W<53!?7^O;,FT@>
MO(Y:032\P*;5D-.&[);DLRY>Y\1;=][9GKIQ0Y@'AN! 0NO7#_]E.L=YO)^1
MJ)/S3#C(T=&1DT$#,AO!\% P2L.M;3U@ZOE4CJLA#^V'MQ)7#]?P-=NCM@RB
M?>6+:;F_STELK^D;<]IES46YO_)CT^N*?FUV6ML87&\ .B%?+V:I,V T"I37
M@4ZG#628%*<XTRQ@ZWZ7@VZH2V^_&1H?,4O'A49GY^2L=]:FPYM@+B5;*TJ+
MKDFO28,S18!P0ENO+?-V2/_JBI(N7?]#('-'870 J>V9-BG"%D[6%!0E:G,M
M1'"<3!W:E N,2Y9\Z]3C[:GKTE<?"GH#":T#T[1NJ_Z_AM&^X*RZ>^_)W%Y.
M(_EB]0>DY6]^X]IOGG48O/OD>Z[Y?_X:/]=NR>_)3ONYE$Q"$,6Q*!59ZB(S
M4-$6LME#@91K3V1K(_D(C2%]V!V.Z[$-9A)W#),_^R&:".'0T)Z IU0;@L<"
M(08#)223),%9\-;6Q%X$CYO'TB?$GR7$;L;&[+=E-(YER0M$5U/)4'/PV5M(
M0OK(C8\Z-9^$-3AN!TM[Z12WSQ%B)^T':RX9[>(J+CA/EX;89K;=)5M%L:A<
MXF 8^9@J! 68@R"33RI&]AA&W7KN[=;$C=N8>KC8V2#"Z<!O>S_]])FX18;_
MIBSF;3B;_/MZ?F&^_+)8WJS%ODJZ19G(\&<1;'"TU<P,H# 2-#JKZCB#X%LG
M#^Q![LCAKF$ ='MP\X&DV0%P/YR>G,PV9QUG%V?]Y[-O7#OR+F<FM 6=5"+G
MV)#YDF,"G@N2,<-0B=;/#=O0-6Z#]<&49'.1= "SBP=D.CCUO-2T\L5JO:J]
MCZ>K50W^TDG^F.DDKU\?GRP77\ZV.PG:*4NF,YCBB8^R]C^6SH"Q=;8+\Y[;
MYH\%NY$Z<C_.YIAY( -@2 %VE&AUM=OK<>6S_1W-B+GUX6/B0S09O:+KI395
M5EJ!LQRA5D(DE9-ALG5)R7:4C=P8\8!@;"6>9CJR8;_K5WD5E]/-V]BBO#BE
M0Y=7.[6VOO^#]NYBO05]C1I6OUU^POEY%ZVKEMD5SIM&6I>TORWGUB#.KKII
M7T*.991"!@]<Z5S;QI4ZO)<NY6!*M*XDW[PHL0GA>[O$-7\PORWG)FM]:>7,
MEL+IX&6>:@<HTLC>90<%N37!.B-9:\UUEXIQK\S#8^J.-[R?7'I461].CX]Q
M^6U1/DP_S:=E&JM"/JOAKS.GB,>QO@[NH,.V_.2]E=HN.VBDY>XN<PFS6+2*
M47- 5_T)YC+!++K-0'NK-I.>6R>_/DS-WC[G8YS]2,Q\0;_]CXD0Z#(J UIG
M#2HF#4%(3M>WHJ-0&&>Z=1N.[2@;N?=O&Y3<\3K;"Z5'!74Y:O=7\F)(^Y[Y
M;COHH_L_:&_ULP5]C;3-Y4JU*>EL41>[0I+*)=2>*N DJXV;?>T!P.D>BEYJ
M'FW)HO6KXV/T[*MQ[OOL*TQ[:Q"+RF"-0U"6$:898X1IJU3FIJ9L'&"SG>B7
M9KBXK6':":%+Q7)A)+Z>$Z].=]<K]WW._FKE2>H::95KA2'DB&^Z.US_U@6.
MG%1&1,E .$<XDG13>9XE)$[2S\**A*TS?;:C;&]-<P^CK_!^#>YT6[*"%K(L
M!53"!#[; -&IC$(7)4MK@VY+TL9NMM@</W?TT  BZE$CO<!9#8-]^)SSNB9@
M+^:[ZJ0'/FEOK;0-A5U%D#1F(XJ-=-^EVFQ3.O#>)2@B%&21%\%:6PI=1)"N
M1W2O"^W>FQQ%]G1A&\@B*CHW]!^?=82DO#-%%E9*\^'?SZ#O>X@Z/0>'CSTO
M-I5ECSKPS336GKDX3R\7,P+VXBS0=O1IF7=W_9[^T+TUXS/I;J0DWQ.I)+^:
M$_8J?\FSQ:9OQR7J+%,N):G 6"E E1# Y>Q!8D5@,-GJUBE]CU.TUV"!<Q9?
ML?0*]9RN]DRT0 K!D)=#)D8PQ4.0F+E.UEDAGP+)$VN,JX4:"OK&2(!&/.U1
MDVQ>NL^LT,VIW,3'\GS7</9C']=@O.R6M#;2&]?6.[JUWM6M<E5J@P9E\@%2
MY!D45W2GU+;1&)B+OJ#3O'7OIF<1V&+.^I.+71V,: WF4AQ(31Z&2LF"#\*
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M -D*"@]!K9%<.H7:ZO+$_IJ/0UY.HL\ZF<VH)JWKR "L-> :1,F62RN<-(?
MVFVZ.@%;*S!L ;:])-,3VEY\N_SROT_SLLX*^_:F3@K;G%&CM Y(9Y3YVH\]
M.456C&!@M"N2<2.P>:;3=I2-ZRMW=]^VDF%/R+Q^VN[N[_Q<B\PP)!.!2<9
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M4BH!5#(:7'TLB#&%HB6F&M 8_OF0]WH#-P+!%L^'NTBD4W")"VN")QZ9KO=
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MT>04+?W_41WWQJZ^^^^BJ2-I3Q!,AY!(_]'Y^@?U2PQS_-__ZW\ 4$L#!!0
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M@ZU1*:9IU[E4\4W+XE!)I;MOFN[?&9;4(IH(N>C^/!8)-^22S\F-2FCZ<]5
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M9.H1BOT3)*XUX'H@H2V[# 1*%SN/'@T5P5#HZ5- 0PU,\=]50@4G/PRD=&]
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M6?4"P$#V-WD" (%9<LX4^63K\=D+.6^_D#;9)Z2U.PYID,0C#<11A;ASQW6
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MBGC)FIIKN4U!*##0):].7+@JCPIT\103O2)D=]*3^7GQQEA*A<&*O. BH,)
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MO'?2;\!._@902P$"% ,4    " #"@F)5G%5RH:_" @!-5!D $0
M    @ $     86QL;RTR,#(R,#DS,"YH=&U02P$"% ,4    " #"@F)52Z"&
M1580  #JLP  $0              @ '>P@( 86QL;RTR,#(R,#DS,"YX<V10
M2P$"% ,4    " #"@F)5D"&YMTD5   PQ0  %0              @ %CTP(
M86QL;RTR,#(R,#DS,%]C86PN>&UL4$L! A0#%     @ PH)B59ZNO@3>4
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M;&\M,C R,C Y,S!X97@S,3$N:'1M4$L! A0#%     @ PH)B5<8(J.1G"
M#"8  !<              ( ! I($ &%L;&\M,C R,C Y,S!X97@S,3(N:'1M
M4$L! A0#%     @ PH)B57-+4W'Y!0  7!L  !<              ( !GIH$
M &%L;&\M,C R,C Y,S!X97@S,C$N:'1M4$L%!@     )  D 60(  ,R@!
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
